0001437749-13-005134.txt : 20130502 0001437749-13-005134.hdr.sgml : 20130502 20130502123640 ACCESSION NUMBER: 0001437749-13-005134 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20121231 FILED AS OF DATE: 20130502 DATE AS OF CHANGE: 20130502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Revolutions Medical CORP CENTRAL INDEX KEY: 0001041009 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 731526138 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-28629 FILM NUMBER: 13806652 BUSINESS ADDRESS: STREET 1: 670 MARINA DRIVE STREET 2: 3RD FLOOR CITY: CHARLESTON STATE: SC ZIP: 29492 BUSINESS PHONE: 8439714848 MAIL ADDRESS: STREET 1: 670 MARINA DRIVE STREET 2: 3RD FLOOR CITY: CHARLESTON STATE: SC ZIP: 29492 FORMER COMPANY: FORMER CONFORMED NAME: MAXXON INC DATE OF NAME CHANGE: 19990302 10-K 1 rmcp_10k-123112.htm FORM 10-K rmcp_10k-123112.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K

Q ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the Fiscal Year Ended: December 31, 2012
 
or
 
¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGE ACT OF 1934
 
REVOLUTIONS MEDICAL CORPORATION
(Exact name of registrant as specified in its charter)

Nevada
001-15165
73-1526138
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification
Number)

670 MARINA DRIVE, 3RD FLOOR
CHARLESTON, SC 29492
(Address of principal executive offices, including zip code)

(843) 971-4848
(Registrant’s telephone number, including area code)
 
Securities registered pursuant to Section 12(b) of the Act:  None
 
Securities registered pursuant to Section 12(g) of the Act: Common Stock, $0.001 par value

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 the Securities Act. Yes ¨ No þ

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No þ
 
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the last 90 days.
Yes þ No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No ¨

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. Yes ¨ No þ
 
 
1
 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ¨
Accelerated Filer ¨
Non-Accelerated Filer ¨
Smaller reporting company þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant on June 29, 2012, based on a closing price of $0.17 per share, was approximately $10,253,579.  As of April 22, 2013, the registrant had 77,610,014 shares of its common stock, par value $0.001 per share, outstanding.

Documents Incorporated By Reference: None.

 
2
 
 
REVOLUTIONS MEDICAL CORPORATION
FOR THE FISCAL YEAR ENDED
DECEMBER 31, 2012

TABLE OF CONTENTS

   
Page
PART I
    
     
Item 1.
Business.
 5
Item 1A.
Risk Factors.
 14
Item 1B.
Unresolved Staff Comments.
 28
Item 2.
Properties.
 28
Item 3.
Legal Proceedings.
 28
Item 4.
Mine Safety Disclosures.
 29
   
PART II
  
     
Item 5.
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
 30
Item 6.
Selected Financial Data.
 31
Item 7.
Management’s Discussion and Analysis of Financial Condition and Results Of Operations.
 31
Item 7A.
Quantitative And Qualitative Disclosures About Market Risk.
 35
Item 8.
Financial Statements and Supplementary Data.
 35
Item 9.
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.
 35
Item 9A.
Controls and Procedures.
 36
Item 9B.
Other Information.
 37
     
PART III
     
Item 10.
Directors, Executive Officers and Corporate Governance.
 38
Item 11.
Executive Compensation.
 40
Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
 43
Item 13.
Certain Relationships and Related Transactions, and Director Independence.
 44
Item 14.
Principal Accounting Fees and Services.
 44
     
PART IV
     
Item 15.
Exhibits, Financial Statement Schedules.
 46

 
3
 

FORWARD LOOKING STATEMENTS

Included in this Form 10-K are “forward-looking” statements, as well as historical information.  Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot assure you that the expectations reflected in these forward-looking statements will prove to be correct.  Our actual results could differ materially from those anticipated in forward-looking statements as a result of certain factors, including matters described in the section titled “Risk Factors.” Forward-looking statements include those that use forward-looking terminology, such as the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “project,” “plan,” “will,” “shall,” “should,” and similar expressions, including when used in the negative.  Although we believe that the expectations reflected in these forward-looking statements are reasonable and achievable, these statements involve risks and uncertainties and we cannot assure you that actual results will be consistent with these forward-looking statements.  We undertake no obligation to update or revise these forward-looking statements, whether to reflect events or circumstances after the date initially filed or published, to reflect the occurrence of unanticipated events or otherwise.
 
 
4
 

PART I

Item 1.  Business.

Since 1996, Revolutions Medical Corporation (“Revolutions Medical,” the “Company,” “we,” “us” or “our”) has been endeavoring to design, develop and commercialize auto retractable vacuum safety syringes. Our present product development effort is focused on the RevVac™ Auto Retractable Vacuum Safety Syringe, which is designed specifically to reduce accidental needle stick injuries and lower the spread of blood borne diseases. The Company also has developed a suite of proprietary MRI software tools; RevColor™, Rev3D™, RevDisplay™, and RevScan™. “MRI” refers to “Magnetic Resonance Imaging,” a widely used imaging system that safely creates many different and detailed views of selected portions of the internal anatomy.  These tools are designed to enhance general diagnostic confidence through education and research use and in the future we believe will have specific commercial applications.

On February 22, 2009, the Company announced that it had received notification from the Federal Drug Administration (“FDA”) that the 510(k) application for the 3ml RevVac™ safety syringe was cleared. Furthermore, FDA clearance is not needed for educational and research use of our RevDisplay™, RevColor™ and Rev3D™ MRI software tools but future applications will most likely require FDA 510(k) clearance. The Company believes that FDA approval is not presently required for our MRI technology.  Section 510(b) of the Federal Food, Drug and Cosmetic Act requires that anyone engaged in the manufacture of a device register their establishment with FDA, and the Company has so registered with FDA and therefore complies with this requirement.  Sec. 510(k) of the Federal Food, Drug and Cosmetic Act requires that anyone who is required to register submit a report to FDA at least 90 days before such person proposes to "...begin the introduction or delivery for introduction into interstate commerce for commercial distribution of a device intended for human use...".  Because the Company intends to make our MRI coloring technology available for educational and evaluation purposes to physicians primarily at teaching institutions, and the Company does not intend at this time for the technology to be used for diagnostic purposes, the Company does not believe that this constitutes commercial distribution and, therefore, the Company is not required to submit a 510(k) report for its MRI technology to FDA at this time.  The Company believes that this technology is an accessory to MRI and is therefore a medical device, and because MRI devices require  marketing clearance by the FDA, our technology would require such clearance were the Company to begin selling it for diagnostic purposes.

According to the Company’s manufacturing agreement with Medical Investment Group (MIG), signed in September 2010, the RevVac™ auto-retractable vacuum safety syringe was required to be in full production by May 2011.  MIG was not able to perform and on September 6, 2011, the Company terminated its manufacturing agreement with MIG and signed a Memorandum of Understanding with Wuxi Yushou Medical Appliances Co., Ltd., a limited liability company organized and existing under the laws of the People’s Republic of China (“Yeso-med”), on September 8, 2011, for the manufacturing and supply of the Company's proprietary RevVac™ safety syringes, including the 1ml, 3ml, 5ml, and 10ml sizes.  On December 1st, 2011 a formal manufacturing agreement was signed between Revolutions Medical and Yeso-med. Yeso-med opened its new production workshop in March 2012 and began full scale manufacturing of the 3ml RevVac™ safety syringe.

The Company’s partnership with the Yeso-med enabled Revolutions Medical to establish manufacturing capabilities.  In September 2011, Yeso-med began establishing a new, state-of-the-art manufacturing facility dedicated to the manufacture of safety syringes.   The new facility, which began operations in March 2012, consists of 21 injection molding machines with complete assembly lines, capable of producing 100,000,000 safety syringes per year and expansion capability to produce 300,000,000 units per annum.  The new facility is over 300,000 sq. ft. with a Class 8 clean room totaling over 32,000 sq. ft.  Yeso-med employs over 470 employees and has been producing medical devices since 1997.  The manufacturing processes have been certified by the FDA, European Community (CE Mark) and ANVISA and has been issued an ISO 13485 certificate of compliance in recognition of their current good manufacturing practices (cGMP).
 
 
5
 

During 2010, Revolutions Medical entered into two university clinical studies utilizing its proprietary MRI software tools. These first two clinical studies are for cases involving head trauma and brain masses. These results are expected to clinically validate the use of its MRI software tools as an additional application to enhance the diagnostic confidence of physicians. In preparation for the expected commercial launch of the MRI software suite of products, the Company hired Strata Corporation in March 2012. Strata is an expert in computer software and programming and the Company believes that by the end of 2013 the first application of  RevColor™, RevDisplay™ and Rev3D™ will be  available.  The launch of this product will be a “software as a service” (SaaS) business model, where customers will log on to our secure website and send current black and white images to the Company via high speed internet (teleradiology), and the images will be sent back to the customer in color and three dimensional with auto segmentation. At first the Company will charge a per-use fee but can expand depending upon volume into monthly service agreements. Potential Revolutions Medical customers could include MRI centers, doctors, hospitals and even patients.

An MRI scanner is a large tunnel-shaped machine that will accommodate an adult lying down. Within the MRI scanner is a large magnet which directs harmless radio signals around sections of the body. When these signals pass through the body, they release a signal. The released signals are picked up by a receiver inside the MRI scanner and then sent to a computer. The computer analyzes the signals and converts them to a visual image that is displayed on a viewing monitor and then printed on special film. The images produced by the scanner are gray-scale images similar to an x-ray.  These gray-scale images can be difficult and time consuming to “read.” A radiologist “reads” these images on film by comparing the different scans of each tissue slice, sometimes evaluating one hundred to three hundred individual gray images to obtain a diagnosis. The successful diagnosis of a condition, using MRI, depends not only on the ability of the radiologist to detect the subtle differences in shades of gray, but also the radiologist’s ability to compare visually the vast number of images.

The Company is engaged in the development of technology which can segment and reference MRI images. By “segmenting” an image, the Company’s technology will let the user select a part of the image (bone, fluid, tissue) and render that selection in three dimensions. Essentially, different components of an image are given different colors and the user can choose the color or colors to be studied, thus eliminating those portions colored with the colors being discarded. By “referencing” the image to a data base, the user can obtain similar, identified images to aid the user in interpretation of the image being studied. The Company filed four US patent applications in June of 2007, each of which received USPTO office actions during 2010 and 2011.  As Revolutions Medical continues to improve and enhance its proprietary software capabilities, and as new information and technologies advance with the imaging market, the Company is ready to protect and preserve its technology by filing additional patents, copyrighting, and other protection measures.

The Company has launched sales of its 3ml RevVac™ safety syringe and recorded revenue in 2012 of $1,189 from the sale of syringes.  These sales have been made primarily to distributors the Company has contracted for use in product demonstrations.  Through increased sales orders, the Company hopes to have enough capital to meets its financial needs in 2013.

Principal Markets

Our 3ml RevVac™ safety syringe is currently being marketed to healthcare providers in the U.S. and internationally which include, but are not limited to, acute care hospitals, alternate care facilities, doctors’ offices, clinics, emergency centers, surgical centers, convalescent hospitals, Veterans Administration facilities, military organizations, public health facilities, and prisons.

The syringe and needle device market continues to be a market in transition.  The nature of the products comprising the market is gradually changing from standard to safety devices.  The impetus for the change to safety devices is the risk that is carried with each needlestick injury which includes the transmission of over 20 blood borne pathogens, including the human immunodeficiency virus (“HIV,” which causes AIDS), hepatitis B, and hepatitis C.  Because of the occupational and public health hazards posed by conventional disposable syringes, public health policy makers, domestic organizations, and government agencies have been involved in the effort to get more effective safety needle products to healthcare workers.  Federal legislation was signed into law on November 6, 2000, by former President William Jefferson Clinton.  This legislation, which became effective for most states on April 12, 2001, now requires safety needle products be used for the vast majority of procedures.  However, even with this requirement, hospitals are slow to follow the law intended to protect healthcare workers.
 
 
6
 

Distribution Method of Products and Services

In the U.S., the vast majority of decisions relating to the contracting for and purchasing of medical supplies are made by the representatives of group purchasing organizations (“GPOs”) rather than the end-users of the product (nurses, doctors, and testing personnel). GPOs and manufacturers often enter into long-term exclusive contracts which can prohibit entry in the marketplace by competitors. In the needle and syringe market, the market share leader, Becton-Dickinson, has utilized, among other things, long-term exclusive contracts which have restricted entry into the market by most of our competitors. The Company has been in direct communication and has shown samples of its RevVac™ safety syringes to many GPOs. We believe that we have a superior product compared to the competition which would allow us to penetrate the market. However, we may not be successful in obtaining any contracts with GPOs, which would severely limit our product’s marketability in the United States. See “RISK FACTORS.”

We presently have our 3ml RevVac™ safety syringe for sale and expect to have additional products for sale in 2013.  The Company has signed a sales and marketing contract with MedPro Associates, Inc. (MedPro) in October 2012. MedPro has 30 sales representatives throughout the United States who act as an extension of Revolutions Medical sales force. MedPro is responsible for selling the RevVac™ safety syringe line of products primarily to the long term care market and to provide in servicing and marketing support to other distributors and customers.

In November 2012, Revolutions Medical signed a distribution agreement with McKesson, Inc. for the RevVac™ safety syringe line of products.  All current sizes and gauges are listed in the McKesson catalog so customers can easily order product directly through the McKesson sales and distribution ordering system.   A stocking order for inventory was placed and delivered by Revolutions Medical and a new sales initiative program was began in February 2013. McKesson has over 600 sales representatives in the United States and completed its merger with PSS WorldMed in March 2013, bringing its new total to over 1.300 sales representatives.

The Company believes with its sales and distribution relationships with McKesson and MedPro, it is strategically positioned for future growth in market share in the United States for its RevVac™ safety syringe product line.

In 2012, the Company has signed international non- exclusive distribution agreements with several firms, together covering the countries of Israel, Mexico, Malaysia, Brazil, Puerto Rico, Caribbean. Virgin Islands, Qatar, Thailand, and South Korea. The Company believes it will continue to sign new international distribution agreements as the RevVac™ safety syringe product line gets introduced to more markets.

Status of Planned Products

The RevVac™ safety syringe uses vacuum technology to retract the needle into the plunger immediately after use. The syringe cannot be reused once the vacuum is activated. The Company believes its safety syringe has many advantages over its competition including price, ease of use, and safety. We believe that it will help reduce accidental needle stick injuries and also aid in reducing the spread of contagious diseases. The Company also believes that, with the help of government regulation initiatives, individual state laws, and the importance of world health concerns, the safety syringe market will continue to have substantial growth into the foreseeable future. The Company expects to launch sales of its RevVac™ safety syringe in the 1ml size, including insulin and tuberculin syringes, along with the 5ml and 10ml sizes, in 2013.

The Company is currently working on developing, enhancing and securing its proprietary MRI software tools for commercial launch.  The Company believes that once clinical application validations using its MRI software suite of products including RevColor™, RevDisplay™ and Rev3D™ directed at concussions, stroke, Alzheimer’s and breast disease are achieved, it will eventually aid in the enhanced diagnosis, detection, and monitoring of such diseases and afflictions.

When an MRI is taken, the black and white images are sent to a picture archiving and communication system (“PACS”), which displays the images for a radiologist to view. By using high speed internet, these images can be securely sent to the Company’s secure website, after a secure account is opened. This process is called teleradiology. For a nominal fee the Company will use its proprietary software, based upon specific parameters and information provided, and sends back the images in enhanced color and sorted in correct sequence along with the original black and white images in a matter of minutes.
 
 
7
 

Competitive Business Conditions, Competitive Position and Methods of Competition

The safety medical device market is highly competitive. The leading manufacturers and marketers of safety medical devices are Becton-Dickinson, Covidien (Kendall Healthcare Products Company), B. Braun, Terumo Medical Corporation of Japan, Smith Medical, and Johnson & Johnson. Developers of safety medical devices, which we compete against for license and collaborative arrangements with medical device and pharmaceutical companies, include Med-Design Corporation, New Medical Technologies, Retractable Technologies, Inc., Unilife, Inc. and Specialized Health Products International. Our competitors have substantially greater assets, technical staffs, established market shares, and greater financial and operating resources than we do. There is no assurance that we can successfully compete.

Traditionally, competition regarding non-safety medical devices was primarily based upon price with little differentiation between products. We expect our products to compete against both safety products and non-safety products based upon safety and ease of use and disposal. Most of the safety medical devices we will compete with are priced substantially above the cost of non-safety products. Market demand for safety devices is being driven by the estimated costs associated with accidental needle sticks and by government mandates.

We compete primarily on the basis of product performance and quality.  We believe our competitive advantages include, but are not limited to, our superior design and innovation. We believe the RevVac™ safety syringe to be the most effective safety syringe on the market.  Our syringe products include passive safety activation, require less disposal space, and are activated while in the patient, virtually eliminating exposure to the contaminated needle.  Our price per unit is competitive or even lower than the competition once all the costs incurred during the life cycle of a syringe are considered. Such life cycle costs include disposal costs, testing and treatment costs for accidental needlestick injuries, and treatment for contracted illnesses through accidental needlestick injuries.  With our unique design, the disposal costs can be drastically reduced by requiring, in certain situations, just the plunger with the retracted needle to be disposed of in a sharps container. This dramatically cuts the disposal costs compared to other safety syringes on the market that require the entire syringe to be disposed of in a sharps container.
 
We have several major competitors including BD and Covidien Ltd. (“Covidien”) domestically and Terumo Medical Corp. (“Terumo”), and B. Braun internationally.

Included as safety-engineered devices manufactured by BD are the SafetyLok™, a syringe that utilizes a tubular plastic sheath that must be manually slid over the needle after an injection, and the SafetyGlide™, a needle which utilizes a hinged lever to cover the needle tip.  BD also manufactured the Integra 3mL retracting needle product based on a license agreement with Specialized Health Products International, Inc. (formerly the Med-Design Corporation).  Terumo manufactures conventional and auto-disable syringes and operates internationally with sales in more than 150 countries.

Both BD’s SafetyLok™ and Covidien’s Monoject® safety syringes require the use of two hands and several extra steps to activate the tubular plastic shield which must be slid and locked into place to protect the needle.  These products must be removed from the patient prior to activation, resulting in exposure to the contaminated needle.  In contrast, use of the RevVac™ syringe is identical to that of a standard syringe until the end of an injection, when the automated vacuum retraction mechanism retracts the needle directly from the patient safely into the barrel of the syringe.  This allows both hands to remain safely out of harm’s way.

Our safety syringe products have an advantage over non-retracting safety syringes because minimal training and changes to practitioners’ normal routines are required.  Use of our products also prohibits unfortunate and improper reuse.  Several factors could materially and beneficially affect the marketability of our products.  Demand could be increased by existing legislation and other legislative and investigative efforts.  Licensing agreements could provide entry into new markets and generate additional revenue.
 
 
8
 

Sources of Raw Materials and the Names of Principal Suppliers

On December 1, 2011, the Company entered into an International Manufacturing Agreement (the “Yeso-med Agreement”) with Yeso-med. The term of the Yeso-med Agreement is for a period of sixty (60) months commencing on the Effective Date (the “Term”). Pursuant to the Yeso-med Agreement, during the Term, Yeso-med will serve as the Company’s exclusive manufacturer in China of the Company’s RevVac™ safety syringes, including the 1ml, 3ml, 5ml and 10ml sizes. The Company is also pursuing manufacturing capabilities outside of China as market demand increases and the need for more supply grows.

The Company is obligated under the terms of the Yeso-med Agreement to place a minimum of 2,500,000 units per month.  Since its initial order the Company has not met this obligation.  As market conditions and demand improves, the Yeso-med Agreement provides for the Company to satisfy this obligation through orders of additional units. In reaction to the high market demand for the 1ml RevVac™ safety syringe, including insulin and tuberculin, and the possibility of increased sales of the whole product line, both parties are negotiating an acceleration of the production of the 1ml size and the granting of limited licensing and distribution rights in China and other countries. The parties are negotiating an amendment to the Yeso-med agreement to allow both parties more opportunity for success.

Dependence on One or Few Major Customers

We anticipate that our safety syringe will be marketed to the entire field of medical professionals. We do not anticipate being dependent on any particular customer, however, at this time we cannot know if any one customer will account for more than 1% of our anticipated safety syringe sales.

Patents, Trademarks, Licenses, Royalty Agreements or Labor Contracts

Our success depends in part on our ability to maintain proprietary protection surrounding our product candidates, technology and know-how; to operate without infringing the proprietary rights of others; and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by filing U.S. and foreign patent applications related to our proprietary technology, including both new inventions and improvements of existing technology, that are important to the development of our business, unless this proprietary position would be better protected using trade secrets.

Our patent strategy includes obtaining patent protection, where possible, on compositions of design, methods of manufacture and methods of use. We also rely on trade secrets, know-how, continuing technological innovation, in-licensing and partnership opportunities to develop and maintain our proprietary position.

Reflecting our commitment to safeguarding proprietary information, we require our employees and consultants to sign confidentiality agreements.  Furthermore, we enter into research agreements in which we exchange proprietary materials and information with collaborators including material transfer agreements, research agreements, development agreements and clinical trial agreements.  These agreements prohibit unauthorized disclosure of our proprietary information.   To the extent that our consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems.

Even though we employ a number of safeguards to protect our proprietary information, including confidentiality agreements and implementation of physical security and electronic security of information technology systems, we cannot be assured that our proprietary information is protected. Despite our efforts to protect our proprietary information, unauthorized parties may attempt to obtain and use our proprietary information.  Policing unauthorized use of our proprietary information is difficult and the steps we have taken might not prevent misappropriation, particularly in foreign countries where the laws may not protect our proprietary rights as fully as do the laws of the U.S.

In some cases, litigation or other proceedings may be necessary to enforce our patents or protect our know-how or other intellectual property rights.  Any additional potential litigation is likely to result in a substantial cost to us and a diversion of our resources.  We cannot be sure that any of our patents will ultimately be held valid.  An adverse outcome in any litigation or proceeding could subject us to significant liability.
 
 
9
 

We focus special attention on filing patent applications for formulations and delivery regimens for our products in development to further enhance our patent exclusivity for those products. We seek to protect our proprietary technology and processes, in part, by contracting with our employees, collaborators, scientific advisors and our commercial consultants to ensure that any inventions resulting from the relationship are disclosed promptly, maintained in confidence until a patent application is filed and preferably until publication of the patent application, and assigned to us or subject to a right to obtain a license.
  
We do not know whether any of our own patent applications will result in the issuance of any patents. Furthermore, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that any related patent may expire prior to or shortly after commencing commercialization, thereby reducing the advantage of the patent to our business and products.
 
As part of our product development, we have filed or may file patent applications related to new product designs and production methods in the U.S. and in many of the major international markets.

Individual patents extend for varying time periods depending on the effective date of filing the patent application or the date of patent issuance, and the legal term of the patents in the countries in which they are obtained. Generally, patents issued in the U.S. are effective for:

 
·
The longer of 17 years from the issue date or 20 years from the earliest effective filing date, if the patent application was filed prior to June 8, 1995; or
 
 
·
20 years from the earliest effective filing date, if the patent application was filed on or after June 8, 1995.
 
The term of foreign patents varies in accordance with provisions of applicable local law, but typically is 20 years from the earliest effective filing date.

In September 2005, we filed an additional patent on our RevVac™ safety syringe under a joint venture agreement with Globe Med Tech which gives a 50% ownership of this patent to the Company and 50% to Globe Med Tech. The Company filed a lawsuit to rescind, terminate and seek monetary damages for the non-fulfillment and breach of the joint venture agreement and other related agreements with Globe Med Tech in March 2007, in addition to an accounting of expenditures of funds under the terms and provisions of the agreements and to give 100% ownership back to the Company (see Item 3 - Legal Proceedings and “RISK FACTORS”). This patent was issued January 13, 2009. A summary judgment hearing was held in May, 2011, in Tulsa, OK. On August 15, 2011, the District Court of Tulsa County, State of Oklahoma granted Revolutions Medical summary judgment against Globe Medical Tech. On October 21, 2011, Revolutions Medical received journal entry of judgment. The Court requires Globe Med Tech to pay to Revolutions Medical the sum of $311,440, the return of all syringes, design files and sample molds, the return of 266,667 shares of common stock, to assign all rights to the January 2009 issued patent number 11/115,446 and to cease and be prohibited from claiming any interest or ownership to the RevVac™ auto-retractable vacuum safety syringe.  Globe Med Tech’s appeal was denied on December 13, 2011.  On January 30, 2013 the court ruled a Nunc Pro Tunc judgment dismissing all third party and counterclaims by Globe Med Tech. Globe Med Tech is appealing that decision. Revolutions Medical is executing its rights under the judgment against Globe Med Tech to seek all relief and damages.

 
·
RMCP SAFETY SYRINGE PATENTS. A U.S. patent covering our retractable safety syringe design was published on January 28, 2005. This patent will expire on April 9, 2023. The Company has filed applications for foreign patent protection for the following countries: Canada, Mexico, Taiwan, Japan, China, Australia, and in Europe. An international patent has been issued in Mexico, Japan and China. See “RISK FACTORS.”

 
·
RMCP BLOOD SAMPLING DEVICE PATENT. A U.S. patent covering the Company’s blood sampling device was published on April 10, 2003. The Company has not filed any applications for foreign patent protection. See “RISK FACTORS.”
 
 
10
 
 
 
·
The Company filed a provisional patent with the U.S. Patent and Trademark Office on May 3, 2011 and  on May 2, 2012 filed an international provisional PCT patent  These provisional patents provide additional protection for the Company’s auto-retractable vacuum technology for use with prefilled designs.

 
·
PATENT APPLICATIONS FOR COLOR AND 3D MRI SOFTWARE TECHNOLOGY. In June 2007, the Company filed four patent applications with the USPTO related to the Color and 3D MRI technology, none of which has yet been published. The Company also filed an application for foreign patent protection in Europe. All of these patent applications received office actions in 2010 and 2011 requiring the Company to provide more information to the issuing authorities. Although the Company continues to supplement information, there is no assurance that any of the patent applications will be issued or that any patent protection for the Color MRI technology can or will be obtained. See “RISK FACTORS.”

In November 2010, the Company filed a trademark on its logo and several word marks for its product line which include: RevColor™, RevDisplay™, Rev3D™, RevScan™ and RevVac™.

On December 31, 2010, the Company completed a reworking of a worldwide exclusive license with Traxsys, LLC, for a guided navigational Breast Biopsy System (BBS). This BBS facilitates accurate and fast non-palpable lesions and micro calcification localization in the treatment of breast cancer. The BBS localization needle can be modified to use the Company’s proprietary RevVac™ safety syringe technology. Additionally, one of the patents covering the stabilization technology could be used to further enhance the Company's MRI software tools by providing for a proprietary platform for image fusion between MRI and X-Ray. This technology has already received 510(k) clearance from the FDA. After a full due diligence review of the technology, the Company sees a potential synergy between its proprietary MRI software tools and this technology for breast imaging. However, the Company has decided not to invest additional capital at this time and to focus its resources on its RevVac™ safety syringe line of products and applications for its MRI software technology. In the future, the Company could re-license this technology for future products.
 
Need for Governmental Approval

Pursuant to the Federal Food, Drug and Cosmetic Act, the FDA regulates the research, design, testing, manufacture, safety, labeling, storage, record keeping, advertising and promotion, distribution, and production of medical devices in the United States.  The Company’s safety needle devices are considered to be medical devices, are subject to FDA regulation, and must receive FDA approval prior to sale in the United States.

Medical devices are classified into one of three classes, depending on the controls deemed by FDA to be necessary to reasonably ensure their safety and effectiveness. Class I devices are subject to general controls (e.g. labeling, pre-market notification and adherence to Quality System regulations, which have replaced Good Manufacturing Practice regulations.) These devices are subject to the lowest level of regulatory control. Class II devices are subject to general controls and to special controls (e.g. performance standards, post-market surveillance, patient registries, and FDA guidelines). Generally, Class III devices are those that must receive pre-market approval by the FDA to ensure their safety and effectiveness, and require clinical testing and FDA approval prior to marketing and distribution. Class III devices are the most rigorously regulated.

Generally, before a new device can be introduced into the market in the United States, the manufacturer must obtain FDA clearance through a 510(k) pre-market notification or approval of a premarket approval (“PMA”) application. If a medical device manufacturer can establish that a device is “substantially equivalent” to a legally marketed Class I, Class II device, or a Class III device for which FDA has not called for PMAs, the manufacturer may seek clearance from FDA to market the device by filing a 510(k) pre-market notification. The 510(k) pre-market notification will need to be supported by appropriate data establishing the claim of substantial equivalence to the satisfaction of the FDA.

If the Company or its collaborative partners cannot establish that the Company’s safety needle devices are substantially equivalent to legally marketed predicate devices, pre-market approval of the device through submission of a PMA application must be obtained.  A PMA application must be supported by valid scientific evidence, including pre-clinical and clinical trial data, as well as extensive literature to demonstrate a reasonable assurance of the safety and effectiveness of the device.  The PMA represents the most rigorous form of FDA regulatory approval.
 
 
11
 

The Medical Device User Fee and Modernization Act, enacted in 2002, authorizes the FDA to assess and collect review fees for Section 510(k) pre-market notifications and pre-market approval applications filed on or after October 1, 2002. Fees for fiscal year 2007 for small businesses (companies with less than $100 million in sales) range from $3,326 for Section 510(k) pre-market notifications to $107,008 for PMAs, although fee reductions and waivers are available for companies qualifying as small businesses.

There is no assurance that any of our other planned products will qualify for the 510(k) pre-market notification approval process or that the Company will have the funds necessary to seek FDA approval. There is no assurance that any of our other planned products will obtain FDA approval.

If FDA approval is received on future planned products, however, then the Company and/or its collaborative partner (relating to manufacturing and marketing) would also be required to comply with FDA post-market reporting requirements, including the submission of reports on certain adverse events and malfunctions, and requirements governing the promotion of medical devices. In addition, modifications to our devices may require the filing of new 510(k) submissions or pre-market approval supplements, and we will need to comply with FDA regulations governing medical device manufacturing practices. The FDA requires medical device manufacturers to register as such and subjects them to periodic FDA inspections of their manufacturing facilities. The FDA requires that medical device manufacturers produce devices in accordance with the FDA’s current Quality System Regulation (QSR), which governs the methods, facilities and controls used for the design, manufacture, testing, packaging, labeling and storage of medical devices.

There is a different set of regulatory requirements in place for the European Union (EU). In the EU, a company putting a medical device onto the market must comply with the requirements of the Medical Devices Directive (MDD) and affix the CE mark to the product to attest to such compliance. To achieve this, the medical devices in question must meet the “essential requirements” defined under the MDD relating to safety and performance, and the relevant company must successfully undergo a verification of its regulatory compliance by a third party standards certification provider, known as a “Notified Body.” The nature of the assessment will depend on the regulatory class of products concerned, which in turn determines the precise form of testing to be undertaken by the Notified Body.

The requirements of the MDD must be complied with by the “manufacturer of the device,” which is defined as the party responsible for the design, manufacture, packaging and labeling of the device before it is placed on the EU market, regardless of whether these operations are carried out by this entity or on its behalf.

Accordingly, where medical devices are marketed by our potential licensees or by collaborative partners under their names, compliance with the MDD will be their responsibility. In the event that we decide to manufacture devices to be distributed in the EU market under our name, all compliance responsibilities will be borne by us.

There may be numerous other approvals needed before our products can be sold in countries other than the United States or the European Union. There is no assurance that the Company or its collaborative partners, if any, will be successful in obtaining such approvals.

Effect of Existing or Probable Governmental Regulation

The World Health Organization estimates that 1.3 million people die each year as a result of unsafe injection practices, which can include syringe re-use and needlestick injuries. Unsafe injection practices result in the transmission of a number of blood-borne diseases such as HIV/AIDS and hepatitis C. The U.S. Centers for Disease Control and Prevention estimates that 385,000 needlestick and other sharps-related injuries are sustained by U.S. hospital-based healthcare personnel each year. The U.S. Occupational Safety and Health Administration, or OSHA, estimates that when other secondary healthcare settings are also taken into account, there are as many as 800,000 needlestick injuries to U.S. healthcare workers each year. To help minimize the transmission of blood-borne pathogens caused by unsafe injection practices, many international healthcare and pharmaceutical markets are transitioning to the mandatory use of safety syringes.
 
 
12
 
 
In many sophisticated healthcare markets, governments are focused on the mandatory use of safety devices within healthcare facilities to protect healthcare workers from the risk of acquiring blood-borne pathogens via needlestick injuries. Regulatory actions at the federal and state level promote the use of safety needles to reduce the risk of accidental needle sticks. On July 1, 1999, California, through its state Occupational Safety and Health Administration (OSHA) program, began requiring the use of safety needles. Other states such as Texas, Tennessee, Maryland and New Jersey have passed similar legislation.

On November 6, 2000, President Clinton signed the Needle Stick Safety and Prevention Act amending OSHA’s Blood Borne Pathogens Standard to require that employers implement the use of safer medical devices in their facilities. To implement the statutory mandates in the Needle stick Safety and Prevention Act, OSHA has issued a number of further revisions to its Blood borne Pathogens Standard. The revised standard became effective on April 18, 2001. The new standard provisions impose several needle device safety requirements on employers, including:

 
·
evaluation and implementation of safer needle devices as part of the re-evaluation of appropriate engineering controls during an employer’s annual review of its exposure control plan;

 
·
documentation of the involvement of non-managerial, frontline employees in choosing safer needle devices; and

 
·
establishment and maintenance of a sharps injury log for recording injuries from contaminated sharps.

On November 27, 2001, OSHA issued a compliance directive (CPL 2-2.69) that advises OSHA’s regional offices on the proper interpretation and enforcement of the revised Blood borne Pathogens Standard provisions. The compliance directive confirms that the consideration of safer needle devices, in annually reviewing and updating the exposure control plan, is a critical element of the Blood borne Pathogens Standard. The directive also stresses that the standard requires employers to use engineering controls (e.g., safer needle devices) if such controls will remove or eliminate the hazards to employees.

OSHA differentiates safety features in two primary ways. First, it differentiates passive safety features which “remain in effect before, during and after use” from active devices which “require the worker to activate the safety mechanism.” Second, OSHA regulations state that products with an “integrated safety design that is an integral part of the device and cannot be removed” are usually preferred to those with an accessory safety device with safety features that are “external” and “dependent on employee compliance.” We believe the majority of safety syringe products used in U.S. healthcare facilities incorporate active safety features which are not fully integrated within the barrel of the syringe.
 
The European Union has also introduced a directive in March 2010 requiring member countries to introduce laws within three years requiring the use of needlestick prevention products within healthcare facilities. On May 11, 2013 the European Union's new legislation regarding the use of safety syringes will go into effect. Other countries such as Canada, Brazil and Australia have also taken steps to encourage the use of safety syringes. As a result of this existing and proposed legislation, safety syringes are now commonly used within the healthcare facilities in a number of countries.  As a result of these regulatory actions, we anticipate that the demand for safety medical devices such as those we have designed and are designing will continue to increase for the foreseeable future.

Amount Spent on Research and Development

Research and development expenses were $35,544 and $57,000 in 2012 and 2011, respectively.

Costs and effects of environmental compliance

The Company has not spent any sums on environmental compliance and does not expect to be required to spend any sums on environmental compliance in the future, unless the Company chooses to become a manufacturer of its own products. All environmental costs would be borne by the contract manufacturer.
 
 
13
 

Number of total employees and number of full time employees

We presently have four full-time employees.  Services such as product design and development and sales consulting are provided by third parties on a contract basis. Consequently, developing our business may require a greater period of time than if we had full time employees.

Our success depends in large measure on our ability to attract and retain capable executive officers and highly skilled employees who are in great demand.  None of our employees are represented by a labor union and we believe that our relations with our employees are generally good. Generally, our employees are at-will employees.  However, we have entered into employment agreements with certain of our executive officers.

Available information

We file electronically with the U.S. Securities and Exchange Commission (SEC) our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934. We make available on our website at http://www.revolutionsmedical.com, free of charge, copies of these reports as soon as reasonably practicable after filing these reports with, or furnishing them to, the SEC.  The public can also obtain materials that we file with the SEC through the SEC’s website at http://www.sec.gov or at the SEC’s Public Reference Room at 100 F Street, NE, Washington, DC 20549.  Information on the operation of the Public Reference Room is available by calling the SEC at 800-SEC-0330.

Item 1A.  Risk Factors.

You should carefully consider the risks described below, together with all of the other information included in this report, in considering our business and prospects.  The risks and uncertainties described below are not the only ones facing the Company.  Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.  The occurrence of any of the following risks could harm our business, financial condition or results of operations.

Risks Related to the Our Business and Industry

WE REQUIRE SUBSTANTIAL ADDITIONAL CAPITAL TO CONTINUE DEVELOPING OUR PLANNED PRODUCTS. WE MAY HAVE DIFFICULTY RAISING CAPITAL WHEN WE NEED IT, OR AT ALL. RAISING SUCH CAPITAL MAY DILUTE STOCKHOLDER VALUE. IF WE ARE UNABLE TO RAISE CAPITAL, WE MAY BE REQUIRED TO LIMIT OR CEASE OUR OPERATIONS, OR OTHERWISE MODIFY OUR BUSINESS STRATEGY.

We will require substantial additional capital thereafter to commercialize our planned products. Our commercialization efforts will include, but are not limited to, entering into agreements with third parties for manufacturing (including building molds, designing manufacturing processes and obtaining specialized equipment for our retractable safety syringe), marketing and distribution, and obtaining FDA and/or other regulatory approvals, all of which are necessary before our planned products can be sold and which may take a significant amount of time, if not years, to complete.

Due to the current economic conditions and the risks and uncertainties surrounding our Company, we may not be able to secure additional financing on acceptable terms, if at all.  Our estimated working capital requirement for the next 12 months is $2,700,000 with an estimated burn rate of $190,000 per month.  In order to implement our business plan and meet our liquidity needs going forward, the Company may sell shares of its common stock, issue additional convertible debt notes or permit warrant exercises.  If we implement any of the foregoing financing alternatives to pay current or future obligations, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution, or the equity securities may have rights preferences or privileges senior to the common stock. To the extent that services are paid for with common stock or stock options that are exercised and sold into the market, the market price of our common stock could decline and your ownership interest will be diluted.  If adequate funds are not available to us when needed on satisfactory terms, we may be required to cease operating or otherwise modify our business strategy.
 
 
14
 

IF WE DO NOT OBTAIN FDA APPROVAL FOR OUR FUTURE PLANNED PRODUCTS THEN OUR FUTURE PROSPECTS WILL BE HARMED.

Our future planned products may require FDA approval before they can be sold in the United States. There are some planned products for which we have not yet applied for or received FDA approval. However, we have received FDA 510(k) clearance on our 3ml RevVac™ safety syringe.  Our RevColor™ and Rev3D™ MRI software technology does not require FDA approval for educational and research purposes, however, future applications may require 510(k) clearance.  There is no assurance that our other planned products will qualify for the FDA’s 510(k) pre-market notification approval process. The FDA approval process can take years and be expensive, especially if a pre-market approval (PMA) is required. A PMA is much more rigorous and expensive to complete than a 510(k). In addition, the Medical Device User Fee and Modernization Act, enacted in 2002, allows the FDA to assess and collect user fees for 510(k) and for PMA applications. There is no assurance that we will qualify for fee reductions or waivers or that we will have the funds necessary to apply for or obtain FDA approval for our planned products. The FDA approval process could take a significant amount of time, if not years, to complete and there is no assurance that FDA approval will ever be obtained. If FDA approval is not obtained, then we will not be able to sell our future planned products in the United States, which would have a material adverse effect on our future business prospects.
 
OUR PLANNED PRODUCTS MAY PROVE TO BE TOO EXPENSIVE TO MANUFACTURE AND MARKET SUCCESSFULLY, WHICH WOULD HARM OUR FUTURE PROSPECTS.

Our planned products may prove to be too expensive to manufacture and market successfully. Market acceptance of our products will depend in large part upon our ability to demonstrate the operational and safety advantages of our product as well as the cost effectiveness of our product compared to both standard and other safety needle products. If we are unable to produce products that are competitive with standard products, we will not be able to sell our products. This could have a material adverse effect on our operations.

IF WE ARE NOT ABLE TO ESTABLISH MARKETING, SALES AND DISTRIBUTION ARRANGEMENTS FOR OUR SAFETY SYRINGES, THEN OUR FUTURE PROSPECTS WILL BE HARMED.

If we do not enter into successful relationships with third parties to market, sell and distribute our planned products, we will need to develop our own such capabilities. If we choose to establish a direct sales force, we will incur substantial additional expenses in developing, training and managing such an organization. We may not be able to build a sales force on a cost effective basis or at all. Any such direct marketing and sales efforts may prove to be unsuccessful. In addition, we will compete with many other companies that currently have extensive and well-funded marketing and sales operations. Our marketing and sales efforts may be unable to compete against these other companies. We may be unable to engage qualified distributors. Even if engaged, they may fail to satisfy financial or contractual obligations to us. They may fail to adequately market our products. They may cease operations with little or no notice to us or they may offer, design, manufacture or promote competing products.

IF WE ARE UNABLE TO PROTECT OUR FUTURE PLANNED PRODUCTS, OR TO AVOID INFRINGING ON THE RIGHTS OF OTHERS, OUR ABILITY TO COMPETE WILL BE IMPAIRED.

Our commercial success depends in part on our avoiding the infringement of patents and proprietary rights of other parties and developing and maintaining a proprietary position with regard to our own technologies and products. We cannot predict with certainty whether we will be able to enforce our patents. Patents that may be issued, or publications or other actions could block our ability to obtain patents or to operate as we would like. Others may develop similar technologies or duplicate technologies that we have developed or claim that we are infringing their patents.

Although we rely on trade secrets to protect our technology and require certain parties to execute nondisclosure and non-competition agreements, these agreements could be breached, and our remedies for breach may be inadequate. In addition, our trade secrets may otherwise become known or independently discovered by our competitors. If we lose any of our trade secrets, our business and ability to compete could be harmed.
 
 
15
 

Despite our efforts to protect our proprietary rights, we face the risks that pending patent applications may not be issued, that patents issued to us may be challenged, invalidated or circumvented; that unauthorized parties may obtain and use information that we regard as proprietary; that intellectual property laws may not protect our intellectual property; and effective protection of intellectual property rights may be limited or unavailable in China, where we plan to manufacture our retractable safety syringe, or in other foreign countries where we may manufacture and/or sell our retractable safety needle devices. The lack of adequate remedies and impartiality under any foreign legal system may adversely impact our ability to protect our intellectual property.

We may become involved in litigation or interference proceedings declared by the U.S. Patent and Trademark Office, or oppositions or other intellectual property proceedings outside of the United States. If any of our competitors have filed patent applications or obtained patents that claim inventions that we also claim, we may have to participate in an interference proceeding to determine who has the right to a patent for these inventions in the United States. If a litigation or interference proceeding is initiated, we may have to spend significant amounts of time and money to defend our intellectual property rights or to defend against infringement claims of others. Litigation or interference proceedings could divert our management’s time and effort. Even unsuccessful claims against us could result in significant legal fees and other expenses, diversion of management time and disruption in our business. Any of these events could harm our ability to compete and adversely affect our business.

An adverse ruling arising out of any intellectual property dispute could invalidate or diminish our intellectual property position. An adverse ruling could also subject us to significant liability for damages, prevent us from using processes or products, or require us to license intellectual property from third parties. Costs associated with licensing arrangements entered into to resolve litigation or an interference proceeding may be substantial and could include ongoing royalties. We may not be able to obtain any necessary licenses on satisfactory terms or at all.
 
WE MUST OBTAIN REGULATORY APPROVALS IN FOREIGN JURISDICTIONS TO MARKET OUR PRODUCTS ABROAD.

Whether or not FDA approval has been obtained, we must secure approval for our future planned products by the comparable non-U.S. regulatory authorities prior to the commencement of marketing of the product in a foreign country. The process of obtaining these approvals will be time consuming and costly. The approval process varies from country to country and the time needed to secure additional approvals may be longer than that required for FDA approval. These applications may require the completion of pre-clinical and clinical studies and disclosure of information relating to manufacturing and controls. Unanticipated changes in existing regulations or the adoption of new regulations could affect the manufacture and marketing of our products.

IF WE ARE NOT ABLE TO COMPETE SUCCESSFULLY, THEN OUR BUSINESS PROSPECTS WILL BE MATERIALLY ADVERSELY AFFECTED.

Our retractable safety syringe competes in the United States and abroad with the safety needle devices and standard non-safety needle devices manufactured and distributed by companies such as Becton Dickinson (BD), Covidien, (Kendall Healthcare Products Company), B. Braun, Terumo Medical Corporation of Japan, Smith Medical, and Johnson & Johnson. Developers of safety needle devices against which we could compete include Med-Design Corp., New Medical Technologies, Retractable Technologies, Inc., Unilife, Inc. and Specialized Health Products International, Inc. Our MRI software tools, if developed, approved and commercialized, will compete in the United States and abroad against technologies manufactured and distributed by companies such as General Electric and Siemens. Most of our competitors are substantially larger and better financed than we are and have more experience in developing medical devices and/or software than we do. These competitors may use their substantial resources to improve their current products or to develop additional products that may compete more effectively with our planned products, or may render our planned products obsolete. In addition, new competitors may develop products that compete with our planned products, or new technologies may arise that could significantly affect the demand for our planned products. Even if we are successful in bringing our planned products to market, there is no assurance that we can successfully compete. We cannot predict the development of future competitive products or companies.

In the U.S., the vast majority of decisions relating to the contracting for and purchasing of medical supplies are made by the representatives of group purchasing organizations (“GPOs”), rather than the end-users of the product (nurses, doctors, and testing personnel). GPOs and manufacturers often enter into long-term exclusive contracts which can prohibit entry in the marketplace by competitors. In the needle and syringe market, the market share leader, BD, has utilized, among other things, long-term exclusive contracts which have restricted entry into the market by most of our competitors. We may not be successful in developing profitable relationships with GPOs, which would severely limit our product’s marketability in the U.S. We will be materially adversely affected if we are unable to compete successfully.
 
 
16
 

WE RELY ON THIRD PARTIES FOR RESEARCH AND DEVELOPMENT ACTIVITIES NECESSARY TO COMMERCIALIZE OUR PRODUCT.  THIS COULD HAVE A MATERIALLY ADVERSE EFFECT ON OUR FUTURE PROSPECTS.

We do not maintain our own laboratory and we do not employ our own researchers. We have contracted with third parties in the past to conduct research, development and testing activities and we expect to continue to do so in the future. Because we rely on such third parties, we have less direct control over those activities and cannot assure you that the research will be done properly or in a timely manner, or that the results will be reproducible. The cost and time to establish or locate an alternative research and development facility to develop our technology could have a materially adverse effect on our future prospects.

IF WE CANNOT GENERATE ADEQUATE, PROFITABLE SALES OF OUR PLANNED PRODUCTS, WE WILL NOT BE SUCCESSFUL.

In order to succeed, we must develop commercially viable products and sell adequate quantities at a high enough price to generate a profit. We may not accomplish these objectives. Even if we succeed in developing a commercially viable product, a number of factors may affect future sales of our product. These factors include:
 
 
·
Whether physicians, patients and clinicians accept our product as a viable, safe alternative to the standard medical syringe;

 
·
Whether the cost of our product is competitive in the medical marketplace; and

 
·
Whether we successfully contract the manufacture and marketing of the syringe to third parties or develop such capabilities ourselves
 
OUR PLANNED PRODUCTS, IF SUCCESSFULLY COMMERCIALIZED, COULD BE EXPOSED TO SIGNIFICANT PRODUCT LIABILITY CLAIMS WHICH COULD BE TIME CONSUMING AND COSTLY TO DEFEND, DIVERT MANAGEMENT ATTENTION AND ADVERSELY IMPACT OUR ABILITY TO OBTAIN AND MAINTAIN INSURANCE COVERAGE, WHICH COULD JEOPARDIZE OUR LICENSE.

The testing, manufacture, marketing and sale of our planned products will involve an inherent risk that product liability claims will be asserted against us. We currently have an insurance policy in place with the Hartford Insurance Group for coverage of five million dollars per incident; however, this insurance may prove inadequate to cover claims and/or costs related to potential litigation. Even with insurance in place, product liability claims or other claims related to our planned products, regardless of their outcome, could require us to spend significant time and money in litigation or to pay significant settlement amounts or judgments. Any successful product liability or other claim could increase our insurance premiums to the extent that it may prevent us from maintaining adequate liability insurance in the future on commercially desirable or reasonable terms. In addition, product liability coverage in the future may cease to be available in sufficient amounts or at an acceptable cost. Any inability to obtain sufficient insurance coverage at an acceptable cost or otherwise to protect against potential product liability claims could prevent or inhibit the commercialization of our planned product. A product liability claim could also significantly harm our reputation and delay market acceptance of our planned products.

STRINGENT, ONGOING GOVERNMENT REGULATION AND INSPECTION OF OUR PLANNED PRODUCTS COULD LEAD TO DELAYS IN MANUFACTURE, MARKETING AND SALES.

The FDA continues to review products even after they receive FDA approval. Manufacturing and marketing will be subject to ongoing regulation, including compliance with current Good Manufacturing Practices, adverse reporting requirements and the FDA’s general prohibitions against promoting products for unapproved or “off-label” uses. We and any third party manufacturers we may use are also subject to inspection and market surveillance by the FDA for compliance with these and other requirements. Any enforcement action resulting from failure to comply with these requirements could affect the manufacture and marketing of our planned products. In addition, the FDA can withdraw a previously approved product from the market at any time, upon receipt of newly discovered information.
 
 
17
 

UNCERTAINTY OF THIRD-PARTY REIMBURSEMENT COULD AFFECT OUR ABILITY TO SELL OUR PLANNED PRODUCTS AT A PROFIT.

Sales of medical products largely depend on the reimbursement of patients’ medical expenses by governmental healthcare programs and private health insurers. There is no guarantee that governmental healthcare programs or private health insurers will cover the cost of some of our products, if and when they are commercially available, or permit us to sell our products at a high enough price to generate a profit.

OUR LIMITED OPERATING HISTORY MAKES EVALUATING OUR STOCK MORE DIFFICULT.

Since inception in 1996, we have engaged primarily in research and development, technology licensing, and raising capital. This limited history may not be adequate to enable you to fully assess our ability to develop and commercialize our planned products and to achieve market acceptance of our planned products and to respond to competition.

WE HAVE A HISTORY OF LOSSES AND EXPECT FUTURE LOSSES.

We have had annual losses since our inception in 1996. We expect to continue to incur losses until we can sell enough products at prices high enough to generate a profit. As of December 31, 2012, we had accumulated a deficit of $37,938,721. There is no assurance that our planned products will be commercially viable. There is no assurance that we will generate revenue from the sale of our planned products or that we will achieve or maintain profitable operations.
 
To achieve and maintain profitability, we need to generate significant revenues from our existing and future product sales.  Because of the numerous risks and uncertainties associated with medical device development and commercialization, we are unable to predict the extent of any future losses.  We may never successfully commercialize any products, generate significant future revenues or achieve and sustain profitability.

WE HAVE RECEIVED AN AUDIT REPORT WITH A GOING CONCERN DISCLOSURE ON OUR CONSOLIDATED FINANCIAL STATEMENTS.

The continuation of our Company as a going concern is dependent upon our Company attaining and maintaining profitable operations and/or raising additional capital. Our independent registered public accounting firm included, in their audit report on our consolidated financial statements for the year ended December 31, 2012, an explanatory paragraph regarding the substantial doubt about our ability to continue as a going concern. Our consolidated financial statements contain additional note disclosures describing the liquidity condition of the Company. As a result of this uncertainly we may have a more difficult time obtaining necessary financing.

OUR SUCCESS DEPENDS IN LARGE PART ON OUR ABILITY TO SUCCESSFULLY MANUFACTURE OUR PRIMARY PRODUCT, THE REVVAC™ SAFETY SYRINGE, AND ACHIEVE SUBSTANTIAL COMMERCIAL SALES OF THIS PRODUCT TO CUSTOMERS. IF WE EXPERIENCE PROBLEMS OR DELAYS IN MANUFACTURING OR SECURING FAVORABLE AGREEMENTS TO SUPPLY THE REVVAC™ SAFETY SYRINGE TO CUSTOMERS, OUR BUSINESS, INCLUDING OUR ABILITY TO GENERATE SIGNIFICANT REVENUES, WILL BE MATERIALLY AND ADVERSELY AFFECTED.

We have commenced commercial sale of the RevVac™ safety syringe, beginning in the 2nd quarter of 2012. Since the RevVac™ safety syringe is our primary product, any failure or significant delay in successfully commercializing the syringe could materially harm our business and our ability to generate any significant amount of revenues for the foreseeable future. Our ability to generate significant revenues will directly depend on our ability to negotiate successfully one or more supply agreements for the RevVac™ syringe with distributors and to begin supplying substantial quantities of the product under such agreements. We cannot predict with certainty the ability of our distributors to enter into supply agreements for the RevVac™ syringe or what the terms of any such agreements will be. If we are unable to secure favorable supply agreements for the RevVac™ syringe in a timely manner, our ability to generate significant revenues will be materially and adversely affected.
 
 
18
 

OUR RESEARCH AND DEVELOPMENT AND OTHER OPERATING EXPENSES ARE SIGNIFICANT AND WE DO NOT EXPECT TO BE PROFITABLE UNLESS AND UNTIL WE BEGIN TO MANUFACTURE OUR REVVAC SAFETY SYRINGE ON A CONSISTENT BASIS, NEGOTIATE SUPPLY AGREEMENTS WITH DISTRIBUTORS AND ADVANCE COMMERCIAL SALE OF THE REVVAC SAFETY SYRINGE.

We have incurred and will continue to incur significant research and development expenses for other product variants of our technology. We will also incur general and administrative expenses related to increasing our operations, expanding our sales and marketing capabilities, seeking regulatory approvals, and complying with the requirements related to being a public company in the United States. We will not be profitable unless we are successful in developing and commercializing the RevVac™ safety syringe and other new products, obtaining regulatory approvals, and manufacturing, marketing and selling commercial products.

OUR ABILITY TO SUCCESSFULLY MARKET AND SELL OUR SAFETY SYRINGES MAY BE IMPAIRED UNTIL WE ARE ABLE TO OFFER A FULL RANGE OF SAFETY SYRINGES IN SIZES COMMONLY USED IN ACUTE-CARE FACILITIES.

In addition to the 3ml RevVac™ safety syringe, our planned product portfolio will also include the 1ml, 5ml, and 10ml RevVac™ safety syringe sizes. Acute-care hospitals are the largest single healthcare market for clinical syringes. These facilities use a range of clinical syringes, including 1ml, 3ml and 5ml sizes, for the subcutaneous and intramuscular administration of therapeutic drugs and vaccines. We have completed development and secured regulatory approvals only for the marketing and sale of our 3ml RevVac™ safety syringe. While we intend to market the 3ml RevVac™ safety syringe to other healthcare sectors in addition to acute-care facilities, our ability to market and sell our safety syringes successfully may be impaired until we are able to offer clinical syringes in a full range of sizes.
 
OUR SUCCESS WILL DEPEND ON THE FULL COMMERCIALIZATION OF OUR CURRENT PRODUCTS, AND THE DEVELOPMENT AND COMMERCIALIZATION OF OTHER PIPELINE PRODUCTS. THERE CAN BE NO ASSURANCE THAT WE WILL BE SUCCESSFUL IN THESE EFFORTS.

A significant element of our strategy focuses on developing products that deliver greater benefits to pharmaceutical companies, healthcare workers and patients. The development of these products requires significant research and development, clinical evaluations and regulatory approvals. The results of our product development efforts may be affected by a number of factors, including our ability to innovate, develop and manufacture new products, complete clinical trials, obtain regulatory approvals and secure customer orders for these products. In addition, patents attained by others can preclude or delay our commercialization of a product. There can be no assurance that any products now in development, or that we may seek to develop in the future, will achieve technological feasibility, obtain regulatory approval or gain market acceptance.

WE MAY ENCOUNTER DIFFICULTIES MANAGING OUR GROWTH, WHICH COULD MATERIALLY HARM OUR BUSINESS.

We expect to expand our operations and grow our research and development, product development, regulatory, manufacturing, sales, marketing and administrative operations. This expansion has placed, and is expected to continue to place, a significant strain on our management, operational and financial resources. To manage our growth and to develop and commercialize our products, we will be required to improve existing, and implement new, operational and financial systems, procedures and controls and expand, train and manage our growing employee base. In addition, we will need to manage relationships with various manufacturers, suppliers, customers and other organizations. Our ability to manage our operations and growth will require us to improve our operational, financial and management controls, as well as our internal reporting systems and controls. We may not be able to implement such improvements to our management information, disclosure controls and procedures and internal control systems in an efficient and timely manner and may discover deficiencies in existing systems and controls. Our failure to accomplish any of these tasks could materially harm our business.
 
 
19
 

WE DEPEND ON OUR EXECUTIVE OFFICERS AND KEY PERSONNEL AND THE LOSS OF THEM COULD ADVERSELY AFFECT OUR BUSINESS.

Our success depends upon the efforts and abilities of our executive officers and other key personnel, particularly Mr. Rondald Wheet, our Chief Executive Officer, Vincent Olmo, our Chief Operating Officer and Burt Hodges, our Chief Financial Officer to provide strategic direction, manage our operations and maintain a cohesive and stable environment. Although we have employment agreements with Mr. Wheet, Mr. Olmo, Mr. Hodges and other key personnel, as well as incentive compensation plans that provide various economic incentives for them to remain with us, these agreements and incentives may not be sufficient to retain them. Further, the SEC has brought suit against the Company and Mr. Wheet relating to the alleged issuance of misleading press releases, and although the Company and Mr. Wheet are defending against such allegations, the outcome of such lawsuit could result in Mr. Wheet’s separation from the Company.  Our ability to operate successfully and manage our potential future growth also depends significantly upon our ability to attract, retain and motivate highly skilled and qualified personnel. We face intense competition for such personnel, and we may not be able to attract, retain and motivate these individuals. The loss of our executive officers or other key personnel for any reason or our inability to hire, retain and motivate additional qualified personnel in the future could prevent us from sustaining or growing our business. In addition, we have a limited history of operations under our current officers and directors. Our officers have not worked together for an extensive length of time. If for any reason our management members cannot work efficiently as a team, our business will be adversely affected.
 
THE MANUFACTURING FACILITIES OF OUR SUPPLIERS MUST COMPLY WITH APPLICABLE REGULATORY REQUIREMENTS. IF THEY FAIL TO ACHIEVE OR MAINTAIN REGULATORY APPROVAL FOR THESE MANUFACTURING FACILITIES, OUR BUSINESS AND OUR RESULTS OF OPERATIONS WOULD BE HARMED.

Commercialization of our products requires access to, or the development of, manufacturing facilities that meet applicable regulatory standards to manufacture a sufficient supply of our products. In addition, the FDA must approve facilities that manufacture our products for U.S. commercial purposes, as well as the manufacturing processes and specifications for the product. Suppliers of components of, and products used to manufacture, our products must also comply with FDA and foreign regulatory requirements, which often require significant time, money and record-keeping and quality assurance efforts and subject us and our suppliers to potential regulatory inspections and stoppages. If our suppliers do not achieve or maintain required regulatory approval for our manufacturing operations, our commercialization efforts could be delayed, which would harm our business and our results of operations.

THE COSTS OF RAW MATERIALS HAVE A SIGNIFICANT IMPACT ON THE LEVEL OF EXPENSES THAT WE INCUR. IF THE PRICES OF RAW MATERIALS AND RELATED FACTORS SUCH AS ENERGY PRICES INCREASE, AND WE CANNOT PASS THOSE PRICE INCREASES ON TO OUR CUSTOMERS, OUR RESULTS OF OPERATIONS AND FINANCIAL CONDITION WOULD SUFFER.

We use a number of raw materials including polymer plastics. The prices of many of these raw materials, such as those sourced from petroleum-based raw materials, are cyclical and volatile. While we would generally attempt to pass along increased costs to our customers in the form of sales price increases, we might not be able to do so, for competitive or contract-related reasons or otherwise. If we are not able to set our prices to reflect the costs of our raw materials, our results of operations and our financial condition could suffer.
 
DISRUPTIONS IN THE SUPPLY OF KEY RAW MATERIALS AND DIFFICULTIES IN THE SUPPLIER QUALIFICATION PROCESS COULD ADVERSELY IMPACT OUR OPERATIONS.

We employ a supply chain management strategy which seeks to source components and materials from a number of established third party companies. Where possible, we seek to establish dual contracts for the supply of particular components or services. However, there is a risk that our supply lines may be interrupted in the event of a supplier production problem, material recall or financial difficulties. If one of our suppliers is unable to supply materials required for production of our products or our strategies for managing these risks are unsuccessful, we may be unable to complete the production of sufficient quantities of product to fulfill customer orders, or complete the qualification of new replacement materials for some programs in time to meet future production requirements. Prolonged disruptions in the supply of any of our key raw materials, difficulty in completing qualification of new sources of supply, or in implementing the use of replacement materials or new sources of supply, could have a material adverse effect on our results of operations, our financial condition or cash flows.
 
 
20
 

SOME COMPANIES WE MAY UTILIZE FOR THE SUPPLY OF COMPONENTS ARE ALSO COMPETITORS, AND THEY COULD ELECT TO CEASE SUPPLY RELATIONSHIPS WITH US IN THE FUTURE FOR COMPETITIVE REASONS.

Some companies we may utilize for the supply of components for the RevVac™ safety syringe also develop and market their own safety products. These companies may elect to cease supply relationships with us in the future for competitive reasons. This may disrupt our supply chain, cause difficulties in the qualification of new sources of supply and impair our ability to supply customer orders. Such events may have a material adverse effect on our results of operations, our financial condition or cash flows.

THE MEDICAL DEVICE INDUSTRY IS VERY COMPETITIVE.

Competition in the medical device industry is intense. We face this competition from a wide range of companies. These include large medical device companies, most of which have greater financial and human resources, distribution channels and sales and marketing capabilities than we do. Our ability to compete effectively depends upon our ability to distinguish our company and our products from our competitors and their products. Factors affecting our competitive position include, for example, product design and performance, product safety, sales, marketing and distribution capabilities, success and timing of new product development and introductions and intellectual property protection.

OUR COMPETITORS HAVE GREATER RESOURCES.

The three leading manufacturers of hypodermic syringes and blood collection products are BD, Covidien, and Terumo. All three companies offer both standard syringes and at least one safety syringe alternative. These competitors have greater financial resources, larger and more established sales and marketing and distribution organizations, and greater market influence, including long-term contracts. These competitors may be able to use these resources to improve their products through research and acquisitions or develop new products, which may compete more effectively with our products. If our competitors choose to use their resources to create products superior to ours, we may be unable to sell our products and our ability to continue operations would be weakened.

WE MAY BE ADVERSELY IMPACTED BY NEXT GENERATION DRUG DELIVERY TECHNOLOGIES.

Much of our potential sales and potential profitability depends to a large extent on the sale of drug products delivered by subcutaneous or intramuscular injection. Other device companies, and pharmaceutical companies, are attempting to develop alternative therapies or drug administration systems such as needle-free or intradermal injection technology for the treatment or prevention of various diseases. The development of new or improved products, processes or technologies by other companies may render our products or proposed products obsolete or less competitive. If the products developed in the future by our customers or potential customers use another delivery system, our sales and potential profitability could suffer. Furthermore, we will be largely reliant upon the receipt of revenues from the sale of the RevVac™ safety syringe and will not have the benefit of diversification.
 
WE MAY FACE SIGNIFICANT UNCERTAINTY IN THE INDUSTRY DUE TO GOVERNMENT HEALTHCARE REFORM.

The healthcare industry in the United States is subject to fundamental changes due to the ongoing healthcare reform and the political, economic and regulatory influences. In March 2010, comprehensive healthcare reform legislation was signed into law in the United States through the passage of the Patient Protection and Affordable Health Care Act and the Health Care and Education Reconciliation Act. Among other initiatives, the legislation provides for a 2.3% annual excise tax on the sale of certain medical devices in the United States, commencing in January 2013. This enacted excise tax may adversely affect our operating expenses and results of operations. In addition, various healthcare reform proposals have also emerged at the state level. We cannot predict with certainty what healthcare initiatives, if any, will be implemented at the state level, or what ultimate effect of federal healthcare reform or any future legislation or regulation may have on us or on our customers’ purchasing decisions regarding our products and services.
 
 
21
 

WE ARE SUBJECT TO REGULATION BY GOVERNMENTS AROUND THE WORLD, AND IF THESE REGULATIONS ARE NOT COMPLIED WITH, EXISTING AND FUTURE OPERATIONS MAY BE CURTAILED, AND WE COULD BE SUBJECT TO LIABILITY.

The design, development, manufacturing, marketing and labeling of our products are subject to regulation by governmental authorities in the United States, Europe and other countries, including the FDA. The regulatory process can result in required modification or withdrawal of existing products and a substantial delay in the introduction of new products. Also, it is possible that regulatory approval may not be obtained for a new product. Our business may be adversely affected by changes in the regulation of drug products and medical devices.

Our target customers are also subject to government regulations for the manufacturing, approval, marketing and labeling of medical products. An effect of the governmental regulation of our customers’ injectable drug products and manufacturing processes is that compliance with regulations makes it costly and time consuming to transition to the use of our devices for existing products, or to secure approval for pipeline products targeted for use with our devices. If regulation of our customers’ products incorporating our devices increases over time, it is likely that this would adversely affect our sales and profitability.

IF OUR PRODUCTS ARE FOUND TO HAVE DEFECTS OR FAIL TO MEET INDUSTRY STANDARDS, WE WILL INCUR SUBSTANTIAL LITIGATION, JUDGMENT, PRODUCT LIABILITY AND PRODUCT RECALL COSTS, WHICH WILL INCREASE OUR LOSSES AND NEGATIVELY AFFECT OUR BRAND NAME REPUTATION AND PRODUCT SALES.

We may be subject to liability for errors that occur with our technologies due to claims of negligence or product malfunction. Pursuant to our manufacturing agreement, the Company has the right to claim reimbursement for damages due to manufacturing defects but will have product liability insurance in place before delivery of its products. We can still suffer litigation as a result of perceived product malfunctioning, adversely affecting our reputation, planned revenue stream and company. Despite purchasing product liability insurance at the industry standard amount, product liability claims could increase our costs and adversely affect our reputation, planned revenues and, ultimately, lead to additional losses. In addition, product defects could result in product recalls and warranty claims. A product recall could delay or halt production of our product until we are able to remedy the product defects. The occurrence of any claims, judgments or product recalls will negatively affect our brand name image and product sales, lead to additional costs, and adversely affect our financial condition and results of operation.

INTELLECTUAL PROPERTY LITIGATION COULD BE COSTLY AND DISRUPTIVE TO US.

The retractable syringe product lines in which we compete are relatively new inventions with numerous companies having patents. In recent years, there have been several patent infringement suits involving other industry participants. To-date, we have not been subject to any such patent infringement suits and also hold freedom to operate reports which we believe indicate that our technology and associated products are substantially different from other known patents. There is no assurance, however, that third parties will not assert any patent, copyright, trademark and other intellectual property rights to technologies used in our business. Any claims, with or without merit, could be time-consuming, result in costly litigation, divert the efforts of our technical and management personnel or require us to pay substantial damages. If we are unsuccessful in defending ourselves against these types of claims, we may be required to do one or more of the following:

 
·
stop, delay or abandon our ongoing or planned commercialization of the product that is the subject of the suit;

 
·
attempt to obtain a license to sell or use the relevant technology or substitute technology, which license may not be available on reasonable terms or at all; or

 
·
redesign those products that use the relevant technology.
 
 
22
 
 
IF WE ARE UNABLE TO PROTECT THE CONFIDENTIALITY OF OUR PROPRIETARY INFORMATION AND KNOW-HOW, THE VALUE OF OUR TECHNOLOGY AND PRODUCTS COULD BE ADVERSELY AFFECTED.

In addition to patented technology, we rely on our unpatented proprietary technology, trade secrets, processes and know-how. We generally seek to protect this information by confidentiality agreements with our employees, consultants, scientific advisors and third parties. These agreements may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known or be independently developed by competitors. To the extent that our employees, consultants or contractors use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.

WE PURCHASE SOME OF THE KEY COMPONENTS OF OUR PRODUCTS FROM SINGLE SUPPLIERS. THE LOSS OF THESE SUPPLIERS COULD PREVENT OR DELAY SHIPMENTS OF OUR PRODUCTS OR DELAY OUR CLINICAL TRIALS OR OTHERWISE ADVERSELY AFFECT OUR BUSINESS.

All of the key components of our products and related services are currently purchased from a single supplier with which we have a five year contract. Our current supplier is located outside of the United States, which could make us subject to foreign export laws and U.S. import and customs statutes and regulations, thus complicating and delaying shipments of components. If necessary or desirable, we could source our product components and related services from other suppliers. However, establishing additional or replacement suppliers for these components, and obtaining any necessary regulatory clearances or approvals, could take a substantial amount of time and could result in increased costs and impair our ability to produce our products, which would adversely impact our business, operating results and prospects. If our independent contract manufacturer fails to timely deliver to us sufficient quantities of some of our products and components in a timely manner, our operations may be harmed.

OUR RELIANCE ON INDEPENDENT CONTRACT MANUFACTURERS TO MANUFACTURE MOST OF OUR PRODUCTS AND COMPONENTS INVOLVES SEVERAL RISKS, INCLUDING:

 
·
inadequate capacity of the manufacturer’s facilities;

 
·
financial difficulties experienced by manufacturers due to the recent economic recession and continuing economic uncertainty;

 
·
interruptions in access to certain process technologies; and

 
·
reduced control over product availability, quality, delivery schedules, manufacturing yields and costs.

Shortages of raw materials, production capacity or financial constraints, or delays by our contract manufacturers could negatively affect our ability to meet our production obligations. Any such reduction, constraint or delay may result in delays in shipments of our products which could have a material adverse effect on our business.
 
IF WE, OUR CONTRACT MANUFACTURERS OR OUR COMPONENT SUPPLIERS FAIL TO COMPLY WITH THE FDA’S QUALITY SYSTEM REGULATIONS, THE MANUFACTURING AND DISTRIBUTION OF OUR DEVICES COULD BE INTERRUPTED, AND OUR PRODUCT SALES AND OPERATING RESULTS COULD SUFFER.

We, our contract manufacturers and our component suppliers are required to comply with the FDA’s quality system regulations, which is a complex regulatory framework that covers the procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of our devices. The FDA enforces its quality system regulations through periodic unannounced inspections. We cannot assure you that our facilities or our contract manufacturers’ or component suppliers’ facilities would pass any future quality system inspection. If our or any of our contract manufacturers’ or component suppliers’ facilities fails a quality system inspection, the manufacturing or distribution of our devices could be interrupted and our operations disrupted. Failure to take adequate and timely corrective action in response to an adverse quality system inspection could force a suspension or shutdown of our packaging and labeling operations or the manufacturing operations of our contract manufacturers, or a recall of our devices. If any of these events occurs, we may not be able to provide our customers with the quantity of RevVac™ safety syringes they require on a timely basis, our reputation could be harmed and we could lose customers, any or all of which may have a material adverse effect on our business, financial condition and results of operations.
 
 
23
 

OUR OPERATING RESULTS MAY BE ADVERSELY IMPACTED BY WORLDWIDE POLITICAL AND ECONOMIC UNCERTAINTIES AND SPECIFIC CONDITIONS IN THE MARKETS WE ADDRESS.

In the recent past, general worldwide economic conditions have experienced a downturn due to slower economic activity, concerns about inflation, increased energy costs, decreased consumer confidence, reduced corporate profits and capital spending, and adverse business conditions. Any continuation or worsening of the current global economic and financial conditions could materially adversely affect (i) our ability to raise, or the cost of, needed capital, (ii) demand for our current and future products and (iii) our ability to commercialize products. We cannot predict the timing, strength, or duration of any economic slowdown or subsequent economic recovery, worldwide, or in the display industry.

BECAUSE WE PLAN TO CONTINUE USING FOREIGN CONTRACT MANUFACTURERS, OUR OPERATING RESULTS COULD BE HARMED BY ECONOMIC, POLITICAL, REGULATORY AND OTHER FACTORS IN FOREIGN COUNTRIES.

We currently use a contract manufacturer in Asia to manufacture our RevVac™ safety syringe, and we plan to use foreign manufacturers to manufacture future products, where appropriate. These international operations are subject to inherent risks, which may adversely affect us, including:

 
·
political and economic instability;

 
·
high levels of inflation, historically the case in a number of countries in Asia;

 
·
burdens and costs of compliance with a variety of foreign laws;

 
·
foreign taxes;

 
·
changes in tariff rates or other trade and monetary policies; and

 
·
changes or volatility in currency exchange rates.

IF WE FAIL TO MANAGE EXPANSION EFFECTIVELY, OUR REVENUE AND EXPENSES COULD BE ADVERSELY AFFECTED.

Our ability to successfully offer products and implement our business plan in a rapidly evolving market requires an effective planning and management process. The growth in business and relationships with customers and other third parties has placed, and will continue to place, a significant strain on our management systems and resources. We will need to continue to improve our financial and managerial controls, reporting systems and procedures and will need to continue to train and manage our work force.

INCREASES IN FREIGHT AND ENERGY PRICES WOULD INCREASE OUR OPERATING COSTS AND WE MAY BE UNABLE TO PASS THESE INCREASES ON TO OUR CUSTOMERS IN THE FORM OF HIGHER PRICES, WHICH MAY ADVERSELY AFFECT OUR OPERATING RESULTS.

We use energy to process and transport our products. The prices for and availability of energy resources are subject to volatile market conditions, which are affected by political, economic and regulatory factors beyond our control. Our operating costs increase if energy costs, including electricity, diesel fuel and natural gas, rise. During periods of higher freight and energy costs, we may not be able to recover our operating cost increases through price increases without reducing demand for our products. In addition, we typically do not hedge our exposure to higher freight or energy prices.
 
 
24
 

THE MANUFACTURE OF MANY OF OUR PRODUCTS IS A HIGHLY EXACTING AND COMPLEX PROCESS, AND IF WE OR ONE OF OUR SUPPLIERS SHOULD ENCOUNTER PROBLEMS MANUFACTURING PRODUCTS, OUR BUSINESS COULD SUFFER.

The manufacture of many of our products is a highly exacting and complex process, in part due to strict regulatory requirements. Problems may arise during the manufacturing process for a variety of reasons, including equipment malfunction, failure to follow specific protocols and procedures, problems with raw materials, maintenance of our manufacturing environment, natural disasters, various contagious diseases and process safety issues. If problems arise during the production of a batch of product, that batch of product may have to be discarded. This could, among other things, lead to increased costs, lost sales, damage to customer relations, time and expenses being spent investigating the cause and, depending on the cause, similar losses with respect to other batches or products. If problems are not discovered before the affected product is released to the market, recall and product liability costs as well as reputational damage may also be incurred. To the extent that we or one of our suppliers experience significant manufacturing problems, this could have a material adverse effect on our business.

IF WE FAIL TO INCREASE OUR PRODUCTION AND MANUFACTURING CAPACITY TO MEET DEMAND, WE WILL BE UNABLE TO GROW AND OUR ABILITY TO PRODUCE NEW PRODUCTS AND ENTER INTO MARKETS WILL BE LIMITED.

Global growth and demand for our products could increase the utilization of our production and manufacturing facilities, including manufacturing capacity provided by third-party manufacturers and packaging capacity with respect to our products. If we are unable to successfully expand our production and manufacturing capacity, we will be unable to grow and expand our markets or enter into additional geographic markets or new product categories. In addition, failure to successfully expand our production and manufacturing capacity will limit our ability to introduce and distribute new products, including our existing pipeline of innovations and product improvements, or otherwise take advantage of opportunities in new markets. Further, increasing our production and manufacturing facilities requires significant investment and time to build. Delays in increasing capacity could also limit our ability to grow and materially adversely affect our business.

THE SEC HAS BROUGHT SUIT AGAINST THE COMPANY AND ITS CHIEF EXECUTIVE OFFICER, AND IF THE COMPANY DOES NOT PREVAIL IN ITS DEFENSE, THE COMPANY MAY BE OBLIGATED TO PAY CERTAIN AMOUNTS TO THE SEC, WHICH COULD ADVERSELY AFFECT OUR FINANCIAL POSTION

The SEC filed a civil complaint in Federal District Court in Georgia against the Company, alleging that the Company issued four misleading press releases during the period from August 2010 through October 2010 and one misleading press release in July 2011, related to the Company’s production schedule of its auto retractable safety syringe. The SEC names the Company’s current Chief Executive Officer, Rondald L. Wheet, as a co-defendant. Among other relief, the SEC seeks an order requiring the defendants to disgorge money received from its equity line financing from August 2010 through May 2011, in addition to other civil penalty amounts.  The Company believes that these claims are unfounded and is vigorously defending against them; however, should the Company not prevail in such defense the amount of damages owed to the SEC could be substantial and could adversely affect the Company’s financial condition or cause the Company to cease operations.
 
FLUCTUATIONS IN FOREIGN CURRENCY EXCHANGE RATES COULD ADVERSELY AFFECT OUR FINANCIAL CONDITION AND RESULTS FROM OPERATIONS.
 
Changes in foreign currency exchange rates can affect the value of our assets and liabilities, and the amount of our revenues and expenses. We do not currently try to mitigate our exposure to currency exchange rate risks by using hedging transactions. We cannot predict future changes in foreign currency exchange rates, and as a result, we may suffer losses as a result of future fluctuations.
 
 
25
 

Risks Related to Our Common Stock

YOUR OWNERSHIP INTEREST MAY BE DILUTED AND THE VALUE OF THE SHARES OF OUR COMMON STOCK MAY DECLINE BY THE EXERCISE OF STOCK OPTIONS WE HAVE GRANTED OR MAY GRANT IN THE FUTURE AND BY THE COMMON STOCK WE HAVE ISSUED OR WILL ISSUE IN THE FUTURE.
 
As of December 31, 2012, there were 12,100,000 options outstanding, which consisted of options to purchase common stock at exercise prices ranging from $0.08 to $0.50 per share, all of which are exercisable. 5,000,000 options still outstanding were granted in 2007 at an exercise price of $0.08 per share and are considered in the money as of December 31, 2012. 2,500,000 options issued in 2012 exercisable at $0.15 per share are considered out of the money. An additional 1,000,000 options issued at an exercise price of $0.50 are considered out of the money. 3,300,000 options issued in 2011 at an exercise price of $0.30 are considered out of the money. 300,000 options issued in 2012 at an exercise price of $0.40 are considered out of the money. Additionally, as of December 31, 2012, there were 2,880,000 warrants outstanding. All of these warrants were issued in 2012 according to the terms of 21 convertible debt agreements. 1,920,000 of these warrants are exercisable at $0.25 and 960,000 are exercisable at $0.50. The warrants exercisable at $0.25 were originally to expire on March 31, 2013, but were modified to expire on June 30, 2013 . The warrants exercisable at $0.50 were originally to expire on March 31 or June 30, 2013, but were modified to expire on September 30, 2013.
 
We may decide, however, to modify the terms and/or exercise price of these “out of the money” options. To the extent that the outstanding options to purchase our common stock are exercised, your ownership interest may be diluted. If the options are exercised and sold into the market, they could cause the market price of our common stock to decline.

From time to time the Company has issued and plans to continue to issue shares of its common stock to pay current and future obligations. During 2012, the Company issued 2,751,229 shares for services rendered. If and when, and to the extent that, those shares are sold into the market, they could cause the market price of our common stock to decline.

As of April 22, 2013, we had 250,000,000 shares of common stock authorized and 77,610,014 shares of common stock outstanding. The authorized but unissued shares have the same rights and privileges as the common stock presently outstanding. The unissued authorized shares can be issued without further action of the shareholders. If and when, and to the extent that, the unissued authorized shares are issued and sold into the market, they could cause the market price of our common stock to decline.

OUR STOCK PRICE IS VOLATILE AND YOUR INVESTMENT IN OUR SECURITIES COULD DECLINE IN VALUE, RESULTING IN SUBSTANTIAL LOSSES TO YOU.

The market price of our common stock, which is currently quoted on the OTC Markets, has been, and may continue to be, highly volatile. Our stock began trading on the over the counter bulletin board on May 1, 2008. On April 19, 2010, the Company began trading on the OTC Markets. Factors such as announcements of product development progress, financings, technological innovations or new products, either by us or by our competitors or third parties, as well as market conditions within the medical devices industry may have a significant impact on the market price of our common stock. In general, medical device stocks tend to be volatile even during periods of relative market stability because of the high rates of failure and substantial funding requirements associated with medical device companies. Market conditions and conditions of the medical device sector could also negatively impact the price of our common stock.
 
 
26
 

THE APPLICATION OF THE “PENNY STOCK” RULES COULD ADVERSELY AFFECT THE MARKET PRICE OF OUR COMMON SHARES AND INCREASE YOUR TRANSACTION COSTS TO SELL THOSE SHARES.

The Securities and Exchange Commission (the “SEC”) has adopted rule 3a51-1 which establishes the definition of a “penny stock,” for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, Rule 15g-9 requires:

 
·
the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased; and

 
·
that a broker or dealer approve a person’s account for transactions in penny stocks.

In order to approve a person’s account for transactions in penny stocks, the broker or dealer must:

 
·
obtain financial information and investment experience objectives of the person; and

 
·
make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.

The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the SEC relating to the penny stock market, which, in highlight form:

 
·
sets forth the basis on which the broker or dealer made the suitability determination; and

 
·
that the broker or dealer received a signed, written agreement from the investor prior to the transaction.

Generally, brokers may be less willing to execute transactions in securities subject to the “penny stock” rules. This may make it more difficult for investors to dispose of our common stock and cause a decline in the market value of our stock.

AS AN ISSUER OF “PENNY STOCK,” THE PROTECTION PROVIDED BY THE FEDERAL SECURITIES LAWS RELATING TO FORWARD LOOKING STATEMENTS DOES NOT APPLY TO US.

Although federal securities laws provide a safe harbor for forward-looking statements made by a public company that files reports under the federal securities laws, this safe harbor is not available to issuers of penny stocks. As a result, the Company will not have the benefit of this safe harbor protection in the event of any legal action based upon a claim that the material provided by the Company contained a material misstatement of fact or was misleading in any material respect because of the Company’s failure to include any statements necessary to make the statements not misleading. Such an action could hurt our financial condition.
 
MR. RONDALD L. WHEET, OUR CHIEF EXECUTIVE OFFICER AND CHAIRMAN, HAS VOTING CONTROL OF THE COMPANY AND CAN UNILATERALLY MAKE BUSINESS DECISIONS FOR US. ALTHOUGH WE HAVE ONE OUTSIDE DIRECTOR, THERE ARE NO PROCEDURES IN PLACE TO RESOLVE POTENTIAL CONFLICTS AND TO EVALUATE RELATED PARTY TRANSACTIONS THAT ARE TYPICALLY REVIEWED BY INDEPENDENT DIRECTORS.

Because Mr. Wheet owns 1,000,000 Series 2006 Preferred shares, which gives him the right to vote 125 shares to one in addition to the shares of common stock he already owns, voting together as a single class with the Company’s common stock, he controls a majority of the Company’s common stock and can unilaterally make business decisions on our behalf. Although we appointed an outside director, there are no procedures in place to resolve potential conflicts and evaluate related party transactions that are typically reviewed by independent directors.
 
WE HAVE NOT PAID DIVIDENDS IN THE PAST AND DO NOT EXPECT TO PAY DIVIDENDS FOR THE FORESEEABLE FUTURE. ANY RETURN ON INVESTMENT MAY BE LIMITED TO THE VALUE OF OUR COMMON STOCK.

No cash dividends have been paid on the Company’s common stock. We expect that any income received from operations will be devoted to our future operations and growth. The Company does not expect to pay cash dividends in the near future. Payment of dividends would depend upon our profitability at the time, cash available for those dividends, and other factors as the Company’s board of directors may consider relevant. If the Company does not pay dividends, the Company’s common stock may be less valuable because a return on an investor’s investment will only occur if the Company’s stock price appreciates.
 
 
27
 

Item 1B.  Unresolved Staff Comments.

Not applicable.

Item 2.  Property.

On September 1, 2009, the Company entered into a 5 year lease agreement with Osprey South, LLC (“Osprey”), to lease the property at 670 Marina Drive, Suite 301, Building F, Charleston, South Carolina, 29492.  The leased property is approximately 2,395 square feet.  During the course of the 5-year lease, ending on August 31, 2014, the Company is to pay Osprey $4,500 in monthly rental installments payable on the first day of each succeeding month.  On July 1, 2011, the Company entered into an amended lease with Osprey for the office space adjacent to the existing office space on the third floor at 670 Marina Drive. The combined leased property is approximately 5,000 square feet. This property is considered class A office space.  During the course of the 5-year amended lease, ending on June 30, 2016, the Company is to pay Osprey $10,000 in monthly rental installments payable on the first day of each succeeding month The Company incurred $120,000 in office rent to Osprey South, LLC for 2012.  Rondald Wheet is the sole member of Osprey South, LLC.  The contract is a triple net lease with terms based upon market rates for class A office space at the time of the lease signing.

Item 3.  Legal Proceedings.

In September 2005, we filed an additional patent on our RevVac™ safety syringe under a joint venture agreement with Globe Med Tech which gives a 50% ownership of this patent to the Company and 50% to Globe Med Tech. The Company filed a lawsuit to rescind, terminate and seek monetary damages for the non-fulfillment and breach of the joint venture agreement and other related agreements with Globe Med Tech in March 2007, in addition to an accounting of expenditures of funds under the terms and provisions of the agreements and to give 100% ownership back to the Company. This patent was issued January 13, 2009. A summary judgment hearing was held in May 2011, in Tulsa, Oklahoma. On August 15, 2011, the District Court of Tulsa County, State of Oklahoma granted Revolutions Medical summary judgment against Globe Medical Tech. On October 21, 2011, Revolutions Medical received journal entry of judgment. The Court requires Globe Med Tech to pay to Revolutions Medical the sum of $311,440, the return of all syringes, design files and sample molds, the return of 266,667 shares of common stock, to assign all rights to the January 2009 issued patent number 11/115,446 and to cease and be prohibited from claiming any interest or ownership to the RevVac™ auto-retractable vacuum safety syringe. Globe Med Tech’s appeal was denied on December 13, 2011. On January 30, 2013 the court ordered a Nunc Pro Tunc decision denying all counterclaims and third party claims by Globe Med Tech. Globe Med Tech has filed another appeal on March 1, 2013 but the Company has hired legal counsel in Texas to assist in efforts to collect these damages and execute on the court order.

On January 2, 2013, the Company won its arbitration proceeding concerning its counter claims against Richard Theriault, former manufacturer MIG and former consultant SPD.  The monetary award claims included $770,000 in recoupment of production costs plus interest, legal fees and other arbitration costs, which will total close to $1 million dollars. In other claims, Theriault was found guilty of fraud in the inducement and breach of contract and was found to have no rights to any of the Company's proprietary technology, files, drawings, designs, patents or products. The ruling determined that all production mold payments made by the Company to MIG for the manufacturing of production molds had instead been used by Mr. Theriault for other non-production related purposes. The panel of American Arbitration Association ruled that the only assets in which production was funded by MIG from the Company’s production payments were $50,000 in trial molds. The equipment asset on the balance sheet has been reduced by $710,000 and charged to impairment for the payments no longer associated with a production or trial mold. The $770,000 award is for the recovery of damages related to these production payments.  The Company has hired legal counsel in Massachusetts and South Carolina to assist in efforts to collect these damages.
 
 
28
 

On March 12, 2012 the Company filed a lawsuit against Justin Keener and JMJ Financial (“JMJ”) in Charleston County, South Carolina.  The Company sought a rescission and financial relief for the convertible debt agreement signed February 22, 2011. The Company claimed that it was unable to deliver the shares requested in the common stock conversion requests dated January 9, 2012 for 1,000,000 shares and  January 30, 2012 for 1,226,049 shares due to the risk of defaulting on the convertible debt agreement by losing Depository Trust Company “DTC” eligibility. The contract stated that the Company would be considered in default of the agreement if the Company lost DTC eligibility due to a “chill” placed upon the electronic transfer of the stock. The Company had previously been made aware of other companies that had entered into similar agreements losing DTC eligibility and took the position that JMJ had put the Company in an untenable position of either defaulting by losing DTC eligibility or defaulting by failing to issue the requested shares.  The Company claimed that JMJ’s unreasonably high demands for conversion caused a “frustration” of the principal purpose of the contract and supports the rescission of the contract and a return of the parties to their respective positions before the contract was signed.  On April 12, 2012 the Company withdrew the lawsuit filed in South Carolina to pursue its rights and counterclaims in Miami-Dade County, Florida, described below.
 
A lawsuit was filed against the Company by JMJ Financial in Miami-Dade County, Florida on March 15, 2012. The lawsuit claims that the Company breached the terms of the convertible debt agreement by failing to issue shares requested in a stock conversion by JMJ on January 9, 2012 for 1,000,000 shares and on January 30, 2012 for 1,226,049 shares.  JMJ is seeking the delivery of 2,226,049 shares of common stock of the Company, plus costs and prejudgment interest. On August 30, 2012, the Company filed its counterclaims against JMJ, which included fraud by concealment, among other claims. The Company alleges that Keener and JMJ had a responsibility and obligation under Florida law to disclose not to conceal during the negotiations of the agreement the fact that Keener and JMJ had outstanding and current issues with these type of convertible notes with DTC which could do detrimental harm to liquidity and electronic transfer of the Company's stock if DTC eligibility was "chilled". This would severely hamper future capital raising and harm its current shareholders but would solely benefit Keener and JMJ under the default clauses in this agreement.

On September 26, 2012, the Company filed suit in South Carolina Federal District Court against Strategic Product Development ("SPD"), Richard H. Theriault, Vita S. Theriault, Darius R. Theriault, Raminta Theriault, Goddard Technologies, Inc. ("GTI") and others, claiming that the defendants purposely and materially misled and misrepresented capabilities and progress on a variety of initiatives related to the development and manufacture of the Company's RevVac™ Auto-Retractable Vacuum safety syringe to officers and directors of Revolutions Medical, which caused a delay in its production of approximately one year. The suit further alleges that Richard H. Theriault and other defendants defrauded the Company and misappropriated funds in violation of the United States' Racketeer Influenced and Corrupt Organizations ("RICO") Act and that GTI improperly assigned certain rights to the Company's new provisional patents to SPD without authorization. On February 2, 2013, Richard H. Theriault filed for bankruptcy in Massachusetts under Chapter 11.  The South Carolina lawsuit has been temporarily stayed until such time when the arbitration award against Richard H. Theriault and MIG can be ruled on in United States Federal District Court in Massachusetts, granting judgment outside the bankruptcy court. On March 13, 2013, United States Federal District Court in Massachusetts granted an injunction against Richard H. Theriault and MIG, enjoining and restraining them from transferring or alienating any assets in their possession without approval from the Court and a hearing has been scheduled for May 7, 2013.

On October 1, 2012, the Company filed suit in South Carolina Federal District Court against its former President and Director, Thomas G. O'Brien, alleging that O'Brien, as a director and officer of the Company, committed fraud, disregarded his fiduciary duties, and breached other obligations owed to the Company and its shareholders, by facilitating and negotiating contracts on behalf of the Company while at the same time sharing confidential Company information with, and receiving bribes from, Richard H. Theriault, Strategic Product Development (SPD), and Medical Investment Group, (MIG). The complaint seeks to recover actual and punitive damages as well as a return of all salary paid to O'Brien under his employment agreement and over 3.6 million restricted shares.  On January 17, 2013, the South Carolina lawsuit was dismissed without prejudice, so the Company can pursue all of its claims against Thomas G. O'Brien in arbitration.
 
On September 21, 2012, the Company received notification from the SEC that the SEC had filed a civil complaint in Federal District Court in Georgia against the Company, alleging that the Company issued four misleading press releases during the period from August 2010 through October 2010 and one misleading press release in July 2011, related to the Company’s production schedule of its auto retractable safety syringe. The SEC names the Company’s current Chief Executive Officer, Rondald L. Wheet, as a co-defendant. Among other relief, the SEC seeks an order requiring the defendants to disgorge money received from its equity line financing from August 2010 through May 2011, in addition to other civil penalty amounts.  The Company, in consultation with its legal counsel, intends to vigorously defend itself and its Chief Executive Officer, Rondald L. Wheet, against these claims.

Item 4.  Mine Safety Disclosures.

Not applicable.
 
 
29
 

PART II

Item 5.  Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

(a) Market Information

The Company’s Common Stock is quoted on the OTC Markets under the symbol “RMCP.”  The following table sets forth the quarterly high and low sale prices for our common shares for the last two completed fiscal years and the subsequent interim periods. The prices set forth below represent interdealer quotations, without retail markup, markdown or commission and may not be reflective of actual transactions.

Quarter ended
   High     Low  
December 31, 2012
  
$
0.220
    
$
0.040
  
September 30, 2012
  
$
0.250
    
$
0.070
  
June 30, 2012
  
$
0.390
    
$
0.157
  
March 31, 2012
  
$
0.380
    
$
0.220
  
December 31, 2011
  
$
0.320
    
$
0.120
  
September 30, 2011
  
$
0.320
    
$
0.170
  
June 30, 2011
  
$
0.445
    
$
0.220
  
March 31, 2011
  
$
0.480
    
$
0.330
  

Quotations on the OTC Markets reflect bid and ask quotations, may reflect inter-dealer prices, without retail markup, markdown or commission, and may not represent actual transactions.

(b) Holders

As of April 22, 2012, there were approximately 450 holders of record of our common stock. This figure does not take into account those shareholders whose certificates are held in the name of broker-dealers or other nominees.
 
(c) Dividends

We have never paid any cash dividends on our common shares, and we do not anticipate that we will pay any dividends with respect to those securities in the foreseeable future. Our current business plan is to retain any future earnings to finance the expansion development of our business.
 
 
30
 

(d) Securities Authorized for Issuance under Equity Compensation Plan

The following table shows information with respect this plan as of the fiscal year ended December 31, 2012.

Equity Compensation Plan Information
  
Plan category
  
Number of securities to
be issued upon exercise
of outstanding options,
warrants and rights (a)
    
Weighted-average
Exercise price of
outstanding options,
warrants and rights (b)
    
Number of securities remaining
available for future issuance
under equity compensation
plans (excluding securities
reflected in column (a)) (c)
  
Equity compensation plans approved by security holders
     14,980,000       0.24       5,020,000  
Equity compensation plans not approved by security holders
     —       —       —  
Total
     14,980,000       0.24       5,020,000  

Transfer Agent

Our transfer agent is American Stock Transfer and Trust Company at 6201 15th Avenue, Brooklyn, NY 11219.

Item 6.  Selected Financial Data.

Not applicable.

Item 7.  Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Plan of Operation

The Company has begun sales of its 3ml RevVac™ safety syringe through introduction to distributors, advertisements through its online sales program, attendance at numerous industry trade shows and a direct marketing campaign. The Company expects to be in full scale production by August 2013 for its 1ml, 5ml and 10ml RevVac™ safety syringe.  When all sizes of the RevVac™ safety syringe are in production, the Company believes that it can ship a total of 30 million RevVac™ safety syringes for the following twelve month period.

This RevVac™ safety syringe uses vacuum technology to retract the needle into the plunger after use. The syringe cannot be reused once the vacuum is activated. Revolutions Medical believes its safety syringe has many advantages over its competition including price, ease of use, and safety. It should virtually eliminate accidental needle stick injuries and also aid in reducing the spread of contagious diseases. You may view a video of the syringe in use on are website at www.revolutionsmedical.com. The Company also believes that with the help of government regulation initiatives, individual state laws, and the importance of world health concerns, the safety syringe market will continue to have substantial growth into the foreseeable future.

During 2010, Revolutions Medical entered into two university clinical studies utilizing its proprietary MRI software tools. These first two clinical studies are for cases involving head trauma and brain masses. These results are expected to clinically validate the use of its MRI software tools as an additional application to enhance the diagnostic confidence of physicians. In preparation for the expected commercial launch of the MRI software suite of products, the Company hired Strata Corporation in March 2012. Strata is an expert in computer software and programming and the Company believes that by the end of 2012, the first application of  RevColor™, RevDisplay™ and Rev3D™ will be commercially available. The launch of this product will be a “software as a service” (SaaS) business model, where customers will log on to our secure website and send current black and white images to the Company via high speed internet (teleradiology), and the images will be sent back to the customer in color and three dimensional with auto segmentation. At first the Company will charge a per-use fee but can expand depending upon volume into monthly service agreements. Potential Revolutions Medical customers could include MRI centers, doctors, hospitals and even patients.
 
 
31
 

The Company is currently working on developing, enhancing and securing it proprietary MRI software tools for commercial launch.  The Company believes that once clinical application validations using its MRI software suite of products including RevColor™, RevDisplay™ and Rev3D™ directed at concussions, stroke, Alzheimer’s and breast disease are achieved, it will eventually aid in the enhanced diagnosis, detection, and monitoring of such diseases and afflictions.

When an MRI is taken, the black and white images are sent to a picture archiving and communication system (PACS), which displays the images for a radiologist to view. By using high speed internet, these images can be securely sent to the Company’s secure website, after a secure account is opened. This is called teleradiology. For a small nominal fee or monthly subscription, the Company will use its proprietary software, based upon specific parameters and information provided, and sends back the images in enhanced color and sorted in correct sequence along with the original black and white images, in a matter of minutes. A video of the MRI software can be found on the Company’s website.

On December 31, 2010, the Company announced that it had acquired the exclusive rights to license a breast biopsy localization system. The Company recently signed a worldwide exclusive license agreement with Traxsys, Inc. for an image-guided navigation system that incorporates high accuracy breast biopsies systems (“BSS”) to conventional mammography systems, which number more than 50,000 globally. This technology has already received 510(k) market clearance by the FDA. BSS facilitates accurate and fast non-palpable lesions and micro calcification localization in the treatment of breast cancer. It is a low-cost, standalone, stereotactic image-based system which uses data from a pair of mammograms to enable radiologists to accurately position a localization needle or biopsy tool at the location of suspicious abnormalities. The system can also be modified to leverage existing popular biopsy tools. The technology can be used to provide a technology platform for future development, including multi-modal breast imaging for the image fusion of MRI and X-Ray images. After a full due diligence of the technology, the Company sees a potential synergy between its proprietary MRI software tools and this technology for breast imaging. However, the Company has decided not to invest additional capital at this time and to focus its resources on its RevVac™ safety syringe line of products and applications for its MRI software technology. In the future, the Company could re-license this technology.

Results of Operations

For the Year Ended December 31, 2012 Compared to the Year Ended December 31, 2011

Revenues

During the year ended December 31, 2012, the Company had $1,189 in revenues as it began making sales to its domestic and international distributors to assist in the introduction of the RevVac™ safety syringe to primary care, ambulatory care and governmental markets. The Company had no revenue in 2011.

General and Administrative Expenses

During the year ended December 31, 2012, the Company incurred $4,046,080 in general and administrative expenses, compared to $3,781,286 for the same period in 2011.  The Company recorded option expenses of $758,962 for the year ended December 31, 2012 compared to option expenses of $525,554 for the same period in 2011. Further, consulting agreement fees and legal fees were $910,046 and $577,426, respectively, for the year ended December 31, 2012, a decrease in consulting fees of $421,718 and an increase in legal fees of $108,442, respectively, compared to $1,331,764 and $468,984, respectively, for the same period in 2011.  The decrease in consulting fees was partly due to a reduction in consultants retained in 2011 to begin promotion of the RevVac™ safety syringe in various markets and an elimination of fees due to MIG.  The increase in legal fees was due primarily due to the arbitration case against MIG and the SEC civil complaint filed against the Company and our CEO, Rondald Wheet.  A total of $281,504 in prepaid consulting agreements was expensed in the year ended December 31, 2012, compared to $636,856 for the same period in 2011 as the company transitioned from hiring individual consultants to retaining larger distributors.
 
 
32
 

Impairment of assets

Also during the year ended December 31, 2012, the Company removed from the balance sheet and impaired equipment valued at $710,000 for the production of the 3 ml production pilot molds, as the Company determined through the arbitration proceeding with MIG in November 2012 that these molds had not been produced and MIG could not account for the whereabouts of the funds the Company paid toward these assets. Additionally, the Company wrote off prepayment of $80,000 made to MIG in 2011due to the uncertainty of the collectability. In 2011, $328,000 of production mold equipment had been reclassified from the balance sheet to consulting expense in 2011 as the Company learned that some of the trial molds and production molds had not been produced by MIG.

The Company also impaired intangible and goodwill of $38,276 and equipment of $50,000 during the year ended December 31, 2012.

Interest expense

Interest expense increased to $1,727,512 during the year ended December 31, 2012, compared to $567,081 for the same period in 2011.  This increase is due to individual convertible debt agreements and additional convertible debt agreements with Asher Enterprises, Inc. and TCA.

Net Loss

Net loss for the year ended December 31, 2012 was $7,164,311 compared to $4,541,518 for the same period in 2011, as the Company incurred greater expenses primarily related to an increase in salaries, consulting and legal fees, expenses associated with the convertible debt agreements and fixed asset impairment.  The Company incurred a net operating loss of $5,854,475 during the year ended December 31, 2012, compared to a net operating loss of $3,855,309 for the same period in 2011.

Liquidity and Capital Resources

As of December 31, 2012, the Company did not have and continues to not have sufficient cash on hand to pay present obligations as they become due.  In addition, due to current economic conditions and the Company’s related risks and uncertainties, there is no assurance that we will be able to raise additional capital on acceptable terms, if at all, to meet our current obligation over the next 12 months.  Because of the foregoing, the Company’s auditors have expressed substantial doubt about our ability to continue as a going concern.

Net cash used for operating activities for the years ended December 31, 2012 and 2011, was $1,674,342 and $2,563,073, respectively.  The net loss for the years ended December 31, 2012 and 2011 was $7,164,311 and $4,541,518, respectively.  This increase is primarily related to an increase in salaries, consulting and legal fees, expenses associated with the convertible debt agreements and asset impairment.

Net cash used for investing activities for the years ended December 31, 2012 and 2011, was $39,224 and $129,091 respectively.  This cash used for investing activities is a result of patent fees and leasehold improvements.

Net cash obtained through all financing activities for year ended December 31, 2012, was $1,708,776, as compared to $2,627,491 for the year ended December 31, 2011.   In order to fund the completion of the RevVac™ safety syringe production molds, we issued stock options and/or common stock when it is acceptable to third parties for services rendered in assisting us in the product distribution and marketing process. Proceeds from issuance of common stock through cash exercise of stock options and warrants were $258,275 for the year ended December 31, 2012 as compared to $1,654,420 for the year ended December 31, 2011. This decrease is due primarily to a decrease in consulting agreements and the options issued under the terms of these agreements. Proceeds from issuance of notes for cash were $1,450,501 for the year ended December 31, 2012 as compared to $770,500 for the year ended December 31, 2011.
 
 
33
 

As of December 31, 2012, the Company did not have and continues to not have sufficient cash to pay present obligations as they become due.  We are searching for additional financing to generate the liquidity necessary to continue our operations.  Due to current economic conditions and the Company’s risks and uncertainties, there is no assurance that we will be able to raise any additional capital on acceptable terms, if at all.  Because of these uncertainties, the auditors have expressed substantial doubt about our ability to continue as a going concern.  If we obtain additional funds by selling any of our equity securities or by issuing common stock to pay current or future obligations, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution, or the equity securities may have rights preferences or privileges senior to the common stock.  If adequate funds are not available to us on satisfactory terms, we may be required to cease operating or otherwise modify our business strategy.

Because we do not currently generate any cash from operations and have no credit facilities available, our only means of funding is through the sale of our common stock.  We presently have 250,000,000 shares of common stock authorized, of which 72,784,907 shares were issued and outstanding as of December 31, 2012.  If we obtain additional funds by selling any of our equity securities or by issuing common stock to pay current or future obligations, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution, or the equity securities may have rights preferences or privileges senior to the common stock.  If adequate funds are not available to us when needed on satisfactory terms, we may be required to cease operating or otherwise modify our business strategy.

Our estimated working capital requirement for the next 12 months is $2,700,000 with an estimated burn rate of $225,000 per month.

The Company entered into six new securities purchase agreements in 2012 with Asher Enterprises, Inc. (“Asher Enterprises”), pursuant to which the Company issued convertible promissory notes to Asher Enterprises for an original principal amount of $46,000 on February 10, $42,500 on March 20, $53,000 on May 15, $42,500 on June 21, $42,500 on August 10, and $42,500 on November 27 in return for aggregate gross cash proceeds of $269,000. The notes bear interest at a rate of 8% per annum and provide for the payment of all principal and interest 9 months from the date of the note. The principal amount owed to Asher Enterprises at December 31, 2012 is $92,500. The note is convertible at the election of Asher Enterprises into that number of shares of the Company’s common stock. The conversion price equals to the greater of 1) 55% of the average of the lowest three closing bid prices of the Company’s common stock on the OTC Markets during the 10 business days immediately preceding the date of conversion, subject to adjustment and 2) 0.00009. Over the course of the year, Asher elected to convert a total of $357,000 in principal from the notes issued on July 26, 2011 for $40,000, September 1, 2011 for $45,000, November 7, 2011 for $42,500, December 19, 2011 for $53,000, February 10, 2012 for $46,000, March 20, 2012 for $42,500, May 15, 2012 for $53,000 and June 21, 2012 for $35,000. The June 21, 2012 note still had an outstanding principal balance of $7,500 as of December 31, 2012.

The notes issued by Asher Enterprises in 2012 contain a beneficial conversion feature with a minimum conversion price of $0.00009 and no adjustment due to dilutive issuance. As a result, these notes were not bifurcated and valued with an embedded call option. The beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.

On February 22, 2011, the Company issued a $1,050,000 Convertible Promissory Note to JMJ Financial, Inc. (“JMJ”), a private investor. The note bears interest in the form of a onetime interest charge of 8%, payable with the note’s principal amount on the maturity date, February 22, 2014. All or a portion of this note’s principal and interest is convertible at the option of JMJ from time to time, into shares of the Company’s common stock, originally fixed at a per share conversion price equal to 70% of the average of the 3 lowest closing prices for the Company’s common stock in the 20 trading days previous to the effective date of each such conversion. During the course of 2012, the Company did not borrow any funds against this note. Over the course of the year, JMJ elected to convert a total of $15,498 in principal from this note. The principal amount owed to JMJ at December 31, 2012, is $191,663.
 
 
34
 

The following table summarizes total current assets, liabilities and working capital at December 31, 2012, compared to December 31, 2011.
   
December 31,
2012
    
December 31,
2011
(Restated)
    
Increase/
(Decrease)
  
Current Assets
  
$
326,704
    
$
284,712
    
$
41,992
  
Current Liabilities
  
$
4,406,551
    
$
2,855,821
    
$
1,550,730
  
Working Capital Deficit
  
$
(4,079,847
)
  
$
(2,571,109
)
  
$
(1,508,738)
  

As of December 31, 2012, we had a working capital deficit of $4,079,847, as compared to a working capital deficit of $2,571,109 as of December 31, 2011, an increase of $1,508,738.  Factors contributing to the increase in this deficit include an increase in accounts payable due to the initial product purchase with Yeso-med, which increased current liabilities by $208,258, as of December 31, 2012. Payable related to the purchase commitment with Yeso-med accrued in 2012 was $783,593. Accounts payable to other vendors increase by $333,094 from December 31, 2011 to $432,436.  Additionally, the issuance of the convertible notes and the embedded derivatives associated with these notes was $581,557 as of December 31, 2012, as compared to a balance of $522,846 as of December 31, 2011.

Other current assets include the amount related to pre-paid consulting expenses incurred through the issuance and exercise of stock options.  The balance of prepaid consulting fees as of December 31, 2012, was $1,588, compared to $279,868 as of December 31, 2011.

The Company currently generates an insufficient amount of cash from sales to sustain operations and does not have access to traditional credit facilities; however, the Company expects product sales to increase in the second quarter of 2013.  Over the next 12 months, in order to implement our business plan and meet our liquidity needs going forward, the Company may sell shares of its common stock, issue additional convertible debt notes or permit warrant exercises.  If we implement any of the foregoing financing alternatives to pay current or future obligations, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution, or the equity securities may have rights preferences or privileges senior to the common stock.  If adequate funds are not available to us when needed on satisfactory terms, we may be required to cease operating or otherwise modify our business strategy.

Expected Purchase or Sale of Plant and Significant Equipment

None.

Expected Significant Changes in the Number of Employees

The Company began leasing additional space in the same building as of July 1, 2011, and expects to hire between 3 to 7 office personnel to assist with operations as significant sales commence with the 3ml RevVac™ safety syringe.

Off-Balance Sheet Arrangements

We have no significant known off-balance sheet arrangements.

Item 7A.  Quantitative and Qualitative Disclosures About Market Risk.

We do not hold any derivative instruments and do not engage in any hedging activities.

Item 8.  Financial Statements and Supplementary Data.

Our financial statements are contained in pages F-1 through F-27 which appear at the end of this Annual Report.

Item 9.  Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

On March 20, 2013, the Company accepted the resignation of Hood & Associates, CPAs, P.C. (“Hood”), as the Company’s independent registered public accounting firm. Hood’s resignation is solely a result of reaching the prescribed term limit as the Company’s independent auditor as required by the auditor rotation rules and regulations prescribed by the SEC and Public Company Accounting Oversight Board.  Hood’s report on the financial statements for the fiscal years ended December 31, 2011 and December 31, 2010, contained no adverse opinion or disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principle, other than for a going concern.
 
 
35
 

During the fiscal years ended December 31, 2011 and December 31, 2010, and in the subsequent interim period through March 20, 2013, the date of Hood’s resignation, there were no disagreements with Hood on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Hood, would have caused them to make reference to the subject matter of the disagreements in its reports on the financial statements for such year. During the fiscal years ended December 31, 2011 and December 31, 2010, and in the subsequent interim period through March 20, 2013, the date of Hood’s resignation, there were no reportable events as defined in Item 304(a)(1)(v) of Regulation S-K.  Hood provided the Company with a letter addressed to the SEC confirming Hood’s agreement with the foregoing disclosures. A copy of Hood’s letter, dated March 20, 2013, is included with Form 8-K filed with the SEC on March 26, 2013.

On March 22, 2013, the Company approved the engagement of GBH CPAs, PC (“GBH”), as the Company’s new independent registered public accounting firm.  During the fiscal years ended December 31, 2011 and December 31, 2010, and the subsequent interim period prior to the engagement of GBH, the Company has not consulted GBH regarding (i) the application of accounting principles to any specified transaction, either completed or proposed; (ii) the type of audit opinion that might be rendered on the Company’s financial statements, and either a written report was provided to the registrant or oral advice was provided that the new accountant concluded was an important factor considered by the registrant in reaching a decision as to the accounting, auditing or financial reporting issue; or (iii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(v)) or a reportable event (as defined in Item 304(a)(1)(v)).

Item 9A.  Controls and Procedures.

(a) Evaluation of Disclosure and Control Procedures

The Company’s disclosure controls and procedures are designed to ensure (i) that information required to be disclosed by the Company in the reports the Company files or submits under the Exchange Act are recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms; and (ii) that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our principal executive officer evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2012, and concluded that the disclosure controls and procedures were not effective as a whole, and that the deficiency involving internal controls constituted a material weakness as discussed below.

(b) Management’s Assessment of Internal Control over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in the Exchange Act Rules 13a-15(f). A system of internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
 
 
36
 
 
Under the supervision and with the participation of management, including the principal executive officer and the principal financial officer, the Company’s management has evaluated the effectiveness of its internal control over financial reporting as of December 31, 2012, based on the criteria established in a report entitled “Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission” and the interpretive guidance issued by the Commission in Release No. 34-55929. Based on this evaluation, the Company’s management has evaluated and concluded that the Company’s internal control over financial reporting was ineffective as of December 31, 2012, and identified the following material weaknesses:

 
·
There is a lack of accounting personnel with the requisite knowledge of Generally Accepted Accounting Principles in the US (“GAAP”) and the financial reporting requirements of the U.S. Securities and Exchange Commission.

 
·
There are insufficient written policies and procedures to insure the correct application of accounting and financial reporting with respect to the current requirements of GAAP and SEC disclosure requirements.

 
·
There is a lack of segregation of duties, in that we only had one person performing all accounting-related duties.
 
 
·
There are inconsistencies in the application of the Company's policies among business units.
 
Notwithstanding the existence of these material weaknesses in our internal control over financial reporting, our management believes that the consolidated financial statements included in its reports fairly present in all material respects the Company’s financial condition, results of operations and cash flows for the periods presented.

The Company will continue its assessment on a quarterly basis and as soon as we start operations we plan to hire personnel and resources to address these material weaknesses. We believe these issues can be solved with hiring in-house accounting support and plan to do so as soon as we have funds available for this.  There has been no change in its internal control over financial reporting that occurred during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
 
This annual report does not include an attestation report of the Company’s independent registered public accounting firm regarding internal control over financial reporting. The Company’s registered public accounting firm was not required to issue an attestation on its internal controls over financial reporting pursuant to temporary rules of the Securities and Exchange Commission.  The Company will continue to evaluate the effectiveness of internal controls and procedures on an on-going basis.

(c) Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Item 9B.  Other Information.

None.
 
 
37
 

PART III

Item 10.  Directors, Executive Officers, and Corporate Governance.

The following table and biographical summaries set forth information, including principal occupation and business experience, about our directors and executive officers at April 22, 2013:

Name
  
Age
  
Position
  
Officer and/or Director Since
             
Rondald Wheet
  
47
  
Chairman, Chief Executive Officer
  
March 2005
             
Thomas Beahm
  
62
  
Director
  
October 2007
             
Burt Hodges
  
40
  
Chief Financial Officer
  
June 2011
             
Vincent Olmo
  
47
  
Chief Operating Officer
  
April 2011

Rondald L. Wheet

Rondald L. Wheet is the Chief Executive Officer and Chairman of the board of directors of Revolutions Medical Corporation and has served in this capacity since March 2005. Mr. Wheet has over 15 years’ experience in the investment banking industry. Working for several registered broker dealers, including Scott and Stringfellow and Cohig and Associates, Mr. Wheet was instrumental in the capital campaigns for several small cap companies, particularly in the medical field. Between January 2002 and March 2005, Mr. Wheet worked as an outside consultant advising numerous micro and small cap companies on capital financing, strategic partnerships, stock awareness, professional recruiting, and the mechanics of public offerings. He received a Bachelor of Science degree from the University of Towson in Finance and International Business, and he is a past President of the Metropolitan Exchange Club of Charleston, SC. In 2009, he was presented the South Carolina Palmetto Patriot Award.

Thomas M. Beahm

Thomas M. Beahm, MD, FACS, is a member of the board of directors of Revolutions Medical. Dr. Beahm is a practicing plastic surgeon, who lives in Chattanooga, Tennessee. He is an active member of the American Society of Plastic Surgeons, American College of Surgeons, and American Medical Association, and simultaneously owns and runs his own practice. In addition, he is Secretary of Integrated Voice Systems, which has software in over 130 hospitals. Dr. Beahm also has experience directing plastic surgery mission work in various third world countries, coming to the aid of thousands of people in Asia, Africa, and South America. Dr. Beahm received a bachelor’s degree from Pittsburg State University in Pittsburg, KS and a medical doctorate degree from the University of Kansas.

Burt Hodges

Mr. Hodges is currently the Company’s Chief Financial Officer. In this role, Mr. Hodges has management oversight and responsibility for all financial functions and capital resources of the Company, including corporate finance, project finance, corporate accounting, and reporting and risk management. Prior to joining the Company, from December, 2004 to June, 2011, Mr. Hodges was a partner with Accel Financial Advisors, LLC and Accel Tax and Business Services, LLC (collectively, “Accel”), where he provided tax, financial reporting and management advice to corporate clients and individuals. Prior to joining Accel, from July 2000 to December 2004, Mr. Hodges served as a tax resolution specialist and financial planner at J.K. Harris & Company, a tax resolution and financial advisory firm where he worked with corporate and individual clients performing business valuations and consulting on tax and financial matters. Mr. Hodges received his BBA in Finance from the University of Georgia and his MBA from the Citadel. He is a licensed Certified Public Accountant and a Certified Financial Planner.
 
 
38
 

Vincent Olmo

Mr. Olmo is currently Chief Operating Officer of the Company. Mr. Olmo combines over five years of experience in information technology and operations senior management, following an eighteen year career as a delivery manager and application architect. Previously, he was involved with several large financial institutions holding various positions, including chief architect and application services executive. From 2001 through 2006, Mr. Olmo was a Chief Architect for EDS, Inc., an information services company. From 2006 to 2007, he was Vice President of Application Delivery for Realogy, Inc., a company managing franchising rights in the real estate industry. From June 2007 to April 2011, he was an Application Services Executive for Hewlett-Packard, Inc., an information services company which focuses on delivering application development and management services for Fortune 500 companies. Mr. Olmo has a Bachelor of Science degree in Electrical Engineering from Fairleigh Dickinson University and an MBA from Rutgers.

Board of Directors

Directors are elected at our annual meeting of shareholders and serve for one year until the next annual meeting of shareholders or until their successors are elected and qualified. We reimburse all directors for their expenses in connection with their activities as directors of the Company.

Board Leadership Structure and Role in Risk Oversight

Although we have not adopted a formal policy on whether the Chairman and Chief Executive Officer positions should be separate or combined, we have traditionally determined that it is in the best interests of the Company and its shareholders to combine these roles. Rondald L. Wheet has served as our Chief Executive Officer and Chairman since March 2005. Due to the small size and early stage of the Company, we believe it is currently most effective to have the Chairman and Chief Executive Officer positions combined.

Our board of directors is primarily responsible for overseeing our risk management processes. The board of directors receives and reviews periodic reports from management, auditors, legal counsel, and others, as considered appropriate regarding our company’s assessment of risks. The board of directors focuses on the most significant risks facing our company and our company’s general risk management strategy, and also ensures that risks undertaken by our Company are consistent with the board’s appetite for risk. While the board oversees our company’s risk management, management is responsible for day-to-day risk management processes. We believe this division of responsibilities is the most effective approach for addressing the risks facing our company and that our board leadership structure supports this approach.

Family Relationships

Mr. Olmo is the brother-in-law of Mr. Wheet.  Other than the previously disclosed relationship, there are no family relationships among our directors, executive officers, or persons nominated or chosen by the Company to become directors or executive officers.

Subsequent Executive Relationships

No director or executive officer has been a director or executive officer of any business which has filed a bankruptcy petition or had a bankruptcy petition filed against it during the past five years. No director or executive officer has been convicted of a criminal offense or is the subject of a pending criminal proceeding during the past five years. No director or executive officer has been the subject of any order, judgment or decree of any court permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities during the past five years. No director or officer has been found by a court to have violated a federal or state securities or commodities law during the past five years.

None of our directors or executive officers or their respective immediate family members or affiliates are indebted to us.
 
 
39
 

Legal Proceedings

On September 21, 2012, the Company received notification from the SEC that the SEC had filed a civil complaint in Federal District Court in Georgia against the Company, alleging that the Company issued four misleading press releases during the period from August 2010 through October 2010 and one misleading press release in July 2011, related to the Company’s production schedule of its auto retractable safety syringe. The SEC names the Company’s current Chief Executive Officer, Rondald L. Wheet, as a co-defendant. Among other relief, the SEC seeks an order requiring the defendants to disgorge money received from its equity line financing from August 2010 through May 2011, in addition to other civil penalty amounts.  The Company, in consultation with its legal counsel, intends to vigorously defend itself and its Chief Executive Officer, Rondald L. Wheet, against these claims.

Other than with regard to the matter described above, none of the members of the board of directors or other executives has been involved in any bankruptcy proceedings, criminal proceedings, any proceeding involving any possibility of enjoining or suspending members of our board of directors or other executives from engaging in any business, securities or banking activities, and have not been found to have violated, nor been accused of having violated, any Federal or State securities or commodities laws.

Compliance with Section 16(A) of the Exchange Act

Section 16(a) of the Exchange Act requires the Company’s directors, executive officers and persons who beneficially own 10% or more of a class of securities registered under Section 12 of the Exchange Act to file reports of beneficial ownership and changes in beneficial ownership with the SEC. Directors, executive officers and greater than 10% stockholders are required by the rules and regulations of the SEC to furnish the Company with copies of all reports filed by them in compliance with Section 16(a).
 
Based solely on our review of certain reports filed with the Securities and Exchange Commission pursuant to Section 16(a) of the Securities Exchange Act of 1934, as amended, the reports required to be filed with respect to transactions in our common stock during the fiscal year ended December 31, 2012, were timely.

Code of Ethics

We do not currently have a code of ethics that applies to our Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer or Controller, or persons performing similar functions.  Because we have only limited business operations and four officers and directors, we believe a code of ethics would have limited utility.  We intend to adopt such a code of ethics as our business operations expand and we have more directors, officers and employees.

Item 11.  Executive Compensation.

The following summary compensation table sets forth all compensation awarded to, earned by, or paid to the named executive officers paid by us during the periods ended December 31, 2012, 2011 and 2010.
Name And
Principal Position
Year
  
Salary
($)
    
Bonus
($)
    
Stock
Awards
($)(2)
    
Option
Awards
($)
    
Non-Equity
Incentive
Plan
Compen-
sation ($)
    
All Other
Compen-
sation ($)
    
Total ($)
  
Rondald L. Wheet
2012
   $ 240,000     $ 0     $ 0     $ 153,000     $ 0     $ 0     $ 393,000  
Chief Executive Officer
2011
   $ 225,000     $ 40,580     $ 0     $ 162,100     $ 0     $ 0     $ 427,680  
 
2010
   $ 225,000     $ 0     $ 0     $ 0     $ 0     $ 0     $ 225,000  
Thomas O’Brien (1)
2012
   $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
Former President
2011
   $ 124,790     $ 0     $ 0     $ 0     $ 0     $ 0     $ 124,790  
 
2010
   $ 180,000     $ 0     $ 0     $ 0     $ 0     $ 0     $ 180,000  
Burt Hodges
2012
   $ 168,217     $ 0     $ 0     $ 41,958     $ 0     $ 0     $ 210,175  
Chief Financial Officer
2011
   $ 89,375     $ 0     $ 0     $ 69,163     $ 0     $ 0     $ 158,538  
Vincent Olmo
2012
   $ 168,580     $ 0     $ 0     $ 118,458     $ 0     $ 0     $ 287,038  
Chief Operating Officer
2011
   $ 124,625     $ 0     $ 0     $ 117,588     $ 0     $ 0     $ 242,213  

 
(1)
Mr. O’Brien resigned from his position on September 21, 2011.
 
(2)
The value of options was based on Black-Scholes Model. See notes to the financial statements.
 
 
40
 
2012 OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END
 
OPTION AWARDS
  
STOCK AWARDS
  
Name (a)
  
Number of Securities Underlying Unexercised Options
(#)
Exercisable
(b)
    
Number of Securities Underlying Unexercised Options
(#)
Unexercisable
(c)
    
Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options
(#)
(d)
    
Option Exercise Price
($)
(e)
  
Option Expiration Date
(f)
  
Number of Shares or Units of Stock That Have Not Vested
(#)
(g)
    
Market Value of Shares or Units of Stock That Have Not Vested
($)
(h)
    
Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested
(#)
(i)
    
Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested
(#)
(j)
  
Rondald L. Wheet
Chief Executive Officer
     7,000,000       —       —     $ 0.12  
12/31/2013
     —       —       —       —  
                                                                   
Thomas O’Brien (1)
Former President
     —       —       —       —  
12/31/2013
     —       —       —       —  
                                                                   
Burt Hodges
Chief Financial Officer
     800,000       —       —     $ 0.43  
12/31/2013
     —       —       —       —  
                                                                   
Vincent Olmo
Chief Operating Officer
     1,500,000       —       —     $ 0.32  
12/31/2013
     —       —       —       —  
                                                                   
Thomas M. Beahm
Director
     1,500,000       —       —     $ 0.20  
12/31/2013
                                
 
(1)
Mr. O’Brien resigned from his position on September 21, 2011.
 
DIRECTOR COMPENSATION

The following summary compensation table sets forth all compensation awarded to, earned by, or paid to the named directors by us during the years ended December 31, 2012, 2011 and 2010.
 
Name
and
Principal
Position
Year
  
Salary
($)
    
Bonus
($)
    
Stock
Awards
($)
    
Option
Awards
($)
    
Non-Equity
Incentive
Plan
Compensation
($)
    
All Other
Compensation
($)
    
Total
($)
  
(a)
(b)
  
(b)
    
(b)
    
(b)
    
(b)
    
(b)
    
(b)
    
(b)
  
Rondald L. Wheet
2012
   $ 0     $ 0     $ 0     $ 153,000     $ 0     $ 0     $ 153,000  
Director
2011
   $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
 
2010
   $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
Thomas M. Beahm
2012
   $ 0     $ 0     $ 0     $ 153,000     $ 0     $ 0     $ 153,000  
Director
2011
   $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
 
2010
   $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
Thomas O’Brien (1)
2012
   $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
Former Director
2011
   $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
 
2010
   $ 0     $ 0     $ 0     $ 0     $ 0     $ 0     $ 0  
 
(1)
Mr. O’Brien resigned from his position as a member of the board of directors on September 21, 2011.

Employment Agreements

Employment Agreement with Rondald L. Wheet, Chief Executive Officer

Effective May 15, 2012, the Company and Mr. Wheet, our Chief Executive Officer, entered into a two (2) year employment agreement, which provides for an annual salary of $247,500.  Under such agreement, Mr. Wheet shall administer, supervise, manage and control the business development of the Company, including the research, development, manufacture, marketing and sales of its current products and any future products that may be added to the Company's business. The Company will provide him with all reasonable and customary fringe benefits, including, but not limited to, participation in pension plans, profit sharing plans, employee stock ownership plans, stock option plans (whether statutory or not), stock appreciation rights plans, hospitalization, medical dental disability and life insurance, car allowance, vacation and sick leave.  The Company will reimburse of all his reasonable and necessary travel, entertainment or other related expenses incurred by him in carrying out his duties and responsibilities under the agreement.  The Company will also provide him with a cell phone, suitable office space, and membership dues in professional organizations and for any seminars and conferences related to Company business.
 
41
 

Mr. Wheet may elect, by written notice to the Company, to terminate his employment with continued pay through the employment agreement term if (i) the Company sells all of its assets, (ii) the Company merges with another business entity with a change in control,(iii) more than 50% of the outstanding stock is acquired by a third party, (iv) the Company requires Mr. Wheet to relocate or assigns duties not commensurate with his position as Chief Executive Officer, (v) Mr. Wheet is removed from the Board of Directors or (vi) the Company defaults in making payments required to Mr. Wheet under this employment agreement. During the term of his employment, Mr. Wheet will not work for or provide any services in any capacity to any competitor and, during the term of his employment and for two years following termination of his employment, Mr. Wheet will not solicit any of the Company’s employees, consultants, customers, vendors or accounts.

Employment Agreement with Vincent Olmo, Chief Operating Officer

Effective April 11, 2011, the Company and Mr. Olmo, our Chief Operating Officer, entered into a three (3) year employment agreement. The agreement provides for an annual salary of $165,000 modified with a cost of living adjustment annually.  He is responsible for all daily operating and production activities of the Company. The Company will provide him with all reasonable and customary fringe benefits, including, but not limited to, participation in pension plans, profit sharing plans, employee stock ownership plans, stock option plans (whether statutory or not), stock appreciation rights plans, hospitalization, medical dental disability and life insurance, car allowance, vacation and sick leave.  The Company will reimburse all of his reasonable and necessary travel, entertainment or other related expenses incurred by him in carrying out his duties and responsibilities under the agreement.  The Company will also provide him with a cell phone, suitable office space, and membership dues in professional organizations and for any seminars and conferences related to Company business.

Mr. Olmo may elect, by written notice to the Company, to terminate his employment with continued pay through the employment agreement term if (i) the Company sells all or substantially all of its assets, (ii) the Company merges with another business entity with a change in control,(iii) more than 50% of the outstanding stock is acquired by a third party, (iv) the Company requires Mr. Olmo to relocate or assigns duties not commensurate with his position as the Chief Operating Officer  and (v) the Company defaults in making payments required to Mr. Olmo under this agreement.  For two years following his resignation or termination, Mr. Olmo will not work for or provide any services in any capacity to any competitor and will not solicit any of the Company’s customers or accounts.

Employment Agreement with Burton Hodges, Chief Financial Officer

Effective June 1, 2011, the Company and Mr. Hodges, our Chief Financial Officer, entered into a three (3) year employment agreement. The agreement provides for an annual salary of $165,000 modified with a cost of living adjustment annually.  He is responsible for all financial functions and capital resources of the Company, including corporate finance, project finance, corporate accounting, reporting and risk management.  The Company will provide him with all reasonable and customary fringe benefits, including, but not limited to, participation in pension plans, profit sharing plans, employee stock ownership plans, stock option plans (whether statutory or not), stock appreciation rights plans, hospitalization, medical dental disability and life insurance, car allowance, vacation and sick leave.  The Company will reimburse all of his reasonable and necessary travel, entertainment or other related expenses incurred by him in carrying out his duties and responsibilities under the agreement.  The Company will also provide him with a cell phone, suitable office space, and membership dues in professional organizations and for any seminars and conferences related to Company business.

Mr. Hodges may elect, by written notice to the Company, to terminate his employment with continued pay through the employment agreement term if (i) the Company sells all or substantially all of its assets, (ii) the Company merges with another business entity with a change in control,(iii) more than 50% of the outstanding stock is acquired by a third party, (iv) the Company requires Mr. Hodges to relocate or assigns duties not commensurate with his position as the Chief Financial Officer  and (v) the Company defaults in making payments required to Mr. Hodges under this agreement.  For two years following his resignation or termination, Mr. Hodges will not work for or provide any services in any capacity to any competitor and will not solicit any of the Company’s customers or accounts.
 
 
42
 

Item 12.  Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The following table sets forth, as of April 22, 2013, the number of shares of our common stock owned by (i) each person who is known by us to own of record or beneficially five percent (5%) or more of our outstanding shares, (ii) each of our directors, (iii) each of our executive officers and (iv) all of our directors and executive officers as a group. Unless otherwise indicated, each of the persons listed below has sole voting and investment power with respect to the shares of our common stock beneficially owned.

Name and Address (1)
Beneficial
Relationship to Company
  
Outstanding
Common Stock
    
Percentage of
Ownership of
Common Stock
(3)
  
Rondald L. Wheet
Chief Executive Officer, Chairman
    
4,371,282
      
5.63
%(2)
Dr. Thomas Beahm
Director
    
3,439,849
      
4.43
%
Burt Hodges
Chief Financial Officer
    
20,000
(4)
    
*
%
Vincent Olmo
Chief Operating Officer
    
735,811
(5)
    
*
%
Thomas O’Brien
      
3,645,625
      
4.70
%
Officers and Directors (4 persons)
-
    
12,212,567
      
15.74
%

* less than 1%

 
(1)
Unless otherwise indicated, the address of each beneficial owner listed above is c/o Rondald L. Wheet, Revolutions Medical Corporation, 670 Marina Drive, 3rd Floor, Charleston, SC 29492.
 
(2)
This percentage does not include shares of Preferred Stock or options to purchase shares of common stock.
 
(3)
Based on 77,610,014 shares outstanding as of April 22, 2012.
 
(4)
This total does not include options to purchase 800,000 shares of the Company’s common stock.
 
(5)
This total does not include options to purchase 1,500,000 shares of the Company’s common stock.

DESCRIPTION OF SECURITIES

General

We are authorized to issue an aggregate number of 255,000,000 shares of capital stock, of which 250,000,000 shares are common stock, $0.001 par value per share, and 5,000,000 shares are preferred stock, $0.001 par value per share.

Common Stock

We are authorized to issue 250,000,000 shares of common stock, par value $0.001 per share, of which 77,610,014 shares were outstanding as of April 22, 2013.

Holders of our common stock are entitled to one vote per share on all matters submitted to a vote of the shareholders. Shares of our common stock do not have cumulative voting rights, which mean that the holders of a majority of the shareholder votes eligible to vote and voting for the election of the board of directors can elect all members of the board of directors. Holders of a majority of the issued and outstanding shares of common stock may take action by written consent without a meeting. Upon any liquidation, dissolution or winding up, holders of shares of our common stock are entitled to receive pro rata all of our assets available for distribution to shareholders. Holders of our common stock do not have any preemptive rights to subscribe for or to purchase any stock, obligations or other securities.
 
 
43
 

Preferred Stock

The Company has 5,000,000 shares of preferred stock ($0.001 par value) authorized. When the Company issues its preferred stock, it is designated with the year of when it is issued. As of March 29, 2013, there were 1,000,000 shares of preferred stock outstanding. On October 24, 2006, the Company designated 1,000,000 shares as Series 2006 Preferred Stock, which were then issued to Mr. Wheet, the Company’s Chief Executive Officer. Each share of preferred stock is convertible, at any time at the discretion of Mr. Wheet, into one share of the Company’s common stock for each share of series of preferred share. Each series of preferred stock has voting rights of 125 votes per share of series preferred voting together as one class with the Company’s common stock. As a result, Mr. Wheet has effective voting control of the Company’s common stock and as such can unilaterally decide on business matters. Upon conversion of the series preferred, each share of common stock resulting from the conversion shall be entitled to one vote per share-not 125 votes per share.
 
Common Stock Options and Warrants Outstanding
 
As of December 31, 2012, there were 12,100,000 options outstanding, which consisted of options to purchase common stock at exercise prices ranging from $0.08 to $0.50 per share, all of which are exercisable. 5,000,000 options still outstanding were granted in 2007 at an exercise price of $0.08 per share and are considered in the money as of December 31, 2012. 2,500,000 options issued in 2011 exercisable at $0.15 per share are considered out of the money. An additional 1,000,000 options issued at an exercise price of $0.50 are considered out of the money. 3,300,000 options issued in 2011 at an exercise price of $0.30 are considered out of the money. 300,000 options issued in 2012 at an exercise price of $0.40 are considered out of the money. Additionally, as of December 31, 2012, there were 2,880,000 warrants outstanding. All of these warrants were issued in 2012 according to the terms of 21 convertible debt agreements. 1,920,000 of these warrants are exercisable at $0.25 and 960,000 are exercisable at $0.50.The warrants exercisable at $0.25 expire on June 30, 2013. The warrants exercisable at $0.50 expire on September 30, 2013.
 
Item 13.  Certain Relationships and Related Transactions, and Director Independence.

Related Transactions

The Company incurred $120,000 in office rent to Osprey South, LLC in 2012. The Company’s CEO and Chairman of the Board, Rondald Wheet is the sole member of Osprey South, LLC. The contract is a triple net lease with terms based upon market rates for class A office space at the time of the lease signing. The monthly rent under such lease is $10,000.

Director Independence
 
The common stock of the Company is currently quoted on the OTC Markets, an exchange which currently does not have director independence requirements.  On an annual basis, each director and executive officer will be obligated to disclose any transactions with the Company in which a director or executive officer, or any member of his or her immediate family, have a direct or indirect material interest in accordance with Item 407(a) of Regulation S-K.  Following completion of these disclosures, the Board will make an annual determination as to the independence of each director using the current standards for “independence” that satisfy both the criteria for the Nasdaq and the American Stock Exchange.

As of December 31, 2012, the Board determined that the no directors are independent under these standards.

Item 14.  Principal Accounting Fees and Services.

Audit Fees

Audit fees consist of assurance and related services that are reasonably related to the performance of the audit or review of our financial statements.  This category includes fees related to the performance of audits and attest services not required by statute or regulations, and accounts consultations regarding the application of GAAP to proposed transactions.  The aggregate audit fees billed for the fiscal years ended December 31, 2012 and 2011 were $38,000 and $18,229, respectively.
 
 
44
 

Audit Related Fees

The aggregate fees billed for assurance and related services by our principal accountant that are reasonably related to the performance of the audit or review of our financial statements, other than those previously reported in this Item 14, for the fiscal years ended December 31, 2012 and 2011 were $0 and $0.

Tax Fees

Tax fees consist of the aggregate fees billed for professional services rendered by our principal accountants for tax compliance, tax advice, and tax planning. These services include preparation for federal and state income tax returns. The aggregate tax fees billed for the fiscal years ended December 31, 2012 and 2011 were $0 and $0, respectively.

Audit Committee Pre-Approval Policies and Procedures

Effective May 6, 2003, the SEC adopted rules that require that before our auditor is engaged by us to render any auditing or permitted non-audit related service, the engagement be:

 
·
approved by our audit committee; or

 
·
entered into pursuant to pre-approval policies and procedures established by the audit committee, provided the policies and procedures are detailed as to the particular  service,  the  audit committee is informed of each service, and such policies and procedures do not include delegation of the audit committee's responsibilities to management.

We do not have an audit committee.  Our entire board of directors pre-approves all services provided by our independent auditors.
 
 
45
 

PART IV

Item 15.  Exhibits, Financial Statement Schedules.

Exhibit No.
  
Description
     
3.1
  
Amended and Restated Articles of Incorporation, dated November 24, 2010 (filed as Exhibit 3.1 on Form 10-K for the year ended December 31, 2010, as filed with the SEC on March 30, 2011)
     
3.2
  
Bylaws (filed as Exhibit 2.2 to our Amended Form 10-SB filed August 15, 2001)
     
4.1
  
Form of Common Stock Certificate (filed as Exhibit 3.1 to our Form 10-SB filed December 23, 1999)
     
4.2
  
$1,050,000 Convertible Promissory Note, dated February 24, 2011 (filed as Exhibit 4.2 on Form S-1, as filed with the SEC on April 6, 2011)
     
10.1
  
Joint Venture Agreement with Globe, dated November 3, 2006 (as filed as Exhibit 10.1 of the Company's Form 10-QSB for the quarter ended September 30, 2006, filed with the SEC on November 17, 2006)
     
10.2
  
Safety Scalpel Joint Venture agreement with Globe dated August 11, 2006 (as filed as Exhibit 10.2 of the Company's Form 10-QSB for the quarter ended June 30, 2006, filed with the SEC on August 19, 2006)
     
10.3
  
Employment Agreement with Rondald L. Wheet (as filed as Exhibit 10.3 of the Company's Form 10-KSB for the year ended December 31, 2007)
     
10.4
  
Employment Agreement with Burt Hodges (as filed as Exhibit 10.1 of the Company’s Form 8-K filed June 7, 2011)
     
10.5
  
Mutual Release and Settlement Agreement between the Company and Gifford M. Mabie, dated April 14, 2006 (as filed as Exhibit 10.13 of the Company's Form 10-KSB for the year ended December 31, 2004, filed with the SEC on April 15, 2006)
     
10.6
  
Agreement and Plan of Merger between Cerro Mining Corporation and the Company. dated May 9, 1997 (filed as Exhibit 6.6 to our Form 10-SB filed December 23, 1999)
     
10.7
  
Agreement and Plan of Merger between Clear Image Acquisition Corporation and the Company dated January 26, 2007 (filed as Exhibit 10.6 to our Form 8-K filed January 26, 2007)
     
10.8
  
Employment Agreement with Vincent L. Olmo (as filed as Exhibit 10.1 to the Company's Form 8-K filed April 15, 2011)
     
10.9
  
Drawdown Equity Financing Agreement, dated April 22, 2010, by and between the Company and Auctus Private Equity Fund, LLC (filed as Exhibit 10.1 to our Form 8-K, filed April 26, 2010)
     
10.10
  
Registration Rights Agreement, dated April 22, 2010, by and between the Company and Auctus Private Equity Fund, LLC (filed as Exhibit 10.2 to our Form 8-K, filed April 26, 2010)
     
10.11
  
Registration Rights Agreement, dated February 24, 2011, by and between the Company and JMJ Financial, Inc. (filed as Exhibit 10.11 on Form S-1, as filed with the SEC on April 6, 2011)
     
10.12
  
Committed Equity Facility Agreement, dated December 29, 2011, by and between Revolutions Medical Corporation and TCA Global Credit Master Fund, LP (filed as Exhibit 10.12 to our Form S-1, filed February 14, 2012)
     
10.13
  
Registration Rights Agreement, dated December 29, 2011, by and between Revolutions Medical Corporation and TCA Global Credit Master Fund, LP (filed as Exhibit 10.13 to our Form S-1, filed February 14, 2012)
     
10.14   Employment Agreement with Rondald L. Wheet (as filed as Exhibit 10.2 of the Company's Form 10-Q for the quarter ended March 31, 2012, filed with the SEC on May 15, 2012)
     
31.1
  
Certification by the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14 (a)) *
     
31.2
  
Certification by the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14 (a)) *
     
32.1
  
Certification by the Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 *
     
32.2
  
Certification by the Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 *
     
101.INS   XBRL Instance**
     
101.SCH   XBRL Taxonomy Extension Schema**
     
101.CAL   XBRL Taxonomy Extension Calculation**
     
101.DEF   XBRL Taxonomy Extension Definition**
     
101.LAB   XBRL Taxonomy Extension Labels**
     
101.PRE   XBRL Taxonomy Extension Presentation**
     
    * filed herewith
     
   
** In accordance with Regulation S-T, the XBRL-related information on Exhibit No.101 to this Annual Report on Form 10-K shall be deemed “furnished” herewith and not “filed.”
 
 
46
 

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


     
REVOLUTIONS MEDICAL CORPORATION
           
           
Date: May 2, 2013
  
By:
 /s/ Rondald L. Wheet
  
       
Name: Rondald L. Wheet
  
       
Title: Chief Executive Officer
      (Principal Executive Officer)
  


Date: May 2, 2013
  
By:
 /s/ Burt Hodges
  
       
Name: Burt Hodges
  
       
Title: Chief Financial Officer
      (Principal Financial Officer)
      (Principal Accounting Officer)
  


Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
 
Name
  
Position
  
Date
         
/s/ Rondald L. Wheet
  
Chief Executive Officer and Chairman
  
May 2, 2013
Rondald L. Wheet
        
         
/s/ Dr. Thomas Beahm
  
Director
  
May 2, 2013
Dr. Thomas Beahm
        
         
/s/ Burt Hodges
  
Chief Financial Officer
  
May 2, 2013
Burt Hodges
        
         
/s/ Vincent Olmo
  
Chief Operating Officer
  
May 2, 2013
Vincent Olmo
        
 
 
47
 
 
REVOLUTIONS MEDICAL CORPORATION
 
INDEX TO FINANCIAL STATEMENTS
 

Reports of Independent Registered Public Accounting Firms
  
F-2
     
Balance Sheets at December 31, 2012 and 2011
  
F-4
     
Statements of Operations  for the Years Ended December 31, 2012 and 2011and From Inception (August 16, 1996) Through December 31, 2012
  
F-5
     
Statements of Shareholders' Equity (Deficit) for the Years Ended December 31,  2012 and 2011 and From Inception (August 16, 1996) Through December 31, 2012
  
F-6
     
Statements of Cash Flows for the Years Ended December 31, 2012 and 2011 and From Inception (August 16, 1996) Through December 31, 2012
  
F-7
     
Notes to Financial Statements
  
F-9

 
F-1
 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
To the Board of Directors and
Stockholders of Revolutions Medical Corporation
(A Development Stage Company)
Charleston, South Carolina

We have audited the accompanying balance sheet of Revolutions Medical Corporation as of December 31, 2012, and the related statements of operations, stockholders’ equity (deficit), and cash flows for the year then ended and for the period from August 16,1996 (inception) to December 31, 2012.  Revolutions Medical Corporation’s management is responsible for these financial statements.  Our responsibility is to express an opinion on these financial statements based on our audit. The financial statements for the period from August 16, 1996 (inception) through December 31, 2011 were audited by other auditors whose report expressed an unqualified opinion on those financial statements. The financial statements for the period from August 16, 1996 (inception) through December 31, 2011 include a net loss of $30,774,410. Our opinion on the financial statements for the period from August 16, 1996 (inception) through December 31, 2012, insofar as it relates to amounts from August 16, 1996 (inception) through December 31, 2011, is based solely on the report of other auditors.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States).  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.  The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.  Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting.  Accordingly, we express no such opinion.  An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.  We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Revolutions Medical Corporation as of December 31, 2012, and the results of its operations and its cash flows for the year then ended and for the period from August 16, 1996 (inception) to December 31, 2012 in conformity with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that Revolutions Medical Corporation will continue as a going concern.  As discussed in Note 2 to the financial statements, Revolutions Medical Corporation has suffered recurring losses from operations and has a working capital deficiency.  These factors raise substantial doubt about its ability to continue as a going concern.  Management’s plans in regard to these matters are also described in Note 2.  The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ GBH CPAs, PC
GBH CPAs,PC
www.gbhcpas.com
Houston, Texas
April 29, 2012

 
F-2
 
 
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
To the Shareholders of Revolutions Medical Corporation:
 
We have audited the accompanying consolidated balance sheet of Revolutions Medical Corporation (formerly Maxxon, Inc.) (a development stage company) as of December 31, 2011, and the related statements of operations, shareholders’ equity, and cash flows for the year ended December 31, 2011 and for the period from August 16, 1996 (inception) to December 31, 2011. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit.
 
We conducted our audit in accordance with auditing standards of the Public Company Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.
 
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Revolutions Medical Corporation as of December 31, 2011, and the results of its operations and its cash flows for the year ended December 31, 2011 and for the period from August 16, 1996 (inception) to December 31, 2011 in conformity with accounting principles generally accepted in the United States of America.
 
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency, which raises substantial doubt about its ability to continue as a going concern. Management’s plans regarding those matters also are described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

As discussed in Note 15, the financial statements as of December 31, 2011 and the year then ended have been restated to correct for certain errors.

/s/ Hood & Associates CPAs, P.C.
 
Hood & Associates CPAs, P.C.
Certified Public Accountants
 
March 30, 2012 (April 26, 2013 as to the effects of the restatement described in Note 15)
Tulsa, Oklahoma
 
 
F-3
 
 
REVOLUTIONS MEDICAL CORPORATION
(A Development Stage Company)
BALANCE SHEETS
 
   
As of December 31,
  
   
2012
    
2011
  
         
(Restated)
  
ASSETS
  
Current assets:
            
Cash and cash equivalent
   $ 54     $ 4,844  
Inventories
     321,791       -  
Prepaid expenses and other current assets
     4,859       279,868  
Total current assets
     326,704       284,712  
                 
Property and equipment, net
     356,656       1,185,664  
Intangibles
     106,687       116,426  
Goodwill
     -       23,276  
                 
Total assets
   $ 790,047     $ 1,610,078  
                 
LIABILITIES AND STOCKHOLDERS’ DEFICIT
  
                 
Current liabilities:
                
Accounts payable and accrued liabilities
   $ 1,122,371     $ 468,468  
Payable to Yeso-med
     1,280,860       352,544  
Accounts payable and accrued liabilities, related parties
     73,957       87,944  
Payable for indemnification
     1,347,806       1,424,019  
Convertible notes, net of discounts of $187,039 and $307,126, respectively
     184,289       80,535  
Convertible notes, related parties, net of discount of $42,534 and $0, respectively
     32,466       -  
Derivatives, note conversion feature
     364,802       442,311  
Total liabilities
     4,406,551       2,855,821  
                 
Commitments and contingencies
                
                 
Stockholders’ deficit:
                
Series 2006 Preferred stock, $0.001 par value, 5,000,000 shares authorized; 1,000,000 shares issued and outstanding
     1,000       1,000  
Common stock, $0.001 par value; 250,000,000 shares authorized; 72,784,907 and 54,729,606 shares issued and outstanding, respectively.
     72,785       54,730  
Additional paid-in capital
     34,319,432       29,497,937  
Subscriptions receivable
     (71,000 )     (25,000 )
Deficit accumulated during the development stage
     (37,938,721 )     (30,774,410 )
Total stockholders' deficit
     (3,616,504 )     (1,245,743 )
                 
Total liabilities and stockholders’ deficit
   $ 790,047     $ 1,610,078  

The accompanying notes are an integral part of the financial statements.

 
F-4
 
 
REVOLUTIONS MEDICAL CORPORATION
 (A Development Stage Company)
 STATEMENTS OF OPERATIONS
 
   
Year Ended
December 31,
2012
    
Year Ended
December 31,
2011
    
From Inception
(August 16, 1996)
Through December 31,
2012
  
         
(Restated)
        
Revenue
   $ 1,189     $ -     $ 1,189  
                         
Cost of revenue
     9,200       -       9,200  
Loss on firm purchase commitment
     783,593       -       783,593  
Cost of goods sold
     792,793       -       792,793  
                         
Gross loss
     (791,604 )     -       (791,604 )
Operating expenses:
                        
Research and development
     35,544       57,000       2,935,949  
Depreciation and amortization
     102,971       17,023       205,111  
General and administrative expenses
     4,046,080       3,781,286       27,298,804  
Impairment of assets
     878,276       -       4,570,007  
Gain on disposal of assets
     -       -       (794 )
Total operating expenses
     5,062,871       3,855,309       35,009,077  
                         
Operating loss
     (5,854,475 )     (3,855,309 )     (35,800,681 )
Other income (expense):
                        
Interest income
     -       10       17,286  
Interest expense
     (1,727,512 )     (567,081 )     (2,629,705 )
Investment income
     -       -       170,753  
Gain (loss) on extinguishment of debt
     13,202       -       (139,712 )
Gain (loss) on change in fair value of derivative liabilities
     131,397       (119,138 )     (45,976 )
Other income, net
     273,077       -       305,892  
Total other income (expense)
     (1,309,836 )     (686,209 )     (2,321,462 )
                         
Net loss
     (7,164,311 )     (4,541,518 )     (38,122,143 )
Net loss attributable to the non-controlling interest
     -       -       (183,422 )
Net loss attributable to Revolutions Medical Corporation
   $ (7,164,311 )   $ (4,541,518 )   $ (37,938,721 )
                         
Weighted average common shares outstanding – basic and diluted
     61,779,765       49,149,099          
                         
Net loss per common share – basic and diluted
   $ (0.12 )   $ (0.09 )        
 
The accompanying notes are an integral part of the financial statements.

 
F-5
 
 
REVOLUTIONS MEDICAL CORPORATION
(A Development Stage Company)
STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
 
   
Preferred Stock
    
Common Stock
    
Additional Paid-In
    
Deficit Accumulated during the Development
    
Subscriptions
    
Treasury stock
        
   
Shares
    
Amount
    
Shares
    
Amount
    
Capital
    
Stage
    
Receivable
    
Reserved
    
Total
  
Balance at Inception (August 16, 1996)
     -     $ -       -     $ -     $ -     $ -     $ -     $ -     $ -  
Cerro Mining/Maxxon- OK merger:
                                                                        
Cerro Mining
     -       -       26,550       27       273       -       -       -       300  
Maxxon-OK:
                                                                        
Shares issued to founders
     -       -       350,000       350       6,650       -       -       -       7,000  
Shares sold for cash to third-party investors
     -       -       28,900       29       574,448       -       -       -       574,477  
Ives transactions:
                                                                        
Investment in Ives Health Company
     -       -       15,562       16       311,246       -       -       -       311,262  
Investment in The Health Club
     -       -       1,750       2       34,998       -       -       -       35,000  
Conversion of Ives debt
     -       -       926       1       26,999       -       -       -       27,000  
Issuance of common stock for:
                                                                        
Cash from third-party investors
     -       -       10,928       11       353,709       -       -       -       353,720  
Cash from related party promissory notes
     -       -       3,225       3       128,997       -       -       -       129,000  
Subscriptions receivable
     -       -       2,638       2       69,798       -       (69,800 )     -       -  
Services rendered
     -       -       4,525       4       173,423       -       -       -       173,427  
Debentures converted
     -       -       5,134       5       74,995       -       -       -       75,000  
Net loss
     -       -       -       -       -       (795,376 )     -       -       (795,376 )
Balance at December 31, 1997
     -       -       450,138       450       1,755,536       (795,376 )     (69,800 )     -       890,810  
Issuance of common stock for:
                                                                        
Conversion of Ives debt
     -       -       2,241       2       54,998       -       -       -       55,000  
Cash from third- party investor
     -       -       2,500       3       90,997       -       -       -       91,000  
Options exercised by third-parties for cash
     -       -       27,293       27       359,873       -       -       -       359,900  
Options exercised by third-parties for services
     -       -       1,207       1       18,099       -       -       -       18,100  
Services rendered by third-parties
     -       -       49,400       49       574,499       -       -       -       574,548  
Debentures converted by third parties
     -       -       27,429       27       274,973       -       -       -       275,000  
Settlement with related party
     -       -       17,500       18       332       -       -       -       350  
Certificates canceled
     -       -       (4,579 )     (4 )     (40,261 )     -       -       -       (40,265 )
Value of services contributed by officer and employees
     -       -       -       -       114,154       -       -       -       114,154  
Compensation cost for stock options granted to non-employees
     -       -       -       -       918,187       -       -       -       918,187  
Cancellation of subscriptions receivable from related party
     -       -       -       -       -       -       69,800       -       69,800  
Net loss
     -       -       -       -       -       (2,584,383 )     -       -       (2,584,383 )
Balance at December 31, 1998
     -       -       573,129       573       4,121,387       (3,379,759 )     -       -       742,201  
Issuance of common stock for:
                                                                        
Cash from third-party investor
     -       -       19,535       20       342,404       -       -       -       342,424  
Less: issue costs
     -       -       -       -       (16,743 )     -       -       -       (16,743 )
Options exercised by third-parties for cash
     -       -       15,000       15       149,985       -       -       -       150,000  
Services rendered by third-parties
     -       -       8,203       8       166,735       -       -       -       166,743  
Value of services contributed by officer and employees
     -       -       -       -       280,000       -       -       -       280,000  
Compensation cost for stock options granted to non-employees
     -       -       -       -       89,728       -       -       -       89,728  
Net loss
     -       -       -       -       -       (1,014,555 )     -       -       (1,014,555 )
Balance at December 31, 1999
     -       -       615,867       616       5,133,496       (4,394,314 )     -       -       739,798  
Issuance of common stock for:
                                                                        
Cash from third-party investor
     -       -       43,139       43       250,345       -       -       -       250,388  
Value of services contributed by officer and employees
     -       -       -       -       405,000       -       -       -       405,000  
Net loss
     -       -       -       -       -       (1,347,859 )     -       -       (1,347,859 )
Balance at December 31, 2000
     -       -       659,006       659       5,788,841       (5,742,173 )     -       -       47,327  
Issuance of common stock for:
                                                                        
Cash from third-party investor
     -       -       327,917       328       1,604,372       -       -       -       1,604,700  
Purchased by employees
     -       -       182,500       183       547,317       -       (547,500 )     -       -  
Issued for repayment of debt
     -       -       2,500       3       7,497       -       -       -       7,500  
Less: issue costs
     -       -       -       -       (85,575 )     -       -       -       (85,575 )
Services rendered by third-parties
     -       -       22,500       23       422,427       -       -       -       422,450  
Compensation cost of stock issued and options granted for services
     -       -       10,000       10       1,487,690       -       -       -       1,487,700  
Compensation cost of stock issued and options granted for services to be amortized
     -       -       -       -       (1,048,754 )     -       -       -       (1,048,754 )
Net loss
     -       -       -       -       -       (2,199,085 )     -       -       (2,199,085 )
Balance at December 31, 2001
     -       -       1,204,423       1,206       8,723,815       (7,941,258 )     (547,500 )     -       236,263  
Issuance of common stock for:
                                                                        
Cash from third-party investor
     -       -       181,250       181       362,319       -       -       -       362,500  
Exercise of options
     -       -       100,341       100       (100 )     -       -       -       -  
Issued for repayment of debt
     -       -       -       -       -       -       102,803       -       102,803  
Cost of stock issued and options granted for services
     -       -       -       -       759,795       -       -       -       759,795  
Compensation cost of stock issued and options granted for services
     -       -       60,000       60       324,440       -       -       -       324,500  
Net loss
     -       -       -       -       -       (1,933,676 )     -       -       (1,933,676 )
Balance at December 31, 2002
     -       -       1,546,014       1,547       10,170,269       (9,874,934 )     (444,697 )     -       (147,815 )
Issuance of common stock for:
                                                                        
MPI settlement costs of stock issued and options granted for services
    -       -       57,000       57       140,643       -       -       -       140,700  
Compensation cost of stock issued and options granted for services
    -       -       350,000       350       139,650       -       -       -       140,000  
Amortized compensation cost of stock issued and options granted for services
     -       -       -       -       288,959       -       -       -       288,959  
Indemnification cost of stock issued and options granted for services
    -       -       200,000       200       79,800       -       -       -       80,000  
Payment towards promissory note balances
    -       -       -       -       -       -       69,201       -       69,201  
Net loss
     -       -       -       -       -       (1,391,518 )     -       -       (1,391,518 )
Balance at December 31, 2003
     -       -       2,153,014       2,154       10,819,321       (11,266,452 )     (375,496 )     -       (820,473 )
Issuance of common stock for:
                                                                        
Cash from third- party investor
    -       -       5,000       5       4,995       -       -       -       5,000  
Exercise of options
    -       -       293,300       293       253,807       -       -       -       254,100  
Exercise of warrants
     -       -       73,100       73       73,027       -       (1,000 )     -       72,100  
Compensation cost of stock issued for services
    -       -       1,642,500       1,643       912,357       -       -       -       914,000  
Payment towards promissory note balances
    -       -       -       -       -       -       18,750       -       18,750  
Net loss
     -       -       -       -       -       (1,552,008 )     -       -       (1,552,008 )
Balance at December 31, 2004
    -       -       4,166,914       4,168       12,063,507       (12,818,460 )     (357,746 )     -       (1,108,531 )
Issuance of Common Stock for Cash:
                                                                        
From third-party investors
    -       -       651,959       652       290,048       -       -       -       290,700  
From the exercise of options
     -       -       90,000       90       44,910       -       -       -       45,000  
Issuance of common stock for subscription
    -       -       260,000       260       33,740       -       (34,000 )     -       -  
Common stock issued for services
     -       -       1,062,500       1,063       475,437       -       -       -       476,500  
Common stock issued pursuant to joint venture
     -       -       291,667       292       137,541       -       -       -       137,833  
Value of warrants granted pursuant to joint venture
     -       -       -       -       499,733       -       -       -       499,733  
Value of options granted for services
    -       -       -       -       130,900       -       -       -       130,900  
Reclassification of receivables against amounts owed
    -       -       -       -       -       -       357,746       -       357,746  
Net loss
     -       -       -       -       -       (1,310,783 )     -       -       (1,310,783 )
Balance at December 31, 2005
    -       -       6,523,040       6,525       13,675,816       (14,129,243 )     (34,000 )     -       (480,902 )
Issuance of common stock:
                                                                        
From the exercise of options for services
     -       -       50,000       50       950       -       -       -       1,000  
From the exercise of options for cash
     -       -       150,000       150       74,850       -       -       -       75,000  
From the exercise of warrants
     -       -       300,000       300       5,700       -       -       -       6,000  
Payment of common stock subscription
     -       -       -       -       -       -       34,000       -       34,000  
Common Stock issued for services
     -       -       275,000       275       107,225       -       -       -       107,500  
Preferred Stock issued for services
     1,000,000       1,000       -       -       19,000       -       -       -       20,000  
Capital contributed by shareholder
     -       -       -       -       3,000       -       -       -       3,000  
Cancellation of Joint Venture with Globe
     -       -       -       -       (625,066 )     -       -       -       (625,066 )
Common stock issued to Globe then returned to treasury
     -       -       (25,000 )     (25 )     (12,475 )     -       -       -       (12,500 )
Compensation cost for option price reduction
     -       -       -       -       50,000       -       -       -       50,000  
Net loss
     -       -       -       -       -       (598,302 )     -       -       (598,302 )
Balance at December 31, 2006
     1,000,000       1,000       7,273,040       7,275       13,299,000       (14,727,545 )     -       -       (1,420,270 )
Sale of common stock for cash
     -       -       845,000       845       299,155       -       -       -       300,000  
Issuance of common stock for Clear Image stock
     -       -       8,273,788       8,274       3,301,241       -       -       -       3,309,515  
Stock compensation
     -       -       -       -       223,246       -       -       -       223,246  
Issuance of common stock:
                                                                        
From the exercise of options for cash
     -       -       125,000       125       9,875       -       -       -       10,000  
warrants
     -       -       345,662       346       6,568       -       -       -       6,914  
Common stock issued for services
     -       -       1,225,000       1,225       388,775       -       -       -       390,000  
Issuance of restricted stock
     -       -       40,000       40       9,960       -       -       -       10,000  
Net loss
     -       -       -       -       -       (4,475,017 )     -       -       (4,475,017 )
Balance at December 31, 2007
     1,000,000       1,000       18,127,490       18,130       17,537,820       (19,202,562 )     -       -       (1,645,612 )
Sale of common stock for cash
     -       -       4,720,978       4,722       300,101       -       -       -       304,823  
Issuance of common stock from the exercise of options for cash
    -       -       2,300,000       2,300       395,317       -       -       -       397,617  
Common stock issued for services
     -       -       1,419,704       1,419       258,501       -       -       -       259,920  
Common stock issued for repayment of debt
    -       -       271,491       271       132,759       -       -       -       133,030  
Common stock issued to Clear Image investors to participate in the merger
    -       -       43,600       43       12,164       -       -       -       12,207  
Stock compensation
     -       -       -       -       342,801       -       -       -       342,801  
Acquired deficit of former minority interest now owned 100%
     -       -       -       -       (209,776 )     -       -       -       (209,776 )
Net loss
     -       -       -       -       -       (1,335,154 )     -       -       (1,335,154 )
Balance at December 31, 2008
     1,000,000       1,000       26,883,193       26,885       18,769,687       (20,537,716 )     -       -       (1,740,144 )
                                                                         
Sale of common stock for cash
     -       -       5,946,446       5,946       1,396,188       -       -       -       1,402,134  
Issuance of Common Stock from the exercise of options for cash
     -       -       171,250       171       13,529       -       -       -       13,700  
Preferred stock issued for services
     500,000       500       -       -       249,500       -       -       -       250,000  
Common stock issued for services
     -       -       1,530,000       1,530       346,770       -       -       -       348,300  
Common stock issued for repayment of debt
     -       -       667,000       667       306,074       -       -       -       306,741  
Stock compensation
     -       -       -       -       1,452,231       -       -       -       1,452,231  
Acquired deficit of former minority interest now owned 100%
     -       -       -       -       (17,998 )     -       -       -       (17,998 )
Net loss
     -       -       -       -       -       (2,463,751 )     -       -       (2,463,751 )
Balance at December 31, 2009
     1,500,000       1,500       35,197,959       35,199       22,515,981       (23,001,467 )     -       -       (448,787 )
Sale of common stock for cash:
     -       -       4,810,287       4,810       1,525,181       -       -       -       1,529,991  
Issuance of Common Stock from the exercise of options for cash
     -       -       150,000       150       37,350       -       -       -       37,500  
From exercise of warrants for cash
     -       -       117,400       117       58,583       -       -       -       58,700  
Common stock issued for services
     -       -       2,194,891       2,194       558,578       -       -       -       560,772  
Common stock issued for repayment of debt
     -       -       399,441       400       530,356       -       -       -       530,756  
Treasury stock
     -       -       -       -       -       -       -       (969 )     (969 )
Net loss
     -       -       -       -       -       (3,231,425 )     -       -       (3,231,425 )
Balance at December 31, 2010 (Restated)
     1,500,000       1,500       42,869,978       42,870       25,226,029       (26,232,892 )     -       (969 )     (963,462 )
Sale of common stock for cash:
     -       -       656,015       656       201,915       -       -       -       202,571  
Issuance of common stock from the exercise of options for cash
     -       -       6,668,000       6,668       1,672,752       -       (25,000 )     -       1,654,420  
Preferred stock forfeited
     (500,000 )     (500 )     -       -       500       -       -       -       -  
Common stock issued for services
     -       -       1,513,874       1,514       479,586       -       -       -       481,100  
Common stock issued for repayment of debt
     -       -       3,191,367       3,191       959,105       -       -       -       962,296  
From convertible debt beneficial conversion feature
     -       -       -       -       94,624       -       -       -       94,624  
Treasury stock
     -       -       (169,628 )     (169 )     -       -       -       969       800  
Issuance of unexercised options
     -       -       -       -       863,426       -       -       -       863,426  
Net loss
     -       -       -       -       -       (4,541,518 )     -       -       (4,541,518 )
Balance at December 31, 2011 (Restated)
     1,000,000       1,000       54,729,606       54,730       29,497,937       (30,774,410 )     (25,000 )     -       (1,245,743 )
Issuance of common stock from the exercise of options and warrants for cash
     -       -       1,235,000       1,235       303,040       -       (46,000 )     -       258,275  
Common stock issued for services
     -       -       2,751,229       2,751       513,360       -       -       -       516,111  
Options issued for services
     -       -       -       -       974,961       -       -       -       974,961  
Warrants issued with convertible notes payable
     -       -       -       -       347,097       -       -       -       347,097  
Convertible notes payable beneficial conversion feature
     -       -       -       -       237,774       -       -       -       237,774  
Common stock issued for repayment of debt
     -       -       13,669,072       13,669       2,305,103       -       -       -       2,318,772  
Common stock issued for indemnification settlement
     -       -       400,000       400       140,160       -       -       -       140,560  
Net loss
     -       -       -       -       -       (7,164,311 )     -       -       (7,164,311 )
Balance at December 31, 2012
     1,000,000     $ 1,000       72,784,907     $ 72,785     $ 34,319,432     $ (37,938,721 )   $ (71,000 )   $ -     $ (3,616,504 )
 
The accompanying notes are an integral part of the financial statements.
 
 
F-6
 
 
REVOLUTIONS MEDICAL CORPORATION
(A Development Stage Company)
STATEMENTS OF CASH FLOWS
 
   
Year Ended December 31,
    
From Inception
(August 16, 1996)
Through December 31,
  
   
2012
    
2011
    
2012
  
         
(Restated)
        
Cash flows from operating activities:
                  
Net loss
   $ (7,164,311 )   $ (4,541,518 )   $ (37,938,721 )
Adjustments to reconcile net loss to net cash used in operating activities:
                        
Depreciation and amortization
     102,971       17,023       205,111  
Stock-based compensation expense
     1,491,072       1,065,458       12,616,731  
Stock option modification expense
     -       -       50,000  
Impairment of assets
     878,276       -       4,570,007  
Gain on disposal of assets
     -       -       (794 )
Amortization of debt discounts
     1,428,978       489,080       1,861,218  
Interest expense incurred on issuance of convertible debt
     182,733       165,442       396,474  
(Gain) loss on change in fair value of derivative liabilities
     (131,397 )     (40,030 )     (175,753 )
Change in operating assets and liabilities:
                        
Inventories
     (321,791 )     -       (321,791 )
Prepaid expenses and other current assets
     275,009       162,181       (4,859 )
Accounts payable and accrued liabilities
     1,533,758       (11,439 )     3,074,372  
Accounts payable and accrued liabilities – related parties
     (13,987 )     63,659       73,957  
Payable for indemnification
     64,347       67,071       1,805,396  
Net cash used in operating activities
     (1,674,342 )     (2,563,073 )     (13,788,652 )
                         
Cash flows from investing activities:
                        
Purchase of property and equipment
     -       (31,777 )     (992,907 )
Proceeds from sale of fixed assets
     -       -       794  
Purchase of license and patents
     (39,224 )     (97,314 )     (161,538 )
Investment in Ives Health Company and The Health Club
     -       -       (261,997 )
Net cash used in investing activities
     (39,224 )     (129,091 )     (1,415,648 )
                         
Cash flows from financing activities:
                        
Capital contribution
     -       -       802,154  
Proceeds from issuance of common stock through cash- exercise of stock options and warrants
     258,275       1,654,420       3,412,412  
Proceeds from issuance of notes for cash
     1,450,501       770,500       2,976,001  
Proceeds from loans from shareholders
     -       -       15,707  
Repayment of loans from shareholders
     -       -       (8,005 )
Repayment of notes
     -       -       (157,325 )
Proceeds for issuance of common stock for cash
     -       202,571       8,163,410  
Net cash provided by financing activities
     1,708,776       2,627,491       15,204,354  
                         
Net change in cash
     (4,790 )     (64,673 )     54  
Cash at beginning of period
     4,844       69,517       -  
Cash at end of period
   $ 54     $ 4,844     $ 54  
 
The accompanying notes are an integral part of the financial statements.
 
 
F-7
 
 
REVOLUTIONS MEDICAL CORPORATION
(A Development Stage Company)
STATEMENTS OF CASH FLOWS


   
Year Ended December 31,
    
From Inception
(August 16, 1996)
Through December 31,
  
   
2012
    
2011
    
2012
  
         
(Restated)
        
                   
Supplemental disclosure of cash flow information:
                  
Interest paid
   $ -     $ -     $ -  
Taxes paid
   $ -     $ -     $ -  
                         
Non-cash financing and investing activities:
                        
Common stock issued for conversion of debt
   $ 2,318,772     $ 962,296     $ 4,687,415  
Shares issued for indemnification agreement
     140,560       184,000       457,590  
Debt discount on convertible notes
     584,871       769,624       2,405,422  
Common stock issued in connection with Merger
     -       -       300  
Common stock issued for acquisition of Clear Image
     -       -       3,093,948  
Common stock issued for investment
                     358,762  
Preferred stock forfeited
     -       500       500  
Payable recorded for purchase of equipment
     -       352,544       289,009  
 
 
F-8
 
 
REVOLUTIONS MEDICAL CORPORATION
 (A Development Stage Company)
  NOTES TO FINANCIAL STATEMENTS
 
NOTE 1 –DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization and Nature of Operations

Revolutions Medical Corporation, a Nevada corporation, (“the Company” or “RevMed”) has been endeavoring to design, develop and commercialize auto retractable vacuum safety syringes.  Our present product development effort is focused on the RevVac™ Auto Retractable Vacuum Safety Syringe, which is designed specifically to reduce accidental needle stick injuries and lower the spread of blood borne diseases.  The Company also has developed a suite of proprietary MRI software tools; RevColor™, Rev3D™, and RevDisplay™.  These tools are designed to enhance general diagnostic confidence through education and research use and in the future the Company believe will have specific commercial applications. The Company’s administrative facilities are located in Charleston, South Carolina. The Company’s primary manufacturing facility is located in Wuxi, China.
 
Development Stage Company
  
Since its inception in 1996, the Company has been considered a development stage enterprise for financial reporting purposes as significant efforts have been devoted to raising capital and to research and development of various safety syringes and its proprietary MRI software tools.

Accounting Estimates
 
The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ significantly from those estimates.

Reclassification

Certain prior period amounts have been reclassified to conform to current period presentation.

Cash and Cash Equivalents

The Company considers highly liquid investments (those readily convertible to cash) purchased with original maturity dates of three months or less to be cash equivalents.

Accounts Receivable

The Company records trade receivables when revenue is recognized.  No product has been consigned to customers.  The Company’s allowance for doubtful accounts is primarily determined by review of specific trade receivables.  Those accounts that are doubtful of collection are included in the allowance.  These provisions are reviewed to determine the adequacy of the allowance for doubtful accounts.  Trade receivables are charged off when there is certainty as to their being uncollectible.  Trade receivables are considered delinquent when payment has not been made within contract terms.
 
The Company requires certain distributors to make a prepayment prior to beginning production or shipment of their order.  Distributors may apply such prepayments to their outstanding invoices or pay the invoice and continue to carry forward the deposit for future orders.  Such amounts are included in other accrued liabilities on the balance sheets.  The Company records an allowance for estimated returns as a reduction to accounts receivable and gross profit.  To date, returns have been immaterial.

Inventories

Inventories include only finished goods and are valued at the lower of cost or market, with cost being determined using weighted average cost.  The Company compares the average cost to the market price and records the lower value.  Management considers such factors as the amount of inventory on hand and in the distribution channel, estimated time to sell such inventory, the shelf life of inventory, and current market conditions when determining excess or obsolete inventories.  A reserve is established for any excess or obsolete inventories or they may be written off. For the years ended December 31, 2012 and 2011, no allowance for inventory was recorded.
 
 
F-9
 

Property and Equipment

Property and equipment, including significant improvements, are stated at cost. Expenditures for maintenance and repairs are charged to operating expenses as incurred. When properties are retired or otherwise disposed of, the cost of the asset and the related accumulated depreciation are removed from the accounts with the resulting gain or loss being reflected in results of operations.

Depreciation and amortization expense is recorded on a straight-line basis over the estimated useful life of the asset as listed below:
 
Asset Category
  
Useful Lives
Machinery and equipment (years)
  
5 
Furniture and fixtures (years)
  
7 
Leasehold improvements
  
Shorter of leasehold improvement life or remaining term of lease

Intangibles

Intangible assets include patents and trademarks, which are valued at acquisition through independent appraisals and amortized on a straight-line basis over periods varying from 17 to 20 years.

Impairment of Long-lived Assets

The Company reviews the carrying value of the long-lived assets periodically to determine if facts and circumstances exist that would suggest that assets might be impaired or that the useful lives should be modified. Among the factors the Company considers in making the evaluation are changes in market position and profitability. If facts and circumstances exist which may indicate impairment, the Company will prepare a projection of the undiscounted cash flows of the asset group and determine if the long-lived assets are recoverable based on these undiscounted cash flows. If impairment is indicated, an adjustment will be made to reduce the carrying amount of these assets to their fair value.

Research and Development

Research and development costs are expensed as incurred.  The Company incurred $35,544, $57,000 and $2,935,949 of research and development expenses for the years ended December 31, 2012 and 2011, and for the period from August 16, 1996 (inception) through December 31, 2012.

Beneficial Conversion Feature

From time to time, the Company may issue convertible notes that have conversion prices that create an embedded beneficial conversion feature on the issuance date. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of any attached equity instruments, if any related equity instruments were granted with the debt. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital.  The debt discount is amortized to interest expense over the life of the note using the effective interest method.

Derivative Instruments

Derivatives are measured at their fair value on the balance sheet.  In determining the appropriate fair value, the Company uses the Black-Scholes option pricing formula.  Changes in fair value are recorded in the statement of operations.
 
 
F-10
 

Fair Value of Financial Instruments

The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e. exit price), in an orderly transaction between market participants at the measurement date.  The Company categorizes its assets and liabilities measured at fair value based upon the level of judgment associated with the inputs used to measure the fair value. Level inputs are classified as follows:

 
·
Level 1 – quoted prices in active markets for identical assets or liabilities.

 
·
Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

 
·
Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.

The following table summarizes fair value measurements by level at December 31, 2012, for assets and liabilities measured at fair value on a recurring basis:

   
Level 1
    
Level 2
    
Level 3
    
Total
  
Cash and cash equivalents
  
$
54
    
$
—
    
$
—
    
$
54
  
                                 
Derivative liability
  
$
—
    
$
—
    
$
364,802
    
$
364,802
  
 
The following table summarizes fair value measurements by level at December 31, 2011, for assets and liabilities measured at fair value on a recurring basis:

   
Level 1
    
Level 2
    
Level 3
    
Total
  
Cash and cash equivalents
  
$
4,844
    
$
—
    
$
—
    
$
4,844
  
                                 
Derivative liability
  
$
—
    
$
—
    
$
442,311
     $
442,311
  

Revenue Recognition

Revenue is recognized for sales when title and risk of ownership passes to the customer, generally upon shipment from the manufacturing facility in Wuxi, China or from our warehouse facility in Ladson, South Carolina; when price is fixed or determinable; and when collection is reasonably assured.

Share-based Compensation

The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the trading price on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.

Income Taxes
 
The Company uses the liability method of accounting for income taxes.  Under the liability method, deferred taxes are determined based on the differences between the financial statement and tax basis of assets and liabilities at enacted tax rates in effect in the years in which the differences are expected to reverse.
 
Earnings (Loss) Per Common Share
 
Basic net income (loss) per common share is calculated by dividing net income (loss) available to common stockholders for the period by the weighted average shares of common stock outstanding during the period. Diluted net income per common share is computed by dividing the net income for the period by the weighted average number of common and common equivalent shares outstanding during the period. The calculation of diluted income (loss) per common share assumes the dilutive effect of stock options, warrants and any other potentially dilutive securities outstanding. During a loss period, the potentially dilutive securities have an anti-dilutive effect and are not included in the calculation of dilutive net loss per common share. For the year ended December 31, 2011, potentially issuable shares, including options and warrants to purchase 18,845,350 shares of the Company’s common stock and notes payable convertible to 4,637,152 shares of the Company’s common stock, have been excluded from the calculation. For the year ended December 31, 2012, potentially issuable shares, including options and warrants to purchase 14,980,000 shares of the Company’s common stock and notes payable convertible to 6,603,582  shares of the Company’s common stock have been excluded from the calculation.
 
 
F-11
 

Subsequent Events

The Company has evaluated all transactions occurring between the end of its fiscal year, December 31, 2012, through the date of issuance of the financial statements for subsequent event disclosure consideration.

New Accounting Standards

The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company.


NOTE 2 – GOING CONCERN

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company is in the development stage and has not established sources of revenues to fund the development of its business and pay operating expenses, resulting in a cumulative net loss of $37,938,721 for the period from inception (August 16, 1996) to December 31, 2012. The ability of the Company to continue as a going concern during the next year depends on the successful completion of the Company’s capital raising efforts to fund the development of its retractable safety syringe. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.


NOTE 3 – PROPERTY AND EQUIPMENT

The following is a summary of property and equipment at December 31, 2012 and 2011:

   
December 31, 2012
    
December 31, 2011
  
Equipment
   $ 353,235     $ 1,113,235  
Leasehold improvement
     44,000       44,000  
Furniture
     49,147       49,147  
Subtotal
     446,382       1,206,382  
Less: accumulated depreciation
     (89,726 )     (20,718 )
Property and equipment, net
   $ 356,656     $ 1,185,664  

For the years ended December 31, 2012 and 2011, the Company recognized depreciation and amortization expense related to property and equipment of $69,008 and $11,135, respectively.

During 2012, the Company impaired $710,000 of the $760,000 production mold payments made to Medical Investment Group, Inc. (“MIG”) in 2011 and wrote off an $80,000 prepayment to MIG. The impairment charge was based upon the arbitration hearing against MIG in November, 2012. The hearing and the final ruling made clear that all production mold payments made by the Company to MIG for the manufacturing of production molds had instead been used by Mr. Theriault, a representative of MIG, for other non-production related purposes. The American Arbitration Association panel ruled that the only assets in which production was funded by MIG from the Company’s production payments were $50,000 in trial molds. From the time that these payments were made by the Company, the Company believed that each mold payment was being used by MIG for the manufacturing of the final production molds for the 3ml RevVac™ auto-retractable vacuum safety syringe. During the arbitration proceeding, Mr. Theriault disclosed that no such payments, besides $50,000 in trial mold payments, were ever used for the production of the final molds for the RevVac™ auto-retractable vacuum safety syringe. The arbitration panel ruled that a total of $770,000 awarded to the Company.  The Company has not received such payment to date. The gain related to this award will be recorded when collected.
 
 
F-12
 

During 2012, the Company also impaired $50,000 for a trial mold that is no longer considered useful to the Company.

NOTE 4 – INTANGIBLES AND GOODWILL

Intangibles

The following is a summary of the Company’s intangibles at December 31, 2012 and 2011:

   
December 31, 2012
    
December 31, 2011
  
Patent
   $ 146,538     $ 107,314  
Licensing agreement
     -       15,000  
Subtotal
     146,538       122,314  
Less: accumulated amortization
     (39,851 )     (5,888 )
Intangibles , net
   $ 106,687     $ 116,426  

The Company owns one published patent on its Auto Retractable Vacuum RevVac™ safety syringe issued in January 2005 and one published patent on its safety blood drawing device issued in June 2003.  In January 2009, a second patent for the RevVac™ auto retractable vacuum safety syringe was issued by the U.S. patent office and published in April 2009 related to the Globe/Revolutions Medical Joint Venture.  Upon the ruling in the Globe Med Tech lawsuit, the Company now has full ownership of the entire patent.  The Company also filed international patent protection rights regarding the RevVac™ Auto Retractable Vacuum Safety Syringe in the following countries: Australia, China, Japan, Taiwan, Mexico, Canada and in Europe. Patents in Mexico and in China were issued in June 2011 and January 2012, respectively. The Japan patent was issued in the third quarter of 2012.

The Company filed a U.S. provisional patent on May 2, 2011, on its new vacuum design for the pre-filled market.  On May 2, 2012, the Company also filed an international Patent Cooperation Treaty (PCT) for this new design.

The Company is also engaged in the development of technology which can segment and reference MRI images.  By “segmenting” an image, the Company’s technology will let the user select a part of the image (bone, fluid, tissue) and render that selection in three dimensions.  Essentially, different components of an image are given different colors and the user can choose the color or colors to be studied, thus eliminating those portions colored with the colors being discarded.  By “referencing” the image to a database, the user can obtain similar, identified images to aid the user in interpretation of the image being studied.  The Company currently owns 4 separate patent applications, filed in June of 2007, each of which received USPTO office actions during 2010, 2011 and 2012.

The licensing agreement provided licensing rights to a Traxis biopsy software product. The Company decided not to pursue this technology and impaired the cost of $15,000 during 2012.

For the years ended December 31, 2012 and 2011, the Company recognized amortization expense of $33,963 and $5,888, respectively.

Goodwill

In 2007, the Company acquired a 62.2% interest in Clear Image, Inc. (“Clear Image”).  Clear Image was a privately held company and was conducting research and development on Color MRI Technology.   The Company exchanged approximately 8.2 million of its common shares which were trading between $0.40 and $0.50 per share at the time of the acquisition.  To arrive at a value for the Color MRI Technology, the Company and Clear Image determined the amount of funding provided for the research and development of this technology by evaluating the amount expended from 1999 until the acquisition date.  The value of the Company’s stock exchanged for the controlling interest exceeded net assets acquired by $23,276 which was recorded as goodwill.  During 2012, all goodwill was impaired.

 
F-13
 

NOTE 5 – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

The following is a summary of the Company’s accounts payable and accrued liabilities at December 31, 2012 and 2011:

   
December 31, 2012
    
December 31, 2011
  
Accounts payable
   $ 432,436     $ 99,342  
Accrued payroll liabilities and related penalties
     411,670       125,239  
Accrued salary
     143,167       120,000  
Accrued interest
     134,559       64,670  
Other accruals
     539       59,217  
Total accounts payable and accrued liabilities
   $ 1,122,371     $ 468,468  

As of December 31, 2012 and 2011, the Company had accrued $411,670 and $125,239, respectively, pursuant to employment state and federal payroll tax liabilities and related penalties.  Although the Company plans to settle these amounts, there is no assurance that its efforts to settle will be successful.  A tax lien in the amount of $1,227 was filed against the Company on June 18, 2012 by the South Carolina Department of Revenue due to these delinquent payments.  Action by federal taxing authorities has not been initiated or threatened at this point.  There is no assurance, however, that such action will not be initiated in the future.

During the year ended December 31, 2012, the Company wrote off $199,336 of accrued salary to and advances from Rhonda Vincent, former CFO, and $79,890 of payables to various vendors as such claims have passed the statute of limitations in Oklahoma, where the Company formerly conducted operations.  Other income of $279,226 was recorded in the statement of operations.

NOTE 6 – PAYABLE TO YESO-MED

On December 1, 2011, the Company entered into a 5-year agreement with Wuxi Yushou Medical Appliance Co., Ltd (“Yeso-med”). Pursuant to the agreement, commencing from the date that Yeso-med demonstrates to the Company’s satisfaction that it has the capacity to commence regular production of the syringes in the 3ml size in the minimum amount of at least 2,500,000 units per month, the Company will place orders of at least 2,500,000 units per month for the term of this agreement. If the Company does not place with Yeso-med the minimum order for a single month, Yeso-med shall have the right to receive payments from the Company equal to 50% of the supply price of each unit below the minimum order amount required for that month.  The Company has the right to have the amount paid under this requirement to serve as payment against future orders provided the quantity ordered exceeds the minimum quantity for that month. In July 2012, Yeso-med met the capacity requirement. However, the Company has not yet placed any order after July 2012.  As of December 31, 2012, a payable was recorded to Yeso-med related to this minimum purchase requirement of $783,593. During the year ended December 31, 2012, $783,593 was recorded as a loss on firm purchase commitments.

The payable to Yeso-med also included amounts due for product purchased of $208,258 as of December 31, 2012 and amounts due for equipment purchased of $289,009 and $352,544 as of December 31, 2012 and 2011, respectively.
 
 
F-14
 

NOTE 7 – CONVERTIBLE NOTES PAYABLE

At December 31, 2012 and 2011, notes payable consisted of the following:
 
   
December 31,
2012
    
December 31,
2011
  
Convertible Promissory Note Payable to JMJ Financial, unsecured, one time interest charge of 8%, due on February 22, 2014
   $ 191,663     $ 207,161  
Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0% per annum, with payment due on April 26, 2012
     -       40,000  
Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0% per annum, with payment due on June 1, 2012
     -       45,000  
Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0% per annum, with payment due on August 7, 2012
     -       42,500  
Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0%  per annum, with payment due on September 19, 2012
     -       53,000  
Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0% per annum, with payment due on March 21, 2013, fully converted in January 2013
     7,500       -  
Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0%  per annum, with payment due on May 10, 2013
     42,500       -  
Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0%  per annum, with payment due on August 27, 2013
     42,500       -  
Convertible Promissory Note Payable to TCA Global Credit Master Fund, LP, secured by all of the Company’s assets, interest rate of 12.0%  per annum, with payment due on January 3, 2013
     62,165       -  
Convertible Promissory Note Payable issued in the course of a private placement to individuals, unsecured,  interest rate of 8.0%  per annum, with payment due on June 26, 2013
     100,000       -  
Total 
     446,328       387,661  
Less: debt discount
     (229,573 )     (307,126 )
    $ 216,755     $ 80,535  

Asher Enterprises

During the year ended December 31, 2012, the Company issued 6 convertible promissory notes to Asher Enterprises for total proceeds of $269,000 in cash (“2012 Asher Notes”). All of the notes were convertible to the Company’s common stock at a conversion price equal to the greater of (1) 55% multiplied by the average of the lowest 3 trading prices for the Company’s common stock during the 10 trading day period ending on the latest complete trading day prior to the conversion date market price and (2) a fixed conversion price of $0.00009 per share. The Company analyzed the conversion feature of the 2012 Asher Notes for derivative accounting consideration and determined that the conversion feature for the 2012 Asher Notes does not qualify for accounting treatment as a financial derivative. The 2012 Asher Notes have a beneficial conversion feature discount of $237,774, within which $170,844 has been amortized. During the year ended December 31, 2012, the Company also recorded interest expense of $118,268 related to the amortization of debt discount on notes issued in 2011 to Asher Enterprises. At December 31, 2012, there was $66,930 of unamortized discount related to the 2012 Asher Notes.

During the year ended December 31, 2012, Asher Enterprises converted principal of $357,000 with accrued interest into 4,952,916 shares of the Company’s common stock.

The 2012 Asher Notes are currently in default as a result of the Company’s failure to timely file its periodically report with the SEC.
 
 
F-15
 

TCA Global Credit Master Fund, LP

On January 3, 2012, the Company entered into a securities purchase agreement with TCA Global Credit Master Fund, LP (“TCA”), pursuant to which, TCA would purchase up to $2,000,000 of the Company’s common stock. The Company agreed to pay a $100,000 facility fee by issuing to TCA a number of the Company’s common shares (“facility shares”). To determine the number of shares issuable to TCA for the facility fee, the Company’s common stock was valued at a volume weighted average price at January 2, 2012. The facility shares should be adjusted 9 months after January 2, 2012 by the volume weighted average prices of the Company’s common stock 5 trading days prior to the revaluation date. On August 13, 2012, the Company and TCA agreed to terminate the committed equity financing agreement based on the Company’s failure to achieve bulletin board listing as required under the agreement. The Company has issued 559,268 common shares in 2012 to TCA which only satisfied $51,924 of the facility fee upon revaluation. As of December 31, 2012, accounts payable included $48,076 for the remaining payable to TCA related to the facility fee.

In connection with the securities purchase agreement with TCA, the Company issued a convertible promissory note to TCA for a principal amount of $225,000 (“TCA Note”).  The note bears interest at a rate of 12% per annum and provides for the payment of all principal and interest 12 months from the date of the note’s respective issuance.  The conversion price was determined by multiplying 95% by the average of the two lowest daily volume weighted average prices of the Company’s common stock on the OTC Markets during the 5 business days immediately preceding the date of conversion.    The Company analyzed the TCA Note for derivative accounting consideration and determined that the TCA Note qualifies for accounting treatment as a financial derivative. The conversion feature of the TCA note was valued at $174,448 on the issuance date and recorded as debt discount. During the year ended December 31, 2011, the Company recognized $174,448 of interest expense related to the amortization of the debt discount.

TCA converted principal of $162,835 into 1,601,255 shares of the Company’s common stock during 2012 and principal of $27,840 into 300,000 shares of the Company’s common stock on January 3, 2013.

JMJ Financial

On February 22, 2011, the Company issued a $1,050,000 convertible promissory note to JMJ Financial, Inc. (“JMJ”). The note bears interest in the form of a onetime interest charge of 8%, payable with the note’s principal amount on the maturity date, February 22, 2014. The note is convertible to the Company’s common stock at a price equal to 70% of the average of the 3 lowest closing prices of the Company’s common stock in the 20 trading days prior to the conversion date. In connection with the note, the Company entered into a registration rights agreement with JMJ to provide JMJ registration rights for common shares underlying this note. The note will only be funded when the conversion price calculated on each payment date is equal to or greater than $0.015 per share and there are sufficient shares remaining in the registration statement. During 2012, JMJ converted $15,498 under this agreement into 180,000 shares of the Company’s common stock. The principal amount owed to JMJ at December 31, 2012 and 2011, is $191,663 and $207,161, respectively, from the $1,050,000 convertible promissory note. The Company analyzed the JMJ note for derivative accounting consideration and determined that the note qualifies for accounting treatment as a financial derivative and recorded an initial discount of $450,000 on the issuance date. During the year ended December 31, 2012 and 2011, the Company recorded $80,000 and $263,309 of interest expense related to the amortization of the debt discount. At December 31, 2012 and 2011, there was $106,691 and $186,691, respectively, of unamortized debt discount related to the JMJ notes.

On February 28, 2011, the Company issued a $500,000 convertible promissory note to JMJ.  The note bears interest in the form of a onetime interest charge of 8%, payable with the note’s principle amount on the maturity date, February 28, 2014.  All or a portion of this note’s principle and interest is convertible at the option of JMJ from time to time, into shares of the Company’s common stock, originally fixed at a per share conversion price equal to 70% of the average of the 3 lowest closing prices for the Company’s common stock in the 20 trading days previous to the effective date of each such conversion. No amount is owed to JMJ from the $500,000 convertible promissory note at December 31, 2012 and 2011.

The Company is currently in litigation with JMJ. See Note 11.

Individual Convertible Notes Payable

During 2012, the Company issued 22 convertible notes payable to individuals for proceeds of $956,501 in cash (“Individual Convertible Notes”). The Individual Convertible Notes mature one year from the date of issuance. Interest accrues at the rate of 8% per year on the outstanding principal amount to be paid at maturity.
 
 
F-16
 

The principal amount of the Individual Convertible Notes and accrued interest are convertible into the Company’s common stock at a conversion price equal to 75% of the average of the daily volume weighted average prices of the Company's Common Stock during the 5 trading days immediately prior to the conversion date, provided that in no event, shall the note holders convert any portion of the Individual Convertible Notes when the sum of 1) the number of shares of common stock beneficially owned by the holder and its affiliates and 2) the number of shares of common stock issuable upon conversion would result in beneficial ownership by the holder and its affiliates of more than 4.99% of the Company’s outstanding common shares. During 2012, $856,501 of the Individual Convertible Notes with accrued interest were converted into 6,934,901 shares of the Company’s common stock. As of December 31, 2012, Individual Convertible Notes includes principal of $75,000 payable to Vincent Olmo, the Company’s COO, with a debt discount of $42,534.

In connection with the issuance of the Individual Convertible Notes, warrants to purchase 3,826,005 shares of the Company’s common stock at $0.25 per share and warrants to purchase 1,913,003 shares of the Company’s common stock at $0.50 per share were issued to investors. The warrants have a term of less than one year and expire on December 31, 2012, March 31, 2013, or June 30, 2013. $347,097 of the proceeds received from the Individual Convertible Notes was allocated to the warrants based on a grant date fair value of $589,416 calculated using a Black Scholes Model with the following assumptions: (1) 3.9% risk-free discount rate, (2) expected volatility of 155.60 ~218.64%, (3) $0 expected dividends, and (4) an expected term of 0.3~1 years based on the term of warrant.
  
The Company analyzed the Individual Convertible Notes for derivative accounting consideration and determined that the conversion feature of the Individual Convertible Notes qualify for accounting treatment as a financial derivative. The conversion feature of Individual Convertible Notes was valued at $777,766 on the issuance date. As a result, some of the Individual Convertible Notes were fully discounted and the fair value of the conversion feature in excess of the principal amount allocated to the Individual Convertible Notes of $182,733 was expensed immediately as additional interest expense. During the year ended December 31, 2012, the Company recognized $885,418 of interest expense related to the amortization of the debt discount. At December 31, 2012, there was $55,952 of unamortized discount related to the Individual Convertible Notes.


NOTE 8 – PAYABLE FOR INDEMNIFICATION

On February 5, 2009, the Company entered into an Indemnification Settlement Agreement with Gifford M. Mabie, founder and former Chief Executive Officer of the Company. Pursuant to the agreement, the Company agreed to indemnify Mr. Mabie for the payment of penalties, prejudgment interest and post-judgment interest to the United States Securities and Exchange Commission (“SEC”) that is part of the Final Judgment, dated March 11, 2005, in SEC v. Maxxon, Inc., Gifford M. Mabie, Jr., Thomas R. Coughlin, Jr. 02-CV-975-H(J) which resulted from actions taken in good faith by Mabie and Coughlin in the performance of duties as an officer and directors of the Company.  The payment amount stated in the Final Judgment is $1,088,067.

The agreement specifies that the Company is to periodically issue shares to a special account for Gifford Mabie in order that shares can be sold each day the market is open until the liability is satisfied.  The special account was initially funded by the Company’s common stock owned by Mr. Mabie. Total amount of stock traded by the special account is limited to 5% of the total trading volume each day. A percentage equal to Mr. Mabie’s federal and state tax liabilities to a maximum of 40% will be retained by the brokerage firm and remitted to the Internal Revenue Service and to the Oklahoma Tax Commission or the Tax Commission where Mr. Mabie resides. If Mr. Mabie receives a tax refund, that refund will be forwarded to the SEC.

On December 14, 2010, the Company issued 400,000 shares of the Company’s common stock, initially valued at $184,000, to the special account. An additional 400,000 shares were issued to the special account on March 15, 2012 with an initial value of $140,560 determined based upon the 10-day average share price prior to the date of issuance.  At each reporting date, the Company revalues the shares held in the special account and adjusts the outstanding balance. Net increases and decreases in the value of the Company’s common shares held in the special account are recorded in the current period statement of operations. As of December 31, 2012, the remaining principal balance, including the estimated taxes, to be paid was $1,347,806 based upon the Company’s valuation of the stock. For the years ended December 31, 2012 and 2011, net loss related to the stock held in the special account was $63,347 and $67,071, respectively.

NOTE 9 – DERIVATIVES – NOTE CONVERSION FEATURE

Due to the conversion feature contained in some of the notes the Company issued, the actual number of shares of common stock that would be required if a conversion of the notes was made through the issuance of the Company’s common stock cannot be predicted, and the Company could be required to issue an amount of shares that may cause it to exceed its authorized share amount. As a result, the conversion feature requires derivative accounting treatment and will be bifurcated from the note and “marked to market” each reporting period through the income statement. The fair value of the conversion future of these notes was recognized as a derivative liability instrument and will be measured at fair value at each reporting period. In determining the fair value, the Company uses the Black-Scholes option-pricing model. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option-pricing model.
 
 
F-17
 

The following is a reconciliation of the derivative liability:

Fair value at December 31, 2010
  
$
160,659
  
Issuance of instruments
    
840,442
  
Decrease in value
    
(40,030
)
Reclassification from liability to equity as a result of note conversions
    
(518,760
)
Fair value at December 31, 2011
    
442,311
  
Issuance of instruments
    
952,214
  
Decrease in value
    
(131,397
)
Reclassification from liability to equity as a result of note conversions
    
(898,326
)
Fair value at December 31, 2012
  
$
364,802
  

The derivative liability was valued under the Black-Scholes model with the following assumptions:
 
  2012   2011  
Risk free interest rate
 0.11%
to
 0.16%   0.17%
to
 0.19%  
Expected life (years)
 0.01
to
 2.1   0
to
 3  
Dividend Yield
  
0%
       0%    
Volatility
 130%
to
 219%   0%
to
 205%  

NOTE 10 - MAXXON/GLOBE JOINT VENTURE AGREEMENT

In September 2005, the Company filed a patent on its RevVac™ safety syringe with Globe Med Tech which gives a 50% ownership of this patent to the Company and 50% to Globe Med Tech. On November 3, 2005, the Company (f.k.a. Maxxon, Inc.,) and Globe Med Tech, Inc. (“Globe”) entered into a definitive joint venture agreement to patent, develop, manufacture, market and distribute safety needle products throughout the world.  The Company and Globe each own 50% of the joint venture.  The Company contributed its safety syringe technology and patent rights related thereto and Globe contributed its safety syringe IV catheter and patent rights related thereto.  In connection with the agreement, the Company issued restricted shares of its common stock, valued at $625,066, to Globe.  Subsequent to December 31, 2006, the Company ended the joint venture and cancelled the shares of common stock and options that were issued to Globe pursuant to the agreement.  This patent was issued January 13, 2009.

On March 1, 2007, the Company filed a lawsuit in the District Court of Tulsa County, Oklahoma against Globe to rescind, terminate and seek monetary damages for the non-fulfillment and breach of a joint venture agreement entered into November 3, 2005, and other related agreements, in addition to an accounting of expenditures of funds under the terms and provisions of the agreements.  On October 29, 2008, the Company filed in the District Court of Harris County, Texas, a lawsuit for fraud and contempt of court for Globe and Andy Hu, individually.  On October 21, 2011, the Company was granted its request for summary judgment against Globe and awarded $311,440 and the return of 266,667 shares of the Company’s common stock by a Federal District Court in Tulsa County, Oklahoma.  In addition to the monetary award and the return of the Company’s common stock, Globe is also required to return all syringes, design files, and sample molds to the Company.  Furthermore, the Court ordered that Globe assign to the Company all rights to the January 2009 United States patent issued for the RevVac™ auto-retractable vacuum safety syringe.  Globe is prohibited from claiming any interest or ownership in the Company’s safety vacuum syringes going forward in the future.

On December 13, 2011, the Supreme Court of Oklahoma denied Globe’s appeal. On January 30, 2013, the court ordered a Nunc Pro Tunc decision denying all counterclaims and third party claims by Globe. Globe filed another appeal on March 1, 2013. The Company has hired legal counsel in Texas to assist in efforts to collect these damages and execute on the court order.
 
 
F-18
 

NOTE 11 – COMMITMENTS AND CONTINGENCIES

MIG and SPD

On January 2, 2013, the Company won its arbitration proceeding concerning its counter claims against Richard Theriault, former manufacturer MIG and former consultant, Strategic Product Development ("SPD").  The monetary award included $770,000 in recoupment of production costs plus interest, legal fees and other arbitration costs, which will total close to $1 million. In other claims, Theriault was found guilty of fraud in the inducement and breach of contract and was found to have no rights to any of the Company's proprietary technology, files, drawings, designs, patents or products. The ruling determined that all production mold payments made by the Company to MIG for the manufacturing of production molds had instead been used by Mr. Theriault for other non-production related purposes. The panel of American Arbitration Association ruled that the only assets in which production was funded by MIG from the Company’s production payments were $50,000 in trial molds. The equipment asset on the balance sheet has been reduced by $710,000 and charged to impairment for the payments no longer associated with a production or trial mold. The $770,000 award is for the recovery of damages related to these production payments.  The gain related to this award will be recorded when collected. The Company has hired legal counsel in Massachusetts and South Carolina to assist in efforts to collect these damages.

On September 26, 2012, the Company filed suit in South Carolina Federal District Court against SPD, Richard H. Theriault, Vita S. Theriault, Darius R. Theriault, Raminta Theriault, Goddard Technologies, Inc. ("GTI") and others, claiming that the defendants purposely and materially misled and misrepresented capabilities and progress on a variety of initiatives related to the development and manufacture of the Company's RevVac™ Auto-Retractable Vacuum safety syringe to officers and directors of Revolutions Medical, which caused a delay in its production of approximately one year. The suit further alleges that Richard H. Theriault and other defendants defrauded the Company and misappropriated funds in violation of the United States' Racketeer Influenced and Corrupt Organizations ("RICO") Act and that GTI improperly assigned certain rights to the Company's new provisional patents to SPD without authorization. On February 2, 2013, Richard H. Theriault filed for bankruptcy in Massachusetts under Chapter 11.  The South Carolina lawsuit has been temporarily stayed until such time when the arbitration award against Richard H. Theriault and MIG can be ruled on in United States Federal District Court in Massachusetts, seeking judgment outside the bankruptcy court. On March 13, 2013, United States Federal District Court in Massachusetts granted an injunction against Richard H. Theriault and MIG, enjoining and restraining them from transferring or alienating any assets in their possession without approval from the Court and a hearing has been scheduled for May 7, 2013.

JMJ Financial, Inc.

On March 12, 2012, the Company filed a lawsuit against Justin Keener and JMJ in Charleston County, South Carolina.  The Company sought a rescission and financial relief for the convertible debt agreement signed February 22, 2011. The Company claimed that it was unable to deliver the shares requested in the common stock conversion requests dated January 9, 2012 for 1,000,000 shares and January 30, 2012 for 1,226,049 shares due to the risk of defaulting on the convertible debt agreement by losing Depository Trust Company “DTC” eligibility. The contract stated that the Company would be considered in default of the agreement if the Company lost DTC eligibility due to a “chill” placed upon the electronic transfer of the stock. The Company had previously been made aware of other companies that had entered into similar agreements losing DTC eligibility and felt that JMJ had put the Company in an untenable position of either defaulting by losing DTC eligibility or defaulting by failing to issue the requested shares.  The Company claimed that JMJ’s unreasonably high demands for conversion caused a “frustration” of the principal purpose of the contract and supports the rescission of the contract and a return of the parties to their respective positions before the contract was signed.  On April 12, 2012 the Company withdrew the lawsuit filed in South Carolina to pursue its rights and counterclaims in Miami-Dade County, Florida, described below.

The Company also claims the default notice issued by JMJ obligated the Company to pay JMJ the outstanding principal balance under the note along with the accrued and unpaid interest. The principal balance due at the time JMJ issued the default notice amounted to $191,663.  The Company disputes JMJ’s claims that the Company was liable for a sum far in excess of this amount based upon the default provision of the contract.

A lawsuit was filed against the Company by JMJ in Miami-Dade County, Florida on March 15, 2012. The lawsuit claims that the Company breached the terms of the convertible debt agreement by failing to issue shares requested in a stock conversion by JMJ on January 9, 2012 for 1,000,000 shares and on January 30, 2012 for 1,226,049 shares.  JMJ is seeking the delivery of 2,226,049 shares of common stock of the Company, plus costs and prejudgment interest. On August 30, 2012, the Company filed its counterclaims against JMJ which included Fraud by Concealment, among other claims. The Company alleges that Keener and JMJ had a responsibility and obligation under Florida law to disclose not to conceal during the negotiations of the agreement the fact that Keener and JMJ had outstanding and current issues with these type of convertible notes with DTC which could do detrimental harm to liquidity and electronic transfer of the Company's stock if DTC eligibility was "chilled". This would severely hamper future capital raises and harm its current shareholders but would solely benefit Keener and JMJ under the default clauses in this agreement.
 
 
F-19
 

SEC

The SEC filed a civil complaint in Federal District Court in Georgia against the Company, alleging that the Company issued four misleading press releases during the period from August 2010 through October 2010 and one misleading press release in July 2011, related to the Company’s production schedule of its auto retractable safety syringe. The SEC names the Company’s current Chief Executive Officer, Rondald L. Wheet, as a co-defendant. Among other relief, the SEC seeks an order requiring the defendants to disgorge money received from its equity line financing from August 2010 through May 2011, in addition to other civil penalty amounts.  The Company believes that these claims are unfounded and is vigorously defending against them; however, should the Company not prevail in such defense the amount of damages owed to the SEC could be substantial and could adversely affect the Company’s financial condition or cause the Company to cease operations.

Employment Agreements

Effective May 15, 2012, the Company and Mr. Wheet, Chief Executive Officer, entered into a 2-year employment agreement.  The agreement provides for an annual salary of $247,500 and other reasonable and customary fringe benefits.

Effective April 11, 2011, the Company and Mr. Olmo, Chief Operating Officer, entered into a 3-year employment agreement. The agreement provides for an annual salary of $165,000 modified with a cost of living adjustment annually and other reasonable and customary fringe benefits.  

Effective June 1, 2011, the Company and Mr. Hodges, Chief Financial Officer, entered into a 3-year employment agreement. The agreement provides for an annual salary of $165,000 modified with a cost of living adjustment annually and other reasonable and customary fringe benefits.  

Lease Agreement

On September 1, 2009, the Company entered into a 5-year lease agreement with Osprey South, LLC (“Osprey”), to lease the property at 670 Marina Drive, Suite 301, Building F, Charleston, South Carolina, 29492.  Pursuant to the lease agreement, the Company was to pay Osprey $4,500 per month.  On July 1, 2011, the Company amended the lease agreement to include the office space adjacent to the existing office space. According to the amended lease agreement, the lease ends on July 1, 2016, and the Company is to pay Osprey $10,000 per month.  Rondald L. Wheet, our Chairman and Chief Executive Officer, is the sole member of Osprey.


NOTE 12 - PREFERRED STOCK AND COMMON STOCK TRANSACTIONS
 
PREFERRED STOCK

Shares Outstanding: Currently, 1,000,000 shares of preferred stock (“Preferred Stock”) are outstanding. Rondald L. Wheet, our Chief Executive Officer, owns 1,000,000 shares of Series 2006 Preferred Stock. Tom O’Brien, our former President, returned 500,000 shares of Series 2009 Preferred Stock upon his resignation in 2011.

Dividends: The holder of the Preferred Stock is entitled to receive, ratably, dividends when, as and if declared by the board of directors out of funds legally available therefore. If any dividend or other distributions are declared on our common stock, then a dividend or other distribution must also be declared on the outstanding Preferred Stock at the same time and on the same terms and conditions, so that each holder of Preferred Stock will receive the same dividend or distribution such holder would have received if the holder had converted his Preferred Stock as of the record date for determining stockholders entitled to receive such dividend or distribution.

Liquidation Preference: In the event of the liquidation, dissolution or winding up, the holders of Preferred Stock are entitled to receive a liquidation preference of $0.001 for each share of Preferred Stock prior to payment being made to any junior stock.
 
 
F-20
 

Conversion: The holders of Preferred Stock may convert each share into 1 share of common stock.

Preemption: The holders of Preferred Stock have no preemptive rights and they are not subject to further calls or assessments.

Voting Rights: The holders of Preferred Stock are entitled to 125 votes for each share of common stock into which their Preferred Stock is then convertible (currently 1 share), voting together with our common stock as a single class. Cumulative voting is not permitted. Upon conversion of a share of Preferred Stock, each share of common stock issued upon the conversion will be entitled to only one vote per share.

Redemption: There are no redemption or sinking fund provisions applicable to the Preferred Stock.
 
2012 COMMON STOCK TRANSACTIONS

During the year ended December 31, 2012, 400,000 shares were issued under the terms of the SEC settlement agreement with Gifford Mabie.  The initial value of these shares totaled $140,560.

In the year ended December 31, 2012, the Company issued 2,751,229 shares of common stock with a total value of $516,111 for outside services.

Also, in the year ended December 31, 2012, the Company issued 1,235,000 shares of common stock for the exercise of warrants and options. The Company received cash of $258,275 and recorded a subscription receivable of $46,000.

Also, in the year ended December 31, 2012, the Company issued 13,669,072 shares of common stock for the conversions of convertible notes and accrued interest totaling $1,420,446. The derivative fair value of $898,326 for the conversion feature of these notes was reclassified on the date of conversion to additional paid-in capital.

2011 COMMON STOCK TRANSACTIONS
 
During the year ended December 31, 2011, 6,668,000 shares of common stock were issued as option holders exercised their options to purchase common stock receiving proceeds of $1,654,420.  Of these options exercised, 2,000,000 options were exercised by our former President, Tom O’Brien at $0.08 per share. The remainder of the options exercised was due from consultants according to the terms of their consulting agreements. 656,015 shares were issued to third party investors and investors under the terms of a Drawdown Equity Financing Agreement. The Company received net proceeds of $202,571 in connection with these share issuances.

Also during the year ended December 31, 2011, the Company issued 1,513,874 shares of common stock with a total value of $481,100 in lieu of cash as payment for outside services.

During the year ended December 31, 2011, the Company issued 3,021,738 shares of common stock for conversions of notes and accrued interest. In connection with the conversions, the reclassification of the derivative fair value related to note conversion feature totaled $963,096.

NOTE 13 - STOCK OPTIONS AND WARRANTS OUTSTANDING
 
The Company’s 2007 Stock Option Plan, revised July 2011, permits the granting of stock options to its employees, directors, consultants and independent contractors for up to 20 million shares of its common stock.  The Company believes that such awards encourage employees to remain employed by the Company and also to attract persons of exceptional ability to become employees of the Company.  The plan allows the Company to issue either stock options or common shares.

During the year ended December 31, 2012, under the terms of the Company’s 2007 Stock Option Plan, 75,000 options were issued for consulting services exercisable at $0.25 per share, 300,000 options were issued for consulting services exercisable at $0.40 per share, and 2.5 million shares were issued to directors and an employee for service provided. The options have a term of 1~2 years and vest upon issuance. Fair value of $429,824 was calculated using the Black-Scholes Model with the following assumptions: (1) discount rate of 0.12% to 0.21% (2) expected life of 0.7 to 2.0 years (3) expected volatility of 159% to 161% and (4) zero expected dividends.
 
 
F-21
 

During the course of 2012 and 2011, the Company entered into several consulting agreements to perform marketing services for the Company as it begins to enter into the production stage for the RevVac™ safety syringe. Consultants are obligated under the contract to promote the product within various spheres of influence. These spheres of influence include, but are not limited to, medical product distributors, hospitals, doctors and government agencies.

Consultants are issued options at a discount to the market price at the date of issuance. These options must be exercised within a 10 day window from the time of issuance. The consultants therefore are committed to purchasing these options in order to enter into the consultant agreement and are obligated to adhere to the terms of the agreement. The agreements are recorded as a prepaid consulting expense upon the commencement of the agreement and expensed each quarter for the duration of the agreement. The amount to be determined for the consulting expense is determined based upon the options issued using the Black-Scholes model. Since the exercise window for these options is so short, the amount of the consulting expense is recorded as the difference between the exercise price and the market price as of the date of issuance. The Company also issued options with a term of 6 months to 1 year. Value for options with such term was calculated using Black-Scholes model.

The following tables summarize information about the stock options for the years ended December 31, 2012 and 2011:
 
   
Number of Units
    
Weighted
Average
Exercise Price
    
Weighted
Average
Remaining
Contractual
Term (in years)
    
Aggregate
Intrinsic Value
  
Outstanding, December 31, 2010
     12,834,750     $ 0.20       1.62     $ 2,708,463  
Granted
     9,307,000       0.34       1.02          
Exercised
     (6,668,000 )     0.25                  
Expired/ Forfeited
     -                          
Outstanding, December 31, 2011
     15,473,750       0.39       2.45       869,825  
Granted
     2,875,000       0.18       0.98          
Exercised
     (575,000 )      0.25                  
Expired/ Forfeited
     (5,673,750 )                        
Outstanding, December 31, 2012
     12,100,000       0.20       1.18       150,000  
 
The following tables summarize information about the warrants for the years ended  December 31, 2012 and 2011:

   
Number of Units
    
Weighted
Average
Exercise Price
    
Weighted
Average
Remaining
Contractual
Term (in years)
    
Aggregate
Intrinsic Value
  
Outstanding, December 31, 2010
     1,871,600     $ 0.50       3.45     $ -  
Granted
     1,500,000       0.50       1.00          
Exercised
     -                          
Expired/ Forfeited
     -                          
Outstanding, December 31, 2011
     3,371,600       0.39       2.45       -  
Granted
     5,739,008       0.33       0.15          
Exercised
     (660,000 )      0.50                  
Expired/ Forfeited
     (5,570,608 )                        
Outstanding, December 31, 2012
     2,880,000       0.33       0.30       -  

NOTE 14 - RELATED PARTY TRANSACTIONS

In connection with the acquisition of Clear Image Acquisition Corp. by the Company, Rondald L. Wheet, Chairman and Chief Executive Officer, received 2,286,000 shares of restricted Company common stock.  Dr. Beahm, a Director, received 1,599,125 shares of restricted RevMed common stock, and Mr. O’Brien, a former Director, received 1,645,625 shares of restricted Company common stock.  Mr. Wheet and Mr. O’Brien were directors and shareholders and Dr. Beahm was a shareholder of Clear Image Acquisition Corp. prior to its acquisition by the Company.
 
 
F-22
 

The Company rents its office space from Osprey South, LLC. Rondald L. Wheet, Chief Executive Officer, is the sole member of Osprey.  Rent expense to Osprey was $120,000 and $99,608 for the years ended December 31, 2012 and 2011, respectively.  Rent payable to Osprey was $19,761 and $8,608 as of December 31, 2012 and 2011, respectively.

As of December 31, 2012, the Company had advances from Vincent Olmo, Chief Operating Officer, and Mr. Wheet of $9,194 and $32,502, respectively, for expenses paid on behalf of the Company. The Company also had a convertible note payable to Mr. Olmo with principal amount of $75,000 and debt discount of $42,534 at December 31, 2012.

At December 31, 2011, the Company had advances from Rhonda Vincent, former CFO, of $79,336 for expenses paid on behalf of the Company. Such payable has passed the statute of limitations and has been written off as of December 31, 2012.

NOTE 15 – RESTATEMENT

The Company restated its December 31, 2011 balance sheet and the statements of operations, changes in equity, and cash flows for the year ended December 31, 2011 to reflect the following adjustments:

 
·
The reclassification of subscription receivable from shareholder of $25,000 to contra equity (originally reported as other current assets).
 
 
·
The elimination of $311,000 gain from litigation and the corresponding amount reflected as due from litigation as the collectability of the gain is not certain.
 
 
 
·
The decrease of $32,633 prepaid consulting expense which represents the difference between the valuation of warrants  based on the Black-Scholes Model and the original valuation improperly determined using intrinsic value.
 
 
 
·
The increase in payable for indemnification of $616,379 which represents Gifford Mabie’s federal and state tax liability retained by the brokerage firm and remitted to the Internal Revenue Service and the increase of indemnification expenses of $67,072 for the change in the value of stock issued to the special brokerage for the benefit of Gifford Mabie.
 
 
 
·
To decrease a payable to SON Medical for $54,832 for services never performed.

The impact of the reclassifications and prior period adjustments on the accompanying balance sheet at December 31, 2011 is as follows:

   
As Originally
Reported
    
Change
    
As Restated
  
Total current assets
   $ 1,978,711     $ (368,633 )   $ 1,610,078  
Total current liabilities
     2,294,274       561,547       2,855,821  
Total equity
     (315,563 )     (930,180 )     (1,245,743 )


The impact of the reclassifications and prior period adjustments on the accompanying statement of operations for the year ended December 31, 2011 are as follows:

   
As Originally
Reported
    
Change
    
As Restated
  
Research and development
   $ 111,832     $ (54,832 )   $ 57,000  
General and administrative expenses
     3,714,214       67,072       3,781,286  
Gain from litigation
     311,000       (311,000 )     -  
Net income available to common shareholders
     (4,218,278 )     (323,240 )     (4,541,518 )
Income per common share – basic and diluted
     (0.09 )             (0.09 )
 
 
F-23
 
 
The impact of the reclassifications and prior period adjustments on the accompanying statement of cash flows for the year ended December 31, 2011 is as follows:

   
As Originally
Reported
    
Change
    
As Restated
  
Net cash used in operating activities
   $ (3,010,275 )   $ 447,202     $ (2,563,073 )
Net cash used in investing activities
     (471,347 )     342,256       (129,091 )
Net cash provided by financing activities
     3,416,949       (789,458 )     2,627,491  

NOTE 16 – SUBSEQUENT EVENTS

Subsequent to December 31, 2012, the Company issued 1,466,657 common shares for the conversion of notes payable of $79,540; 789,700 common shares to officers for settlement of  $71,073 of accrued salaries based on the grant date fair value of the shares; 102,500 common shares valued at  $5,466 to service providers for settlement of accounts payable; 262,500 common shares valued at $26,250, for investor relation services; 1,453,750 shares valued at $130,838 for director fees;  and 750,000 common shares for net cash proceeds of $75,000 related to warrants and options exercised.
 
 
 
F-24
 
 
 EX-31.1 2 ex31-1.htm EXHIBIT 31.1 ex31-1.htm
Exhibit 31.1
 
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
 
I, Rondald L. Wheet, certify that:
 
1.
I have reviewed this Form 10-K of Revolutions Medical Corporation;
     
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:
     
 
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
 
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
 
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
 
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
     
 
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
 
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
 
Date: May 2, 2013
By:
/s/  Rondald L. Wheet
  
   
Rondald L. Wheet
  
   
Principal Executive Officer
Revolutions Medical Corporation
  
EX-31.2 3 ex31-2.htm EXHIBIT 31.2 ex31-2.htm
Exhibit 31.2
 
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
 
I, Burt Hodges, certify that:
 
1.
I have reviewed this Form 10-K of Revolutions Medical Corporation;
     
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:
     
 
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
 
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
 
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
 
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
     
 
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
 
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
 
Date: May 2, 2013
By:
/s/  Burt Hodges
  
   
Burt Hodges
  
   
Principal Financial Officer
Revolutions Medical Corporation
  
 
 EX-32.1 4 ex32-1.htm EXHIBIT 32.1 ex32-1.htm
Exhibit 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002
 
In connection with this Annual Report of Revolutions Medical Corporation (the “Company”), on Form 10-K for the fiscal year ended December 31, 2012, as filed with the U.S. Securities and Exchange Commission on the date hereof, I, Rondald L. Wheet, Principal Executive Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

 
(1)
Such Annual Report on Form 10-K for the year ended December 31, 2012, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 
(2)
The information contained in such Annual Report on Form 10-K for the year ended December 31, 2012, fairly presents, in all material respects, the financial condition and results of operations of the Company.
  
       
Date: May 2, 2013
By:
/s/ Rondald L. Wheet
  
   
Rondald L. Wheet
  
   
Principal Executive Officer
Revolutions Medical Corporation
  
       
 
 EX-32.2 5 ex32-2.htm EXHIBIT 32.2 ex32-2.htm
Exhibit 32.2
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002
 
In connection with this Annual Report of Revolutions Medical Corporation (the “Company”), on Form 10-K for the fiscal year ended December 31, 2012, as filed with the U.S. Securities and Exchange Commission on the date hereof, I, Burt Hodges, Principal Financial Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

 
(1)
Such Annual Report on Form 10-K for the year ended December 31, 2012, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 
(2)
The information contained in such Annual Report on Form 10-K for the year ended December 31, 2012, fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
       
Date: May 2, 2013
By:
/s/ Burt Hodges
  
   
Burt Hodges
  
   
Principal Financial Officer
Revolutions Medical Corporation
  
 
 EX-101.INS 6 rmcp-20121231.xml XBRL INSTANCE 0001041009 2012-12-31 0001041009 2011-12-31 0001041009 rmcp:YesoMedMember 2012-12-31 0001041009 rmcp:YesoMedMember 2011-12-31 0001041009 2012-01-01 2012-12-31 0001041009 1996-08-16 2012-12-31 0001041009 2011-01-01 2011-12-31 0001041009 rmcp:CerroMiningMember us-gaap:CommonStockMember 1996-08-16 1997-12-31 0001041009 rmcp:CerroMiningMember us-gaap:CommonStockMember 1997-12-31 0001041009 rmcp:CerroMiningMember us-gaap:AdditionalPaidInCapitalMember 1997-12-31 0001041009 rmcp:CerroMiningMember 1997-12-31 0001041009 rmcp:MaxxonOKFoundersMember us-gaap:CommonStockMember 1996-08-16 1997-12-31 0001041009 rmcp:MaxxonOKFoundersMember us-gaap:CommonStockMember 1997-12-31 0001041009 rmcp:MaxxonOKFoundersMember us-gaap:AdditionalPaidInCapitalMember 1997-12-31 0001041009 rmcp:MaxxonOKFoundersMember 1997-12-31 0001041009 rmcp:MaxxonOKThirdPartyMember us-gaap:CommonStockMember 1996-08-16 1997-12-31 0001041009 rmcp:MaxxonOKThirdPartyMember us-gaap:CommonStockMember 1997-12-31 0001041009 rmcp:MaxxonOKThirdPartyMember us-gaap:AdditionalPaidInCapitalMember 1997-12-31 0001041009 rmcp:MaxxonOKThirdPartyMember 1997-12-31 0001041009 rmcp:IvesHealthCompanyMember us-gaap:CommonStockMember 1996-08-16 1997-12-31 0001041009 rmcp:IvesHealthCompanyMember us-gaap:CommonStockMember 1997-12-31 0001041009 rmcp:IvesHealthCompanyMember us-gaap:AdditionalPaidInCapitalMember 1997-12-31 0001041009 rmcp:IvesHealthCompanyMember 1997-12-31 0001041009 rmcp:IvesHealthClubMember us-gaap:CommonStockMember 1996-08-16 1997-12-31 0001041009 rmcp:IvesHealthClubMember us-gaap:CommonStockMember 1997-12-31 0001041009 rmcp:IvesHealthClubMember us-gaap:AdditionalPaidInCapitalMember 1997-12-31 0001041009 rmcp:IvesHealthClubMember 1997-12-31 0001041009 rmcp:IvesDebtMember us-gaap:CommonStockMember 1996-08-16 1997-12-31 0001041009 rmcp:IvesDebtMember us-gaap:AdditionalPaidInCapitalMember 1996-08-16 1997-12-31 0001041009 rmcp:IvesDebtMember 1996-08-16 1997-12-31 0001041009 rmcp:ThirdPartyInvestorsMember us-gaap:CommonStockMember 1996-08-16 1997-12-31 0001041009 rmcp:ThirdPartyInvestorsMember us-gaap:AdditionalPaidInCapitalMember 1996-08-16 1997-12-31 0001041009 rmcp:ThirdPartyInvestorsMember 1996-08-16 1997-12-31 0001041009 us-gaap:CommonStockMember 1996-08-16 1997-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 1996-08-16 1997-12-31 0001041009 1996-08-16 1997-12-31 0001041009 us-gaap:CommonStockMember 1997-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 1997-12-31 0001041009 us-gaap:ReceivablesFromStockholderMember 1997-12-31 0001041009 rmcp:ServicesRenderedByThirdPartiesMember us-gaap:CommonStockMember 1996-08-16 1997-12-31 0001041009 rmcp:ServicesRenderedByThirdPartiesMember us-gaap:AdditionalPaidInCapitalMember 1996-08-16 1997-12-31 0001041009 rmcp:ServicesRenderedByThirdPartiesMember 1996-08-16 1997-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 1996-08-16 1997-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 1997-12-31 0001041009 1997-12-31 0001041009 us-gaap:CommonStockMember 1998-01-01 1998-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 1998-01-01 1998-12-31 0001041009 1998-01-01 1998-12-31 0001041009 rmcp:ThirdPartyInvestorsMember us-gaap:CommonStockMember 1998-01-01 1998-12-31 0001041009 rmcp:ThirdPartyInvestorsMember us-gaap:AdditionalPaidInCapitalMember 1998-01-01 1998-12-31 0001041009 rmcp:ThirdPartyInvestorsMember 1998-01-01 1998-12-31 0001041009 rmcp:ExercisesByThirdPartiesForCashMember us-gaap:CommonStockMember 1998-01-01 1998-12-31 0001041009 rmcp:ExercisesByThirdPartiesForCashMember us-gaap:AdditionalPaidInCapitalMember 1998-01-01 1998-12-31 0001041009 rmcp:ExercisesByThirdPartiesForCashMember 1998-01-01 1998-12-31 0001041009 rmcp:ExercisesByThirdPartiesForServicesMember us-gaap:CommonStockMember 1998-01-01 1998-12-31 0001041009 rmcp:ExercisesByThirdPartiesForServicesMember us-gaap:AdditionalPaidInCapitalMember 1998-01-01 1998-12-31 0001041009 rmcp:ExercisesByThirdPartiesForServicesMember 1998-01-01 1998-12-31 0001041009 rmcp:ServicesRenderedByThirdPartiesMember us-gaap:CommonStockMember 1998-01-01 1998-12-31 0001041009 rmcp:ServicesRenderedByThirdPartiesMember us-gaap:AdditionalPaidInCapitalMember 1998-01-01 1998-12-31 0001041009 rmcp:ServicesRenderedByThirdPartiesMember 1998-01-01 1998-12-31 0001041009 rmcp:ServicesContributedByOfficerAndEmployeesMember us-gaap:AdditionalPaidInCapitalMember 1998-01-01 1998-12-31 0001041009 rmcp:ServicesContributedByOfficerAndEmployeesMember 1998-01-01 1998-12-31 0001041009 rmcp:OptionsGrantedToNonemployeesMember us-gaap:AdditionalPaidInCapitalMember 1998-01-01 1998-12-31 0001041009 rmcp:OptionsGrantedToNonemployeesMember 1998-01-01 1998-12-31 0001041009 us-gaap:ReceivablesFromStockholderMember 1998-12-31 0001041009 1998-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 1998-01-01 1998-12-31 0001041009 us-gaap:CommonStockMember 1998-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 1998-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 1998-12-31 0001041009 rmcp:ThirdPartyInvestorsMember us-gaap:CommonStockMember 1999-01-01 1999-12-31 0001041009 rmcp:ThirdPartyInvestorsMember us-gaap:AdditionalPaidInCapitalMember 1999-01-01 1999-12-31 0001041009 rmcp:ThirdPartyInvestorsMember 1999-01-01 1999-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 1999-01-01 1999-12-31 0001041009 1999-01-01 1999-12-31 0001041009 rmcp:ExercisesByThirdPartiesForCashMember us-gaap:CommonStockMember 1999-01-01 1999-12-31 0001041009 rmcp:ExercisesByThirdPartiesForCashMember us-gaap:AdditionalPaidInCapitalMember 1999-01-01 1999-12-31 0001041009 rmcp:ExercisesByThirdPartiesForCashMember 1999-01-01 1999-12-31 0001041009 rmcp:ServicesRenderedByThirdPartiesMember us-gaap:CommonStockMember 1999-01-01 1999-12-31 0001041009 rmcp:ServicesRenderedByThirdPartiesMember us-gaap:AdditionalPaidInCapitalMember 1999-01-01 1999-12-31 0001041009 rmcp:ServicesRenderedByThirdPartiesMember 1999-01-01 1999-12-31 0001041009 rmcp:ServicesContributedByOfficerAndEmployeesMember us-gaap:AdditionalPaidInCapitalMember 1999-01-01 1999-12-31 0001041009 rmcp:ServicesContributedByOfficerAndEmployeesMember 1999-01-01 1999-12-31 0001041009 rmcp:OptionsGrantedToNonemployeesMember us-gaap:AdditionalPaidInCapitalMember 1999-01-01 1999-12-31 0001041009 rmcp:OptionsGrantedToNonemployeesMember 1999-01-01 1999-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 1999-01-01 1999-12-31 0001041009 us-gaap:CommonStockMember 1999-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 1999-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 1999-12-31 0001041009 1999-12-31 0001041009 rmcp:ThirdPartyInvestorsMember us-gaap:CommonStockMember 2000-01-01 2000-12-31 0001041009 rmcp:ThirdPartyInvestorsMember us-gaap:AdditionalPaidInCapitalMember 2000-01-01 2000-12-31 0001041009 rmcp:ThirdPartyInvestorsMember 2000-01-01 2000-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2000-01-01 2000-12-31 0001041009 2000-01-01 2000-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2000-01-01 2000-12-31 0001041009 us-gaap:CommonStockMember 2000-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2000-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2000-12-31 0001041009 2000-12-31 0001041009 rmcp:ThirdPartyInvestorsMember us-gaap:CommonStockMember 2001-01-01 2001-12-31 0001041009 rmcp:ThirdPartyInvestorsMember us-gaap:AdditionalPaidInCapitalMember 2001-01-01 2001-12-31 0001041009 rmcp:ThirdPartyInvestorsMember 2001-01-01 2001-12-31 0001041009 us-gaap:CommonStockMember 2001-01-01 2001-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2001-01-01 2001-12-31 0001041009 us-gaap:ReceivablesFromStockholderMember 2001-01-01 2001-12-31 0001041009 2001-01-01 2001-12-31 0001041009 rmcp:ServicesRenderedByThirdPartiesMember us-gaap:CommonStockMember 2001-01-01 2001-12-31 0001041009 rmcp:ServicesRenderedByThirdPartiesMember us-gaap:AdditionalPaidInCapitalMember 2001-01-01 2001-12-31 0001041009 rmcp:ServicesRenderedByThirdPartiesMember 2001-01-01 2001-12-31 0001041009 rmcp:StockIssuedForServicesMember us-gaap:CommonStockMember 2001-01-01 2001-12-31 0001041009 rmcp:StockIssuedForServicesMember us-gaap:AdditionalPaidInCapitalMember 2001-01-01 2001-12-31 0001041009 rmcp:StockIssuedForServicesMember 2001-01-01 2001-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2001-01-01 2001-12-31 0001041009 us-gaap:CommonStockMember 2001-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2001-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2001-12-31 0001041009 us-gaap:ReceivablesFromStockholderMember 2001-12-31 0001041009 2001-12-31 0001041009 rmcp:ThirdPartyInvestorsMember us-gaap:CommonStockMember 2002-01-01 2002-12-31 0001041009 rmcp:ThirdPartyInvestorsMember us-gaap:AdditionalPaidInCapitalMember 2002-01-01 2002-12-31 0001041009 rmcp:ThirdPartyInvestorsMember 2002-01-01 2002-12-31 0001041009 us-gaap:CommonStockMember 2002-01-01 2002-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2002-01-01 2002-12-31 0001041009 us-gaap:ReceivablesFromStockholderMember 2002-01-01 2002-12-31 0001041009 2002-01-01 2002-12-31 0001041009 rmcp:StockIssuedForServicesMember us-gaap:CommonStockMember 2002-01-01 2002-12-31 0001041009 rmcp:StockIssuedForServicesMember us-gaap:AdditionalPaidInCapitalMember 2002-01-01 2002-12-31 0001041009 rmcp:StockIssuedForServicesMember 2002-01-01 2002-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2002-01-01 2002-12-31 0001041009 us-gaap:CommonStockMember 2002-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2002-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2002-12-31 0001041009 us-gaap:ReceivablesFromStockholderMember 2002-12-31 0001041009 2002-12-31 0001041009 us-gaap:CommonStockMember 2003-01-01 2003-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2003-01-01 2003-12-31 0001041009 2003-01-01 2003-12-31 0001041009 us-gaap:ReceivablesFromStockholderMember 2003-01-01 2003-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2003-01-01 2003-12-31 0001041009 us-gaap:CommonStockMember 2003-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2003-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2003-12-31 0001041009 us-gaap:ReceivablesFromStockholderMember 2003-12-31 0001041009 2003-12-31 0001041009 rmcp:ThirdPartyInvestorsMember us-gaap:CommonStockMember 2004-01-01 2004-12-31 0001041009 rmcp:ThirdPartyInvestorsMember us-gaap:AdditionalPaidInCapitalMember 2004-01-01 2004-12-31 0001041009 rmcp:ThirdPartyInvestorsMember 2004-01-01 2004-12-31 0001041009 us-gaap:CommonStockMember 2004-01-01 2004-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2004-01-01 2004-12-31 0001041009 2004-01-01 2004-12-31 0001041009 us-gaap:ReceivablesFromStockholderMember 2004-01-01 2004-12-31 0001041009 rmcp:StockIssuedForServicesMember us-gaap:CommonStockMember 2004-01-01 2004-12-31 0001041009 rmcp:StockIssuedForServicesMember us-gaap:AdditionalPaidInCapitalMember 2004-01-01 2004-12-31 0001041009 rmcp:StockIssuedForServicesMember 2004-01-01 2004-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2004-01-01 2004-12-31 0001041009 us-gaap:CommonStockMember 2004-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2004-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2004-12-31 0001041009 us-gaap:ReceivablesFromStockholderMember 2004-12-31 0001041009 2004-12-31 0001041009 rmcp:ThirdPartyInvestorsMember us-gaap:CommonStockMember 2005-01-01 2005-12-31 0001041009 rmcp:ThirdPartyInvestorsMember us-gaap:AdditionalPaidInCapitalMember 2005-01-01 2005-12-31 0001041009 rmcp:ThirdPartyInvestorsMember 2005-01-01 2005-12-31 0001041009 us-gaap:CommonStockMember 2005-01-01 2005-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2005-01-01 2005-12-31 0001041009 2005-01-01 2005-12-31 0001041009 us-gaap:CommonStockMember 2005-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2005-12-31 0001041009 us-gaap:ReceivablesFromStockholderMember 2005-12-31 0001041009 rmcp:StockIssuedForServicesMember us-gaap:CommonStockMember 2005-01-01 2005-12-31 0001041009 rmcp:StockIssuedForServicesMember us-gaap:AdditionalPaidInCapitalMember 2005-01-01 2005-12-31 0001041009 rmcp:StockIssuedForServicesMember 2005-01-01 2005-12-31 0001041009 rmcp:CommonStockIssuedPursuantToJointVentureMember us-gaap:CommonStockMember 2005-01-01 2005-12-31 0001041009 rmcp:CommonStockIssuedPursuantToJointVentureMember us-gaap:CommonStockMember 2005-12-31 0001041009 rmcp:CommonStockIssuedPursuantToJointVentureMember us-gaap:AdditionalPaidInCapitalMember 2005-12-31 0001041009 rmcp:CommonStockIssuedPursuantToJointVentureMember 2005-12-31 0001041009 rmcp:WarrantsGrantedPursuantToJointVentureMember us-gaap:AdditionalPaidInCapitalMember 2005-12-31 0001041009 rmcp:WarrantsGrantedPursuantToJointVentureMember 2005-12-31 0001041009 us-gaap:ReceivablesFromStockholderMember 2005-01-01 2005-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2005-01-01 2005-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2005-12-31 0001041009 2005-12-31 0001041009 rmcp:ExercisesByThirdPartiesForServicesMember us-gaap:CommonStockMember 2006-01-01 2006-12-31 0001041009 rmcp:ExercisesByThirdPartiesForServicesMember us-gaap:AdditionalPaidInCapitalMember 2006-01-01 2006-12-31 0001041009 rmcp:ExercisesByThirdPartiesForServicesMember 2006-01-01 2006-12-31 0001041009 rmcp:ExercisesByThirdPartiesForCashMember us-gaap:CommonStockMember 2006-01-01 2006-12-31 0001041009 rmcp:ExercisesByThirdPartiesForCashMember us-gaap:AdditionalPaidInCapitalMember 2006-01-01 2006-12-31 0001041009 rmcp:ExercisesByThirdPartiesForCashMember 2006-01-01 2006-12-31 0001041009 us-gaap:CommonStockMember 2006-01-01 2006-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2006-01-01 2006-12-31 0001041009 2006-01-01 2006-12-31 0001041009 us-gaap:ReceivablesFromStockholderMember 2006-12-31 0001041009 2006-12-31 0001041009 rmcp:CommonStockIssuedForServicesMember us-gaap:CommonStockMember 2006-01-01 2006-12-31 0001041009 rmcp:CommonStockIssuedForServicesMember us-gaap:AdditionalPaidInCapitalMember 2006-01-01 2006-12-31 0001041009 rmcp:CommonStockIssuedForServicesMember 2006-01-01 2006-12-31 0001041009 rmcp:PreferredStockIssuedForServicesMember us-gaap:PreferredStockMember 2006-01-01 2006-12-31 0001041009 rmcp:PreferredStockIssuedForServicesMember us-gaap:AdditionalPaidInCapitalMember 2006-01-01 2006-12-31 0001041009 rmcp:PreferredStockIssuedForServicesMember 2006-01-01 2006-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2006-01-01 2006-12-31 0001041009 us-gaap:PreferredStockMember 2006-12-31 0001041009 us-gaap:CommonStockMember 2006-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2006-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2006-12-31 0001041009 us-gaap:CommonStockMember 2007-01-01 2007-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2007-01-01 2007-12-31 0001041009 2007-01-01 2007-12-31 0001041009 rmcp:ClearImageAcquisitionCorpMember us-gaap:CommonStockMember 2007-01-01 2007-12-31 0001041009 rmcp:ClearImageAcquisitionCorpMember us-gaap:CommonStockMember 2007-12-31 0001041009 rmcp:ClearImageAcquisitionCorpMember us-gaap:AdditionalPaidInCapitalMember 2007-12-31 0001041009 rmcp:ClearImageAcquisitionCorpMember 2007-12-31 0001041009 rmcp:ExercisesByThirdPartiesForCashMember us-gaap:CommonStockMember 2007-01-01 2007-12-31 0001041009 rmcp:ExercisesByThirdPartiesForCashMember us-gaap:AdditionalPaidInCapitalMember 2007-01-01 2007-12-31 0001041009 rmcp:ExercisesByThirdPartiesForCashMember 2007-01-01 2007-12-31 0001041009 us-gaap:WarrantMember us-gaap:CommonStockMember 2007-01-01 2007-12-31 0001041009 us-gaap:WarrantMember us-gaap:AdditionalPaidInCapitalMember 2007-01-01 2007-12-31 0001041009 us-gaap:WarrantMember 2007-01-01 2007-12-31 0001041009 rmcp:StockIssuedForServicesMember us-gaap:CommonStockMember 2007-01-01 2007-12-31 0001041009 rmcp:StockIssuedForServicesMember us-gaap:AdditionalPaidInCapitalMember 2007-01-01 2007-12-31 0001041009 rmcp:StockIssuedForServicesMember 2007-01-01 2007-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2007-01-01 2007-12-31 0001041009 us-gaap:PreferredStockMember 2007-12-31 0001041009 us-gaap:CommonStockMember 2007-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2007-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2007-12-31 0001041009 2007-12-31 0001041009 us-gaap:CommonStockMember 2008-01-01 2008-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2008-01-01 2008-12-31 0001041009 2008-01-01 2008-12-31 0001041009 rmcp:ExercisesByThirdPartiesForCashMember us-gaap:CommonStockMember 2008-01-01 2008-12-31 0001041009 rmcp:ExercisesByThirdPartiesForCashMember us-gaap:AdditionalPaidInCapitalMember 2008-01-01 2008-12-31 0001041009 rmcp:ExercisesByThirdPartiesForCashMember 2008-01-01 2008-12-31 0001041009 rmcp:ExercisesByThirdPartiesForServicesMember us-gaap:CommonStockMember 2008-01-01 2008-12-31 0001041009 rmcp:ExercisesByThirdPartiesForServicesMember us-gaap:AdditionalPaidInCapitalMember 2008-01-01 2008-12-31 0001041009 rmcp:ExercisesByThirdPartiesForServicesMember 2008-01-01 2008-12-31 0001041009 rmcp:ClearImageAcquisitionCorpMember us-gaap:CommonStockMember 2008-01-01 2008-12-31 0001041009 rmcp:ClearImageAcquisitionCorpMember us-gaap:CommonStockMember 2008-12-31 0001041009 rmcp:ClearImageAcquisitionCorpMember us-gaap:AdditionalPaidInCapitalMember 2008-12-31 0001041009 rmcp:ClearImageAcquisitionCorpMember 2008-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2008-01-01 2008-12-31 0001041009 us-gaap:PreferredStockMember 2008-12-31 0001041009 us-gaap:CommonStockMember 2008-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2008-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2008-12-31 0001041009 2008-12-31 0001041009 us-gaap:CommonStockMember 2009-01-01 2009-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2009-01-01 2009-12-31 0001041009 2009-01-01 2009-12-31 0001041009 rmcp:ExercisesByThirdPartiesForCashMember us-gaap:CommonStockMember 2009-01-01 2009-12-31 0001041009 rmcp:ExercisesByThirdPartiesForCashMember us-gaap:AdditionalPaidInCapitalMember 2009-01-01 2009-12-31 0001041009 rmcp:ExercisesByThirdPartiesForCashMember 2009-01-01 2009-12-31 0001041009 rmcp:PreferredStockIssuedForServicesMember us-gaap:PreferredStockMember 2009-01-01 2009-12-31 0001041009 rmcp:PreferredStockIssuedForServicesMember us-gaap:AdditionalPaidInCapitalMember 2009-01-01 2009-12-31 0001041009 rmcp:PreferredStockIssuedForServicesMember 2009-01-01 2009-12-31 0001041009 rmcp:CommonStockIssuedForServicesMember us-gaap:CommonStockMember 2009-01-01 2009-12-31 0001041009 rmcp:CommonStockIssuedForServicesMember us-gaap:AdditionalPaidInCapitalMember 2009-01-01 2009-12-31 0001041009 rmcp:CommonStockIssuedForServicesMember 2009-01-01 2009-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2009-01-01 2009-12-31 0001041009 us-gaap:PreferredStockMember 2009-12-31 0001041009 us-gaap:CommonStockMember 2009-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2009-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2009-12-31 0001041009 2009-12-31 0001041009 us-gaap:CommonStockMember 2010-01-01 2010-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2010-01-01 2010-12-31 0001041009 2010-01-01 2010-12-31 0001041009 rmcp:ExercisesByThirdPartiesForCashMember us-gaap:CommonStockMember 2010-01-01 2010-12-31 0001041009 rmcp:ExercisesByThirdPartiesForCashMember us-gaap:AdditionalPaidInCapitalMember 2010-01-01 2010-12-31 0001041009 rmcp:ExercisesByThirdPartiesForCashMember 2010-01-01 2010-12-31 0001041009 rmcp:CommonStockIssuedForServicesMember us-gaap:CommonStockMember 2010-01-01 2010-12-31 0001041009 rmcp:CommonStockIssuedForServicesMember us-gaap:AdditionalPaidInCapitalMember 2010-01-01 2010-12-31 0001041009 rmcp:CommonStockIssuedForServicesMember 2010-01-01 2010-12-31 0001041009 us-gaap:TreasuryStockMember 2010-01-01 2010-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2010-01-01 2010-12-31 0001041009 us-gaap:PreferredStockMember 2010-12-31 0001041009 us-gaap:CommonStockMember 2010-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2010-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2010-12-31 0001041009 us-gaap:TreasuryStockMember 2010-12-31 0001041009 2010-12-31 0001041009 us-gaap:CommonStockMember 2011-01-01 2011-12-31 0001041009 us-gaap:CommonStockMember 2011-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0001041009 rmcp:ExercisesByThirdPartiesForCashMember us-gaap:CommonStockMember 2011-01-01 2011-12-31 0001041009 rmcp:ExercisesByThirdPartiesForCashMember us-gaap:AdditionalPaidInCapitalMember 2011-01-01 2011-12-31 0001041009 rmcp:ExercisesByThirdPartiesForCashMember us-gaap:ReceivablesFromStockholderMember 2011-01-01 2011-12-31 0001041009 rmcp:ExercisesByThirdPartiesForCashMember 2011-01-01 2011-12-31 0001041009 us-gaap:PreferredStockMember 2011-01-01 2011-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2011-01-01 2011-12-31 0001041009 rmcp:CommonStockIssuedForServicesMember us-gaap:CommonStockMember 2011-01-01 2011-12-31 0001041009 rmcp:CommonStockIssuedForServicesMember us-gaap:AdditionalPaidInCapitalMember 2011-01-01 2011-12-31 0001041009 rmcp:CommonStockIssuedForServicesMember 2011-01-01 2011-12-31 0001041009 us-gaap:TreasuryStockMember 2011-01-01 2011-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2011-01-01 2011-12-31 0001041009 us-gaap:PreferredStockMember 2011-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2011-12-31 0001041009 us-gaap:ReceivablesFromStockholderMember 2011-12-31 0001041009 us-gaap:CommonStockMember 2012-01-01 2012-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-12-31 0001041009 us-gaap:ReceivablesFromStockholderMember 2012-01-01 2012-12-31 0001041009 rmcp:CommonStockIssuedForServicesMember us-gaap:CommonStockMember 2012-01-01 2012-12-31 0001041009 rmcp:CommonStockIssuedForServicesMember us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-12-31 0001041009 rmcp:CommonStockIssuedForServicesMember 2012-01-01 2012-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2012-01-01 2012-12-31 0001041009 us-gaap:PreferredStockMember 2012-12-31 0001041009 us-gaap:CommonStockMember 2012-12-31 0001041009 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0001041009 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2012-12-31 0001041009 us-gaap:ReceivablesFromStockholderMember 2012-12-31 0001041009 rmcp:IvesMergerMember 1996-08-16 2012-12-31 0001041009 rmcp:ClearImageShareholdersUnderShortFormMergerMember 1996-08-16 2012-12-31 0001041009 2013-04-22 0001041009 2012-06-29 0001041009 us-gaap:MinimumMember 2012-01-01 2012-12-31 0001041009 us-gaap:MaximumMember 2012-01-01 2012-12-31 0001041009 rmcp:BeneficialConversionFeatureMember 2012-01-01 2012-12-31 0001041009 rmcp:StockOptionsAndWarrantsMember 2011-01-01 2011-12-31 0001041009 us-gaap:ConvertibleDebtSecuritiesMember 2011-01-01 2011-12-31 0001041009 rmcp:StockOptionsAndWarrantsMember 2012-01-01 2012-12-31 0001041009 us-gaap:ConvertibleDebtSecuritiesMember 2012-01-01 2012-12-31 0001041009 rmcp:EstimatedUsefulLifeMember 2012-01-01 2012-12-31 0001041009 us-gaap:MachineryAndEquipmentMember 2012-01-01 2012-12-31 0001041009 us-gaap:FurnitureAndFixturesMember 2012-01-01 2012-12-31 0001041009 us-gaap:LeaseholdImprovementsMember 2012-01-01 2012-12-31 0001041009 us-gaap:FairValueInputsLevel1Member 2012-12-31 0001041009 us-gaap:FairValueInputsLevel3Member 2012-12-31 0001041009 us-gaap:FairValueInputsLevel1Member 2011-12-31 0001041009 us-gaap:FairValueInputsLevel3Member 2011-12-31 0001041009 rmcp:MoldProductionPaymentsMember 2012-01-01 2012-11-30 0001041009 rmcp:MoldProductionPaymentsMember 2011-12-31 0001041009 rmcp:MoldProductionPaymentsMember 2012-01-01 2012-12-31 0001041009 rmcp:MoldProductionPaymentsMember 2012-12-31 0001041009 rmcp:MedicalInvestmentGroupMIGMember 2012-12-31 0001041009 rmcp:MoldProductionPaymentsMember 2012-12-01 2012-12-31 0001041009 us-gaap:EquipmentMember 2012-12-31 0001041009 us-gaap:EquipmentMember 2011-12-31 0001041009 us-gaap:LeaseholdImprovementsMember 2012-12-31 0001041009 us-gaap:LeaseholdImprovementsMember 2011-12-31 0001041009 us-gaap:FurnitureAndFixturesMember 2012-12-31 0001041009 us-gaap:FurnitureAndFixturesMember 2011-12-31 0001041009 us-gaap:LicensingAgreementsMember 2012-01-01 2012-12-31 0001041009 rmcp:ClearImageMember 2007-01-01 2007-12-31 0001041009 rmcp:ClearImageMember us-gaap:MinimumMember 2007-12-31 0001041009 rmcp:ClearImageMember us-gaap:MaximumMember 2007-12-31 0001041009 rmcp:ClearImageMember 2007-12-31 0001041009 rmcp:ClearImageMember 2012-01-01 2012-12-31 0001041009 us-gaap:PatentsMember 2012-12-31 0001041009 us-gaap:PatentsMember 2011-12-31 0001041009 us-gaap:LicensingAgreementsMember 2011-12-31 0001041009 2012-06-18 0001041009 rmcp:AccruedSalaryMember 2012-01-01 2012-12-31 0001041009 us-gaap:AccountsPayableMember 2012-01-01 2012-12-31 0001041009 rmcp:LiabilitiesWriteOffMember 2012-01-01 2012-12-31 0001041009 rmcp:YesoMedMember 2012-01-01 2012-12-31 0001041009 rmcp:YesoMedMember 2011-12-01 2011-12-31 0001041009 rmcp:RelatedToMinimumPurchaseRequirementMember rmcp:YesoMedMember 2012-12-31 0001041009 rmcp:YesoMedMember 2012-01-01 2012-12-31 0001041009 rmcp:ProductPurchaseMember rmcp:YesoMedMember 2012-12-31 0001041009 rmcp:EquipmentPurchaseMember rmcp:YesoMedMember 2012-12-31 0001041009 rmcp:EquipmentPurchaseMember rmcp:YesoMedMember 2011-12-31 0001041009 rmcp:AsherNotes2012Member 2012-01-01 2012-12-31 0001041009 rmcp:AsherNotes2012Member 2012-12-31 0001041009 rmcp:TCAGlobalCreditMasterFundLPMember 2012-01-01 2012-01-03 0001041009 rmcp:TCAGlobalCreditMasterFundLPMember 2012-01-03 0001041009 rmcp:TCAGlobalCreditMasterFundLPMember 2012-01-01 2012-12-31 0001041009 rmcp:TCAGlobalCreditMasterFundLPMember 2012-12-31 0001041009 rmcp:TCANoteMember 2012-12-31 0001041009 rmcp:TCANoteMember 2012-01-01 2012-12-31 0001041009 rmcp:TCANoteMember us-gaap:SubsequentEventMember 2013-01-01 2013-01-03 0001041009 rmcp:JMJNoteMember 2011-02-22 0001041009 rmcp:JMJNoteMember 2012-01-01 2012-12-31 0001041009 rmcp:JMJNoteMember 2012-12-31 0001041009 rmcp:JMJNoteMember 2011-12-31 0001041009 rmcp:JMJNoteMember 2011-01-01 2011-12-31 0001041009 rmcp:JMJNote2Member 2011-02-28 0001041009 rmcp:JMJNote2Member 2012-12-31 0001041009 rmcp:JMJNote2Member 2011-12-31 0001041009 rmcp:JMJNote2Member 2012-01-01 2012-12-31 0001041009 rmcp:IndividualConvertibleNotesMember 2012-01-01 2012-12-31 0001041009 rmcp:IndividualConvertibleNotesMember 2012-12-31 0001041009 rmcp:IndividualConvertibleNotesMember us-gaap:ChiefOperatingOfficerMember 2012-12-31 0001041009 rmcp:Warrant1RelatedToIndividualConvertibleNotesMember 2012-12-31 0001041009 rmcp:Warrant2RelatedToIndividualConvertibleNotesMember 2012-12-31 0001041009 rmcp:WarrantsRelatedToIndividualConvertibleNotesMember 2012-01-01 2012-12-31 0001041009 rmcp:WarrantsRelatedToIndividualConvertibleNotesMember us-gaap:MinimumMember 2012-01-01 2012-12-31 0001041009 rmcp:WarrantsRelatedToIndividualConvertibleNotesMember us-gaap:MaximumMember 2012-01-01 2012-12-31 0001041009 rmcp:IndividualConvertibleNotesMember rmcp:RelatedToConversionFeatureMember 2012-01-01 2012-12-31 0001041009 rmcp:JMJFinancialIncMember rmcp:DueFebruary222014Member 2012-12-31 0001041009 rmcp:JMJFinancialIncMember rmcp:DueFebruary222014Member 2011-12-31 0001041009 rmcp:AsherEnterprisesIncMember rmcp:DueApril262012Member 2011-12-31 0001041009 rmcp:AsherEnterprisesIncMember rmcp:DueJune12012Member 2011-12-31 0001041009 rmcp:AsherEnterprisesIncMember rmcp:DueAugust72012Member 2011-12-31 0001041009 rmcp:AsherEnterprisesIncMember rmcp:DueSeptember192012Member 2011-12-31 0001041009 rmcp:AsherEnterprisesIncMember rmcp:DueMarch212013Member 2012-12-31 0001041009 rmcp:AsherEnterprisesIncMember rmcp:DueMay102013Member 2012-12-31 0001041009 rmcp:AsherEnterprisesIncMember rmcp:DueAugust272013Member 2012-12-31 0001041009 rmcp:TCAGlobalCreditMasterFundLPMember rmcp:DueJanuary32013Member 2012-12-31 0001041009 rmcp:DueJune262013Member us-gaap:PrivatePlacementMember 2012-12-31 0001041009 rmcp:IncludingRelatedPartiesMember 2012-12-31 0001041009 rmcp:IncludingRelatedPartiesMember 2011-12-31 0001041009 rmcp:AsherEnterprisesIncMember rmcp:DueApril262012Member 2012-12-31 0001041009 rmcp:AsherEnterprisesIncMember rmcp:DueJune12012Member 2012-12-31 0001041009 rmcp:AsherEnterprisesIncMember rmcp:DueAugust72012Member 2012-12-31 0001041009 rmcp:AsherEnterprisesIncMember rmcp:DueSeptember192012Member 2012-12-31 0001041009 rmcp:AsherEnterprisesIncMember rmcp:DueMarch212013Member 2011-12-31 0001041009 rmcp:AsherEnterprisesIncMember rmcp:DueMay102013Member 2011-12-31 0001041009 rmcp:AsherEnterprisesIncMember rmcp:DueAugust272013Member 2011-12-31 0001041009 rmcp:TCAGlobalCreditMasterFundLPMember rmcp:DueJanuary32013Member 2011-12-31 0001041009 rmcp:DueJune262013Member us-gaap:PrivatePlacementMember 2011-12-31 0001041009 rmcp:PayableForIndemnificationMember 2012-01-01 2012-12-31 0001041009 2009-03-11 0001041009 2010-12-01 2010-12-14 0001041009 2012-03-01 2012-03-15 0001041009 rmcp:NoteConversionFeatureMember 2012-01-01 2012-12-31 0001041009 us-gaap:MinimumMember 2011-01-01 2011-12-31 0001041009 us-gaap:MaximumMember 2011-01-01 2011-12-31 0001041009 2005-11-03 0001041009 2005-11-01 2005-11-30 0001041009 2011-10-01 2011-10-21 0001041009 2013-01-02 0001041009 2013-01-01 2013-01-02 0001041009 rmcp:MoldProductionPaymentsMember 2013-01-02 0001041009 rmcp:JMJFinancialIncMember 2012-01-09 0001041009 rmcp:JMJFinancialIncMember 2012-01-30 0001041009 rmcp:JMJFinancialIncMember 2012-03-15 0001041009 us-gaap:ChiefExecutiveOfficerMember 2012-05-15 2012-12-31 0001041009 us-gaap:ChiefOperatingOfficerMember 2011-04-11 2012-12-31 0001041009 us-gaap:ChiefFinancialOfficerMember 2011-06-01 2012-12-31 0001041009 rmcp:OspreySouthLLCMember 2009-09-02 0001041009 rmcp:OspreySouthLLCMember 2009-09-01 2011-06-30 0001041009 rmcp:OspreySouthLLCMember 2011-07-01 2016-06-30 0001041009 rmcp:Series2006PreferredStockMember 2012-12-31 0001041009 rmcp:Series2006PreferredStockMember 2012-12-31 0001041009 rmcp:Series2009PreferredStockMember 2012-01-01 2012-12-31 0001041009 rmcp:GiffordMabieMember 2012-01-01 2012-12-31 0001041009 rmcp:WarrantsAndOptionsExercisedMember 2012-01-01 2012-12-31 0001041009 rmcp:WarrantsAndOptionsExercisedMember 2012-12-31 0001041009 rmcp:FormerPresidentMember 2011-01-01 2011-12-31 0001041009 rmcp:ThirdPartyInvestorsAgreementMember 2011-01-01 2011-12-31 0001041009 2011-07-31 0001041009 rmcp:ForConsultingServicesExercisableAt0.25Member 2012-01-01 2012-12-31 0001041009 rmcp:ForConsultingServicesExercisableAt0.40Member 2012-01-01 2012-12-31 0001041009 rmcp:ForDirectorsAndEmployeeServicesMember 2012-01-01 2012-12-31 0001041009 us-gaap:StockOptionsMember us-gaap:MinimumMember 2012-01-01 2012-12-31 0001041009 us-gaap:StockOptionsMember us-gaap:MaximumMember 2012-01-01 2012-12-31 0001041009 rmcp:BeginningOfPeriodMember 2010-12-31 0001041009 rmcp:BeginningOfPeriodMember 2011-01-01 2011-12-31 0001041009 rmcp:EndOfPeriodMember 2011-12-31 0001041009 rmcp:EndOfPeriodMember 2011-01-01 2011-12-31 0001041009 rmcp:EndOfPeriodMember 2012-12-31 0001041009 rmcp:EndOfPeriodMember 2012-01-01 2012-12-31 0001041009 us-gaap:ChiefExecutiveOfficerMember 2012-01-01 2012-12-31 0001041009 us-gaap:DirectorMember 2012-01-01 2012-12-31 0001041009 rmcp:FormerDirectorMember 2012-01-01 2012-12-31 0001041009 rmcp:OspreySouthLLCMember 2012-01-01 2012-12-31 0001041009 rmcp:OspreySouthLLCMember 2011-01-01 2011-12-31 0001041009 rmcp:OspreySouthLLCMember 2012-12-31 0001041009 rmcp:OspreySouthLLCMember 2011-12-31 0001041009 us-gaap:ChiefOperatingOfficerMember 2012-12-31 0001041009 us-gaap:ChiefExecutiveOfficerMember 2012-12-31 0001041009 rmcp:FormerCFOMember 2011-12-31 0001041009 rmcp:ReclassificationOfSubscriptionReceivableMember 2011-01-01 2011-12-31 0001041009 rmcp:EliminationOfGainFromLitigationMember 2011-01-01 2011-12-31 0001041009 rmcp:DecreaseOfPrepaidConsultingExpenseMember 2011-01-01 2011-12-31 0001041009 rmcp:IncreaseInPayableForIndemnificationMember 2011-01-01 2011-12-31 0001041009 rmcp:IncreaseOfIndemnificationExpenseMember 2011-01-01 2011-12-31 0001041009 rmcp:DecreaseInPayableToSONMedicalMember 2011-01-01 2011-12-31 0001041009 us-gaap:ScenarioPreviouslyReportedMember 2011-12-31 0001041009 us-gaap:RestatementAdjustmentMember 2011-12-31 0001041009 us-gaap:ScenarioPreviouslyReportedMember 2011-01-01 2011-12-31 0001041009 us-gaap:RestatementAdjustmentMember 2011-01-01 2011-12-31 0001041009 us-gaap:SubsequentEventMember 2013-01-01 2013-04-30 0001041009 rmcp:ForSettlementOfAccruedSalariesMember us-gaap:SubsequentEventMember 2013-01-01 2013-04-30 0001041009 rmcp:ForSettlementOfAccountsPayableMember us-gaap:SubsequentEventMember 2013-01-01 2013-04-30 0001041009 rmcp:ForDirectorFeesMember us-gaap:SubsequentEventMember 2013-01-01 2013-04-30 0001041009 rmcp:WarrantsAndOptionsExercisedMember us-gaap:SubsequentEventMember 2013-01-01 2013-04-30 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure iso4217:USD compsci:item 54 4844 321791 4859 279868 326704 284712 356656 1185664 106687 116426 23276 790047 1610078 1122371 468468 1280860 352544 73957 87944 1347806 1424019 184289 80535 32466 364802 442311 4406551 2855821 0 0 1000 1000 72785 54730 34319432 29497937 71000 25000 37938721 30774410 -3616504 -1245743 790047 1610078 187039 307126 42534 0 0.001 0.001 5000000 5000000 1000000 1000000 1000000 1000000 0.001 0.001 250000000 250000000 72784907 54729606 72784907 54729606 1189 1189 9200 9200 783593 783593 792793 792793 -791604 -791604 35544 57000 2935949 102971 17023 205111 4046080 3781286 27298804 878276 4570007 794 5062871 3855309 35009077 -5854475 -3855309 -35800681 10 17286 1727512 567081 2629705 0 170753 13202 -139712 131397 -119138 -45976 273077 305892 -1309836 -686209 -2321462 -7164311 -4541518 -38122143 -183422 -7164311 -4541518 -37938721 61779765 49149099 -0.12 -0.09 26550 27 273 300 350000 350 6650 7000 28900 29 574448 574477 15562 16 311246 311262 1750 2 34998 35000 926 1 26999 27000 10928 11 353709 353720 3225 3 128997 129000 2638 2 69798 -69800 4525 4 173423 173427 5134 5 74995 75000 -795376 -795376 450138 450 1755536 -795376 -69800 890810 2241 2 54998 55000 2500 3 90997 91000 27293 27 359873 359900 1207 1 18099 18100 49400 49 574499 574548 27429 27 274973 275000 17500 18 332 350 -4579 -4 -40261 -40265 114154 114154 918187 918187 69800 69800 -2584383 -2584383 573129 573 4121387 -3379759 742201 19535 20 342404 342424 -16743 -16743 15000 15 149985 150000 8203 8 166735 166743 280000 280000 89728 89728 -1014555 -1014555 615867 616 5133496 -4394314 739798 43139 43 250345 250388 405000 405000 -1347859 -1347859 659006 659 5788841 -5742173 47327 327917 328 1604372 1604700 182500 183 547317 -547500 2500 3 7497 7500 -85575 -85575 22500 23 422427 422450 10000 10 1487690 1487700 -1048754 -1048754 -2199085 -2199085 1204423 1206 8723815 -7941258 -547500 236263 181250 181 362319 362500 100341 100 -100 102803 102803 759795 759795 60000 60 324440 324500 -1933676 -1933676 1546014 1547 10170269 -9874934 -444697 -147815 57000 57 140643 140700 350000 350 139650 140000 288959 288959 200000 200 79800 80000 69201 69201 -1391518 -1391518 2153014 2154 10819321 -11266452 -375496 -820473 5000 5 4995 5000 293300 293 253807 254100 73100 73 73027 -1000 72100 1642500 1643 912357 914000 18750 18750 -1552008 -1552008 4166914 4168 12063507 -12818460 -357746 -1108531 651959 652 290048 290700 90000 90 44910 45000 260000 260 33740 -34000 1062500 1063 475437 476500 291667 292 137541 137833 499733 499733 130900 130900 357746 357746 -1310783 -1310783 6523040 6525 13675816 -14129243 -34000 -480902 50000 50 950 1000 150000 150 74850 75000 300000 300 5700 6000 34000 34000 275000 275 107225 107500 1000000 1000 19000 20000 3000 3000 -625066 -625066 -25000 -25 -12475 -12500 50000 50000 -598302 -598302 1000000 1000 7273040 7275 13299000 -14727545 -1420270 845000 845 299155 300000 8273788 8274 3301241 3309515 223246 223246 125000 125 9875 10000 345662 346 6568 6914 1225000 1225 388775 390000 40000 40 9960 10000 -4475017 -4475017 1000000 1000 18127490 18130 17537820 -19202562 -1645612 4720978 4722 300101 304823 2300000 2300 395317 397617 1419704 1419 258501 259920 271491 271 132759 133030 43600 43 12164 12207 342801 342801 -209776 -209776 -1335154 -1335154 1000000 1000 26883193 26885 18769687 -20537716 -1740144 5946446 5946 1396188 1402134 171250 171 13529 13700 500000 500 249500 250000 1530000 1530 346770 348300 667000 667 306074 306741 1452231 1452231 -17998 -17998 -2463751 -2463751 1500000 1500 35197959 35199 22515981 -23001467 -448787 4810287 4810 1525181 1529991 150000 150 37350 37500 117400 117 58583 58700 2194891 2194 558578 560772 399441 400 530356 530756 -969 -969 -3231425 -3231425 1500000 1500 42869978 42870 25226029 -26232892 -969 -963462 656015 656 201915 202571 6668000 6668 1672752 -25000 1654420 -500000 -500 500 1513874 1514 479586 481100 3191367 3191 959105 962296 94624 94624 -169628 -169 969 800 863426 863426 -4541518 1000000 1000 54729606 54730 29497937 -30774410 -25000 -1245743 1235000 1235 303040 -46000 258275 2751229 2751 513360 516111 974961 974961 347097 347097 237774 237774 13669072 13669 2305103 2318772 400000 400 140160 140560 -7164311 1000000 1000 72784907 72785 34319432 -37938721 -71000 -3616504 1491072 1065458 12616731 50000 1428978 489080 1861218 182733 165442 396474 321791 321791 -275009 -162181 4859 1533758 -11439 3074372 -13987 63659 73957 64347 67071 1805396 -1674342 -2563073 -13788652 31777 992907 794 39224 97314 161538 261997 -39224 -129091 -1415648 802154 258275 1654420 3412412 1450501 770500 2976001 15707 8005 -157325 202571 8163410 1708776 2627491 15204354 -4790 -64673 54 69517 0 0 0 0 0 0 2318772 962296 4687415 140560 184000 457590 584871 769624 2405422 300 3093948 358762 500 500 352544 289009 Revolutions Medical CORP 10-K --12-31 77610014 10253579 false 0001041009 Yes No Smaller Reporting Company No 2012 FY 2012-12-31 <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 1 &#8211;DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Organization and Nature of Operations</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Revolutions Medical Corporation, a Nevada corporation, (&#8220;the Company&#8221; or &#8220;RevMed&#8221;) has been endeavoring to design, develop and commercialize auto retractable vacuum safety syringes.&#160;&#160;Our present product development effort is focused on the RevVac&#8482; Auto Retractable Vacuum Safety Syringe, which is designed specifically to reduce accidental needle stick injuries and lower the spread of blood borne diseases.&#160;&#160;The Company also has developed a suite of proprietary MRI software tools; RevColor&#8482;, Rev3D&#8482;, and RevDisplay&#8482;.&#160;&#160;These tools are designed to enhance general diagnostic confidence through education and research use and in the future the Company believe will have specific commercial applications. The Company&#8217;s administrative facilities are located in Charleston, South Carolina. The Company&#8217;s primary manufacturing facility is located in Wuxi, China.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Development Stage Company</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Since its inception in 1996, the Company has been considered a development stage enterprise for financial reporting purposes as significant efforts have been devoted to raising capital and to research and development of various safety syringes and its proprietary MRI software tools.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accounting Estimates</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160; Actual results could differ significantly from those estimates.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Reclassification</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Certain prior period amounts have been reclassified to conform to current period presentation.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash and Cash Equivalents</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company considers highly liquid investments (those readily convertible to cash) purchased with original maturity dates of three months or less to be cash equivalents.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accounts Receivable</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company records trade receivables when revenue is recognized.&#160;&#160;No product has been consigned to customers.&#160; The Company&#8217;s allowance for doubtful accounts is primarily determined by review of specific trade receivables.&#160; Those accounts that are doubtful of collection are included in the allowance.&#160; These provisions are reviewed to determine the adequacy of the allowance for doubtful accounts.&#160; Trade receivables are charged off when there is certainty as to their being uncollectible.&#160; Trade receivables are considered delinquent when payment has not been made within contract terms.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company requires certain distributors to make a prepayment prior to beginning production or shipment of their order.&#160;&#160;Distributors may apply such prepayments to their outstanding invoices or pay the invoice and continue to carry forward the deposit for future orders.&#160; Such amounts are included in other accrued liabilities on the balance sheets.&#160;&#160;The Company records an allowance for estimated returns as a reduction to accounts receivable and gross profit.&#160;&#160;To date, returns have been immaterial.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Inventories</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Inventories include only finished goods and are valued at the lower of cost or market, with cost being determined using weighted average cost.&#160; The Company compares the average cost to the market price and records the lower value.&#160; Management considers such factors as the amount of inventory on hand and in the distribution channel, estimated time to sell such inventory, the shelf life of inventory, and current market conditions when determining excess or obsolete inventories.&#160; A reserve is established for any excess or obsolete inventories or they may be written off. For the years ended December 31, 2012 and 2011, no allowance for inventory was recorded.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Property and Equipment</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Property and equipment, including significant improvements, are stated at cost. Expenditures for maintenance and repairs are charged to operating expenses as incurred. When properties are retired or otherwise disposed of, the cost of the asset and the related accumulated depreciation are removed from the accounts with the resulting gain or loss being reflected in results of operations.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Depreciation and amortization expense is recorded on a straight-line basis over the estimated useful life of the asset as listed below:</font> </div><br/><table cellpadding="0" cellspacing="0" width="97%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" width="29%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">Asset Category</font></font> </div> </td> <td align="left" valign="bottom" width="4%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="bottom" width="47%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">Useful Lives</font></font> </div> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="top" width="29%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Machinery and equipment (years)</font> </div> </td> <td align="left" valign="bottom" width="4%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="47%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5&#160;</font> </div> </td> </tr> <tr> <td align="left" valign="top" width="29%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Furniture and fixtures (years)</font> </div> </td> <td align="left" valign="bottom" width="4%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="47%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7&#160;</font> </div> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="top" width="29%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Leasehold improvements</font> </div> </td> <td valign="bottom" width="4%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="47%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shorter of leasehold improvement life or remaining term of lease</font> </div> </td> </tr> </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Intangibles</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Intangible assets include patents and trademarks, which are valued at acquisition through independent appraisals and amortized on a straight-line basis over periods varying from 17 to 20 years.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Impairment of Long-lived Assets</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company reviews the carrying value of the long-lived assets periodically to determine if facts and circumstances exist that would suggest that assets might be impaired or that the useful lives should be modified. Among the factors the Company considers in making the evaluation are changes in market position and profitability. If facts and circumstances exist which may indicate impairment, the Company will prepare a projection of the undiscounted cash flows of the asset group and determine if the long-lived assets are recoverable based on these undiscounted cash flows. If impairment is indicated, an adjustment will be made to reduce the carrying amount of these assets to their fair value.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Research and Development</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Research and development costs are expensed as incurred.&#160;&#160;The Company incurred $35,544, $57,000 and $2,935,949 of research and development expenses for the years ended December 31, 2012 and 2011, and for the period from August 16, 1996 (inception) through December 31, 2012.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Beneficial Conversion Feature</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">From time to time, the Company may issue convertible notes that have conversion prices that create an embedded beneficial conversion feature on the issuance date. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of any attached equity instruments, if any related equity instruments were granted with the debt. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital.&#160;&#160;The debt discount is amortized to interest expense over the life of the note using the effective interest method.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Derivative Instruments</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Derivatives are measured at their fair value on the balance sheet.&#160;&#160;In determining the appropriate fair value, the Company uses the Black-Scholes option pricing formula.&#160;&#160;Changes in fair value are recorded in the statement of operations.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair Value of Financial Instruments</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e. exit price), in an orderly transaction between market participants at the measurement date.&#160;&#160;The Company categorizes its assets and liabilities measured at fair value based upon the level of judgment associated with the inputs used to measure the fair value. Level inputs are classified as follows:</font> </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="top" width="3%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="3%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;</font> </div> </td> <td valign="top" width="78%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 1 &#8211; quoted prices in active markets for identical assets or liabilities.</font> </div> </td> </tr> </table><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="top" width="3%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="3%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;</font> </div> </td> <td valign="top" width="78%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 2 &#8211; other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.</font> </div> </td> </tr> </table><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="top" width="3%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="3%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;</font> </div> </td> <td valign="top" width="78%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 3 &#8211; significant unobservable inputs that reflect management&#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date.</font> </div> </td> </tr> </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table summarizes fair value measurements by level at December 31, 2012, for assets and liabilities measured at fair value on a recurring basis:</font> </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level&#160;1</font> </div> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level&#160;2</font> </div> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level&#160;3</font> </div> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font> </div> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents</font> </div> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">54</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">54</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="48%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Derivative liability</font> </div> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">364,802</font> </div> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">364,802</font> </div> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table summarizes fair value measurements by level at December 31, 2011, for assets and liabilities measured at fair value on a recurring basis:</font> </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level&#160;1</font> </div> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level&#160;2</font> </div> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level&#160;3</font> </div> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font> </div> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents</font> </div> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,844</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,844</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="48%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Derivative liability</font> </div> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">442,311</font> </div> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">442,311</font> </div> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Revenue Recognition</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Revenue is recognized for sales when title and risk of ownership passes to the customer, generally upon shipment from the manufacturing facility in Wuxi, China or from our warehouse facility in Ladson, South Carolina; when price is fixed or determinable; and when collection is reasonably assured.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Share-based Compensation</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the trading price on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Income Taxes</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company uses the liability method of accounting for income taxes.&#160;&#160;Under the liability method, deferred taxes are determined based on the differences between the financial statement and tax basis of assets and liabilities at enacted tax rates in effect in the years in which the differences are expected to reverse.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Earnings (Loss) Per Common Share</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Basic net income (loss) per common share is calculated by dividing net income (loss) available to common stockholders for the period by the weighted average shares of common stock outstanding during the period. Diluted net income per common share is computed by dividing the net income for the period by the weighted average number of common and common equivalent shares outstanding during the period. The calculation of diluted income (loss) per common share assumes the dilutive effect of stock options, warrants and any other potentially dilutive securities outstanding. During a loss period, the potentially dilutive securities have an anti-dilutive effect and are not included in the calculation of dilutive net loss per common share. For the year ended December 31, 2011, potentially issuable shares, including options and warrants to purchase&#160;18,845,350 shares of the Company&#8217;s common stock and notes payable convertible to 4,637,152 shares of the Company&#8217;s common stock, have been excluded from the calculation. For the year ended December 31, 2012, potentially issuable shares, including options and warrants to purchase 14,980,000 shares of the Company&#8217;s common stock and notes payable convertible to 6,603,582&#160;&#160;shares of the Company&#8217;s common stock have been excluded from the calculation.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Subsequent Events</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has evaluated all transactions occurring between the end of its fiscal year, December 31, 2012, through the date of issuance of the financial statements for subsequent event disclosure consideration.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">New Accounting Standards</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company.</font> </div><br/> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accounting Estimates</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160; Actual results could differ significantly from those estimates.</font></div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Reclassification</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Certain prior period amounts have been reclassified to conform to current period presentation.</font></div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash and Cash Equivalents</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company considers highly liquid investments (those readily convertible to cash) purchased with original maturity dates of three months or less to be cash equivalents.</font></div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accounts Receivable</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company records trade receivables when revenue is recognized.&#160;&#160;No product has been consigned to customers.&#160; The Company&#8217;s allowance for doubtful accounts is primarily determined by review of specific trade receivables.&#160; Those accounts that are doubtful of collection are included in the allowance.&#160; These provisions are reviewed to determine the adequacy of the allowance for doubtful accounts.&#160; Trade receivables are charged off when there is certainty as to their being uncollectible.&#160; Trade receivables are considered delinquent when payment has not been made within contract terms.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company requires certain distributors to make a prepayment prior to beginning production or shipment of their order.&#160;&#160;Distributors may apply such prepayments to their outstanding invoices or pay the invoice and continue to carry forward the deposit for future orders.&#160; Such amounts are included in other accrued liabilities on the balance sheets.&#160;&#160;The Company records an allowance for estimated returns as a reduction to accounts receivable and gross profit.&#160;&#160;To date, returns have been immaterial.</font></div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Inventories</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Inventories include only finished goods and are valued at the lower of cost or market, with cost being determined using weighted average cost.&#160; The Company compares the average cost to the market price and records the lower value.&#160; Management considers such factors as the amount of inventory on hand and in the distribution channel, estimated time to sell such inventory, the shelf life of inventory, and current market conditions when determining excess or obsolete inventories.&#160; A reserve is established for any excess or obsolete inventories or they may be written off. For the years ended December 31, 2012 and 2011, no allowance for inventory was recorded.</font></div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Property and Equipment</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Property and equipment, including significant improvements, are stated at cost. Expenditures for maintenance and repairs are charged to operating expenses as incurred. When properties are retired or otherwise disposed of, the cost of the asset and the related accumulated depreciation are removed from the accounts with the resulting gain or loss being reflected in results of operations.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Depreciation and amortization expense is recorded on a straight-line basis over the estimated useful life of the asset as listed below:</font> </div><br/><table cellpadding="0" cellspacing="0" width="97%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" width="29%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">Asset Category</font></font> </div> </td> <td align="left" valign="bottom" width="4%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="bottom" width="47%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">Useful Lives</font></font> </div> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="top" width="29%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Machinery and equipment (years)</font> </div> </td> <td align="left" valign="bottom" width="4%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="47%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5&#160;</font> </div> </td> </tr> <tr> <td align="left" valign="top" width="29%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Furniture and fixtures (years)</font> </div> </td> <td align="left" valign="bottom" width="4%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="47%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7&#160;</font> </div> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="top" width="29%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Leasehold improvements</font> </div> </td> <td valign="bottom" width="4%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="47%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shorter of leasehold improvement life or remaining term of lease</font></div></td></tr></table> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Intangibles</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Intangible assets include patents and trademarks, which are valued at acquisition through independent appraisals and amortized on a straight-line basis over periods varying from 17 to 20 years.</font></div> P17Y P20Y <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Impairment of Long-lived Assets</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company reviews the carrying value of the long-lived assets periodically to determine if facts and circumstances exist that would suggest that assets might be impaired or that the useful lives should be modified. Among the factors the Company considers in making the evaluation are changes in market position and profitability. If facts and circumstances exist which may indicate impairment, the Company will prepare a projection of the undiscounted cash flows of the asset group and determine if the long-lived assets are recoverable based on these undiscounted cash flows. If impairment is indicated, an adjustment will be made to reduce the carrying amount of these assets to their fair value.</font></div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Research and Development</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Research and development costs are expensed as incurred.&#160;&#160;The Company incurred $35,544, $57,000 and $2,935,949 of research and development expenses for the years ended December 31, 2012 and 2011, and for the period from August 16, 1996 (inception) through December 31, 2012.</font></div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Beneficial Conversion Feature</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">From time to time, the Company may issue convertible notes that have conversion prices that create an embedded beneficial conversion feature on the issuance date. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of any attached equity instruments, if any related equity instruments were granted with the debt. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital.&#160;&#160;The debt discount is amortized to interest expense over the life of the note using the effective interest method.</font></div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Derivative Instruments</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Derivatives are measured at their fair value on the balance sheet.&#160;&#160;In determining the appropriate fair value, the Company uses the Black-Scholes option pricing formula.&#160;&#160;Changes in fair value are recorded in the statement of operations.</font></div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair Value of Financial Instruments</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e. exit price), in an orderly transaction between market participants at the measurement date.&#160;&#160;The Company categorizes its assets and liabilities measured at fair value based upon the level of judgment associated with the inputs used to measure the fair value. Level inputs are classified as follows:</font> </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="top" width="3%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="3%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;</font> </div> </td> <td valign="top" width="78%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 1 &#8211; quoted prices in active markets for identical assets or liabilities.</font> </div> </td> </tr> </table><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="top" width="3%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="3%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;</font> </div> </td> <td valign="top" width="78%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 2 &#8211; other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.</font> </div> </td> </tr> </table><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="top" width="3%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="3%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt">&#183;</font> </div> </td> <td valign="top" width="78%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 3 &#8211; significant unobservable inputs that reflect management&#8217;s best estimate of what market participants would use to price the assets or liabilities at the measurement date.</font> </div> </td> </tr> </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table summarizes fair value measurements by level at December 31, 2012, for assets and liabilities measured at fair value on a recurring basis:</font> </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level&#160;1</font> </div> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level&#160;2</font> </div> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level&#160;3</font> </div> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font> </div> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents</font> </div> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">54</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">54</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="48%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Derivative liability</font> </div> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">364,802</font> </div> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">364,802</font> </div> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table summarizes fair value measurements by level at December 31, 2011, for assets and liabilities measured at fair value on a recurring basis:</font> </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level&#160;1</font> </div> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level&#160;2</font> </div> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level&#160;3</font> </div> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font> </div> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents</font> </div> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,844</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,844</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="48%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Derivative liability</font> </div> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">442,311</font> </div> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">442,311</font></div></td></tr></table> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Revenue Recognition</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Revenue is recognized for sales when title and risk of ownership passes to the customer, generally upon shipment from the manufacturing facility in Wuxi, China or from our warehouse facility in Ladson, South Carolina; when price is fixed or determinable; and when collection is reasonably assured.</font></div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Share-based Compensation</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the trading price on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.</font></div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Income Taxes</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company uses the liability method of accounting for income taxes.&#160;&#160;Under the liability method, deferred taxes are determined based on the differences between the financial statement and tax basis of assets and liabilities at enacted tax rates in effect in the years in which the differences are expected to reverse.</font></div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Earnings (Loss) Per Common Share</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Basic net income (loss) per common share is calculated by dividing net income (loss) available to common stockholders for the period by the weighted average shares of common stock outstanding during the period. Diluted net income per common share is computed by dividing the net income for the period by the weighted average number of common and common equivalent shares outstanding during the period. The calculation of diluted income (loss) per common share assumes the dilutive effect of stock options, warrants and any other potentially dilutive securities outstanding. During a loss period, the potentially dilutive securities have an anti-dilutive effect and are not included in the calculation of dilutive net loss per common share. For the year ended December 31, 2011, potentially issuable shares, including options and warrants to purchase&#160;18,845,350 shares of the Company&#8217;s common stock and notes payable convertible to 4,637,152 shares of the Company&#8217;s common stock, have been excluded from the calculation. For the year ended December 31, 2012, potentially issuable shares, including options and warrants to purchase 14,980,000 shares of the Company&#8217;s common stock and notes payable convertible to 6,603,582&#160;&#160;shares of the Company&#8217;s common stock have been excluded from the calculation.</font></div> 18845350 4637152 14980000 6603582 <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Subsequent Events</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has evaluated all transactions occurring between the end of its fiscal year, December 31, 2012, through the date of issuance of the financial statements for subsequent event disclosure consideration.</font></div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">New Accounting Standards</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company.</font></div> <table cellpadding="0" cellspacing="0" width="97%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" width="29%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">Asset Category</font></font> </div> </td> <td align="left" valign="bottom" width="4%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="bottom" width="47%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">Useful Lives</font></font> </div> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="top" width="29%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Machinery and equipment (years)</font> </div> </td> <td align="left" valign="bottom" width="4%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="47%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5&#160;</font> </div> </td> </tr> <tr> <td align="left" valign="top" width="29%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Furniture and fixtures (years)</font> </div> </td> <td align="left" valign="bottom" width="4%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="47%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7&#160;</font> </div> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="top" width="29%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Leasehold improvements</font> </div> </td> <td valign="bottom" width="4%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="47%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shorter of leasehold improvement life or remaining term of lease</font> </div> </td> </tr> </table> P5Y P7Y Shorter of leasehold improvement life or remaining term of lease <table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level&#160;1</font> </div> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level&#160;2</font> </div> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level&#160;3</font> </div> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font> </div> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents</font> </div> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">54</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">54</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="48%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Derivative liability</font> </div> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">364,802</font> </div> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">364,802</font> </div> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level&#160;1</font> </div> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level&#160;2</font> </div> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level&#160;3</font> </div> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font> </div> </td> <td align="left" valign="top" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents</font> </div> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,844</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,844</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="48%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="10%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Derivative liability</font> </div> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">442,311</font> </div> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td align="right" valign="top" width="10%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">442,311</font> </div> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table> 54 54 364802 364802 4844 4844 442311 442311 <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 2 &#8211; GOING CONCERN</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company is in the development stage and has not established sources of revenues to fund the development of its business and pay operating expenses, resulting in a cumulative net loss of $37,938,721 for the period from inception (August 16, 1996) to December 31, 2012. The ability of the Company to continue as a going concern during the next year depends on the successful completion of the Company&#8217;s capital raising efforts to fund the development of its retractable safety syringe. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.<a id="eolpage36" name="eolpage36"><!--EFPlaceholder--></a></font> </div><br/> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 3 &#8211; PROPERTY AND EQUIPMENT</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following is a summary of property and equipment at December 31, 2012 and 2011:</font> </div><br/><table cellpadding="0" cellspacing="0" width="99%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31, 2012</font> </div> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31, 2011</font> </div> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> &#160; </td> </tr> <tr style="background-color: #C0FFFF;"> <td valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Equipment</font> </div> </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.5pt"></font>353,235</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-0" style="MARGIN-LEFT: 7pt"></font>1,113,235</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> </tr> <tr> <td valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Leasehold improvement</font> </div> </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-1" style="MARGIN-LEFT: 33.2pt"></font>44,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-2" style="MARGIN-LEFT: 34.4pt"></font>44,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> </tr> <tr style="background-color: #C0FFFF;"> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Furniture</font> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-3" style="MARGIN-LEFT: 33.2pt"></font>49,147</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-4" style="MARGIN-LEFT: 34.45pt"></font>49,147</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> &#160; </td> </tr> <tr> <td valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Subtotal</font> </div> </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-5" style="MARGIN-LEFT: 26.55pt"></font>446,382</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-6" style="MARGIN-LEFT: 17.8pt"></font>1,206,382</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> </tr> <tr style="background-color: #C0FFFF;"> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Less: accumulated depreciation</font> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-7" style="MARGIN-LEFT: 24.35pt"></font>(89,726</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-8" style="MARGIN-LEFT: 25.6pt"></font>(20,718</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> </tr> <tr> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 4px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Property and equipment, net</font> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-9" style="MARGIN-LEFT: 4.5pt"></font>356,656</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> &#160; </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-10" style="MARGIN-LEFT: 7pt"></font>1,185,664</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> &#160; </td> </tr> </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the years ended December 31, 2012 and 2011, the Company recognized depreciation and amortization expense related to property and equipment of $69,008 and $11,135, respectively.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During 2012, the Company impaired $710,000 of the $760,000 production mold payments made to Medical Investment Group, Inc. (&#8220;MIG&#8221;) in 2011 and wrote off an $80,000 prepayment to MIG. The impairment charge was based upon the arbitration hearing against MIG in November, 2012. The hearing and the final ruling made clear that all production mold payments made by the Company to MIG for the manufacturing of production molds had instead been used by Mr. Theriault, a representative of MIG, for other non-production related purposes. The American Arbitration Association panel ruled that the only assets in which production was funded by MIG from the Company&#8217;s production payments were $50,000 in trial molds. From the time that these payments were made by the Company, the Company believed that each mold payment was being used by MIG for the manufacturing of the final production molds for the 3ml RevVac&#8482; auto-retractable vacuum safety syringe. During the arbitration proceeding, Mr. Theriault disclosed that no such payments, besides $50,000 in trial mold payments, were ever used for the production of the final molds for the RevVac&#8482; auto-retractable vacuum safety syringe. The arbitration panel ruled that a total of $770,000 awarded to the Company.&#160;&#160;The Company has not received such payment to date. The gain related to this award will be recorded when collected.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During 2012, the Company also impaired $50,000 for a trial mold that is no longer considered useful to the Company.</font> </div><br/> 69008 11135 710000 760000 80000 50000 770000 50000 <table cellpadding="0" cellspacing="0" width="99%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31, 2012</font> </div> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31, 2011</font> </div> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> &#160; </td> </tr> <tr style="background-color: #C0FFFF;"> <td valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Equipment</font> </div> </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.5pt"></font>353,235</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-0" style="MARGIN-LEFT: 7pt"></font>1,113,235</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> </tr> <tr> <td valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Leasehold improvement</font> </div> </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-1" style="MARGIN-LEFT: 33.2pt"></font>44,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-2" style="MARGIN-LEFT: 34.4pt"></font>44,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> </tr> <tr style="background-color: #C0FFFF;"> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Furniture</font> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-3" style="MARGIN-LEFT: 33.2pt"></font>49,147</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-4" style="MARGIN-LEFT: 34.45pt"></font>49,147</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> &#160; </td> </tr> <tr> <td valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Subtotal</font> </div> </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-5" style="MARGIN-LEFT: 26.55pt"></font>446,382</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-6" style="MARGIN-LEFT: 17.8pt"></font>1,206,382</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> </tr> <tr style="background-color: #C0FFFF;"> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Less: accumulated depreciation</font> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-7" style="MARGIN-LEFT: 24.35pt"></font>(89,726</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-8" style="MARGIN-LEFT: 25.6pt"></font>(20,718</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> </tr> <tr> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 4px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Property and equipment, net</font> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-9" style="MARGIN-LEFT: 4.5pt"></font>356,656</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> &#160; </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-10" style="MARGIN-LEFT: 7pt"></font>1,185,664</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> &#160; </td> </tr> </table> 353235 1113235 44000 44000 49147 49147 446382 1206382 -89726 -20718 <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 4 &#8211; INTANGIBLES AND GOODWILL</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Intangibles</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following is a summary of the Company&#8217;s intangibles at December 31, 2012 and 2011:</font> </div><br/><table cellpadding="0" cellspacing="0" width="99%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31, 2012</font> </div> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31, 2011</font> </div> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> &#160; </td> </tr> <tr style="background-color: #C0FFFF;"> <td valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Patent</font> </div> </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-11" style="MARGIN-LEFT: 4.5pt"></font>146,538</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-12" style="MARGIN-LEFT: 7pt"></font>107,314</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> </tr> <tr> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Licensing agreement</font> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-13" style="MARGIN-LEFT: 65.45pt"></font>-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-14" style="MARGIN-LEFT: 34.45pt"></font>15,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> &#160; </td> </tr> <tr style="background-color: #C0FFFF;"> <td valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Subtotal</font> </div> </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-15" style="MARGIN-LEFT: 26.55pt"></font>146,538</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-16" style="MARGIN-LEFT: 27.8pt"></font>122,314</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> </tr> <tr> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Less: accumulated amortization</font> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-17" style="MARGIN-LEFT: 24.35pt"></font>(39,851</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-18" style="MARGIN-LEFT: 32.25pt"></font>(5,888</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 4px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intangibles , net</font> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-19" style="MARGIN-LEFT: 4.5pt"></font>106,687</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> &#160; </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-20" style="MARGIN-LEFT: 7pt"></font>116,426</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> &#160; </td> </tr> </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company owns one published patent on its Auto Retractable Vacuum RevVac&#8482; safety syringe issued in January 2005 and one published patent on its safety blood drawing device issued in June 2003.&#160;&#160;In January 2009, a second patent for the RevVac&#8482; auto retractable vacuum safety syringe was issued by the U.S. patent office and published in April 2009 related to the Globe/Revolutions Medical Joint Venture.&#160;&#160;Upon the ruling in the Globe Med Tech lawsuit, the Company now has full ownership of the entire patent.&#160;&#160;The Company also filed international patent protection rights regarding the RevVac&#8482; Auto Retractable Vacuum Safety Syringe in the following countries: Australia, China, Japan, Taiwan, Mexico, Canada and in Europe. Patents in Mexico and in China were issued in June 2011 and January 2012, respectively. The Japan patent was issued in the third quarter of 2012.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company filed a U.S. provisional patent on May 2, 2011, on its new vacuum design for the pre-filled market.&#160;&#160;On May 2, 2012, the Company also filed an international Patent Cooperation Treaty (PCT) for this new design.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company is also engaged in the development of technology which can segment and reference MRI images.&#160;&#160;By &#8220;segmenting&#8221; an image, the Company&#8217;s technology will let the user select a part of the image (bone, fluid, tissue) and render that selection in three dimensions.&#160;&#160;Essentially, different components of an image are given different colors and the user can choose the color or colors to be studied, thus eliminating those portions colored with the colors being discarded.&#160;&#160;By &#8220;referencing&#8221; the image to a database, the user can obtain similar, identified images to aid the user in interpretation of the image being studied.&#160;&#160;The Company currently owns 4 separate patent applications, filed in June of 2007, each of which received USPTO office actions during 2010, 2011 and 2012.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The licensing agreement provided licensing rights to a Traxis biopsy software product. The Company decided not to pursue this technology and impaired the cost of $15,000 during 2012.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the years ended December 31, 2012 and 2011, the Company recognized amortization expense of $33,963 and $5,888, respectively.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Goodwill</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In 2007, the Company acquired a 62.2% interest in Clear Image, Inc. (&#8220;Clear Image&#8221;).&#160;&#160;Clear Image was a privately held company and was conducting research and development on Color MRI Technology.&#160;&#160; The Company exchanged approximately 8.2 million of its common shares which were trading between $0.40 and $0.50 per share at the time of the acquisition.&#160; To arrive at a value for the Color MRI Technology, the Company and Clear Image determined the amount of funding provided for the research and development of this technology by evaluating the amount expended from 1999 until the acquisition date.&#160;&#160;The value of the Company&#8217;s stock exchanged for the controlling interest exceeded net assets acquired by $23,276 which was recorded as goodwill.&#160;&#160;During 2012, all goodwill was impaired.</font> </div><br/> 15000 33963 5888 0.622 8200000 0.40 0.50 23276 23276 <table cellpadding="0" cellspacing="0" width="99%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31, 2012</font> </div> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31, 2011</font> </div> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> &#160; </td> </tr> <tr style="background-color: #C0FFFF;"> <td valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Patent</font> </div> </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-11" style="MARGIN-LEFT: 4.5pt"></font>146,538</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-12" style="MARGIN-LEFT: 7pt"></font>107,314</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> </tr> <tr> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Licensing agreement</font> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-13" style="MARGIN-LEFT: 65.45pt"></font>-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-14" style="MARGIN-LEFT: 34.45pt"></font>15,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> &#160; </td> </tr> <tr style="background-color: #C0FFFF;"> <td valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Subtotal</font> </div> </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-15" style="MARGIN-LEFT: 26.55pt"></font>146,538</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-16" style="MARGIN-LEFT: 27.8pt"></font>122,314</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> </tr> <tr> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Less: accumulated amortization</font> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-17" style="MARGIN-LEFT: 24.35pt"></font>(39,851</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-18" style="MARGIN-LEFT: 32.25pt"></font>(5,888</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 4px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intangibles , net</font> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-19" style="MARGIN-LEFT: 4.5pt"></font>106,687</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> &#160; </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-20" style="MARGIN-LEFT: 7pt"></font>116,426</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> &#160; </td> </tr> </table> 146538 107314 15000 146538 122314 -39851 -5888 106687 116426 <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 5 &#8211; ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following is a summary of the Company&#8217;s accounts payable and accrued liabilities at December 31, 2012 and 2011:</font> </div><br/><table cellpadding="0" cellspacing="0" width="99%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31, 2012</font> </div> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31, 2011</font> </div> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> &#160; </td> </tr> <tr style="background-color: #C0FFFF;"> <td valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable</font> </div> </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-21" style="MARGIN-LEFT: 4.5pt"></font>432,436</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-22" style="MARGIN-LEFT: 7pt"></font>99,342</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> </tr> <tr> <td valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued payroll liabilities and related penalties</font> </div> </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-23" style="MARGIN-LEFT: 26.55pt"></font>411,670</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-24" style="MARGIN-LEFT: 27.8pt"></font>125,239</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> </tr> <tr style="background-color: #C0FFFF;"> <td valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued salary</font> </div> </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-25" style="MARGIN-LEFT: 26.55pt"></font>143,167</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-26" style="MARGIN-LEFT: 27.8pt"></font>120,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> </tr> <tr> <td valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued interest</font> </div> </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-27" style="MARGIN-LEFT: 26.55pt"></font>134,559</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-28" style="MARGIN-LEFT: 34.45pt"></font>64,670</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> </tr> <tr style="background-color: #C0FFFF;"> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other accruals</font> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-29" style="MARGIN-LEFT: 49.9pt"></font>539</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-30" style="MARGIN-LEFT: 34.45pt"></font>59,217</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> &#160; </td> </tr> <tr> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 4px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total accounts payable and accrued liabilities</font> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-31" style="MARGIN-LEFT: 4.5pt"></font>1,122,371</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> &#160; </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-32" style="MARGIN-LEFT: 7pt"></font>468,468</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> &#160; </td> </tr> </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of December 31, 2012 and 2011, the Company had accrued $411,670 and $125,239, respectively, pursuant to employment state and federal payroll tax liabilities and related penalties.&#160;&#160;Although the Company plans to settle these amounts, there is no assurance that its efforts to settle will be successful.&#160;&#160;A tax lien in the amount of $1,227 was filed against the Company on June 18, 2012 by the South Carolina Department of Revenue due to these delinquent payments.&#160;&#160;Action by federal taxing authorities has not been initiated or threatened at this point.&#160;&#160;There is no assurance, however, that such action will not be initiated in the future.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the year ended December 31, 2012, the Company wrote off $199,336 of accrued salary to and advances from Rhonda Vincent, former CFO, and $79,890 of payables to various vendors as such claims have passed the statute of limitations in Oklahoma, where the Company formerly conducted operations.&#160;&#160;Other income of $279,226 was recorded in the statement of operations.</font> </div><br/> 411670 125239 1227 199336 79890 279226 <table cellpadding="0" cellspacing="0" width="99%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31, 2012</font> </div> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31, 2011</font> </div> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> &#160; </td> </tr> <tr style="background-color: #C0FFFF;"> <td valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable</font> </div> </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-21" style="MARGIN-LEFT: 4.5pt"></font>432,436</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-22" style="MARGIN-LEFT: 7pt"></font>99,342</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> </tr> <tr> <td valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued payroll liabilities and related penalties</font> </div> </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-23" style="MARGIN-LEFT: 26.55pt"></font>411,670</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-24" style="MARGIN-LEFT: 27.8pt"></font>125,239</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> </tr> <tr style="background-color: #C0FFFF;"> <td valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued salary</font> </div> </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-25" style="MARGIN-LEFT: 26.55pt"></font>143,167</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-26" style="MARGIN-LEFT: 27.8pt"></font>120,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> </tr> <tr> <td valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued interest</font> </div> </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-27" style="MARGIN-LEFT: 26.55pt"></font>134,559</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-28" style="MARGIN-LEFT: 34.45pt"></font>64,670</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> &#160; </td> </tr> <tr style="background-color: #C0FFFF;"> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other accruals</font> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-29" style="MARGIN-LEFT: 49.9pt"></font>539</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> &#160; </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-30" style="MARGIN-LEFT: 34.45pt"></font>59,217</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> &#160; </td> </tr> <tr> <td valign="bottom" width="70%" style="PADDING-BOTTOM: 4px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total accounts payable and accrued liabilities</font> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-31" style="MARGIN-LEFT: 4.5pt"></font>1,122,371</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> &#160; </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> &#160; </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-32" style="MARGIN-LEFT: 7pt"></font>468,468</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> &#160; </td> </tr> </table> 432436 99342 411670 125239 143167 120000 134559 64670 539 59217 1122371 468468 <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 6 &#8211; PAYABLE TO YESO-MED</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 1, 2011, the Company entered into a 5-year agreement with Wuxi Yushou Medical Appliance Co., Ltd (&#8220;Yeso-med&#8221;). Pursuant to the agreement, commencing from the date that Yeso-med demonstrates to the Company&#8217;s satisfaction that it has the capacity to commence regular production of the syringes in the 3ml size in the minimum amount of at least 2,500,000 units per month, the Company will place orders of at least 2,500,000 units per month for the term of this agreement. If the Company does not place with Yeso-med the minimum order for a single month, Yeso-med shall have the right to receive payments from the Company equal to 50% of the supply price of each unit below the minimum order amount required for that month.&#160;&#160;The Company has the right to have the amount paid under this requirement to serve as payment against future orders provided the quantity ordered exceeds the minimum quantity for that month. In July 2012, Yeso-med met the capacity requirement. However, the Company has not yet placed any order after July 2012.&#160;&#160;As of December 31, 2012, a payable was recorded to Yeso-med related to this minimum purchase requirement of $783,593. During the year ended December&#160;31, 2012, $783,593 was recorded as a loss on firm purchase commitments.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The payable to Yeso-med also included amounts due for product purchased of $208,258 as of December 31, 2012 and amounts due for equipment purchased of $289,009 and $352,544 as of December 31, 2012 and 2011, respectively.</font> </div><br/> 5-year 2500000 0.50 783593 783593 208258 289009 352544 <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 7 &#8211; CONVERTIBLE NOTES PAYABLE</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At December 31, 2012 and 2011, notes payable consisted of the following:</font> </div><br/><table cellpadding="0" cellspacing="0" width="98%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</font> </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December&#160;31,</font> </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible Promissory Note Payable to JMJ Financial, unsecured, one time interest charge of 8%, due on February 22, 2014</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">191,663</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">207,161</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0% per annum, with payment due on April 26, 2012</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">40,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0% per annum, with payment due on June 1, 2012</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">45,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0% per annum, with payment due on August 7, 2012</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">42,500</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0%&#160;&#160;per annum, with payment due on September 19, 2012</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">53,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0% per annum, with payment due on March 21, 2013, fully converted in January 2013</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,500</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0%&#160;&#160;per annum, with payment due on May 10, 2013</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">42,500</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible Promissory Note Payable to Asher Enterprises, unsecured,&#160;interest rate of 8.0%&#160;&#160;per annum, with payment due on August&#160;27, 2013</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">42,500</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible Promissory Note Payable to TCA Global Credit Master Fund, LP, secured by all of the Company&#8217;s assets,&#160;interest rate of 12.0%&#160;&#160;per annum, with payment due on January 3, 2013</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">62,165</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible Promissory Note Payable issued in the course of a private placement to individuals, unsecured,&#160;&#160;interest rate of 8.0%&#160;&#160;per annum, with payment due on June 26, 2013</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">100,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total&#160;</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">446,328</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">387,661</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Less: debt discount</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(229,573</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(307,126</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">216,755</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">80,535</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Asher Enterprises</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the year ended December 31, 2012, the Company issued 6 convertible promissory notes to Asher Enterprises for total proceeds of $269,000 in cash (&#8220;2012 Asher Notes&#8221;). All of the notes were convertible to the Company&#8217;s common stock at a conversion price equal to the greater of (1) 55% multiplied by the average of the lowest 3 trading prices for the Company&#8217;s common stock during the 10 trading day period ending on the latest complete trading day prior to the conversion date market price and (2) a fixed conversion price of $0.00009 per share. The Company analyzed the conversion feature of the 2012 Asher Notes for derivative accounting consideration and determined that the conversion feature for the 2012 Asher Notes does not qualify for accounting treatment as a financial derivative. The 2012 Asher Notes have a beneficial conversion feature discount of $237,774, within which $170,844 has been amortized. During the year ended December 31, 2012, the Company also recorded interest expense of $118,268 related to the amortization of debt discount on notes issued in 2011 to Asher Enterprises. At December&#160;31, 2012, there was $66,930 of unamortized discount related to the 2012 Asher Notes.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the year ended December 31, 2012, Asher Enterprises converted principal of $357,000 with accrued interest into 4,952,916 shares of the Company&#8217;s common stock.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The 2012 Asher Notes are currently in default as a result of the Company&#8217;s failure to timely file its periodically report with the SEC.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">TCA Global Credit Master Fund, LP</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On January 3, 2012, the Company entered into a securities purchase agreement with TCA Global Credit Master Fund, LP (&#8220;TCA&#8221;), pursuant to which, TCA would purchase up to $2,000,000 of the Company&#8217;s common stock. The Company agreed to pay a $100,000 facility fee by issuing to TCA a number of the Company&#8217;s common shares (&#8220;facility shares&#8221;). To determine the number of shares issuable to TCA for the facility fee, the Company&#8217;s common stock was valued at a volume weighted average price at January 2, 2012. The facility shares should be adjusted 9 months after January 2, 2012 by the volume weighted average prices of the Company&#8217;s common stock 5 trading days prior to the revaluation date. On August 13, 2012, the Company and TCA agreed to terminate the committed equity financing agreement based on the Company&#8217;s failure to achieve bulletin board listing as required under the agreement. The Company has issued 559,268 common shares in 2012 to TCA which only satisfied $51,924 of the facility fee upon revaluation. As of December&#160;31, 2012, accounts payable included $48,076 for the remaining payable to TCA related to the facility fee.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the securities purchase agreement with TCA, the Company issued a convertible promissory note to TCA for a principal amount of $225,000 (&#8220;TCA Note&#8221;).&#160;&#160;The note bears interest at a rate of 12% per annum and provides for the payment of all principal and interest 12 months from the date of the note&#8217;s respective issuance.&#160;&#160;The conversion price was determined by multiplying 95% by the average of the two lowest daily volume weighted average prices of the Company&#8217;s common stock on the OTC Markets during the 5 business days immediately preceding the date of conversion.&#160;&#160;&#160;&#160;The Company analyzed the TCA Note for derivative accounting consideration and determined that the TCA Note qualifies for accounting treatment as a financial derivative. The conversion feature of the TCA note was valued at $174,448 on the issuance date and recorded as debt discount. During the year ended December 31, 2011, the Company recognized $174,448 of interest expense related to the amortization of the debt discount.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">TCA converted principal of $162,835 into 1,601,255 shares of the Company&#8217;s common stock during 2012 and principal of $27,840 into 300,000 shares of the Company&#8217;s common stock on January 3, 2013.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">JMJ Financial</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On February 22, 2011, the Company issued a $1,050,000 convertible promissory note to JMJ Financial, Inc. (&#8220;JMJ&#8221;). The&#160;note bears interest in the form of a onetime interest charge of 8%, payable with the note&#8217;s principal amount on the maturity date,&#160;February 22, 2014. The note is convertible to the Company&#8217;s common stock at a price equal to 70% of the average of the 3 lowest closing prices of the Company&#8217;s common stock in the 20 trading days prior to the conversion date. In connection with the note, the Company entered into a registration rights agreement with JMJ to provide JMJ registration rights for common shares underlying this note. The note will only be funded when the conversion price calculated on each payment date is equal to or greater than $0.015 per share and there are sufficient shares remaining in the registration statement. During 2012, JMJ converted $15,498 under this agreement into 180,000 shares of the Company&#8217;s common stock. The principal amount owed to JMJ at December 31, 2012 and 2011, is $191,663 and $207,161, respectively, from the $1,050,000 convertible promissory note. The Company analyzed the JMJ note for derivative accounting consideration and determined that the note qualifies for accounting treatment as a financial derivative and recorded an initial discount of $450,000 on the issuance date. During the year ended December 31, 2012 and 2011, the Company recorded $80,000 and $263,309 of interest expense related to the amortization of the debt discount. At December 31, 2012 and 2011, there was $106,691 and $186,691, respectively, of unamortized debt discount related to the JMJ notes.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On February 28, 2011, the Company issued&#160;a $500,000 convertible promissory note to JMJ.&#160;&#160;The&#160;note bears interest in the form of a onetime interest charge of 8%, payable with the note&#8217;s principle amount on the maturity date,&#160;February 28, 2014.&#160;&#160;All or a portion of this note&#8217;s principle and interest is convertible at the option of JMJ from time to time, into shares of the Company&#8217;s common stock, originally fixed at a per share conversion price equal to 70% of the average of the 3 lowest closing prices for the Company&#8217;s common stock in the 20 trading days previous to the effective date of each such conversion. No amount is owed to JMJ from the $500,000 convertible promissory note at December 31, 2012 and 2011.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company is currently in litigation with JMJ. See Note 11.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Individual Convertible Notes Payable</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During 2012, the Company issued 22 convertible notes payable to individuals for proceeds of $956,501 in cash (&#8220;Individual Convertible Notes&#8221;). The Individual Convertible Notes mature one year from the date of issuance. Interest accrues at the rate of 8% per year on the outstanding principal amount to be paid at maturity.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The principal amount of the Individual Convertible Notes and accrued interest are convertible into the Company&#8217;s common stock at a conversion price equal to 75% of the average of the daily volume weighted average prices of the Company's Common Stock during the 5 trading days immediately prior to the conversion date, provided that in no event, shall the note holders convert any portion of the Individual Convertible Notes when the sum of 1) the number of shares of common stock beneficially owned by the holder and its affiliates and 2) the number of shares of common stock issuable upon conversion would result in beneficial ownership by the holder and its affiliates of more than 4.99% of the Company&#8217;s outstanding common shares. During 2012, $856,501 of the Individual Convertible Notes with accrued interest were converted into 6,934,901 shares of the Company&#8217;s common stock. As of December 31, 2012, Individual Convertible Notes includes principal of $75,000 payable to Vincent Olmo, the Company&#8217;s COO, with a debt discount of $42,534.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the issuance of the Individual Convertible Notes, warrants to purchase 3,826,005 shares of the Company&#8217;s common stock at $0.25 per share and warrants to purchase 1,913,003 shares of the Company&#8217;s common stock at $0.50 per share were issued to investors. The warrants have a term of less than one year and expire on December 31, 2012, March 31, 2013, or June 30, 2013. $347,097 of the proceeds received from the Individual Convertible Notes was allocated to the warrants based on a grant date fair value of $589,416 calculated using a Black Scholes Model with the following assumptions: (1) 3.9% risk-free discount rate, (2) expected volatility of 155.60 ~218.64%, (3) $0 expected dividends, and (4) an expected term of 0.3~1 years based on the term of warrant.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company analyzed the Individual Convertible Notes for derivative accounting consideration and determined that the conversion feature of the Individual Convertible Notes qualify for accounting treatment as a financial derivative. The conversion feature of Individual Convertible Notes was valued at $777,766 on the issuance date. As a result, some of the Individual Convertible Notes were fully discounted and the fair value of the conversion feature in excess of the principal amount allocated to the Individual Convertible Notes of $182,733 was expensed immediately as additional interest expense. During the year ended December 31, 2012, the Company recognized $885,418 of interest expense related to the amortization of the debt discount. At December 31, 2012, there was $55,952 of unamortized discount related to the Individual Convertible Notes.</font> </div><br/> 269000 0.00009 237774 170844 118268 66930 357000 4952916 2000000 100000 559268 51924 48076 225000 0.12 174448 174448 162835 1601255 27840 300000 1050000 0.08 15498 180000 191663 207161 450000 80000 263309 106691 186691 500000 0.08 0 0 500000 956501 0.08 856501 6934901 75000 42534 3826005 0.25 1913003 0.50 347097 589416 0.039 1.5560 2.1864 0 P109D P1Y 777766 182733 885418 55952 <table cellpadding="0" cellspacing="0" width="98%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</font> </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> <td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December&#160;31,</font> </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible Promissory Note Payable to JMJ Financial, unsecured, one time interest charge of 8%, due on February 22, 2014</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">191,663</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">207,161</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0% per annum, with payment due on April 26, 2012</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">40,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0% per annum, with payment due on June 1, 2012</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">45,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0% per annum, with payment due on August 7, 2012</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">42,500</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0%&#160;&#160;per annum, with payment due on September 19, 2012</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">53,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0% per annum, with payment due on March 21, 2013, fully converted in January 2013</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,500</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0%&#160;&#160;per annum, with payment due on May 10, 2013</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">42,500</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible Promissory Note Payable to Asher Enterprises, unsecured,&#160;interest rate of 8.0%&#160;&#160;per annum, with payment due on August&#160;27, 2013</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">42,500</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible Promissory Note Payable to TCA Global Credit Master Fund, LP, secured by all of the Company&#8217;s assets,&#160;interest rate of 12.0%&#160;&#160;per annum, with payment due on January 3, 2013</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">62,165</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Convertible Promissory Note Payable issued in the course of a private placement to individuals, unsecured,&#160;&#160;interest rate of 8.0%&#160;&#160;per annum, with payment due on June 26, 2013</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">100,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="70%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total&#160;</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">446,328</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">387,661</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Less: debt discount</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(229,573</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(307,126</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">216,755</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">80,535</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table> 191663 207161 40000 45000 42500 53000 7500 42500 42500 62165 100000 446328 387661 -229573 -307126 216755 80535 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.12 0.12 0.08 0.08 <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 8 &#8211; PAYABLE FOR INDEMNIFICATION</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On February 5, 2009, the Company entered into an Indemnification Settlement Agreement with Gifford M. Mabie, founder and former Chief Executive Officer of the Company. Pursuant to the agreement, the Company agreed to indemnify Mr. Mabie for the payment of penalties, prejudgment interest and post-judgment interest to the United States Securities and Exchange Commission (&#8220;SEC&#8221;) that is part of the Final Judgment, dated March 11, 2005, in SEC v. Maxxon, Inc., Gifford M. Mabie, Jr., Thomas R. Coughlin, Jr. 02-CV-975-H(J) which resulted from actions taken in good faith by Mabie and Coughlin in the performance of duties as an officer and directors of the Company.&#160;&#160;The payment amount stated in the Final Judgment is $1,088,067.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The agreement specifies that the Company is to periodically issue shares to a special account for Gifford Mabie in order that shares can be sold each day the market is open until the liability is satisfied.&#160;&#160;The special account was initially funded by the Company&#8217;s common stock owned by Mr. Mabie. Total amount of stock traded by the special account is limited to 5% of the total trading volume each day. A percentage equal to Mr. Mabie&#8217;s federal and state tax liabilities to a maximum of 40% will be retained by the brokerage firm and remitted to the Internal Revenue Service and to the Oklahoma Tax Commission or the Tax Commission where Mr. Mabie resides. If Mr. Mabie receives a tax refund, that refund will be forwarded to the SEC.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 14, 2010, the Company issued 400,000 shares of the Company&#8217;s common stock, initially valued at $184,000, to the special account. An additional 400,000 shares were issued to the special account on March 15, 2012 with an initial value of $140,560 determined based upon the 10-day average share price prior to the date of issuance.&#160;&#160;At each reporting date, the Company revalues the shares held in the special account and adjusts the outstanding balance. Net increases and decreases in the value of the Company&#8217;s common shares held in the special account are recorded in the current period statement of operations. As of December 31, 2012, the remaining principal balance, including the estimated taxes, to be paid was $1,347,806 based upon the Company&#8217;s valuation of the stock. For the years ended December 31, 2012 and 2011, net loss related to the stock held in the special account was $63,347 and $67,071, respectively.</font> </div><br/> 1088067 400000 184000 400000 140560 63347 67071 <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 9 &#8211; DERIVATIVES &#8211; NOTE CONVERSION FEATURE</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Due to the conversion feature contained in some of the notes the Company issued, the actual number of shares of common stock that would be required if a conversion of the notes was made through the issuance of the Company&#8217;s common stock cannot be predicted, and the Company could be required to issue an amount of shares that may cause it to exceed its authorized share amount. As a result, the conversion feature requires derivative accounting treatment and will be bifurcated from the note and &#8220;marked to market&#8221; each reporting period through the income statement. The fair value of the conversion future of these notes was recognized as a derivative liability instrument and will be measured at fair value at each reporting period. In determining the fair value, the Company uses the Black-Scholes option-pricing model. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option-pricing model.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following is a reconciliation of the derivative liability:</font> </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="85%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair value at December&#160;31, 2010</font> </div> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="12%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">160,659</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="85%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issuance of instruments</font> </div> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="12%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">840,442</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="85%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Decrease in value</font> </div> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="12%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(40,030</font> </div> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </div> </td> </tr> <tr> <td align="left" valign="bottom" width="85%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reclassification from liability to equity as a result of note conversions</font> </div> </td> <td valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(518,760</font> </div> </td> <td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </div> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="85%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair value at December&#160;31, 2011</font> </div> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="12%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">442,311</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="85%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issuance of instruments</font> </div> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="12%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">952,214</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="85%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Decrease in value</font> </div> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="12%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(131,397</font> </div> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </div> </td> </tr> <tr> <td align="left" valign="bottom" width="85%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reclassification from liability to equity as a result of note conversions</font> </div> </td> <td valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(898,326</font> </div> </td> <td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </div> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="85%" style="PADDING-BOTTOM: 4px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair value at December 31, 2012</font> </div> </td> <td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 4px double"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">364,802</font> </div> </td> <td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The derivative liability was valued under the Black-Scholes model with the following assumptions:</font> </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" width="48%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td colspan="3" valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td colspan="3" valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Risk free interest rate</font> </div> </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.11%</font> </td> <td valign="bottom" width="5%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.5pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">to</font> </div> </td> <td valign="bottom" width="5%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.16%</font> </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.17%</font> </td> <td valign="bottom" width="5%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.5pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">to</font> </div> </td> <td valign="bottom" width="5%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.19%</font> </td> <td valign="bottom" width="1%"> &#160; </td> </tr> <tr> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected life (years)</font> </div> </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.01</font> </td> <td valign="bottom" width="5%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.5pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">to</font> </div> </td> <td valign="bottom" width="5%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.1</font> </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: right"> 0 </td> <td valign="bottom" width="5%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.5pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">to</font> </div> </td> <td valign="bottom" width="5%"> 3 </td> <td align="left" valign="bottom" width="1%"> &#160; </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dividend Yield</font> </div> </td> <td valign="bottom" width="5%"> &#160; </td> <td valign="bottom" width="5%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.5pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0%</font> </div> </td> <td valign="bottom" width="5%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: center"> &#160; </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: center"> &#160; </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0%</font> </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: center"> &#160; </td> <td valign="bottom" width="1%"> &#160; </td> </tr> <tr> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Volatility</font> </div> </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">130%</font> </td> <td valign="bottom" width="5%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.5pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">to</font> </div> </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">219%</font> </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0%</font> </td> <td valign="bottom" width="5%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.5pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">to</font> </div> </td> <td valign="bottom" width="5%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">205%</font> </td> <td valign="bottom" width="1%"> &#160; </td> </tr> </table><br/> <table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="85%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair value at December&#160;31, 2010</font> </div> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="12%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">160,659</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="85%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issuance of instruments</font> </div> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="12%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">840,442</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="85%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Decrease in value</font> </div> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="12%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(40,030</font> </div> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </div> </td> </tr> <tr> <td align="left" valign="bottom" width="85%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reclassification from liability to equity as a result of note conversions</font> </div> </td> <td valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(518,760</font> </div> </td> <td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </div> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="85%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair value at December&#160;31, 2011</font> </div> </td> <td align="right" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="12%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">442,311</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="85%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issuance of instruments</font> </div> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="12%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">952,214</font> </div> </td> <td align="left" valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="85%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Decrease in value</font> </div> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="top" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="12%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(131,397</font> </div> </td> <td align="left" valign="top" width="1%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </div> </td> </tr> <tr> <td align="left" valign="bottom" width="85%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reclassification from liability to equity as a result of note conversions</font> </div> </td> <td valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(898,326</font> </div> </td> <td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </div> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="85%" style="PADDING-BOTTOM: 4px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair value at December 31, 2012</font> </div> </td> <td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </td> <td align="right" valign="top" width="12%" style="BORDER-BOTTOM: black 4px double"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">364,802</font> </div> </td> <td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table> 160659 840442 -40030 -518760 952214 -131397 -898326 <table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" width="48%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td colspan="3" valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> <td colspan="3" valign="bottom" width="5%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> &#160; </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Risk free interest rate</font> </div> </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.11%</font> </td> <td valign="bottom" width="5%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.5pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">to</font> </div> </td> <td valign="bottom" width="5%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.16%</font> </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.17%</font> </td> <td valign="bottom" width="5%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.5pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">to</font> </div> </td> <td valign="bottom" width="5%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.19%</font> </td> <td valign="bottom" width="1%"> &#160; </td> </tr> <tr> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected life (years)</font> </div> </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.01</font> </td> <td valign="bottom" width="5%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.5pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">to</font> </div> </td> <td valign="bottom" width="5%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.1</font> </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: right"> 0 </td> <td valign="bottom" width="5%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.5pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">to</font> </div> </td> <td valign="bottom" width="5%"> 3 </td> <td align="left" valign="bottom" width="1%"> &#160; </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dividend Yield</font> </div> </td> <td valign="bottom" width="5%"> &#160; </td> <td valign="bottom" width="5%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.5pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0%</font> </div> </td> <td valign="bottom" width="5%"> &#160; </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: center"> &#160; </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: center"> &#160; </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0%</font> </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: center"> &#160; </td> <td valign="bottom" width="1%"> &#160; </td> </tr> <tr> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Volatility</font> </div> </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">130%</font> </td> <td valign="bottom" width="5%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.5pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">to</font> </div> </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">219%</font> </td> <td valign="bottom" width="1%"> &#160; </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0%</font> </td> <td valign="bottom" width="5%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.5pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">to</font> </div> </td> <td valign="bottom" width="5%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">205%</font> </td> <td valign="bottom" width="1%"> &#160; </td> </tr> </table> 0.0011 0.0016 0.0017 0.0019 P3D P2Y36D P0Y P3Y 0.00 0.00 1.30 2.19 0.00 2.05 <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 10 - MAXXON/GLOBE JOINT VENTURE AGREEMENT</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In September 2005, the Company filed a patent on its RevVac&#8482; safety syringe with Globe Med Tech which gives a 50% ownership of this patent to the Company and 50% to Globe Med Tech. On November 3, 2005, the Company (f.k.a. Maxxon, Inc.,) and Globe Med Tech, Inc. (&#8220;Globe&#8221;) entered into a definitive joint venture agreement to patent, develop, manufacture, market and distribute safety needle products throughout the world.&#160;&#160;The Company and Globe each own 50% of the joint venture.&#160;&#160;The Company contributed its safety syringe technology and patent rights related thereto and Globe contributed its safety syringe IV catheter and patent rights related thereto.&#160;&#160;In connection with the agreement, the Company issued restricted shares of its common stock, valued at $625,066, to Globe.&#160;&#160;Subsequent to December 31, 2006, the Company ended the joint venture and cancelled the shares of common stock and options that were issued to Globe pursuant to the agreement.&#160;&#160;This patent was issued January 13, 2009.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 1, 2007, the Company filed a lawsuit in the District Court of Tulsa County, Oklahoma against Globe to rescind, terminate and seek monetary damages for the non-fulfillment and breach of a joint venture agreement entered into November&#160;3, 2005, and other related agreements, in addition to an accounting of expenditures of funds under the terms and provisions of the agreements.&#160;&#160;On October 29, 2008, the Company filed in the District Court of Harris County, Texas, a lawsuit for fraud and contempt of court for Globe and Andy Hu, individually.&#160;&#160;On October 21, 2011, the Company was granted its request for summary judgment against Globe and awarded $311,440 and the return of 266,667 shares of the Company&#8217;s common stock by a Federal District Court in Tulsa County, Oklahoma.&#160;&#160;In addition to the monetary award and the return of the Company&#8217;s common stock, Globe is also required to return all syringes, design files, and sample molds to the Company.&#160;&#160;Furthermore, the Court ordered that Globe assign to the Company all rights to the January 2009 United States patent issued for the RevVac&#8482; auto-retractable vacuum safety syringe.&#160;&#160;Globe is prohibited from claiming any interest or ownership in the Company&#8217;s safety vacuum syringes going forward in the future.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 13, 2011, the Supreme Court of Oklahoma denied Globe&#8217;s appeal. On January 30, 2013, the court ordered a Nunc Pro Tunc decision denying all counterclaims and third party claims by Globe. Globe filed another appeal on March&#160;1, 2013. The Company has hired legal counsel in Texas to assist in efforts to collect these damages and execute on the court order.</font> </div><br/> 0.50 625066 311440 266667 <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 11 &#8211; COMMITMENTS AND CONTINGENCIES</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">MIG and SPD</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On January 2, 2013, the Company won its arbitration proceeding concerning its counter claims against Richard Theriault, former manufacturer MIG and former consultant, Strategic Product Development ("SPD").&#160;&#160;The monetary award included $770,000 in recoupment of production costs plus interest, legal fees and other arbitration costs, which will total close to $1 million. In other claims, Theriault was found guilty of fraud in the inducement and breach of contract and was found to have no rights to any of the Company's proprietary technology, files, drawings, designs, patents or products. The ruling determined that all production mold payments made by the Company to MIG for the manufacturing of production molds had instead been used by Mr. Theriault for other non-production related purposes. The panel of American Arbitration Association ruled that the only assets in which production was funded by MIG from the Company&#8217;s production payments were $50,000 in trial molds. The equipment asset on the balance sheet has been reduced by $710,000 and charged to impairment for the payments no longer associated with a production or trial mold. The $770,000 award is for the recovery of damages related to these production payments.&#160;&#160;The gain related to this award will be recorded when collected. The Company has hired legal counsel in Massachusetts and South Carolina to assist in efforts to collect these damages.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On September 26, 2012, the Company filed suit in South Carolina Federal District Court against SPD, Richard H. Theriault, Vita S. Theriault, Darius R. Theriault, Raminta Theriault, Goddard Technologies, Inc. ("GTI") and others, claiming that the defendants purposely and materially misled and misrepresented capabilities and progress on a variety of initiatives related to the development and manufacture of the Company's RevVac&#8482; Auto-Retractable Vacuum safety syringe to officers and directors of Revolutions Medical, which caused a delay in its production of approximately one year. The suit further alleges that Richard H. Theriault and other defendants defrauded the Company and misappropriated funds in violation of the United States' Racketeer Influenced and Corrupt Organizations ("RICO") Act and that GTI improperly assigned certain rights to the Company's new provisional patents to SPD without authorization. On February 2, 2013, Richard H. Theriault filed for bankruptcy in Massachusetts under Chapter 11.&#160;&#160;The South Carolina lawsuit has been temporarily stayed until such time when the arbitration award against Richard H. Theriault and MIG can be ruled on in United States Federal District Court in Massachusetts, seeking judgment outside the bankruptcy court. On March 13, 2013, United States Federal District Court in Massachusetts granted an injunction against Richard H. Theriault and MIG, enjoining and restraining them from transferring or alienating any assets in their possession without approval from the Court and a hearing has been scheduled for May 7, 2013.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">JMJ Financial, Inc.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 12, 2012, the Company filed a lawsuit against Justin Keener and JMJ in Charleston County, South Carolina.&#160;&#160;The Company sought a rescission and financial relief for the convertible debt agreement signed February 22, 2011. The Company claimed that it was unable to deliver the shares requested in the common stock conversion requests dated January 9, 2012 for 1,000,000 shares and January 30, 2012 for 1,226,049 shares due to the risk of defaulting on the convertible debt agreement by losing Depository Trust Company &#8220;DTC&#8221; eligibility. The contract stated that the Company would be considered in default of the agreement if the Company lost DTC eligibility due to a &#8220;chill&#8221; placed upon the electronic transfer of the stock. The Company had previously been made aware of other companies that had entered into similar agreements losing DTC eligibility and felt that JMJ had put the Company in an untenable position of either defaulting by losing DTC eligibility or defaulting by failing to issue the requested shares.&#160;&#160;The Company claimed that JMJ&#8217;s unreasonably high demands for conversion caused a &#8220;frustration&#8221; of the principal purpose of the contract and supports the rescission of the contract and a return of the parties to their respective positions before the contract was signed.&#160;&#160;On April 12, 2012 the Company withdrew the lawsuit filed in South Carolina to pursue its rights and counterclaims in Miami-Dade County, Florida, described below.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company also claims the default notice issued by JMJ obligated the Company to pay JMJ the outstanding principal balance under the note along with the accrued and unpaid interest. The principal balance due at the time JMJ issued the default notice amounted to $191,663.&#160;&#160;The Company disputes JMJ&#8217;s claims that the Company was liable for a sum far in excess of this amount based upon the default provision of the contract.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A lawsuit was filed against the Company by JMJ in Miami-Dade County, Florida on March 15, 2012. The lawsuit claims that the Company breached the terms of the convertible debt agreement by failing to issue shares requested in a stock conversion by JMJ on January 9, 2012 for 1,000,000 shares and on January 30, 2012 for 1,226,049 shares.&#160;&#160;JMJ is seeking the delivery of 2,226,049 shares of common stock of the Company, plus costs and prejudgment interest. On August 30, 2012, the Company filed its counterclaims against JMJ which included Fraud by Concealment, among other claims. The Company alleges that Keener and JMJ had a responsibility and obligation under Florida law to disclose not to conceal during the negotiations of the agreement the fact that Keener and JMJ had outstanding and current issues with these type of convertible notes with DTC which could do detrimental harm to liquidity and electronic transfer of the Company's stock if DTC eligibility was "chilled". This would severely hamper future capital raises and harm its current shareholders but would solely benefit Keener and JMJ under the default clauses in this agreement.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SEC</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The SEC filed a civil complaint in Federal District Court in Georgia against the Company, alleging that the Company issued four misleading press releases during the period from August 2010 through October 2010 and one misleading press release in July 2011, related to the Company&#8217;s production schedule of its auto retractable safety syringe. The SEC names the Company&#8217;s current Chief Executive Officer, Rondald L. Wheet, as a co-defendant. Among other relief, the SEC seeks an order requiring the defendants to disgorge money received from its equity line financing from August 2010 through May 2011, in addition to other civil penalty amounts.&#160;&#160;The Company believes that these claims are unfounded and is vigorously defending against them; however, should the Company not prevail in such defense the amount of damages owed to the SEC could be substantial and could adversely affect the Company&#8217;s financial condition or cause the Company to cease operations.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Employment Agreements</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Effective May 15, 2012, the Company and Mr. Wheet, Chief Executive Officer, entered into a 2-year employment agreement.&#160;&#160;The agreement provides for an annual salary of $247,500 and other reasonable and customary fringe benefits.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Effective April 11, 2011, the Company and Mr. Olmo, Chief Operating Officer, entered into a 3-year employment agreement. The agreement provides for an annual salary of $165,000 modified with a cost of living adjustment annually and other reasonable and customary fringe benefits.&#160;&#160;</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Effective June 1, 2011, the Company and Mr. Hodges, Chief Financial Officer, entered into a 3-year employment agreement. The agreement provides for an annual salary of $165,000 modified with a cost of living adjustment annually and other reasonable and customary fringe benefits.&#160;&#160;</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Lease Agreement</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On September 1, 2009, the Company entered into a 5-year lease agreement with Osprey South, LLC (&#8220;Osprey&#8221;), to lease the property at 670 Marina Drive, Suite 301, Building F, Charleston, South Carolina, 29492.&#160;&#160;Pursuant to the lease agreement, the Company was to pay Osprey $4,500 per month.&#160;&#160;On July 1, 2011, the Company amended the lease agreement to include the office space adjacent to the existing office space.&#160;According to the amended lease agreement, the lease ends on July 1, 2016, and the Company is to pay Osprey $10,000 per month.&#160;&#160;Rondald L. Wheet, our Chairman and Chief Executive Officer, is the sole member of Osprey.</font> </div><br/> 770000 1000000 50000 710000 1000000 1226049 191663 2226049 247500 165000 165000 P5Y 4500 10000 <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 12 - PREFERRED STOCK AND COMMON STOCK TRANSACTIONS</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PREFERRED STOCK</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Shares Outstanding</font>: Currently, 1,000,000 shares of preferred stock (&#8220;Preferred Stock&#8221;) are outstanding. Rondald L. Wheet, our Chief Executive Officer, owns 1,000,000 shares of Series 2006 Preferred Stock. Tom O&#8217;Brien, our former President, returned 500,000 shares of Series 2009 Preferred Stock upon his resignation in 2011.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Dividends</font>: The holder of the Preferred Stock is entitled to receive, ratably, dividends when, as and if declared by the board of directors out of funds legally available therefore. If any dividend or other distributions are declared on our common stock, then a dividend or other distribution must also be declared on the outstanding Preferred Stock at the same time and on the same terms and conditions, so that each holder of Preferred Stock will receive the same dividend or distribution such holder would have received if the holder had converted his Preferred Stock as of the record date for determining stockholders entitled to receive such dividend or distribution.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Liquidation Preference</font>: In the event of the liquidation, dissolution or winding up, the holders of Preferred Stock are entitled to receive a liquidation preference of $0.001 for each share of Preferred Stock prior to payment being made to any junior stock.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Conversion</font>: The holders of Preferred Stock may convert each share into 1 share of common stock.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Preemption</font>: The holders of Preferred Stock have no preemptive rights and they are not subject to further calls or assessments.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Voting Rights</font>: The holders of Preferred Stock are entitled to 125 votes for each share of common stock into which their Preferred Stock is then convertible (currently 1 share), voting together with our common stock as a single class. Cumulative voting is not permitted. Upon conversion of a share of Preferred Stock, each share of common stock issued upon the conversion will be entitled to only one vote per share.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Redemption</font>: There are no redemption or sinking fund provisions applicable to the Preferred Stock.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012 COMMON STOCK TRANSACTIONS</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the year ended December 31, 2012, 400,000 shares were issued under the terms of the SEC settlement agreement with Gifford Mabie.&#160;&#160;The initial value of these shares totaled $140,560.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the year ended December 31, 2012, the Company issued 2,751,229 shares of common stock with a total value of $516,111 for outside services.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Also, in the year ended December 31, 2012, the Company issued 1,235,000 shares of common stock for the exercise of warrants and options. The Company received cash of $258,275 and recorded a subscription receivable of $46,000.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Also, in the year ended December 31, 2012, the Company issued 13,669,072 shares of common stock for the conversions of convertible notes and accrued interest totaling $1,420,446. The derivative fair value of $898,326 for the conversion feature of these notes was reclassified on the date of conversion to additional paid-in capital.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011 COMMON STOCK TRANSACTIONS</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the year ended December 31, 2011, 6,668,000 shares of common stock were issued as option holders exercised their options to purchase common stock receiving proceeds of $1,654,420. &#160;Of these options exercised, 2,000,000 options were exercised by our former President, Tom O&#8217;Brien at $0.08 per share. The remainder of the options exercised was due from consultants according to the terms of their consulting agreements.&#160;656,015 shares were issued to third party investors and investors under the terms of a Drawdown Equity Financing Agreement. The Company received net proceeds of $202,571 in connection with these share issuances.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Also during the year ended December 31, 2011, the Company issued 1,513,874 shares of common stock with a total value of $481,100 in lieu of cash as payment for outside services.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the year ended December 31, 2011, the Company issued 3,021,738 shares of common stock for conversions of notes and accrued interest. In connection with the conversions, the reclassification of the derivative fair value related to note conversion feature totaled $963,096.</font> </div><br/> 1000000 1000000 500000 0.001 125 one 400000 140560 2751229 516111 1235000 258275 46000 13669072 1420446 6668000 1654420 2000000 0.08 656015 202571 1513874 481100 3021738 963096 <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 13 - STOCK OPTIONS AND WARRANTS OUTSTANDING</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company&#8217;s 2007 Stock Option Plan, revised July 2011, permits the granting of stock options to its employees, directors, consultants and independent contractors for up to 20 million shares of its common stock.&#160;&#160;The Company believes that such awards encourage employees to remain employed by the Company and also to attract persons of exceptional ability to become employees of the Company.&#160;&#160;The plan allows the Company to issue either stock options or common shares.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the year ended December 31, 2012, under the terms of the Company&#8217;s 2007 Stock Option Plan, 75,000 options were issued for consulting services exercisable at $0.25 per share, 300,000 options were issued for consulting services exercisable at $0.40 per share, and 2.5 million shares were issued to directors and an employee for service provided. The options have a term of 1~2 years and vest upon issuance. Fair value of $429,824 was calculated using the Black-Scholes Model with the following assumptions: (1) discount rate of 0.12% to 0.21% (2) expected life of 0.7 to 2.0 years (3) expected volatility of 159% to 161% and (4) zero expected dividends.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the course of 2012 and 2011, the Company entered into several consulting agreements to perform marketing services for the Company as it begins to enter into the production stage for the RevVac&#8482; safety syringe. Consultants are obligated under the contract to promote the product within various spheres of influence. These spheres of influence include, but are not limited to, medical product distributors, hospitals, doctors and government agencies.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Consultants are issued options at a discount to the market price at the date of issuance. These options must be exercised within a 10 day window from the time of issuance. The consultants therefore are committed to purchasing these options in order to enter into the consultant agreement and are obligated to adhere to the terms of the agreement. The agreements are recorded as a prepaid consulting expense upon the commencement of the agreement and expensed each quarter for the duration of the agreement. The amount to be determined for the consulting expense is determined based upon the options issued using the Black-Scholes model. Since the exercise window for these options is so short, the amount of the consulting expense is recorded as the difference between the exercise price and the market price as of the date of issuance. The Company also issued options with a term of 6 months to 1 year. Value for options with such term was calculated using Black-Scholes model.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following tables summarize information about the stock options for the years ended December 31, 2012 and 2011:</font> </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number of Units</font> </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercise Price</font> </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></font></font></font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></font></font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Remaining</font></font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractual</font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Term (in years)</font> </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Aggregate</font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intrinsic Value</font> </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, December 31, 2010</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,834,750</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.20</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.62</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,708,463</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,307,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.34</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.02</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> &#160; </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercised</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,668,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.25</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> &#160; </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expired/ Forfeited</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, December 31, 2011</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,473,750</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.39</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.45</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">869,825</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,875,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.18</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.98</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercised</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(575,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.25</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> &#160; </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expired/ Forfeited</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,673,750</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> &#160; </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 4px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, December 31, 2012</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,100,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.20</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.18</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">150,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following tables summarize information about the warrants for the years ended&#160;&#160;December 31, 2012 and 2011:</font> </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number of Units</font> </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercise Price</font> </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></font></font></font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></font></font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Remaining</font></font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractual</font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Term (in years)</font> </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Aggregate</font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intrinsic Value</font> </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, December 31, 2010</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,871,600</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.50</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.45</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,500,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.50</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.00</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercised</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expired/ Forfeited</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, December 31, 2011</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,371,600</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.39</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.45</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,739,008</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.33</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.15</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercised</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(660,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.50</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> &#160; </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expired/ Forfeited</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,570,608</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> &#160; </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 4px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, December 31, 2012</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,880,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.33</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.30</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table><br/> 20000000 75000 0.25 300000 0.40 2500000 P1Y P2Y 429824 0.0012 0.0021 P255D P2Y 1.59 1.61 0.00 P6Y P1Y <table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number of Units</font> </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercise Price</font> </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></font></font></font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></font></font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Remaining</font></font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractual</font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Term (in years)</font> </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Aggregate</font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intrinsic Value</font> </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, December 31, 2010</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,834,750</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.20</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.62</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,708,463</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,307,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.34</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.02</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> &#160; </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercised</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,668,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.25</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> &#160; </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expired/ Forfeited</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, December 31, 2011</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,473,750</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.39</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.45</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">869,825</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,875,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.18</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.98</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercised</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(575,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.25</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> &#160; </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expired/ Forfeited</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,673,750</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> &#160; </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 4px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, December 31, 2012</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,100,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.20</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.18</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">150,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number of Units</font> </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercise Price</font> </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></font></font></font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></font></font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Remaining</font></font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractual</font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Term (in years)</font> </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Aggregate</font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intrinsic Value</font> </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, December 31, 2010</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,871,600</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.50</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.45</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,500,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.50</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.00</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercised</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expired/ Forfeited</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, December 31, 2011</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,371,600</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.39</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.45</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,739,008</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.33</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.15</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercised</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(660,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.50</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> &#160; </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expired/ Forfeited</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,570,608</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"> &#160; </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 4px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, December 31, 2012</font> </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,880,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.33</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.30</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table> 12834750 0.20 P1Y226D 2708463 9307000 0.34 P1Y7D 0.25 15473750 0.39 P2Y164D 869825 2875000 0.18 P357D 575000 0.25 -5673750 12100000 0.20 P1Y65D 150000 1871600 0.50 P3Y164D 1500000 0.50 P1Y 3371600 0.39 P2Y164D 5739008 0.33 P54D -660000 0.50 -5570608 2880000 0.33 P109D <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 14 - RELATED PARTY TRANSACTIONS</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the acquisition of Clear Image Acquisition Corp. by the Company, Rondald L. Wheet, Chairman and Chief Executive Officer, received 2,286,000 shares of restricted Company common stock.&#160;&#160;Dr. Beahm, a Director, received 1,599,125 shares of restricted RevMed common stock, and Mr. O&#8217;Brien, a former Director, received 1,645,625 shares of restricted Company common stock.&#160;&#160;Mr. Wheet and Mr. O&#8217;Brien were directors and shareholders and Dr. Beahm was a shareholder of Clear Image Acquisition Corp. prior to its acquisition by the Company.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company rents its office space from Osprey South, LLC. Rondald L. Wheet, Chief Executive Officer, is the sole member of Osprey.&#160;&#160;Rent expense to Osprey was $120,000&#160;and $99,608 for the years ended December 31, 2012 and 2011, respectively.&#160;&#160;Rent payable to Osprey was $19,761 and $8,608 as of December 31, 2012 and 2011, respectively.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of December 31, 2012, the Company had advances from Vincent Olmo, Chief Operating Officer, and Mr. Wheet of $9,194 and $32,502, respectively, for expenses paid on behalf of the Company. The Company also had a convertible note payable to Mr. Olmo with principal amount of $75,000 and debt discount of $42,534 at December 31, 2012.</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At December 31, 2011, the Company had advances from Rhonda Vincent, former CFO, of $79,336 for expenses paid on behalf of the Company. Such payable has passed the statute of limitations and has been written off as of December 31, 2012.</font> </div><br/> 2286000 1599125 1645625 120000 99608 19761 8608 9194 32502 75000 42534 79336 <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 15 &#8211; RESTATEMENT</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company restated its December 31, 2011 balance sheet and the statements of operations, changes in equity, and cash flows for the year ended December 31, 2011 to reflect the following adjustments:</font> </div><br/><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent-35" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top" style="LINE-HEIGHT: 1.25;"> <td style="WIDTH: 18pt"> <div> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font> </div> </td> <td style="WIDTH: 18pt"> <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="display: inline; font-family: Symbol, serif;">&#183;</font></font> </div> </td> <td> <div align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline">The reclassification of subscription receivable from shareholder of $25,000 to contra equity (originally reported as other current assets).</font></font> </div> </td> </tr> </table><br/><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent-36" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top" style="LINE-HEIGHT: 1.25;"> <td style="WIDTH: 18pt"> <div> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font> </div> </td> <td style="WIDTH: 18pt"> <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="display: inline; font-family: Symbol, serif;">&#183;</font></font> </div> </td> <td> <div align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline">The elimination of $311,000 gain from litigation and the corresponding amount reflected as due from litigation as the collectability of the gain is not certain.</font></font> </div> </td> </tr> </table><br/><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent-37" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top" style="LINE-HEIGHT: 1.25;"> <td style="WIDTH: 18pt"> <div> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font> </div> </td> <td style="WIDTH: 18pt"> <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="display: inline; font-family: Symbol, serif;">&#183;</font></font> </div> </td> <td> <div align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline">The decrease of $32,633 prepaid consulting expense which represents the difference between the valuation of warrants&#160;&#160;based on the Black-Scholes Model and the original valuation improperly determined using intrinsic value.</font></font> </div> </td> </tr> </table><br/><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent-38" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top" style="LINE-HEIGHT: 1.25;"> <td style="WIDTH: 18pt"> <div> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font> </div> </td> <td style="WIDTH: 18pt"> <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="display: inline; font-family: Symbol, serif;">&#183;</font></font> </div> </td> <td> <div align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline">The increase in payable for indemnification of $616,379 which represents Gifford Mabie&#8217;s federal and state tax liability retained by the brokerage firm and remitted to the Internal Revenue Service and the increase of indemnification expenses of $67,072 for the change in the value of stock issued to the special brokerage for the benefit of Gifford Mabie.</font></font> </div> </td> </tr> </table><br/><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent-39" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top" style="LINE-HEIGHT: 1.25;"> <td style="WIDTH: 18pt"> <div> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font> </div> </td> <td style="WIDTH: 18pt"> <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="display: inline; font-family: Symbol, serif;">&#183;</font></font> </div> </td> <td> <div align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline">To decrease a payable to SON Medical for $54,832 for services never performed.</font></font> </div> </td> </tr> </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The impact of the reclassifications and prior period adjustments on the accompanying balance sheet at December 31, 2011 is as follows:</font> </div><br/><table cellpadding="0" cellspacing="0" width="99%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" width="58%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As Originally</font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reported</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As Restated</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="58%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total current assets</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,978,711</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(368,633</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,610,078</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="58%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total current liabilities</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,294,274</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">561,547</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,855,821</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="58%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total equity</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(315,563</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(930,180</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,245,743</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> </tr> </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The impact of the reclassifications and prior period adjustments on the accompanying statement of operations for the year ended December 31, 2011 are as follows:</font> </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As Originally</font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reported</font> </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change</font> </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As Restated</font> </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="58%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">111,832</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(54,832</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">57,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="58%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General and administrative expenses</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,714,214</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">67,072</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,781,286</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="58%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gain from litigation</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">311,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(311,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="58%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net income available to common shareholders</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,218,278</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(323,240</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,541,518</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="58%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Income per common share &#8211; basic and diluted</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.09</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.09</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> </tr> </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The impact of the reclassifications and prior period adjustments on the accompanying statement of cash flows for the year ended December 31, 2011 is as follows:</font> </div><br/><table cellpadding="0" cellspacing="0" width="99%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" width="58%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As Originally</font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reported</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As Restated</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="58%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash used in operating activities</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,010,275</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">447,202</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,563,073</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> </tr> <tr> <td align="left" valign="bottom" width="58%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash used in investing activities</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(471,347</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">342,256</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(129,091</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="58%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash provided by financing activities</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,416,949</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(789,458</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,627,491</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table><br/> 25000 311000 32633 616379 67072 54832 <table cellpadding="0" cellspacing="0" width="99%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" width="58%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As Originally</font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reported</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As Restated</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="58%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total current assets</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,978,711</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(368,633</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,610,078</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="58%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total current liabilities</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,294,274</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">561,547</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,855,821</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="58%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total equity</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(315,563</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(930,180</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,245,743</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> </tr> </table><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As Originally</font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reported</font> </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change</font> </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As Restated</font> </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="58%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">111,832</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(54,832</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">57,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="58%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General and administrative expenses</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,714,214</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">67,072</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,781,286</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="58%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gain from litigation</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">311,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(311,000</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="58%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net income available to common shareholders</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,218,278</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(323,240</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,541,518</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="58%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Income per common share &#8211; basic and diluted</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.09</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.09</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> </tr> </table><table cellpadding="0" cellspacing="0" width="99%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" width="58%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As Originally</font></font> </div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reported</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As Restated</font> </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="58%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash used in operating activities</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,010,275</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">447,202</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,563,073</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> </tr> <tr> <td align="left" valign="bottom" width="58%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash used in investing activities</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(471,347</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">342,256</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(129,091</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="58%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash provided by financing activities</font> </div> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,416,949</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(789,458</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </td> <td align="right" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,627,491</font> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table> 1978711 -368633 2294274 561547 2855821 -315563 -930180 111832 -54832 3714214 67072 311000 -311000 -4218278 -323240 -4541518 -0.09 -3010275 447202 -471347 342256 3416949 -789458 <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 16 &#8211; SUBSEQUENT EVENTS</font> </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Subsequent to December 31, 2012, the Company issued 1,466,657 common shares for the conversion of notes payable of $79,540; 789,700 common shares to officers for settlement of&#160;&#160;$71,073 of accrued salaries based on the grant date fair value of the shares; 102,500 common shares valued at&#160;&#160;$5,466 to service providers for settlement of accounts payable; 262,500 common shares valued at $26,250, for investor relation services; 1,453,750 shares valued at $130,838 for director fees;&#160;&#160;and 750,000 common shares for net cash proceeds of $75,000 related to warrants and options exercised.</font> </div><br/> 1466657 79540 789700 71073 102500 5466 262500 26250 1453750 130838 750000 75000 EX-101.SCH 7 rmcp-20121231.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Statement - Balance Sheets link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Statements of Operations link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Statements of Stockholders’ Equity link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Note 1 - Summary Of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Note 2 - Going Concern link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Note 3 - Property And Equipment link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Note 4 - Intangibles And Goodwill link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Note 5 - Accounts Payable And Accrued Liabilities link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Note 7 - Convertible Notes Payable link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Note 8 - Payable for Indemnification link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Note 10 - Maxxon/Globe Joint Venture Agreement link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Note 11 - Commitments And Contingencies link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Note 12 - Preferred Stock And Common Stock Transactions link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Note 13 - Stock Options And Warrants Outstanding link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Note 14 - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Note 15 - Restatement link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Note 16 - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Note 1 - Summary Of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Note 3 - Property And Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Note 4 - Intangibles And Goodwill (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Note 5 - Accounts Payable And Accrued Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Note 7 - Convertible Notes Payable (Tables) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Note 9 - Derivatives - Note Conversion Feature (Tables) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Note 13 - Stock Options And Warrants Outstanding (Tables) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Note 15 - Restatement (Tables) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Note 1 - Summary Of Significant Accounting Policies (Detail) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Note 1 - Summary Of Significant Accounting Policies (Detail) - Estimated Useful Lives of Property Plant and Equipment link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Note 1 - Summary Of Significant Accounting Policies (Detail) - Fair Value, Assets and Liabilities Measured on Recurring Basis link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Note 2 - Going Concern (Detail) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Note 3 - Property And Equipment (Detail) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Note 3 - Property And Equipment (Detail) - Summary Of Property And Equipment link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Note 4 - Intangibles And Goodwill (Detail) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Note 4 - Intangibles And Goodwill (Detail) - Summary of Intangible Assets link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Note 5 - Accounts Payable And Accrued Liabilities (Detail) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Note 5 - Accounts Payable And Accrued Liabilities (Detail) - Summary of Accounts Payable and Accrued Liabilities link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Note 7 - Convertible Notes Payable (Detail) link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Note 7 - Convertible Notes Payable (Detail) - Notes Payable link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Note 7 - Convertible Notes Payable (Detail) - Notes Payable (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Note 8 - Payable for Indemnification (Detail) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Note 9 - Derivatives - Note Conversion Feature (Detail) - Reconciliation of Derivative Liability link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - Note 9 - Derivatives - Note Conversion Feature (Detail) - Fair Value Assumptions, Derivative Liability link:presentationLink link:definitionLink link:calculationLink 045 - Disclosure - Note 10 - Maxxon/Globe Joint Venture Agreement (Detail) link:presentationLink link:definitionLink link:calculationLink 046 - Disclosure - Note 11 - Commitments And Contingencies (Detail) link:presentationLink link:definitionLink link:calculationLink 047 - Disclosure - Note 12 - Preferred Stock And Common Stock Transactions (Detail) link:presentationLink link:definitionLink link:calculationLink 048 - Disclosure - Note 13 - Stock Options And Warrants Outstanding (Detail) link:presentationLink link:definitionLink link:calculationLink 049 - Disclosure - Note 13 - Stock Options And Warrants Outstanding (Detail) - Stock Options and Warrants Outstanding Activities link:presentationLink link:definitionLink link:calculationLink 050 - Disclosure - Note 14 - Related Party Transactions (Detail) link:presentationLink link:definitionLink link:calculationLink 051 - Disclosure - Note 15 - Restatement (Detail) link:presentationLink link:definitionLink link:calculationLink 052 - Disclosure - Note 15 - Restatement (Detail) - Reclassifications and Prior Period Adjustments link:presentationLink link:definitionLink link:calculationLink 053 - Disclosure - Note 16 - Subsequent Events (Detail) link:presentationLink link:definitionLink link:calculationLink 000 - Disclosure - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 rmcp-20121231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION EX-101.DEF 9 rmcp-20121231_def.xml XBRL TAXONOMY EXTENSION DEFINITION EX-101.LAB 10 rmcp-20121231_lab.xml XBRL TAXONOMY EXTENSION LABELS EX-101.PRE 11 rmcp-20121231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION XML 12 R39.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 5 - Accounts Payable And Accrued Liabilities (Detail) - Summary of Accounts Payable and Accrued Liabilities (USD $)
Dec. 31, 2012
Dec. 31, 2011
Accounts payable $ 432,436 $ 99,342
Accrued payroll liabilities and related penalties 411,670 125,239
Accrued salary 143,167 120,000
Accrued interest 134,559 64,670
Other accruals 539 59,217
Total accounts payable and accrued liabilities $ 1,122,371 $ 468,468
XML 13 R54.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 16 - Subsequent Events (Detail) (USD $)
 12 Months Ended 4 Months Ended 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2000
Apr. 30, 2013
Subsequent Event [Member]
For Settlement of Accrued Salaries [Member]
Apr. 30, 2013
Subsequent Event [Member]
For Settlement of Accounts Payable [Member]
Apr. 30, 2013
Subsequent Event [Member]
For Director Fees [Member]
Apr. 30, 2013
Subsequent Event [Member]
Warrants and Options Exercised [Member]
Apr. 30, 2013
Subsequent Event [Member]
Dec. 31, 2012
Warrants and Options Exercised [Member]
Debt Conversion, Converted Instrument, Shares Issued 13,669,072 3,021,738           1,466,657  
Debt Conversion, Converted Instrument, Amount (in Dollars) $ 1,420,446 $ 963,096           $ 79,540  
Stock Issued During Period, Shares, New Issues       789,700 102,500 1,453,750 750,000   1,235,000
Stock Issued During Period, Value, New Issues (in Dollars) 516,111     71,073 5,466 130,838 75,000   258,275
Stock Issued During Period, Shares, Issued for Services 2,751,229 1,513,874           262,500  
Stock Issued During Period, Value, Issued for Services (in Dollars)   $ 481,100 $ 405,000         $ 26,250  
XML 14 R48.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 12 - Preferred Stock And Common Stock Transactions (Detail) (USD $)
 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2005
Dec. 31, 2004
Dec. 31, 2003
Dec. 31, 2000
Preferred Stock, Shares Outstanding 1,000,000 1,000,000        
Preferred Stock, Voting Rights 125          
Common Stock, Voting Rights one          
Stock Issued During Period, Value, New Issues (in Dollars) $ 516,111          
Stock Issued During Period, Shares, Issued for Services 2,751,229 1,513,874        
Stockholders' Equity Note, Subscriptions Receivable (in Dollars) 71,000 25,000        
Debt Conversion, Converted Instrument, Shares Issued 13,669,072 3,021,738        
Debt Conversion, Converted Instrument, Amount (in Dollars) 1,420,446 963,096        
Debt Instrument, Convertible, Beneficial Conversion Feature (in Dollars) 237,774 94,624        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 575,000 6,668,000        
Stock Issued During Period, Value, Stock Options Exercised (in Dollars)   1,654,420 45,000 254,100 140,700  
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in Dollars per share) $ 0.25 $ 0.25        
Stock Issued During Period, Value, Issued for Services (in Dollars)   481,100       405,000
Warrants and Options Exercised [Member]
            
Stock Issued During Period, Shares, New Issues 1,235,000          
Stock Issued During Period, Value, New Issues (in Dollars) 258,275          
Stockholders' Equity Note, Subscriptions Receivable (in Dollars) 46,000          
Series 2006 Preferred Stock [Member]
            
Preferred Stock, Shares Outstanding 1,000,000          
Preferred Stock, Liquidation Preference Per Share (in Dollars per share) $ 0.001          
Series 2006 Preferred Stock [Member]
            
Preferred Stock, Shares Outstanding 1,000,000          
Series 2009 Preferred Stock [Member]
            
Stock Repurchased and Retired During Period, Shares 500,000          
Gifford Mabie [Member]
            
Stock Issued During Period, Shares, New Issues 400,000          
Stock Issued During Period, Value, New Issues (in Dollars) 140,560          
Former President [Member]
            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period   2,000,000        
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in Dollars per share)   $ 0.08        
Third Party Investors Agreement [Member]
            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period   656,015        
Proceeds from Stock Options Exercised (in Dollars)   $ 202,571        
XML 15 R46.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 10 - Maxxon/Globe Joint Venture Agreement (Detail) (USD $)
 1 Months Ended 12 Months Ended
Oct. 21, 2011
Nov. 30, 2005
Dec. 31, 2007
Nov. 03, 2005
Percentage Of Definitive Joint Venture Agreement       50.00%
Stock Issued During Period, Value, Restricted Stock Award, Gross   $ 625,066 $ 10,000  
Granted Request For Summary Judgment Awarded $ 311,440      
Return Of Common Stock (in Shares) 266,667      
XML 16 R33.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 2 - Going Concern (Detail) (USD $)
 12 Months Ended 16 Months Ended 197 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2009
Dec. 31, 2008
Dec. 31, 2007
Dec. 31, 2006
Dec. 31, 2005
Dec. 31, 2004
Dec. 31, 2003
Dec. 31, 2002
Dec. 31, 2001
Dec. 31, 2000
Dec. 31, 1999
Dec. 31, 1998
Dec. 31, 1997
Dec. 31, 2012
Net Income (Loss) Attributable to Parent $ (7,164,311) $ (4,541,518) $ (3,231,425) $ (2,463,751) $ (1,335,154) $ (4,475,017) $ (598,302) $ (1,310,783) $ (1,552,008) $ (1,391,518) $ (1,933,676) $ (2,199,085) $ (1,347,859) $ (1,014,555) $ (2,584,383) $ (795,376) $ (37,938,721)
XML 17 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 18 R25.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 5 - Accounts Payable And Accrued Liabilities (Tables)
 12 Months Ended
Dec. 31, 2012
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]
   
December 31, 2012
   
December 31, 2011
 
Accounts payable
  $ 432,436     $ 99,342  
Accrued payroll liabilities and related penalties
    411,670       125,239  
Accrued salary
    143,167       120,000  
Accrued interest
    134,559       64,670  
Other accruals
    539       59,217  
Total accounts payable and accrued liabilities
  $ 1,122,371     $ 468,468  
XML 19 R50.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 13 - Stock Options And Warrants Outstanding (Detail) - Stock Options and Warrants Outstanding Activities (USD $)
 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Stock Options, Granted, Number of Units 2,875,000 9,307,000
Stock Options, Granted, Weighted Average Exercise Price (in Dollars per share) $ 0.18 $ 0.34
Stock Options, Granted, Weighted Average Remaining Contractual Term (in years) 357 days 1 year 7 days
Stock Options, Exercised, Number of Units (575,000) (6,668,000)
Stock Options, Exercised, Weighted Average Exercise Price (in Dollars per share) $ 0.25 $ 0.25
Stock Options, Expired/ Forfeited, Number of Units (5,673,750)  
Warrants, Granted, Number of Units 5,739,008 1,500,000
Warrants, Granted, Weighted Average Exercise Price (in Dollars per share) $ 0.33 $ 0.50
Warrants, Granted, Weighted Average Remaining Contractual Term (in years) 54 days 1 year
Warrants, Exercised, Number of Units (660,000)  
Warrants, Exercised, Weighted Average Exercise Price (in Dollars per share) $ 0.50  
Warrants, Expired/ Forfeited, Number of Units (5,570,608)  
Beginning of Period [Member]
    
Outstanding, December 31, 2010   12,834,750
Outstanding, December 31, 2010 (in Dollars per share)   $ 0.20
Outstanding, December 31, 2010   1 year 226 days
Outstanding, December 31, 2010 (in Dollars)   $ 2,708,463
Stock Options, Outstanding, Weighted Average Remaining Contractual Term (in years)   1 year 226 days
Outstanding, December 31, 2010   1,871,600
Outstanding, December 31, 2010 (in Dollars per share)   $ 0.50
Outstanding, December 31, 2010   3 years 164 days
Warrants, Outstanding, Weighted Average Exercise Price (in Dollars per share)   $ 0.50
Warrants, Outstanding, Weighted Average Remaining Contractual Term (in years)   3 years 164 days
End of Period [Member]
    
Outstanding, December 31, 2010 15,473,750  
Outstanding, December 31, 2010 (in Dollars per share) $ 0.39  
Outstanding, December 31, 2010 1 year 65 days 2 years 164 days
Outstanding, December 31, 2010 (in Dollars) 869,825  
Stock Options, Outstanding, Number of Units 12,100,000 15,473,750
Stock Options, Outstanding, Weighted Average Exercise Price (in Dollars per share) $ 0.20 $ 0.39
Stock Options, Outstanding, Weighted Average Remaining Contractual Term (in years) 1 year 65 days 2 years 164 days
Stock Options, Outstanding, Aggregate Intrinsic Value (in Dollars) $ 150,000 $ 869,825
Outstanding, December 31, 2010 3,371,600  
Outstanding, December 31, 2010 (in Dollars per share) $ 0.33 $ 0.39
Outstanding, December 31, 2010 109 days 2 years 164 days
Warrants, Outstanding, Number of Units 2,880,000 3,371,600
Warrants, Outstanding, Weighted Average Exercise Price (in Dollars per share) $ 0.33 $ 0.39
Warrants, Outstanding, Weighted Average Remaining Contractual Term (in years) 109 days 2 years 164 days
XML 20 R42.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 7 - Convertible Notes Payable (Detail) - Notes Payable (Parentheticals)
Dec. 31, 2012
Dec. 31, 2011
Private Placement [Member] | Due June 26, 2013 [Member]
    
Convеrtiblе Promissory Notе Payablе, Intеrеst ratе 8.00% 8.00%
JMJ Financial Inc [Member] | Due February 22, 2014 [Member]
    
Convеrtiblе Promissory Notе Payablе, Intеrеst ratе 8.00% 8.00%
Asher Enterprises Inc [Member] | Due April 26, 2012 [Member]
    
Convеrtiblе Promissory Notе Payablе, Intеrеst ratе 8.00% 8.00%
Asher Enterprises Inc [Member] | Due June 1, 2012 [Member]
    
Convеrtiblе Promissory Notе Payablе, Intеrеst ratе 8.00% 8.00%
Asher Enterprises Inc [Member] | Due August 7, 2012 [Member]
    
Convеrtiblе Promissory Notе Payablе, Intеrеst ratе 8.00% 8.00%
Asher Enterprises Inc [Member] | Due September 19, 2012 [Member]
    
Convеrtiblе Promissory Notе Payablе, Intеrеst ratе 8.00% 8.00%
Asher Enterprises Inc [Member] | Due March 21, 2013 [Member]
    
Convеrtiblе Promissory Notе Payablе, Intеrеst ratе 8.00% 8.00%
Asher Enterprises Inc [Member] | Due May 10, 2013 [Member]
    
Convеrtiblе Promissory Notе Payablе, Intеrеst ratе 8.00% 8.00%
Asher Enterprises Inc [Member] | Due August 27, 2013 [Member]
    
Convеrtiblе Promissory Notе Payablе, Intеrеst ratе 8.00% 8.00%
TCA Global Credit Master Fund, LP [Member] | Due January 3, 2013 [Member]
    
Convеrtiblе Promissory Notе Payablе, Intеrеst ratе 12.00% 12.00%
XML 21 R37.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 4 - Intangibles And Goodwill (Detail) - Summary of Intangible Assets (USD $)
Dec. 31, 2012
Dec. 31, 2011
Intangible Assets $ 146,538 $ 122,314
Less: accumulated amortization (39,851) (5,888)
Intangibles , net 106,687 116,426
Patents [Member]
    
Intangible Assets 146,538 107,314
Licensing Agreements [Member]
    
Intangible Assets   $ 15,000
XML 22 R52.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 15 - Restatement (Detail) (USD $)
 12 Months Ended
Dec. 31, 2005
Dec. 31, 2011
Reclassification of Subscription Receivable [Member]
Dec. 31, 2011
Elimination of Gain from Litigation [Member]
Dec. 31, 2011
Decrease of Prepaid Consulting Expense [Member]
Dec. 31, 2011
Increase in Payable for Indemnification [Member]
Dec. 31, 2011
Increase of Indemnification Expense [Member]
Dec. 31, 2011
Decrease in Payable to SON Medical [Member]
Prior Period Reclassification Adjustment $ 357,746 $ 25,000 $ 311,000 $ 32,633 $ 616,379 $ 67,072 $ 54,832
XML 23 R47.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 11 - Commitments And Contingencies (Detail) (USD $)
 0 Months Ended 12 Months Ended 197 Months Ended 1 Months Ended 11 Months Ended 12 Months Ended 8 Months Ended 21 Months Ended 19 Months Ended 22 Months Ended 60 Months Ended
Jan. 02, 2013
Dec. 31, 2012
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Mold Production Payments [Member]
Nov. 30, 2012
Mold Production Payments [Member]
Dec. 31, 2012
Mold Production Payments [Member]
Jan. 02, 2013
Mold Production Payments [Member]
Dec. 31, 2011
Mold Production Payments [Member]
Dec. 31, 2012
Chief Executive Officer [Member]
Dec. 31, 2012
Chief Operating Officer [Member]
Dec. 31, 2012
Chief Financial Officer [Member]
Mar. 15, 2012
JMJ Financial Inc [Member]
Jan. 30, 2012
JMJ Financial Inc [Member]
Jan. 09, 2012
JMJ Financial Inc [Member]
Jun. 30, 2011
Osprey South, LLC [Member]
Jun. 30, 2016
Osprey South, LLC [Member]
Sep. 02, 2009
Osprey South, LLC [Member]
Gain Contingency, Unrecorded Amount $ 770,000                                  
Proceeds from Legal Settlements 1,000,000                                  
Property, Plant and Equipment, Gross   446,382 446,382 1,206,382 50,000   50,000 50,000 760,000                  
Asset Impairment Charges   878,276 4,570,007   50,000 710,000 710,000                      
Requested Shares Of Common Stock Conversion (in Shares)                         2,226,049 1,226,049 1,000,000      
Principal Amount Due                           191,663        
Annual Salary Agreement                   247,500 165,000 165,000            
Lease Agreement Term                                   5 years
Lease Agreement, Monthly Payment                               $ 4,500 $ 10,000  
XML 24 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 3 - Property And Equipment
 12 Months Ended
Dec. 31, 2012
Property, Plant and Equipment Disclosure [Text Block]
NOTE 3 – PROPERTY AND EQUIPMENT

The following is a summary of property and equipment at December 31, 2012 and 2011:

   
December 31, 2012
   
December 31, 2011
 
Equipment
  $ 353,235     $ 1,113,235  
Leasehold improvement
    44,000       44,000  
Furniture
    49,147       49,147  
Subtotal
    446,382       1,206,382  
Less: accumulated depreciation
    (89,726 )     (20,718 )
Property and equipment, net
  $ 356,656     $ 1,185,664  

For the years ended December 31, 2012 and 2011, the Company recognized depreciation and amortization expense related to property and equipment of $69,008 and $11,135, respectively.

During 2012, the Company impaired $710,000 of the $760,000 production mold payments made to Medical Investment Group, Inc. (“MIG”) in 2011 and wrote off an $80,000 prepayment to MIG. The impairment charge was based upon the arbitration hearing against MIG in November, 2012. The hearing and the final ruling made clear that all production mold payments made by the Company to MIG for the manufacturing of production molds had instead been used by Mr. Theriault, a representative of MIG, for other non-production related purposes. The American Arbitration Association panel ruled that the only assets in which production was funded by MIG from the Company’s production payments were $50,000 in trial molds. From the time that these payments were made by the Company, the Company believed that each mold payment was being used by MIG for the manufacturing of the final production molds for the 3ml RevVac™ auto-retractable vacuum safety syringe. During the arbitration proceeding, Mr. Theriault disclosed that no such payments, besides $50,000 in trial mold payments, were ever used for the production of the final molds for the RevVac™ auto-retractable vacuum safety syringe. The arbitration panel ruled that a total of $770,000 awarded to the Company.  The Company has not received such payment to date. The gain related to this award will be recorded when collected.

During 2012, the Company also impaired $50,000 for a trial mold that is no longer considered useful to the Company.

EXCEL 25 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\X-&8P93=B8E]F8S0T7S0V,61?83(P,U\P83,T M-V-C,S`P8S0B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/E-T871E;65N='-?;V9?3W!E#I.86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T871E;65N='-?;V9?0V%S:%]&;&]W#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?,E]';VEN9U]#;VYC97)N/"]X.DYA;64^#0H@ M("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I7;W)K#I7;W)K#I7;W)K'AO;D=L;V)E7TIO:6YT7U9E;G0\+W@Z M3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I7;W)K#I7;W)K M#I7;W)K#I%>&-E;%=O#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/D%C8V]U;G1I;F=?4&]L:6-I M97-?8GE?4&]L:6-Y7SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?,5]3=6UM87)Y7T]F7U-I9VYI9FEC86YT7S$\+W@Z3F%M M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O6%B;&5?06YD7T%C,3PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?-U]#;VYV97)T:6)L95].;W1E#I7;W)K#I7 M;W)K#I%>&-E;%=O M#I7 M;W)K5]/9E]3:6=N:69I M8V%N=%\R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O M#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DYO=&5?,5]3=6UM87)Y7T]F7U-I M9VYI9FEC86YT7S0\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I% M>&-E;%=O#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?-%]);G1A;F=I M8FQE#I7;W)K#I%>&-E;%=O6%B;&5?06YD7T%C,CPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?-5]!8V-O=6YT#I7;W)K#I%>&-E;%=O6%B,SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/DYO=&5?-U]#;VYV97)T:6)L95].;W1E#I7;W)K#I% M>&-E;%=O#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?.5]$97)I=F%T M:79E#I7;W)K'AO;D=L;V)E7TIO:6YT7U9E;G0Q/"]X M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?,3)?4')E9F5R#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/DYO=&5?,31?4F5L871E9%]087)T>5]4#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/DYO=&5?,35?4F5S=&%T96UE;G1?1&5T86EL7U)E8SPO>#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DYO=&5?,39?4W5B#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C M=%-T#I0#I0 M#I0&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T* M("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I M=&@@36EC'1087)T7S@T9C!E-V)B7V9C-#1? M-#8Q9%]A,C`S7S!A,S0W8V,S,#!C-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL M93HO+R]#.B\X-&8P93=B8E]F8S0T7S0V,61?83(P,U\P83,T-V-C,S`P8S0O M5V]R:W-H965T'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$2!#;VUM;VX@4W1O M8VLL(%-H87)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^9F%L M2!#96YT3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^,#`P,3`T,3`P.3QS<&%N/CPO'0^ M665S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^3F\\2!&:6QE3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^4VUA;&QE3QS<&%N/CPO'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E6%B;&4@9F]R(&EN9&5M;FEF:6-A=&EO;CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$F5D.R`W M,BPW.#0L.3`W(&%N9"`U-"PW,CDL-C`V('-H87)E'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAAF5D/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XU+#`P,"PP,#`\3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\X-&8P93=B8E]F8S0T7S0V,61?83(P,U\P83,T-V-C,S`P8S0-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#1F,&4W8F)?9F,T-%\T-C%D7V$R M,#-?,&$S-#=C8S,P,&,T+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'1I;F=U:7-H;65N="!O9B!D96)T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XQ,RPR,#(\'!E;G-E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X-&8P93=B8E]F8S0T7S0V,61? M83(P,U\P83,T-V-C,S`P8S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO.#1F,&4W8F)?9F,T-%\T-C%D7V$R,#-?,&$S-#=C8S,P,&,T+U=O'0O:'1M;#L@ M8VAA&5R8VES97,@8GD@5&AI2!4:&ER9"!087)T:65S(&9O&5R8VES97,@8GD@5&AI&5R M8VES97,@8GD@5&AI2!4:&ER9"!0 M87)T:65S(&9O2!) M;G9E2!);G9E2!4:&ER9"!087)T:65S M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S2!4:&ER9"!087)T:65S(&9O&5R8VES97,@8GD@5&AI&5R8VES M97,@8GD@5&AI&5R8VES97,@8GD@5&AI2!4:&ER9"UP87)T:65S(&9O&5R8VES97,@8GD@5&AI M65E65E65E'AO;BU/2RP@1F]U;F1E'AO;BU/2RP@5&AI'AO;BU/2RP@ M1F]U;F1E&]N+4]++"!4:&ER9"U087)T>2!;365M8F5R73QB2!;365M8F5R73QB M2!3=&]C:R!;365M8F5R73QB M&]N+4]++"!&;W5N9&5R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$&5R8VES97,@;V8@3W!T:6]N'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$&5R8VES97,@;V8@3W!T:6]N'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$&5R8VES97,@;V8@3W!T:6]N'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M&5R M8VES97,@;V8@3W!T:6]N'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES97,@ M;V8@3W!T:6]N'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S&5R8VES97,@;V8@3W!T:6]N'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S&5R8VES92!O9B!787)R86YT'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES97,@;V8@3W!T:6]N'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$&5R8VES92!O9B!787)R86YT'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES97,@ M;V8@3W!T:6]N'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!I;G1E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES97,@;V8@3W!T:6]N'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!3=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S&5R8VES97,@;V8@ M3W!T:6]N'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XQ,#(L.3'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6%B;&4@86YD(&%C8W)U960@;&EA8FEL:71I97,\+W1D/@T*("`@ M("`@("`\=&0@8VQA6%B;&4@86YD(&%C8W)U960@;&EA8FEL:71I97,@ MXH"3(')E;&%T960@<&%R=&EE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!A;F0@5&AE($AE M86QT:"!#;'5B/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S&5R8VES92!O M9B!S=&]C:R!O<'1I;VYS(&%N9"!W87)R86YT'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S6UE M;G0@;V8@;&]A;G,@9G)O;2!S:&%R96AO;&1E'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S6%B M;&4@'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0@0FQO8VM=/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TQ)3D4M2$5) M1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@ M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$ M:G5S=&EF>3X-"B`@("`@#0H@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^3D]410T*("`@("`- M"B`@("`@("`@,2`F(S@R,3$[1$530U))4%1)3TX@3T8@0E5324Y%4U,@04Y$ M(%-534U!4ED@3T8@4TE'3DE&24-!3E0-"B`@#0H@("`@("`@($%#0T]53E1) M3D<@4$],24-)15,\+V9O;G0^#0H@#0H@("`@("`\+V1I=CX\8G(O/CQD:78@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY2979O;'5T:6]N28C.#(R M,3L@;W(@)B,X,C(P.U)E=DUE9"8C.#(R,3LI(&AA2!3>7)I;F=E+"!W:&EC:"!I2!A;'-O(&AA M2!-4DD-"B`@#0H@ M("`@("`@('-O9G1W87)E('1O;VQS.R!2979#;VQO2!B96QI979E('=I M;&P-"B`@("`-"B`@("`@("`@:&%V92!S<&5C:69I8R!C;VUM97)C:6%L(&%P M<&QI8V%T:6]N6QE/3-$)TQ)3D4M2$5) M1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@ M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$ M:G5S=&EF>3X-"B`@("`-"B`@("`@("`@/&9O;G0@3PO9F]N=#X-"B`@("`@#0H@("`@ M("`\+V1I=CX\8G(O/CQD:78@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^06-C;W5N M=&EN9PT*(`T*("`@("`@("!%2!A8V-E<'1E9"!A8V-O=6YT:6YG('!R:6YC:7!L97,@ M*"8C.#(R,#M5+E,N#0H@#0H@("`@("`@($=!05`F(S@R,C$[*2!R97%U:7)E M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!& M3TY4+5=%24=(5#H@8F]L9"<^4F5C;&%S6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SY4:&4-"B`@("`@#0H@("`@("`@($-O;7!A;GD@8V]N2!L:7%U:60@:6YV97-T;65N=',@*'1H;W-E(')E861I;'D- M"B`@#0H@("`@("`@(&-O;G9E6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`- M"B`@("`@("`@/&9O;G0@2!R96-O2!D971E2!O9B!T:&4- M"B`@("`@#0H@("`@("`@(&%L;&]W86YC92!F;W(@9&]U8G1F=6P@86-C;W5N M=',N)B,Q-C`[(%1R861E(')E8V5I=F%B;&5S#0H@("`@#0H@("`@("`@(&%R M92!C:&%R9V5D(&]F9B!W:&5N('1H97)E(&ES(&-E2!A2!F;W)W87)D('1H92!D97!O0T* M("`@(`T*("`@("`@("!R96-O6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^ M26YV96YT;W)I97,\+V9O;G0^#0H@("`@(`T*("`@("`@/"]D:78^/&)R+SX\ M9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@ M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@("`@ M/&9O;G0@2!E>&-E0T*("`-"B`@("`@("`@;6%Y(&)E('=R M:71T96X@;V9F+B!&;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R M,#$R#0H@#0H@("`@("`@(&%N9"`R,#$Q+"!N;R!A;&QO=V%N8V4@9F]R(&EN M=F5N=&]R>2!W87,@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+5=%24=(5#H@8F]L9"<^4')O<&5R='D-"B`@("`-"B`@("`@("`@86YD($5Q M=6EP;65N=#PO9F]N=#X-"B`@("`@#0H@("`@("`\+V1I=CX\8G(O/CQD:78@ M6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E. M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@ M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN M92<^07-S970-"B`@("`@#0H@("`@("`@("`@("`@("`@0V%T96=O6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI M9"<^#0H@("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A% M24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[ M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS M1&QE9G0^#0H@#0H@("`@("`@("`@("`@("`@/&9O;G0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY-86-H:6YE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N M/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0T-R4^#0H@#0H@("`@("`@ M("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXU M)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@ M(`T*("`@("`@("`@(#QT6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E. M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@ M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE'1U6QE/3-$)TQ) M3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L M:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SY,96%S96AO;&0-"B`@("`-"B`@("`@("`@("`@("`@("!I M;7!R;W9E;65N=',\+V9O;G0^#0H@(`T*("`@("`@("`@("`@("`\+V1I=CX- M"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/@T*("`@("`-"B`@("`@("`@ M("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY) M;G1A;F=I8FQE#0H@(`T*("`@("`@("!A6EN9R!F6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!& M3TY4+5=%24=(5#H@8F]L9"<^26UP86ER;65N=`T*(`T*("`@("`@("!O9B!, M;VYG+6QI=F5D($%S2!T;R!D971E&ES M="!W:&EC:"!M87D@:6YD:6-A=&4@:6UP86ER;65N="P@=&AE#0H@("`-"B`@ M("`@("`@0V]M<&%N>2!W:6QL('!R97!A6EN9R!A;6]U;G0@;V8@=&AE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=( M5#H@8F]L9"<^4F5S96%R8V@-"B`@("`-"B`@("`@("`@86YD($1E=F5L;W!M M96YT/"]F;VYT/@T*("`-"B`@("`@(#PO9&EV/CQB6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY297-E87)C:`T*("`@("`-"B`@("`@ M("`@86YD(&1E=F5L;W!M96YT(&-O'!E;G-E9"!A2!I;F-U M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY& M6EN9R!C;VUM;VX@&-E0T*("`@ M#0H@("`@("`@(&ENF5D('1O#0H@("`@(`T*("`@("`@("!I;G1E'!E M;G-E(&]V97(@=&AE(&QI9F4@;V8@=&AE(&YO=&4@=7-I;F<@=&AE#0H@#0H@ M("`@("`@(&5F9F5C=&EV92!I;G1E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY$97)I=F%T M:79E6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@/&9O;G0@6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-0 M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P M<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@("`@/&9O;G0@2!M96%S=7)EF5S(&ET6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!4 M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@ M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!S>6UB;VPL('-E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY,979E;`T* M("`@("`-"B`@("`@("`@("`@("`@("`R("8C.#(Q,3L@;W1H97(@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F M="!V86QI9VX],T1T;W`@=VED=&@],T0S)3X-"B`@("`@#0H@("`@("`@("`@ M("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('-Y;6)O;"P@6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-0 M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P M<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^3&5V96PF(S$V,#LQ/"]F;VYT M/@T*("`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@ M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A M;&EG;CTS1'1O<"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@ M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@ M"<^#0H@(`T*("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE"<^#0H@(`T* M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@("`@(`T*("`@("`@ M("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@ M("`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M.R!&3TY4+5=%24=(5#H@8F]L9"<^5&]T86P\+V9O;G0^#0H@(`T*("`@("`@ M("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T* M("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@"<^#0H@(`T*("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SY#87-H#0H@("`@#0H@("`@("`@("`@("`@("`@86YD(&-A6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@] M,T0Q)3X-"B`@("`@#0H@("`@("`@("`@("`@(#QD:78@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/@T*("`@(`T*("`@("`@("`@ M("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@ M("`@#0H@("`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXD/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I M=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D(&%L:6=N/3-$6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q% M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`- M"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXU-#PO9F]N=#X-"B`@("`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`- M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI M9VX],T1L969T('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/@T*("`@("`-"B`@ M("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V M86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@ M("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@ M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@ M=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$ M;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)V)A8VMG6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E. M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@ M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S@R,3([/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@ M("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q M)3X-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L M:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@ M("`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXD/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L M:6=N/3-$6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXS-C0L.#`R/"]F;VYT/@T*("`@ M("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]T M9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1T;W`@=VED=&@] M,T0Q)3X-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`\+W1A M8FQE/CQB6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M.R!&3TY4+5=%24=(5#H@8F]L9"<^3&5V96PF(S$V,#LQ/"]F;VYT/@T*("`@ M#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^ M#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS M1'1O<"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@"<^#0H@(`T*("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE"<^#0H@(`T*("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$ M)U!!1$1)3D6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@("`@(`T*("`@("`@("`@("`@ M("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5. M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2 M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@ M("`@("`@("`@/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&-O M;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+5=%24=(5#H@8F]L9"<^5&]T86P\+V9O;G0^#0H@(`T*("`@("`@("`@("`@ M("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY#87-H M#0H@("`@#0H@("`@("`@("`@("`@("`@86YD(&-A6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X- M"B`@("`@#0H@("`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXD/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\ M+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D(&%L:6=N/3-$6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q% M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`- M"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S@R,3([/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX- M"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@ M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F M="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@("`@ M("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F M;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T* M("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED M=&@],T0Q)3X-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F M="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@("`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X- M"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY$97)I=F%T M:79E#0H@("`@(`T*("`@("`@("`@("`@("`@(&QI86)I;&ET>3PO9F]N=#X- M"B`@("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@ M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A M;&EG;CTS1'1O<"!W:61T:#TS1#$E/@T*(`T*("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q% M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`- M"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S@R,3([/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX- M"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@ M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F M="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@("`@ M("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F M;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/@T*("`-"B`@("`@("`@("`@("`@ M/&9O;G0@6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-0 M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P M<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@(`T*("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF M>3X-"B`@("`-"B`@("`@("`@/&9O;G0@2!U<&]N('-H:7!M96YT(&9R;VT@=&AE#0H@("`@(`T*("`@("`@("!M86YU M9F%C='5R:6YG(&9A8VEL:71Y(&EN(%=U>&DL($-H:6YA(&]R(&9R;VT@;W5R M('=A6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T M.R!&3TY4+5=%24=(5#H@8F]L9"<^4VAA6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"B`@("`@#0H@("`@ M("`@($-O;7!A;GD@97-T:6UA=&5S('1H92!F86ER('9A;'5E(&]F(&5A8V@@ M'!E;G-E(&ES(')E8V]G M;FEZ960@8F%S960@;VX@87=A&-EF5D(&%S(&%N(&%D9&ET:6]N('1O#0H@("`-"B`@("`@("`@ M<&%I9"UI;B!C87!I=&%L+CPO9F]N=#X-"B`@(`T*("`@("`@/"]D:78^/&)R M+SX\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5. M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2 M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@ M("`@/&9O;G0@&5S/"]F;VYT/@T* M("`-"B`@("`@(#PO9&EV/CQB6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SY4:&4-"B`@("`@#0H@("`@("`@($-O;7!A;GD@=7-E&5S+B8C,38P.R8C,38P.U5N9&5R('1H92!L:6%B M:6QI='D@;65T:&]D+"!D969E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY"87-I8PT* M("`-"B`@("`@("`@;F5T(&EN8V]M92`H;&]S2!T:&4@=V5I9VAT960@879E2!O=&AE2!D:6QU M=&EV92!S96-U65A2X\+V9O;G0^#0H@("`@#0H@("`@("`\+V1I=CX\ M8G(O/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"B`@("`@ M#0H@("`@("`@(&%C8V]M<&%N>6EN9R!F:6YA;F-I86P@2!I2!O9B!T:&4@0V]M<&%N>0T* M("`-"B`@("`@("`@=&\@8V]N=&EN=64@87,@82!G;VEN9R!C;VYC97)N(&1U M2!I9B!T:&4@0V]M<&%N>2!I7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!!;F0@17%U:7!M96YT/&)R/CPO2P@4&QA;G0@86YD($5Q=6EP;65N="!$:7-C M;&]S=7)E(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U) M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[ M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@("`-"B`@("`@ M("`@/&9O;G0@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E. M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@ M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@ M("`@("`@/&9O;G0@2!O9B!P2!A;F0@97%U:7!M96YT(&%T#0H@("`@(`T*("`@("`@("!$96-E;6)E M6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE"<^#0H@("`@#0H@ M("`@("`@("`@("`@("8C,38P.PT*("`@("`-"B`@("`@("`@("`@(#PO=&0^ M#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@"<^#0H@("`-"B`@ M("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X- M"B`@("`-"B`@("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q,R4@6QE/3-$)TQ)3D4M M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$8V5N=&5R/@T*("`@("`-"B`@("`@("`@("`@("`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^ M1&5C96UB97(-"B`@("`-"B`@("`@("`@("`@("`@("`@(#,Q+"`R,#$R/"]F M;VYT/@T*("`@("`-"B`@("`@("`@("`@("`@("`\+V1I=CX-"B`@("`-"B`@ M("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@ M("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,24@"<^#0H@(`T*("`@("`@("`@("`@("`F(S$V M,#L-"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!! M1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@ M(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*("`@#0H@("`@("`@ M("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$58 M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/@T*(`T*("`@("`@("`@("`@("`F(S$V,#L-"B`@("`@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E/@T*("`@("`-"B`@("`@("`@("`@("`@)B,Q-C`[ M#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4 M+4%,24=..B!L969T)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/@T*("`-"B`@("`@ M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SX\9F]N="!I9#TS1%1!0C$M,"!S='EL93TS1"=-05)'24XM M3$5&5#H@-W!T)SX\+V9O;G0^,2PQ,3,L,C,U/"]F;VYT/@T*("`-"B`@("`@ M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`F(S$V,#L-"B`@ M("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^ M#0H@(`T*("`@("`@("`@(#QT6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY,96%S M96AO;&0-"B`@("`-"B`@("`@("`@("`@("`@("!I;7!R;W9E;65N=#PO9F]N M=#X-"B`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@ M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@("`@("`@("8C,38P.PT*("`@ M("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H@("`-"B`@("`@("`@("`@("`@)B,Q-C`[ M#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N M="!I9#TS1%1!0C$M,R!S='EL93TS1"=-05)'24XM3$5&5#H@,S,N,G!T)SX\ M+V9O;G0^-#DL,30W/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@ M("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M(%!!1$1)3D6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F M="<^#0H@(`T*("`@("`@("`@("`@("`F(S$V,#L-"B`@("`@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C M:R`R<'@@6QE/3-$)TU!4D=)3BU,1494.B`S-"XT-7!T M)SX\+V9O;G0^-#DL,30W/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@ M("8C,38P.PT*("`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@ M("`@("`@/"]T6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!I M9#TS1%1!0C$M-2!S='EL93TS1"=-05)'24XM3$5&5#H@,C8N-35P="<^/"]F M;VYT/C0T-BPS.#(\+V9O;G0^#0H@("`@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T M)SX-"B`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@ M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@("`@("`@("8C,38P.PT* M("`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^#0H@(`T*("`@("`@ M("`@("`@("`F(S$V,#L-"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)TU!4D=)3BU,1494.B`R-"XS-7!T)SX\+V9O;G0^*#@Y+#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P M>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^#0H@(`T*("`@("`@("`@("`@ M("`F(S$V,#L-"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE M/3-$)TU!4D=)3BU,1494.B`R-2XV<'0G/CPO9F]N=#XH,C`L-S$X/"]F;VYT M/@T*("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@ M,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXI/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^ M#0H@("`@#0H@("`@("`@("`@/"]T6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/@T* M("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXD/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@ M#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1% M6%0M04Q)1TXZ(')I9VAT)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!I9#TS1%1!0C$M M.2!S='EL93TS1"=-05)'24XM3$5&5#H@-"XU<'0G/CPO9F]N=#XS-38L-C4V M/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@ M("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@#0H@ M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXD/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@ M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q) M1TXZ(')I9VAT)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!I9#TS1%1!0C$M,3`@"<^#0H@(`T*("`@("`@("`@("`@("`F(S$V,#L-"B`@("`@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@ M("`@("`\+W1A8FQE/CQB0T*("`@(`T* M("`@("`@("!R96-O9VYI>F5D(&1E<')E8VEA=&EO;B!A;F0@86UOF%T M:6]N(&5X<&5N2X\+V9O;G0^#0H@("`@(`T*("`@("`@ M/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!4 M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@ M("`-"B`@("`@("`@/&9O;G0@6UE;G1S(&UA9&4@=&\@365D:6-A;"!);G9E M6UE;G0@=&\@34E'+B!4:&4@:6UP86ER;65N="!C M:&%R9V4@=V%S(&)A6UE;G1S(&UA9&4@8GD@=&AE($-O;7!A;GD@=&\@34E'(&9O M2!A2!-24<@9G)O;2!T:&4@0V]M<&%N>28C.#(Q-SMS#0H@#0H@("`@("`@('!R M;V1U8W1I;VX@<&%Y;65N=',@=V5R92`D-3`L,#`P(&EN('1R:6%L(&UO;&1S M+B!&6UE;G0@=V%S M(&)E:6YG('5S960@8GD-"B`-"B`@("`@("`@34E'(&9O7)I;F=E+B!$ M=7)I;F<@=&AE(&%R8FET6UE;G0@=&\@ M9&%T92X@5&AE(&=A:6X@6QE/3-$)TQ)3D4M M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@("`@/&9O;G0@2X\+V9O;G0^#0H@("`-"B`@("`@ M(#PO9&EV/CQB3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\X-&8P93=B8E]F8S0T7S0V,61?83(P,U\P83,T-V-C,S`P8S0- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#1F,&4W8F)?9F,T-%\T M-C%D7V$R,#-?,&$S-#=C8S,P,&,T+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0@0FQO8VM=/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X- M"B`@("`@#0H@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q M,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^3D]410T*("`@("`-"B`@("`@("`@ M-"`F(S@R,3$[($E.5$%.1TE"3$53($%.1"!'3T]$5TE,3#PO9F]N=#X-"B`@ M("`@#0H@("`@("`\+V1I=CX\8G(O/CQD:78@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I% M.B`Q,'!T)SY4:&4-"B`@("`@#0H@("`@("`@(&9O;&QO=VEN9R!I"<^#0H@("`- M"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@("`@/"]T M9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q,R4@6QE/3-$)TQ) M3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L M:6=N/3-$8V5N=&5R/@T*("`@("`-"B`@("`@("`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L M9"<^1&5C96UB97(-"B`@("`-"B`@("`@("`@("`@("`@("`@(#,Q+"`R,#$Q M/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@("`@("`\+V1I=CX-"B`@("`- M"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X- M"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H@(`T*("`@("`@("`@("`@("`F M(S$V,#L-"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@ M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/@T*("`- M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SX\9F]N="!I9#TS1%1!0C$M,3$@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@ M("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@ M("`@("`@("`F(S$V,#L-"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT"<^#0H@("`@#0H@("`@("`@("`@ M("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SY,:6-E;G-I;F<-"B`@("`-"B`@("`@("`@("`@("`@("!A9W)E96UE;G0\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@ M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,24@"<^#0H@("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@ M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C M:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!I9#TS1%1!0C$M,3,@ M"<^#0H@(`T*("`@("`@("`@("`@("`F(S$V,#L-"B`@("`@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$58 M5"U!3$E'3CH@"<^#0H@(`T*("`@("`@("`@("`@("`F(S$V,#L-"B`@("`@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@ M(`T*("`@("`@("`@(#QT6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T* M("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`- M"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@("`@/"]T M9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q,B4@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`F(S$V,#L-"B`@("`@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T* M("`@("`@("`@(#QT"<^#0H@("`@#0H@("`@("`@("`@("`@(#QD:78@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY,97-S.@T*("`@("`-"B`@("`@("`@ M("`@("`@("!A8V-U;75L871E9"!A;6]R=&EZ871I;VX\+V9O;G0^#0H@("`@ M#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^ M#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@"<^#0H@("`-"B`@ M("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X- M"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SX\9F]N="!I9#TS1%1!0C$M,3<@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$58 M5"U!3$E'3CH@;&5F="<^#0H@(`T*("`@("`@("`@("`@("`F(S$V,#L-"B`@ M("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)U!!1$1)3D"<^#0H@("`-"B`@("`@("`@("`@ M("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@ M("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%, M24=..B!L969T)SX-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@(`T*("`@("`@("`@("`@("`F(S$V M,#L-"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M(#PO='(^#0H@(`T*("`@("`@("`\+W1A8FQE/CQB2!O=VYS(&]N92!P=6)L:7-H960@<&%T96YT(&]N(&ET2!S>7)I;F=E(&ES2!T:&4@52Y3+B!P871E;G0@;V9F:6-E(&%N M9"!P=6)L:7-H960-"B`@#0H@("`@("`@(&EN($%P2!A;'-O(&9I;&5D#0H@("`@(`T*("`@("`@("!I;G1E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"B`@("`@ M#0H@("`@("`@($-O;7!A;GD@:7,@86QS;R!E;F=A9V5D(&EN('1H92!D979E M;&]P;65N="!O9B!T96-H;F]L;V=Y#0H@("`@(`T*("`@("`@("!W:&EC:"!C M86X@28C.#(Q-SMS#0H@("`@(`T*("`@("`@ M("!T96-H;F]L;V=Y('=I;&P@;&5T('1H92!U65AF%T:6]N(&5X<&5N2X\+V9O;G0^#0H@("`@(`T* M("`@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X- M"B`-"B`@("`@("`@/&9O;G0@&-H86YG960@9F]R('1H92!C;VYT2`D,C,L,C3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\X-&8P93=B8E]F8S0T7S0V,61?83(P,U\P83,T-V-C,S`P M8S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#1F,&4W8F)?9F,T M-%\T-C%D7V$R,#-?,&$S-#=C8S,P,&,T+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6%B;&4@06YD($%C8W)U960@3&EA8FEL:71I97,\ M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L M6%B;&4@86YD($%C8W)U960@3&EA8FEL:71I97,@1&ES8VQO6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X- M"B`-"B`@("`@("`@/&9O;G0@2!O M9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&%C8V]U;G1S#0H@(`T*("`@("`@("!P M87EA8FQE(&%N9"!A8V-R=65D(&QI86)I;&ET:65S(&%T($1E8V5M8F5R(#,Q M+"`R,#$R(&%N9`T*("`@("`-"B`@("`@("`@,C`Q,3H\+V9O;G0^#0H@(`T* M("`@("`@/"]D:78^/&)R+SX\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS M<&%C:6YG/3-$,"!W:61T:#TS1#DY)2!S='EL93TS1"=&3TY4+49!34E,63H@ M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^#0H@("`-"B`@ M("`@("`@("`\='(^#0H@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$-S`E('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@(`T*("`@("`@("`@("`@("`\ M9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@ M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE. M+5))1TA4.B`P<'0G/@T*("`@#0H@("`@("`@("`@("`@("`@/&1I=B!S='EL M93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E3 M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@ M,'!T)R!A;&EG;CTS1&-E;G1E6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)V)A8VMG6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY!8V-O=6YT6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@ M("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@ M("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@ M("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M,B4@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@)B,Q-C`[ M#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@ M("`@("`@("`F(S$V,#L-"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`- M"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@ M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@ M("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@("`@ M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q,B4@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`F(S$V,#L-"B`@("`@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@ M(`T*("`@("`@("`@(#QT6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY!8V-R=65D M#0H@(`T*("`@("`@("`@("`@("`@(&EN=&5R97-T/"]F;VYT/@T*("`@#0H@ M("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@ M("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,24^#0H@("`@(`T*("`@("`@("`@("`@("`F(S$V,#L-"B`@("`@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/@T*("`@("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@ M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q,B4@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@ M("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@ M("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M,B4@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/@T*(`T*("`@("`@("`@("`@("`F(S$V,#L-"B`@("`@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@ M("`@(#QT6QE/3-$)U!!1$1)3D6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!4 M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@ M("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^#0H@(`T*("`@("`@ M("`@("`@("`F(S$V,#L-"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^#0H@(`T*("`@ M("`@("`@("`@("`F(S$V,#L-"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1) M3D6QE/3-$)U!!1$1)3D6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M"<^#0H@("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@ M("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX- M"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@ M("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX- M"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@(`T*("`@("`@("`@("`@("`F(S$V,#L-"B`@("`@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T* M("`@("`@("`\+W1A8FQE/CQB2!H860@86-C2!P;&%N&EN9R!A M=71H;W)I=&EE2!T;R!A;F0@861V86YC97,@9G)O;2!2:&]N9&$-"B`@(`T* M("`@("`@("!6:6YC96YT+"!F;W)M97(@0T9/+"!A;F0@)#'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!4 M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`@("`@ M#0H@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!& M3TY4+5=%24=(5#H@8F]L9"<^3D]410T*("`@("`-"B`@("`@("`@-B`F(S@R M,3$[(%!!64%"3$4@5$\@64533RU-140\+V9O;G0^#0H@("`@(`T*("`@("`@ M/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!4 M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@ M("`-"B`@("`@("`@/&9O;G0@65A<@T*("`@("`-"B`@("`@("`@86=R M965M96YT('=I=&@@5W5X:2!9=7-H;W4@365D:6-A;"!!<'!L:6%N8V4@0V\N M+"!,=&0-"B`@#0H@("`@("`@("@F(S@R,C`[665S;RUM960F(S@R,C$[*2X@ M4'5R28C.#(Q-SMS('-A=&ES M9F%C=&EO;B!T:&%T(&ET(&AA7)I M;F=EF4-"B`@(`T*("`@("`@("!I;B!T:&4@;6EN M:6UU;2!A;6]U;G0@;V8@870@;&5A2!D;V5S(&YO="!P;&%C92!W:71H M(%EE6UE;G1S(&9R;VT@=&AE M($-O;7!A;GD@97%U86P@=&\@-3`E(&]F('1H92!S=7!P;'D@<')I8V4-"B`@ M#0H@("`@("`@(&]F(&5A8V@@=6YI="!B96QO=R!T:&4@;6EN:6UU;2!O6UE;G0-"B`@#0H@("`@("`@ M(&%G86EN&-E961S#0H@("`-"B`@("`@("`@=&AE(&UI;FEM=6T@<75A M;G1I='D@9F]R('1H870@;6]N=&@N($EN($IU;'D@,C`Q,BP@665S;RUM960- M"B`@(`T*("`@("`@("!M970@=&AE(&-A<&%C:71Y(')E<75I2!H87,@;F]T#0H@(`T*("`@("`@("!Y970@ M<&QA8V5D(&%N>2!O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV M('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`@#0H@("`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^ M3D]410T*("`@("`-"B`@("`@("`@-R`F(S@R,3$[($-/3E9%4E1)0DQ%($Y/ M5$53(%!!64%"3$4\+V9O;G0^#0H@#0H@("`@("`\+V1I=CX\8G(O/CQD:78@ M6%B;&4@8V]N6QE/3-$)T9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)U!!1$1) M3D"<^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^1&5C96UB97(F M(S$V,#LS,2P\+V9O;G0^#0H@("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@ M(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R M/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=( M5#H@8F]L9"<^)B,Q-C`[/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@(#PO M=&0^#0H@("`@#0H@("`@("`@("`@/"]T6QE/3-$)V)A8VMG6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@+3$X<'0[($1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P M<'0G(&%L:6=N/3-$;&5F=#X-"B`@("`-"B`@("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/@T*("`-"B`@("`@("`@("`@ M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,3(E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@ M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXQ.3$L-C8S/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T M)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@+3$X<'0[ M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`@("`-"B`@("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6UE;G0@9'5E(&]N($%P M6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@ M("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXM/"]F;VYT/@T* M("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@ M;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL M93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@(`T*("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SY#;VYV97)T:6)L90T*(`T*("`@("`@("`@("`@("`@(%!R;VUI M6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$R)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@(`T* M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY#;VYV97)T:6)L90T*(`T* M("`@("`@("`@("`@("`@(%!R;VUI6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N M/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T* M("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXT,BPU,#`\+V9O;G0^#0H@(`T* M("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@ M(`T*("`@("`@("`@(#QT2!. M;W1E(%!A>6%B;&4@=&\@07-H97(@16YT97)P6UE;G0@9'5E(&]N(%-E<'1E;6)E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL M93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@(`T*("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SY#;VYV97)T:6)L90T*(`T*("`@("`@("`@("`@("`@ M(%!R;VUI6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O M;G0@6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXM/"]F;VYT/@T*("`-"B`@("`@("`@("`@ M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY#;VYV97)T:6)L M90T*(`T*("`@("`@("`@("`@("`@(%!R;VUI6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$)TQ)3D4M2$5) M1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$;&5F=#X-"B`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"=415A4+4%,24=..B!R M:6=H="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"=415A4+4%,24=. M.B!R:6=H="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)V)A8VMG6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@+3$X<'0[($1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`@("`-"B`@("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE28C M.#(Q-SMS#0H@("`-"B`@("`@("`@("`@("`@("!A6UE;G0@9'5E(&]N($IA;G5A M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^ M#0H@(`T*("`@("`@("`@(#QT6QE/3-$ M)U!!1$1)3D2!.;W1E(%!A M>6%B;&4@:7-S=65D(&EN('1H92!C;W5R6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]- M.B!B;&%C:R`R<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M(%!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^ M#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXM/"]F;VYT/@T*("`- M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W M6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE M/3-$)V)A8VMG6QE/3-$)TQ)3D4M M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$R)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@ M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXS.#"<^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@(`T*("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P M>"!S;VQI9#L@5$585"U!3$E'3CH@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/@T*("`-"B`@("`@("`@ M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1R:6=H M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^#0H@(`T*("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXH,S`W+#$R-CPO9F]N=#X-"B`@("`-"B`@ M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D"<^#0H@(`T*("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@#0H@("`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD M/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@ M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(')I9VAT)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXX,"PU,S4\+V9O;G0^#0H@(`T*("`@("`@ M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H@(`T*("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L M9"<^07-H97(-"B`-"B`@("`@("`@16YT97)P6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I% M.B`Q,'!T)SY$=7)I;F<-"B`@(`T*("`@("`@("!T:&4@>65A28C M.#(Q-SMS(&-O;6UO;B!S=&]C:R!A="!A(&-O;G9E2!T:&4@879E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY$=7)I M;F<-"B`@(`T*("`@("`@("!T:&4@>65A2!F:6QE(&ET6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T M.R!&3TY4+5=%24=(5#H@8F]L9"<^5$-!#0H@("`@#0H@("`@("`@($=L;V)A M;"!#6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`- M"B`@("`@("`@/&9O;G0@2!A("0Q,#`L,#`P(&9A8VEL:71Y(&9E92!B>2!I2!S:&%R97,F(S@R,C$[*2X@5&\@9&5T97)M:6YE('1H92!N=6UB M97(@;V8-"B`-"B`@("`@("`@0T*("`@(`T*("`@("`@("!S:&%R97,@ M0T*("`@#0H@("`@("`@('1H92!V;VQU;64@=V5I9VAT960@879E M2!A;F0@5$-!(&%G2!F:6YA;F-I M;F<@86=R965M96YT(&)A28C.#(Q-SMS(&9A:6QU2!H87,@:7-S=65D#0H@("`@#0H@("`@ M("`@(#4U.2PR-C@@8V]M;6]N('-H87)E2!F964@=7!O;B!R979A;'5A=&EO;BX@07,@;V8-"B`@("`@#0H@ M("`@("`@($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3(L(&%C8V]U;G1S('!A>6%B M;&4@:6YC;'5D960@)#0X+#`W-@T*("`@("`-"B`@("`@("`@9F]R('1H92!R M96UA:6YI;F<@<&%Y86)L92!T;R!40T$@2!I6UE;G0@;V8@86QL#0H@#0H@("`@("`@ M('!R:6YC:7!A;"!A;F0@:6YT97)E2!R96-O9VYI>F5D("0Q-S0L-#0X(&]F#0H@(`T* M("`@("`@("!I;G1E'!E;G-E(')E;&%T960@=&\@=&AE(&%M;W)T M:7IA=&EO;B!O9B!T:&4@9&5B=`T*("`@("`-"B`@("`@("`@9&ES8V]U;G0N M/"]F;VYT/@T*(`T*("`@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)TQ) M3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L M:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@("`@/&9O;G0@2!N;W1E('1O($I-2B!&:6YA;F-I M86PL($EN8RX-"B`@("`-"B`@("`@("`@*"8C.#(R,#M*34HF(S@R,C$[*2X@ M5&AE)B,Q-C`[;F]T92!B96%R28C.#(Q-SMS M(&-O;6UO;B!S=&]C:R!A="!A('!R:6-E(&5Q=6%L('1O(#6EN9R!T:&ES(&YO=&4N(%1H92!N;W1E('=I;&P@;VYL>2!B M92!F=6YD960@=VAE;B!T:&4-"B`@(`T*("`@("`@("!C;VYV97)S:6]N('!R M:6-E(&-A;&-U;&%T960@;VX@96%C:"!P87EM96YT(&1A=&4@:7,@97%U86P- M"B`-"B`@("`@("`@=&\@;W(@9W)E871E28C.#(Q-SMS(&-O;6UO;B!S M=&]C:RX-"B`@("`-"B`@("`@("`@5&AE('!R:6YC:7!A;"!A;6]U;G0@;W=E M9"!T;R!*34H@870@1&5C96UB97(@,S$L(#(P,3(@86YD#0H@#0H@("`@("`@ M(#(P,3$L(&ES("0Q.3$L-C8S(&%N9"`D,C`W+#$V,2P@2!N;W1E+B!4:&4@0V]M<&%N>0T*("`@("`-"B`@("`@ M("`@86YA;'EZ960@=&AE($I-2B!N;W1E(&9O65AF%T:6]N(&]F('1H92!D M96)T(&1I6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-0 M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P M<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@("`@/&9O;G0@2!I0T*("`@#0H@("`@("`@(&1A=&4L M)B,Q-C`[1F5B28C.#(Q-SMS M(&-O;6UO;B!S=&]C:RP@;W)I9VEN86QL>2!F:7AE9"!A="!A('!E<@T*("`@ M#0H@("`@("`@('-H87)E(&-O;G9E28C.#(Q-SMS(&-O;6UO M;B!S=&]C:PT*(`T*("`@("`@("!I;B!T:&4@,C`@=')A9&EN9R!D87ES('!R M979I;W5S('1O('1H92!E9F9E8W1I=F4@9&%T92!O9@T*("`@("`-"B`@("`@ M("`@96%C:"!S=6-H(&-O;G9E6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5. M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2 M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@ M("`@/&9O;G0@2!I6%B;&4@=&\- M"B`@("`@#0H@("`@("`@(&EN9&EV:61U86QS(&9O65A M6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SY4:&4-"B`@("`@#0H@("`@("`@('!R:6YC:7!A;"!A M;6]U;G0@;V8@=&AE($EN9&EV:61U86P@0V]N=F5R=&EB;&4@3F]T97,@86YD M#0H@("`@(`T*("`@("`@("!A8V-R=65D(&EN=&5R97-T(&%R92!C;VYV97)T M:6)L92!I;G1O('1H92!#;VUP86YY)B,X,C$W.W,-"B`@("`@#0H@("`@("`@ M(&-O;6UO;B!S=&]C:R!A="!A(&-O;G9E2!O=VYE9"!B>2!T:&4@:&]L9&5R#0H@(`T*("`@("`@("!A M;F0@:71S(&%F9FEL:6%T97,@86YD(#(I('1H92!N=6UB97(@;V8@2!T:&4@:&]L9&5R(&%N9"!I=',@869F:6QI M871E28C.#(Q-SMS(&-O M;6UO;B!S=&]C:RX@07,@;V8@1&5C96UB97(@,S$L#0H@("`-"B`@("`@("`@ M,C`Q,BP@26YD:79I9'5A;"!#;VYV97)T:6)L92!.;W1E'!I65AF5D M('1H92!);F1I=FED=6%L($-O;G9E&-E'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA6%B;&4@9F]R($EN9&5M;FEF:6-A=&EO;B!;365M8F5R73PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`@("`@#0H@("`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^ M3D]410T*("`@("`-"B`@("`@("`@."`F(S@R,3$[(%!!64%"3$4@1D]2($E. M1$5-3DE&24-!5$E/3CPO9F]N=#X-"B`@(`T*("`@("`@/"]D:78^/&)R+SX\ M9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@ M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@("`@ M/&9O;G0@&5C=71I=F4@3V9F M:6-E2X-"B`@#0H@("`@("`@(%!U6UE;G0@;V8@ M<&5N86QT:65S+"!P&]N+"!) M;F,N+"!':69F;W)D($TN($UA8FEE+"!*2!F=6YD960@8GD@=&AE($-O M;7!A;GDF(S@R,3<[2!T:&4@8G)O:V5R86=E(&9I6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY/ M;@T*("`@(`T*("`@("`@("!$96-E;6)E2!V86QU M960@870@)#$X-"PP,#`L#0H@(`T*("`@("`@("!T;R!T:&4@2X\ M+V9O;G0^#0H@("`@(`T*("`@("`@/"]D:78^/&)R+SX\6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T M)SY$=64-"B`@("`@#0H@("`@("`@('1O('1H92!C;VYV97)S:6]N(&9E871U M2!I2!U M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"B`@("`@#0H@ M("`@("`@(&9O;&QO=VEN9R!I3H\+V9O;G0^#0H@(`T* M("`@("`@/"]D:78^/&)R+SX\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS M<&%C:6YG/3-$,"!W:61T:#TS1#$P,"4@6QE/3-$)TQ) M3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L M:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T* M("`@("`@("`@(#QT6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/@T*("`@(`T*("`@("`@ M("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T* M("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$)U!!1$1)3D2!T;R!E<75I='D@87,@82!R97-U;'0@;V8@;F]T90T*(`T* M("`@("`@("`@("`@("`@(&-O;G9E6QE M/3-$)U!!1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT M/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@ M(#QT6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY)6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)V)A M8VMG6QE/3-$)TQ)3D4M2$5)1TA4 M.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2 M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F M=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M(&%L:6=N/3-$"<^#0H@(`T*("`@("`@("`@("`@ M("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5. M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2 M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE2!A"<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5. M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2 M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH.#DX M+#,R-CPO9F]N=#X-"B`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@ M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS M1&QE9G0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@"<^#0H@("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL M93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E3 M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@ M,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@("`@("`@("`@/&9O;G0@ M6QE M/3-$)V)A8VMG6QE/3-$)U!!1$1)3D6QE/3-$ M)U!!1$1)3D6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q% M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`- M"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@("`@#0H@("`@("`@ M("`@("`@("8C,38P.PT*("`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@ M#0H@("`@("`@("`@("`\=&0@8V]L6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P M>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R)SX-"B`@#0H@("`@("`@("`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=% M24=(5#H@8F]L9"<^,C`Q,CPO9F]N=#X-"B`@("`-"B`@("`@("`@("`@(#PO M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,24@"<^#0H@("`- M"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@("`@/"]T M9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,R!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0U)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B M;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!& M3TY4+5=%24=(5#H@8F]L9"<^,C`Q,3PO9F]N=#X-"B`@("`-"B`@("`@("`@ M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24@"<^ M#0H@("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@ M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`\+W1R/@T*("`-"B`@("`@("`@ M("`\='(@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY2:7-K#0H@("`@#0H@("`@ M("`@("`@("`@("`@9G)E92!I;G1E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY% M>'!E8W1E9`T*("`@#0H@("`@("`@("`@("`@("`@;&EF92`H>65A6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXP+C`Q/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@ M("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M-24^#0H@("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`T+C5P="<@86QI M9VX],T1C96YT97(^#0H@("`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SYT;SPO9F]N=#X-"B`@("`@#0H@ M("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@ M("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M-24^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SY$:79I9&5N9`T*("`@#0H@("`@("`@("`@("`@ M("`@66EE;&0\+V9O;G0^#0H@("`@(`T*("`@("`@("`@("`@("`\+V1I=CX- M"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/@T*("`@("`-"B`@("`@("`@ M("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`- M"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U)3X- M"B`@("`@#0H@("`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXP)3PO9F]N=#X-"B`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@ M("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U)2!S='EL M93TS1"=415A4+4%,24=..B!C96YT97(G/@T*("`-"B`@("`@("`@("`@("`@ M)B,Q-C`[#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@ M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@("`@ M#0H@("`@("`@("`@("`@("8C,38P.PT*("`@("`-"B`@("`@("`@("`@(#PO M=&0^#0H@("`@#0H@("`@("`@("`@/"]T6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY6;VQA=&EL:71Y/"]F M;VYT/@T*("`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@ M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$-24@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`P M<'0[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"B`@ M("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXR,3DE/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@(#PO=&0^ M#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24^#0H@("`@(`T*("`@("`@("`@("`@("`F(S$V,#L-"B`@("`@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#4E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'AO;BP@26YC+BPI(&%N9"!';&]B92!-960@5&5C:"P@26YC+@T*("`@#0H@ M("`@("`@("@F(S@R,C`[1VQO8F4F(S@R,C$[*2!E;G1E2!A;F0@1VQO8F4@96%C:"!O=VX@-3`E(&]F('1H M90T*(`T*("`@("`@("!J;VEN="!V96YT=7)E+B8C,38P.R8C,38P.U1H92!# M;VUP86YY(&-O;G1R:6)U=&5D(&ET2!A;F0@<&%T96YT(')I9VAT2!S>7)I;F=E($E6(&-A=&AE=&5R(&%N9`T*("`@("`-"B`@ M("`@("`@<&%T96YT(')I9VAT2!I6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-0 M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P M<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@("`@/&9O;G0@2P@3VML86AO;6$@86=A:6YS="!';&]B92!T;R!R97-C:6YD+`T*(`T*("`@ M("`@("!T97)M:6YA=&4@86YD('-E96L@;6]N971A&%S+"!A(&QA=W-U:70@9F]R(&9R875D(&%N9"!C;VYT96UP=`T*(`T*("`@ M("`@("!O9B!C;W5R="!F;W(@1VQO8F4@86YD($%N9'D@2'4L(&EN9&EV:61U M86QL>2XF(S$V,#LF(S$V,#M/;@T*(`T*("`@("`@("!/8W1O8F5R(#(Q+"`R M,#$Q+"!T:&4@0V]M<&%N>2!W87,@9W)A;G1E9"!I=',@2!J=61G;65N="!A9V%I;G-T($=L;V)E(&%N M9"!A=V%R9&5D("0S,3$L-#0P(&%N9"!T:&4-"B`@(`T*("`@("`@("!R971U M2!A M=V%R9"!A;F0-"B`@("`@#0H@("`@("`@('1H92!R971U7)I;F=E0T*("`-"B`@("`@("`@28C.#(Q-SMS('-A9F5T>2!V86-U=6T-"B`-"B`@("`@("`@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SY/;@T*("`@(`T*("`@("`@("!$96-E;6)E2!C;&%I;7,@8GD@1VQO M8F4N($=L;V)E(&9I;&5D(&%N;W1H97(@87!P96%L#0H@("`-"B`@("`@("`@ M;VX@36%R8V@F(S$V,#LQ+"`R,#$S+B!4:&4@0V]M<&%N>2!H87,@:&ER960@ M;&5G86P@8V]U;G-E;`T*(`T*("`@("`@("!I;B!497AA&5C=71E(&]N('1H92!C;W5R="!O7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0@0FQO8VM= M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$;&5F=#X-"B`@("`@#0H@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^3D]410T* M("`@("`-"B`@("`@("`@,3$@)B,X,C$Q.R!#3TU-251-14Y44R!!3D0@0T]. M5$E.1T5.0TE%4SPO9F]N=#X-"B`-"B`@("`@(#PO9&EV/CQB6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L M9"<^34E'#0H@("`@#0H@("`@("`@(&%N9"!34$0\+V9O;G0^#0H@("`@#0H@ M("`@("`\+V1I=CX\8G(O/CQD:78@2`R+"`R,#$S+"!T:&4@ M0V]M<&%N>2!W;VX@:71S(&%R8FET2P@9FEL97,L(&1R87=I M;F=S+"!D97-I9VYS+`T*("`@#0H@("`@("`@('!A=&5N=',@;W(@<')O9'5C M=',N(%1H92!R=6QI;F<@9&5T97)M:6YE9"!T:&%T(&%L;`T*("`@("`-"B`@ M("`@("`@<')O9'5C=&EO;B!M;VQD('!A>6UE;G1S(&UA9&4@8GD@=&AE($-O M;7!A;GD@=&\@34E'(&9O6UE;G1S+B8C M,38P.R8C,38P.U1H92!G86EN#0H@("`@#0H@("`@("`@(')E;&%T960@=&\@ M=&AI6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T M)SY/;@T*("`@(`T*("`@("`@("!397!T96UB97(@,C8L(#(P,3(L('1H92!# M;VUP86YY(&9I;&5D('-U:70@:6X@4V]U=&@-"B`@("`@#0H@("`@("`@($-A M2!O M9B!I;FET:6%T:79E2!I;B!I=',@<')O9'5C=&EO;@T*("`@#0H@("`@("`@ M(&]F(&%P<')O>&EM871E;'D@;VYE('EE87(N(%1H92!S=6ET(&9U2!A2!I;B!-87-S86-H=7-E='1S('5N M9&5R#0H@(`T*("`@("`@("!#:&%P=&5R(#$Q+B8C,38P.R8C,38P.U1H92!3 M;W5T:"!#87)O;&EN82!L87=S=6ET(&AA2!S=&%Y960@=6YT:6P@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=% M24=(5#H@8F]L9"<^2DU*#0H@("`@#0H@("`@("`@($9I;F%N8VEA;"P@26YC M+CPO9F]N=#X-"B`@#0H@("`@("`\+V1I=CX\8G(O/CQD:78@2`F(S@R,C`[1%1#)B,X,C(Q.PT*(`T*("`@ M("`@("!E;&EG:6)I;&ET>2X@5&AE(&-O;G1R86-T('-T871E9"!T:&%T('1H M92!#;VUP86YY('=O=6QD(&)E#0H@(`T*("`@("`@("!C;VYS:61E2!L;W-T M#0H@(`T*("`@("`@("!$5$,@96QI9VEB:6QI='D@9'5E('1O(&$@)B,X,C(P M.V-H:6QL)B,X,C(Q.R!P;&%C960@=7!O;@T*("`@#0H@("`@("`@('1H92!E M;&5C=')O;FEC('1R86YS9F5R(&]F('1H92!S=&]C:RX@5&AE($-O;7!A;GD@ M:&%D#0H@(`T*("`@("`@("!P2!L;W-I;F<@1%1#(&5L:6=I M8FEL:71Y(&]R#0H@("`-"B`@("`@("`@9&5F875L=&EN9R!B>2!F86EL:6YG M('1O(&ES2!H:6=H(&1E;6%N9',@9F]R M(&-O;G9E6QE/3-$)TQ)3D4M M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@("`@/&9O;G0@2!A M;'-O(&-L86EM2!D:7-P=71E2!W87,-"B`@("`- M"B`@("`@("`@;&EA8FQE(&9O6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I% M.B`Q,'!T)SY!#0H@("`-"B`@("`@("`@;&%W2`S,"P@,C`Q,B!F;W(@ M,2PR,C8L,#0Y#0H@#0H@("`@("`@('-H87)E2!F:6QE9`T*("`@ M#0H@("`@("`@(&ET6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^4T5# M/"]F;VYT/@T*("`-"B`@("`@(#PO9&EV/CQB6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"B`@("`@#0H@("`@("`@(%-%0R!F M:6QE9"!A(&-I=FEL(&-O;7!L86EN="!I;B!&961E28C.#(Q-SMS#0H@#0H@("`@("`@('!R;V1U8W1I M;VX@28C.#(Q-SMS(&-U2`R,#$Q+"!I;B!A9&1I=&EO;B!T;R!O=&AE M2!A;6]U;G1S+B8C,38P M.R8C,38P.U1H92!#;VUP86YY(&)E;&EE=F5S('1H870@=&AE2!N;W0@<')E=F%I;"!I;B!S=6-H#0H@ M(`T*("`@("`@("!D969E;G-E('1H92!A;6]U;G0@;V8@9&%M86=E6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@("`@/&9O;G0@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q% M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X- M"B`@("`-"B`@("`@("`@/&9O;G0@6UE;G0-"B`@("`@#0H@("`@("`@(&%G2!O9B`D,C0W+#4P,"!A;F0@;W1H97(@2!A;F0@37(N($]L;6\L($-H:65F M($]P97)A=&EN9PT*(`T*("`@("`@("!/9F9I8V5R+"!E;G1E2!A;F0-"B`@(`T* M("`@("`@("!O=&AE6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I% M.B`Q,'!T)SY%9F9E8W1I=F4-"B`-"B`@("`@("`@2G5N92`Q+"`R,#$Q+"!T M:&4@0V]M<&%N>2!A;F0@37(N($AO9&=E65A2!F6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E. M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@ M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@ M/&9O;G0@65A2!/2`Q+"`R,#$Q+"!T:&4@0V]M<&%N>0T*("`@(`T* M("`@("`@("!A;65N9&5D('1H92!L96%S92!A9W)E96UE;G0@=&\@:6YC;'5D M92!T:&4@;V9F:6-E('-P86-E#0H@("`@#0H@("`@("`@(&%D:F%C96YT('1O M('1H92!E>&ES=&EN9R!O9F9I8V4@2!I7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA2!. M;W1E($1I'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q% M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X- M"B`@(`T*("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^4%)% M1D524D5$#0H@("`@(`T*("`@("`@("!35$]#2SPO9F]N=#X-"B`@#0H@("`@ M("`\+V1I=CX\8G(O/CQD:78@2P@,2PP,#`L,#`P('-H87)E&5C=71I=F4@3V9F:6-E6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@("`@/&9O;G0@ M6QE/3-$)T9/ M3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE)SY$:79I9&5N9',\ M+V9O;G0^.@T*(`T*("`@("`@("!4:&4@:&]L9&5R(&]F('1H92!02P@9&EV:61E;F1S('=H96XL(&%S(&%N9"!I9B!D96-L87)E9"!B M>2!T:&4@8F]A6UE;G0@8F5I;F<-"B`@("`@#0H@("`@("`@(&UA9&4@=&\@ M86YY(&IU;FEO6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5. M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2 M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@ M("`@/&9O;G0@6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE)SY# M;VYV97)S:6]N/"]F;VYT/CH-"B`@#0H@("`@("`@(%1H92!H;VQD97)S(&]F M(%!R969E6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[ M($1)4U!,05DZ(&EN;&EN92<^4')E96UP=&EO;CPO9F]N=#XZ#0H@(`T*("`@ M("`@("!4:&4@:&]L9&5R2`Q#0H@("`-"B`@ M("`@("`@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@ M8F]L9"<^,C`Q,@T*("`@("`-"B`@("`@("`@0T]-34].(%-43T-+(%1204Y3 M04-424].4SPO9F]N=#X-"B`@#0H@("`@("`\+V1I=CX\8G(O/CQD:78@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF M>3X-"B`@("`-"B`@("`@("`@/&9O;G0@65A2!I6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@("`@/&9O;G0@2!O=7(@9F]R;65R(%!R M97-I9&5N="P@5&]M#0H@("`@(`T*("`@("`@("!/)B,X,C$W.T)R:65N(&%T M("0P+C`X('!E2!I;G9E6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SY!;'-O#0H@#0H@("`@("`@(&1U65A M6UE;G0@9F]R(&]U='-I9&4-"B`- M"B`@("`@("`@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5. M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2 M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@ M("`@/&9O;G0@2!I7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/&1I M=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2 M24=(5#H@,'!T)R!A;&EG;CTS1&IU6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q% M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X- M"B`@("`-"B`@("`@("`@/&9O;G0@28C.#(Q-SMS(#(P,#<@ M4W1O8VL@3W!T:6]N(%!L86XL(')E=FES960@2G5L>2`R,#$Q+`T*(`T*("`@ M("`@("!P97)M:71S('1H92!G&-E<'1I;VYA;"!A8FEL:71Y('1O(&)E8V]M92!E;7!L;WEE97,@ M;V8@=&AE#0H@("`-"B`@("`@("`@0V]M<&%N>2XF(S$V,#LF(S$V,#M4:&4@ M<&QA;B!A;&QO=W,@=&AE($-O;7!A;GD@=&\@:7-S=64-"B`@(`T*("`@("`@ M("!E:71H97(@'!E8W1E9"!V;VQA=&EL:71Y(&]F(#$U.24@=&\@,38Q)2!A;F0@*#0I M#0H@#0H@("`@("`@('IE6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SY$=7)I;F<-"B`@(`T*("`@("`@("!T:&4@8V]U2!S>7)I;F=E+B!#;VYS=6QT86YT6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY#;VYS=6QT86YT'!E;G-E(&ES(&1E=&5R;6EN960@8F%S960-"B`-"B`@("`@("`@=7!O M;B!T:&4@;W!T:6]N&5R8VES92!P65A6QE/3-$)U!!1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@("`@(`T*("`@("`@("`@ M("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E. M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@ M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@ M("`@("`@("`@("`@/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@ M("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4 M.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2 M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N M=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y% M+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG M;CTS1&-E;G1E6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`-"B`@("`@("`@("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@#0H@("`@("`@("`@("`@(#QF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X M)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4 M97)M#0H@#0H@("`@("`@("`@("`@("`@*&EN('EE87)S*3PO9F]N=#X-"B`@ M("`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@ M("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4 M.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2 M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N M=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y% M+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG M;CTS1&-E;G1E6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SY);G1R:6YS:6,-"B`-"B`@("`@("`@("`@("`@("!6 M86QU93PO9F]N=#X-"B`@("`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`- M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W M6QE/3-$)V)A8VMG6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q% M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`- M"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL M93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@(`T*("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@ M("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SY'6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$P)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@ M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"=415A4+4%,24=..B!R M:6=H="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@ M/&9O;G0@6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@("8C,38P.PT*("`@ M("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@ M;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY% M>&5R8VES960\+V9O;G0^#0H@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L M:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@ M("`@("`@/&9O;G0@6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH-BPV-C@L,#`P/"]F;VYT M/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/@T* M("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@ M86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@ M("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@("`-"B`@("`@ M("`@("`@("`@/&9O;G0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"=415A4 M+4%,24=..B!R:6=H="<^#0H@(`T*("`@("`@("`@("`@("`F(S$V,#L-"B`@ M("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@ M/&9O;G0@"<^#0H@(`T*("`@("`@("`@("`@("`\ M9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@ M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`R<'@@"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$P)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@4$%$1$E.1RU" M3U143TTZ(#)P>"<^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D"<^#0H@("`-"B`@("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/ M33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@ M("`@("`@("`@/&9O;G0@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/33H@,G!X)SX- M"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@(`T*("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY/ M=71S=&%N9&EN9RP-"B`@#0H@("`@("`@("`@("`@("`@1&5C96UB97(@,S$L M(#(P,3$\+V9O;G0^#0H@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N M/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T* M("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ-2PT-S,L-S4P/"]F;VYT/@T* M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@ M("`@("`@("`@/&9O;G0@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXP+C,Y/"]F;VYT/@T* M("`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\ M=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T* M("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@(`T*("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SY'6QE/3-$)U!!1$1)3D"<^#0H@#0H@("`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL M93TS1"=415A4+4%,24=..B!R:6=H=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<^ M#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D(&%L:6=N/3-$"<^#0H@(`T*("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/ M33H@,G!X)SX-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D(&%L:6=N/3-$"<^#0H@(`T* M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+4)/ M5%1/33H@,G!X)SX-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T* M("`@("`@("`@("`@/'1D(&%L:6=N/3-$"<^#0H@ M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y' M+4)/5%1/33H@,G!X)SX-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@(`T* M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SY%>&5R8VES960\+V9O;G0^#0H@(`T*("`@("`@("`@ M("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T* M("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH M-36QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T* M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX- M"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXP+C(U/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@(#PO=&0^ M#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H M="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)SX-"B`@#0H@("`@("`@("`@("`@("8C,38P.PT*("`@("`-"B`@("`@ M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY%>'!I"<^#0H@(`T* M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!! M1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P M)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@4$%$1$E.1RU"3U143TTZ M(#)P>"<^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[(%!!1$1)3D"<^#0H@("`-"B`@("`@("`@("`@("`@/&9O M;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X M)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P M)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@4$%$1$E.1RU"3U143TTZ M(#)P>"<^#0H@("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@ M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H@(`T* M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@(`T*("`@("`@("`@ M("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E. M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@ M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)U!! M1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1% M6%0M04Q)1TXZ(')I9VAT)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ,BPQ,#`L,#`P/"]F;VYT M/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@ M"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXP+C(P/"]F;VYT/@T*("`@("`-"B`@("`@("`@ M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T* M("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/33H@-'!X)SX-"B`@(`T* M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L M:6=N/3-$"<^#0H@(`T*("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H M=#L@4$%$1$E.1RU"3U143TTZ(#1P>"<^#0H@("`-"B`@("`@("`@("`@("`@ M/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!4 M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@ M(`T*("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!4:6UE"<^ M#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@(`T*("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!! M1$1)3D"<^#0H@ M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)TQ) M3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L M:6=N/3-$8V5N=&5R/@T*("`@("`-"B`@("`@("`@("`@("`@("`@(#QD:78@ M6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SY%>&5R8VES90T*("`@("`-"B`@("`@("`@("`@("`@("!06QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S M;VQI9"<^#0H@("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ) M3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L M:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@/&1I=B!S='EL M93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E3 M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@ M,'!T)R!A;&EG;CTS1&-E;G1E6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5. M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2 M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`-"B`@("`@("`@ M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@ M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494 M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E6QE/3-$)TQ)3D4M M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$8V5N=&5R/@T*(`T*("`@("`@("`@("`@("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SY#;VYT65A6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!! M1$1)3D"<^#0H@ M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)TQ) M3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L M:6=N/3-$8V5N=&5R/@T*("`@("`-"B`@("`@("`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SY/=71S=&%N9&EN9RP-"B`@#0H@("`@("`@("`@("`@("`@1&5C M96UB97(@,S$L(#(P,3`\+V9O;G0^#0H@(`T*("`@("`@("`@("`@("`\+V1I M=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@ M("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ+#@W,2PV,#`\ M+V9O;G0^#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@ M("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,24@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T* M("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T* M("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXS M+C0U/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@ M("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T* M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXD/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^ M#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,3`E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXM M/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@ M("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@ M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXQ+#4P,"PP,#`\+V9O;G0^#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X- M"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXP+C4P/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@(#PO M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"=415A4+4%,24=..B!R M:6=H="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$P)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@ M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T* M("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T* M("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@ M/&9O;G0@6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=4 M15A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H M="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT M6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F M="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXM/"]F;VYT/@T* M("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@ M;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D"<^#0H@("`-"B`@ M("`@("`@("`@("`@/&9O;G0@"<^ M#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$P)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@4$%$1$E.1RU"3U14 M3TTZ(#)P>"<^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[(%!!1$1)3D"<^#0H@("`-"B`@("`@("`@("`@("`@ M/&9O;G0@"<^#0H@#0H@("`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS M1"=415A4+4%,24=..B!R:6=H=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@ M("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M(%!!1$1)3D"<^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@"<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"=415A4+4%,24=. M.B!R:6=H=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@("`-"B`@("`@("`@ M("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)V)A8VMG6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H M="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"=415A4+4%, M24=..B!R:6=H="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L M:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@ M("`@("`@/&9O;G0@6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXM/"]F;VYT/@T*("`-"B`@ M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@ M("`@("`@("`@/&9O;G0@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXU+#6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@ M("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXP+C,S M/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@ M("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$P)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@(`T*("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T* M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SY%>&5R8VES960\+V9O;G0^#0H@(`T*("`@("`@ M("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T* M("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@ M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXH-C8P+#`P,#PO9F]N=#X-"B`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@ M("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXP+C4P/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@(#PO M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"=415A4+4%,24=..B!R M:6=H="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@("8C,38P.PT*("`@("`-"B`@ M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY%>'!I"<^#0H@ M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@(`T*("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y' M+4)/5%1/33H@,G!X)SX-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@(`T* M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U!!1$1)3D"<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$P)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@4$%$1$E. M1RU"3U143TTZ(#)P>"<^#0H@("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@ M("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@ M"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@(`T* M("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q% M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`- M"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@("`@#0H@("`@("`@("`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR+#@X,"PP M,#`\+V9O;G0^#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@ M("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,24@"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U!! M1$1)3D"<^#0H@#0H@("`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"=415A4 M+4%,24=..B!R:6=H=#L@4$%$1$E.1RU"3U143TTZ(#1P>"<^#0H@("`-"B`@ M("`@("`@("`@("`@/&9O;G0@"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)U!!1$1)3D"<^#0H@#0H@("`@("`@("`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"=4 M15A4+4%,24=..B!R:6=H=#L@4$%$1$E.1RU"3U143TTZ(#1P>"<^#0H@("`- M"B`@("`@("`@("`@("`@/&9O;G0@"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE M/3-$)U!!1$1)3D"<^#0H@#0H@("`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS M1"=415A4+4%,24=..B!R:6=H=#L@4$%$1$E.1RU"3U143TTZ(#1P>"<^#0H@ M("`-"B`@("`@("`@("`@("`@/&9O;G0@"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA2!4'0@0FQO8VM=/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TQ)3D4M M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$:G5S=&EF>3X-"B`@("`@#0H@("`@("`@(#QF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^3D]410T*("`@ M("`-"B`@("`@("`@,30@+2!214Q!5$5$(%!!4E19(%1204Y304-424].4SPO M9F]N=#X-"B`@(`T*("`@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)TQ) M3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L M:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@("`@/&9O;G0@2!T:&4@0V]M<&%N>2X\+V9O;G0^#0H@(`T* M("`@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF M>3X-"B`@("`-"B`@("`@("`@/&9O;G0@2!R96YT2XF(S$V,#LF(S$V,#M296YT(&5X<&5N6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY!2P@9F]R(&5X M<&5N2!A;'-O(&AA9"!A(&-O;G9E'!E;G-E6%B;&4@:&%S('!A'1087)T7S@T9C!E-V)B M7V9C-#1?-#8Q9%]A,C`S7S!A,S0W8V,S,#!C-`T*0V]N=&5N="U,;V-A=&EO M;CH@9FEL93HO+R]#.B\X-&8P93=B8E]F8S0T7S0V,61?83(P,U\P83,T-V-C M,S`P8S0O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"B`@("`@#0H@ M("`@("`@($-O;7!A;GD@2P@86YD(&-A M6QE/3-$)V1I6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\ M9F]N="!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!$25-0 M3$%9.B!I;FQI;F4G/E1H90T*(`T*("`@("`@("`@("`@("`@(')E8VQA6QE/3-$)U=)1%1( M.B`Q.'!T)SX-"B`@(`T*("`@("`@("`@("`@("`\9&EV/@T*(`T*("`@("`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T* M("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!S='EL M93TS1"=724142#H@,3AP="<^#0H@("`-"B`@("`@("`@("`@("`@/&1I=B!S M='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!-05)'24XM3$5&5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<^#0H@("`-"B`@("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C M9F9F9F9F.R!$25-03$%9.B!I;FQI;F4G/E1H90T*(`T*("`@("`@("`@("`@ M("`@(&5L:6UI;F%T:6]N(&]F("0S,3$L,#`P(&=A:6X@9G)O;2!L:71I9V%T M:6]N(&%N9`T*("`@("`-"B`@("`@("`@("`@("`@("!T:&4@8V]R2!O M9B!T:&4@9V%I;B!I6QE M/3-$)U=)1%1(.B`Q.'!T)SX-"B`@(`T*("`@("`@("`@("`@("`\9&EV/@T* M(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`-"B`@("`@("`@("`@("`@/"]D M:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@ M(#QT9"!S='EL93TS1"=724142#H@,3AP="<^#0H@("`-"B`@("`@("`@("`@ M("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!-05)'24XM3$5& M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H@("`-"B`@("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"="04-+1U)/54Y$ M+4-/3$]2.B`C9F9F9F9F.R!$25-03$%9.B!I;FQI;F4G/E1H90T*(`T*("`@ M("`@("`@("`@("`@(&1E8W)E87-E(&]F("0S,BPV,S,@<')E<&%I9"!C;VYS M=6QT:6YG(&5X<&5N6QE/3-$)T9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)TQ)3D4M M2$5)1TA4.B`Q+C(U.R<^#0H@#0H@("`@("`@("`@("`\=&0@6QE/3-$)U=)1%1(.B`Q.'!T)SX-"B`@(`T*("`@("`@("`@("`@("`\ M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU,1494.B`P M<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"B`@(`T*("`@("`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!3>6UB;VPL('-E M3X-"B`@#0H@("`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T)!0TM'4D]53D0M0T], M3U(Z("-F9F9F9F8[($1)4U!,05DZ(&EN;&EN92<^5&AE#0H@#0H@("`@("`@ M("`@("`@("`@:6YC"!L:6%B:6QI='D@6QE/3-$)U=)1%1(.B`Q.'!T)SX-"B`@(`T* M("`@("`@("`@("`@("`\9&EV/@T*(`T*("`@("`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]T M9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!S='EL93TS1"=724142#H@,3AP M="<^#0H@("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E. M1$5.5#H@,'!T.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P M="<^#0H@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N M="!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F.R!$25-03$%9 M.B!I;FQI;F4G/E1O#0H@("`@(`T*("`@("`@("`@("`@("`@(&1E8W)E87-E M(&$@<&%Y86)L92!T;R!33TX@365D:6-A;"!F;W(@)#4T+#@S,B!F;W(-"B`- M"B`@("`@("`@("`@("`@("!S97)V:6-E6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE"<^#0H@("`@#0H@("`@("`@("`@("`@(#QF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&-O;'-P86X] M,T0R('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY! M"<^#0H@(`T*("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SY!6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@ M("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXD/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@ M("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,3$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ+#8Q M,"PP-S@\+V9O;G0^#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`- M"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$Q)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@ M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!S='EL93TS1"=415A4+4%,24=..B!R M:6=H="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O M;G0@6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXR+#@U-2PX,C$\+V9O;G0^#0H@("`@(`T* M("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@ M(`T*("`@("`@("`@(#QT3PO9F]N=#X-"B`-"B`@ M("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@ M("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E/@T*("`@(`T*("`@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$Q)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@ M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$Q)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^ M#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$Q)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H M="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P M>"!S;VQI9"<^#0H@("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@/&1I=B!S M='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@ M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=( M5#H@,'!T)R!A;&EG;CTS1&-E;G1E3PO9F]N=#X\+V9O;G0^#0H@("`@(`T*("`@ M("`@("`@("`@("`@(#PO9&EV/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SY297!O"<^#0H@ M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0 M041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&-O M;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY#:&%N M9V4\+V9O;G0^#0H@("`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@ M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P M>"!S;VQI9"<^#0H@("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@ M6QE/3-$ M)V)A8VMG6QE/3-$)TQ)3D4M2$5) M1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@ M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$ M;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@ M("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`- M"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SY'96YE6QE/3-$)V)A8VMG6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$Q)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H M="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!S='EL93TS1"=415A4+4%,24=..B!R M:6=H="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY.970-"B`@(`T*("`@ M("`@("`@("`@("`@(&EN8V]M92!A=F%I;&%B;&4@=&\@8V]M;6]N('-H87)E M:&]L9&5R6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!S='EL93TS M1"=415A4+4%,24=..B!R:6=H="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@ M("`@("`@("`@/&9O;G0@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,S(S+#(T,#PO9F]N M=#X-"B`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@ M("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@ M("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH-"PU-#$L-3$X M/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@ M("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F M;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@ M/"]T6QE/3-$)V)A8VMG6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!4 M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@ M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@ M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXH,"XP.3PO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@ M("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T* M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!S='EL M93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@(`T*("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)U!!1$1)3D6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@("`-"B`@("`@("`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D"<^ M#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#)P>"!S;VQI9"<^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-0 M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P M<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O M;G0@"<^#0H@(`T*("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE"<^#0H@(`T*("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SY.970-"B`@(`T*("`@("`@("`@("`@("`@(&-A6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@ M("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXD/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@ M("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3$E('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXT-#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)TQ)3D4M2$5)1TA4 M.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2 M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F M=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$Q)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@(`T* M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$Q)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@ M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXH,3(Y+#`Y,3PO9F]N=#X-"B`@("`-"B`@("`@("`@("`@ M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE2!F:6YA;F-I;F<@86-T:79I=&EE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/@T* M("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@ M86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@ M("`-"B`@("`@("`@("`@("`@/&9O;G0@'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@ M("`@/&9O;G0@2!I6%B;&4@;V8@)#7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA2`H M4&]L:6-I97,I/&)R/CPO2!497AT($)L M;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=B!S='EL M93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E3 M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@ M,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@2!A8V-E<'1E9"!A8V-O=6YT:6YG('!R:6YC:7!L97,@*"8C.#(R,#M5 M+E,N#0H@#0H@("`@("`@($=!05`F(S@R,C$[*2!R97%U:7)E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY# M97)T86EN#0H@("`@#0H@("`@("`@('!R:6]R('!E6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q% M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X- M"B`@("`-"B`@("`@("`@/&9O;G0@2!C;VYS:61E0T*("`-"B`@ M("`@("`@8V]N=F5R=&EB;&4@=&\@8V%S:"D@<'5R8VAA2!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@ M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494 M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@ M6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I% M.B`Q,'!T)SY4:&4-"B`@("`@#0H@("`@("`@($-O;7!A;GD@F5D+B8C,38P.R8C,38P.TYO('!R;V1U8W0@:&%S(&)E96X@ M8V]N2!R M979I97<@;V8@6UE;G0@:&%S(&YO="!B965N M(&UA9&4@=VET:&EN(&-O;G1R86-T#0H@#0H@("`@("`@('1E6QE/3-$)TQ)3D4M M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@("`@/&9O;G0@2!R M97%U:7)E2!S=6-H('!R97!A M>6UE;G1S#0H@("`@#0H@("`@("`@('1O('1H96ER(&]U='-T86YD:6YG(&EN M=F]I8V5S(&]R('!A>2!T:&4@:6YV;VEC92!A;F0-"B`-"B`@("`@("`@8V]N M=&EN=64@=&\@8V%R2P@4&]L M:6-Y(%M0;VQI8WD@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA M6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@ M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@("`@ M/&9O;G0@2!E>&-E0T*("`-"B`@("`@("`@;6%Y(&)E('=R M:71T96X@;V9F+B!&;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R M,#$R#0H@#0H@("`@("`@(&%N9"`R,#$Q+"!N;R!A;&QO=V%N8V4@9F]R(&EN M=F5N=&]R>2!W87,@2!;4&]L:6-Y(%1E>'0@0FQO M8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-0 M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P M<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY00T*("`@("`-"B`@("`@("`@86YD(&5Q=6EP;65N="P@:6YC;'5D:6YG M('-I9VYI9FEC86YT(&EM<')O=F5M96YT'!E;G-E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T M)SY$97!R96-I871I;VX-"B`@("`-"B`@("`@("`@86YD(&%M;W)T:7IA=&EO M;B!E>'!E;G-E(&ES(')E8V]R9&5D(&]N(&$@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^/&9O;G0@3PO9F]N=#X\+V9O;G0^#0H@#0H@("`@("`@("`@("`@(#PO9&EV M/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\ M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/@T* M("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0T-R4@6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-0 M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P M<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN92<^57-E9G5L($QI=F5S M/"]F;VYT/CPO9F]N=#X-"B`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@ M(`T*("`@("`@("`@(#QT0T* M("`@(`T*("`@("`@("`@("`@("`@(&%N9"!E<75I<&UE;G0@*'EE87)S*3PO M9F]N=#X-"B`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@ M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^#0H@("`-"B`@("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SY&=7)N:71U6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI M9VX],T1T;W`@=VED=&@],T0T-R4^#0H@#0H@("`@("`@("`@("`@(#QD:78@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXW)B,Q-C`[/"]F;VYT M/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@ M(#QT6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TQ) M3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L M:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!4:6UE65A2!T;R!D M971E&ES="!W:&EC:"!M87D@ M:6YD:6-A=&4@:6UP86ER;65N="P@=&AE#0H@("`-"B`@("`@("`@0V]M<&%N M>2!W:6QL('!R97!A6EN9R!A;6]U M;G0@;V8@=&AE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY297-E87)C:`T*("`@("`- M"B`@("`@("`@86YD(&1E=F5L;W!M96YT(&-O'!E;G-E9"!A M2!I;F-U2!497AT($)L;V-K M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=B!S='EL93TS M1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q! M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T M)R!A;&EG;CTS1&IU6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E. M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@ M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@ M("`@("`@/&9O;G0@2!U2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"B`@("`@#0H@("`@ M("`@($-O;7!A;GD@;65A2!C871E9V]R:7IE6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY, M979E;`T*("`@("`-"B`@("`@("`@("`@("`@("`Q("8C.#(Q,3L@<75O=&5D M('!R:6-E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L M:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0S)3X-"B`@("`@#0H@ M("`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('-Y;6)O;"P@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@ M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!S>6UB;VPL('-E6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I% M.B`Q,'!T)SY4:&4-"B`@("`@#0H@("`@("`@(&9O;&QO=VEN9R!T86)L92!S M=6UM87)I>F5S(&9A:7(@=F%L=64@;65A6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX] M,T1T;W`@"<^#0H@(`T*("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE"<^ M#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U!!1$1)3D6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@("`@(`T* M("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q% M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T* M("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^3&5V96PF(S$V,#LS/"]F;VYT M/@T*("`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@ M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A M;&EG;CTS1'1O<"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@ M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@ M"<^#0H@(`T*("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)U!!1$1)3D6QE/3-$)V)A8VMG6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q% M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`- M"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)TQ)3D4M2$5) M1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@ M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$ M;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S@R,3([/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@ M("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q M)3X-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L M:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@ M("`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXD/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L M:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L M:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@ M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T* M("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED M=&@],T0Q)3X-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F M="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@("`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D(&%L:6=N/3-$6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V M86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO M='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X- M"B`@("`@#0H@("`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXD/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\ M+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D(&%L:6=N/3-$6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X- M"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!4 M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXS-C0L.#`R/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@("`@/"]D M:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@ M(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@#0H@("`@("`@("`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T M;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/@T*("`@(`T* M("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T M)SY4:&4-"B`@("`@#0H@("`@("`@(&9O;&QO=VEN9R!T86)L92!S=6UM87)I M>F5S(&9A:7(@=F%L=64@;65A6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@ M"<^#0H@(`T*("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE"<^#0H@(`T* M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@("`@(`T*("`@("`@ M("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@ M("`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M.R!&3TY4+5=%24=(5#H@8F]L9"<^3&5V96PF(S$V,#LS/"]F;VYT/@T*("`@ M#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^ M#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS M1'1O<"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@"<^#0H@(`T*("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE M/3-$)U!!1$1)3D6QE/3-$)V)A8VMG6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)TQ)3D4M M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S@R,3([/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@ M("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q M)3X-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L M:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@ M("`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXD/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L M:6=N/3-$6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V M86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@ M("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@ M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@ M=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$ M;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)V)A8VMG6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E. M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@ M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S@R,3([/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@ M("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q M)3X-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L M:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@ M("`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXD/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L M:6=N/3-$6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT M/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\ M=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1T;W`@=VED=&@],T0Q,"4^#0H@ M(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXT-#(L,S$Q/"]F;VYT/CPO9&EV/CPO=&0^/"]T6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`- M"B`@("`@("`@/&9O;G0@2!U<&]N('-H M:7!M96YT(&9R;VT@=&AE#0H@("`@(`T*("`@("`@("!M86YU9F%C='5R:6YG M(&9A8VEL:71Y(&EN(%=U>&DL($-H:6YA(&]R(&9R;VT@;W5R('=A2!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@ M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494 M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^/&9O;G0@ M6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SY4:&4-"B`@("`@#0H@("`@("`@($-O;7!A;GD@97-T:6UA M=&5S('1H92!F86ER('9A;'5E(&]F(&5A8V@@'!E;G-E(&ES(')E8V]G;FEZ960@8F%S960@;VX@87=A M2!B92!A9&IU&-EF5D(&%S(&%N M(&%D9&ET:6]N('1O#0H@("`-"B`@("`@("`@<&%I9"UI;B!C87!I=&%L+CPO M9F]N=#X\+V1I=CX\2!;4&]L:6-Y(%1E>'0@ M0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T M>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE2!M971H;V0@;V8@ M86-C;W5N=&EN9R!F;W(@:6YC;VUE#0H@(`T*("`@("`@("!T87AE"!B87-I'!E8W1E9"!T;R!R979E0T*("`@ M("`-"B`@("`@("`@9&EV:61I;F<@;F5T(&EN8V]M92`H;&]S2!T:&4@=V5I9VAT960@879E28C.#(Q-SMS(&-O;6UO;B!S=&]C:RP@ M:&%V92!B965N(&5X8VQU9&5D(&9R;VT@=&AE#0H@("`@(`T*("`@("`@("!C M86QC=6QA=&EO;BX@1F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R M,#$R+`T*("`@(`T*("`@("`@("!P;W1E;G1I86QL>2!I2!497AT($)L;V-K73PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/&1I=B!S='EL93TS1"=,24Y%+4A% M24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[ M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS M1&QE9G0^/&9O;G0@6QE/3-$)TQ) M3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L M:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5. M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2 M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@ M("`@/&9O;G0@2!D;V5S(&YO="!E>'!E8W0@=&AA="!A;GD@ M2!;4&]L:6-Y(%1E>'0@0FQO M8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-0 M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P M<'0G(&%L:6=N/3-$:G5S=&EF>3X\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T M)SY&6EN9R!C;VUM;VX@&-E0T* M("`@#0H@("`@("`@(&ENF5D('1O#0H@("`@(`T*("`@("`@("!I;G1E'!E;G-E(&]V97(@=&AE(&QI9F4@;V8@=&AE(&YO=&4@=7-I;F<@=&AE#0H@ M#0H@("`@("`@(&5F9F5C=&EV92!I;G1E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA"<^#0H@("`@#0H@("`@("`@("`@("`@("8C,38P M.PT*("`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H@("`-"B`@("`@("`@("`@("`@)B,Q-C`[ M#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@ M(#QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@ M6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@("`- M"B`@("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^1&5C96UB97(-"B`@("`-"B`@ M("`@("`@("`@("`@("`@(#,Q+"`R,#$R/"]F;VYT/@T*("`@("`-"B`@("`@ M("`@("`@("`@("`\+V1I=CX-"B`@("`-"B`@("`@("`@("`@("`@/"]D:78^ M#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@ M"<^#0H@(`T*("`@("`@("`@("`@("`F(S$V,#L-"B`@("`@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@(`T*("`@("`@("`@("`@("`\ M9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@ M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE. M+5))1TA4.B`P<'0G/@T*("`@#0H@("`@("`@("`@("`@("`@/&1I=B!S='EL M93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E3 M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@ M,'!T)R!A;&EG;CTS1&-E;G1E6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@ M("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@ M("`@("`F(S$V,#L-"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T* M("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T* M("`@("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@ M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@ M("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXD/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@ M#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!I M9#TS1%1!0C$M,"!S='EL93TS1"=-05)'24XM3$5&5#H@-W!T)SX\+V9O;G0^ M,2PQ,3,L,C,U/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@ M#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T* M(`T*("`@("`@("`@("`@("`F(S$V,#L-"B`@("`@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT M6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY,96%S96AO;&0-"B`@("`-"B`@("`@ M("`@("`@("`@("!I;7!R;W9E;65N=#PO9F]N=#X-"B`-"B`@("`@("`@("`@ M("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@ M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@("`@ M#0H@("`@("`@("`@("`@("8C,38P.PT*("`@("`-"B`@("`@("`@("`@(#PO M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,24@"<^ M#0H@("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@ M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R M<'@@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!I9#TS1%1!0C$M,R!S='EL M93TS1"=-05)'24XM3$5&5#H@,S,N,G!T)SX\+V9O;G0^-#DL,30W/"]F;VYT M/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\ M=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^#0H@(`T*("`@("`@("`@ M("`@("`F(S$V,#L-"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T* M("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)TU!4D=)3BU,1494.B`S-"XT-7!T)SX\+V9O;G0^-#DL,30W/"]F M;VYT/@T*("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/ M33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@("8C,38P.PT*("`@("`-"B`@ M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@/"]T6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!I9#TS1%1!0C$M-2!S='EL93TS M1"=-05)'24XM3$5&5#H@,C8N-35P="<^/"]F;VYT/C0T-BPS.#(\+V9O;G0^ M#0H@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@ M("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@ M("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@ M("`@#0H@("`@("`@("`@("`@("8C,38P.PT*("`@("`-"B`@("`@("`@("`@ M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,24@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$58 M5"U!3$E'3CH@;&5F="<^#0H@(`T*("`@("`@("`@("`@("`F(S$V,#L-"B`@ M("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)TU!4D=)3BU, M1494.B`R-"XS-7!T)SX\+V9O;G0^*#@Y+#6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E' M3CH@;&5F="<^#0H@(`T*("`@("`@("`@("`@("`F(S$V,#L-"B`@("`@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]- M.B!B;&%C:R`R<'@@6QE/3-$)TU!4D=)3BU,1494.B`R M-2XV<'0G/CPO9F]N=#XH,C`L-S$X/"]F;VYT/@T*("`@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A M<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F M;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@ M/"]T6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@#0H@("`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/@T* M("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX- M"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SX\9F]N="!I9#TS1%1!0C$M.2!S='EL93TS1"=-05)'24XM M3$5&5#H@-"XU<'0G/CPO9F]N=#XS-38L-C4V/"]F;VYT/@T*("`-"B`@("`@ M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[ M(%1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/@T*("`-"B`@ M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@("`@ M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SX\9F]N="!I9#TS1%1!0C$M,3`@"<^#0H@(`T*("`@("`@ M("`@("`@("`F(S$V,#L-"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`\+W1A8FQE/CQS<&%N M/CPO'0@0FQO8VM= M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\=&%B;&4@8V5L;'!A M9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS1#$P,"4@6QE/3-$)U!! M1$1)3D6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&-O;'-P86X],T0R M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C M:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@ M8F]L9"<^3&5V96PF(S$V,#LQ/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`@ M(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@ M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1'1O<"!S='EL93TS1"=0 M041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L M:6=N/3-$;&5F="!V86QI9VX],T1T;W`@"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P M>"!S;VQI9"<^#0H@("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)U!!1$1) M3D6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^ M5&]T86P\+V9O;G0^#0H@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N M/3-$;&5F="!V86QI9VX],T1T;W`@"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY#87-H#0H@("`@#0H@("`@("`@ M("`@("`@("`@86YD(&-A6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$ M;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@ M("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD M/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI M9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@("`@("`@(#QD M:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/@T* M("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXU-#PO9F]N=#X-"B`@("`@#0H@ M("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@ M("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1'1O M<"!W:61T:#TS1#$E/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q M)3X-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI M9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@("`@("`@(#QF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX] M,T1T;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L M:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@ M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T* M("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED M=&@],T0Q)3X-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)V)A8VMG6QE/3-$)TQ) M3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L M:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S@R,3([/"]F M;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F M="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@("`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T M;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/@T*("`@(`T* M("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!4 M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXS-C0L.#`R/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@("`@/"]D M:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@ M(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@#0H@("`@("`@("`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M(#PO='(^#0H@(`T*("`@("`@("`\+W1A8FQE/CQT86)L92!C96QL<&%D9&EN M9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)2!S='EL93TS1"=& M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;B<^#0H@(`T*("`@("`@("`@(#QT6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^ M3&5V96PF(S$V,#LQ/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`@(#PO9&EV M/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\ M=&0@86QI9VX],T1L969T('9A;&EG;CTS1'1O<"!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$ M;&5F="!V86QI9VX],T1T;W`@"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI M9"<^#0H@("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^5&]T86P\ M+V9O;G0^#0H@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F M="!V86QI9VX],T1T;W`@"<^ M#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SY#87-H#0H@("`@#0H@("`@("`@("`@("`@ M("`@86YD(&-A6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V M86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@("`@("`@ M(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT M/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S@R,3([/"]F;VYT/@T*("`@ M(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX] M,T1T;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L M:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@] M,T0Q)3X-"B`@("`@#0H@("`@("`@("`@("`@(#QD:78@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/@T*("`@(`T*("`@("`@("`@ M("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N M/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@("`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@] M,T0Q)3X-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V M86QI9VX],T1T;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D(&%L:6=N/3-$6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SY$97)I=F%T:79E#0H@("`@(`T*("`@("`@("`@ M("`@("`@(&QI86)I;&ET>3PO9F]N=#X-"B`@("`-"B`@("`@("`@("`@("`@ M/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@ M("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E M/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S@R,3([/"]F;VYT/@T*("`@ M(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX] M,T1T;W`@=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L M:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@] M,T0Q)3X-"B`@("`@#0H@("`@("`@("`@("`@(#QD:78@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/@T*("`@(`T*("`@("`@("`@ M("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS M1#$E/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@'0@0FQO8VM=/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E M;&QS<&%C:6YG/3-$,"!W:61T:#TS1#DW)2!S='EL93TS1"=&3TY4+49!34E, M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^#0H@("`- M"B`@("`@("`@("`\='(^#0H@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(Y)2!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+5=%24=(5#H@8F]L9"<^/&9O;G0@3PO9F]N M=#X\+V9O;G0^#0H@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@ M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/@T*("`@#0H@("`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0T-R4@6QE/3-$)TQ)3D4M2$5) M1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@ M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$ M;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN92<^57-E9G5L($QI=F5S/"]F;VYT/CPO9F]N M=#X-"B`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@ M(#QT0T*("`@(`T*("`@("`@ M("`@("`@("`@(&%N9"!E<75I<&UE;G0@*'EE87)S*3PO9F]N=#X-"B`-"B`@ M("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@ M("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$-"4^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY&=7)N M:71U6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T* M("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED M=&@],T0T-R4^#0H@#0H@("`@("`@("`@("`@(#QD:78@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXW)B,Q-C`[/"]F;VYT/@T*("`@(`T*("`@ M("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$)TQ)3D4M2$5)1TA4 M.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2 M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F M=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X-&8P93=B M8E]F8S0T7S0V,61?83(P,U\P83,T-V-C,S`P8S0-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO.#1F,&4W8F)?9F,T-%\T-C%D7V$R,#-?,&$S-#=C M8S,P,&,T+U=O'0O:'1M;#L@8VAA'0^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#)P>"!S;VQI9"<^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M/@T*("`@#0H@("`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A% M24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[ M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS M1&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!! M1$1)3D6QE/3-$)V)A8VMG6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SY%<75I<&UE;G0\+V9O;G0^#0H@(`T*("`@ M("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M/@T*("`@("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@ M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX- M"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXD/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@ M("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,3(E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N M="!I9#TS1%1!0C$@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T* M("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@6QE/3-$)TU! M4D=)3BU,1494.B`S,RXR<'0G/CPO9F]N=#XT-"PP,#`\+V9O;G0^#0H@(`T* M("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@ M("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@ M("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M,B4@6QE/3-$)TU!4D=)3BU,1494.B`S-"XT<'0G/CPO M9F]N=#XT-"PP,#`\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@ M("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)V)A8VMG"<^#0H@("`@#0H@("`@("`@ M("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SY&=7)N:71U6QE/3-$)U!!1$1) M3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P M>"!S;VQI9#L@5$585"U!3$E'3CH@"<^#0H@("`-"B`@("`@("`@("`@("`@)B,Q-C`[ M#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N M="!I9#TS1%1!0C$M-"!S='EL93TS1"=-05)'24XM3$5&5#H@,S0N-#5P="<^ M/"]F;VYT/C0Y+#$T-SPO9F]N=#X-"B`@(`T*("`@("`@("`@("`@/"]T9#X- M"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H@(`T*("`@("`@("`@("`@("`F M(S$V,#L-"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SY3=6)T;W1A;#PO9F]N=#X-"B`-"B`@("`@("`@("`@("`@/"]D:78^ M#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@ M("`@("`@("8C,38P.PT*("`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@ M#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@ M6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@ M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@6QE/3-$ M)TU!4D=)3BU,1494.B`Q-RXX<'0G/CPO9F]N=#XQ+#(P-BPS.#(\+V9O;G0^ M#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@ M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,24@6QE/3-$)V)A M8VMG"<^#0H@("`@#0H@("`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY,97-S.@T*("`@ M("`-"B`@("`@("`@("`@("`@("!A8V-U;75L871E9"!D97!R96-I871I;VX\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@ M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,24@"<^#0H@("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@ M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C M:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!I9#TS1%1!0C$M-R!S M='EL93TS1"=-05)'24XM3$5&5#H@,C0N,S5P="<^/"]F;VYT/B@X.2PW,C8\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/ M5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/@T*("`-"B`@("`@("`@("`@ M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,24@"<^#0H@ M("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@("`@ M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@ M6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!I9#TS1%1!0C$M."!S='EL93TS M1"=-05)'24XM3$5&5#H@,C4N-G!T)SX\+V9O;G0^*#(P+#"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SY00T*("`@#0H@("`@("`@("`@("`@("`@86YD(&5Q=6EP M;65N="P@;F5T/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`@(#PO9&EV/@T* M("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H@("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@ M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX-"B`@ M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@ M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B M;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX-"B`@(`T*("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0@0FQO8VM= M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\=&%B;&4@8V5L;'!A M9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS1#DY)2!S='EL93TS M1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;B<^#0H@(`T*("`@("`@("`@(#QT"<^#0H@("`@#0H@("`@("`@("`@("`@("8C,38P.PT* M("`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H@("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@ M("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT M9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E. M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@ M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@("`-"B`@ M("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^1&5C96UB97(-"B`@("`-"B`@("`@ M("`@("`@("`@("`@(#,Q+"`R,#$R/"]F;VYT/@T*("`@("`-"B`@("`@("`@ M("`@("`@("`\+V1I=CX-"B`@("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@ M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^ M#0H@(`T*("`@("`@("`@("`@("`F(S$V,#L-"B`@("`@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@(`T*("`@("`@("`@("`@("`\9&EV M('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5)) M1TA4.B`P<'0G/@T*("`@#0H@("`@("`@("`@("`@("`@/&1I=B!S='EL93TS M1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q! M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T M)R!A;&EG;CTS1&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@ M("`F(S$V,#L-"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@ M("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@("`@ M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@("`@ M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXD/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@ M("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!I9#TS M1%1!0C$M,3(@6QE/3-$)U!!1$1)3D6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`- M"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@ M5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^#0H@(`T*("`@ M("`@("`@("`@("`F(S$V,#L-"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1) M3D6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!I9#TS1%1!0C$M,34@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@ M("`@("`F(S$V,#L-"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T* M("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T* M("`@("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@ M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@ M("`@#0H@("`@("`@("`@("`@("8C,38P.PT*("`@("`-"B`@("`@("`@("`@ M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,3(E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@ M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SX\9F]N="!I9#TS1%1!0C$M,38@6QE/3-$)U!!1$1)3D6QE/3-$)TQ) M3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L M:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UEF%T:6]N/"]F;VYT/@T* M("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@ M6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXI/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^ M#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@"<^#0H@("`-"B`@ M("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X- M"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SX\9F]N="!I9#TS1%1!0C$M,3@@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXI/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@ M#0H@("`@("`@("`@/"]T6QE/3-$ M)V)A8VMG"<^#0H@("`@#0H@("`@("`@("`@("`@(#QD:78@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY);G1A;F=I M8FQE6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[ M(%1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/@T*("`-"B`@ M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@("`@ M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SX\9F]N="!I9#TS1%1!0C$M,3D@"<^#0H@(`T*("`@("`@ M("`@("`@("`F(S$V,#L-"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[(%!!1$1)3D'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA6QE M/3-$)T9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1) M3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@(`T* M("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q% M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*("`@#0H@("`@("`@("`@ M("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U) M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[ M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)V)A M8VMG6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SY!8V-O=6YT6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/@T*("`@("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@ M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q,B4@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@ M("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@ M("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M,B4@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/@T*(`T*("`@("`@("`@("`@("`F(S$V,#L-"B`@("`@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@ M("`@(#QT6QE/3-$)TQ)3D4M2$5) M1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@ M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$ M:G5S=&EF>3X-"B`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@ M("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@ M("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@ M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@ M("`F(S$V,#L-"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SY!8V-R=65D#0H@(`T*("`@("`@("`@("`@("`@(&EN=&5R97-T M/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@ M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,24^#0H@("`@(`T*("`@("`@("`@("`@("`F(S$V M,#L-"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@)B,Q-C`[ M#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/@T*("`@("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@ M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q,B4@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`F(S$V,#L- M"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO M='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$)U!!1$1)3D6QE/3-$)TQ)3D4M M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F M="<^#0H@(`T*("`@("`@("`@("`@("`F(S$V,#L-"B`@("`@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C M:R`R<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[(%!!1$1)3D6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@ M;&5F="<^#0H@(`T*("`@("`@("`@("`@("`F(S$V,#L-"B`@("`@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B M;&%C:R`R<'@@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[(%!!1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5. M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2 M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE"<^#0H@("`-"B`@("`@("`@ M("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`- M"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4 M+4%,24=..B!L969T)SX-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@("`-"B`@("`@("`@ M("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`- M"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4 M+4%,24=..B!L969T)SX-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@(`T*("`@("`@("`@("`@("`F M(S$V,#L-"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@(#PO='(^#0H@(`T*("`@("`@("`\+W1A8FQE/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE M/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=( M5#H@8F]L9"<^)B,Q-C`[/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@(#PO M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@8V]L6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#)P>"!S;VQI9"<^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T M>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@ M/&9O;G0@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E. M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@ M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@ M("`@("`@("`@("`@/&9O;G0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B,Q M-C`[/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@ M("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H@("`-"B`@("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@ M8F]L9"<^,C`Q,3PO9F]N=#X-"B`-"B`@("`@("`@("`@("`@/"]D:78^#0H@ M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^ M#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE2!.;W1E(%!A>6%B;&4@=&\@2DU*($9I;F%N8VEA;"P-"B`@(`T*("`@("`@ M("`@("`@("`@('5N2`R M,BP@,C`Q-#PO9F]N=#X-"B`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`- M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI M9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@("`- M"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L M:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@ M("`@("`@/&9O;G0@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M2!.;W1E(%!A>6%B;&4@=&\@07-H97(@16YT97)P6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^ M#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)V)A8VMG6QE/3-$)TQ) M3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$;&5F=#X-"B`@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6UE;G0@9'5E(&]N($IU;F4@,2P@,C`Q M,CPO9F]N=#X-"B`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@ M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1R M:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@("`-"B`@("`@ M("`@("`@("`@/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O M;G0@6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXT-2PP,#`\+V9O;G0^#0H@(`T*("`@("`@ M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@ M("`@("`@(#QT6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E. M1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`@("`-"B`@ M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6UE M;G0@9'5E(&]N($%U9W5S="`W+"`R,#$R/"]F;VYT/@T*("`@(`T*("`@("`@ M("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T* M("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@ M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXM/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@ M("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$R)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@(`T*("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T* M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SY#;VYV97)T:6)L90T*(`T*("`@("`@("`@ M("`@("`@(%!R;VUI6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@ M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXU,RPP,#`\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@ M("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@+3$X<'0[($1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,3AP=#L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`@("`-"B`@("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6UE;G0@9'5E(&]N($UA2!C;VYV97)T960@:6X-"B`-"B`@("`@("`@("`@ M("`@("!*86YU87)Y(#(P,3,\+V9O;G0^#0H@(`T*("`@("`@("`@("`@("`\ M+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`- M"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXW+#4P,#PO M9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@ M("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R M)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@(`T*("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)V)A8VMG6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!4 M15A4+4E.1$5.5#H@+3$X<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,3AP=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`@ M("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXT,BPU,#`\+V9O;G0^#0H@(`T*("`@("`@("`@("`@ M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXM/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE2!.;W1E(%!A M>6%B;&4@=&\@07-H97(@16YT97)P6UE;G0@9'5E(&]N#0H@#0H@("`@("`@("`@("`@("`@075G=7-T)B,Q M-C`[,C6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO M='(^#0H@(`T*("`@("`@("`@(#QT2!.;W1E(%!A>6%B;&4@=&\@5$-!($=L;V)A;"!#2!A M;&P@;V8@=&AE($-O;7!A;GDF(S@R,3<[6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@ M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXV,BPQ-C4\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@ M("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX- M"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXM/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@ M#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T* M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SY#;VYV97)T:6)L90T*(`T*("`@("`@("`@("`@("`@ M(%!R;VUI6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^#0H@(`T*("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ,#`L,#`P/"]F;VYT/@T*("`@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@ M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$"<^ M#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T* M("`@("`@("`@(#QT6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS M1"=415A4+4%,24=..B!R:6=H="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO M='(^#0H@(`T*("`@("`@("`@(#QT6QE M/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!B;&%C:R`R<'@@"<^#0H@(`T*("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE"<^#0H@(`T*("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P M>"!S;VQI9#L@5$585"U!3$E'3CH@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/@T*("`-"B`@("`@("`@ M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@/"]T6QE/3-$)V)A8VMG6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@#0H@("`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/@T* M("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX- M"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXR,38L-S4U/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!0041$24Y'+4)/5%1/33H@-'!X)SX-"B`@#0H@("`@("`@("`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D(&%L:6=N/3-$"<^#0H@(`T*("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\X-&8P93=B8E]F8S0T7S0V,61?83(P,U\P83,T-V-C,S`P8S0-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#1F,&4W8F)?9F,T-%\T-C%D M7V$R,#-?,&$S-#=C8S,P,&,T+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0@0FQO M8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\=&%B;&4@8V5L M;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS1#$P,"4@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SY&86ER#0H@("`@#0H@("`@("`@("`@("`@("`@=F%L=64@870@ M1&5C96UB97(F(S$V,#LS,2P@,C`Q,#PO9F]N=#X-"B`@("`@#0H@("`@("`@ M("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@ M("`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1T;W`@=VED M=&@],T0Q)3X-"B`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@ M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ-C`L-C4Y M/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@ M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS M1&QE9G0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^#0H@("`@(`T*("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/@T*("`-"B`@("`@ M("`@("`@("`@/&9O;G0@6QE/3-$)TQ)3D4M M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXX-#`L-#0R/"]F;VYT/@T*("`@("`-"B`@ M("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@ M("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P M('=I9'1H/3-$,24^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY$96-R96%S90T* M("`@#0H@("`@("`@("`@("`@("`@:6X@=F%L=64\+V9O;G0^#0H@("`-"B`@ M("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@ M("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X- M"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E M/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH-#`L,#,P/"]F;VYT M/@T*("`@("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@ M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@ M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^#0H@("`@(`T*("`@("`@("`@("`@ M("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5. M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2 M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SY296-L87-S:69I8V%T:6]N#0H@#0H@("`@ M("`@("`@("`@("`@9G)O;2!L:6%B:6QI='D@=&\@97%U:71Y(&%S(&$@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@ M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P M>"!S;VQI9"<^#0H@#0H@("`@("`@("`@("`@(#QD:78@6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X- M"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY& M86ER#0H@("`@#0H@("`@("`@("`@("`@("`@=F%L=64@870@1&5C96UB97(F M(S$V,#LS,2P@,C`Q,3PO9F]N=#X-"B`@("`@#0H@("`@("`@("`@("`@(#PO M9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@ M("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X- M"B`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO M='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X- M"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@ M(#QT6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/@T*("`@(`T* M("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$)U!!1$1)3D2!T;R!E<75I='D@87,@82!R97-U;'0@;V8@;F]T M90T*(`T*("`@("`@("`@("`@("`@(&-O;G9E6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI M/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@ M("`@("`@(#QT6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SY&86ER#0H@("`@#0H@("`@("`@("`@("`@("`@ M=F%L=64@870@1&5C96UB97(@,S$L(#(P,3(\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@ M("`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1T;W`@=VED M=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX-"B`@("`- M"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D M;W5B;&4G/@T*("`@("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=, M24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@ M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A M;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)TQ)3D4M M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N M/3-$6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXS-C0L.#`R/"]F;VYT/@T*("`@("`-"B`@ M("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@ M("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P M('=I9'1H/3-$,24@"<^#0H@ M("`-"B`@("`@("`@("`@("`@/&9O;G0@"<^#0H@("`@#0H@("`@("`@("`@("`@("8C,38P.PT*("`@("`-"B`@("`@ M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@8V]L6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R M)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^,C`Q,CPO9F]N=#X-"B`@ M("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H@("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@ M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!C M;VQS<&%N/3-$,R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U)2!S='EL93TS M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^,C`Q,3PO9F]N M=#X-"B`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H@("`-"B`@("`@("`@("`@("`@)B,Q-C`[ M#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`\ M+W1R/@T*("`-"B`@("`@("`@("`\='(@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SY2:7-K#0H@("`@#0H@("`@("`@("`@("`@("`@9G)E92!I;G1E6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SY%>'!E8W1E9`T*("`@#0H@("`@("`@("`@("`@ M("`@;&EF92`H>65A6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXP+C`Q/"]F;VYT/@T*("`@("`-"B`@ M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$-24^#0H@("`@(`T*("`@("`@("`@("`@("`\ M9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@ M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE. M+5))1TA4.B`T+C5P="<@86QI9VX],T1C96YT97(^#0H@("`@(`T*("`@("`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SYT M;SPO9F]N=#X-"B`@("`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@ M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$-24^#0H@("`@(`T*("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY$:79I9&5N9`T* M("`@#0H@("`@("`@("`@("`@("`@66EE;&0\+V9O;G0^#0H@("`@(`T*("`@ M("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E M/@T*("`@("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@ M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0U)3X-"B`@("`@#0H@("`@("`@("`@("`@(#QD:78@ M6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXP)3PO9F]N=#X-"B`@(`T*("`@("`@("`@ M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0U)2!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G/@T* M("`-"B`@("`@("`@("`@("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@("`@ M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)3X-"B`@("`@#0H@("`@("`@("`@("`@("8C,38P.PT*("`@ M("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@/"]T6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SY6;VQA=&EL:71Y/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`@(#PO M9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[(%1%6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU,1494.B`P<'0[($U!4D=) M3BU224=(5#H@,'!T)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR,3DE/"]F;VYT/@T*("`@("`- M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`@(`T*("`@("`@("`@("`@ M("`F(S$V,#L-"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`-"B`@("`@("`@("`@("`@/&9O M;G0@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X-&8P M93=B8E]F8S0T7S0V,61?83(P,U\P83,T-V-C,S`P8S0-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO.#1F,&4W8F)?9F,T-%\T-C%D7V$R,#-?,&$S M-#=C8S,P,&,T+U=O'0O:'1M;#L@8VAA'0^/'1A8FQE(&-E;&QP861D M:6YG/3-$,"!C96QL6QE/3-$ M)T9/3E0M1D%-24Q9.B!T:6UE"<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@ M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[(%!!1$1)3D"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@ M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@("`-"B`@("`@("`@ M("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SY%>&5R8VES90T*("`@("`-"B`@("`@("`@ M("`@("`@("!06QE/3-$)U!! M1$1)3D6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@("`@(`T*("`@("`@("`@("`@("`\ M9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@ M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@ M("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U) M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[ M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R M/@T*("`-"B`@("`@("`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y% M+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG M;CTS1&-E;G1E6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*(`T*("`@("`@("`@("`@("`@ M("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SY#;VYT65A6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[(%!!1$1)3D"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@ M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@("`-"B`@("`@("`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY/=71S=&%N9&EN9RP-"B`@#0H@("`@ M("`@("`@("`@("`@1&5C96UB97(@,S$L(#(P,3`\+V9O;G0^#0H@(`T*("`@ M("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@ M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXQ,BPX,S0L-S4P/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X- M"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/@T*("`-"B`@("`@("`@("`@ M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,3`E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@ M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXP+C(P/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@ M("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^ M#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@ M/&9O;G0@6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXY+#,P-RPP,#`\+V9O;G0^#0H@("`@ M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@ M("`@("`@("`@/&9O;G0@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXP+C,T/"]F;VYT/@T* M("`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\ M=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T* M("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@(`T*("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$P)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@(`T* M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P M)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@(`T*("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@ M("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@ M("`@("`@("8C,38P.PT*("`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@ M#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T* M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SY%>'!I"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$58 M5"U!3$E'3CH@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T* M("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T M>6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@(`T*("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL M93TS1"=415A4+4%,24=..B!R:6=H=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<^ M#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[(%!!1$1)3D"<^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@ M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX- M"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXR+C0U/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@(#PO=&0^ M#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H M="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@ M(#QT6QE/3-$)U!!1$1)3D"<^ M#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!0041$ M24Y'+4)/5%1/33H@,G!X)SX-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1) M3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXP+C$X/"]F;VYT M/@T*("`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@ M("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!! M1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXP+CDX/"]F M;VYT/@T*("`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@ M("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M(%!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/ M5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@ M("`@(#QT6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI)B,Q-C`[/"]F;VYT/@T*("`-"B`@ M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX] M,T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@("`-"B`@ M("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L M:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@ M("`@("`@/&9O;G0@6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL M93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O M;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$)U!!1$1)3D6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^#0H@(`T*("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXH-2PV-S,L-S4P/"]F;VYT/@T*(`T*("`@("`@ M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H@(`T*("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@(`T*("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"=4 M15A4+4%,24=..B!R:6=H=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@("`- M"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!! M1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@(`T*("`@("`@("`@("`@("`F M(S$V,#L-"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/ M5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@ M("`@(#QT6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SY/=71S=&%N9&EN9RP-"B`@#0H@("`@("`@("`@("`@ M("`@1&5C96UB97(@,S$L(#(P,3(\+V9O;G0^#0H@(`T*("`@("`@("`@("`@ M("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D(&%L:6=N/3-$"<^#0H@(`T*("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L M:6=N/3-$"<^#0H@(`T*("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H M=#L@4$%$1$E.1RU"3U143TTZ(#1P>"<^#0H@("`-"B`@("`@("`@("`@("`@ M/&9O;G0@"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U!!1$1)3D6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXQ+C$X/"]F;VYT/@T*("`@("`-"B`@("`@ M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@ M("`@("`@/&9O;G0@6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/33H@-'!X)SX-"B`@ M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@(`T*("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SY.=6UB97(-"B`-"B`@("`@("`@("`@("`@("!O9B!5;FET M"<^#0H@#0H@("`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SY!=F5R86=E/"]F;VYT/CPO9F]N=#X-"B`@("`@ M#0H@("`@("`@("`@("`@("`@/"]D:78^/&9O;G0@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[(%!!1$1)3D"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@ M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@("`-"B`@("`@("`@ M("`@("`@("`@(#QD:78@6QE/3-$)TQ)3D4M2$5)1TA4 M.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2 M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N M=&5R/@T*("`@(`T*("`@("`@("`@("`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@#0H@("`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY!9V=R96=A=&4\+V9O;G0^/"]F M;VYT/@T*("`@("`-"B`@("`@("`@("`@("`@("`\+V1I=CX\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@ M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@ M/&9O;G0@6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ+C`P/"]F;VYT/@T*("`@("`-"B`@ M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=. M.B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)V)A8VMG6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-0 M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P M<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H M="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$P)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@(`T*("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@ M("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O M;G0@6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4 M+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@"<^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U!!1$1)3D6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C M:R`R<'@@"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!0041$ M24Y'+4)/5%1/33H@,G!X)SX-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@ M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/33H@ M,G!X)SX-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@(`T*("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@(`T* M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY/=71S=&%N M9&EN9RP-"B`@#0H@("`@("`@("`@("`@("`@1&5C96UB97(@,S$L(#(P,3$\ M+V9O;G0^#0H@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O M;G0@6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXS+#,W,2PV,#`\+V9O;G0^#0H@("`@(`T* M("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L M:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@ M("`@("`@/&9O;G0@6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXP+C,Y/"]F;VYT/@T*("`@ M("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@ M;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL M93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@(`T*("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO M='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X- M"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX- M"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXP+C$U/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@(#PO=&0^ M#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H M="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT M6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXI)B,Q-C`[/"]F;VYT/@T*("`-"B`@("`@("`@ M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1R:6=H M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@("`-"B`@("`@("`@ M("`@("`@/&9O;G0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@ M/&9O;G0@6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=4 M15A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO M='(^#0H@(`T*("`@("`@("`@(#QT6QE M/3-$)U!!1$1)3D6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S M;VQI9#L@5$585"U!3$E'3CH@;&5F="<^#0H@(`T*("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXH-2PU-S`L-C`X/"]F;VYT/@T*(`T*("`@("`@("`@("`@ M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H@(`T*("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)U!!1$1) M3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[(%!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y' M+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X M)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@(`T*("`@("`@("`@("`@("`F M(S$V,#L-"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/ M5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@ M("`@(#QT6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SY/=71S=&%N9&EN9RP-"B`@#0H@("`@("`@("`@("`@ M("`@1&5C96UB97(@,S$L(#(P,3(\+V9O;G0^#0H@(`T*("`@("`@("`@("`@ M("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D(&%L:6=N/3-$"<^#0H@(`T*("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M(&%L:6=N/3-$"<^#0H@(`T*("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/33H@-'!X)SX- M"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D(&%L:6=N/3-$"<^#0H@(`T*("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/33H@-'!X M)SX-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D(&%L:6=N/3-$"<^#0H@(`T*("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/33H@ M-'!X)SX-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO M='(^#0H@(`T*("`@("`@("`\+W1A8FQE/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W M:61T:#TS1#DY)2!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^#0H@#0H@("`@("`@("`@/'1R/@T* M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4X M)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@("`-"B`@("`@ M("`@("`@("`@/&9O;G0@"<^#0H@("`-"B`@("`@("`@("`@("`@ M/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@(`T* M("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q% M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T* M("`@#0H@("`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=( M5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U! M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E M;G1E3PO9F]N=#X\+V9O;G0^#0H@("`@(`T*("`@("`@("`@("`@("`@(#PO9&EV M/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY297!O6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE M/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SY#:&%N9V4\+V9O;G0^#0H@("`@#0H@("`@("`@("`@("`@ M(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@ M("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D"<^ M#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#)P>"!S;VQI9"<^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-0 M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P M<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O M;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)V)A8VMG6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/@T*("`-"B`@("`@("`@ M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,3$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX- M"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXH,S8X+#8S,SPO9F]N=#X-"B`@("`-"B`@("`@("`@("`@(#PO M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4;W1A;`T*("`@ M("`-"B`@("`@("`@("`@("`@("!C=7)R96YT(&QI86)I;&ET:65S/"]F;VYT M/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXR+#(Y-"PR-S0\+V9O;G0^#0H@("`@(`T*("`@ M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N M/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T* M("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXU-C$L-30W/"]F;VYT/@T*("`@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL M93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O M;G0@6QE/3-$)V)A8VMG6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q% M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`- M"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXH,S$U+#4V,SPO9F]N=#X-"B`@("`-"B`@("`@ M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O M;G0@6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXH.3,P+#$X,#PO9F]N=#X-"B`@("`-"B`@ M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@ M/&9O;G0@6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,2PR-#4L-S0S/"]F;VYT/@T*(`T* M("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/@T*("`-"B`@ M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@/"]T6QE/3-$)T9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&-O;'-P86X],T0R M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C M:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY!6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D"<^#0H@(`T*("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE"<^#0H@#0H@("`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&-O;'-P86X],T0R M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C M:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY!"<^ M#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T* M("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXD/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@ M("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,3$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH-30L M.#,R/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@ M("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXD/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@ M#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3$E M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXU-RPP,#`\ M+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@ M("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$)TQ)3D4M2$5) M1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@ M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$ M;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@ M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXS+#6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXV-RPP-S(\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T M9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXS+#6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@ M("`@("`@(#QT6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXS,3$L,#`P/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=. M.B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/@T*("`-"B`@("`@("`@ M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1R:6=H M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@("`-"B`@("`@("`@ M("`@("`@/&9O;G0@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@ M(#QT6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@ M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T* M("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!S M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@(`T*("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q M)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@(`T*("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$Q)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@ M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@ M("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT M/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@/"]T M"<^#0H@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C M:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY!"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!! M1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&-O M;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SY!6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M(#PO='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`- M"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXD/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@ M("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3$E('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,BPU-C,L,#6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F M;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@ M/"]T6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SY.970-"B`@(`T*("`@("`@("`@("`@("`@(&-A6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@ M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXH-#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@ M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXS-#(L,C4V/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T M)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO M=&0^#0H@("`@#0H@("`@("`@("`@/"]T6QE/3-$)V)A8VMG6QE/3-$ M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!S='EL93TS1"=415A4+4%,24=. M.B!R:6=H="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!S='EL93TS1"=4 M15A4+4%,24=..B!R:6=H="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!S='EL93TS M1"=415A4+4%,24=..B!R:6=H="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&-L=61E9"!F'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X-&8P93=B8E]F8S0T M7S0V,61?83(P,U\P83,T-V-C,S`P8S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO.#1F,&4W8F)?9F,T-%\T-C%D7V$R,#-?,&$S-#=C8S,P,&,T M+U=O'0O M:'1M;#L@8VAA2!/9B!3:6=N:69I M8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A$971A:6PI("T@17-T:6UA=&5D M(%5S969U;"!,:79E2!0;&%N="!A;F0@17%U:7!M96YT M/&)R/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$2!A;F0@17%U:7!M96YT+"!%'1U65A'0^4VAO7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!!;F0@17%U:7!M96YT("A$971A:6PI("A54T0@ M)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@ M8V]L'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\X-&8P93=B8E]F8S0T7S0V,61?83(P,U\P M83,T-V-C,S`P8S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#1F M,&4W8F)?9F,T-%\T-C%D7V$R,#-?,&$S-#=C8S,P,&,T+U=O'0O:'1M;#L@8VAA'1U'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6%B;&4@06YD($%C8W)U960@3&EA8FEL:71I97,@ M*$1E=&%I;"D@*%531"`D*3QB7)O;&P@5&%X M97,L($-U'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S6%B;&4L($-U'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA2!O9B!!8V-O M=6YT6%B;&4@86YD(&%C8W)U960@;&EA8FEL:71I97,\+W1D/@T* M("`@("`@("`\=&0@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X-&8P M93=B8E]F8S0T7S0V,61?83(P,U\P83,T-V-C,S`P8S0-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO.#1F,&4W8F)?9F,T-%\T-C%D7V$R,#-?,&$S M-#=C8S,P,&,T+U=O'0O:'1M;#L@8VAA&EM=6T@6TUE;6)E6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%SF%T:6]N M(&]F($1E8G0@1&ES8V]U;G0@*%!R96UI=6TI/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XQ+#0R."PY-S@\'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!0'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S2!2871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E8W1E9"!$:79I9&5N9"!087EM96YT'0^,2!Y M96%R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,R!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^,"!Y96%R65A65A'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA2!.;W1E(%!A>6%B M;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2`R,BP@,C`Q-"!;365M8F5R73PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!.;W1E(%!A M>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2`S+"`R,#$S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA6%B;&4@*$1E=&%I;"D@+2!.;W1E2!.;W30M2!087EA M8FS0M2P@26YTT+5RT+5S="!R8730M3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M6%B;-"U+"!);G30M7+0M7-T(')A=-"U/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+C`P)3QS<&%N/CPO6%B;-"U+"!);G30M7+0M7-T M(')A=-"U/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+C`P)3QS M<&%N/CPO2!.;W30M2!087EA8FS0 MM2P@26YTT+5RT+5S="!R8730M3PO=&0^#0H@("`@("`@(#QT9"!C;&%S2!.;W30M2!087EA8FS0M2P@26YTT+5RT+5S="!R8730M3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$6%B;-"U+"!);G30M7+0M7-T(')A=-"U/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+C`P)3QS<&%N/CPO2!.;W30M2!087EA8FS0M2P@26YTT+5RT+5S M="!R8730M3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA6%B;&4@9F]R($EN9&5M;FEF M:6-A=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/CPO'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA2`H55-$("0I/&)R/CPO2!A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^,R!D87ES/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,"!Y M96%R3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E8W1E9"!L:69E("AY96%R65A65A3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X-&8P93=B M8E]F8S0T7S0V,61?83(P,U\P83,T-V-C,S`P8S0-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO.#1F,&4W8F)?9F,T-%\T-C%D7V$R,#-?,&$S-#=C M8S,P,&,T+U=O'0O:'1M;#L@8VAA'AO;B]';&]B M92!*;VEN="!696YT=7)E($%G'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!3;W5T:"P@3$Q#(%M- M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S2P@56YR96-O'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2P@ M4&QA;G0@86YD($5Q=6EP;65N="P@1W)O'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\X-&8P93=B8E]F8S0T7S0V,61?83(P,U\P83,T-V-C,S`P8S0- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#1F,&4W8F)?9F,T-%\T M-C%D7V$R,#-?,&$S-#=C8S,P,&,T+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^;VYE/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$2!3:&%R92UB87-E M9"!087EM96YT($%W87)D+"!/<'1I;VYS+"!%>&5R8VES97,@:6X@4&5R:6]D M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-S4L,#`P/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S&5R8VES92!0&5R8VES960@6TUE;6)E'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!.;W1E+"!3=6)S8W)I<'1I;VYS(%)E8V5I=F%B;&4@ M*&EN($1O;&QA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G0@07=A2!3:&%R92UB87-E9"!087EM96YT($%W M87)D+"!/<'1I;VYS+"!%>&5R8VES97,@:6X@4&5R:6]D+"!796EG:'1E9"!! M=F5R86=E($5X97)C:7-E(%!R:6-E("AI;B!$;VQL87)S('!E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!. M=6UB97(@;V8@4VAA2!3:&%R92UB87-E9"!0 M87EM96YT($%W87)D+"!/<'1I;VYS+"!697-T960@:6X@4&5R:6]D+"!&86ER M(%9A;'5E("AI;B!$;VQL87)S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$2!2871E+"!- M:6YI;75M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3DN,#`E M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$2!2871E+"!-87AI;75M/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-C$N,#`E/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES86)L92!A="`D M,"XR-2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$&5R8VES92!0'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$65A6UE;G0@07=A'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^-B!Y96%R65A&EM=6T@6TUE;6)E6UE;G0@07=A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^,B!Y96%R65A65A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A&5R8VES92!0'0^,S4W(&1A>7,\&5R8VES960L($YU;6)E&5R8VES960L(%=E:6=H M=&5D($%V97)A9V4@17AE'!I&5R M8VES92!0'0^-30@9&%Y65A'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M65A7,\&5R8VES92!0'0^,2!Y96%R(#8U(&1A>7,\'0^,3`Y(&1A>7,\'0^,3`Y(&1A M>7,\3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\X-&8P93=B8E]F8S0T7S0V,61?83(P,U\P83,T-V-C M,S`P8S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.#1F,&4W8F)? M9F,T-%\T-C%D7V$R,#-?,&$S-#=C8S,P,&,T+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!3;W5T:"P@3$Q#(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\6%B;&4\+W1D/@T*("`@("`@("`\ M=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X-&8P93=B8E]F8S0T M7S0V,61?83(P,U\P83,T-V-C,S`P8S0-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO.#1F,&4W8F)?9F,T-%\T-C%D7V$R,#-?,&$S-#=C8S,P,&,T M+U=O'0O M:'1M;#L@8VAA6%B;&4@9F]R($EN9&5M;FEF:6-A=&EO;B!;365M M8F5R73QB'!E;G-E M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$2!F:6YA;F-I;F<@86-T:79I M=&EE'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$2!F:6YA;F-I M;F<@86-T:79I=&EE'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S XML 26 R43.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 8 - Payable for Indemnification (Detail) (USD $)
 0 Months Ended 12 Months Ended
Mar. 15, 2012
Dec. 14, 2010
Dec. 31, 2012
Dec. 31, 2011
Mar. 11, 2009
    $ 1,347,806 $ 1,424,019 $ 1,088,067
Stock Issued During Period, Shares, for Indemnification (in Shares) 400,000 400,000      
Stock Issued During Period, Value, for Indemnification 140,560 184,000      
Net Loss on Stock Held in Special Account for Indemnification     $ 63,347 $ 67,071  
XML 27 R29.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 15 - Restatement (Tables)
 12 Months Ended
Dec. 31, 2012
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]
   
As Originally
Reported
   
Change
   
As Restated
 
Total current assets
  $ 1,978,711     $ (368,633 )   $ 1,610,078  
Total current liabilities
    2,294,274       561,547       2,855,821  
Total equity
    (315,563 )     (930,180 )     (1,245,743 )
   
As Originally
Reported
   
Change
   
As Restated
 
Research and development
  $ 111,832     $ (54,832 )   $ 57,000  
General and administrative expenses
    3,714,214       67,072       3,781,286  
Gain from litigation
    311,000       (311,000 )     -  
Net income available to common shareholders
    (4,218,278 )     (323,240 )     (4,541,518 )
Income per common share – basic and diluted
    (0.09 )             (0.09 )
   
As Originally
Reported
   
Change
   
As Restated
 
Net cash used in operating activities
  $ (3,010,275 )   $ 447,202     $ (2,563,073 )
Net cash used in investing activities
    (471,347 )     342,256       (129,091 )
Net cash provided by financing activities
    3,416,949       (789,458 )     2,627,491  
XML 28 R28.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 13 - Stock Options And Warrants Outstanding (Tables)
 12 Months Ended
Dec. 31, 2012
   
Number of Units
   
Weighted
Average
Exercise Price
   
Weighted
Average
Remaining
Contractual
Term (in years)
   
Aggregate
Intrinsic Value
 
Outstanding, December 31, 2010
    12,834,750     $ 0.20       1.62     $ 2,708,463  
Granted
    9,307,000       0.34       1.02          
Exercised
    (6,668,000 )     0.25                  
Expired/ Forfeited
    -                          
Outstanding, December 31, 2011
    15,473,750       0.39       2.45       869,825  
Granted
    2,875,000       0.18       0.98          
Exercised
    (575,000 )      0.25                  
Expired/ Forfeited
    (5,673,750 )                        
Outstanding, December 31, 2012
    12,100,000       0.20       1.18       150,000  
   
Number of Units
   
Weighted
Average
Exercise Price
   
Weighted
Average
Remaining
Contractual
Term (in years)
   
Aggregate
Intrinsic Value
 
Outstanding, December 31, 2010
    1,871,600     $ 0.50       3.45     $ -  
Granted
    1,500,000       0.50       1.00          
Exercised
    -                          
Expired/ Forfeited
    -                          
Outstanding, December 31, 2011
    3,371,600       0.39       2.45       -  
Granted
    5,739,008       0.33       0.15          
Exercised
    (660,000 )      0.50                  
Expired/ Forfeited
    (5,570,608 )                        
Outstanding, December 31, 2012
    2,880,000       0.33       0.30       -  
XML 29 R44.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 9 - Derivatives - Note Conversion Feature (Detail) - Reconciliation of Derivative Liability (USD $)
 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Fair value at December 31, 2010 $ 442,311 $ 160,659
Issuance of instruments 952,214 840,442
Decrease in value (131,397) (40,030)
Reclassification from liability to equity as a result of note conversions (898,326) (518,760)
Fair value at December 31 $ 364,802 $ 442,311
ZIP 30 0001437749-13-005134-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-13-005134-xbrl.zip M4$L#!!0````(`*%DHD+XF;MX)S(-(LE0ER[*WLFU+VU*2G7/K5@HBAQ)60(#!0[+6A_O;;\_@#0Q` M@`!(@!K76K$L$H-^=T]W3\_/_^/DA/N(;.0:/EIR]R^<>?&=O_Z>.^$NG/7F M=F%R5[8/GRY\\PG![^PGY,*_X?-'W]_\^,,/S\_/IPOXJK0Y@;M`'OX% M=W)RQN$___?_]3-^R86+\"M^Y'Z']WPV7CA>X$3A1TG\492Y7^\N.)$7I/`A M>.+;O6MQW]:6[?WS3>9%^->GCOOP@\CST@^F[?F&O4!OPF_^B#\U6WQ_B=)O MDV]Z:''ZX#S]`!_`$X)XP@LGDI!=?EEX(EI;_2'\,/ZJNUYL\-+:635 M?/F_/\&W,[#X+QOD48$AGU"@,3U'%@6MC@GA-^('(M%)'J")4@I[$==GB2PL MZ+K^`_DT^:I'^QX`(/SPWY\_W2X>T=HX2>0A%E2.^QDO\J-'/O^*5AQ9]$>, M[3_?>.9Z8V%"DM\]NFCUSS>8T2SY!?P*W.)?[DR0<\(*"B'3"RE%U?_^>:, M!Y1X6>!Y_>RZ_^0OB#^U0:YIK/,OY+0PC\C+(7_2<+//\2_2U9*GPMQ M_"%",EXIC[200UH8-])"3TB+>4[_^0<(\F>T_(S6]\A]<[8W"L!R'GI8HQ03 M\KO03/V(OFTLF"<_ODF,C0_WCX:+GH'AF/YT7&6WKF]_.+8 M"!3`>4'H%KE/)BCGG6O8'G8-COWNY3;8P*+(/?]F>F_.L&+\F$/^YQ^H+S_+ M0/Q#`O+!A5?*"R_CXY[YV)<^RG]^<)VU\(MA8^&X<\9L@P%1UW\/4=)9[%AY M($#Z6RXG%LA>IM^-B!7_;D=B*2&QU//@`5RJ6J+66,F%@3WAYR>"NE=RJ5G9 M$E)JC='5Y61+:"%;0D_$TJBR!3]J?UX@UW4^F[9I/X2VY$_8>ZP=^]9W%G\E M%G<:]O9=X)DV\KSSQ=^!Z9G8I&8,:0G3[<:TE;'W@4$8]DMXN?^"=W!@[&W? M"T&(OU:B;B44G2WZ;CJ*I:(GL9NG?KR%K.U/?9F\]2IO<;20E:".$82^58+. METM">,.Z,$;/_N78=_=HNLL;<'HO]9OG8^)I$><: M53P2KW/X8$>M,!\-Y8^)WY3%;PC;IC45J.UA#Q,O%OS4"ULQYUQ%:R9.X^.= M7AT$73TA[S^08?F/6(H-^_A]4`7&#?1QVA[HX`&06$P-MY(])GK3%;T!;)HH M-!2F!K$/$RT6^%0+6C%'74%I)DHCXYO4*.BQ@OM7T#)!0[@NBCT2OW/XD*>8 M,FXC>4SP)BMX0]@SI8DH;8MVF$RQ2*=2PHH):AJA7[L,C8IA->W'&,'WZ-Y_ M'2XFQ?3X*PF'#VKFC<7NM;BC@\O?P?S0X:5Q2W([9?R>).PCE MJQ2["?.X)G<]Z9T<6],G@RMBDG**3JCMLPGI9V MUJ3/XDE*7Q$^_X.6[UZ2>-Q$TSV;2=]J-$'V%52N#^[@Y9J47R.!G/H9S^F) MY^N-W.6:#&$3CC%QG##O:Q)QYXM%L`XL/!OX/5IAW-\'KFD_O$=/R'(V&%_0 MK0.IAP3*1`JU*"L9H\`Y/KGFETK1N9!FW!DVC M@>!5&6Q]!]F;=NUQ&D+X>KV'PK<7R=(]'V,39!.'75ELXB$R*W63R*%L[QRR)M+)G'N*TO?>M@S*DY*( M,3<0O2HG6ET(Z*>]C0DG!C M`EVO5O`[]]Q>7D:W\+X*<]6,!LQP[5U\JVL/[5C'!/08I*$ZZW^]P0KB?70- M^/[RSLE<(][\.,$T160[ZJ]L=O#AY;0ZY;^=6:]=$B?,]GR_\)R=J#S,B$W:0O6/L#QF;$(XC MQ7(0D13;B^1K%+H)C%DX7[&WT3J)ZJL7Q@ES?E[)>=9@/*(>SE?E./5N,GF4CG/,POEZ M'>>\.CO-&HR/VG'.JW/#K,&8-1B/7GRK\\BLP?B@#<8'D8;JG#-K,&8-QN.1 MT\JL.&LP/F:V5V?W6?//:)I_#B\F^9NU=-:9.51GIMY3<]=<*W!L^J'$5'SY M$-R<%[G)C/-8C/,0[,XWXHZR,6$`M/4TY2<"F%$P@G]D#:FOIB$5L[MIA$.^ MVT^$HPL[R!YK2'T5#:F'$DFQO4B^1J&;,(>E2@ZSY"8SSF,Q MSD.P6\^S>XRARP!H`U#9:$1(HQ&A?3[L`PDQZ8Q%0 M*D6@T43*XQ*$PXVD'($DJ%62L#=UGPZMM$JMV?D$Z+@5:7H'[%Z7)Y]W$\CM M"5DFGBSFZ$M8]4["RL1QPKP7JK.JQ%1?>5Z`EDWO-IVD%-2@6G52M^465V=96U?31\YZR=<3A^!H,BYZCM+ MP@_7[23TU3D@*`6>L63ZGEN=^F.E6F0EL\ZCLO',VW M*XZNFC$(SKD,FYB&ER+K77M5O6MBBYA5["MF%?D=I(_UKKV:WK7#"*707BA? MI=A-F<=B)8_9MOG8G(Q4R6NVW7XE)EVN%`&V:SM4[]IA)$&IDH2Q[?9&0"NU M4FM8!?YU5>`/(W_:;O+'*O"OJ@)_&-F<[R2;KU;ZILSJZA0IJ_&,I\9S>$&1 M^%S]@*42AJOYB'W5/R2AP#.6$MAS!;X_5HI%5C+K/!KK/`C#I0+#62[G,!7X M_CB:[V$;74YF$)QS&2DI#2\E%C\,F-&06D2(4F\1HEK):Q9W[#UQJ"W/UARK;'$82]&K#R:+\T43YAQ<4.9^#83'4<%&_U%<$+`L% MGK%8:,\YF/Y8*199R:SS:*SS(`R7"@QG@=EAR6NVW7X=)EWAJT1@;#'^"&@E5*H+V^$>JO1P&$D0*R6!G8)X7:<@#B-_ MTF[RQTY!O*I3$(>137DGV7RUTC=E5E>G2%F-9SPUGA$(2GX0&DLE#%?SD?NJ M?RA:@6^.HFN]A&UUV;A"< M<_DV)0TO%5:!?U45>*5%S*KT%;.JX@[2QRKPKZ8"?QBAE-H+Y:L4NRGS6*[D M,=LV'YN342IYS;;;K\2DJU4B,+88?P2TRN>DF$$<;N>J]+:+FQ=XQ@S;GO.( M_;%2+["2I94.DU;JC:,:7QE_L$:6U]7(GU3+F.*3,3>!Z`?C<.^<7Q[3]WP#%P$63KCXDROYLN,N[EPW* MR$0K_!M52IG/["BL%UL\M)W5&D(3>TBBTS:"CYJ M5*PM)GA_-UP7%O0^XO]V-3+9!LUKTY]L_;H\;1'CT!0A&(!DXG':,1C"!\QSP\L'%T?QB`XYS*@ M:FH-U3\OOR%W87K(>_>2M.29X#`:%@6G(ORT0*@IZJ\@J92SPVH+.ZSV9H?E M[B)ZQ'FHL2TN:]7QUH4H$ MQI:2&P&M\DE+E96S#G0V0^TK):OGKU$9G

`Y)7(%U.P MQY&/&DT":!">%9*LQY:E&6F`-@@KY2(KF6,=C6,=A.&Y=*R6QE0:L[P#9K"T M%F&1UEM8I%;RFEGLO6^I#R,"6I4(C*TR.@):S:M-HX4,]VH-=O]\`:+F$7&Z M<-S-Y'N,WP6>:2//R^"5K0#4X_V:BJ>'$;IS2^(K=GK#]YX/[DWBH=HE2L5[$NN;%7IT2Y MP#/6[3;5I4(C,W8'9Y6$E^I+JS1:#1]'*_*@DM"-Y%DC4:O MM='H,.(J=A)7)I#3YKZT`_?9%46O](JBPXBHW%U$V15%K[RSZ3"2JW267":; M1R$(:G4"CQW8',LYNM?E5?.7PC-!?)V"F"E7S/LJ5TCSEJ)U+!F/R0G:&$K! M_8F=WD[LF&"-D8MR=4*?E?;'4]H_?``C"P5U9SUS`_?,]:?C8M%2LRZ&T=ME MJ<`SUHTPU4!)EHNL9(YU-(YU$(;GFR1'UT8R",ZYE)N>QI$Z\S8#YK+T%J&@ MWELHJ%7RFGFIO9=:#B,"\RH1&)NQ&P&M]$IU83USHVE)>E467.&[B>2Q9)"G M)*"OV-LH0B=Q90(Y;>Z+E=QG%S^._OZ\PU[\>!B!E3H*++OX<02"^YK]K=Q- M@)F('IE!4YHD]]I-&9N(>-`"L@[W<`]KLE[7'K91QGE7%\NDDSG4'F6U.F.^ MG5U,&B?-^LI,.:L#CZ@./`)!R?=3%D-MUF#5CT7(%+_UOHK?*E]@W:1#WO$% MFX/P3"CP[#@BPK''8H.P4BRRDCG6T3C601B>;XX<7<_!(#AG@>.0J7YV@9?6( M\=0C1B`HN>/A(!ZLT#]LH3]E7=;6,K60Z"QU!BLXWR:BQML31]'N]JAV?WBC?R]H2 MQR>FK]FDBAV$EHGE<1@NJ5(&6'7U"%6^.EG.NB?&TSTQ`D%1"@4RMK4>N"VQ MMX*8KA9KFTRS1Z/9@S!<*S"\04+^V'A\N'3X(!S-I3C%U$V+1Y+)&&?J0&SA M:<7>/*U>R>LCRPM,82-^"!&0>+Y2!)@I/U1E\S"2(#0Q_"S+/9KTX6MR51(O M=I'.(_-FDQ+3U^Q8D\Y M$XE7"ZP[CFAX-.'G(#S3"CP[LAAQI$'9(*R<%UG)'.MH'.L@#-<+#&>IJL-4 M'7KCJ!"E(=7SX$'0=34;)E\]X7V"^S!%9E[[C\B]-1]L6'@!!/KBV`O#>[QS M#=LS%M@">^]>?K7-OP/T'GD+U]S@WV4V3T7D][%5P@PXX>[4&HW7[:+@HE'3O5QO^>_OHN#[L*=<%(7DE$M*6,OM)N1Q,AL(3\:)X MOG%A76G$$Q^D$UX^$<4>C&=XHES4?PE(CF'$.,/.6CT1]1YPKDZK?#9M.?V M\G?#A8#'GUKIXQR67)I6X)M/Z!8M8).-C\->?EM8P1(M,>YX^Q;`C@X>NUY= M&JX-VW#O!H=F$*N]>Z$OD)&@6CKMRWH"B=4IRT_(\$CF_FJ]<9TG4O[SCMP2U.!\W):@V.?UP3#=WPPK0% M)URD%Z;'_`2-=R_)C_\!KS#,+0:I@!*K1GEY'@ECL`*-A)[U.IDJ396KQ M<"O3U(-I:E_G6R5QWH"I3%,GQM12EH__XCR%FRR(,"`N60:DE^+&>"G%5A-A M7$#M?+)P`6//%\9'WR3%( M[>R#:1OVPK0?,MW;[R`Z>S"L2X+.]>H"/X7<#:A5B??UQ)G6 M?1R6G1CW/5OV8DZ,4@XY(G['7VY<`!FM!A?GO3&^32.F+AY^9`6(?14@!E'# M8DZ+L?,`[.Q/.XO'&UF%>!\5XB$T4RZFHQ@K]\S*WK12KLY#?3(7F$3VP_F# MBXK&=AHLA9VIZ:-/YA-:7ME`IP?IGXU^.2Z;[%$QN%=['?:Q! MSK9T\5HB";R6.:8Z.:5^%P`G$;!X`=KLF96G3/?9J,-KS?D+W^V+O[FL%(6K MY2.&KY+%;5Y]P*.-J3-(1:2S,Y"WBDCQS"(3D?&>E1Q$1)0M(L)\PSCX5'U* ME7'L&**U8J[K!E:;9C%AIR`]A^[$=L_%O!9CW61VRWHQ)8]X%R=\SE?+-P`+6\-RW!?$DF>B""GO:*?3./>M/"_8^XN4ZJ-Z<3?'C?&"FS8F%PYNX7BQ:26'YM&SO?IH7DPK$WF_NV#[KU>K MJ3FM9'[D]8J,FKNR%\X:?7%LG,(W?.R84J6OQ/?H9:#Z;-X?R',^H^4$8\[; M8+.Q\`#1M4G:Q3*,SB%U],Q5LGUFN4DR$V8N&;Y@>&CYT7&6N+D0=!JM-Y;S M@E!\O4)FBN2[%R(.`$1[,>A7!H06'6:]S8%1B@?TOB(R'_G.B=+0-X&[>`1R M?D5_!Z:+TNZ>LHQ,0T":!'F-B;!=-HY6=H=(;"C:,;J;*7%U!%ZI.+4^:OZ- M=?#XK0\5869I^K4TQ5ZRI%=GFYP=DZ15(-WDQ`23MA;2IA;;W9BT,6DK2EMO M&6FU)COK/2*7'+W"_YR:\ZR<)TQ#Z]AW[VKQU"?C;4^\'<0#E)*IT4]_WEV< M?[2<>\.Z<-$2,#$\'[D?`GOYZ69Z;F"`TYU;Z3/*)@W\7:D')8_ZZ9BPC%Y8 M\G76D/V=K4;UW0\-)8&)PK3L1E_!03&MR\1EO.(R2+Q1[.X#_#"U)LCLRL@P MA]+4+N=4YW6FG;%JNJ8W-W--2B)]*<_7/V^#>P_]'0!6ET\H,QC@E7&Z568G M3[+RF4HJ30>=_Y*3-ZF%O$E];1$T/KK9[P.Z)[G%7S[_;&7 M:PBUZG0<8]64+;U6S,`Q=HXKQM*D0MF%,6A.SKQTS2PP$.K9@?8OP9E^FD_F,HCO+":7]I$$]/0J;Y7,WH;D47>>SOF"4V0LGUZKW5QHR<0_ M+QY-M+J.3WU=KU;F`KE'TS[3G;UMP(@.3MR0`EO:8N>]>\E^4K@#M9K^DXO; MYL644'0KL)"<*&E@4Z8A<:2[\WH5(7CM?C4?'K."UQKS:158Y\41_1&^XJOE M='/,)\;IZC.P\9W?KY;GS3$_YFZ;>76;5FLZE6*(VV\;M!,:M#_3$ M$-PND&T`'VEGXRN(?>SG;N;%\\F_?/XE:CW%=U`M(IE\'Z`/Z-X-#/=%%.%[ M\M1$<8`>6RJE^C[^5ZE"%1R96E/#O#A!D,D?D[_M\M=;Z4LOGF4F!_0N"3@;/X7>6J.9/)+Y>":RD5<^=LG5"6&+)].[ITH4V,OA+8",A)X%,_@XH M?P5V3,[^B:WL7_`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`T;G6*;OSI?J&,+`J%&Z;& M3(".%R2)/4B)F).2/S\[UO+&=98!&4T*.V_L2R8XT1=P`$KX+S<6"-.YO4RN M5W]7S'G68;RW*F!_XA_VY>CQG;C4J1ZO.L>]\YR3_BZ_U7O@<]3[PF]E-./T MX3B-8Y[.G`Y[2Y*L#N/T^#@=9JNRGNPY70_5>]G12U``0\1AG""/UKV(WX_>^^)W+B88<;YKG`VO1 M1TY4BA->@15YA$@Z5"8=8Y(.S'&MJ72HO4E'\8S@+3R//!!6]<9%*^2Z:$D: MIZ8F'0GTO]JF#R+PQ5AG.5V/YJ2&1LA2\:S=L?`P.2P>73V0Z>#KPL21K?9KQ$I*.-[W)S??KL, MQ#77&T*TRV_(79@>6DY0$.I&?VS%](AOP)*EX@PRQO<]\'T0'SZO;#K[X+AK MY()?\PB1)U>5:6W&J0COL8_T(#UJDEXI`'>/IAL2ZP8L6.<^?RHJ$].:.C_8!N&CCH9EL9-0R/PK$XH8X>,6"JE.*-Z;+EH0 MAV$O+]<;RWE!**;6],J;6P1B.[+'?E1'KLF3X611M(^(CE!33N],0P[.GPUW MF09)J7@4463W_/8F6=4Y.)IDE4\1,4R;CI"I0VTLBA^\KD2-KE?MXQKJ!)UZMP*-5).\:Q(XA4E>K\V]8C)M/@ M])1/F!Q`'JI3;W$J:F(9UUWXGT?UF'L1E.KL6EC0+7']"-F>J5\WY/R1*'MU M`FS:K>*MF=^R$?PHF%\],(DQ?[_'Q`ZP_2JVH#&63^^6":68RV),G-R=\+)2 MO+9QZSGNX^/FH8]Q#Z&<:C'!Q;;3>]].#\)7H6!TPWW#Q8?KH[>W!4PG9VI5 ML3+B_8H6^(A2,DG\>H6GR2]3C+:A.[?I*M7A9VU?DQ10X7_XK\/S<(QEJITF5_(;MZ2WR?8MHP?7J?+%P`[2\ M-2P#CYZ*CG95"\5DQ*+^%.E6$@QQ%RL3TZ*8RBW$E`SP^1(V)9FO1#&PSE,O` M6V;W"VMD>(&+SDS/D45!^_'7V_<__Q#_DDO7P\]G_IU=[@:YWJ/A(B\CGDOS M">0JAS5^Y$NPQMU13O:[KQ,F[AK#?> MPOP1PSP0X^)^+\-[!..$_\+W[#T9%L+FRK\`P_5BV@^_&5:`./SP5[0*-8J+ M](W\8E'HG7O#+='"7!N6]\\W_)LS188WMWG56=_P%7K`"O#)5!$*E"RDPV57/\B^,"OQ1U>XB<%WXYNYOEN>*GKZ7NGB1+:TA MJ&>#J.ES=;X=A@(4YYZ'?*\S_I*H:GQ&#'++GNW\TBTHSV5-$)N^M/).S&XB MIZBJHF;)7OV6WD"J)XL@S`$HN3E,157T#?O!Q!/8"#WA2Y??%E:P!.W]Z#C+ M9].R=J>7P*OJ7,NJZ/:W]0_C-@*JLJAVA;$['*(D:ADP,J^B:-/N+-%TGI>U MHAI5F8H.9%5A!Z'-J2\JO"F?#0&1C=)XGTSCWK1,WT3=398@B**D9;Q%B[=2 MB-,/R%M`K7B7RA_(&>1A.]AD_QD MX',_?;HJ297G?";0K7M+R3;L"M(65R2+DB#L"%+F*QVV7#*O*DH&A,RJ%"/> M\)W;=AR*,A<;O_/"6:]-TH>`LY<@][B3'-F+3GCS64VJ7/^L%TCJJ;$3)/F[ MCSKF1B"@Y'-;WN+2E"U7J]=OL?ZM7X_IY-A]H*Z)VES),R"[<*&N;RR+XR-Z1L=]I"2+`FZ+&5W_O17T&*Y]L!L,0FZK&NZ MI.T"#"':HV,MD>OA3;G_@EU/]EB:EYY+ZR`J>3EM]=:S@2#>0E2E-XC?HR=D M.23=<>L;#^B2W-'AFAYZCU:X5`/A;+`.B)=_'[A@MHI/=!!4$(RY)N;<9%=H M]HI>/9`'1*_,^2L[RKS<."[F_+GON^9]X(==^%\<&R/@.I8%7[G" MKT=>A\CK1%(%5F:>"**L:+(T/*:9F`EBA?);^LMD;7O3 M67^`M4Q];82'8`K7'8W@2LNO@9ML77 M+FG>6)+8[P:YM[A.G0,N+?@W)J`$4)[RO%`57%>]MW:OT0G8&I(.`BSYAG<> M^(^.BQF2`MF6EE=?/D#,SI,_52`6W[:%[2V!JZ'=8,!=>5[0F6I"$\#"-U&L MR\Y@;:-7_V!=!SX^@81=^SY(EGE=[P#V0KQZ`#,[WOT9P`8O'1#45N:O,Z@] M&S\Q,C#TI`7-O/0%V39A[!VR7LP>3BW).J_5`%5I77:#:*N'D#515WFU%XCZ M,W8-"-78DO1MYQJ0K!ZVK[`SMX/Z_'#E..5R2TJF*A6O?-;^A5&SOGH>/`BZ MKK9_8Y'^GG^]BC[M`U%=S.MR9OE21K[AJQNC7/ONS![MD^-YU_9-X"X>#0]E M,O=]$$";2XHN19NSRC>==06G,5&:PD-C#FZX\6YA6]X+8711TZ4B?Y)7=("@ M.2VV@E#H8'*!7C>NLS)K=YM-*7"BZ8*:3:5EUJ?8GX9O;XQ]_>L+ELA#!@C) MN;W,Y">C5LH^2"$IN4Z4VO>5O?[.X%5.\2E6>+1<2+(O\!JS4M1!J66].82% MU,K&A=7""U'0QD(DE6DOS\/DQ]:.D,9.CQ=U+9?[W_[>,C6[0MN4YX+&BU)[ M8'N%M;D`\(H@[$+:@HE!-G(-"W]QN39MT_-=TL+0HZ;+O*SR\XPR;7EGOU`V M9;ZDS05QKAX(RN9LAY!V/L_9\*UPEEM8K]8;PW2Q@;B`,/BAGPAWKLUSS;KT M-Q7['5N#TYA4,K'AQ:Y>"D!%-AJF'89)[TUOXWAF.!IS>^]OBR@DR[^ZUY6` M2X9E1^SMA7,*KXKSK)TNO:4H1:W`:*R"'TH,!JS1U)X'K:T6CT@5:!< MV0MGC3!'>XD8E3G$29I"@25]4259FL'2E#\GU0SJ#9;FL:RDS'E>G=.D-@<- MY9A5.!@G_%:3LG'C`"+CY*K><]8=G.89`"WGT:I!HITN(1_U&`8`,)J2/:M4 M>$?)U+6`H7%4KVK\7*@#85<(FCMP%4)B7JDE0[V(;#D9U906-;(:'XKJ!$<+ M*>4U1=H"3UB]$7C-RV]8Y0/3>PSGB."";B_R*HG9AN.M[RP*3R<@FYM! M0=)S)P";P%G='YT)1I+?;>%S$LT=` MF[->5O1LO+T#H-?^(W*_.+:3]YP]6GU1D_*15.T;2\'#SO`U#_9X9:Z++0`L M'LX8D'B@W+P^EW+G,FH`ZP&RQEJBSE4Q&PD.3+'F2B%*HB"K8E.2E4XCKTR_ MM]A=$U0Y=T0D7;_,KV;O;LP@69$%19CW^>X6L?E<$($-$OWM>7%`?AJN=^WO M;.$VYY(L9J6D+1A%4Y5;8!CIR;V"(KV-0=A=B'H#H84LE3K(BT#D(/@=F0^/ M/EJ>/X'./Z`O`3X&>[TBY=Y,M?>=X9D+G"LWK<#?6IQOQ#-2M]H71JN#=_RXJ:82OAK&G,:,4<$2>)/LX'REEH>09GUK2TC?!9YI([!BB[\A\B?IQ+AW/31=4:/(M8O_QC8NQ[QF[2H: M57_A1^W/"^2ZSF<3@QR-9LNT792/I8==0*JB9#:D_:!0"CVV+EM M^6"CV@)TYBZ`76A``N46Z-?"N4>T]:UH5YP$JR"!U!\-]D0!@=]&@M)^HXV< M;V/T_A5?$*HU_[/Q[9MC7__G!R>P\4&.QNHO*?D.P/[T?V^J((@%0=B%&&'Q MH4]#L#_\I6;XMS$(JMHO,?9%"KD1*8I%P78:T#.RO9@&>E"?(\'=H^F&]XPV MCPWF^A"V85_"H%8(0SM*D):?Z7E'K2GR;-!@KB7,^V8W;$?T_(5V>8 M2^CI??K+]*QV;N1B*/&F'?X]J"Z**FY*W09"W56Q25=R^X-MX'<&\S%)'`ZMM/#XI$9A$<%^T35Y[7#4NI(W2QJ MND7ND[G8+L\UH6R\Q%>$"UYH^>XE\:/I+;S;A5Y6L@ZH'?3M;'(-\A0>#HHY M/KK8,H[8`\YR3>LZN'9 MK`85-`41[ZF`KPN`XZ/^X9/+A3GBD,P='XNM!2X M7C,^5W*S2VD$CU#=K3*RTVYQ6S:]?RR;9VKW@I^^`WYM MM!4?M&J[,4SP'0!AA6^/##8BYVP[Q=Q5.?:PVM M6!4EAB2%U(D4963UIOK>"=D.6B_O@'"M2#RVZ6_7O&'9?O05&C>M'08 M_*LW$XWQ;[7AG_--VY8JZ#$@+:KW&DUI4<)6Z&@%AJM>*95[B]Z*5[KD_1>O,+'=9HJ.9T&0Q&A>N.R0_T*T%3DADF%.C1W MJ6%U2W)ILJCON8;5)6FEC:V&U5-2"OB@:]+H:EB-DTYBKS6L_I),770#GYL9 M52YI=[T1VMJF(='H1V,DJ6$&>_B6V<9:(I7*;VU@#B^XQ#G:E;D`38K,](5A M+Y"U?6Q3%U4XD14MN0VT$H*S"CC+$/8JW"8.I'4D]D7E2%6AB[`-E4 M^`@82@,P>H^UU.J<:?SX!1XJA\?,X7#K>@60(1=\Q.5Z8SDO:+?MI2`+2J?F ML:'(49UC;$>.H1&.YFNA)3YR"VY\^^4BU3G$:#O[T37@^TLR2!!U8*X.V^EY M-IM$A;4DT>TQJDX%;L>H%YAW[ZY5\]7Y>=ON@9;-M27YZ0!Y_O!KT9*U!6S' MP9`UUK]3UXBHS&5IG@GV>^J/:NX)MD&P:W^4JA4DKD$/I28)V6$NO?9'M8.' M[.-K+[SOVA^ES@OPM#%YLB`*TKR80>^W/TK5BP!VDG1)TG1-*:9_2B!W`;C> M4FBR*/+%G'L3EO:Q^=1R88^>ZJ/>[?"GKDBM#P(,61+O'T]RI=>(BOZ:L`.& M[68SB#+?-G0;ZL2K)K;'EH*/V`,^-\8+N9#S>I6L@#H294HM-JY M":J6&]Q=`PYED/BNP,M5P/<*7N]59$VI)'I/O2-"H]:V0_6.#(H_WM]MM_H' MZAW1U&Z8M]K6X_;-CI08DA1:)U*46,XW[A7KH7>D;=U8FU"[R39O% MJ"F-83(X@^*-&^<[)'$&PECOAG$K#5=5K4&$N__$W;PZT-WES*.:]][C0;,Z MVATP72O.FYNZ_9*C.ASNE*[M'>'6RSN=%`#M)NBSILB044PQ]IA;G M^5QH4=(U*3\S9:^I13V-1$1P(LGM.3S?*;4HXVLIQY1:[!]/G$C?^?S4$!@* M.V#8*JY2>$EN&TT/E5K4Q?;84O"9[];.-$Q\J$N5.+4J[_#-SVWN<>.GRU78 M#0I_X\A$5ZJIWRV4DF1MGJU=]11*-2;H5@AV#:7T3.A""-4@E%)TGE<'"J7: MP<,3:(8,I72M`$^[AO?Y?"YO+SEV`G!>!+"3I"N:+`K;"]]=`-;S`!=-AR:5 MSD4V>'T?@93`YR*,]!Y"7N@420%"NM#TM-OP':H#H(FK?`V&$.^I!1>VG3L@ MV"XKR M!8'7*HG>4Y."N$O,L8_2Y;"XXV3<&.O7`C_OAG6KM)TH=IYEN;>=%.PVH:%>>K=7H@Q@Z",-YM=,C<#H5J]8Z^%M5VS81S M3=4[-6$,A7WU[KX.>PI^[3?X9?S(F='SM0,VXM^D\P''2FD?!';D>PE\8*&Y MIL3G?>L!*H[5Z`)^X\!G1P!;5Q$$H7K;T_%TFJ#K_+RNA617D)M3<2L,NY8^ MA.QU]$U32B(OYR]@R!<_.N3%6X)#KO+AM[1I=`)'*8#3JL=+$Z5YJ4>]3^C4 M(G0=AW?+@JCLTL'1`F2M`'(OJ:6>8[#)"-[!_-<.3<:.HS(K\#@JV.T*FB)(SF%D5!%-KC6\9HY[3R ML">]!%&LQ*[1UDHJ5%'=UFC: M"3ZQ"%\G4=?GFJQ+6T_$=`-9*H#<-I\!5D\M=1[T#&,^IU961UG;(4W5Z_9) MRMD.*;4=4J.)69V'8`RXR]@5-=(Z/=++``1)K42J7;6)5YL>/CK`!E'2JK`L MX]&XJ-0%CR[Q=2<5DYJ-W=@20WG.P&7WYZ'2F7:CNQ&ZF0%\5`6+P!882F*Y M6&E>2?S6@W[+0S*[ M=,ONBP!-&=@W?COG#"2]6E\Z'E;5!25[R4-O:8[&1-X.P\YI#CF?5VADN@5% M&BK-T0X"1RA`$Z[-,=1.71LMQG]N M.V?53Y6_?SQQ'F1$XTD$6=T!PU8-]+H^+H2U]@@7&3C>^YT%>5Z)7@.OJDO2 MB`?P[HP<3U`;;6).UBO1:C<)2)HWN('W4%@J?!66)3SD?OILR+X^_NWUZG?# MQ>,!F]VZV$V1-$E($@M5`)33"JZS0&A)XH_HJ\E(X:'4(AL_U+V?LB_?&=I^ MI%V3^.RYK#T!KPB5P+>-((5\UJ$>_IZ@;ZJ"FBBT`&[0XYV*6$GQCHTT@BIW M/M@YT.F@09`F`T&Z320>"EUI-W3;W2@F2DTKD%3DA\)=W@GW$G;RGJ;+=9 MFD2-LJ"J^D!)S7;@D.O(U"UGISJ!HQ7`:974%'E54DI;G3Z3FLJ\"%\W41?G MPEQ6MQ_TZ@:T7@"Z=5)3T31YV*2FFD^NEQ52X.>*U#Y?W4M:4\UY)R6U&TJG MM*:J"'III.4!#Z/UCR89VCF:^[H%5=P!P5:I%AU$=SS#$56I/;YEC':>%#AP M2E.5*[';KGMZFTZOO3<>[HH:COB[9M@,9]Q:'=+=[\Y0HVOE.ZN.4*^V2'M`^0(!T&: MM(R4QD&,(4>H50>MO>4(94V1I1'F"+7J>+9%CE#6U/;S!BJQ>Q>`W4>>=[Z` M39E'2!QNSZX`TM0HLG5'K,KB<@6 M06Q!G5HTRH9B2+(HGY)$V3#L6P,Z[:1W<+]B8K MLJYKO=)H;Q0JQKLM*+17&NQP?*BGO:L@\7J+PT5=`&ZZ$=T1I!L("=PP,(`- M@F4`J5?F@GSW?/FOP/-QYKM>7/1*DK;<RUU7T5JAK3,OM,.QC-H%OKE0A*^;J,L"A+FE)IF>"W5]YU[H,'8B:_Y01TD=Y3EX MDRUG-`8N"\QS6T,UM1WJGTES6G[X^2X)H%8GQ???5#LX$4B[^VA[BN=R=_1; M-9%UI46;'-$.Y%`ZDZ,\\'#X&DP7(Z#N@#$N6S;/`/=A`8;E^I`T(%.<.@O] MD-AKW;!O=ZO2O#,MAB3%O!,I2C,5N^I^'\M07=7S\;/:.M71KKC: M&]CY8]%%6K8M^0Y9\]6K0[]2YGJ7P%]L9O\.4/@=$'.>X#W"ZJ]>'=DVP+G= MQ`1-+"541D&"ZC!O.PG*2'8K!0^JV=41W8V+5LAUT;*6W?EO54^I[W8%V%!L M'AK[5KNZ/>)=';PVP[N5DNMCI$!U]-B(`N6)87WAF)8GO#NG@L[7_B-R]Q%M M2CFT&H-6MEH]8=4T$.T-[K@6>OD-E^T0!%V.NS1MG/'^XOC(.[>7[]%]6'7= M2_Q_@GODU$R6OQ6$E`U-CQ@VY4[O.-RYR/`"]R43'G]%ONDVR&EUV?*>B/FP MM1J,=K%*;IVOR"R4UOK=#)\T#<"H4+5).;='JR^=$42Y::1]""P;ZXW0_!*C M9GBT[X'H*XW1<"!L9W";TG8G@!H7W^&%U63K5$15]+F4+0Z6V@5V[!9H+I1; M(-BU5T#DA4):9\>M1J%!M%.MMCU0]!W`MG.>;O84H')*6\A:->6BBV92X`"Q$!K M3[:M"8$&YXI%/I>]TE+#I370C'FS(V34T\/]GS7=&1>>8++3`=,AL%`KL6AW M#E@7E/$@I54A1=F*[GC8=_]G0$1^7BUQ%C+:9 MH]S]'?O86T>VR.?[R3K2A2=4D5N09$M7]K[((/`MR=#NH"8/6[8>SW;LC2I" M.ZJ4\=:5['U*O>+=?OO4F^D6)3$WZV2H%OWF9GE7D/KNJA(%L9+$?755B2V" MFD/T%0U+`S+$J&'<;9_-(\,@S8Q*[9X*QNV,7U2,]WS84?Y:O/GPUW^='-%0,&2*L5K__; M"<)V,MP`T7X3;G)#!AX6OW[V<[I>&J^Y"[9#(]MT+]@B4FS!O>;%05&HYDJG M5%1A[WU313S M,VY*=D%083LK;`-BH"*AF#-?\]1\S9M$,YK(Z]KVB;3[FC&\,S9D3IDXFE'" MHCBOQ*-ETZK0]([2X0N%HEZ%5`EL>2ZVG0;8'.P.*6J)K^1+3REJL6&5=%N. M>LCLY*!4X$,:C/C`NR@)W?!OI<*Z(@D=KU<;EAAB)V*4T-74_:"[8QY/DG9` MMWU.3Q9TC2]>[]LBIS=0EF=P[/D0]Y$=DA$EN3O>[2Y5G"NM'7_\BN9LH_`FV!U>VY[L!V1!DE$88-#X6-4'6,VQL!UH[ MRWW1Y8*H+H$S(-F,>5LA;*&^';'M)[P6)%%K<,/*V)!O&H8+DL27L@T]H;>? M'CY)K9;JSCU\LJ1FP]3)#6X6I?S,OXXTP5OH2<[>%:5Y2SJTNS5,4'ML:MPG M6?1V9"G7:/DV<\U;(KY#1UQ?2159G.=BL\%:^)HG3'8#J;H.]I4409&K MZV"[EP\;$WHK##L7F62A8#;'4(MK#=3@M3A9+'J7!A="S>>2H$O51.I$HE8` M\2$XVXZ7=0)(*@#4*NR8:ZJNS@>\K%24Y2)\G:R"R"N2IFV=VMR5R_D"8MDN M:#(OR,7$VYYJ<7)NNZ*GYDMO,C)8EU6Y=(WJ`6MQNV+#A[B,IA8G:Y5XM$L6 MZ*HP'\WMG:(\KT*KE(_E14':GHL^P"6=HJQ7\J:O(R,:/C0RYB,C@]*`M'4T MS.\=!/O\I>OML6^GPHK8,-U728LA22%T(D4)V<8W\W9"=LBK0>QBO) M\\YM5@/6W3OMA555RVGS>.ON'3;)N6MCIU%Z[FDK+?$JKS7HK_R$KHB@U*E)U![EY;F-'H`:N&/5$\Q-!T_5YO^6DO9*A*1\' M1[1Y#4JIA+EK@EQ6)4T1JDM6NU?Z&I-Y*PP[UX.4?+=!<1=3&;= M;Z_PB47XNED%?,9'+H6"/9?-U'PMLF079'FN;2LV#E0T4[.)$(%/C)?`-^GA MFPN\6`+\@$6S7;'A0UQ&4UW*W6B>QZ-5T*B`0I;4\8!HJ55HE0'7=7U`P#LD MTU2MDC>OY?;*86DP]MLK177>#?M6FW5-&O'ME:*J=R)%"=G&M8)Z9#M-6NOD M$@7<`K._VRN[>#PA>U)P3[=7]N79E+DREUI`WQ/P3?V7,F]UN^:0E5Z-;R(@ MN]=^1$&7YPU<]2&*O`/BSH>8C[&^JPE=L&ZEA:"&#>97['^4G"9V($$12977 MM+:S+:J1[+?.T\E72;HNRY,X7]EE7]HJCRI=;A7N&;%^'K5E5014FSKI/H\ M5U+;AG,XOK[/D^E[PU,JX-G*"/&"WN>%.GM#6\@C74)+5+2A[D?JO_8RERL5 MM:?:BZJJ\[$/$!R4"GQ(@S$/$)PKW?!O54)5\468#=,_!R*'VHT<7]$"F4]8 MF4F".N.3*Z*;1O=E'*K)>ZYUHD:)_8HL-QVOMHW]I":4WZW`NU?(A"C3M)L5 MI^;S2O0:;SXS=H>5#6.L!/6M"VGH(]4H(6UY#O@W2`6L\ MN;O4*^/7+N=[!&G>H&7\$#6>`7$GB0-AE#4>O=&.I8\:CZSIRKSM.(%]U'AT ML0,)RLU?0K?#F@/6>#KM3B78MDC9_L8=BCS[2OWOBB@?HME;*6!O^/;C>W1% M%_B&=UJ-ILY3&;,6D5-%4>^ORD/3U%3T,P^]0S;)^QE6NNH'9/B!B_;"4UD5 MY;S2M@63=L"P3U0;<[`75(J,R^4ZXPN_?-,=.-EW(J@@D9G=<34<@U?>.IA+ MC$;'6MR`B.E2)6+;4]P]5!F'0ZVISLR;!B-52+0^9D8_N9?=T7Y%84H017%/ M",57M'`>;'/KF<*>[.)4J]O4T72E4)]80RC*UL#-?CHRG;EIG".D*Q!$,BKU43J5+1L6_\" M<`:]1JY;H4J7=4V7AAQ=J:M%^+KUT/":)LNETU<]5\MUK0!T'VGO/HOG]86Z M$T&4%4TN7NM51222BB0U.GN!\&XHD6B,Z]TC2H\F1.;\W%[&AQ2BA'BSA+2> M2_&*J:D6&UV^+2EI-KH7>(M$.%\[@>U?KS*NZR-^"L03/Y>^J%YZ=L22#W&, M$&P,RUG_".B5"+2;'2+Q,M\>G0%X(O%\)4IM=5M64RELA57/.,E5&)5:HN:B MMH-4#7G21.*%)CK2X:2)I@AB@PF2!ZA"#(D['V(^PBJ$Q(M=L&Y57Q,DJ>E5 MX?NL0H`][$""$I*J('1B=&J.(B_9LJ32CY/0-5E7A<@Z50%RUA'8IJ:R(3`Y MXL6!1?B]WTW_,9.G_.+XR+LQ7K!WV8O+E35>UR($&D-6=+F]H-24YKN#/&QR MOB>.B)*F:3VDM`=%MG$HT0LR`Y8_NVTP)%75^>SQO;;USSW5`KML,#"./5;( M]H5Q7\K(*P+?\+KK\11_FZNG,&]\_+19`33C%6@ARI6]1&O;!%4/4[[(]RV$ M%:-IBUHGA96S[6D[@7>V,X)#*:B\&T)GN[-J'XHGR+R@C@FQIBH%@"N[`KY; M/4/B*V'KF#O5!%66A.93#5LDZL&NYC*2XACJ&>V!&KJ>(?%J`:+M1DX3M;FL M9^]W[+&>T1(@/@1GP*NX)%XK`-1N^R,)NBQM.TO7";YY$;YN]0Q-E^::N&T* M8E%61E>()X0$`BD[3J.?!@Z#K:@V)1."9UF;>,W&QF;ST9V>9N-7+ M;_B!VCUL8\B43-!8_[KB!.:U`S'ROZ,IQGAO^-[T%CB?#GYE;0;K?D1+G.?. M>F]]*V5B=A=`FXJ6#$E7Y4;9K#+0>:@AB,:M=0A>0_Z^LJ_@ M6=MWW)XV]I(H:-F>]=H74L1W9P";T[(=A%N@`T7<0+#W/HK6([J?V\MK_Q&Y MYYZ'_%[H>B+B(9)Z'=A-0!D"*H8FZ&[TCQ:2Q6\ESI@3O;U0&">.P` MXNH"+`"_<6%_]QY*]N_\)%R'K(/\5%E28X+LRU>/0#$C>5%XS5A%!"W MV)[PBH0/K;4'FM(RCUL;;USGR5RBY;N77SU(-?`#5[G"]]\ZLV50:P! M=C(;]#=_/ZW;OP?0&WLM45'!RDLC`KVQO(!-U^9S5=F9[L7YUL9+?+@#C_%Q M$2P##_HO-Y9A^^#9<'IMLZV/G9%GK#MMBP'_`&N;\=F:2+V0.@6]]9HFT7(!N?4M4D MX6!`-O%)0* M6UM^97$>4<8NIU6)].3*Y;=%@VLG=CH4T.+=9P/`W"[)S.\$=/]0-\\GR((( M_]L-[&H93@]`X;QU/Z4GA5=X@2Z_^==MN>6E.6Q->:]IO%)U2PH%M!X@:^[# M=$WEFY*M$K#,KO^E-]`$1>,K[NTIOJ^TK_F*-I$SOEX-`MRI,WUS"9>FBQ#_4HCF;=^M(2NSN!V9SG@BKE3N\V`K19 M&/+!M.'IWL,^0>/GFJ9N#4(HKV\8/[4$O+%,J*(F-PC\]@9X"[,E\K*D;(^U MZ:`7@,G&RE71"%_-MO>P39$W/2'B;UP\'?./=@BJKV<18 M:^B'`;]YK%.G2I3I0L['0].80E]+(-+IZ8V?I6BHGN`NBNHPT;P=D?F,T;-M2Y M)F?O/FA&T!U.7']Q[`582UC(@Y#`)36Q?@*^Z,A'=VA:'9#;';'&^9.YW'@8 M^R@0:RYUBJ;HO6&6R15ENT.OXP.@R5GD/J1-F$';+3`O,>GS3\C]P&YM6;]A+L$K;3FT*X=!'43S?N`"#5#ZC MJ:D"S^.>@&8O+$%W$]Q;YN*#Y1BU@B<)X;1'4?\EL&FA*R\JDJ+I63@R2Y]E MV'`.W%EB#GVPC(?&M%_!FU"X>FZ![,H1^O"):UBX:>W;?Z*7QF^`"%7@98&H M3>5J9USY?:$@?$4;?+K'?KCU#3_P&K_V#^3EWD==K:`BX5=_`SVS?<-]^6!: MX"P;O_&+DWUA817JF\A'%R#<#X[;G*"W(!WP')?@PN'C=X;]DGU];NDSRKM_ M1Y;UG[;S;-\BPW-L"%BPGW1WQ+9BM;.R^4D5^P/\ICEU\7_SEJBP4N6[PA"E MW=L^_$%[5V:E,YII#3]O:_[P?[,6D+I:>8-F/H2MH[8?M1OC:,P!RV`B[P[> M^\["-9ZF0/POR_]I:3YQGO]BH7_^K[\#Q__IT]67RY/_N+SZ^!]W/W+"J:C\ MQ-U=_O?=R=67]Y=?X%?\QO^)>W]U>_/I_(\?N7O\OI^XS^=?/UY].?ET^2'^ M1O2;K^$Z\*MP="3`S)Y MOVE;IHU^XCYH3_/+.7,,>Y0MZYKXZ:\../KV]^C^7@!&!COSB M]PC)>XB/4QB^7-]=TN`0N/]EK#<__<^Y*`@_O;^\O?AZ=7-W=?V%N_[`O?OU M%JAV>\N=?WG/W?[Z&9#_`__^]NKCEZL/5Q?G7^ZB)=/USB\NKG_]6HBN&.F;D3Y]7R8T+9,YB54=%]P5(?&,,V#=)V-I@'G* M_/:[6*U$_B?_$97T)')SR;>$GSC'Y3(/`2#PNLSGWW,0C7/W"-D4FD"T@XPG M!^]B.=^!N`M?8SJ#O\F8!R(?"PCY<.\.D/O?B#,"WRD!Y2*(8Q8^Z5!X,A9! ML.8\8X7\%\Y[P4LC[S0$2%#YG]*?K@.7VT`,"7:>9F(VKK,,%GX,#-F_H-4* M_#UG>MP*>R#8%SHV!W2"0.#I-V,1H2W/Q8+4@H$!P.%;*:"_A8#>AH#>AH#. MN.='<_&(7Q#2`DA96,C;0'"*G8YEO6":P28R6`!A%@MS"2`"FVV$EO`"D$AP M/J;]KX`<2`5:EB7#$`)8XG5$!3!68(:NS;BEJ:'"WET^MTE\E$6 M$-`.SR&I_[38ICNA1\Z[WI;2SC)?/5*GR\Z(TNF/A1 M[2>O*&O&)OC9ZQEQKP9IH<]_")J"\<6CGBNR.KA?V=A!0?Q9,#&*_#* MCB'OUT-CZ7M%AY(XD-("Q+Q3#<3(Y=5"*[\HK(>S#>E^MPC)):C5&HPR"^); M6X1,0)4/1-'&"`-TK!JITH).^R@\-V02:P`JN<:>\=GT'[E?3V]/RZ%&%*]` M[`@1(U@9;#L27F(?#$MOP)7G=@+I4NE"'\_/;W)AOHO(X2(/.W"P-4230,U0I!Y(V-7FB8,)2DQ<'#%##"\URTI:S, MW`)B5DQO83E>M,/$F1AL-P"RTAI3.17M+!`RI*SY2Q*VL4F7B#7-TQ:[@!L%80PH3HD MJI6&(VY"?A*3Q.:1$IXLPKI$O%24$B`\HP<*C&GMM0$WX=(L+;9_^#,NTZ'+ M[$]?H4.\98AW"J`@YL,CV'W+!'+C?7-Z]/B[T`W@-)!IO90\ZR)M`B+J!#S[ M'N\.2+%]&88Q2Y3,?6,KWK6^]J7!QL$)QGDM_$ M:8*E$]S[J\`JI04^#)!#J"PL=9R3*J)>KD M0<16*7E5N#_`V=D<4'GRDU#?LL+./_)MV-98P1(EF=4$P0(U/$2--)PGTR/; M$[Q6B%(8523(AJLNP6H9BY=HGT#U=U3*)OCEP"F2A0(:A@$P?%BIN$09/8(<-8EOA`],%6:%LVP,[IAB\J1:*\)U)ZJFXT!*!0OT=X("* M`!.=YR12:CM^**EKO"9V&>&^E51%B@MAPDXR4S-^HQ1MU"/QP)OD<(R"XWK) MEMT(\PXOU/1O&'L3;PT.WPY3!\0:D22%RWF/9I++(U)'H0'NV'.IQNU]%J"U M\4*J%R^<%RP>,U#1]"$1[U&*]LC!^HHM`!YV2,$I MFXR(RHWWAD5LB/>(D%]9G4M,>WG-V#$9=L$BQ5F`):ZJ!JY-$K]&6&5,B_@Y M@B>V.342)*Q_86R\-``FH6-+%&:*2(8(+J,3I:0."EF)"4V0]\6>',,4N#<>XX% M7TS6-O/!\CDIJKE/]"T%(`?&.11&;.LQR^O7QK\'7,O9`.R48:?^#)M\'^&R MQ.J4^Q!^F7M!!G`,M_8LN??@$O"A%DX29AQN&Z7I4F#+; M2+!Y3CSE-"U-&:0M`9NPY2GW^V.FFR^_4<9HQPU"$,>9N#D!&Q<X-#YX!60A]5.KG M`P_A!$SDQ[-BY\$O/1]1^O7N$?BI'W?E=-C_N8"X8F,LL>9'-.4CUN!/O(VQ M*'_R;"[]Q^AWNO:/Z+=9ON38X!,VV,`&M\Y!E'Y1\7S9G*84"1'V79H`)9\N M*Z0.!XCI[^\=WW?6%(Q%G8;QN^NO[R^_GKR[OKN[_HP5P5C\Q8F;;QQ$,^:R M'N88LM'J7@<=;,A\>G30Y'V9X@+6%YH_B/_$AZ#R&E/='Y1%.U&B8@B:?,%? M5KCXO@1/_DJ90YF7IENG;43;$T6HQH>IXL%5\=?0FWTRGXJ)G3IGU9N^ MA9^[%<^'+B*'R#V(R(,+$=GR9($;_'_D_N<%_P'^_%3/B19"[#N;.F=2;WU> MHSBF+_UL+![A>9>V2XS_Y+8SW'=D\_\]L^VCM^UTM4@,.U.+:I8IM3RK$*#! M[2HSE8>4B0^!:YN9:F"5J5R9W\(,3;6E'$2"F+7L1!%F+7=FF39*:\FBT,D( MT"=\!!F/3:LQK=E\>5V!J#<92YB_N^%DII-)_I8CHG@^8'**I_QR9\59L7)D M52#*9KNX_&&0DC+IIJ/U%\1_R#K["D;J#'3X&6E''GV1)(_7_GMXXJO&6`_/ MCCT\,0%+4A@=#XP;>3:&GY[QPPVQN(G#BZ=UY-IYRDNE,SF3>1"FO42X6DM. M(FXV^("T87G9I:Y5#[$*A*UO6"H\O>?CH-!YN'Y8\!0W7)J]D`S+% M>N48^RFNUKBXGC;+YFK9GQS[`?B%"]'AK8"LAZ7_IF;G%-X)D=Q MO>#A`7E^='0A-"QKK,*X@\HD`O4#OM`/JD3/T$K_0>R<+W^/S4DIQP M/.7.UTYX=#CIF:N9WY1ILS-Q-_Y?T;%C#F&2)=T4I%,.CUDP2WV_<=N?$UDV M3)>PU3=L5GXYY:XR-"OU6)=)&!E3W%D&YA$?FHVI$S;*4,]6Q_C@<3C10?FP M==WY5W3Z(^(^[.VB>=9`ZT5Z&#%=:F4YSUZ^!0#O"3?1>(J,).2EB=I/$YTN M)TTP"VR>2DAWN)]9-\1BAQ3]45,ZG?T"GXOZ]SMQ5B\0S9:F7CZ2%$PTVMAN`^(C-5D M^\)=+`:>T%ND;7P<`/^='\=%`A8\:CEW1-XF-W-D(KIT*7*L:9'RBAR=B$ZV MXHO3?-RNRV%=6F+]O:_D=V:-%8K&J(;''"PY;$8F MWQ@E[*A'#`@AELDQU$R4D`G$D&N1F&-!IKD#"T%82O1VHG@0/Q.]+@>":<-7 M2""4G&'('+K-=0!'*;#`QN<+PH&!F^B*S!@J\@9C!4$>MS+=],!+CDPD8HXC MY6BM*,2$D!-OV]-X$R]8T2(=OC@Z/I,G$)F%F^%#<&QT^D_T*]XP/`S_@&PEHK:Q)&_02W?OA<$837ZH-R"[RC&LEA]G^ M7'*`$"_/Q>%N^%;JS#IX!OS>Q@E/;D91*3YDN`Q/RQ@0YAOF\J2\(XFFRU5Z MY3P$`&"::4D'?.;I'-Y@ES0=)]W#V69A(CGAT2N*]"$RR0H/STQ66R/_T:$? M8V&&>8H`H_4NG?DQ82EF'D?(:V3@N6KQ$48P8UE;ECNG M7&0-.;9,5=2KW$&XT-!NPN&.V`OA-]!4E;PT[Y8#+SK'^`ZWH9[<+AX=/+S` M"0=K8I^;'2^;#7@=%Y\NH8)WD>1#LLC&VWPW/-!-X10Y+QB/BFMR8&3LXCFN M_?.'"K'X+?9?'Y*!?5NLPKBI?G"CL"4)&YD$CXQD38J7YI6X M#ZF.D8GH*W+..3H+')XX3O.L12&\CZ>6A&?:R#E>G"HCF3TR"<(D'^#+FKP5 MGL!`H68,[PML>4\!(HB,H[/.W^.C>WA!,NT!YXOQ.L:"?M/!/?*?P\$G8=K4 M@,AC80+1_&3`9$2\S+R-W`HDDM^6<5B$!RT@J`EYT'!29M:49^Q:F*X,-I$Q MMW`*@E9#_E>P?%A'0S4=?)@KG@<6#MK8!``"&9:/9XN$K\J-QZ$S_Q-Y7?0X M24:G\_P,G/O`AX6]`Y_"$GC^\,>P]MD,*K%&EET),EIWW8%KWLL:7/$,K*MK MKK;S;"[M]]A7`_YI\X8]K2/W^WM1/6*3JZ6\<"\3AY\CR1:2X,+N,MP+AUZ0 MY*^K9)%<9D)NK8E\&#Z7G;JLVEQR;W*T+MK`[4%"F==B7HMY+>:UF-?:@^IM]5I2SFME_55@EST6M6$@_A-- MG\I^,8OVATR!\K:V/AT%* MPF^AMF:68_K>1DZ\8J5AY&$V9?(V160V94Q*P\C#;,KD;8K$;,J8E(:1A]F4 MZ=F4.\,WO.[#FS MY^.T8,R>,WL^-->8/3\^>\[R+*.NSXRCY#(%:C+Q8@09CUN9+#V8@#"",((P M$\($A!&$$829$"8@C"",(!,@"#,A3$#RG[/.WZ/*OA<'[].HE)F?/*5,WO.[#FSYWL7<&;/&_%44N79 MG*=/'AJ2M;NIY5$9*6:RFFFO,9#.3S4QVWP67\#,V`GLD([`%-@*;C<"> M@DW9,?!Y+=.M$O*P,7"C'`/'1F"/66D8>9A-F;Q-82.P1Z4TC#S,IDS>IK`1 MV*-2&D8>9E.F9U/8".R1*$I=7I8UPD^T3,5&8$]$^UCI=F]<8Z7;XRO=RK.Y M3)_.-)8P@K5-,D/.##DSY,R0LS;X"5HP9L^9/1^::\R>,WO.[#FSY\R>,WN^ M=P%G]IPE6D9NNII4:,91=)D"-9EX,8*,QZ],EAY,0!A!&$&8"6$"P@C"",), M"!,01A!&D`D0A)D0)B#YSUGO[U&EW]D0[/$K'JM&[8UKK!IU?-4HUETP3@O& M[#FSYT-SC=ES9L^9/6?VG-ES9L_W+N#,GC?K%I/%F230YYD-R=K7-5&5H3UZ MM*G&C=DM9K_X M*3TLJ2OIFGFMZ>&)UIBV_T9+,B+;,RQ8]?D1V:!*OH7(9!77]/[BG!7G/-O( M]1[-#,BSKA0LVCLWAQ_$$;VX%"HJ_ M2EL+\`E6QL(/R*AM^(D4=H`.W._!-W/&73R:ML$!N&01)W"Y9\-%CT[@4:0G M^_@G8^DY]HR[=0+_D;LP7`(44->`=\Y:5H2X!">,[XZ19S/$XQKM]9[=M6W#X"PT_N M#2\>VYZ!Y<)9;Y#M&97V@E&ZRE14S.?'%#7L%PZ!)5L;/E9ST/'L'/.ANB"`4JY+.NCX9.G'UP#D%C":GB6?^"1Z?_P^W=X)MW)[>+1P98H M6@JK)GRAO-C:62*+:&("R,)9KXFA`0GQ."(B>'@_7MMW#3QM/]3T\F+1MPA, ML!#^F:P2PGK*W>61CJU!^>8`%VW@W>2>`F(,'<\GUA7_@U"%0)RWOLX3#3L!Y0'[Y0[]T+4LRJ6+K3(:!@L@7]&!702NI,%/8KS":Q0 MF,`SX"46/@&:X#HCH,12!]@$BU#FBH#$[\;0Q\))'-D*F>`]LOQ_-$$X@>^& M5:)+^GW.Q=)]RMVXZ,D$=V*]9''*H8V9ZI666ALOW#U0<8F]?HB0BU;8.X34 M!9]F6,47XG\7,_6\:RF9>*4^[R&U#)*RUD?`.(;+0R?6_& MF2L0F)<9AZ4Z@YF!;\7@\%T4!+=$=G+^W5R>@,0LC(WI&Q;=B8W;L!XH$JMU M9%P>DY]^M9?(I:X^`U^Q0B[ECAFR&M'&U)OD?=;27,&CR,86\![YSPC9 M-$NX@JC47IA@7#P?3`H)L;&3(>J/[ZHA&%(OP*&Z:&0;H46&YXE1)-X"0`%+ M9H:0O2##);\.'5%%+)^%'^.9M?5@96%#@9@MZ<>67!JN#=)+<[;??7(\[WON M!@3T(HR/2`0]R9W(P8W,.]"G1$F%>!U,Z!OTJ@V%S_FB0+F M.0A)DN*/%\XL%*%""4SJ<;,#H3ORH8X9C". MH^"ERX@D]9)1@@2G"M:1KR)+F$\H-K^P:G:?!5$=!(AXAT(L>WDI\'L.K.-R M&\?'(25)QB2+>OA*L_`BM`RRIV4ZOP_1-SB,0D2!,%#?LFZ10H_`&A)NPC,G M1>0P=[!4V`[AO!4L"?&JO`N-VG@U+#@QG#E*GW(?.B(DL])2(>"86A&+PEQ1S"70WDW@PL;+0YG+DN:SN:S,)(4OTBO5 MSLRN*.DPT7[RDR=J;PT4^8B+=AL"4P)FAHFY3@RP=!L9)G*X-X#OP+2683D M\JER3#DC\&[[.U!9#N'L'`FPP!K@E)_M&8M0[9U%'BDNI0XDT@L$NR`8G6E;-:\L/Q2$)9<<(+%!3R9_&:/\?/_>JAZ]5E4KP!P^'# ME[^BU3_?+.0_/X#?%WXQ;&S/[AQ)`".'?WQS-BXWLV=#<%Z2L2Q3$V+6-(\P M(]#&"&QSMY7A;D0D*2)Z#H$DRP,4U MN,IE_%+MD\H"DE.FI6%H*+AAYTGX5%2K\S)Y%$K=%-;(U+32_0ZX8%(ZBTTS M,--:1LEE6KHJM90@!-'.QO$R/"K8XHRNIO8V;S?+=O4&@'1O"*A?T<(":I-W M8AZ?DPH@IME[Y"U<(-K,6WLLO&)=_*@A^;#(S@L MRP1RX[PW[O$('>]WH?]RD;$TX];"7$DEE]#%>Y+ODRSF,HR5'-=\`)]N0;2" M6RLAA%H:/JW^2P(`%R%N#01Y]/`F!X(EDKB^1Z6+]IHH>R-M+3O8.]=8(GCN M&MQ(@\VO?[]56"5VIDCB<(57`@JUH9KX@)@IH\%4^#)!#KBDN4&+;"# MIR1(BM3)@XBM7O*J<..$VV5R0.7)3_9`24LVJ3'G*XDI@@5J>+0N>=(VZ85U M(](VAU$*@Z,$V7#5)5A%`PQ2=?6,3MD$OQPX1;)00,/P@(5W'W"_T&H5->Z# MK0S+ZF$,"';>B!OS31=D)! M[[A>DLLPPH0,81ZED1AO(4@T``&%'>94B#4BV1LW/>41:H))VZ*#940NU;B] MSP*$.VJ-S08LBQWG-V#'A+HR<14J;J%T$R&&3!_\+6[#) M1KRHI4YJFU,C0;8-#R[IOW"=E>G302SM*'$X.DO>G.Y)S36&R35+;<]P7MH/*-M$S\=V$(*UOY`_"_>%Y)UU^-F*D)*T]9$N%1(<91Z@EMW#@X,A8-%9/'+X,(ZA$[0(JEF+4D3R84 M'TS&.'K(LD)8DA?,HI-&R%J!L5^A+#PT@&9A"V.4?8L(!HB&AS>BO47,2$JL MA\@Y$2P%SKWG6/#%9&TS'WR?XW0[79-WT>X_K/*MX)Y5;U@);$$RH0->[93<&TI0Y\-+Q*KTF%,JD.I\@VT M@@"N%_LO-Q8NT=I+G.L@@1#S*KMYE9B@E*[6)9=0E[6Q[^)S"K3EBN1%,7FS M'92%'@K8&H>%07*DC-9L&'9B^:&CX"YQ$7`9G9^,SZ9' M[#N$^613/4N.)HN@@ M*W8>_-+S$>6<]3T"[_?CKISVPPYEB%8V^%BH_1#1E(]8@S_Q-L:B_$EVR(NN M15->`(\38"23SL.=1=U&L;OKK^^O_QZ\N[Z[N[Z M,U8$`V(`+Q+`SM:AFF5++LPH!&MRN,E-Y2)GX$+BVF:E95IG*E?DMS-!46\I!)(A9 MRTX48=9R9Y9IH[26+`J=C`!]0H:'\!R6&M.:S9?7UIN2KUP;#T]]QFU#&\-/CV[BWCC<,H*G1H7S8[/-0^6E%J`67C05-)IT8=I+ MA*NXY(#I9N,:IF=87K8,1NI=Y="[4`#+EKO",V0>0.*^D`&,N!0J:+C.*_(T M7T0V)LV:-[9H:UG!,U\I/!UF+C]APY73<4FHU/(_/\-JZV#]F32NO#F[$;0_ M4NB:O.JL.W1*-73&MQQT(M\-NJLUKM]C.WKMOB=5=,.Z7GUR[`>R3,@#U@VS MH\E,B$OI1<`T!KW"C00AE5D;9O^M\_CH1S34&[>&8U.5#!X/.Q03)H16N&P% M0U.'!U%;+_DS).:*-"B&IG1ANHM@C9O8<>LZ^F9Z9>M,3L,\DY/P7O#P@+QX M9DKH`-;8U.*^.I/(3=CD@K]`[;\$Z),V@R>$YW^3A>_Q*<`E.0Y\RIVOG6@" M8MQ)21M[5#[6:.(S'W_%TQ.C"4WQX9QP`CG^4E&JXV;0:-H*H4O84![-USWE MKC(T*W7RETD8.3W<;PAN#!\WCJD3-CI11QO$^)!9,N&:=W!T\+3([7I4O&8F$P+!][3;\(Q#EE)R$L3M1\J&NX0C?+&_;6X9R,[ M/=BKAJD$%:%E2@O_@^\Y*SK_KP"8X2[P:=7WZ`E9#MD47(8M/2R^;S/#(21D M1<=4AKC,4>UPIT^!N`7J+E/JAC<5)+.W;8_XIJ*M3/HFMQPF2K[(O964F2++ M,^ZMHN'YF%6@O!5G.GQ5E_5P)$P(>`G*I(FSQ2`Y-REA`N,43O`?0G M`T^SK8^7)4&MC.[?D8L?\`R?"S(?`)]B_8#PZ7\41_RCTZ0]FZF41$652$G& M131C?>:[V"HLG$7:QL=A\-_YVUY(:(;'_.5&6H2#6XK^1W9HU5R._XO&4ROQ,?4(0HN+1(_2HD\O1RUPL9 M)>RH1VRB>8?QL>["E4M1R(EMR()@V?,7THCN!R!F> MS"'V7*]ZE*P-;'R^AH2'.!1>(+1,(EOR!F,%X2RW,EV/,LTTWAO$>X)HK2B8 MAN`:)Y+2R!HO6-','[XX.CZ6)Q"6)\/WC04^HH3[?]+##EG/Y_EN$!UB"._' M2;KXPV>R7^&>47PA%*WI.FG87Z+[Z,8HH"Q@Z9F+/.-:R6&VDYP!9EN'%/B4HXGM^*N*!/`0`8)K[2Z\/ MRM,9Q`%O4>/V^*3//=O63B0GN0VL"%0X)!X/>$]6"V]8:>*&JQUJ\3!P4]<[ MWM#_X&XU)2%-%JY2A6*Y_UT.I"3R2Y,JCLGU=ZJ%`L+`-=O&*S/(7_2=,EH_[D*HNQ!1+ M")'L,.8ANWDR%2#->A>9?Q]/*@I/B)*S]CAQ2?*L9/J+23X@EP*L\-05"C73 MR]N^,T\!(HC>HWD$W^.#L'A!,N$%9^_3RP7*=CB^K"U.8AL0'2W,37A/3SBF M89V:`1I=R&YC6SYF$1Y;@L`KY$'#L<%9#Y$QEV'RF-S43"(SG*Z@=63\*U@^ MK*,)PPX^&AG/&`R'ZVP"`"'P0C9$K\J-Q*(S_Q-Y7?0X*0VDHT@-G!G"!_J] M`Y]I%'C^\(<:]]E:+;&VL%T),A[7W%]GF/>R!C<\P[<(FZOM/)M+^SU$V8!_ MVKQAA_C(_?Y>5(_8Y&HIYSB!2V9'"C]Q^#F2$"))..PNP_UZZ`4]VE7'\1\3 M=Q3ANGCLP_"4@]1E48<6[+4M.]]*>+S.A?D6YEN8;Z&PE?F6/?L6,>=;PDF9 MV0E$SCT>3V:$!0RR:TC\"WW!I.VFZ%V2BB_.F#OWCELU[27^0W8[T=X.-FH& M94\7;>#V(*',:S&OQ;P6\UK,:^U!];9Z+2GGM;+^*K#+'HO:U!#_B6:Y96X; MRPWJOR?UU&A,&,YZ/V>[>\O+T7*18?]PX)%^C#C#BG+MR^6%"LZSA>^K$*S# MN+\QBO-A\_IACI74]\([M(,UOM@!9Y(,HSU\S8.558E,*=*GW9A+9L72 MZP-Q5KHH=ODD-9FEYZ+D+E]\C(B:%&8YX>X14.ZT3X&N)D;L]=-K_1+8P2$GX+=36S'), MW]L`EU>L-(P\S*9,WJ:(S*:,26D8>9A-F;Q-D9A-&9/2,/(PFS(]FW+G^(:U MEVX1IBB3FW%8/?V.5@,9F]*-8-[;!7V&1/R'S"XIW!!.+P/L21U=/`6E7A]S MJ=Q&(_^FH'T]U'7+Q&`Z0>/:VST5NGH1<+[,U)%Q-(-1#9`#\U21#VJVAE+4 MR5HN9L>9'1^::\R.'Y\=3QIFQ'V-=F?V?`AQ9_:\[L.;/GS)[O7<"9/6_$4TF59W.>/GEH2-;N MII9'9:28R68F>VBN,9/-3#8SV7T77,+/V`CLD8S`%M@(;#8">PHV91A-F7R-H6-P!Z5TC#R,)LR>9O"1F"/2FD8>9A- MF9Y-82.P1Z(H=7E9U@@_T3(5&X$]$>UCI=N]<8V5;H^O="O/YC)].M-8P@C6 M-LD,.3/DS)`S0\[:X"=HP9@]9_9\:*XQ>\[L.;/GS)XS>\[L^=X%G-ESEF@9 MN>EJ4J$91]%E"M1DXL4(,AZ_,EEZ,`%A!&$$82:$"0@C"",(,R%,0!A!&$$F M0!!F0IB`Y#]GO;]'E7YG0[#'KWBL&K4WKK%JU/%5HUAWP3@M&+/GS)X/S35F MSYD]9_:K%M,%F>20)]G-B1K7]=$58;VZ-&F&C=FMR9E MM[+6*<.K3.J<_!A/+_[YA\`[>3",S8\?#-/]#0_#_9Q.XKUQ+'/Q$O[W#GWS MWV&:G7$QTW^.G_V*GI`=H*]HX3S8IF\Z=N$9;@'PP3^^HM4_WRSD/S\`;L(O MABWR@GCG2,)[M,`_OCD[,%_+(Y3;,W#;P.3:03,1)2FZE2$NU5/%WRQ*P,AG M4VGCR,Z;MO]&2C)+V#`M6?7Y$-FBC;R$R@<0UO;\X9\4YSS9R MO4=S0PL1-G@*M#1<].H&'BC+! MY1[_9"P]QYYQMT[@/W(7A@NZ:AL_A0AO7'.!,$U6YC<@A^.6;-L2^]VFEV4I-TE:S/0(!W MAH>6%\YZ@VS/P,]<;_!_S^WEE8T'3)E/Z,8R;"]<:BJ&J;#UV;-5(H0]N<>4 M+8M6EM;UNZ-QFJ;Z7>6@1JEB8CZFJ&&_<`ALYMKPL4$!:Y(=5[_BD+%X!)BP M;W6(@',&J#^%/89/GGYP#4!B":OAZ?J!1^;QP^_?X2EQ)[>+1P?;O&@I;`3@ M"^7%ULX2643G$T`6SGI-3!J(B,<1&<'C]/':OFO@^?>A32DO%GV+P`0+X9_) M*B&LI]Q='NG8[I1G^;MH`^\F-P<0L^MX/K'C^!^$*@3BO)UWGI!+HSU^Y@D3 M'L.-7--9F,Y+PB%*_X=F&#.P.27#.7&=9[,)2"%W"=B M5.'1;XM'PWY`>?!.N7,O1#VK8^E"BXR&P1+X9U1`)Z$[6="CN+G`"H4)?!!> M8N$3H`FN,P)*+'6`3;`(9:X(2/QN#'TLG,1EKI`)?BK+_T<3A!/X;E@ENJ3? MYUPLW:?3'!::FU\<+=`Q67.+X($7+1"ONAD+K@/0VK M^$+\[R)F^-O8.;B)Q/C1[Y:Q;.:EXI2[_`94\DH+&=\`(ANM3-^;<>8*!.9E MQF&ISF!FX'LJ.'P[!,$MD9U<)&$N3T!B%L;&]`VKB;OMV]QD8$7><>D0XA;(__1(5IK+!9.8!.E MQ1;+S/(FI[%@@S(IG^2G7^TE&K$;T/?57>:^X-%?P*+*Q MC;U'_C-"-LW6KB#"MA(X0>DM*G)DLJLD"%VPN2F;& M1GYD@;CO+$)M""1RT3,.Z2!>6@06":ON7^C:!S$EMFCE]8PGP[3(Y5.@B?'" M>(<`L3T8,@K;XR@T"G1A8X#_]8QP=A.'*:#,Q@.*8_LDV*<0--J)!#X8*YO` M%T7-Z?*GW'O3"O"Z&=`W:12>BW?S1`%C'X0D2?''"V<6BE"A!%+UN-D!N4LL MW,QC'??#29422>LDH08*3*.O(\Y$E(*R+ MC3FLFMT70A0*`2W>41$_45X*O*@#Z[C"86A&+PBQ: MS"70WDW@PD;10YGKEN:SN:S,)(4OTBO5SLPN+NE1T7[R. M&>*,8I[JV+.%'65)S_"'$^29/N=G/,\WYD-)'`I\J6!"Z3%UIO+23)F+M-"U M)3`E:&J8E.-(@T!O2_16W(*>`Y]B/;U-C,1E!`6.[2Z(.P@WMZOBZN=K'/)S M@6V&\6!(B#?Y&%$2M&R4**11HO#G+<8_W#1[L&O^/1*#ST3(WD!4OS#7AN7] M\\W5EP]OSH0Y:"4H98IN+_"?Q>*[9[+,*\ERD0KC>W3OIR!4$$8&BP$&8PBZ M'((P>M6NHJV\R&`NX,]QR(O(5Y*EK;RH8,S`E@TO+[?!O0>!'+B#RR><,J;6 MN*>RI3QP62@A9=F-A,2=8*5ZO.4@"#@XA&LA9'L(L0PNL-B>L0B#%F>17%\< M9I6JRAM13MOT<9'7`V].PJD9)9*"K[M.\/!(#8CCN@V)I^Q%4L.A)*Z\L*Q> M(RZXTNM#?.XM("S'B7I00,^$76OC,*.17I\5K0&PY3S)$MZXC@T_+D*8)VT8 M#IYK@L=H\I<2F[O%>TE2K&)9\9XMQ=+!+62P10YSLZ"6AL^%M3U<`XHV0=B( M).R@)$YRVL`]FV!PPKTYYP$IS)6YP"5E$UZ)LP[4)#;$#('EDWV(LXF4&79< MJ8G8.!ZI@C2)4X\-4\>"J&'H<[A/LI+UMVC;`@9=L\WGY^=!%['MN"_WD M0>),ZJW/:Q3']*6?C<4C/.^^5)@2_`1(&8M.U&$6VC MX_JH?"XS_N.L."M6CJP*<):Y0CC-[J*U8=JD5Q&YZS357EZ*K+.O8*3.0(>? ME0^M;T_0ERI^E8^D>?EB4E^L3.HG>^'L0G%:_T;YHP&DZ6N+G5`[0"I50IJ$ MHK#0ARC<3`#5V@+:#,Y2R>,)>46(*TNH?R86_BICQF.0(R780=C#[S?`EP9] M*$T__X^3$^[_^?WS;_+_^__\]V(3?/O#5O3EO[6GAS]>[%_?!\\?-5?7_E/\ MUZ]W+YZE/2W^S5N_^/-?+S[=+/_X/Y:DV/]]?WWQ_NKEX]W?2+YZ^NON\>_Y M_/UJJ?_ZY7^_TR[N%^HG:V.O`N2AV[\U^>K3P^;A\O8_M:_+7__^M_3YK^?- MX\HPO?^4;Q_^0_RO7[_^AV.]^]T,/OSVE_9_[N?S+Y^O_]NZ_?K??P5W__OI M_O?SM7=^_?SKP[^NSO_]R31^\^^_?12O]8=?Y`_NW][_OOIZ_<>[K_+]!W_S MD?]E^6)>_W+W]AV\8B6@86N5\E$"5(*P,U1G](S*M&4B>6U_15%?0NX;]Z[ MPTJ^6[F]GQ*:P/.'KZ'MH8B61>[F_/W[JR\?DR2]N/G&(I/6%)H\>6";`_H1 M$T)L)4)MRSRC*_3@Q@B(JK9F,O9?[/F$GI"5.0FPGZH-4QI&'F937HE-$9E- M&9/2,/(PFS)YFR(QFS(FI6'D839E>C;ESO$-:[^U&Z8H4RF?LLO7.LK'A>$] M;FE-(6,WO.[#FSYWL7<&;/69YEW):K27UF'"67 M*5"3B15?;]/7+-)P/?K5(MH%QZ[>F4\[L.;/GS)[O7<"9/6_$4TF59W.>/GEH2-;NII9'9:28R68F>VBN M,9/-3#8SV7T77,+/XD'HA#Q',_5X^(9E-O.8C3,JD(?-_1KEW"\V\WC,2L/( MPVS*Y&T*FWD\*J5AY&$V9?(VAH2<:SS>:)U M"3;S>"+:QVIU>^,:J]4=7ZU.GLUE^CB>L801K$^.&7)FR)DA9X:<]3U/T((Q M>\[L^=!<8_: MCU_Q6#5J;UQCU:CCJT:Q[H)Q6C!FSYD]'YIKS)XS>\[L.;/GS)XS>[YW`6?V MO%FWF"S.)($^SVQ(UKZN$9H,[=&C335NS&XQNS4Y23[(Z-^??PB\DP?#V/QX MNWA$R\!"UZL/ANG^9E@!.O<\Y'OG]O)3E,HVD?<9&5[@HN6U_14M`M!MWS#+8`&L"3YQ4(2E3_/O>N5)+Q'"Y$7Q#^3!:[L3>![9(B6\!FM[Y'[ MAENBA;DV+.^?;_@W9XJ<(MH8F+-$)OM%A,^C,1"H:9$BYMY+\N`7Y`OUI%8; MD%JBDEI2Y3DOICAL@^.L/[#K"=L1L)YD6,O!*+2087DN[R@:_>,AY+$8!M)N M$CQO0&BZ!(./`A=U$`G>0M=N@'TR@?Q+^%)*\H\.V.\+QUX@U_[B^"@/C?SG M!W!:PB^&C=7ISDDUZ^S`L*GS8]P)>LM\3V MQME@6#!4#XB,"'N$!6W'YY"'(S+3>XRARB[F.8&[`/(X*\Z%50`.C_,=;A7` M`L6EX3LF('L?>$!DSRLOAM^Z,5XX9X-<,!V`"/JV0;:'O!FL[@46^1T`;7"+ M8!U8Q+Q`_.H7J04&A(#T5M)FNC2?::+`K1R70`1KF\Z26X'U@*46:..;CLU] M=QX\@/@4%Q+4&2?HNOH]1@H,##')G"3,.&QJ"'VYR+KA]V684R([+%##*FX9 MN#%[;3!RW`LR7*`>H+^D4,H)&><%"R"^MPJP&*PW%B*X%`")55S[R>,6QL;$ MDQ>+P+F&Z1%ZKX!,_E86NLAWC448J!>7\HP5`FIX+Q@?%)*(*O1+AX@7\,`* MEECD7B@2L<1*'7[??S1\;HTWBJ`J0"2,N>&"'.?0!;$N@138Y`*1>@Z<8M-@ M<.8R,@K(L3:@"I(:61K;6"/Z1['I^Q\G)YZ*I^%9:QGJ,GE7*>=:; MK]4Z2A\\V5TU MEIL&ZB!YW5J7%AO!2B7#?V(#V3!73LV6#YE2MYUGU]A$Q`K_T4X-:%I`Y.'\ MT]7'+S]R.!`!Q[[+9'!FHYB-8C9J;S:J:3V/V:@,A)T5O:[*-\39HI:Q9GV/ MVLAW6%E0!ZOX)MF"[3T,@]7"MXK^E@K]*#QM42,;03Z5KI2&=!&W$:99_\>P M+0[QXDD&\.[\G4"!.Z?8\JE27"0AK:1(,U%2&OF?<7F-K4;R4)K%%)XI_+`* M?\)O4WFM4N&%F2!4JOSKUO7S^*I*W.6QP>+:JK:(,7W96,PYE( MW<([?2;(VM2<":LP'P1T9@K&;0KD)G%E=5Z^VA8P8\!2=Y.(#&^#>]_!C?PL M)\#>0@UDJ:RX]189FSVIC',V/3>K-WMF,U#:?QR%[B98U,Z-FE'&`V95;//?A>PP>=Y8 M.ZYO_CO\130$$1X(<\F^4R9%Q9PK/`-1U6<\/R8?8G,>S+#L[QT,:WFDK^ M3>,0\'@9+(A(K!V+C,H,)R.NC269;O@9+KC\F_A)^^QT,VL0P3J7EV\?1=9[6"?W%OYWGXLN"A""(" MR]7'+1&D,WQ=\+@TT+S.+L[Q.\FPTS!)/HK0X-[#P+PG=%A:>M$F&2QJ6E2%R M>3$*U>]?!N M'`]Y(?O.U_".!3#^/.5(,;-R[GE.;+V`#(@0&!LJ3%1,'L>V7O`(6^23F;// MC^;BL811!A0L(7C^*$$]I"@>UUHQU;0(3F:AA%G/R`7E4D)=PV-O73R-E-#\ ME/L0+5Y<"$H;I MJ6R592D5[Y)4K1P*^_'WI;7%?45/OQF+B*#R7`2C&OC.26;&*X1`BR!81Z-= M::8IF?;Z/AUCFU5A@&B!$!Y_.,M+;A'#93B;-*:1[>`9MX\)Y6=`'\]<@CTN M\K*X4$Y79R''@/9N2-ID&'!*J9""%+L6TC0A)'FN,: M_0#$,A??:EI("./9<)$Q^NLM8K$>CI#]X*B^$(\C$HIHE/UY[ M"38B!!E;XTQ,`F\U:3.=,5CAI.I[1&(>`N7S(]BVA6-9$'*@)8LW!HXW#,MS M,D%'I#M8FHV,*:3'NR"`)IX$SED.B*N+1P5C%<0+@2[AV=-%D:O;EE6P,AUT MW&9L,?5JD4PH77.;0?6,X_R]!JH.P7/V6H-T^0YO5[-O%]*W%V]5$`0(UQN_ MG=R)SC361*J;=20!`+?U(XZ8`4 M[]"HY#0$K5X]V!)?N$&C#;!J'MAZ,,YB(KOK!?YN'./^[IH^NH:8N!9,H4K* MV@`\#^&M`*!/JHJ%FW5:`*FT)&H.YH_@2B[(:/8'9"]>?K5C/W&^=@(PGK5` M2T6@PUU0N@DB>R`(G>C2H.4!WP+*60\Z)T6V)P)X1ZE0FJE<,]G8;1#\\RZ=:C;1YB-HK9*&:CV'3KH[91(S_D4W.^:?P9LRRH M;+IU3=?&*#PM&W8[Y9.@%+C9=&MV.)LI_+$J/)MN/8B^[_]("@OQV'3K:,GI MNH5QG'&INOY$AFVZ]*U@L`\"F6Q]#%H!IY8$AG[!6LNG6 M+#O7>(O&8C`VW9IMX@^"UE%OXMETZV,:.?5/[\0R<9=.MV73K/8'.C,UK-S9LNO4XIULWF$^5FRV'U^EE ML)92F%&5/$L=[20IDI@=^[9]0EF/H*J%R6KUH.(!=:U@[0U.K4#2Y+S/57JH MASXY2Y9;C2KK#>)Y@;+CAU@OT#AIV85U/IC?\$\5`.N"K!U&@.7B:,`)`)T' MN3B"4I95:2[N.EMO=ZB$/"&+FB_R+<'*PW6>UH^R8RWA9POA'V"%\\P4_,K5 M=Z?KR5S71#4S0J\GB,[VCV@]JTY$7A/F@R/ZT7&6>-`O?.7*]@W[P02W2^82 M>I39K:TF#1XPN;2]1V.'"'/;C-_:^4!?KN\N:7#(7#(57?B)N_IR=_[EX]6[ M3Y>WW/F7]]S'Z^OWOU]]^K2EKR&7:;+&,FJYOKMAWPQ(I=MCU&PWLCIS24-6 M=%>.93G/>'*\Z7$&YP7KM>&^Q%/M*3/_`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`2_Y$S?X\X#W^&^(M\U%B%U"]+YF[$(@C5\XPE^B@8OR',1!,A8(?^%\UY< MTWY`G.EY`2QNVMPOAAW@F0TBSRO%U?#@A3IHHD6!(\Z26[H&F02Q1$_F`I7I MFGEE`&O"^Z33C!`F/UWE8-)G>*X$6CCVDB*$$3@KQR4#)\IH&YA>;DHOT#M" MH!#RDMC&Y'DVO!C>^Q>R]*^GMZ<)]JL58$BHDU"FM!3@>;YQ38L@`2"$:7V` M!J_VT7+NT0\`KF,%.,/O<9_1TEP85IELOS@FO/(W>&_@(BK!?MT`._"J;F"1 M41QV^@Z\+DW@[M#BD;.,9R\P_5EV6`:'M=Y,KV<8H!"?#:`S^$1 MZQG\NVR$_#"6BJS>$GF`?F(N-RXZ@9=DE3%]=&VX?R&Z0E]G7RSFS0=%P;/^ MI*#BH>##PWA2&?DE=^]1%B4 M#3]:$HLZH:N+J+Q8`C-MK.]T^EQZ'D;?L*R7&7QW12<`=[C`3R`G7O2'0+)F>>\K2QUM`$("6 M%>*3%998Z@K20H]G0A(!*@:W-"!>,+Q(G!*2./>^`:SS`#'+<&=EVIA+S)N5 MB56'B#A9SLQ0UHP,(5A@/S1[N?BJ"`TA04S8K3'6(G`Q2ZUP.T$3+AF$$`0: MC&_L2XS-QH+XDW!B%GF>.+(@+I[79APR%H]E;.'C4-E=M$`@54ONU]N;N^LD M2EZ$[%T&.,S"'H./9H)0`(LFO5'#B7';]/'-YK/B,X/IR<`PB@"ER7P8Q=1$ MX.]*U-X(+Q*XDS M]N59@TO"7%C`Q(H?ZKQ'S.S;\-!%)#44-:T,.IF85(C)!\>ENC^@^@LRP-!B M'[6L&;^8]ZIEEH#^.P^V^>]"]QJ'OFU`UH@=>2M),UV5R))O28&<8CYS6Y0M M93K&Y>V3FN+YOM/3EH,'REOWL=PM"AC?R$+6ZYA,X>`@%'I&U M).$A@1?4#W\!9]7`DA,W@#Q8*_7O1:^<"_X!*1+ZX2#^+K'F5!"YC',]!@0@KO,-PAT"[?Q4Y""ZLJ+("&]C`?9UO,/-).P>P2-Y40!"TB*^ M:Y#4T#WRGQ&$N&_Y4YD/#0Y_JO#9=-(51`?`*Z&E4L$P@1!=.0BP;8&X0YL%=@$U<2K MQZ\L,+.&DZN22[X'KF!\XI`]?F&97,2ND]>ZSIH3=%WGX'NF520<184@LJ;G M,G%(0:A9-T/8\\&F%*F4BE),!3RHW'6L*"<:*21\#2$2J,`VSR!#SLM4BM49 M:/%6E&:BIL829GC$S>&-!SQ-4Y:'R-I2T7N?!,'B#"R=E7P;KTP)_L/(:(=H M.!T:WVZZ>_$6@BL"`I:5ZU7Q\0^F;8*VDI"_]F8'H6I(_)_)7(OS.$2E7_$@ M*+F+-!I"540F.QR__&`=#M5C[@LWP$@0W60&]M>^L'C?P,[0J5GHA!2ZXGT" M"L1;S8&+Q3H!\(MC+PSO\=J],5P_^L=YJN97D8J=1]HCI"##;@"5I$+,0,UK M"=2\]B>QA<04EH5!>G/&GZIBYOZ*MF`5I>(66Y,KDO,.U?,&N::SO"6>);-0 MA@6AU^D)HQ/ES=D[G(%^YM@789Y&4)>A.`WS2\\/OG M%MA$HB")%0V=;ZVY4[:`7M!*40+_DD*[*TQ%W.)/4UOY:>L5/&JEH6Z'`_W= M9R6+KT&I_PE:[:(GN<,UNM^M'CF;P?[E9>7RG_$;1_W7H`R%L MIC:;JC.<+&YO[O#!:;`GY$ M8X38W'^:D62CO9C&'ZO&L[G_!XD&QY=,9)$@F_L_3A?#YO:,?&X/F_O/DJ', M$C!+P.;^L[RCP_*.;.[_'L!B\\79W/_C2!HL,S>'1.NXS0V;^W]$QF;D.4DV]Y_-_6_AYM@@[J-O MU#J>0=QL[C^;^[\WT)FY>>WFALW]']_<_\P,AO8G_2D32&J>_>ANG6Z@9>C,^=X`$_+$+`(FBBT9W12P\[3^D!T*M#L-3R1]K@B-0*UX=PLIW0'Z M>D*?Y.__+KKY?ON4]7Y^^N/EW=75W> MU@10N7R*-98!H^.;VIQ>-X*G\'->L%[CRSQJIB$:DCV(X?NC['1IRP$2=L#--HBX;, M1C$;Q6P4&\-TU#9JY*T'->W*K*.`O/<\O[&BO#[:86VOY1RNGV!+H684GIA- M;9GTL0^QTYPF61)GLD2KO8W;K6RUHNPH%M/X8]7X#G.:='TFR6SF&9;AOK#`BQGX41OXSM.,I)F@TD_*O'83S_3RP)!/62^[3C/BISD^W,2_=NM[?/"ZJ/IR1YIB@5.^97;KF97AX8\BGK MY?;!.K7CN%6Y.K_\NK5RY(DL-DJR-]6Z]A\S+9^4MY-S/H9%JS:.)TP;51LV M&^76":\QCW(3MT^@T4_U2H>C5)5-1NUNV)&,@X#.;,&X;8&T=3Q,??2IZ#-1 MJ$BR,W,PAAP?FZ78FP[=D5M@ZL-,0=#9PD9D<9G*&-SD=#H'(ZGP&_]_:FL5,3?IYDX&+^%_CF*Q4 M&%[B&O4#P6P-L`VP&T&KEN#Y>DK96^!;0.L#L'G%>L%@@SUL%%AWB M"'MD@R3@%YO8W"^!C3AA/BLM M1>3@_H5\_]8)_$?NP@`.F+8!\K(Q7!]S#K_I*WI"=H"X)?P_@V618$L$S_X= MX(>`EV0*)AW)!9E4"&^.6%^"#(B`9X$9`)/CAE+P:&#Z^T!#0AOX)3EHY+CP MUHH#_5L"G,B45BWB\BP^;I[%Y('O[Y1.6!U`PB!:XKX^.O33*$/UF MVGAJRHP#.[`&2"X^7,]"&ZGIL[G.X_6CC`$Q/$^&:SH!S5*#FBT=%TR>%PK9 MPC+,-9;])P0K>!X`B)'#MC,@:)6!L1>!ZV)0=YY="@X4_&<. MTHIWG,6DZPC/MN&Z"KCP=O"XZ\7F1_CH$SBI\]`9U0H4,E%[,CK_-O+H(53H3O8F> MYH>CMQIX>RP#.`]:06#C-YN#SD;;L=%V;/SF\19WF8UB-HK9*#9^<\PV:N1- MT37]X.-/=V5!9>,W7^7)E]=0JYW(N1HV?I-F1=E9-Z;QQZKQ;/PF&TOP:H)` M-GYSJAYC'"=8)F+3V?A-%LDQO1R?7K+QFP<,MUB";L*Q&1N_R0S\!`P\&[_) M`B^FE^/32S9^D^6Y6"P5_6'C-W<'B]EM-G[S."PWT\L#0SYEO63C-U]G(HN- MWV3C-ZO5Y=!MV&SD7B>\QCQRCXW?9$?4FAXW?'-WXS73L3Y?9/M2)5]DUHDE4 ML-07QUYT'L4EB;*D5@X-H[VL.,FH(WSUH[ET79+%EN`5H:N8Y=47!1L/,RM2 MD<+HKJ#V->>L(:AD?IC9-T4%60*2EL"L>QE%)KO`MXV,//SI!-]5U-$QB$X+ MDJPH&38W>%G/\-733Y5S"M,(O!QTI!)3-J3]4E'):DJ+-U*TI2=XZZFJZ**@ M[0IQG4&G.JV>)1:V0+`#:C>[LKFIZAV;>DY`<`7_ZPF9UKA01GH6!QU63@S\ M\P_D.9_1,AIN>';@G-SV5I`=8N]MHW=K)_]\N;Z[I,&A1I'F7!0$'*G^QX'!1.'+WV?0?N=^#;R;W1^`].@$'&F`N#(L[WVPLDTPYOW!. M9]PGO]RB^5W,=Y'_"2O/R1HMDU\)/WU_RMUD)L%C0)/WSBBX+9PU?(1G<8:S MEO$#2SPAGHQ9CU\`YF;MV)[OPB=>M&X)LH@@B5QJ/WF<9_BFMXIF=D>3V\E( MA8&G@/HO]-GF$62(<]%#`($.MW$=/!H9K^2LPB'&+WA4-?+BH<;2VN(\ M\]^HG'.(OK`V;7,=K#/#W`$B"QF>SXDSA2<]W,0,>]PF:;U(5P$:^(^%.==X M#OD&]O6(P_.578^^:&FIY"7AHG@F-%D79&D=HF=Z*>=.N:M5AN9EHG-+!X5S MVD-8B(0EW,NB3J#$KRN!9`#M[`<+Q6@FCWN/!B!)AF'CE4B>`@N!"WIA/E$G M^<=SZ%.A2M3E[P`$'9Y6^'\D?`Q`[E^`P>:B+%;P'60L'@G%N'MD.<\4?"*& MNK"ZB94QQ2\'%I%`@E[54/K,C0Q>'EN,?YG^1,'"EV\,1#^"7ZMD!H21E:E251 M\E0H9`D)N"M\20$0/AS?GEB3TF)KY.<5-H/:*?,7:=8YG0(O9%4J7)CSX$!!?S25>+I#<2N`>-BNFT" M=P%XH!PG\:AU;2[-%%TZ+8%#1N=734T(NY\"*%;FG M(A=C5BW#(?W\?"8J<\S2RMMAHH6+"\7OP;*X(:)86'JN@Z?1PPL0)`5@BM46@^KX/X)-C/]R!5[R)L+U(1!XS^0:YIK,L[C>4<+\1 M[9;2_890W&^$T5H*/C?CFC#]5XHG[C0$I,8:> MO*V?R:_F\P9_?@V=PYT3$2V&YFOJ$T($:ID#9AZL_+:T M/09:P\TV'<+Z-S=+Q=?#-R]0^"8TG/';&E`3K"@8T>;4[`*M7H#V,C:_;>"= MZV"9M\/;%5@UG_02=@(67`=XCI;`OD?W_M8\T)9[(\:6]QE?TD?+)7TNKK_\ M=OGU[@HG?O`3MW$:J*;0.LX@L/[@S*#AW[E/"3CKXB/8U*"T$P[DVS,]/PS! M:$F1E6/!CA5V!3_6M234L*6GVU3FA[Y-98>64+J(#'X@:;_M%NE6M[?VB+WW MY/=/H%KS6$LS.E78'0T]WHFPE_[D-OMS_D0_N\#>3P*>"/.M MBAM^I4/CT5X4-WWOA6,_(=P/;0(7+2<<8Z-"'C)P#%N\6BX#^1"Z_D_9J3FY=A5L'Q` M]VZ`;PT719*FD;>?^NC3Q&3YESF[T65:TFM./;!;8J8Q\$G0A9FJ2@U"IG$Y MZWIG,T%=8_9G9SUC]F>Z]D?DM9F@T@\O,_LSO*XUB?]92'\<(?VY]XA<[A(' MYQO7])`WJ]#X7%2?!/.X79R$\J?\/TBOLV';P7I&NI.KC6K2/1R%_]PYO-OB M1+7N"G86YC,W.SGZ3,'=GO08A3`_NPO5F`':6<&8`9J^`9(K;]9@5F@:)\5`=C6H,O6@#;SC3:#,?Z3V444MPJW:.-'`SOU:H#8-F)27HIY M\>E[<;:-.+0P,0.TLX(Q`S1]`Z1(K&@P[FT$VQFPG4%_18//AKMXY,2P04B: M<:O`LE[PT#:,&9G97X7:+X8='BV&YUACT41<$'/1TW?16D6BCSEHMDV8@HXQ M&S1]&\3R%"/>(;!"`]M.C*30\-EX`2QGE9L$MDT8I0MB+GKZ+IHU!(Q"HI@5 MVEG+F!6:OA5B&X41;Q18[/^*8_]4UHJ;@)@(Y:=K=@E;(;91&/%&@5447N&NXN[BG/MH.?>& MQ5W`AL'TN<^&YR=U`,IB'T`F9MRGFQD7;3*X^Q<@BQ5=_AWRO9IO"">+68D7+/,;UI;+S<>^B6"91)9) M;.8"1Y9)E&5U)HGSR47XVVS6Y&2*V:&=]8S9H>G;(6FNS51V&_2H(^OC+6P< M5T#]"7G>CW6EA"6Z][FEZ2U@8^1/,MYF.2N6LV(Y*SH!OQ-%?:9HC0XHCTQ$.K=)U71KWD8_C7O?M#_.,!\^K_"CS?7+W4 M&8(=R']'R/\%R/^52O[H%[]'*-X[UC*%@`PT*M(_,]^HUN'G,NKCI_*P9$[? M]SYP3?NAS%M\PN(%&2Z'["5:>'D&;(P+3S]U'D)>`"C%9$EDA MSPI\LNK2>,$WC9C.$LL*_HT3'M"Q``?/IXG$>F,A'^57@`7Z+PROP&%2M3&\L*?@K3P.K>AS2KP'@T7G7)W&9DV M;,-Z^3>L5H!H!;P)W#S=TX52R0O%C%![B+@]3 MF)82PHZ,4GH`#L`3J.833)E?E,D8L32BR6$(-'\&NKU5U9DN\1B@P$[H5P=7 M`:TB_T^9/]ZG/RZ)`DW&TRN7LTXE[Q;*3D6)B@[",I=QN?7^1\#QS&!ZX)!MUZPZ5BBE0'! M!+'NH,(>_CD]OUJ4.1HW5X9I84N-]1[@A657)CZ>ZWM1(&`N#,MZ*4F,BS9@ M54(9PVO?7EY06<\XWW9G='=Q3H&"-J8IF<94LZEE=*=JW#7-@.5G0Q5"!D0, M*#&D#B@;.4]N^B:BS+?:!.X"HA<(#B#X#\^J$SVI&K>5\K'@[+/;("P6F6W. M#+_%"XSP'#P)G6;D!<].8"T3$&BF(-C@1]Z*V$D01['5V$>FG:NP4TE4A=$E M(<0&=@$&Q$S1"U;&PK1,'VP+0GC+@V,?$L)A'`S.#HA';``9\5*=DX;EX98Q?G.1&9%GQ+!GYZ?%T7H6QUEF%]=B=XDCMR?#PNZ: M;#2?'"M8TW:#SPBG)_'7HGUCM'7RTRL;0Q$.@_D8-)K/#I'R'HG4W,,:2ZR; ML+3.`6#^(SB6%1;1PL+`17I<$\)<`6%=7$&/<#+44;)[3"^_R701IEL8A.-= MYFF)^-=V-(R:$ZCJC?=G1/02&0Z%`A:C(XIA,WV,(FS_"=_#S13`EZK]/:C@ M,MI#-Y*'C#LV%H\F@DW7?6#!#AN<_;UCN$O.,CT_$U7F]I@>$`*`P68*+`H* M!3.!)K\EQMNK<`]"$0M%T6YGQ6NE";Q5A MIHMRS/><(0@VL'2&<[#=\2JBE[I=3[3=];#1"4>+V`LKP('U6WD^XS65MF"L MM2Y:&Z9-$BKYL8B%_5!)A;)K(40+?9@'KO7`5S0/#%L:&RV(&B>19>IIZQSK MC*ZEA:2F49?#S%CT\F)&9I,%&^HDIR$JQ,,5/75%IC+G>VB#9.ZBI"688L/U MTET;\0=NQAAE%B9S,C,W!!-;!K@]F28-G[%A644\SR-F9S2(H>^0% M5D`KLLXR&LU)LVAV!D5BSF"1#>;G4SCP!^PCJD0[31]5)P>QA\QDT2"4B'*I M+UB%=>4?Y81J$5/\J?_LQ!G5)1CJ[U#CY*GUW<7^!;FOQ`8J33O6@1, M`4OO`5J>%SHX<[V&&!&H;>&,*AC`99SZ6E:-*4I)2*5R%>5I65**G&'=(#.< M&J9!L2@5D:2E0)-UPR2F&0EMNFPYKYY+:]:D,$H2":EX_"W@J: M/)/E>TE-_0!W;OA!EBD&>4DOGPKS'@E'/Q%#6_K@D_@9,JW&7=E M+TXIBV1#3Q2'DY=.T$.=,KU/4I]&ID'DE\ MG:_F6XV6J\_ER?HO`,1J+*?*4G`?5!5!K[:<@0M0M M%:;=+!?E4;)YA82GBQY,SX\B.](>YQ6V8451P.*,PA/`U)6>WY$-IW\I9:"A6$M@C`Z@M\A M8Y&9X&F$8D:DHK27<#@`/N[P@(#6)JT)@D(V8P0;XFS#PJQ!BSZ]8(7+Y_A5 MD8=-4Q*1%.2(YOGP+I+-*0GF^]3%SPBUTR#CK:#,9'V>9(7,#.\H*A-&'_.& MCC^?)*9M'!X1Q0P\A[$H!A2TKU0$I>T>0KL+P+\5=`B.5(E0]ZV(#RZI\$FZ MW;1>9LF6M4STU$C7F>1TY'I*L%XV+6[HW*`5-@L47='=FEG1`6EJN># MNCG*;5-HFQB0`-,GSV0;..2(9K2M4*4X;BMV$U@2AUJUQTXW56\CL0PYKTHS MB=J%%F3R"Z.Y*A&8K?@ MKC;#%]EU"W4/[^91>$?#GO1TNCA&P_J1I@@+:9PH,JB",)O:S(>.1;9%QM?9 MQ/8!JUCH4##]HFZ)6>@IC!ZW;6TI#N(LDJXQ9T9/I!%YLJ]!J%66$"VG,7.,=#L&\`/Z326ER7YQ8 MR(!YV?BAZ.ES!2A^JZ.GQA\EB8@L/E!K3?%.3!:''@Y'N6+!%Y&X1 M"BLH1?6BBYTQ:ZHLX47HA/6Y0AR::84IDH"T$Y]U00F[J'PQ`!WX\1 M;1!R)<:2GN,0/RXAPKIQ792TMWJQOX[O#9R'Y5"R+"U8(+X]\&$S;<>G*?*[ M4W`L][AF:F)G3"-P'-\P=]"7.Z#5US&?:F4HN\7*;X?S7<]&X000B=MV[42J M/P7$:+4A.4 M\QNVPZ$G\.(S'*5"O)YD+Q[!RH[G)`T\#%@!:.[B][-&@[7KE4UW_ M1UVF+VLSKLI+$X:W6MA'E.E"^PV>P%F\:VOMS"K!OKB^IMY\ M%1(MGT4*DWCB3)%D5GT=M&!8N(N*U&,UV+6)Y$W;N$RG\!4Y;,535T>3N9;H#W9 MO&^,?HE22=^QP3W@;X2YEI5ANF%K$[$$RER?R8*:J7Y1*!60U)#!O2/C,FX7 MX%L`FL_.$EFIN*\<@.R9?!$XMR9)LW2*;F9?`8Y:.@47XYK>7RE;X':4J?)L1$]A(4 MBIPIEK_G8J>7233%WXXEAS^5_C^!R(>7Z]Z.OU!&*F("RT(,D1O*E=AJ%20M MC&6[#1LU*=+J;K55X_RQ\0;!3':=1D>UZ3V-Y<7H38X8L&W6I$2L3,^CIFDS M357IA3X<&\6'#2'4=];4O?I6?A%#OPIPY!W;@'(K9%0\+U@NGXXT!,GHVP); M?GK7;VF#6;*GQ?Q7;0*,M.O-Q9DF2<0Z1W7'96Y+992B66.Y-+'@`1C%DF5% M?VAZ^J'$?OKI]FR'Z'RN@)&?9RND)=Q:=HAFVD$+N)U3\NBYRJBBX(/&%1?_XA\$X>#&/SXWO`]3U`8CD>B-<=^N:_PZ;V+'[3 MS_$7;R(7_P$<.WEQ?,EM8)O^5[3ZYYO`6[[!(NO#(N07"TD5_L3?%WXQ;$RF M.T<2@';XQS_)D5^R$/[G9T+/-T#ZA;DV+.^?;_@W9Z*JPW8AA;4*A+,BK!BI M*]OSW0#;F@P5+Q*%NL%I!R$'_`W>8.)8KX0%AO9ZU1QVY9=LEE.E_@0F8D!F2*!X90;X%4#7EFZSC-J>+V*A1*KQXV+UF:P'A`C0>/G M<@:CK;"<-610G,"]C$S/@"B`C5;G#9A2`.F,*W$B_^BOJ06+B5"/1EM5`>!5 M59?X*M@I`%0`G4K919PP29K'Y,4S@DOSM3;35/H][]$*"W#GO4/S1 MLIY?4A&QZ*<_[R[.PR/HX0GT\``Z/G_^Z89NTWCRY^A^@$Y0>$ M&KE'.=267>$6LF"7WUWT)`2ED"UA#'9#AE^$[()]#/G(VRI/2J4\M8*?")>B MZ#G#U0S$U'\4,;^-S^C6T[TG%(`%BJ"+P MZB4N[](-F#:7=XSPAN167Q@2%DI12-$+!W=Q*1I/C+0H?D#WN!7QSU\^_U*M M0+S"-_8IPSB5YO`2I\)7VJR63J6S9FC5^X):DBNR/M])"0;4@5UP"2W6O)NX ME\1J)Y$O;IIKZ0][,57:(8K:"3(I!UF],HJ\)JA"Y_BN;KI,X0_NN)O#V\ES]T#98B*@EK([$74GL#2Z4/8( M5C^!3O5VII6(MLKH5M;.KJ(Z"L4AXNRYT%("_[QX--'J M>D/::.R':SS%`+E4'FK-EA*$&LK;B/"%K!+`?O0PB#1 M22#N+@RPUY9X7IJ<,/1*"2(,"M^S,.P8$LWE2J<4OW(G)'$!7]9X76L6(^7+ MJE@MG)_-;V_/K@(96/)+1'M0)242+`K99(D3>$M1^^T)R^C?O#? MDM;S!KA6E\Q;X_KG9],VU\&ZC+D,-O=4452^'G4Z`B4;TQON:I^X&]\J<1=/ MA;DJ#X[[^^C00*1Q)9^R=[O1D-U%N,^:HWR'#S;L3:+/;@1>?]\,*0Q9.[6E MX3*C:CHC^\^IS;6<,_TR87(*T(E,L:I*T M6RY^D))"?RF5N2(+N[6']+D[[Y+RXDEWG%+9A$3?@>D^.C$%?[$VQB+\B?9RY7U M.>UVY58W'E?]HN+YN@N!HSNCW?)8B\RG^0O@T\O&&UXGK?%-+H`7C^CVZ#XN M@&]"GWT0J':44"W-Z%1I1+>%@S4I)IS82MP$J?&]\$!3SG,L<]E(\@YX@'-! MQO1NY__^):!P:JT,$!ZJ4'=`*R<;\4$MQH163""3[+89K08D;JR?MO/L&IL( ML?`?[724IJ*$;^>?KCY^^9'#3N8G;B0^XB`FD+D.YCJ.VVI1KWMCOF)X7R$P M7W$8VO=L\\+/W0H$PXU=#K5[L%P/+FR4ER=@)AWW1^Y_7O`?X,]/15(-N`NL MD9C=U/9$F&]5W/`K330W1:P6T($WHYGL"%T_.>XF'6^,$RCQJ-;R%3/5MB>P MR;6+:#DC\SGKAH8O\5".TF"=^$_I]I:Z@;$Y\>W%Q&3Y1^X;V3:KA+')QO7--#WJQ"XW-1?1+,)R/S3_G, M'>*SS(U^=(HD%^21\)\[AW=;G*A&EZ?43A?.22D+\YF;'3-]IN!N3WJ,0IB? MW85JS`#MK&#,`$W?`,GAW8?,"HTVVF?9?K8U.-#6@%R0(%1O#-BV8(1>AWGE MZ7MEMBTXM#`Q`[2S@C$#-'T#)"ML6S#N;0&+]%FDWV,1('@(8#6-%0$FYDR8 MLYV^LV71_J&%B1F@G16,&:#I&R!\LS"+]L<<[;,B`-L:=-D:9,0U^6E3<\(W MLXLH;A5NT<8/+XH4]&J`V#9B4EZ*>?'I>W&VC3BT,#$#M+.",0,T?0.D2*QH M,.YM!-L9L)U!?T6#SX:[>.3$L$%(FG&KP+)>\/BU<.X]O*\*M5\,.SQ:#,^Q MQJ*)N"#FHJ?OHK6*1!]ST&R;,`4=8S9H^C:(Y2E&O$-@A0:VG1A)H>&S\0)8 MSBHW"6R;,$H7Q%ST]%TT:P@8A40Q*[2SEC$K-'TKQ#8*(]XHL-C_%\*-I:Q0"2BAPV,F5QJ MGQ1$J%2@U43V5QTA$UJK\(JN=&ARE]3XMB*]:-(4;%Y];FMX"-D;^).-M MEK-B.2N6LZ(3\#M1U&>*UNB`TKBD;A^F;9KZ^UL+*AV;+>)-/KX]N?7LF(!*W=()["S5P3?LEW]L>`Z'>?5(5 MW:J*-+D#4\=M^NK"\O`S MW-^./_[YA\`[>3",S8^WBT>T#"QTO;I]=%S_#KGK]^@>_O[FO\/Y\C.RQL_N M>K'Y,=-3G_;.X];YJ'/^H^MX'A?8IO\5K?[Y)O"6;_`P?Q_6(K]82//YG^?> M]4H2WJ,%ON#KSU\^__+!M`U[81K6E;WX3.X%^_-]@#Z@>Q>?AA5%^)X<_OX- MMT0+GG'YK#=A81K#=T]!PZ0B=T1%X35.&0Z.A\`1TR MVBDSV2F'TCG\SA)5S$8J/C(/?PZ*CM`&'7P00JA&1FF-3*^HB*TX0T9;:=7( MB,J!.2.U02>Y+U#0*U%2I/;"UBM&8 MA5GD13RZ"%P7#4ETL#R:HJ1PU\.1&M3N<'=5`E0'XG#8];;!&B%V,B^T"D[J]EL= MT1N&>SWN)\>(G\R+;?A7L\'LAMTPO.MK\SP^W&1>:K\IJ-A-CU$N^\P6C!$_ MF6^UV=Z:/ABA:^@[0S)*%/M+F8Q32I4V+)P(F?@S(T:O=!<@% M_L\/KK,60*`P5^ZN>#XU[92[2VS96Y,'S3L2/`ST9X7BW?+[!#5\,= MZ6KX@IZYK]2NAN@7OT<8WCO6,H7AR_7=)0V..9>,Y!9P?\8?Y^\^7<)"7SE, MEL]?KCY<79S?75U_J6VTRYUD@Y_OW1_B'P_(A7^!9S%7+[7]\P/P(7W?M4UY M8YPKXQ0\WX_79]GYZ!PBBH3G'_H.9]">+T@\=XM\WPH''YX_N"C\B0P;_&BN M5HZ[Y#Z?Q/-RFU>*]P53F84+N%G=PT_7CR::,5=?D.+P#>?$'>]@E?! M[_.#W$]+/2XW@>L%1CA^$7_1B(')(TA^O8QF-!)$7DI+?78CB#%,Y.EX;B(` ML4&V8>&\\(S;N.A?P?(!?T*3[61\(\9NXWC^2?SM]*,(V%_!A`)4Q'1YM+5N M\9A($[^6K';Y;?%HV`\$+5Q9P8SX+M8DD?_I]O(B^9?PT_?P#L,O-A69'J#E M^C%A<6;5XGZ)()QQ2VQ%.;(SX02!R(J";^WE\-HE1CYABGW[YM@S$)#%Z:S, M?.X7%WY]]P@RZW%?3P'RX.$1Q)LB%?!-CA=/+GX[T37EY#^^^^5[[OG1!#B` M9(&%P5J!8>:,!19`C_.-OY`-D%&$]<%QX,L&EL;[EXBGF'[QR^,YGQOD8O$S M[`5]SN8R"$F/J0]?""42+[0T7;3P'=>+R$CC72*RE`&==QGA,M:D2.01_Q5# M1MA"6_671)8\[JTPX^?S&:]JI_13,LQ2;AE71.=<8D,X;P.AR`K+`%:EG$4! M^H,6@P29SA*,HF6]4*`G8V4Y[]%P$?FZ$:X(&F&'4/\%Q62FL$=QFT&)%GT!(3[)F)2<&ML($GMW%47,,!4==Z7;ZIS_-Q M1.8\V^'#B4D^Y8Z7$0C/X.\*-."BGMKI&LZT/`20P36!&B\F#' MOB7,,&,Q61O?S'6PQA#*_#_`L5I6R5\!^UWD&Z:=$OK>=?Z"Y0&PE>FNR4M< M!!A'**>6*NO8P2=A'_`5/2$;I/46N4]@Z,C#D9^Z_LLRL`7G[@#6U/?0Y)1\ M/_\UL.+@]3+N%>377"+OE+M:9>A66@Q,+()0`(POH9&+5N2V%Z(%X3\(73`= M0'V>#7=9Q#+K22\O:$:2&3 M)2]),0VAAL\R1N7)L/#*P/ZWPES&JY>O'8TDMJ#ZH+4V9RR7)@X=X-<%X)Y! M/LMQ$D&#OAZ>HAW%2"2>%L0P]J6&SA$"(?B8$&\%F9\I*@\;7="]=:C`A@?_ M#39.Z/\%_@2,30D[XRG4;@(WGD&^(/_%:A?"N28!;=LD>"@S@.5&,1*$D(12F&144L.1@[#%Q@.7VPMP`6!&9 ML)9$72P$(MACF&L23X+E3&_GS>O)/8Y!S27QW!!*2K(VF_-J41)KKM`J4#S< M&$94)\I[RGV(/,(+,B!81B0HR*)+"[^(.F%&X\31C+-!`"S#(DAL_C#>CULN.\77FR$7%08ML%U]E>JFV MGTD(B_:"`/8(;^Q+K9%S8*H6->=5OJ+0LWJ+:7M%+.![V(#:#S=$M&^)OM0! M&&I4"48QS*F%B33^SA'DZ,2OP%0`4&U+[YH`4HD"$!&#Z!V;FVR3+_ M`7;FRKX-S59/X3MVB&'9MX5_(!&7[@HA&G[L>7MM=S:?OWEU^O?CN_N_KM\C;W>_PT M=W']Y;?+K[LT["8MNIR#F7]W+A/L!8^#C780`,(TD M+/X.3%)I6,&V/@-O&:IT(1RTK8TE@F^X.(-+OAGO9[:'^>68G@"V,&QX&XF" M<5UYX6-$2=(C0X!%!#B-4`DNN*I`$GV&G4U015D_C/_:@*6,P`.PP5C"@5GMD?I&M0F!]!Z(%E)J567%B)(F&R M4X!ME)\M8V0VFIGDRKVY"MR%D23@8SZ1+V6J#R3SN$S1RRT8IB4SU8GBAC/< M/.59;`,#*5NR>#=URN',Y,HPW?R.+TN)@!`B_,"C;!6)P!$)P[NZ!YL0'B?\ MLS3+Y$J3VG.1_%F*K6%[2FXC!M9GP#.*N^SB&B$-3KDK.TD-Q#NZ=)E\MB7P MP@UX&;-W>*+`R>WBT;&PEFZP4SW!*0.\Y-I9(HN\*,Z*S)+7E#*@,6U7+D+) M!CU#GI0H'N<%@*!!46'7->#S&=E`0XS@Q-F/=:,A:IA!1A1P"V19&RR-]D.$ M-A]1#W_B;8Q%^9/<,`B>.O2KU8B&JE]4/%\;!XQN*-I<89>8-)G.\2&Q@13R M<*DMC_-8:1HURM_1+UFCDWJ/DYA]9T-3FY)0T,"-MW%24>JJ;7<3AB MSFR)]FTJ=U.;.<;!V3:7^9DLB\PQCM@QLDWVQ+SH^ZB)I]J+FG:X MU6XP:YFY3^8^F?LF08MLFR.),.K-^LNC""Y`)SH:SL/AFM>>UH M,\H@ M.3QQ+IZ`9H>7>U1,0,NL1&:>A9/FR;"V9&Z7X7G!FLQ'\ZA#N-)%JG5=D*@;B?JTQ:1!I]_NOKX MY4=N06X/:^3X>C9\M4-L*\+TW:GDTAZ) MZ64='O7%'M/[JR:E@6>XIO<0NH9_T$:/=D8G:U2H^YB]QMK\J0#*/$R!9BM= M1I)GD$\5JAY4A`14B1R42;ZS]TUFWXP<4H#5O0MPPSZ/_D*?8[(W&K,WS-X, MS<@A!5@_6GMSZ'XI%AXW$\++;_A2-Y3BR:/VE7Q MS0XT,F_%O-5(O95X>LCTT%&&QSP+6)D)Z)>1TN`=(JU4E>5H61#:Y!2>^60N MD5T3A/YA(FLY:YVZ4./KK@[>@!/X`:38,PA](A MEHV+W_2Z`Z'?',OP24,I]$7P\:MWW>.)+Q'"_SCFS-"RJ,YWC#B##";P\;N&&]BG/9JD\=Y MN'@DT<9H56221X6W9"%?^\%?=L?X>`_U[B,ORL(#-NQ\3R1DTUH'B7688QR$ M;>R.\?$[1K;)GI@79S>>=LWCF; M=[[/6(/-.^\6F[!YY_W&,NR.\=?JN,84[+!LQ\2$A]TQOD=BL_3(J$*0\6Z' M1A%2L#O&QU]=8"[T\"Z4E=W'I#6O'6WF&`=G&[MC?/R.D6U$)^9%6=E]%+KU MVM%F[G-PMK$[QH_2@(\I#,[QP)L3O&7\'@@$YB,#(9&$5(Q^X8'[\9 MK8N)PL_B85*9"5(-9T.=Q2]+IDJEW_\4Y1],Y%T$K@O/<8%MAF.D`F_Y)C]7 M2ISS?YY[UZMXGA3_AENBA;DV+.^?;_@W9T`*5=%3".O>K'Y,>XX MN%YE<*@#1LT.N1+2(5="`:BYS,NR^/,/U6\Y*]+GR@[K-G']YLJF8M('=",%&$N:;R M$:$[`G3633:J!Z#E8=85413D?_\ZD#`HH2ID&`@T6VYL/[VV]F%5:B0((T%X!* MQSD]%)="5E;FDTME904S_L![1-+7WCA/8GY6[C"LV?![@\1OQ7JWX]YW?4<7 MO^_#6TG>J+WYO<8MW$;>NQ,WOV]%0'8D'RT0CT/>_-8&\>A4KI+N6FBX0^N$ M?RW)0TX#QN`1H)`LC)3`C`Y:G=7I%N8GNDX7=5,/\UTOY"X%>'BT%W4?)=Z, M"&\(;W:]D+L48.DU+4>!-XZR1PTH0L-V%[.V\K&LM5:4<+3FA M38[..L^.S;PE3NB_'.;:G=;,@]DH0O[ONH*3Y&N=G;LNW,;>V6ODMT;X`=2H M&XPYE`Y1-BY]TNMVA'[W73/BQ7&T"[T9!_5>0SM.WA;%V1O).,*$;(D:@\XA MDWCR':>=:\=1I_&.UITB+#L2+#LDXFB#HT:<99ZU^*QZENL[3S&,XLGGWAY[2+ MYSWZ;TZU$TW3=VI6D,ZJ=A?EL^C6%KIM$O3Z-X$&OU:HQ:-(W: M\V2K5V.RJVFD)0_W+)AMJ@2G-[V+Y?05G])$8Y=1U52F3V^,?_6&ZQ'V?1QK M+JBG-]J_]L6QYG('Z[@CJM(]C=5*TN1DG2&4HAFIQ4>?[H#B1H=$]T%QGB[9 MC7V#.>@GO89S*!.SJUEL8-Y@%L;)*CC=YRPVLFYKR=-^9K&!<>-KH0VV,`MQ M=O8+BYY\^])[!@O(CS!?.*'E^B&0N]FIU];F7S>(4NYYE'(%4N#\V?E9"<\JB%R5\ M"1SOD4'H&#TIGUW_@2E?8,![9CTI7Y\"\,F9 M8^O.Z,D)4SHBOT2EZ=GX_2I=\+WR0T^4:T^Y\I^3EEBJ9,KOIB=_G9@GU<$` M=+[YGJI<>M:)^@-_:'EP\5'UA^\2QAB&]C/_1?:W_O,/"L^RP`B.!]2:@&53 M@&@,4)5_^_">3$>>X3>`0(KY"`[Z+&&(8(T*`SPSUY^K"HA"/#4M_";^$?S% MHD6EQSG83A@%SD,,<)PLFL>8[3)E'OAV;$4A<"?PX\[_J/ M@JY$J'@R,E0"!E8!A@*Z`A;YU>7,I[+PY,7'7/ZN6"8,`^N+/Y(1MO31TIE? M>OA8#PQ8U@ZWN!BH9RC-F6B4A=L!*P@/P(`N<-`&*N&3"7_!0E0GBE.R_-D, MM#Z,`/94T57.QK9R;X?&0-6&0QC>EV`*YX^4_KOX(63_B1.A7>A.IPU5F3RD MU(,'*[A3EA"^(A9V&W'=Y/,ELRK.B/_2%UX!_`[F]14XGW(I0P_P3K";220% MF!*W:X0U1ZZO9I@.#RY";`8OBY/5!2I-3I8<72'S)C5OUS+S]L4,`'"$>(WD MULTUOX;@[>$%$OCQA2.THZ)=YWX<\#;2][$;FOBG%[VHRO5?KOD$I($8F'B- M4R(U(!L@@Y;CV>KB&@,BS!P//6`4P)"QOQ2021:!."BV.3,?8<)3/^#4>+[W M?AJ[0*N+$B;'HX=`P.H49K.@&YF-*!J:18)2DUBXO3&UC5Q%$)$R>,J&#%48 M3$*0;3NH4L@!TU-,RT)&`20B?0R<;P\^CX5^*M/8L[$SCLT"&4`B!Y!;H4#J MP']V1"\=83D*M$A53RH1UU;D06SO(D$88>`X"TQ'(%",DA?_[B0!`VS5`N_QW;CUR.RE*.=)I?S0"1 M^6T/GM/O:_S-#,>+K`>S%@<>SM<`VS$=>K9M.)XEOAK55B3H(Q,.A)?4E!:T]I_"D]\10KMSSEL5*E,Y6KV+.4F\`'N(,7F`U#&XE4O'")!*7C M)I@%7$K#BL0+O'8"C(4"D#KQ-017X<@G.IWX2YYP!P3E54B`)W.?*U<:88)Z M)THQ;'L"$_3$$8C_J;E@]=O\=`T M9)GWE.-?/A3[QBP,9^[8\5SH2O43!CT.OK9+8':2M)-=XXN)NS!T:JDN.OA9@$E_]89PM'GP`^7]SS4QR)9FE!][_C6N@DIBVT^ M/PO_YU:X/I_\X$YX.K\DCLY9XM4LG<%$S`"\+9&C-M*7"S,`SP@>>9;#CBT_OG/+LUF.7%8\Y\3OE[.H"_KZZO[SZ_/'J M_/+C'641MK`07RX_R_QRL)IW-Q?D9VW+S\J<_Z+_DX6L8O-!,0/PN@->MX5. MN,48-H^5Y?D\BP4>.D`BD.PQZZ)&=<[I(\].I9LK!N15@>GDN?IN6U_)QB#PL1?_%"; M]"X'H++Q'<]R8QZ-CT::JFD:^DL!@_F+9X&?FF3VD8.6'P)SYFXLS9NG48N: M^&A3)ERK)"%47`H^D%K:U"DGIL$)C?P('3VP#SP[]E979O`V_/I$@5A;C"G6 M1\T7I)KC-C$Y%@,5C['C@K>*622>8DGB'\>#V0FGJ90;6W0M>?H>EI-_*Q\5 M*'LRGS'QEN;E>1[KI;1948Z!D_!M[H<_\\AP'CABE?*=!C6-S.W`_`I"F47L MH5H=482Z(0:+Z2Z,<)Z#V$6!MIG((*8A-WCXTMV%?)TQY(=A7T2W[YEI,_3N MB_H%DT217HBK\\%RX4\R>0NC@S=OVOP:>P;_^\"8I\0A$/A0#;"_!"?Y^O(G MBK7'5&=AU#3?"`XO<):%)[(Y(E>`?N8B26>@B8YE>LI903+/PM"W'/$:^)?P MK"YOXWLNWAH8,F`3R!.7Y^)4N9S$?","&,@Y!OY,98IU87UAI&PU^)[#VT&J MK))=!N"4*Y@LQ`!S04*;.:5I1/-@NK@+HH1/#-Z$`&M1XOFJ0,@%ZL')?SO2 MQ5-Y9B8EEF"7R:TZ>!D<$>V8!U\(DR)/`3+:#YB?QH(3?M=B*)F'5F$"1((T# MVH.@BX<)7Y^8EP:C3$Q'LH&P-/9%@?L"7`2X`M6)(H&U=WX<5??)S\W`!RPP MF\7%,JXG7*R)?3#_ M/)$0E+LURN].9"IW)\6W+LS`B4/EMO3FK0F&)3(K`E?XRF??MKG3E%HW!PT; M%C^DGLSG^\O$D\G=A;"R#9;E3+D10T;9;,H\VT1<25#?%7OT,U!!A`^W:DUF M3BC24C:^#-@>E##X\8>J`IQLFU1P` M2)$?%/>^R[EQWXW%?O<7<)PMTTU\-F`6-]>8O'3-%Y1/=)MS_)0D^J:8`PS\ M;PZN#BP4^*8*-K(36"[VO\0.`GHH#/-R=:8WE^*"9Y![F@6Y@)?H[#&[)OU? MK#@!>>`4@C_&UT]L-L+4GAU>^^=[9:#Z?V%W+%>JN:MN.U;6,$GU\VQ.=7X7W`F523\7U`342>IP!*B M+H(9"%S0<-#"M+RFX#%7O>65A:(A5K$"(:(L2^BW*>N*-DVE!1T_ATVS(-3B M=V=%#M80V.PA*E17E:QU0?`R\RF8I)&'NY_U>JCP#'#+S1 MH%C@F-3MY`5+Q:(2&?)9V>U?Z6_!H^*^49I\G8C%Y'/6,1;'_Y?5D@@*^(*5 M-Z[3WQH0!&G]2?I-.V:)LR*I"W+"OWADSZ9H`3AR>ZM8_B`KM'#]$']]P0#$ M'7"$7Y3[`"0NXWBA%OOB_KQ0B;W(<&#VHR-N4A-KEJ4+PRBITDV"ECQ#';N8 M^:H(`>:&'3LIODOG6*E@4YQ2J(`SJ28_@>8B92E3S>*\K"?'=0LS4^:NB:YJ M/)=Y\?A(AIF"P/<<*[.>*7ER,5<&VYC)RFN1)FK MOQ8JM+H4O@@G:`D+J<=%^8X]O/;0QYG#DD(L`22"";!%RJV`$VE@6*6J('-3 M5++$8RY(7B)$$'\!GLXQ#A%1_4(NO2XI'\;SNW[BY<%X>`X,3UJD"X_>&LR^JL&EIR%("[BOJ<54SF#";F875P2JZ&+: M`9A@?$A6-YI6H2Y$.M)J>UZ?SD0AIP@*1;%IH>2'.^J..7/>7Z!FEBHB"];* MA>#/-OG6A!4X#Y@E9J[_E1RF]1VF^R=IUC6OA`S]=#,RR7QQJ^#YD6-E1Q`` M*C*'M@!'#S#1]*1(<0-G;O+OBXT,"``CD`.$F4S_*H*=;AGP2#RI-\>R=$SI M%TZ36%80)\F.V)N;3LW.H]@M%-8BU_GT&6BK$I/)PVWNY_%Y2O5M@2/FC,NS M+78.)[HZ'/;J`+$V\6X[(1@!6,$%<,Q78M&FF[)M!M?A]@*!TL0":<#S@*?? MOUD\NYB<5A,DP_S#!>M;-]4L8[.(<)2DWT@'SZHV*P58OH\G0I0D,"DNN]"[ M,FA*A$I$)0EJ9H6/BCX0P"\4(7UB0<26;1W1&@D>6[A/;PN(AG M[8WE0XJ3%H4#8.7TO,HK(9*B")E/"6YNEF'+X0XM?OR(448Z/4DH7%VL0EG* M0E4*3E)DY;-JCD^\PD&RF7Z.=2ZF*\[Z`>)@Z%2HI"B[[M4T?&T$C@XS#Y7G M&+WD?G9J?5`T:H_MI"H!LL\C5U$5R(V+V)OD-(-%"))%K'+'8X]^Y"3)\TJL MQ.O<32MQ\,ND5UB$4RF:0^X=Q4&0'2<(,U.'E2DO/QG8Z`>!0Z2"5,$L9-4!_A@0OX3.W;*TR4!V$)BOQ39%V1I6HE"$.&2 M3FX8$+(D288"`0HD@M60P9289%/M"10.:!!'"7`CS<')!*83)C$_SDM(L&!D M3N9D>@:"-!K&,D@B<\T,CF9R_)1FXG MAWKW\9P<_FTY_,#,+!=J.<^.R_,@@,W M0D<5+=(S5'$@ML_-)$Q`[Q7P@)DA3]BEZ*S,>7V]A*-\^R,Q?F#XM+190'[^ M$-\43@`K/$M>KE9X//+FE]A]2<[;+.S`2TJK%LU9H?(GW7WAV_IHV6-QB"X[ M#U;>5)>T<.![CK"0GCEC8?V)OL2FG#]ATO@C/VX"GHELKM=BTUX%J?)L$V#Q MUQ/E#RS;@G7$]A>6_S[;\SY1SG*SOCA-D:%.#B0!A>@8(4*+@RW)L<'<4\JV MT24;P6"E'T&^1)'I"U8V,:`^.=^&?&/\F(N"6I+FR/'T65[_5AA,)A.X[R66 MTRD?K4P<%M0.J6`PS\1"3Q%/K4Z#/2!/GED>SH65='KJ<`48^O*ZSR2\!8OR M[``;1"Y3,(S[#$+E:B*XV<_*D_\5C:D*=H_;N:(#B&X/9DC!(<>IXXYSE?OX MJ%!D`I/`,2]U4V#P3/AQF:URKKEH=N,'='0BW+Y(TD#P3=-&=YY7TTRG25E8 M$RW*MT+`_4D6#-.#:(,7LP\6ZJVD3`3`0[AQ<@M-9F5=^_P1[(?_DG<#*&A= MEBDG`[ZV`?_(-2,#[.(VYTL6TYD);X]:3K6Y7`9$-!VLLAE<%K=^:G(G@M,#?ULU:+7V]1_`JRIM1X MMJMDK2A8^G!0VDV]F'RD_[$D.KQS4(#NG(JF=<-<#IKNOY]%>TS<'>F):N4 M``0UK4+?3_;-"9-^8OGO"B2?67@F2VQ]R5C&(VQ!G)1OXDV&M3!^-N?J<@(3 MAFK:ZZK08K',:S`=8G]L7M@J*1J/.G97,T.8K@,!"M/ORDPH'+:LX31NF#K/&W*LUQ%BL;/(9]/Q\M^\_.:EA^K.1!YD60<. M0^.=3PS14**WT'9C-`+.%YI:KWB2I%__C3AB'F+7BE_QL-X=BR(WJ49;2IA> M['31N_=E)+X?OCG5-:U,Y+)'GE:HXZ!TXP(Z`.<_I@=#5S=?,8P2X_[\`J;O M)LN9WB2'):LMMH&K@PJ]2XA8H/@,:^TOL_.EY_S0Z5)*>SV]OBE[IEJ M.2&I:":=4)*-\CN^>5QJB7*>;Y"OZ,-B]#BC)PGY?_[RY9?,N[WTK"JQO"5+ M)A5K4'*Z?=K[HJ^0MB;QAC'4^I,UB2]0?Y,6#PF]O(C9FTP0"'VB#X>] MM"]2Y8$[8.:`4ZD/P'58@YG&]S+SC$<==SR6D?23DO$S:;T/E+XLJARW.9E] M2?\IO`'NEX*[G-WA,OA7\LSJ@`N, M*7_A"_HV[DL"RTOYT],$?Q)*L!58PBHY467&]',Y6T;!,NZL0VMJCV(W6W'3Q]O M;S]>*'?WU^?_FS3;^O+E^BIYX_[V[.KN[/S^\OI*UGB+\@-KKT?&8K'EBH$"K4>I;HOL[+[$H+\Y-R+HHCW!>U M4C-:[%50K@?!8[S8,8/7:A:S-S?99QP52S=JF(%L%SHG[$12="%"Z]+N718Z M2P;[ZH6R62AW+,`S)GB3@;)`XHER[U<:^5X7]MX_P$\]04G24PQ&P'-CF)80 M9UD8WG-2.)`G*V_-29@LDL!KT!4LF@MXZRE3>MC)\<1!12JG.XQNI9>UE;?P M?UI<<=SM%"$$4(F%% M#![+M,#-%.=1>$,!'\_LRV[7*/0?B:.\OS]O\3RWAP7ORP=69EBWQ(_G/%22 M_\7G+1ZR661_4H07FC-93I.?@$F*X].O%6XZR*IM0E4)?5'(A,<")"/E0K!( M`>]1E2Q[_I#"]&7K5^`$[XR1#"^*=WECO*PP+#FP*KXAK;I.:J;ANX@Z%0YE MA=TB#<=/(N=W$)2KHT3'.V1T6/"#91(NZ$ZG6:'++Z\W%2H>!@QT'_+1G'2!13= M]*?\-P2M\#-Q8IOZBAIC$F=K`\A-;_[41'=<[IOQ9J7+>`*T2G:J>IJ@TCHQD!Y MYL?7JG:H=#225UR4^CF7MM"=0!9P1*(+:GY2[IV5QOV*7AV'/_D'%0D2V_6/ MC,LKK]_('?KTMCX\&8$=-ZKM<<`M#\,3Y3R>Q2YOVI@.Z82B^AZ]QX@W9OUM M[J(AT7O#19V;TH+ MG_9\9-]88#EAONSY&%_-(."':0O72)?[;62I4LL,G\0)J\%8-48#22#&&]HF MEPF8_!BG%3CSY"8,'(9[`SA&?XB$DU2U4*IZZG`X4;61L4JL\F"@;ONSVF^$ MM[E+6G%E%XIR9$*G\JVN]@U-[?>'-0?8P4*"$/'@:&I"^);9K[?CR5CM&4,) M<3+"ILPLM+8/LVXH)NXK\D!,'(=)PAZ>U)??Q)[%0YC!3,Z#\V;ECOW>\=*V M(Y2AWYJSJY.SVTIG%_Z+UV&/I44118TI>B889B;N+^ZD"5.1[8LE9LL6N9IJ MED.8*[[)$`?6$YYX*`TO;(YH"R+JT>6.CZX.!WU$GA.E<%0DA8;T,1DY,-W% MIL)5HOC4\AD\O-141=SGG2=*12B+516X%XN;,>-"$D7^BU;,J) M09C#3H;BUN?LUK>0WW.?GCJ1M[0JAB9.=F6T_2ZA9)2M6(F8G]6;,8V/EJA&X,Z&HKC54]Y%,YS;?1@WV/E<[F2P>32 M>)*FFJ.R51_]SO"MV0JL@,^ MF\X#C_?TM<%P]2S*U"R"]=*IB_<_^<%=XN6L6I9:6:F<-!P-=,.8-%R""AV2 MT]/?OQ9-B,YGGSI3,;+=B;=>?3'U87J2EEB].Z8`]1 M7D=XGA907WIA%,08^!2U3]^:[NN]X7"BC8Q\%NL1?+P]H7_P^%PW%S3I;0TG0Y7JQ6SJ:Y&HZF( M0\I]6)!FRETSC]TN2K\WKIO+GY]XCC%+,=8=R5^,!C9:K/(L\:L?T.?&&)IY M(?=1SQ"''D5F\,-+_IWDC/`9WD2Z,')XZ8F'_\'0UP,?'J3??&3IYS>!T]@/ M_PX^&=P1'Q=8M-<)[EZU^[U)+7?N,1%[@WG8RS3QFI_REHO4$+Q&?;5)7*'^ MBV%,WDAF;7W?WOS0X&O&8*3+6]S43V:'3G%S8-8'>F\\ZN_)*5XRC\TAN3_6 M]09H)2=@I_Y)\V7H:88^ZHTW=T\JR[`-%Z7I"DR&/6VRF8=2ICE+]/'&+QF, MWHJLY#E>7%,!T?!X&D.TLC5$3WF?;)Y?W_!]<]X8XH^SV]NSJ_L[Y?JW^[M[ M>.?RZC,=J=[^37JE&QC`,1LEAQ&$15&P*1D>GW_F]BZ_46(Q@2\."(@>>?S* MK4;;LKBOD<\ ME^PI&)HR;E[Z<0%WIPW3\I_S.0"HPA/ M8,-$B[24[PVMS*RV9G?N8LM$U_6_EJ[OR.Y&JXZ87/A:7G\_/Y&27%%&&KW7 MDG!YG??WPL-(5((6RT_J"LV3+O)=F/H7WV9NOCD\]1$3>`D./$^3W]6'+#$Z+=J(;?T.&P6KK?U/>&3_`BN"EPMA9UIDFWQD5$+10 M>7ZB)9QXURO\[-G'\VOB&FE@UV#"Q]>',#QR[%W_A\7Y_9<%?O[[K(D'U3YL M%9;0+(I[J_GUE5RQ*F4/Q6;5U28D>#V0N$BG6O;%Z_!8@"5NRLP,_F(RO2_6 MX":5NIFY#<$M`'/YZ`@OA5,BCG`FS:N3'JF54ID(C7TZW"U[_MVT$LSLCXV? M%Z_&PNLF3`0HD"55P;G>I!S&[&(>,^F&3%JYME86)$YR:B*WF:G%`3MHYE"= M*(#0*6RL8:674%<'2RK5"Z;GOE3$RCL#/10K4X7D2NZ>US48[87W&_&_BEK1 M*+WW>O$)Q3"AIC)3M$KBL[5XJ^WD+KRD4".Q?`52\_L#"ZK);X2K@D/^^,(! M.6[X@XHQ+5P]CB7[_*AK,DSIX)W\\HVB/F3(AY/*#[[@$>]YP/`(0!$IT;YY MH:S:M'"\>C9#]9\56L.4YY,,8I<[*17&^D]L!LB:%`[M."B5A)5GE5[3%OG2 MB]C2ED6).U?@=&%">#Z]\$5^5?@BS[,99HN;G'E,UWW!Q9FABR,Y`W+G8`5. MZ4Q3*I^"OJ+\A-AV*GSR@TBMD3\IJ287;D$._074J'(KK51-'->AZ-3/C:O.';<3A2=,11UJ MZL-GQTH+%A;#:SZ,U&.5KAT=>-E6EBAW\/E5GR#6\0R$R/DOGN-%=TLHN/F` M_>IXCS3Y!J+%SWFCA5?K\/^HL_;7BF1MQ3:C'7G>-!*>\QX9Z6+`5^ M@M=@5#_YZMC14_*>KFE_2]ZN]$%(.1YQCGO`\6!9CK3R1LWOEPJ$F'(45'VA MPJ=VS0U!&!+F[S_X4>3/)).[.;O`U.O[#]?W]]=??E*,^;?E>>6-9745YPJ/ M;7)#4T$F(KN6@1F3ML>-SK/"\E$74EX8:XG+A^O;BX^W&7\>$)V12WAQBF,W ME9P#`K'%O;LJH8MD[GA=KV)$1-DRXC\PJ+]YCOR64BE#,UB4B6ACP?#\KX$Y M3V8J_EA+./B:G?UZ^?GJ)P6!Z&>E@3YU7IT(60A9UD>6%A(J([6MQ,HHW;7" M=';PM!*LK.CU?]2S>-$%[R8_DHJXE1RH5=Z]L"`M]EI&#"_F:T@Z^0GD)[2$ M%>0GD)]P:#^A?;364=M2>NN()3?LZ`9?UX%OQ MEI9UZ>"WO%YT\5ZPS4*48V'X>5(8$YMN`T8<,%3#JS[KY/^=XXG=L!\H3NM$ M<$)Q&L5I1QZG==,N+L$J^5XH6/5F01>&$/6H,T0*#X/:K@N MRC)*'L,_-BSWP-J^L%/RO^<:Y_@W\_+6;)I#4>Q;J4__EN#9,*!42J? MU;)H8:?R46A`5NURG?Y;K%;2FNR-;$]+BRSCEUJM)0EZ4T'H@@XV\,AD8X< M$PR]76W57B/\:">&U-Y+IT[@LQ?P(2_H^."'O*#E7M#)T"`8.KQ($0QMK&:= M@"'R@J1L,=21-E;[PQYA4*L3D)13/'Q.\3,VPUJLC-E#-I],4Y4GQV2:R$-> MRIZ)VM-&_)8T,E$'ERO"HHUUC;"H^UBDG?3Z!$.'%RF"H8W5C&"H^S"DGVB4 M-&R!2!$,;:QF!$/[@:%\!@01+($%1=N=$2D9W+RVR1/>=!AO=L$> M0IQ-N$:.S\:*1D"T'R"B_%YK\WM[2=EMI5/%:T_KS9V`V3^F"UU]_"<_F#*G MMO:O[:F_U]?-Y#OXL[R92:((RXS8:V&>U(*MPSVYA=LS`]]O,4^V%PO:J!?' MJQ'"31'N53.(_/!U_?!F2M=]IA&"M4)!7X>P$8(1@A&"M9B7A&"$8(1@A&"= MXV63["Q57W8L3;M12T=]=7JG??E:VC`D([FAD3PLA.L#M3_J44O'PPL5`='& MBD9`U'T@TDYZ$_E>+<$0P5`GU(Q@J/LP9)STJ7*\!2)%,+2QFA$,=1^&QL.) M.JXYPT(XU(YTY%XRC%0L^LJ;0%(EZ*[W3%X+P[J[9V>HX]&@H_TDCWO;CL". MP*Z5#.LNV&DG^IAPKJWB1SA'.-E3C20U!:2=M MD6_4$/1`%JQS#4'?#=1A)\^PMW"';9N7$%$S*O+#V^.'4VW`<2-7RQ3T=0@; M(1@A&"%8BWE)T2TKJ%R*;'W*O>ZJRZ>Q.L_0L21L M4V'I@B[O+`D+3%)L/WYP68,L[*MA7_,T;!W_ZO*P^V6A;JBZIG7PWO>J93Y* M;284I&"@;3#7(!B0R=3>JTJ/H_?(4:HGP1K!&L':)O[:L;0:.4KU)%@C6"-8 MV^A.B[H8E'"MG?EA\9GYX#+^,?SU$/R8OCQ@=O7?<1@YTY=E\KP!^^\Y^Z^` M_;(\*YUFHA/%L9@;.?QD\<.H',S-R?$\Q'_PX4J(G MIGPU`VR"&BZN&WR7?_["S"!4F&>F5?VDC%I2V%I+^NO>J/F]Q$;LOHY\[4J3 M[N)&`[OUZG:G+1]U(>6%L9:X+"_O;2HY!P1EBWD1"U;[&#M>UZL8(;%NQ\V? M*K]Y#B#N:B=DF_M*W^CWH6+[K@W>3'V3,+S$>VD@.URKL7%J3MR)81TA!7D M)Y"?<&@_H7VTUE';4GKKB"4W[.@&7]>!7.E8+1/T[ON7W1U\M6>\8FGK\9:6 M=>G@MVQF.I[C/:ZI2<<Q;,ZN3_G>.)'3)IKC9MKQ&#M!-I+U#YU`E^"'X(?KK&GR[`4.^D3Y<1M4"D"(8V M5K-.P!!Y05*VO-\B6PAXUN!:D]0C91,/GTW\C(_A#B$.(0XA#B$.(0XK2(:TTR@WM)]FVE6<9K3PC. MG8#9/Z8+77W\)S^8,J>V"+'M2]4,>E4=9G;C_C?3PNXSC2"M%1K[.H2-(&TW#"-(*S*- M(*T5&OLZA(T@;3<,(T@K,HT@;2\)72KU[%AF=Z-&E/KJC%#[4KR'2Z"UW&I* MV/-J^-.%GVJ-&E&V1*\*BC76-L*C[6*2=]"8$0X<7*8*AC=6,8*C[,&10 M0\I6B!3!T,9J1C#4?1CJ7&7,L0!0DU0D91"Q`U"1S2$6,'4LS4K_*0ZL5V;+79\O>#8=+;K\A8U;#MA^6 MBA5A$6%1R_C3!2RBZV_:(5($0QNK&<%0]V&(PONV<(V`:&-%(R#:#Q#E,R!? MI649P+TD]:@O)?6EI+Z4BWRCOI0'LF"=ZTOY;J`.1IHZE)8YMMF2MK!-R`]; M3$52QZ/]^>'4\8@Z'A&4M44`"=((T@C2"-*ZP$N*3PGIVL2PW2)=QW*MQXU! M33*P[:O!7`IU?4K7[JK9I+$Z-=&QO&U38>F"+N\L;PM,4FP_?G!9@\3MJV%? M\\QM'?_J4K?[9:&ACL=+BD<[9IR/4J$)"%L8($@X]EH8MFF`(!.R?1>G=O(( M/.$+7/-B-GG?AB%=T]F MP#Z8(;-OS)<9\Z+PGGV+/F`Z]C2AYN_I>/EWBZ.=!8'I/3+\[8>7RG!G7\W` MOHHQ[7D]Y9^&9W'TY`?.?YFMQ)X3W;+I/]Z$_),WB@7<@N?S]ZQ^7_OS++R> M]O1?8A1,"9RS",F7T1!X[W M>,,"Q[?%S^1/_QSX8;ARJOJ?GT"R]%],#S/#]WY/OV`6OOSSDQ^<^UX8NQ$\ M[HX%SX[%PJ0Q`*[_6:2=&(,O/+5BGQ[":`J=SBTOSJ?V6!>.7,G"CG5AS:0.+>>&:\.<4/5@G4 M=F8I8^JNQ,OX+E;UM1KQZBWJW\;RU3;9VC[#N&SU5X)5]V2KMXQ5%T[`K,@/ MPC//_CB;N_X+8RG3JCQZ/P!4'VQ-J*28];#:/#PLF@?!^K"PS?<'0R>.V6?/ M+#`?V2V;F8X'[X-H1(%I1;'IWK-@9I29U=/[MN8 M550X[=`N>:3ZI.?BN%;BIUZ`" M2B;8LJ!4A8GW$8TU^%4^\24D+;J!FU-?+\(RZDM27:7>T#>B?F.%R)YQ!F@\ M$Z1^_#8'@&V+%G_&K$C.W`U+)'_>Y#O.FX M3O2"PI@L_'(U:0)=X$_I)X/)%H!K;>(/PCC<4-V(=3NF%U%F@L0%<%%_-T?;(<#+\K%/-Z*@.<#IZU%0 M-(X02?QA(KNCHFN6Y:V:KO$I3U1BQ*98S'7GIHW#)-E`+4D^XB?AW+2JGY13 MOM*<[UH9Q+HW:GZ_-,DI*DVW73RZ]N&?[F9>&Z3\7]WY`,M'34AY8:PE+LN/ M8#>5G`/6&%L`XBQ8O3VSXW45:>JZ$F=_JOP&YBZ4;E7OKK!XDYT>.CU"R$+( MLCZRM)!0&:EM)59&Z:X5IK.#I\G.LJ+7_U'/XI*MZ2P_DJ3O2@[4*N]>6)!N M#2TCAF\;-22=_`3R$UK""O(3R$\XM)_0/EKKJ&TIO77$DAMV=(.OZT"N=*R6 M"7KW_ M\L+,()0VL)3037$:Q6DM807%:<<9IW73')P]/@;LT8S:GKB[!*OE>*%CU9D$ M7CM"UJ#-$+CLQ%9[&X`M]8<.C%)=;>XE/2^^.RVE6X&J/*%;@?9XG/FP7JQN MJ.->7QU)[TIL\P'F8S%\V[%(,ASJ/$>."8;>KK9JKQ%^M!.CB_UACAI\R`LZ M/O@A+VBY%W0RE/84EDZ=8(A@J'UJU@D8(B^HIO7Q2!NK_6$76X(>"P8U24!2 M3O'P.<7/>'RQ[NY6RA.2:>H>?[I@HB9J3QMUM#O_L9@HPB+"(L(BWE2Z3S!T M>)$B&-I8S0B&N@]#^HE&2<,6B!3!T,9J1C"T'QCJV%VCQP(137)Z5%38L01@ M>DQ?F@*D_%\+492L3/>=W7=#=3@ZW-[^TE9;>53A6O M/:TW=P)F_Y@N=/7QG_Q@RIS:VK^VI_Y>7S>3[^#/\F8FB2(L,V*OA7E2"[8. M]^06;L\,/(+KDTF#-[CGY#4SB/SP[[_X_3B%BA"L%0KZ.H2-$(P0C!"LQ;PD M!",$(P0C!.L<+YMD9ZGZLF-IVHU:.NJKTSOMR]?2AB$9R0V-Y&$A7!^H_5&/ M6CH>7J@(B#96-`*B[@.1=M*;R/=J"88(ACJA9@1#W8,M$"F"H8W5 MC&"H^S`T'D[4<"T8ZE>:O=Y:+6BSR8)UK"/INH`X[>8:]A3MLV[R$B)I1D1_>'C^<:@.. M&[E:IJ"O0]@(P0C!",%:S$N*/@G8CA;8.I8X/6[(:9).;5]!Y5)DZU/N=5== M/HW5>8:.)6&;"DL7='EG25A@DF+[\8/+&F1A7PW[FJ=AZ_A7EX?=+PMU0]4U MK8/WOE57H.4CT)U@C6"-8V\=>.I=7( M4:HGP1K!&L':1G=:U,6@A&OMS`^+S\P'E_&/D>?XAV(QUYV;-J86DXEI"1_Q MDW!N6M5/RD(LE>*UF%'W1LWOEZZ7R()O.[&]=ME!=X6H`8B]NJU*RT=-2'EA MK"4NRVL]FTK.`?<_+.9%+%AM<':\KEFQ@M M:DA$R$+(LCZRM)!0&:EM)59&Z:X5IK.#_\$P\EH\R53_1SV+2[:FL_PX>V:! M^??"@K0WU3)B;@+'8@U))S^!_(26L(+\!/(3#NTGM(_6.FI;2F\= ML>2&'=W@ZSJ0*QVK98+>??^RNX.O]HQ7+&T]WM*R+AW\ELU,QW.\QS4UZ9CC MM',8.#"M*#;=!HPX8*AVSX)9G?R_J,PF_FVY,6;M60^"RXI/V'DYO!06A;6]H.'*P6A"SI(!9J'*-`\K!>KJ^.1K@X[>7/OL=@^PJ)7@D5O5YNV MUXA!VHFT,:1\Z@0_!#\$/UWC3Q=@J'?2IYMI6B!2!$,;JUDG8(B\("E;WF^1 M+00\:W"M2>J1LHF'SR9^#DRO]GH(RA"2/>H>?[I@EW1U4-LR3#Y_,E'D&[=/ MUPB+NH]%E"ELAT@1#&VL9@1#W8=O-'Q]#56V?3UJUD^EP>VHKX5YS2]'K>%>W=VHE)?\[G8@KT8(-T6X M5\V@5]5A9C?N?S,M[#[3"-):H;&O0]@(TG;#,(*T(M,(TEJAL:]#V`C2=L,P M@K0BTPC2]I+0I5+/CF5V-VI$J:_."+4OQ7NX!%K+K::$/:^&/UW8R>RI/6I$ MV1:Y(BS:6-<(B[J/1=I);T(P='B1(AC:6,T(AKH/0P8UI&R%2!$,;:QF!$/= MAZ'.5<8<"P`U2452=O'PV45J3'EP52&[]/KLTD`=]2:JIHW)1SZ\7!$6;:QK MA$7=QR+MI-+RD>+1CQODH%9J`L(4!@H1CKX5AFP8(,B';=W%J)X_`$\X1SA'.$-\(M2R>+S\P'E^''?_\QF%GSG^XBW_KK>AXY MOA>>>?8?9H!M*L-"=O*>?8L^8++U-'W8W^/P_:-IPH^?S(!],$-FG_NS.?-" M$\V8QYT8>7_"LWY@N^=?;5#.SD@86G7,4\SQE[3G3+IO]X$^+OPC>* M!![^_GMZPP/'M+SQ?^D:QF>7, M3#?\QYO+JT]O3G5CW.N/!MK??]P9[:>[8\X?#-6?V6?/+#`?67K$_R9P+):S M+`YMX,'V&&>\.=5.C-VP;-F,3B5\?%C]U(>UGWK+9J:#/#@'7@6F%<6F>\^" MF;'(O-&?GT"']5],#R]\NO=3-NJU;#R]T?]E&,.+!>;M=QK;ELC?68A/]>R/ MW^;,@I?W/KY5H.SL\3%@CV;$+H$2QPL=ZW?3C= M&\].)J_?00?O$QQ>>F+NGP,_#%?`XK!./"LP..EI(TW;HDI+B-W`3(1K/>6[ MT;`1OSCZ]?IKL&I[LSB5N8(L]P;4X)E!P<@`? M4"Y;A_4#)[5^8)6)IS?&O_1A_]`>8!<(7QSV]#$Y?\N;+)6?L8^"'DU@GX M"!DY6Q.B]X/AEOW9E;3+(6J??O]`*_D,1A._W]`U;:OVKU-^_WH<.USNMX5^ M_T"O4T:IWZ__:S@XM-N_=3S;C>N_GE!J&+QO5X7;X/I?^9Z@YN-_8B=ZN?3" M*(BYB=OC_MAXI`^WPM@U9I/S4&Q%;OK(ZI.B)Q;3A(HZ^\&+0(K&NMV M3/FTL@";(-5W4%.'8=O8@NLE"9C636Y;?L)*TLI1Y]:VD00*;P,MUIS!Z5[@ M(KFI"<*(R>E&1(LWW':N:ZO1_KVXJ1M^@CK;YGT>@?R M#KKG'*RS12#;9VG'9"LXVQ+#N9T-F=9-:YOQVG9]@G5RF;V)IJV3,G^5/D'S M;&BO1SY!0QQ8LA$QV(/"K^\4[-PKV/Y>Q?OA<$L^?P.JJV'I3N0_>]X>U7H/ MKGZC:6VM.'0E.5G;X1UL?0Q&VG`_1JWZ"ZHI]56ZE)ZB2-_Y()OG@NW9.P]7U_4<9'7I? M>:_#:N1_,3Y2'%SX&JK3IO:A`E6>;KJW\>J+\\<18I"KG3Z83`*D*:"C\X;!I M92@`0BN.G&>F7$^G@(6!J@3,8O"&K1BJ,1YB'QY%P#^2"/\3`6;BG0E5JC@A M,-'9#.838GG.2>$H7_;J(CA1/C#S::8JIG+AP/,B/ZCV_,KHT-7!9*+JQD!* MAW++GK_`_XC'5D;A9*B<`U_@N=>"C+&ACW[^$#C,0QJF?C`#5R(C)7NT5%_4 M87^@#NNH*7-!(@?U?$'Z^,K54ZM\90&3464GM(?\MYRR)U!_EKR1L5SY:L([ MQ2]4.%8OB(G@S<'.!$KD*TX4%D5X\7QF64!/EAV,)2"1`LG]DW2Q4QD+T"3S M5?"Y\BKAW(3_3L$L*M?A/&`ORIT?1T^J\NNOYR?5X]`RQ`"0D(&"$_*U#'V7 M5<>9B9Y\(#CBJ5+IO@5B%?8-W0^&PI,0"/)8D<"WNB'Z?V4_1AE^"R``L0UJ M*Z?E!60T5)AG@]85^P(NBB&Z!%P),`^*NAUB90/,SEU"Z-Q\P3)*(+1"74XX M$#I11T.=C_YVS*DS.2!4^A3B5R2$5>BI/^],*B)5D;-0\D39"JA%,%*>3%LQ M[6?3L^`Y7&%^=^`U,+XBW=?NS$\UXWK.L/3/>\PU(\5J@=SPY+=@JR;]?,&+ M@MTSU(%FE!==Y1*=:$8(DN?8"F#M`WLRW2D.&*4H4$&`$^6^,">(K7PQ,70V MP`V/'!1ASX]859X+@W%+`Y,4?@F@NVV)*HP'W`W"N-GN(P-R$ M%GY8'0R_W8=9]H`#4745I%:`[,`J(8\D3USDK;Y*PF^?$.\E(R6BKZ:.T/FG M:U4L^T3M]8;+Y%,J`$6KK]S%UE,F?D\F#A!B'I:;D\B,8I!.7S*.Z\R<2)39 MJE`ON%$=C&+VE3$ MGY^X1JV:"T04PTWF4I[,K\P,V9EGHP-CNA\35VMIN>F@EG#AY7#W$9Q'>>VI M4,$?,B'BSD1#&(=)]`QP(C>:17D:Y[F7>`5.8GB3 M6.D=\7[A<%?-TQ?<6IMT'2I; MW9_=?_P"+.E@QGWY]1&'39%AC`'A!F;)*A&3\F"Z&"`I89IVE8V51BKBF"4& M'+[`#U`-5;&>'_U'=A*$Q#F#8*/2?LIXU#:]X#K[2@&`ZR(%GI!S^P69!\HB5O6LQUYZ:- M.W^23S`16?W$L9,WD&4._I\-SWG?&TA;0$I[0*[54;#NC9K?+VUZF-P\4VJ\ M&/ES"8E5O5O>Q3-I]E@W ML7POQZIM,4O0V!@*ESUJU[R7#6X[X=PU7_+!\1OOI^;,<>'-NY<96"A5"2&D MG/Y<6<9Q;V$95W7@W.**-EFS56:G)6OPX>S\?S_?7O]V=?'^_/K7Z]N?E/^9 M\G\%DRN>*S%EU0D$"RX9&J$P?@BMP.&%&,F.)<=QS/75W]RB%/?^>)+/$+E= ML#@6+]5(S)CRS@\<@&C3=5_JI3M@30B_ M^":7ZT3.H_A"33B7_L,8S/(#W(KU>05CNN&9!%["J-EQV:)6QRD^,4Q&=7$` M\\%QT9`F.V*<1B?$_=CZP2P61/"]E5:3C&9J-$=D-,EH-I5R,IID-%^=T;29 M%>"VI["8ACKL]90Y!&Y8R`$A7QB[O*(IJ?"HE\:O3X[UA!$?F$R>"46K9CO3 M*8.`SV+*`XN^8H%&)$_)IO\`!N/,@G]-[M>0%>+QXPA8:K)BP`]XI^G[.PMB M6N#Z%]]F+D_!(GEI#)L_M7Y^SFP>8&;7?0&6@04#3P//"X;('"=M=K0DRX"/ M8*OC78IX<^,])N--QKNIE)/Q)N/]ZHRWXR7&&X+'M(H2=Q`106=>*2'\=J@/ MU=YHLH8%_PS6&S!>^0*Q*BL<-@F5*0/D-UU9W7KZC^^)*I'Y#4+@--8-&(:O M8#:3PQ\/@?\7/P^H3)U@5KM,:*X#-L/"3ALST?C32S1$:+IOV3/S(`R_8\$S MGG)H$-=G7`.V+'(JJV3E+!NIVLBHYUBZ62MV>7$1\"]NZ7D.'@OU(*C'2KV$ M[MHY8L6W`],IL"09_(%Y;.KP2NMD0>I8SM>)7(QU7(P)N1CD8C25V:!`M$T M/U-B-[!9[3%9+:ND*\]KI^)64TWGS,#D1NE&QF(Q@CB?(TX%S_E!A0J["V5J M24)',2U+U.AA>F6A#B\_.+8H9UF!G!/B;HLHA*LK?6M>^[:)PU%T*":30_L3 MLFJU%5Y!LTN$!^,FMWL;LHN7I2K=A5N#MW&_=R,.=9Y!EH_:D7+(2/C0D&V& MC&\?KF\O/MYF;'O`Y"XR#\^>.W:%A4W\KSWB=S&V6>V[M9!0&:F[ELM=#GY6 M;2^0_[O.*]Q6A]0U:UBT*SN;Q6U29K?G*.A`%]#+H++S2$FFA$S)#DW)SI;Z MG&<^]Y1E).0AY"'D(>19Y;K=)L?ZR!_JFM(M2\IE.R'%.3R`ZCP&?NS9[T%/ M_>`GY7_.M4_PK]G6ASRYMF[N8Z75:UG*<,^:>N]'IKLL4"H?"MJW,U'D5H!= M:C=26LILU0!6DR3"3OGS5B90N^7+2L84Y.Q0J*VKD]%8'>EZHWQ&NXS@*D#K MG+X1!FVL:X1!W<6@=[WA&`O.FYA\0J#LD3]L49H(>3;6,$*>[B*/K@YU3=5& M8_)^6AWL4_S>H?@]+?1V&`7Q9,:.A3]=,&>&:DSZJC'JDSD[O%P1%FVL:X1% MW<>BP5!7!_U1@\TWPB'"H7;J&>%0]W'(4,>#@3HV:(.CW2$^[>OI`W4PI(TTVDCKH(81`AT!`DUZFJJ/-4(@0J#N:1@A MT!$@D*X:_8$ZZLN\(`*@W0'0LB!??$:=-%K222.[J*I\3U7>LZ4XV,IKJ,R` MM:G-1@OZ=DDTXSL:;:Q[UNZ(K=&K8\6ZIPZ_XWQAA82#)SFI3P;UR7C=?3*^ M^PAHYP&0;`'9@O5M`36Z(.@@Z%`(.EH$'+5P@K5L!QA#0LH'C,#ZZD> M$C#79K-GYOIS3)@UC&:HHN4PAKU[NSET,%-^,%/7L8MX`X-(FS@[U37"GXWU MC/"GN_CS3MQB0/A#52R$.X0[>V/+8(17E6^1-\>/.M2*XM6%[9^9A_<.UN;3 M,&@W[9GC.6&$M2W/++O0;[5J4?1.5JP#_.F"->NI([VO&CKUHVB!7!$6;:QK MA$7=QZ+D$E_RK`F%VL830J%7@T+@$8UUU1@/R2-J=91/._E=2PF8CE?+'D69 MPN\5[$GYR(^ZT#9^=V"=S-X1F#U=K\MKD\DC][L3>D8XU'T<>K<,B`B):&._ MU1I&"-1]!'I/&N^37N'>_QCU9!>HT2VC9SJ-BL8`=`1`%#/Z*E& MG\)Z0J`.:A@AT!$@4%\=]'5UH),+U)ZND[29W]$/6=!*>A7!#:- M#5W_67DP0\<2I_8=-Y;WU*!$0`M1GJS@$5A![42;D`$\C`?^'1CS:I2(0*;[ M(+,+]AP_TE`Q4:L4C8"H^T!$WDZ[PGWQ&5TRT<9+)BPS?%*F>#_$AI=,..'J M.R;2X4KQ?%D,MG/%Q&1R^!LFUJY>63-%59I:DR:YK\1DDP)F9(N=JGOS@47A#R$ M/!LQB)"GEHF%;D/#N1(^_` M224Y77$16K=)18VD:TKB54W75&,TH!TJJH@GX"'@V1-;^OV1:FAT<\;!=8WP M9V,](_SI+OZ\,]3!$)R?48\7!)@'_K.#9W$>7I2IXYF>M3H10'F`%J([6;_N6[^> MVM>'ZJ0O.VXJGS_9/_+$VZ=KA$7=QZ)WH_%$[0]DC>ZDLRS2,$*C[ M"&2H0V.D]NN2`81!!R[L%Y])&G'\_<?N$&6T_< M\,X3B]\]RQI/*+'G1+=L^H\W<6B_42R8#_LFWK#Z0^//3\`0_1?3PPX2]WY/ MOV`6OOQS<<3KZ5W\$%J!,\>_X%/F/"/Y7W@3BC>*S2QG9KKA/]YH;TZ-@:9I M^4P:$7J:LF^;\^O5SN^CZ\P@9!=3PYLQ\8N_9K=?2J?5T_5-YK7M2?5K)P7_ M&S`S9-?3FX#-3<<^![&)7:Q/^/AMSKQ0OEP]8]CK;;!XAT9D-]V!M--I'$K4]NN')RU].%*2U;L^%(&QD'%\71 M2E',5NS>O[N^^L)L>((KG=&@/^ZM/Z.%A;JSGI@=N\#+CT'@!^=^$#"+H^>9 M9Q>&S(<([V$^'S!7N3"YXM2,?&K&FU-N#(^D2\[:!6C4(V>7?C8=+U[)ME=_ MO+B%A,I(W;5<[G)PZI'S':D7.A-.IH1,2L^;Y]0CI^N*1 M.4>(2E1@=X0%=O=^9+K+`B4K#@),09IAR"*ZL;H%-N^8=I#I<+B4+;HZ&8W5 MD4X[QRW0-\*@C76-,*B[&/2N-QRKPYZL/85T]H1`5#]'R$/(LPWO9ZAKJC:J M*=TE[&E)L$_Q>X?B=]K@B+ M-M8UPJ+N8]%@J*N#FCY=A$.$0UW0,\*A[N.0H8X'`W5LT`9'NT-\VL\_MGP` M^T_L1"\KA8?B_U9@.=FZ[MNZ=SU]@+W>:2.--M*ZIV&$0$>`0).>INICC1"( M$*A[&D8(=`0(I*M&?Z".^G3;37NZXHK/BOUOMM-00=>T0W=46+]:H5YFUCU5 M=<2X\^I8L>[YLN\X258AX>#I+.J(0!T17G='A.\^[-=Y`"1;0+9@?5M`+0T( M.@@Z%(*.%D''+6P0M4*1UBM`(K'S,!ZJH<$T[,5FSTSUY]CH]"&T0S5 M+AS&L',!@:1TO4[U37"GXWUC/"GN_CS;M`G_*%Z!<(= MPIV]LF4P4C5-6B=%J-..&)_"]L.'[9^9QX+LF($\:#?MF>,Y8128D?/,%":N M4:'K>,F*'0=_NF#->NI([ZN&3IT'6B!7A$4;ZQIA4?>Q:`B>]4@:T!,*$0IU M019G"[Q4WN]F7MO&[`^MD M]H[`[.EZ75Z;3!ZYWYW0,\*A[N/0NV5`1$A$&_NMUC!"H.XCT'O*0+8WZJ=` M_O"!_!6+Y)$!_G,\RY\QQ7PV'9>WBHA\!=Z9^9X2/ID!>_)=FP5TP4!W,)ML M6O=MVCO^XL;RG M!B4"6HCR9`6/P`IJ)]J$#.!A//#OP)A7HT0$,MT'F5VPY_B1AHJ)6J5H!$3= M!R+R=MH5[HO/MG^=P&1RZ-L$UJY46#,=L79#U-<#1!MSJ/,,6K=G;(EMAHQO M:W:2;5E>C&XCH-L(=M*"M#.W$:SM;31J"-Q]I"130J:DBQW)NW.9`2$/(<]& M#"+D:27R',=="(1*5(IQ[*482X]C6&;XI,0AL^$IBC]GV&O1>U1,*W*>G"Z M1OBSL9X1_G07?]X9ZF`(SL^H1XY/:\HP&I8H4/2^AZ5N'KT[WC,+*7HG(W:4 M_.F$,>N/=+77'S79CR-K1F%\NS2,$*C["-3K&ZHQD+D8XU'T< M>J<;$U6;Z.0)M3&NIRW\HTL"S`/_V;&9K3R\*%/',SUK=2*`\@`M1'>R?MVW M?CVUKP_525]VM%`^?[)_Y(FW3]<(B[J/1>]&XXG:'\B:FDEG3TA$.!XPTL#%D4 M*K'G1+=L^H\W<6B_42R8$OR$OV'UA^,_S\+K:4^_8):AZ?J?=Q;S3'C$3<"> M'3\.W9?TJ.T7-GM@P1O%9I8S,]WP'V^T-Z?Z9#0>Z7H^`_',4V4C8B8+Q"2G M6G">^8RE=+SO#D;HWY.6/7YU85; ME\;-^388ZH/^:!5UWT&<7B9MD3OCP6!LZ.MQYRX":4_NK/CXG]B)7BX]RXVQ M4\D-+`1HRUD4!=<`(J8&5A/@)$7[)FY_AQ)^OAMSKR0+9W<2/OS$Y@$ M_1?3P[G=^YL#H:Z/>T8^U:4T26#I.^:@U\YAC:4:]+^+_,_,8X'IPM?/[)GC M.6&$IYJ>V7X7H3?2^X9>`-L59&U[(MM8B>%(&QEKS:!,O^EXO_IA>,MI55&O3U@;[%5?IH!AZ8U1!"BCOL",Z_A8`O6H"7B(;O\*[AX8[$T(`)8F/` M?'8KJ).LR+D9/MTD>W(?7GX+F7WI7:?':\^R;;E]:17X/IHQ&I36JR&),H7: MRNRVH4O]_LC0C,VFU612EVE-]?Z7#!C4*T9#S2EL*(YKSVT;"];K&\9@N-FL MFDSJ4[KWO?<%Z_7UX:0_63DU"84-%VSMN6W%6HW&D_Y@O(UIW<4/(?M/C+[[ ME*C;O?/MQ]_/]^`WXH'W^'_]XMWPTJ%8+`ZX?@Q_1E:^MP M=L#Y_&&YY%96//(5$$^N.4I/5Q445%6)GI@"KL_<]%X4)PQC\&!TM3\EX2@^?;5I6@#,*31?P M$09_,/$($CP,"%^A!-@8]=330TN4JC*KW-'7<&_-1;0=3\-EL\@&F M#`>6L`6OT8%Q5:TB$3B>QR)>/E89#WAG,6:'0M0&_.>!B"Z1Q5_-`)X,L_%PBJ&L[+JT]O3G402-#W?![KT5=- M-J_\_=D,95A?[A5\Q[3`'QA-!L78M2E)DNP6#PK%7"_B`-.N?#M)\`!0F7\4 MKERE7NUT/OE!GOZXGIX)V+I+4$O,KN%2`JB.M,7D\4K::[8+JK_['=5=,F79 M\NUZOKC&.B#]RLF6B3[=R>+VUY@LA^\;@=YK+2Y8GT%+%G?7\\5=-D"EM==V M/>45[W.*A'6%7'K4\1MN9X&CMSZNK>+)1S6SN^/Q+<[\^QKX=E] M3+VX]4PF*.0FJ+KME=SI3+5DGAL`ZO_[__S]QV\/@2M>__]02P,$%`````@` MH62B0FW4O5OL"@``:H$``!4`'`!R;6-P+3(P,3(Q,C,Q7V-A;"YX;6Q55`D` M`RZ6@E$NEH)1=7@+``$$)0X```0Y`0``[5U;<^*X$GX_5?L??+(OY]040R"9 MS:62J2*09)A)`@MDDMFMK2W9%J");Y%L`OGU*QG#^(*P,1*&[.S+9HS1U^I/ MW6JU6N+LOZ62<@TMB($+=46=**C^/]?\OU)2ZK;I=#6D-"V7?JJY:`3I,VL$ M,?TW_7SHNLYIN?SR\O)>HZ\2#6%(;`]KD+`'2JGT46'__?*?,P92QY!!G"H/ M%.<63)3]BE*MG!Y43ZN'RGVOKE3W*P?3+]%O&,AZ4@&!RM@T+'*^%P(;J]AX M;^-!N;J_?U">O;@W??-TS!Y$WG\Y\-^NG)R*[%'I4JU=%!Y/R;ZWL>I MYA3E#-L&[,"^XHM^ZDX<>+Y'D.D83"+_V1##_OD>-C6'ME*I5JK3-GYE3_ZF MC!';0#K3_04P6$^Z0PC=/84U?-]I1OJ`X<@V/-8U8D(=:.L/V_D8H.B&K440#6;@-IX!&D"%QOF>1TH#`)R_:X1`E]0] MC/V1&28@$,JW]#X@JF_NP??*C)@R-%PR>^)35=JO!%;_ZV*`D)I6%I6-IIKE M#ZK+9P^-@$%;)#6W#C">(&OP%1@>E-&%;,!SUQ$=`34<[2/`VDQ&^F>"_JA? M#=XH$S8@66LE1,U^]OT^MLT4)EU[9?W96(?X?*^RI[Q`-!BZ[$_:MUR4->D4 M:]&/)W=0RN"*M+_U!$2U$>BY*D+/;0P=@/3+L0,M`B5:\V*@'V)OI=XYV@D( M.(@1L*8KE>=#MT+-B_0;(X#C0'+KM8UMAP;JDS:=\%SJP)CS%BN*(Z_R4T+74L!:X!H\#.5B()?6?3U9OETC[1U@9^-@(2*4Y,D&3E_"L+.NOV(9T2=%\4:<'Y(ICR MQT)'HMA1$8MDDCH5/=_6;=.T+;FL)3"*==CR&$LJDS6QQU4O?^T@:!ZYLUW8]52B8>3XR:`.U"!=LZOQ-)FL MZ6*9`)&>OBW&5V0B&5"4UK#F!AQ!P_9#]JX+!O"2">I@1&`#]I&&W)JF>293 M-M0;'J9=B7]#QM@0(-5;]>XB"`N&T(?$$,HWAD*9:;H$3'9=Q@A)Q132'MG377H M9&7)6@"&`8H?_!QZHB8=T8D@?^MO:M_8A+2LMH>U(2`PY#LR;8GSOUUXH+Y$ MK6D=YSK)?$E03)':V.XC*>FVIVW7;RE+6`B;&4_M)">U]I" M\1,#/CF,UPKO6PXK;Z-S9[";*66T)$'R"]R!!%+]LLJ#T-HG:%C.4%\&6'!J MF$M?U`26JHQG%SE3#@Z&&O+EIG\;T%>'I==,%KZ]^L_E)!4RX!:[(LO$53;] M\0/^?).97^1J,!C=1!8B+A-T!"5:51KD#E"5JC7!25U_0[)I.@!A9K_U(<`# M.?Z:@U3TNCD3*SPMB=ZJO0;(FD:;#40QYA(YPY+F\2G.+>[%@Y`D.D>]LRX[*(G%>Y(.M,7.P M0E'BKX.G3,FB1'T/GB]#<(<0;G5U3$`M/;Z]$6)KZDO'T.@=OIA.@1&[B$+M%1D)! M@?9_$U/),PW39:UA0JW/M.Z?2_[SX?;KX5]_/FJ.-_YF?3C17X]&@V\3Z[[A MO5P?X9.C+]7O][T),8Y&VNN^\=D]OJ_?M/5O?Q@''ZQ'M55O-"?7O6=XV!P] M]8;/Q\>-OGYR?_?NXJBN:K_=&([5]R"!W>>CP^;-P!E<=K\<=?3[Y]>#VZ<7 M9]@'B'PY[`X^57^_[WRRC8L'Y%U]?3KZ0ST^OKMM/1K=SN.3UWLW4A]J)JFU M7NX'WYNUUQL$OKKJ^+K:.AE\/KS"S^1=L]/Z=M$Y5*]'0XO/SU>G5RJOQM@Y#U41K7'[G>UWZR=G_^EU+N=X*AV@>,PR?W"]4]X MF;2=6QW+.Y+NR80<;:,3F=R$0!2@>*TO['#LF,^<%L%%/Q'LHHXNK"Y$T2NC M-,9RJ)6?$RF^)&9^K'^-M1M5"6N&CN41HC)=3.X)J[69>\<:NZ1#6MG?"NAK MY*'^A9YK14ZY1B+V&/K/34Y)G!6R^]D=`@PO`)637>M#(PYI_'&0BMY76X\S MGOI$'8>?WM+"ZD);_GF)6UM'?32]9&CASF)0MZGC")C]-(:\Y3;TV$/$O(&IC:"+/E,)8*NBN!Q89U)I,_JP3;*@T MD"$N]OS!,KUECIWXWT!.+C/VCGK/U74<,'LDIHJ8!J@8`G:Z:_K_IA6[(:RV MZ(8P.=G77)(4OU)>@_6\V@_&P+&0@LE4(3K0/^[7!K@P[F,B[/;LN[+"`[I/ MA`2R2?0`]W*#:" M&XB"")N&7'Y=@SS7FE.2-\9V-NW/AD'R/A*QVS33\KZBMFD6H>?W4K1U#4*= M7%'^NL"`K3[W'D5)M1R9X;=V#EHR'F([U]E5+7(#B(:>_JGBGEW3*`*&FZ4X M._J6+M6R\KN"FGD;W&+XC=^SN1%:$Z`[;Z_I:DWN&JU5-I<$G-61;XK"'WAO MD+V0,L7>7,:1]`I9P-**BA,6H8N)$]A]/GX1#RN&D7;C8@KBMN;PEY#."P86 MZ9-;VK9Z$B\2=_S8>Z43T@/`&+"S]1K$&DI.6D56D(2' MRR9=NN3*3Y2'KK((6_\)6&V)DZ_&4K@PB5\(O.$&>1U>Q4/<7I@92?G'@#75_H4_@!;J%G*/)\=.2ZU249JB/"GZWBW[&SB))_"'( MO++DG49C@`7UD]>E8N?4=0=&I+XVBYZ%7EH8R$H!V;FY'AAO=!1G@B[8OPKF M-YNV11[[#4"[P`!XLTXJ%?:M&6^ZGI?-H+FOIMBP6\X"^Z:8S:1GWDFC_/?# M%!=@K`)?_*I6)-4K*3[EU-+"B/BLS#!5&HS[8^,?4$L#!!0````(`*%DHD)A M_M$0NDT``";[!0`5`!P`&UL550)``,NEH)1 M+I:"475X"P`!!"4.```$.0$``.U]ZY/;-K+O]UMU_P>?W"_WUI;7KV2=;&U. ME>;E579FI)T9VYMSZE2*0T(2$XI40'(\RE]_`9"42(D@``I-@%[LA[4S'J(; MO\:CN]&/O_W'RYO7ERY<_^^174S_$*$UR[*.4_N#%RY?_^8+^ M[W__K[]1(N<841)_??&9T+GQMB]>OWGQ]LU?W[W]Z]MO7WQ\.'_Q]O6;=\5' MY(LHC'][]%+TXGD=Q>F/W]2(/3_BZ,\)7KYZ^_KUNU?5+WY3_.9?G^D/&K__ MY1W[[3<__/##*_:ONU]-P[9?),.^>?6OF^M[?X76WLLP3C,O]BF!-/QKRGYX MG?A>%B:Q!%\ON+]!_^ME]6LOZ8]>OGG[\MV;/S^GP8Y%\CM!MB-3'^"[5\4_ M?L,`>_'B;SB)T!U:O&!S_&NVW:`?OTG#]2:BK+.?K3!:_/@-7OL;0N[-VS=O M"V+_A_[D%R+:-(G"@`KIS(OHE.]7"&7?O*`#?[R;-B:+T5,2Y12#=(V"T/YA%&A]GV@0SQ-L'OU#GN&.L5P+H^]]+5591\.0W: MW2BOJ@/N="YODPRI<\6^TK86Z6BO^S'Q6C<6K_LR\EK;PBF&Z\W':XU;KARQ M/R^,&9VMA M#F;=:^)-YPZ8^'Z2QUD8+^=$K?!#E)YMV=^VZGQVC*43S0?O,4(]=.K:MYJ7 M7C%J3\E6'^N'J.]:VWVM]Z"MACV1*ZT'[6[04YG2?-#NQSV9,>T';6WHTYF# M6?>:>-.Y`R[3+%Q3J^UCBA9Y=!T^H319S'&R03C;SHF)GWEQ0&W/#;63&1OJ M,^A%1=\DK[P0?_*B'$W2%&4I(74=>H]A%&;D,KA!7IIC%"3Q'?)SC,D]<>:E M8=ISJB?0TG2`W.?KM8>WLQV^D],%*#&FMH.FI)4LIG15+$,R>('E:;SSQM-X M#.THE2I'.O>VE`99!.0G.$?UM7#J;.1I:#YH*XH])W`\A-[[O#'VR1Y/X8CZ MF"='0A+[1'+,=YXL+A`.GSSZKE!)=-L3,,7TS4AI=W\F4 M)?YOLX(:V6^?/8S)S97.\HR^@03D-)_0=Z"3MK> M6HYY&D>Z[;-JV!.YTFJ?[08]E2G-]ME^W),9TVZ?U88^G3F8=:^)-[`=H(L_ MH+V@C3VX7:&/1=#]H9%-P)VBDTO8/:.54QV[YR+Q^\.OY\(&:3M1?&O7DMOJZM5PAN5V0([.>/Z.6.LAK#;0/4CRP0 MB!DT+]=H_8BP(KZ-3_?G/P2;7A2I,4<_V+-$%FL8AW1S71/B#;;0?IRZ7G48"WCFPBC:$K^FK8B MQN:]\-)'-OGRXU?TP'J%HBRM?L*.L)>OWY1!>/^G@TIMH?5GNC0S`1G>VYDE MIWO13G"39[(4*E;*52&W;,IO%CA9R\@E2_A`)#A`^,=OR$56+.B_^DFE7;3WH%WGIH=RZ`QAIO M"/]$U(\7R^%BZ+T_%3FK^+HH;UWSZ^&`([CU<*QRM"X&+1OLE,5S*");%\\O MKVU=/O`+J%*PQ[""J)S*-?2F8PTIK2!FVOV,TN0&!3>E@BEA##:_`)554_G5 M(:?VHY/*J0T-N%U;O)=.'M.,9KI`[,$#"F`JF8R0I)2S0T@DEGN?!7^>8_K< MV"4`7F!_ZY>E@6T?KEVS+;%]VX5MKW5-4Q7()J1_T&B&)R^BKT^3[-S#>!O& M2_;$"+'H9`X"_G9"!LXP-2EP\!$?8R=`` MDQ+Y=]HOD$8(8STF#N@\ZJ1G6KF5TINZ$0,3U&'L'Z%V^>Q'.8VHH;KXEW#O MJ]-[@4C0M58I4T.O%-ZWFL\W2/'416#_WCF"^COM^Z20+]PM8O]:KQ`H(?Z+ MIM7,[J]::"XY^EBL7YG=?4'`\,-,R<*3'\U:T%51*87R7MNZKZL5=3YZ6-IM MG]L-?->\2Z2_UW_"-./6)VUQZY#*K`)Y"U3=CC79.+140)7Q$^H0[7!2;`AL M?.(ZE(QV@_V`WAV*:(S!W,/#;K9VNH;-^7XBXT"HV<1G?)84KQ(\C0.TCG?Q M\U*7$__KQD:W$7K1["6,Q7Y>X:**%S5WZND_@/M$0-%Z2\FK3NI@ M7Y;Y)B@`%)X*^?%H%$J@@IFCQSE=L!=6)[WQ"*\;-K%EVU-:-6(0PJD//PZE MH0&(V';M>5NMUV&1-D-/?"8!J?>YLP\T!>5'BD3"I/BG+AHB43 MA]0WYV'/85'HE>K?]_ECZN.PJ`9PAWQ$E#JPE`@5!@P:I(JR5`16[%+H:<8\ MH2AAS]SDUERB2UHS?(/#%%53\/U\G3,KZR*G98$.OX`Q=D[F:B0GK0[\Q:_; MNK;^-"Z?UN<)9H!F&0X?\XS5H$ENDYCF_1"8R&A+5GT>I2#&L";.S!P6:F:! M+B%4%WC'#7ZJ97WP1%IP"VQNM].TV/J0QZV2F#"X^&^OFGF?M53:H1-"#VM0 MN?Q0EQ_J\D-=?JC+#W7YH2X_U,KEX_)#77[HUY$9*(`K#66R`*".C/W]T[_QXS*9Q2L99RXA%EV])1-3T5I-2L26P M`TM.;;[2$)-OAAG3`7LLF"/,3@OXMRTNY5%(4!9%P!2Q.@.,6CK)LU6"Z3J" M%]\1Q3'XXT2@P022M5&=IFD^G)A*:M:F#<@@)0X&TR:<6EGLH214)SE*,34P MTYSDU/*R/>2])4-V#*>?%'S"<+)3)3?$5=5%SF+M7@HMB0PJ/2*"NZ)XI$:A M^7%QD@CSTR09X/NID]XX9=1V.W5$"%KR.'?83;KGX>N>X]QSW.G/<14;]SZ* M/1PF8*]LK82@=&*=3V?M"(&EQ59D/L;I!ODLD)Q#I/9LAM[%)K3'@D9M'NJLVDV M6Y2$8/37.H%1P'Z`B7;G?U$0)4G363S/L;_R4E1+69)Z0.-_;;/O0S1QN&1O M*E#VW'J?1$!6=).$S6+@P@+C&M=]8VL`!RHL^($NW1 ME,>R-B5H36<^L3'L@`ZHA%[SGKI-BL@L:#G=6O9!21U&X>DB:'\);@%@,K7" M^D94;#!1>ED9$O+W"#%HXF!21`>T%&?1%50A0=?Z9B*3U`A-B)G:H]Z]%.5UOO!!3'L]7'E["F'X<2B-X@>)A M).4Z[[>#"..%GGX1IILD99C,%G"%0[L)VG]-"0`3IXSIT?0&T?#&L&5:D)%. M`NLOAN*)B*X#4$'4R-B_,UK!J63!M_35'2JS;(5P0:04NE()EH[/K;V\A?.N M<.Y*:#ZA*T?*'#<%;<@D92XM^Y<_'Z9*-GSSOV\1?$8`4-D])#$&2_\(E@I^ MW6%QAP(';%IS2&9\NZ'1P49SE!M5R5)ZW2"BE5T^TRLH#],5)3Y;T)A_*#VV MF^@H7D`DL*NDUED\_-2"D#6U>O;*F5I-7((&]>,G82\^V M^]^9>UOZ,\;9GKTXH+UD;[TU&J*"F$8^X70&J72,UF7?7N-)IW"@6L%#<`M= M3TSS8C);9,S(>I)*-U%_,+Z,,Z*A'-\'G`?BVJ\#RD'#X7XT.?VI.C42O[0= MR)T0_M)8S29.1X[X#\#[!>HT.Z9Q>`9)XV?B+%!"3__>/=H`A:5!CYLDI@<, M>"YL*T$P:4`DQ;9#IKFQY*1&XICC(@63HMM&COX5(T!_FYBH^0-.L&)%(CO`$*BPB9`RS-$G)S^3)Z%. MZ<'4/"E+B.\*I!7EZ^8Y3G./'`_)3PF9^B=R4N08*12\5QO1<`00X/-`K4J[ M$L3:U1+&Q&>/3BI+/]#_UR!EE?%,QZ(,(60E?#6K.(7GZYG<_V&*R&0>5B$F M\\"T*]E5@JN^#@K2E1[LWV#[R@,+4ZR'3__<2U=:A%H;R&2,BEEIUM&4*=:O MX[+MMSLEAC$:+F;D4N7O1^T=59M5S]L$!U$>WHH3M].?SJ\,#Z;;[%P)^^4` M)X]C(D:ST:5ET0(.S+,8I[$YG$2Z"9H\!*6%(\!,0J?H)ZI:0^JB175[7VI` MV:EQ8%`QD9>E(JCZU8R*DWW/^?2*S*76F!A.H$*:XS@MQ=#!^$$?,/+2'&^! M+[$V,J,X*%OQ$9:8'BO5QJ>J*(F!TFZ["4W:QW$A&S5`).4CB`1400$@G-R'-`U9YDCCZ MRBC*TC%%^\5_/&T@T^?&>WY.XMD_KI*E*VH6\>+50#G?6LXAD0=]RY*8VD]=%L42-&7V8?5JARQ\\6I>]Q$@=5)&[YVE`L'+FK6@LE M>RNUZ813K%YIDK12(X7N$<8HF:-^"EIUK_;%4$CZ=.`/![+[H)/#0KONU4F[ MHONZ^-])HC@<:XR[H0T2<1L^*'EH%(?=&K`2)L+&>D#BT"<-F_5A%3S$;?/` M#BMMPACII='$0JI9'HPD=`G"=*:7%E'(-,,#$H0F.8S_UI9KA@<@`CT2^!HN M:ID>>">^'!?O3;_=(+Q$6,F2$(]BOP0DD)#HCJ>K'D/AJZP:'!0NM!EFJ^0Q M0I^\*$>3-`V7,8RG\42.+-;%=&$N[L;7UXLLY"P]9*U1MA_0_ZR),YNU$MU" M@.H:6`LS*M*5Y@B'2<`6Z7D2/R%,JYW0VX3^/0L)@_?()[])(Y_!'HAZ,V2M MP:`);W'+PMZM[QZS/?V2.@JF,;FSJ@/3 M.$#K.%R$/DO.OT=95O1`D-/1E$:T^8SN`Y!4#T-@,86QPKM6OY%'H&;W0PRJ MIR'=[?NM73N]SU#,LH&]:'\87"&/5@2".D65^1B!FMT/7XD>B:?7G"B6UGW^ MF/HX+)Y.(20KH&CS02L+FNX.BT6:3)U&05;I`.WZWN*-(YX[4*_#+@WW*)]A M:`OBF($Q[!M%2"5:*>J4;%V/-2-:'@?6VPBJB(K;)?8Y(6 MG>@+)BW;Y[!?#0I@;LE)C;)$/IW-L>M^SCH"X_FK5[0!652BQ=K@\` M)]@=(DIGZ&=E1AZK4O(U<;:B1A74N_RBD!<9S:(7<2)O2?LJ1!7 M4N=[67J6J/LU3S-6A?(AX=1>FV4KJ')ULL2M/;)[X%B%A>OM8399)^2*^(-Y M>=A+]Z[2Z'F2RKDQ!4/8;!9(05`!#Y2=1<;*=DL=4MPJB22E?X"\!M M-J#(>K!A_7G7"]M*U-K;/LF,$U]Z<35UO`JZL7P;I/?J[VY^4S/<'1??Y(:(4Q+>;+O!"3.+A`CT4C#Q`34(T!FS=C M3T@KV6I-Y=D34'CP.?K(VGN),\<*RN%\)LR+TZC1>X="N/1U929&ZRGI`K82 MLV8G28-:Y:G)0@PCRPYJUFX[&:2J%&EM?@\5';3=)*DE\1,^BW!45#Y[[.[> M9%D`;^IM\]4$L-ATD4:CP-Q'D0HL'&`MP8<2MOT(5<*PDJ;VCEUP0QL#";*-N M\6[L@V4E4`"'3-%6KBJU6YT2]&$$Y)KJI#>*6ZL;L4I2G7Z7$RXQ2J9'9&;' MY]8>?,)Y5UAK#'.ITE*SPJF&TG-*/#HTZ/@YN<!6)CU#`FDF6L&G*(5:+J<@+TV27[XJ=5 M1+K"]N!^;.^-+YAT!;/>/).=_7^'-H6].5O0O$YI8Z_U8\M!YD^Z`EEOG@FM MVO]`A)EZ?E'%5\DAS/O8=I"YDZY`UE8P@]&K"CLI@7OTD=W7YO$<*RS%<05_ M>[6?$:'P6^U?FO_0F"MZSF@WU)W^UYCMER]?_HS14Q+E3,)K07@/CB,IIAG$YW,-Q(IEFAA^JY#*8 M)>Q%T6D63A.(XVY>29R1Y799E(?X\9L4+OEO4UD(=>8EV?^#R M_^6U%2L`?@V@A9='F6V+X)=::50]A\!.-2WJ?RKV#6M\9%!5['.$-13SYNR! M&FON^V8Q&[;LU/21]IB\7R4X(P;86ED,RH,:]K"<)"IU!,7]KWK(L53=F?]G M1C0#CS8;FA#FGU@)1+5RPK*#V>RU5X1%HBF9B_7K[ONMN@;%X7^:LY_KH:,T MUC/VPP@1RI3F0T+^0F?P,:7%)D_=0KIH&;C`>LM2+\A0&_(";3#R0Q823/X> M(09I'-03PR'VJ13=,8E;#5!A]T&74S^2T8U*$BN96@;OLB30E%^UZXX68U0,EZV`)\Z+*H33._<*#37-[P8K< M!S(1>EW.XHLPW21%^?O9@G$!(JQN@B8>L4X6F0!#L';0S?HR],62T/=I.]@Y M1NLP7X-L-B'1L=H%$G"*>QEJ+DU]D*$-HRQ*TA[9W:>.K;`S8N^=>H%P^$1X M?D*ULV+W,V*HP`A61'2L.U4"3HG>BCT\7RLO7J*Z,&*`7(?>8QCU<'\I MC6B_#TP-(-UMXBM.I[%/\[[1!2K^G,93LNMC\@%01YQN@N:4FC[KM5D@I!-( MF8<"30(D5S!1B8.+,DZT/+/)3)A#'4Y=[@E?&BZUL+$9UI957>8 M^G]\GU"I3W&8M2#%R=>T%N2@ESC7@=;"'8IH=-G)*F>/\?)4QB@X&S+?8P!>JZ4 MI3Z"O'T5+,4;\=1W?ZH'IKK>_;L&L]_FD89%8I^=5$OA(6$M3#$B:X2LBFP[ MC[PX(R<&;6>Z`:MP*4_=$H^\Q-IM*[P@`Z_8(CHY1^W>B]!L,:R(%E^1_&H@ MZE9R!(I6"^\#*JUMU,>KM+9B*7[A/E5IO0IC+_8U*:U=@XU+:>V$1>+U^F25 MYCR),QP^YBPOD)75A-9B6BC:\KPIL4AY>DL;CD#!_`UU:1]@1-2D744`O[6( M`K=^A?QXUEQGDJ)2!TS&F7[ZMMN7YCQ.\=>_Y0ZH61%^>L)>.P0/)NBT3K'F M;=T.(;`C>F/;=W(@0JF1NV(2Z6PQA.@ZZ8U5=-T@@CG4&@MFSP&_!RS$[N/0 M'?O!R0=4:`!HO/%JQ:B'N_CJ1,>Z(R7@A#(9.,9DRP0&-,S;J(_7,&_%$BKJ ME3)`]%_Z!_6M/GD1/16*2H>'#Y@0$E6B;V]YI7YPP@6[MO,Q(>L-XRU96JQ6 MZ7#R/"0\@LTIB2!(C.M]OMD4)7>\B,:_DR%S3$_X\LZ8QHL$KXN^;RJ^LS[C MVEU]JQ=2E66OT1^S#].L/!A0L-69)'\53A4OQW8'&*4LI'"!B2RZ"OJC*)#!J*6*?S7 M@![05^E'/AV<2GN>8W_ET3X)G$!HGB"D1C+G[#A5*')`23CXC16-I^K--RQ_%'KGRHJ>03%9+/UU$4E7/^V^E?2WJ M,KN;&C9)%/I$L7@@A^M9!!0C(TEY%"W19%&4]9L94K1>NW8\3M5RJI93M9RJ MY50MIVII5K6NP]_S,`BS[3XVXD-"](3S)/81CIFG`T!>,F1M3EA4@D\J5,24 M=E6J5TZ_\&>O<(`ZM!2HF]_/HD:G-)B-:9\ M4>W+:5Y.\W*:E].\G.;E-"^G>6G3O#XD2?`EC"(6GM0LL3>0[J7(@;7)-WT1 ME6OT:T[W8JXOIWTY[/N?E@W(JE%.A M3*E0JP1G#PBOZ39Z(!^`J5"MA,:@0K4C!*="'=(#5*`XI`;R.W7I3UW+LE,Z M<&X^`4D@]:E#1$:UIQ,%!.857`7BL8P^9[9?3H:1]Q.:01UGGD821Y#1LT$E\OB M#`7G:[7<4'"^5N=K=;[6,?I::;)%MKU!V2H):EUO!W*_*E`?@9JE@N4H5"^7 MR>+T+J=W.;W+Z5U.[W)ZE^9F(U4<9$H[<"6LD!N*_>'B#A4YL#Z31151ZS-9 M7KMT%J>".17,J6!.!7,JF%/!]+\%ZX;>O`-I7_+$K5>\%'`< MA\[EDCN`\2;/T?N5A M=.81@G-ORSPZL$D@)[(TCF214W$?15*)RRQQ^IO3WYS^YO0WI[\Y_0U"?ROU MA;F'L^T#]H@6P1I/#_5JJ4)^%'J9$I[CT<%1AU&\@JLC6TKYK7:?R[F7KF@",?F#9K,\>1&U@0IC M`C8A6XKP"%SPD@B6$GRG6Y5XP%Y`6\W,LA7"50<:LJH0X83HH*59""!`.<(C M$*`D@J4`O]4M0%H[*2;_O!U@TW%IV7_O\6$J!?,=Q`W(Z=4^@*BD:8_!QR8/ M9"G,O^BUA0^;O5Y1D-!U^(0"N`-23'04RHH$=J70WFO73J;KC1=BRN(,7X3I M)DF]:+:X3N(EHU\P-,2YV8>/$5Q]_?`MQ?V][IOP#J6(3)%J4Q?H"44).R(N MGVGV#J`B(T-V#(>L%'RE['[0[6O$1%G*R)H98C=V4+.^?$`74I4IK]W=>$4V M^2GI>=3Y2[?M)Z1.F,>'G)F3V.?\$\.!JHDIW#771\VK-^9O;"M M9*W=)T/()6OTX#T/8M)S:(W!I.?!5$F&[VSI5_[;PW$8+],YPFS!#"`>$4GK M=Y80LTI67?X7+3%,@VDL!CBA9Y=!TN5`+J^%^;]81FBYT'NGB:(YQK=+'7$M: MIY$YCD^G\0!^0D9OOZ6-J1JUH.?,60(G@:X MK=40&^J:ZV;K%#:GL#F%S2EL3F%S"AN8PG:_2G#V@/":%A$<2"GCT!Q5M!@/ M-[N;=NRU*]=MUNE73K]R^I73KYQ^Y?0K./UJ7R9H7Z$9N(F'+.UQ.;I$0.HM M'U[1WR4%3.--GJ4UI]H_-H0N=G#V.B/:0SHE)D7AR$ M\9*CJG$RUU7&LUK/4D=G'(_&KA>Q4Z6<*N54*:=*.57*J5)@7LU+C!-\GF", M_$I[J+7"VK>^&LK3V8.?<7D_^P!NJ\9V5#+I":7)HI'[Z]5S?]E-XI0ZI]2Y M2I*NDJ1&Z;E*DJZ2I*LD::Z29$7_QO-7Y!;`VSKMMG*2>@391;'?2RJY$=@P$M!1],Y!"7=)OY.Z@,6QD8 MM33;(17N2D/^CX-"LUYKH=FDK="L*V'AW"#FW""[=7NVW?WU[R'"9):K[35M M5`KE"9&D#/GBKM$;(HLCC`'=UOHR/>8#SC&BQH!Q%XG:JAU`&NP%5(D/ M&.>)LLQ-NE$&DKB<3T5+U#KE^0V@<=Y!SJBMU^NLZPI#;P`)Z%MI(?MV6/F] M_6KE]U;%U:)/?N^&E=^[KU9^[^"]+N=>NB+V)?V#VIA/7M1@_"),*2DR(0AI MRA.WOIJD`HY`-^$^:ZRRL?=W^BW*WD`(4$AS!(4.Q+C9V^GF/E^O/;R=[4)* M)BW1),Z1XAPI+I[$Q9.`1""X>!(73^+B24S%DPP00](:-S*V)^T^P2(N],#. MT`,()X8+\`$,\!$6IM!WDWW`23JL0EE0''5(00D:3&S(Q/?S=1[1B(4+M,'( M#UD-$_+W"#&(XF"R3G`6_L%^SF420JC:>!N!ET.?'"2](?HV]2T"D7XG/:LS MVN40*^7T3G3ZFG-;)8O6=CNN7.<@/JN__(]_>/^/M[]^?-BFT?LG_X_7T4_9]Q_/K^?!S_\5 MO?LN_M?C[/QBNOWP\#OZ=OKTV\/J]^^_OU@$/WR\_=/9^_-'_R_7T29>Y"A% M][^__W9ZO=PL+^__\?XN^/C['^]N?ONR62V\,/W'M_?+O[_]Y\>[OR?1V>

OS^^]N;V;^B^[M__98__.GI\?-DG4YF7SXN?YU._K@.O4_9X_.' MM[,?EC]]>X5_3_\TO9O]?';W[>-5MOGP^J=@&\Y^>KA[P&??3=]_N[I\E_]I M]7?TN'R_O`U>)?,_?7A_F?S\SQ]__)\7Y_=W+U_"W=Y?AQ>OHT'6V?;&^S7! MYY&7IF`Q40KDQQ(8I8(H4'04GX4]`[?>&M#1I\H"H)XE%R"EO@\DA=Z.N!6" M!PJ3ZB-Z>.%W!DL-*GU0O^&<@E9M:=H4%<'3@">A'Y?(/YI80T1^":$.,FV6E"I\1J_I*Z7V1@&?*X M&(._L0^X4GE,.L4,Y%L24!RY^.3<2Z9]2P?M`CUNNT#G;QK$W^2\*R)YN$** MKI"B*Z1XHHA<(46K"BD>W,+G.<:(/5;=)K%?_`?0TZZ0[!BT,"GXP%[NJ;9$ M*),I10_>,TH'E)X4:3#%0J?\Y$"$R_`I6;CW(K+]!Y=A)]F1[$`Q?%+&D++D MB-V%,$JS@<].&;)CD)P4?*7DOM4KN5FV0OC8W!Q*@BKD1Q'IHH1G*=+OM)L% M!Y?QI,VC8$C!D>?%^DS*_BB7@O]+MZEAJ'%'-1]7X]GYFYR_R?F;G+_)^9N< MOTE_XX[\,0V#T,-;8K&AV8(U_@([X+C$QI%BG!#-!@EJEJ/D87F2.SD"+.&CE;P1: MIUYY@"5?UFA3:DWZ<$>X#%GC"BS$EFKF1TM@#Z0!2]"&.?#3!"1UE"D)B/4`_^GFI_)(]J)I[+<>WKY]2[#^5D$0 MO&\-PR]20G:8<^>NV4BIB$W(/HO>_H4"J8;R\8=F3QL5A%LFK3USM*+U4QZC M-^KP'GXVHO5[-&/Q(=%OZ>;+/,W>]UBZ1Q^.:.D>3UJV;HTRP/=HDS$:;WY0 M![G]8Y,!J"HPI=PR:>V1:'M:VS>O M^\#;_&Q$I_#1C.6"O7J>PF_?JX/;\J5!"U']$&[.N83WO6;SA-ZG7DS5P7?J M"+=\.1*$V^9<(OP]`,)$8V'JH"J^A]^-Y7H[GG`)[@]:;S9BO4=YP!SZ+'=] M3HS-L+U2+`?D[A&,IK.(0M!V>`M0``N2F[,V'6@>>3Z"+7G-H62VE(9TW$RS M0F0[9MJ%Q%;&>1(_(;(8'B,T)\R':9K@+7T2*T.?6ZJ@C]L7<=.%Q7OHN*M?^-V4?$N*MY%Q0.) M"#I\Y_#2W3=<@E'$.NB-)%6T"S&8YY5IFN9>[!/E?J_VR>56MW]IT#DBD4G- MF2U8W"JQ6S'R4G2!BC^G<:N,(;:#+&FC#@#)_HN2(,J\XO38(L2:B+PT)0>G MS^R)*S*'O1V17/Z>DS\GZ>0.I>2PGBUH0&:11$P/<;G-="H-J\\W/2A*==@T M8&Q>>2'^Y$4YFI##9;UAO]1I<#I[T]F;9NS-.R]>@J7.[`<'DX)&P[(&!418 M$!N^S7+DG?^UWQ_`KNBP_([6R/X$K\])=SCS(85#8TX.-[,1R%+0Z0\TKLC? MD!FO\S7<&T63@"&5@[>]ZIO[``DP;]&-]PR,>(.`S8@WD=!NJU9TVI2MNS#] M[0HC5'^M@!"&-.TQ5#F2!Q+FL&JC?_F\07Z&@@>$UT,)L$%S!`]T8MQTQY/+ M4+X(G\*`F%!#;KU6VF/=>NU`PF3S=='_E$3$;*7VJ@E1'E`?^78\Q%(R\M6` M"X.%>,P*[KTX^.QA[,59.LNS-"/_'<;+B9^1E4G=;,Z/X?P8IOT8YQ@Q'^(% MX0;*G7%$8P2OY<>X`!7HK=%1<'*T?`9JTDCY.WAK:5]]MV6R$"ZC8SJ2/A`. MK"8](3U`A7F,9L3.T#*,8W*+S19SA,,D4(B>Y7UKTA;G;[\=OMPI@_CM+N.@ M![3'7QE1^&0A;9FD>+WV4S=6'D9G'AGI/%EOR'[S"A@P]<'0"^!LN_^5N;=E M]0Z^>#@H5;B:WG:;0[FF]#-I;>@`H%SL7T&?4;A<$6MF\H2PMT27ST19"5,T MQZ$/HPD/Q+K5+^:#RQ$L`H:Q]RB>P:/R#.X0!9G\_)S8'-CSL]R+J`?L+=BJ M''@:8_!E&1$OC%OLU+WV":64^SC8N6,3^J.Z$V6YQ&A)8)V2&85$C?:9Z\C& M4[3_9+[Z6_P$.8L]@$96[@?F[9O&A7+;TEW'CC79QN:_Q2W>*A_M>?[2W*9* M[%JG/VID?P0/%(-*4UP?P8P2R3FR2^ZI-U52^7ACHVZI<7;C.4[MP$NJ9$7/ M)Z?$_XVF*Z#@(B=*Q++8?VQB:?V]KMJ"`H##+R98JSMH0LQ%VD[+1QA`S_37H?*=+KO); M`V1@]V7^-HD+_HM4HEJ"G]WO(2I\?Q6GGQ8!5@M0U\L)>^+KS?HQQ]D*X8>5 M%Y_RH,)Y-S7/I;TYHY8`M%N>VJ)P]Q/K8_F<,#&>\2._5&UAV.;#TSZT=DM8 M7U'\67]MR/%J\]JS`9[,-UE)NU.VB":)D(R6X8'X2_)JG&9MHE1GJ\D)=7JBKIVQGAJBKI^SJ*;MZ MRD`B@JVG7)&=D]LZ3/(TVMZA38*)(@%7?TI(TZPF)],_1AX^F4.P9]U%E%:+ M:Z\OP4FMB]QX!-8)&MPVFZ0I.JR`K4F[F#RA&V(L(W4FP)LBD&685R`%E)2)I_54GQ$R<9==/5H3]ZR1-RW:&#\DU MP6;)_&OW*,L*+PF(Q*0(C\`_*XD@5$;:+5A\N2%47$XGR?K->&@ M=J2?>6GH0XA2E841"%4958GTJU[BO?0P?3]/YPA77O[0IR=Z&.49S'NTB*3U M9ZD0,W'SX;Y;\=Q+5W.NE*H%TH2WT<&U`:2]WM MC@4\3.,GHN::DF<;]?'*LQ5+N)0>#A=78>S%OBF)ME$?KT1;L93(D3'VK$S; M.UV@C%SQK@FO>S0V^6@\B;,PH#H*L?OND9]CMGLNGZD/!@6T31F-`,DS9EO, M%D=JSK9]`*BG9TAV1_"`#2HML&?P=J*WWKJU?#+D0JG1'*1?4L>;^``;3[QR MZC(P)GZ8EW:Y!6"V4+1E:T#N!=_UWM/=>T]K%K?KO>=Z[[5#YWKOG6:JNMY[ M5B(.W'NOR-JH5<6:[%L$*93[[Q[!Y,.NK':^3V'I!D.XYOLUO6'-L+.07*H7 MZ#';,PJW!40D#;Y)J,A,&D&@5H<4&71-&`VF<4;V,F6`!5E]3-$BCZ[#!4RG M-1FZUC\KR:$'I;2[Z!>(Z)?.2#8C7KS).LEA(B[T,&:_Y#4)0!C%9L6;Q>MO M=#P`N%<+]VKA4MU""?0VE,,F0!;VF-*I04@+I?HX3$ M*6DXS4J&K'$=2V%E2\FS#BF,]UJ"-(P2)BE/D^H8G#1EU;1^+C??ISZ;E-[W MZ77BL;>072#J'?)1^$1/EO1L>XV67G099V&VG2W.Z5<(;SS".^0YK)6_$1B\ M>N4!MFQJM"FU)GVXRZ_*2S$(NN$'F$?<))O;J8?%*('1&,8?,=4.-!V$01"2/1J807-)`J(SA#D M/@6GK%FH$L'1.8!A)XJ"M;`70B<@4';-!=I@Y(?L'0SBN&N,/X*,IB8>$D=0 M_[(^T_7&"S'EZ'SEX25,OAF'T@@DP<-(XM5>KTT(UH):0'$,Y6)$H.DM`\/. MR3E&F^)P_(S#C%QP"ZGKHN4SJSWMW+D*:[;TK@%""_03!0_%_O9C3$Y!2BF` MBT41D;0^&$R(F5R]%L./(BQZQ#V+N&<1,\\B+A.I(Q-)E]?#92*Y3*0.Z.`R MD<[RE)Q!:3KQB6*8%I,'VNL\4I!:GL;-ST5J.,'0OV($^)HI)CI0$G#'62-8 ML2*1'6`(Y+T64H;Q7ECI@P:@ M7(<^G7&\G"S)%<)]S=)54)Y'S*S7N.&JYC`0<)53/@Z*B:< M1\C#T[6W1`I/[$48$;R"$I\R#U2_._9&529/O^5B7^+]-TS1'P46.:0\:UN:5Y>C7;P*@ MAT=9XM:_5"O@*&X)TT^2E%1+VW)-HMJ//H83LPZ&,$9`EX-XGF-_Y95]QR<1 M^Y[\^$.2!%_"*(*+\^C-B_7;JC_*XDXP_:)X2C)[50HJ9YE#:01QA3R,)+NW MF([6*8J]N'@=%Z]C)EZ'UDU*8F:DS;(5PD49`*(F)KNV+$!/5I*41_):)8LC M5/E&$7785RHE^D,\*G>\4*FM>#49*Q9\!Y)-GY)^3V"=?,0/CD&_```-PIHV'),CLG];5`R='H$`R<,Z! M(AV&68.&8R.L6X:P$7%5GTX44!.=YIR3BQ.M-U&R1>B>\!KZ*'W`7IQZ?L'C M?;[91"'"8-4F3^,([AS369CR1-3ABBBKC;8*8OG4$1P M`3VG<094@5/#\C%[)=FV@B0O)/5PF8GODZ^#>R_R\%8A8J;M.Y.1%X-9&+NH MFU;D8)Q859V:N;>E/,.%DK43,O@\-:A8!7#K]6$4`7,H(FI+\)"4P8C5H]H= M8B$'5)]1V)/RH_V[2%059-TE-\K:!JS634560:#M7_Y;"8\#GD0@CKJ@=C4] M>HB*]ZWA0*CA!<8%41QOTTMHM8E5I4,4Q,;_VFQX39]GJYT(.B#1'AC,"/Z, MTN0&!0JX-[\P'2VHQ?[>P7^`!ISI5VJ@1$TA,XT>O&>4GI/]C(`Z*O&I61^_ MU(441"]<0N$Z1'%;J!EG0S2_,+TAQ`6;#F:H-_29=XKU/=(MS@G@3U6LXO0Z M-&K7"<0I41_>^F.A@050//!U$B\?$-Y9'>1F7X>L]NA#N$9%>#*$(*3H6B\A M.?3DRH]I%%UI2?XS]UC]V=*2'%B./";L/>Q.`%8<1]S/-C_B@*PIG_SA+EQ[-VHVGBHI$,+$6GR>L8MM&:001WCR,2J%\K]4[0H/'9_'Q MTDBEM@;_:YOS6$03+X'^00"T\5#ZLG&J"Z9WP?2&^J;FCRFYR\G`ET]E=7BP M6!8.J9&$RW.1@GE:;"$'&%;")6:\!8Q@@0HDI!+FH5=,0`$<78(R&I>A04QR ML12G73NN/72O]M#ZBU6Y]M`2*].UA[;B;+.\/31[]9TM/GL8>W$VPW?A;>O_`M;@09[Z*+(Q5-"4J;ITNDSA3LH6*N;+OZLO M9Y[X8`L.'U.".1\Y0C+:TD*SB%Q;:M>6^K2VU)W!F_W>V%U;:M>6VK6EMDWN ML)X$UPJM#0K-44RN%9IKA=8!'9RA?($>LVFD_QHKTAO/)ARAY]*)S MC((PN_%2HA]=Y7%P/5?(?#MA$P&[8K" M=#HB'^`[W+B>0NU(N)Y"7T=/H4FZ0IA9XQ0NE2HI;1^:#7@6Z83[^B:MDX9) M("9W"J6D=K76OC!\C4IC>C!/B-33GVY^4H2R^<58H#R8ISBHHC>4*AO^X!.3 MJ5BJ2!YN<;VU-:9Q$#Z%04[4QB1^0CBCC9/8Z:*`KG`0HSD[TH"+L1`^M_2+ M.5F%:#&K"DC,%HO01QA.A^@B9U10_%?_1I!)%UHP;L>J4%&Q+*CI?(6\+,N"E-TRD MSL5;$*DIC#HRJ:G@!>!C*[E(0:2F,.K(I*:"%TQ'RCE.?(2"](I,A9$K\X\A ME`@N+?NK'/!A@GM9;^J@M66QOT59XCY(EU!YXM:6/^B!HV;+4\C!&8H)9GY8 M[?J:9C2H4+OX&$'MA'[XZK:-=R$_C=;"E+>+,&510'.,UF&^AA"MF*C5=<@4 ML`,+7^2NHJIY\.7S!L7IL#OSD+;-%3;4@83I(]ND_S'VBD5%S--R+<%+L(WH M*#:@!'8RY9MZRVU_3I?K!@6U@`)6H1!,WY&B/98-*`>DL.03C""+'MY%;V\S MXFQR,`H=5@51<=4H=1N?5DM*8M:5O2J@-%EBA/8+ZB$Y0]4_'130XUCXJF-: MK(SVPTBBZE0?65UY/JON?850JT'/$4?+9U;?6MRY5E:Y]OH&5++%+KO(:;7U MHFQEL?MNT1?V3T!50J0H6RTN510K*6ITKARNF'MB:J3TZ4)U?^P_M%DCZ)AN M!6Y7[8*>;Y,''DQ`ER*/U"BV`1>G2C0`6=)-_;XRR.X(NXSG8%\<%-Y(ZJ1N M\4W?!\M*I/K=%G77-#TXO=A'A>L$VH=_0,UZ);H+J4H^'1E;&HN#W.9T+K/% M/6W:PFK%GWM1A(*S;?4P5/[B0"A.O0(R3..AZ6S.MOM?(5H`LQ:_ M>#B@#9BR[?Z.25F7@X>5%\\VK'S$!S:':5PHT)\1G0H*)D2M(+<.^\<+`MBN MN.3M?4IB%*/M" MN,80KC&$J<80KF+Z2173`5H-N(KIXI7I*J;;4"C-UHKI11.UXF7F*L%3Z\V6X)_RJ8UJLN/;#2*)(O499,85:KZAX M0UK[XM0+'YG2V.I2ND59T?2.L?-W%`73^)X>G%Y4UJ;L*:M>`]N^M_JA)1.2 M;HN52,U$9R(Z$]&9B,Y$=":B,Q&=B:C)1*QUU;XHT7E"/R5DKI_(SW.\#P27 M,QH5QK,Z($<='9A2QEWJ^!U*,QQ2MS_[+?;B_@$311#F:NK#B-4R/A%C&0-5 M?4>RH`<4W-'RF2G5V^_S]=K#VY_R8+F+JY`,_)8=R]X'2S5(Q+9HGY)(9)_' MM"[M+D=&"ONV[RS'N76J8BO1%A.1/24Z(]$9B6:,Q#E.B#F5;><1.:TF,8M] MVQ3!<;18,I3)*$,6T$S1:$-*`0A5V)M+_+C0]2#2JY$U;F0JK&PI>=8AA6G9 M)T$:Q@J5E*=)>Q1.FJ#=_5SS4\/-3R&Z<+GFIZ[Y::>03!Z4KOFI:WYJ5_-3 M_4GOKOFI:W[*H>V:GWYMS4^K7@OE7+QH&OMJG25:OC08S=2G=QAG^@`EP6?I M!J/M?9)GJ^OK5D<^T_E$4D:/^A+8ZY071W0@XC(@ZYL8B(AY:$TJY^J]PD43#'29`S6[3* MT52X73H',/Q`J%>Y/CT1A$0TXT8F#."N_W!@IH$%&U. M=)(%31@3T\_=F*8HFZXW7H@IK?.5AY>OY%Y"@.B4JX\:+B;KLX+&+%"Y\]_LQ^F-OF M*JRVKP[I)(YSW:D')[5]:JR]US598^;[7X7&-ZA6_CVNO<'!M^@@D(IB'Z+WO`BT0QBCX2*!)S[:T8SU0R<23EY#)Q[#I@03)Q M]#?$)8)W?`3)R'58B+6VD:/Z&4_%:Z?S"5#^B5&,9DW:$^J2,R MR&BW.8OJQPB'*'W[^O5?=DXB9E0IR$,PA-F80KZ78U\`6@"![I#J)M$?3L>] M?8CQX,Z!`*1R_8=PL2`#WWB/(5+`NN4SPR$IW?D:W+D"Y/U=)7B-,)%A2MMH MJ9SD[5\:C%.3`)4S6P7KRD"6B>!M2^=1V&=35DU>B;(SJ]I[%5U@`X75)![% M=!29*)!B)P<)0.#J@M4%7P82YUF:>7%`=%#0-S8.26L#5Z4Q`W),,W)W:)-C M?T4[T9+ER$+=U'(%Y=5.@;V\MT'YPZF_7TKZKK%OTA?W3D$7>#RF/0FZR*`I3E32+D965-R'%`\(CR*"4 M1%`B*4K_/BQ^3HO1(_P4^@;VXS$'UE]SJH@*$[-.$.PJB$^ M?TQ]'!8&YOYQ`4RNT@R,03`^@VKBFAEV6OWPP@9*9*/S0BUHCV&C2H/9"5+W6X:RL&>7,E!2(Z% M,Q03S&@EI3V#5\BC?9:@Q*K,QPBTIG[X5M+67]:E\])G_WCHU!UK#T%#"M?P%X`$+P.426:5>26=NRUV,F=PD'*G`5@EN@@QIJ M,9E-6C:RGJ1NAG[IYY0KL*(.N\''4(VK!H4XZK5'*6\Z?-O9S:O77?O]`52; MKE(*AVMD7XJ[/B>0#+(:A<-C2@XWPR4.9*"#V]UUEQ]0T#>-EY<0NGRKHK3W)7O_Y[7=JJ9?R`QI],)9.FE/#"":=7H:';U]K MEM-NP*]'3GN,P/;318B1SRHMQ,'E>A,E6X0J;M0$)#&2V2@J%='(P*+9")#6 M37BJR6U.^9HMBB"@29ZM$AS^`11NHYU)ZV-B`>0"F1#+#0YKG098J[7>O-B_ M'GJC/.C!<;CJ/L:$>,TNH49,VHC489K>=?(%X>)OX3H$Z6P)RN\(`G9AY251 M-+3_*GL4'X./G*"Q6D6`@W"Q.T2!)3^GW4*QYV>Y%]%&36_!%M_`TQA%_)`) M\0I3G8=5I,JI?&)-!*O8QBLOQ"R*RBIU2L#J:$]!#5*2R-/NM:QV)*;QABSV MBS!EU0KOR&0AED87N1&(MQ,MB1SL8>^H';<3HM>MJU!88BZ2)4;/*I`\,T!N MO^H;1T)8PA3Q82^6+HX_)1$9)@JS+=T;I0/;JKM&G7O[;;@!)0F5U#[`%`K? M_E@78\F]6XPU20H3\2U:C!?A$RTR&4!I6/!,CT!/&T!R,D4">CQBE'9`X8FK MW_]2#Q?\KVW6G403E\CAMRJQI\SL<:D]+K7'4&J/ZVYEN+L50#R4ZV[ENEMU M"\EUMY*4T_DJ1(O+9^232_T)S1:+T$<8+NRMBYQ19;J[-+X46E"9'U7("IQ4 M#BB8C+.2D\,A)$`=?8IF"%WX=W9^:('55F`[IJN[06]AXJ0;C+;W29ZMKJ_/ M%9!M_=!Z9-NG"_62STZI&='Y/!J".,R9SB$WEC.=AY9$>\"^Q\KYU4SY1-E_ M8_V2/YHDU+.MJZYMH+JV?D7T&GDI8BTIXLR+J-0D+,Q/=]/_L@1P])[40.43J4S&1) MVU^241I$F8;!?1MX["J[L@:I$_A_T M':R(>@+96T*BHY"6!':R'3ML>=.BCUKN0R:H]NUL5#\G][/:FL-!['&9=XXSM M'.O$1,8-UKTX&OGRBS`#6.N>1&DG50`/6-<8N8]8]T+5"`A MA3J[FL4$Y!WK$I11[Y@&,H4&2W1 M?-BU5@%J\2BC\<-+``*52T3#]XJ`2ZIBE*&7M"Q?%=%79`@4F0,@5=04.;`^ M3%P542!C4LC&9$U/4S,BK6C;7*I%'4B]1^6>2Y?_-'C^4] M$![!VYHD@KH?JZ56D,FF]SP.K+\I51$5/WQKWYDFYD*X""@G M5Y&G87^!W:T/S[>$E9S#M,"T7XVT>W_*#I1D;< MUZ&_-#X1FS+./+R]"B.$M8GA<-AQ[((C,,1-#/KBSBB<$[:6"=9V]C0''8GJ M>("$1`W_GI!_1E'TCSCY$M\C+TUB%#`'3T=HCQKXO.%'(@8N.A*5_GO[#0IO MFS;+MGU8V\\>#A@5[IT9H+V1W]O05^0G&LY]WL"6W[Q[HQ!/X_4$L#!!0````(`*%DHD+%HX#0 M^XT```BR!P`5`!P`&UL550)``,NEH)1+I:" M475X"P`!!"4.```$.0$``.V]:W/D-I(H^OU&W/^`,[-WPHY5MZ6V9SSV[&Z$ M6H\>V>J65E+;.\>QL4%5H22.66299*F[YM=?//@`BTB\2`*49C=BQVJ)2"0R M$XE$(A__]G]>O4+O<(KSJ,1+=+]#\_4SF>1_MT.$1>G/T_==OOG_S#?IX=X+>'!Y]S0>1$4F<_GH? M%1A]7B=I\>^_$R;[?)\GK[/\X:LWAX=??U5_^#O^Y?>?Z2\ZWW_ZFGU]]-UW MWWW%_MI\6L2R#PG8HZ_^Z_WE[>(1KZ-7<5J44;J@$Q3Q]P7[Y66VB,HX2PWP M0N`7]%^OZL]>T5^].GKSZNNCUY^+Y>_^@U,.H7_+LP3?X!5BJ']?[C;XWW]7 MQ.M-0C%BOWO,\4J.29+G7]'Q7Z7X@1*?SO(=G>7H3W26WU>_OHSN',!+NJ[#BP^Z*L6T83^XI(@U$$5?RYQNL3+&ED*0D$V-@-C4@.8@LX6':`) MI7^6US#9S/_^NWR]V/S/VRBAW+I]Q+@LCN^+DHINEU+T.T*)HS=';SBU?Z\8 M2198(T%GZ:!1R[O-VLC>*7!%<$/L_R>Y3YC,DD_3!T+2]-7'V]_]1_4MXA__ MVU<,SG^@#KK'>9=P4;ZHIR4_:O"MOOAJD9%I-N6K1,1ZE6=K$Y*7F79I3(9& M)7)B3=]#+8'1+_7W_]W2^OE1^U#8LL8[:UN\>HBBS?_Q'E>ZZ!88D>""_K?:*L=%`1Y`XXC^W@Q?_5'($`/$\OKT]N[L-+EMR=HBR(EG-5WU\)]4/?11DQQ*GJ/0X>BZ4/;3> M5NQ0.]GF.4Y+U=8";#OY2+^VG10'8-=4WZ*(??R]L'V\VQM*HC?V!KPXC]8= MB(1L&^V1&##OGAV]!]EW)U'Q2`Y)^I^SW[;Q4Y20.8KC\B3*\UV$J[5TD3X1D%F^ M^X`GL94Z\/V*D3@U("WU)S$N`FEZ%1]$2>@MQI7AUSG>1/'R[/,&IP6NM-D4 MG)=/-/;)KQ(`*0:`)%3?(LP_YG>YK'PDU[1%Y[P*:_,IN2?*"[SV`:<4/_0F ME)GN!%/<`LJLC!+]W4HM+'<4""@7`2\#"H'HKZNCC2UU2+;!>;F[)E0IR?E$ MSZ;-FL"=Z!!1SN?[KJA"!E0N?`A3*KC^_@"EN`Q^/S?A95>Q:);O+E87:4FH M%M\GF`LK@7CV>9%LE\32H6ZD3W&23&.C&,SK\^`R00BT:.JA@4\J&V9V#1W# MM0\XQZ84)E%@O.HEC6#4?PYZ$5(QOL_<`3;*=,;)^+XK,XM$:8K,R`2!;0_7 M77&*5_$B+JV\DN;0_'HJC?$"I.'R MXOCMQ>7%W<79+3K^<(IN[ZY.?OSKU>7IVRX4%>+R2(:)XP MDG;$'-XQ%(S8=ZY#:_7_H@%@HGK6$,D^M[>-X3P8],IQO%ADV[0LKJ-=1`W\ M=$E^DV_Q4IAL2N^2Q?3>7Z#-<8/>^RL(:,-!,&=#Q(&(0AG:2K27@8XI:4FG M`1>)[DS^Y+(C@J$$4.,MKT2LS-#?"!ZOUG@9]%ZIYI5"?O9$90Q!N<$)C=*] MCG*_ZDP^KT^WE0E"`Y77`AS2$M3QI;##UBGWL M:3T:,AM80?FP]N](I#_L!'O:1?CP!![JV/Z0E=B#6:&9<8*=K`SJ46(#767; M02BEH]B;&W#TYD_TJ"@VF*5/ M);M0F0-V[._$_N@)YBR,(L"]LR>)BH+(/%Y.*)DVT_N^B%G@9BZT>T9+3XJ9 M$'_SYN"/7W_#9?@0D-X0HNL@+*(BM*F)8.[>`D`IY`F$;S/6YLPK_*- M<3XN)`DC1!'87]"0L.QLO8[+-0NZ39=$L9=Q^H#3Q40BH)K./RU."9L]+6>B5V[2[UTIP2:H0_6FB=J7PEH.ER@3$EA1/V:N>0COP^8/FWS M:>V.SK<H6)N<`?IB?+NY%-,WHBJ4K#2Q"` M=B^F^1&(@/T3:D:A@@X[(#>5UX>'1_1B@YXHC`/TQX/#PT/Z_ZB@2<#D--B6 MCUD>_P,O_X*.]O\8%P5U\;)H^VU)"W[00+_05J=""/:"[*4TW%,&UB9'EDXK M?+TY?-J;^Y,K[`ER#0'$["_HS1\/58+V[9N#;__\S<%WA]\RV?KC-P??OOGN MX$]$A)6"U[UVOPXMAY`P[-LK/7H.>:1?+F/J[XR2ZRA>7J0GT28F]O\D+UC` M5-X?W^5X0&]5S=>(IMB\BE.TX`-"BXN&=9T'*,62W:_(XJE,$P/*'?7^W&[O MBT4>;^A\Q0U>8')#OP>J*`VM2F*%P)@N<%F-IA&(!)W)XM=$9]6?![UH.7&_ M4S7$FC+.'O!33!1\QA)7;LOH`9_16FN;/"YP;4TN%MOUEKDK3[-<9SG=E,=EF;K&@N_&$3P\:5)_7QX4Q4YW,%#F[G&$W\']-H3:6?7(M/ MJ^=F(Y>S!;CQY4L;$V:.G<$K_0?^2E_!.$`"%%2#"1R_;\W;-I[?CE)>'=EV MN$FS+@0V;@B]XJ+(\ET==]'$5WQ!+NFG1,]'>?%EN,PW;UQT=W^?XOOR(BW* MG&T_K>X8Z]JCF]1_-(4&HP&Q/VJA#!=H8:Y:AN`AJ54\1>^&2DQ&0-UHB2L?(`/3P;YJGWU]"5-XI2A14K`Q5*N M9'$*]Q/7Y+C>7R9%<55 M>DW(_1@56$@C-#J*X=$A2NZ`V$"%9\GWB%AMFVH$6K1#@E8IU?&DK4JJ7+&W M\U>)AK1R;$7Y59RO9>0/&[OG[LK`/A,ZC0#VUC'@0:*RWM.'J@_2I&UAX=G-^WCPX''"KNL$%)DC37HA">DLURS0W:=6$7J5) MB0IXX>9C6/2\D"85^+0W8F/W4JY;^Y!4^U.\R?$B9I<@\G."68I(NCSF48R2 M`$$-[=EZL-U&< M4]UY\ACE#]-XGX&9/)>QER(!-%:6>2J[$B-()Y$QU`.W9".([N`AY6]>%SZCB]X@O=-`NT@7V1I3$9Q4-H1I1K_) MF0M'BX76(]/QV`7VQ?1Y)!6,O=6Y*`[V+'!%6[!S8)6L606X*(;[[>(&(P)Q MG_6>C]D(]$6E&K[\/EQ0BYX3S5N.9K$>V[BI,9'ZXN1TGTDDRVA,&-3'[2)] MP@5[G>/PIRSR`L[EU0D'80%WX69_KN0HM"-=QZ]N_VW%2H?8?S6@"?T;^U.$ MJ>^VAX5.1"H5$_A\![BSUYF]MR[GA]A],?N`O6@/.DU0Q4$0``6B_G)?:\Q! M90C\46F+>GE#%`6]AA;4I)?8?::3%2 MN2.^H%>&+ZE7`G=&LJ8S9&QPS[PQD_<=%'J2C-%`1G"%-+^;2$7I)PW72@;` MR$SR%H_DCY@H,[2*XCJ-D/PN15CK2>-ULYJMRS4G]` M8&O=2IPFDB0>H3>5LU:`'D)6VND!X2"Z?0YNV3X3NN4>.JMP5QJX;/VYH:K] MVB/A]:)GC9Y&L%`DP*"-UFG%ZS1+7PF@B%KBL,*><,[BT=%23O0;O//!$%6XF[P4]9LN6)G._Q,EZ0X_`DRS=9WHON"BYV6I$::(G_C..' MQQ(OCY_(2?J`/VS7]SB_6K&$;B&?^VU4Q`L:K1@3PDU3(L(1$Z_*T`U'0#YK M8"CBT%AR$ZT0T"L-@%AQZ*._H'L*F`>_0>8CB M/(ORE(`MZFH]'H1>-Z7/R$4-+CHM2XLWB1*L$5I%S:=0`FS(?U%236CF\"#9 M2]?OUU-WKH>A`#7)46Y<&`-&S*A`AJP3)`<3-E74CHW28@T:RG@Y`BV1TE?3 M@/DEC4EX>7P;DCA4*QN\/,G6U.G!+-?C/*>N:3;[VUW[S76TH[\[_A3E2_8_ M=V0*HJ6N"7L^1&M\FJVC>)*4D$GP]&KR3;$"J`$?'8#H"/0+_S!43(X/,>MT MN)F*R,[Q>6=I29N6R'8&<,9V1WAM-]&9&A"NZIN^9'E7K%+2-OJSOQ9G]QY7 MN52BLI3(RW1:3CZ15]M=A@$D"?R0;3X.*Q)&S.J8W.!2AU3X3:*B/K"GDQ/) M+-X+'?50@$IJT`\;.VT>,@)SJ5-80[Y$=V/K[;:(4UP4QPLB>CQ[A/V8XPDM M)_VDOD5'BQ$@2?4X)`P\0/50B:D30K2,>2Q*FAE%QFP[/(F-#C36&UFT-CB/ MLR6Y'N6ERK-OW%+O;43^N<`'-#-[KX]9$%/9J$L>W!=O$FJ?I98=FZ&K.TSL MYT;K00D"4Y?)[M?&#K(%]96Q&WFH'BN`9XAPEU9%.6Q9#>P`>V\/"^6N4U/Y M.1#9H=(=[P^(\SQ['U,G^_OH\^_ZUN($&>9T'.(# MO^(C7Z&K']&:#0Z82&?,JK;YHQ$)_+FWC?"1=NM4\V0F2783,6B('UMB0=<= MKGDT#-<@5SG]+XW?8.U4CHLB?DBG.8('8N2W*L@P9*WN:WTK>R[W-`>!T5SB M;&GH6B!`.W6Q/WE=5P]>/W(4T$B,"-12!=C/7UA&N7D@/*!<8_(Y*H7O@]7Z-6)!PWGE,CT= MHEI$9-NL3_#0!7['(_RA4_1`Q_O(#[S3;4XN4-?,*\2,QY,L?2)BSZJ0\9_+ MF!R6MWA!OJ1)HY.Y^9T1\OF8/0A3L$-`\RTZ[22*!W-@#Q6.GJ][$,D&>,4I M/=M)JBGP\B(E>XFU8Q&MOZ,I9-L2`[\UB&U0,Y1>];TC3)JYBPQT<\ZM">5L M&M';"5D2W0]-#\/SS,ZGK`4R085&M:VD00BRF:IA--9C(?2H1*LL#WH7,>52 M>YB;$,!K8)X)1E*S2L63V5QH)F'0H;,W374&\E^3J4ZBXM&W==6=W)OWP1HU MA8+`2RIZB'X5-`+,FL>F1E*?$$/"!.03B0>8?U&4S>[WM<(<,3-)5+^+ST@\ M%8PWD$^(/J.U?;_=WA>+/-ZP&_`4$JF9T?,K@1H;*-=,_"9X7 M[.:0[\#AH..4_]?(B%:-]^A55J!A(@_SN8Z9,J5-5].L?"H76*/.;G'^%"_\ MN[SZ"(3H9F>%H?Y4K+\,'AWFPGEK4ZU#%^3!'L+KB>WXU2>)JH\RY=Q2NLX?\A*7+#N]XWB2NM0:!#R;>5;( M@5W@Z@^""Z<3LQ5EK@WHX682MD`L[,#>(&^-R?=GUDJ"1G5YM_8@>C;G]#[L[3\S&OB+5-N@^CO+7+_J>>OF=*W0\]_T0@P3:`+O3>4_#"RW*BQFY,=1 MH&DAP,_OLCQ4K'5T<\XE+.-53/Z.BQ.J\I-]F873!_L#)Q"S9;9@D2Z=_MVZ M%G<5#K=!"1!^3H-O#XSG7> M77O#Q^:ZU0;KXF*RS:KG:,EN"RT+IZDUAK\ID\AYE(D0`C:]M/T$E6A*\CHV26OFCBH-`0M3GF3XPDJJ3Z=IXJ6:SW=91A4R.D70,7A"G"TFG.MT_M(M MUMY-WY%2"L@AC%$QW/L5%L;%1!ID]D?@>ZR>-SUE`ZS=XSU6C8GR"-";@<^7 M!1.^D8]FS^WC.`N3;IA--T-#P<52./3K"C9$:)@]=_@BF>3J2C8`/]HV/QQ= MD@9O\H$WMSE*D),('88ZKG4X#=SKAW/.IQ[$+/>#_7B=Y67\#V;/LED:]P\U M(8PVNP:$3Q>`&A6H\8\PB$J1TBGM7W#,.-2(C`$);/W3QJ(XWN%P.('Z&7X^ M#'7MS5+IN&D=T;TWHU-BE&/B6_DH)&AHL^>RNL!5(:69,CKT%M;Q8^.8(`+]NV?AQ"!MBQ$^O`[=##M MW9SNYGM]Q,-XEKD+8QS(,U7NCMI]=JD,XYW(LTYJ&,HRE_0&BRG&5`0S?&X? M10_,5:IYL'!_FP4"`4+25"^ M!GM7/CJ&M*V<52L?^QV8ED4;I7YK!]`\7HA$E`SL##ZX:MQ;%\N;XS.1C&?: MLZI'C!D\$^WCI+,OY!P""KN^+'8-RF2XSN,LYW'#-WA!^SSSE`G:>'?Y]VU1 M4@?'-/:%R<1^\QR,<`+4Q?X`*I0Y7N#XB7;M*5#T$,5I459=OPJ4?0J7V.;$ M_*YE8DJH\=ZEAA]%P5JNJ)"QO.7.+0+)3GN%Z\*BP\;F_CJ7[I,C,V38_;3= M]\5==KQH#0UM]R4WR>B79ZQIL6BH$I,T27=J#R&_X-+N-\&L%4S.936\)H M&$F:KJ5[$/G3,U(4-`T%1O7OC%`(;[\*WEPL:MN'H]GY<2PKJ_6JWLW`I+9^ M$P*JWHG68S,$HU^#H(-"0U30C^384$>," M&082/J$KY`9'"8/"0OK?QVF6"UW?0_E(-%C-S7FB1A=*#5G\MJ4V-5KB5;R( M6?CI*LO7.$?C/A]U'9!$1!3&HA&7R.:SMDT;0/=-W"JOU%`:,4A!78`#Y&3_5;:3D1T MK1MH+[!Q-8IR+ZK&B0U3_;90QI/56O0%^I>\U<\+\[@"K=- M<5W!&V7SJ,OO66AM;=BQ^.(8=GO,(G^J.EM\PGVSYJJ8U6]!)H\QF5:(V25^4`.B M?,0("S'9E?)"4;I$GZJP9L;CA=@;_07S=NP27F0!=X^XC16OE-MQNJRCQJLH M4H=Z?,-F"I,:/AAOZTPT:S&O7Z^#IY^/)DV:,&87#LSCF=D%]8F5Y!R\]\]! M@@:DYU?0F^1_>?=B0'F"@_WK0P@50,55GZ.XK=M05"-"=K[1<:,1'>5R?08@ MJQ"1:0<%X8/N\%$H/V`?UGN;P_TY+A\%9PSKNGL=[6C&A='&-(?F_1)EC!JP M<^OQM01](A`ZOKN4PD`;#B2HW6'-TT;([(CD\0IEA9AL_]NQ+^S3@"?^N5^3 M!+.AT4<7Z1*OTR9MZ1:798+[R6Z`XK"#&*2QG0V&<"^5UBP53J*X"X><3#6@ MU^'2DYR8W#:+LB:7O_YYMJA)>WI9LS+DB>"9E\YM^FPFLGK/=H,\Q8O(N(I& M\PYN+Z7RK@KS%ECPS=R=E/Z*;SCC.(Y6FD$7KSDPW+F\V"W9R+AJ^$*=(^=) M]JFP2JU60_"<6JU$!E`R[1A6.(+ZS]BPL$:T$6,:P=&OVZ=S0XN-;.]#;)`F M5S]W=@S+K69)L+?Q`]<*:?F!($]FN2-WIX),0+3$AVB-3[-U%$\2T6$UO]<` M>1O,(!7\F,L4,3/,GLK9BJH\]_60U!!0U(,(6N+7E8VO? MV%#&WX7:`BNIU6K",-DQ]C(9Y[-^;*W#/N#R(EUD:WQ9)>P<2?A$/D()^7L8 M,T**JDP?2];BW/E%C(*C86OI(DXPF8""OLO(#Y2Q'PN\O$B'ZN.QYO);$'`D MK*'(M18Z*C-:_XO#1VDEBO2W]&=F7VQIZ":YSNH4OO^XIW'%J(V*&I'X/N/A MQD-;=IR,*#1`O,PPZ-;/'KJWOZ.0WH:ON-X<_TYW"/M.KER/BB M6KC;4XD0"/L^6S;>S3-.&D/'HQ)$B$=6-4J@_Y%ZNWE`'UH+PVI!>1WTLF?& M*<'UI26!MXN='A=PWZKX$>[^-CHO!I2BZ38AI`EQIW&QH&'NUSE>Q]OU%)Y' M_:1ALL!T:!FVI63YD\MJ:.CV!,8,[N1=&5%B@D3?NO2`]`29.+EW?VY/;RVV M>$%I"W5QBTJ]D=O$8LN2SXE0QIVH]&ZF;U@_BJTD&*7ORB@VGC?K.\[+%#]$ M)5ZJKP5Y_$0VT1-^%\4IOWOR+4&.KR^H-]_R:^)A'V+1_)'RE&TBN(< M/=%23ES1U+!0$D?W<<*N0Z$9JEFSG)-&A'*.%&3T$^^.18%+FE1PV9+-[MG" M"J+_MPL;]*`'C$;H!*<$`\-NJ8+`!>[/Y<3=UB=N32I_+QJVJ$F?-L_L'&`[7Z0+6ML5GV+^WXOT@AQ!*1D03].]2SUAB!-.B1%HJ31?A#VJC/@G M'E/ZU0Z)!^E#OZ;==./E:55SIS)GB"RSQWXNV7[DS`B3>0B@":IPP28ZM#:A MN8;,6"0)LZ73LE*=,F25V`^49_>'W?WYS=/07E'.HY/N\(^>S%'*YC%A)MX2*;BV\^N<%GZ`? MX6YTC;:!%R0-Q@)!T-KE(]$7RPK&EVC)RA:S:A#DN*6N5O*O#:M*12]JM11+ M(F7 M;W=@L,<49Z3%[.,?CV561HDF*M(0.T`%?3"),@IMZ]E+P%ZTI0V-G`Z_3O0L MO?@78\6]JX"%C7M78&88]Q[7$.89]V[`1WGXM(XR8>+>-5B9Q+U+&3:_N/>I M&#?`'TQ.Q[I4*>]&0-0144#E[IH0O"0WS#/RV\UDK9?-9Q_Q$#/WU)GC!WGG M"%*/$2^K@<&#K6PYW^G^[(=?5Q+4!.H"XR7;"O<1@F^6OF54HOI M??>9LL`-="!S"%R3%@0&ZT,2?R9VUQP\QP[,[S8(MR.0^WV@MQDNR"4]?:#! M'=,]>^@G'54B!ZC.?<0,-&82+UA8$%68&S*A&)DV"V4)<5BI(Z6$&%7LJ+'` M?N=)XMKYYB-L#4Z*%UW^!;U=7I!_H+_B*"D?:4'O393R8_KN$3>_3K;WU*/PE$>8D M="\$UN[:1%"X<+9I4&TU^+//"UXIWK2AH#F\(._-%@@"(D6M;&;OQ"G5:]3M MD-%8)4MR-M;]":H'ZCBOZOC)6A6$?(UV M$`VABZ$=E?W58;3$3/H0W?%!=3-_A+J,Y6.>;1\>F:R\ZC2E@/G]S\'N(>_8 MXE1M@PN:J#3U";@WF\^FSC`:1FY2441Y_?->FZC0QZ"1,1*N)(O2VAU/RQ]4I]RLC"R(JY!\20GAKK-N\*;R;5VM M?`B8T"M_.T M9K;>8E,V:!WC54?B@?/XJB.;?3ZO.A+L=*\ZFPH$NM])G;>!7QGMA<#@80Z-%F7-.2HW1=QJGVUFJO(D9(RBK#5VS"].\[1ZCYK37QF35D6OU MQNUFPYO01`FM[Y5DQ3;';:^+BY08>&OV5F'72\8!KM]ZT0X80F4?!4BLYAL' MQ4SE^FV9/L74X+X/Z$,?P.^V&*$CY3P6=G9$45I$TI:[0*GF?R96.Y7I:C.9 M>>6VZRA>3F%J=N#[3G5OI];5\*,E.(*[J&6\Z&:=[RW(]?[!^R3<19^I]VG\!P+0U[[&1&A@TGYV)?>&?K(*N" MEX8M6#%CYMH]9@%05<58O#R:Q*NEG=3W8X`6(\O^O8L&7EWU.OBY9^8ULN(T($+T!E&C M!(C=J=@0@!7T%FJPLZ?\U\$TIP6OFN/;@`C>,D#TN,B;+NDX$M!F'IT;KNU] M>HW,+RCX%+-VLC_'Y>-[G#_@W&@OF\(:_=5!NZ4-,;,PCF(F3Q4$'G;/803> MYI;\A!O:*RCDLT.Y!5[2QST;UH6LB#X]VX9U,E<9&"Q;NHB#F+.=N3V[_$SQ MLKQS1>U0>NDZ27"4HXMU]#"#1G264F!JHO:H-=)AQJH8UCG\;F=8%T0(>U2- MDJ5PQ6GLD-+5358S[*0N9?3LNO0K2+);?S`_79I654[IV9#EL2+&!=W^'/Y-J&N M7*O`)3N0GF.6K)`#7PU+C([0*W2[7:^C?(>N5D@`C%K(J`8=-H[%B;&_,[5QYQ`CI[X=QF! M>$+7D*=4`5CI1'"PYQ+]$!XJ1?>&*#HV#E4#0U;BUW&A45K*E0YX!;^,R:F[ MC,M=&\RW/]44RLED6I]UOBSP`F2K(U*(?A@XQ-R"LZ+F,:6`<^T>>6G8=C8W M*\T)\`1);DIUY8*D2I5]3519#1,1>.BL?S$(4Z4,]!FMD&,ND9.E3Y#IW# MJY-G#(Q5&OF/1",WS3UK7SE5R]4,Z#)\L]HQ):-1U6/0=$!2\(Z^X<7LO>XT M6T>Q63=/8*COU,\>!JK47>%C]`O_?`:9FR#]N\F9\I4.N10YRMT4I[8K*B%\ M28ZXZMH9UQHODFL\DT,]Q)D^4(C$PWT(8=WT7QU-.^0,U\'P^W"HP49U_GY+ MSE\AH)CY.ANQG$&$M.EQ:D("]X<_`/H42A&:*LC3'H",*@E"I[%"J"L-^T1U MI%JQX^/<[6.6EWFZBH\5'IFS]3+[?02/MB/HVTS?C4VF=Z M&KB62^B")@-D)OI(@07`5-X3`>5X@%E^Y.M71$;7B'Y_@.@(F74?)%!`S;U. M9(!BU0/"5*22.;WT=,\JST$H4DS,Q&=>_C(U]V#IV3^J[`\J^I11[M[C\C%; M"KWOB$G^0Q:GY4_D'^1,'.S_&F$:O^;U<(25L7J'Y$A\'WW^G*5?O4NR>XP8 M5%2!1<>]?.40A^-XLM$1\(-*M1C,^L4>M<2`^]OQ7;X*?+_8D'?=L#,U:OL M)AO=.C_6M'-]*6;9;U43&*[HJ?(8JG/MH7I6M]8(*C7M&Q;SB%"/-Y?FI;QRLE5J91J)SU7M5M0BE.KGJI%F@JVU9E,2H($=K M.'4\LJ2T[X@CTG?`>^,P+"9YEQR(4ICWRV%(0^^7 MJQW%G'7J(HF*H@G0<#2V#VI(2`.(F@[,4,^"4D+)NNWCMMNO%`0^$D\F.!D(1(0 M0&S`W)<].9J9,U+'R8[S4;EVQRPH55&>\6J*35B>0A9.:8Z08SVF+^KQ7P9\ MBK%AG5FE,%7-"1_'ABENTA:&AM7=7AJ?[*L*BD'^%RF!Q"IU?HC6$P98@W.- M?M]1A5=#6*@R.=KO#Q`=$3Q[TI1]^_D1[UF)^-(SMX, M_@O$=!$`1.4CKV+:?';`%<\._5+]=SX>%SG+1&F1K'A8`:(XRWF=\_W;T_'R M[UL>#WB*BT4>;\1RP>,6(;+$(8C_SQ9+PTNVF3"&*4/D)AK=4D0.1'/W8@/PG!#!3JG5O>`#.A;W71 MDJ:/7Y6/.*^SRLF^P&2R^P3SJ:803[.)`XBG$6)0IV(ZELDG&]W6:&G'SUI0 MK:1!%%1SHKDWPZ9.C"S?>5"=X%S^K4D(%;!3>O6YD9B%$#$='[NMM!6+GZ3& MI0?A,IX[A+_4%#F7RI9S-BOMQ,&HLB4DLX[:KUO![3Q.XQ)?QD]X.=T1K9\T MR*U'BQ:H&_>*_QT@/O05&SM?\31F?E=WFE#)_5YSL=Y$<4X%_2H_C8M-5D3) MU>HR2Q_8''Q2'V>U"QX!S$H7/"%!;D"A+$=$SW+.H^^QQ$-E6RM7`^29CZY=\$S1@V00SH>,0!(@##;&[RU&(C2 M:4>K0;&43SC=LC9[#REKDNM!2/63!HH3UZ`%'M!L'!(&SEI1&O.\>R*;$&=( M7;$Z;4=,[.$Y@JPV^X)L`:*MJ0.AF,Y\=$'#?XZQ/9)@L;(VATR$=5!E9U;M M`"IXS%U5S%FT!TA1M_B9&X$'*&(",UOCN^BS%\<],%<(Q[T<%=`Y13]'Y/LY M^Z'4G.RZGQ3+'^*Z/XOR-$X?BFN<,V'V(%6Z*;VK20U"4&VQ:A0BPWB.[7Q% MS9#+G;IA!D094A9D+YK:V\7';.(0Q4--$#.-LY^O*%HQ7A5_K[SF.,GD!_Q) M"/;-LY3\N&!7*G_B:8U#D!N0+990PA'^U`D6[P":]=7(551$@78BHOO%"7Q9 MG;:VM\FT$_C957'H!BBY/[_-PN'O%RF^"K5>-'Y>^;9#JA\T_E6UU>I3=XL$\E1-(:,=NWIT%CEW'&DQ::-K]@-OO&XZ8S3\NW;MD339/D(`EZ2[ MZ]P.E@$"`^P`*UH.<7\T4YJTGO,I\P[X!*E$,`!A@XU@W!M1L27"[@AWN9)O M#4V$D>1,&K\V M@.2N'5%I+>EJA4$);&,&7*>&`3UCSPAYA`Y.#`44"5':M8W`1!XP$ MR#-V=[B+E]PZ<:2V6]&[NK3-\F.!5]N$>EN*JQ7H[K=KZ^D(VWOS:D=$H5BD M&AKBX!"#1T6^ABA[*`I7E&V@"+3=.P=0<6R7K>S%>2B2LDI[;KQ&O]1P0UF1 M;<870]FN M\"J04@3F(IHRY``AO<11@6FC,12O-WGVQ*.R9AI%H>*ZD5R"A!GND;)Y298; M>B/[HYP0"I<"Z8*NU@_E$AHQ%]?3$(&2.IZ<*>Q9K0U&6&9+#@V7D=F4_RL@ MHIWI&B`@2^PMFE_^-<8Y+7NPFRYNUPZ!4)O!!#D#?2B".1""R%`#2AK6.YM\ M<:UDZ'+&U<1SM@/D!3>;N=HV45-(L/GD/EP!UECI2K8NZ`^X!1'TJF3-:'U9 M5H@D`Z*NVD?86I?OFED^X/)H"BG4SNFG)XY5GAUP_'9YR+XXUA8^4.GJFGK<-( M(]=:NW1G&_IXL=BNMZS/ZBG>Y'@1LT`8\G."JSHCQ^LL+^-_L-^#J$PA@*/A MYM<(&@MMT'M<%-^CJ)T$+859PLKVV-(D[H)1R3K,#-O/WG`SP4`H(7IZ:G#2 M&%_9JI_/$_(AV)A3_1-<20$O#I`0=?K@F*NR2X, MVCEG(["J.X/J()N;Y(%7!J.U3R!;@I$F&F.>I0W"PO<[DC6&QB9_)`P*_V;D M+`^&(JNBEGL4"3S?!SQ-F(AZQOE()\%&JQP+=(!2'-B78L9#0RFK5^W8;+TV M4$U2F=TNC%:0`UXB;?#47RQ-D^4#-@$?POK^#<>:?`%NI;8X:FZJY@419A%G M'ICA0ZZY>W.=;/,<,__8![)F_H^)7+G::3V??P8H` M5*/5#WE8H"),X).5)'?19UQX%#:CJ;WH34ND8)%CNG##AS=A$E0G4EV98WXO MV.`T2CJG8;"'`!ON[TFF,:&&Q$!6\]Q&293'WH53.:U_3:A#22.6!1VZ"^TH ML>"H1."TRQ_2#Q03GI6>SUR3:3U+F@%*&DF+*PB!VR(;,W2ORZ?1ZIT%K6[H MO6<[^A(XF^E]A2XYX`9((&\2'U$041(X6\N!T:(@VA)CM.N&]&H3Z`YBCLOH M"5I9&24R-\I03`')O:/S4.C`,"P3]D M)6XFG3#M4#I/B,(J,D2@I@STT]K-$_B2HN)3IY4"M#RO%T@("YEKK4/E.41] MC$7R(:ZOVP6Y'.=Q]C$M-G@1KV*\G"Z6`Y[,L\D-(@)6-.+?'R!AQ'SRT[1, M[)8@4JW=O1!7Q`J#TKI?-%KC:G671VD1L>)&$TJ4?E:O^DB/#R1A454XE@X] MX%$^Y)_"<(FX!9$U8SYWA,Z,+D-<5Y?X(4K.:`'#'>V;:535DM8L7U:?!KZ0:)[M0?Y)BKQ;4E?_*YQ3KM`1P^3 M%#FPF-UWHKDI8@I5_8??'QU^^^U?&.^JG_?4=O-;QM/J7P6_VW*%$> MU;\,_0YF+S.P/M&2UBF3Z@;39<0)3^$2Z] M?X/+?LD$_Z:%`T<;`\.6/O[BW2PQDYUF9JR;@X_.-Q\/)S@S-JRD-%%4>:FV M&?;6B]^:31D6:'1=#YYCB M&J`]7`8B#=\..E`1E9:VDAH]A3"#C*("1>1PHL"IEMP[FXK7`77E2#(C&J.# M2>WUHC$46^#R,8YD!'5;SU`TIKN[G*7+(3>7(YN;2W!W][BWEB/G6XM8CGF[ MYKV\AOJD;&'Z+KIHB9^^_Z``YV!V_BE'#C(R;3QWP(X1*KP@"2*?$FL4XR:CASZ@A8X(MF4TU-)!2Y!1>M_4 MLYQ]WN!%B9>T2[DO$>S,Z;FNDP8=J(MA]0FY_JPP^F*'H[SX#Z\T-AF<*'??^"_X!YD-QM=+Q\ M:>[)98]1CM]&!5Z>9.L-3@L&_9B*U0-KIO9VUWYR'>U8AY%/4;ZLA%"0O`]; MZN>?PDH:'\FQG5N&@6"C+P0J'M%^=Z"('0N3YC:5Q'6RXB8A](#XF!$1^AG' M#X^T-NT3SJ,'?/89YXNXP-=YO)CDCN(+]2F."/_[4K5$I]V*OHA3=)HE2907 MB*P'%123+U_,)C81YXFVMI97`[+_*0KW>BSOK;&\P?34)[\_R5)FWVVCA#KB MWDRV]STO8P)_FXT:\+O:80=XL*T?1K)[:B``KX)9VC_A@N*8+AOO>T9_)5[] M'AYR_$`N!A<$[S@MX@5S7-#[V8QJ'RBSQ('YC M;D^(Z@,M>15&A15*L[N]CXB^WR=*CRNSW+@U*%3!0C4PQ*!I;_1S/:?'EW2K MK3\R/UV#5H;>/``+HD*0%O,PO)` MO6"TY^A%&'\3C>E<&%D21CQ7O^/;(&47%&7J#Q,VFBR,EZ=;K,_:`Y#E84;Z`"T7K)4>!P)%]!$K3%YOE:JW0HF<#&3:>ZS@3?* M41=I=H8(FW&HU?HL358GR1_5:K5G:C`7]'F6KW!,ZXD4_&R+,#2IW).$Q!B8>YV7BKD9 M?,\V%NEPPG`9?X*D.^ILQ>NE.MY>1#3-)$6!S276?ZS`8.FU<^,\2S_.\XX& M"5:7)>@KMJU<-Z!0`ZNJ^2`/4WB.*OCEQ"CT+`L_5\P/6OU M:0LZ!E\SY%NBDR)F7*&%@!F*6M30_8[?MZKO-AP]%%'\#NK"@$(E792Q%K@E M01)EM6&1B=KD4VTP1Y7!C.OKWH8B^SIPPF=H9O6S1T-C)(F!]'$*SF?Q,M-Y M6/K/_XIU>(S86?Y?+ZP#\H6NM^=$[%X0G4"=FY_!,"##S(SEO?%@+P8=5 M$L1?!RV_,2,.RA7:3)";\,'*X+R>$1'LC^Z@5:SG1+[9"_AA@)@*[5*ZXD%N`HL]Y,%%8"H]WLJI!U^JS%"6'(H# M8W7^5Z!#'!^W_AC3OV@UB=G/ M\PFXC_XSL9GM5V9@0K_49'MW*?;S+"SGU?-*P+?,^E"?78;I^,]*")]).H[W M;-'Y1$B7NC^H/8Y0"_A] M0*Q[)`.%."PD``MYGKASNQ%\1ZIY"U)RPT]FV=JQ=3;=0(/Q^-!O,/9Q4>"R M@)AWEY7D.%ML\YPYF-FW82_"'%_9+4%X..$+G\*O(YG% M=SGM/@J`9NY*0=(."WP?A3DER@6P3,_.+EI^YS%+EN0LK6V71;*EYLEUEC.C MIRSS^'Y;TN+3=QFYN;*@)7*/(I]@%&)*%[ M*>=WQ':\S(KB!B<1*]QS223K@>GW6UR6";-:IU`89A/[E6HCG`"E0LDH$J+`B2"CG M\@3':1FS$RA^PK>8W+$9T`_1&I]FU$\]A2FGG=.O[:9#!S#6Q&&H'7>`Z$CT M"Q\;SHMHR^".*\N$(JYW"2+#<8DO"6@BT"6A:$R,/N8\(S*^VB:7\6J2%D)& M\WHW+TVP`@20#WW%QJ)V,&*C#Q`?CRB`P#X9&XZ+8FA,&Y^/3C5R-[C`A`:/ MU+#%3SC)-O2630LJIP48(EH/8H:_,`Q5X^;5EUNY1!G##&CBJC7D*NGL,_7` MX>4YP9N^X&YYO/W5:O\."/;U]KU8TX/Z`U MQ$]"W]YD[!"9WUN.=\.1V4$7ZTT4Y_20/2$ZX`&^-K.O4?LYJKZ?P6-Z;PW@ MXSJP6O]G)[F6$WU8[JX)C4O:1N.W;ETROIA0POZQDX6O7.>XRBS\F1R%^&JUZNI%(&9-,FR*\U`=E-9'`M!Y M[8>(?8G(IV$#CV"R-X%%P.J+W<>4J-8L)T;/=%:[;DKO MZER#D.H16QA&;OW-P,IX#MI`Q9"S^X_9.D*$J"\H%WJYGF_V]">VI[/5*G#% M'^=-/214I3VNKU9[_IN"NW82ZMJ98GN;3NW?=##$#-CO@@%';LS[/K_B`%4^ M008CM`UMR7]1"=A0:4BL)=$I>1G_H[I2[\\TB;M(/6,(3Z8:)(4%Z)D71-N/$95CO)QPL:37[_+LN6G.$FF\TR.4K`Z5(E&R!]%V@#ZLH;77+O'1:U2_FWRF``]2<[`/6TU[(SWR/ MHV)+KD57Z0T-P*`F*$U>*#ZFV7V!\R<:H'"1;K8E^3,A!QG%E/';70UC=T(S MKJ>3^>F1]AMZ._EZH-!),B]B$]/P\68@8B/G$[OK348[49=>>.(!`+;^A)&B"I[?RT#6'Z9I0^T/EKM":'9X3&K6W07K_%TE8^-YO4N)"98 M04J$#'U%VT^U[K5V]`&BXZM'AM!U=2PXWJFT8TJ;2:3Q?9S&Z^WZ/[=16A*# M]P;S)S:_H@DAX3_0Q1I'-ZFM@*$:&JK!!;^\.4N*F4BKJ.C#*[7]]4E*XJKM"\A M!530F`Y`62I3XD6X*RJXC/Y=1KW@T+1[1-XQ*1:;-/[)MU94;23(,<13SM.*]L M*O+QDO4OPVA3JZ]%@Q_-6+TG?XGB)?VQF3'&^>N0'AI/!_^PEJ';^X(0F18) M>*+7-#)DNL+()PK14KUX@(E#`5O,]8@,0'3&?5RHM$SO!6\JU.\=RL>>E MJU75-N$JOZ$E]R>,/5!,Y_<%58$)%%K`WCB)'JS&T!AI-JHO44&""/2<[,0, M:-;/;I;_]G]>O4*__/S^IV_^^Y?_6FRVG_^6_O&[Y3^^?7KXVR[]>+K]].[; M_+MO?WSS]X]WNR+Y]FGQC\/DA_+/'T\NKY=_^[_)UW],_^O^ZN3T8O?N[C?\ MS<73KW>/O_WYSZ>KY7_[3K]_^W_L___G# M^ZO_2FYO_NO7[=V_/MW_?+PNCJ\^?7SX^\7Q/\CI_%-Y__G=FZOO'G[XYCS_ MK?C7BYNKO[V]^>;^O-R\._QAN8NO?KB[NSXZ+'W^XRHZO=IOM MGW???O/Q__[KN[>KXW__]_]&)[P8 MP3YD&0:[^>ACF%'=6CW25;KG`ESGV0+C94$KE7S(2EQ?4Z>0$G"N(+4`I*B` M"=_\WM)__"2A\1DG>+[LNVIHZC="%"OV:XD[^HE")KG/;#)R M*>ZG<<%\O]CCWLO*97)0CT5?5*/#LU6[0*G[VXPJL]J[=<*EIBZD M>K\V>:H5E+!)!Z9KM=J&4CJ-?Y,VV'M=%#^F$9.;]0*JQ?< M"JI095-R\(>24QN!V!=78YKYOR]JT>/ISCP-^DAY8.@YRV'5B>1S21*W(X$3 MCR5$=`Z*$=K1U"\CQP\YQJTLW65O%JUHIZ@&3$?$W4DD=/& M>5E2WSVV13K[V6>B,^.J-%?S1_\;1X='@,/9!4_[#5(#K,(6VF_V]X08S'!1 M8O$!=#;;PU":M'O"A,JNMG[=SADO::DFG!;L+?:8SO#`'%QO=^TGU[R:_/&G M*&=M0$X.36"3LCZ?$2FE* MTTSBYYC-X@)LV-DL7E6S]-4]G1V)&"(!17HHBM]5:"*&YP'BF`H&?U$55BL) MLJC"EK;A80J$:(W:%U3CC"JD^2>(HHV$0E*ZJ*E@A53GP%:I.VHNR(5IX-5, M?TP,_C5'_"8N?CW/,1;O9]#M1Q`]`<(!HC`0!=*]SX;N`6NX6IF@V%$J@/:4 M(4@C619$ZG[*$B+7U.7FPLP:"FK!=+DY%U[*EVO*316QG)],5!.=QK2O>EJK ME4F,=:OY_?M;;-#3EU&42VT-ISZ+^^;X'$Y)%T$QE6@I)8/X+U18TA(CSJJ) M#@X>4:I;G2W?6HKX3^UW""&0,'H]M^6@[+HP/DNZ]Z9UQA MFF/.O@W<3,XY^B%(^0;HP5-+[*+^.NR&&/2JZ[TN3,7M\RR_2)=XG<:K>-$T M299%30>MD``AVZ.O9EENE4N5X1@P4LHX"EN8ON,*+?$;$+FSRFBES`ZTX.\C M0]C>R*(+"9T##(')F-4TKHA"(/V6AK-#SD$\&22I=`8L$^3&99U$JHCF&%_V M`9>\$!>;\J\X65ZDM\1@CZ.D*H[F*)1.@'TK3QO0M@$%!<\+B;F*6G(5Q>I;,<",Z7$7 M:.!+1X!3,\"]T%Z32JO^$48^,8<-937;W6ZLQ7M'`S!H&8D!0!:5U2P9U"-CSMG416%+* M_X./2CO>X*+,8^KX9E^Q9_9W>=4B4*9V#.XX+3)W7,IFC,(B`*)C0"`.TVA"6K>4I**UA5']`;=A/C_'B$6VBG`6_1_1/ M]+URB9]PDFVX'RU";![RAYCV1XU0BC\AS+N!1.F2_3,J"EP6-$*04)PHY?LM M;2>*,(LD>XW(C6F'8\B><7W#ES^_/4L["7'U.9\*P3#(Q2^T2/T3)+2[+!$\60*><+T@,E0HC MHX*O;!`21H6*+;#A*92I**6`X\M.I6IPY9'M2&Y;ZUE3"BWT(MKHM,7\29*^.%_NI]1!/GJ^L,"N.1Z M2(":I_JP#O0CGP:V1$&RMP:G?'5N;#Y.TRW14%%"3!<[KZQ\I-]8!"D.4*]O M]BWB'TNMIF2K\ZQZ7<'V'MR7W],=E6(O0/#]P"$9GT7'3,A.$#5J#K5(F37,0/N M`'(A6;K_^'MS\T-VW>P9:EECJ/'[Y:(!$;0_V.2V61!GD-Q^D%>/49M'S\[(DRG4,U19D#T`[2NCO$-'Q>T>^B8Y_BA@TG?.IWP"NDJ?)B14]D]V[(H MHW1)3B;8P*CYP<8UU=B%H:%KU"G7I62-BA1#WA@8W!M<]]E='J?+&US2+KS] ML-TI=K_5_(%BN`S14V:G"##82W4%19Y-%3R[VT4J>E%:-F0;]DPF[I'+^+=M MO&0V`_\#3A=XTG-+,6V('B8&>&D/M$J!"H-1.YH**Q?465:7L!`'6-/"9',N MC]*=X*>,7K*FJURHF,U[Y248%U-!Y&.J$H/S,*Q`+L)"U5OY@!9.@A=H:E&" MI@I4!ER*C$%#%$B*0IVQ&@YV2X'#BP[2M,V\LX%M+'N_$43@BGX>NC\XA::; M!,2'Z%.R-W&(VIHFB+FGDN^U*)E-ZU8K03!-J>AU*9D%*\5N8S18$N=/\6*8 MOJG^2D-0:W`S5CR]I5LK((!XX;H*/6;)DGS(:XW2AA>WV_MBD<=5^4F\P/&3 MJG"3".0/T28K_E)7H*7`"*-%<*B%-\--;$H*D.EVM`S6]M6NHR#8`]:R+>,_ M72O&HTEV]5`KD?WQJBX"R#-!EA"?1RA'?=764>23"36GYYD0Y[)V]P,Y4Z=*DE'/FGP3!U0 MX4A=O6*ZCI6R#I_`8ZR>S:@S)U<>.SE&N6%7Y[#D@CW#JYF`*L;0-JRJ*,TBTW,LH3)W'FA( M/61C2$'O;[^/Z1+G@MUT3?A:=$SY&[JS+[-/..<_Q>NX]'>BC83O;/K0C;,> MRY/N0')L;>G$G5L!8G/W>E&R60\0PX#_`S$<]!?M&9V"XXJ]_D`^'!."VA)G$@-:DC`;3\= M-9@\^^4&*.8AA"+`/:Y"^2>6&UA[N^;9L%6#ZFR.O<%+F>YNUR@(/K/H:I:W M1)WI$3>:8(]RW3/@IFOKY@;*1;HA6N4T+EAI9+%)XR2]#R73A6S0V4='W]J0 MCSE`]:C]=JIA^]W!_)2VN@,(,*@CN,L)I^N]=S39B3$-MB$R*Z9;SG0'AW4W MR6=E/AI+]2A6HAD;G1-$G(\Q\PZ_[XD-N]ZN9V4=VF/_?!X!K-<64!'L=;P^ M0!5*X?VC&V0R/[E*Z+'7J=M6Y1'C M+\'BW::[=X$JC_!HG]=U-2J`Z-X^GR`\&:_V,*\=%-Z5V0-`A!]=7Y*"9(@6,;#)DH"I/)F@>( MU>D6WV4WF%P!J7G(6G7Y$B_3J?U7:C/$#)`W,IKV.:O&HPI`V%1A.RYW/GW;5&J2KBRP57X`]H?CMKQP1.%#-8HXYX% M<=S?FK;W54N]LR?R/W=DR/'G>)IXTXR)*>1&.D^HDL`"#F8UZ]`O_.O_#OVVKF(7 M7*I.6*J[CB$74^;.XG5(J*\K2\D_B\DTC7+"T4T2I;)1H0)(4%6NIOUV7]V$ M2C,Q8&,WET2W]B'57H5:>-/IGOXDX[\"J,2G-[]!?4.9Q@E,1"HA8$X$!J/P<#4[6?V[PR!\B7L):(CM994I.X%O!=68'A*;Z9C82(F6)*!']18U@HO%<,';F MOIE.&E33^?5B*#`QL+_J-$`V#+V9BWO#@)N*1,`>#5Q='L<+EE!87$<[6LEY MPN-*.M'8803*4TJ&`1PWP+Y%U<=]J0D40@`S:R]P`%CJ@'`!5JIC*M.[!>[5 M2`EX"9P<6M1WR1W=U5#+$QSK^[#.4OR]YFK%O)H7Z2);XP]9FM5A?E/I M$L.9?1NX9FC!+S1\,*W+R+WC?/P!$B%(KNV!WFXL>+_WH&-*)'=+^N0QQJNS MSWBQ+>,G?+5:Q0N<3_@*J)C.\WL@C`DD=W0$:H:@:LQL;F`&K.R(EX8`@\NT MO-U=QM$]2ZF;UE6IG-"K#:5$!1"KYD.YMS&P:QQF(>`1!]8]J*'R`J=1'F?7 M.7Z*LVV1[&[P)J,M6J935-HY_6HK'3I0R%TU[`"U`U$]4JJXPL3#&#*X$Q)C M0A'GFD!UO$T]R^3Q59V)?%K\4@PTXC0'':5DD31VJK?`(19]CEGT\"F!/9GM MOC^'3['8GQQR"K`]A^A7<[&W`ZJ41.,HMOWT$?!2@!B78R;+^. M3V9':]"*<[D.#)/,L.B`CH'ZR^1^V`V?B MXL4VCVF%B"FS*=53>G45JG$!7_&;44P_H7;<3*)'#-G:?;+7DV)(E9HXQPOR MY^GD:F\&KX^GW;DAIT[UT3RB$.4,Z?AQ^HL:\A1ZE^.HV.:[B9.U9=-XE04) M`H!`U%^"&=LAY$+!)E$XH%4.D1"A1M&NFRLK_F6RV%7SV7V;/J:(@9906\>J ME[\8R/JQY737&+(BB/M+>MN:?<)HC?XLWFLA]5!0]LRMRX+.)P8#9%2OJ6U_ ME0/C#\_C-$H7<93XB3\$I@L0?RC'1!E_V`R99_RAFI6]^$,%`5PU#BL[^I@E MRXOU)L^>)O^R;%GP MUVLTEBG$_GAQR$D>?(Q4'(@J4$^2>SL,/& M$1!Y-P-GFKE*^W4>/Q'K[SJ)%GA:MR@PDU_IE",!ABBQCU'S]5PTI9II>X50 MH?4.39O]D)6XN,R(4++\*7:NIP\W>(')E/<))C>+2_P0)6=I&9>[J]4)'87S M#;N`3!E","9^(9)TQT`<-`#(.,0'TN=I<>B,8NZF$#%9CO!HE![@XZTZUTVG M=[L3^+XF=V8'I++Z9C87&RE+1/GI+\K]0OP^6CS&*D0W6'@^*-`1P/:#?;@L"MBB.%P1H$4]9IQ.:RK>6`?``Y*C^ M&@F?SR683\,\47Y4BQX0X->M>#ZA#UJ626HH[].,_3 M%&B\C*-\=QLE>.I84'`RW[&@$"(*R>'?'R`Z`@P+#29!2A[N2Q&\=.>`/@]F MC]34\2!&7I]N[B<7>A=^6=H/.Q=![OIV$?!Y43GS7GJ+Z=2W"R@EW=TP]8JK.^:QK&?$QC6I7W M0[2>,'D8F,MKG!>$A;8C$/N>%FJF(V8B.#KV27L#R18^J)D+?59OVH?Z":@` MI@L04"''1!E0T;9:G65`A9J5O8`*!0&+E.<&7 M5KS;\M[;5ZNS*$^)'!?7..?OX3LY@,G>#2=$U^L]8;IU0)<*84`GK2-\VJL' M&>S<,R:F_8!+B:PDP-=^ZT%\'<1.4&!B70_BZ[EX9@RXJ:L'\?4(IL+[Z//$ MC]>=";P_7HNS@X^2G^?U>"UC2??9<7]1[H]%0J@$56[,'TQ#,J>\@6CG])UH MHD8'3"]IAB'*0"0,G(TLF;*WFV=B0`];?9.O%YO_X5$X??./_I$)R]&;2E3V M/_=TE=B;%O+R\^BKP._-`$4I)V7+&-N`!=O;2R:7-;"7$W&^!'3H,\^@G"0X MRB_6T0,67OE/LGPCTZ_`1M#!\'$Y,4$$O&B348@-ZP1LT('ATZELN-3(A@DA MQC_%U'O.`"?91K3CSDO@S*'++8P!KQPLQ3OZOWAYOS`E4@4`T#W66(04$5F!D(F0-?&X&S)=7HKS5JK6") MGDQ#P*PLM:Q\T;P\G$#'+[,%*R#*'$PC,/1(Q="'BJ$;B*&O_SD8>>1P@V;S MG&?Y2986VX0^X-1Y7F>?<;Z("WJ#.BX/7[_YH\6)8`70R\.O-5J03XYVYVU@ MH!H($J"@XQ(=OD9O_AC\_NS,W$8"K2DVP157?3+88B@[&@"F'G2X&I7H7RBH M&1ST7EEZZ!06P*8Z+AYQ?L92E?*XP,5%NK!0(O!HGWX4$`OH$8I^CX0!M$G8 M'"P*+3,:"5$OV:\+1HF+;"^;TO_9,L#5A5,;$U69G;OL(EW&3_%R&R5"^3B6 MBNAP]S.'ZN^XM\9-=PFL:S&1NU\+"HD5!1FP64B;,[M[UJ<=^;P;`$YHJBZ( M!PV?2WL^__-P>H!=4%L=!'B9Q_=;,N?;714X1I,0JXH3-GK($J0W7[,=7E#$ M,C32,_2?@ M[+Z;VX][RAY/F8>J8>^BR]Y,8&]=7J=X_4_%UB/GUXO3+3[>/FR+\LVWY!B0 MAHX!9X1\I+>C0#H]5&YXBQ'_&/&OY^%+4M*^D09XH;ZU-(B)3!EW:'Z``*H_ M-YJ[/Q->1SOJ#SK/3]\%*(.PKUQ\]B0 MACQJQ,2$#+XWJ0%.LNU:\V9ER)L7P1SWW5QY>&DMJ;O'.&=EEF-<4&]P5#Q: M;&DC0-[VM0DV4`!I=A@5(UF^YV.GX/^MV%<&_5E2A;?F]T4,6FP7<.P M^WV&K6"&O3".A;D/F6(GNP5UV%8RMFT$MBT(@*!WGTG9Y7[/88\`S.=&=;#M MN]G^0.]/9GL(*%_+N#>5?CP'A:LB?/>)1K;&`,]C$C3@ES$EK9\9L5V?PBZ> M<$'[)%ELJKTA_AZQNA,#VXA^Q+M9S>)6(J=OPT[)DKR_&O5QD&T9^M4!0-CY M4W7`"\U;G++Z-/4#4$'L@G,<608&ZZ%X#0?6H@/5:6S&H78@JD;.0HL:LZN1 M%C-:>([R-4)*MD^M.?1B6'3H&O-YB_.8GJ>'?VI*PH#-W>`W5Q4(GR:G&A7X M635FMM#AGU!;X0?JYQ;D4<:`1>(CC(X&?HU3/4+`FZ@-5UX`6US-6'+9O,5E MF;"."E>KNII\Y4:T"]?6`_+FTC/!1A&=W8Y%5RM4CT:UNSB\'6?#-C%JUXPH MOAUZIHA!<=<"NS(3=KTP?KD[],D,=9/7<[M8*?E(G_N[/[UB0S>M=\^!()@@ M(@'37I0!8*$!-JD<$VA7ZFG^[(CNOM-.\8(VS,57*W*";Z)XV>9/G'W>X+2P M.6N-@?DTGTV1@J)5JN'TP*T`B/DT%8AY;%U;9K81%C8T\FMHVZ`FC7RI^9=9 M\^^%,M#9LSQ&3H51"H4O][-;RH1=V+Q_5ZIMA+Q%ZH-7+[9CJH-E5L/+X,^A M6[FGOB6?;\D5/DHB>J\?=,N6``IXR^YC8W/+IJ-1/7P&6]R&;8I;&T"4\+=L M.6+&MVP-NUX8OP;8_EM\O,GCY,V?+*,PI`.]VO02!%31YO1;Q#^>@SRH"-^) M>I:NT;/]#:`!1IE7M#X`XS">&\%=[>4F=FIW08[M@GQ5'#_D&&P!#6PV`S#^ M(C;TR`#;L`UIW*%F*&K&SN!0-6=7(S&&U/`>`&*&EVP'6[/I!?%I0$@);5B3 MI>SIZZ(HMB/4G;.#Z//LM<(,JC?)8%0/GQS*K*O/.?&W+7AH33&_1[PU?M(B ME2J6SK$*G6>>'HY_2FLCVZV1E(6X=Q@;<\;.LAJ=9X8>.9J%9T49KVDIBH\% M7FV3RWAE$[8=_2-?K= M;A`:<%2]FMC/C=RNF^L&+VC7LR;5]VI%FULO\GA#_]4VL;#8=I8@O;TXV.$% M]ROI`*&O#R(8U,*9B5_-C<.-P#E0S??CA#V*,JW0XVQFP=F7S]4!F?])O([3 M:IIW49S2?CB7<1D_V%;S,(/D,3K!""'(WF['4B5"1R,Z'+7CYV']V;"OM02- M*>,_:L$8-ZF9+K`MJ]BVTK/MQ?'-,9KA.L^6VT5)+NZ+Q\@J<%$^TE\!']GT M8+MN]BVJ/Y[%/E92OJT!`R[3>UD>"!-I,1X#BC\[D@^*&GA/D'PD6\BZ1%U_ MH.>H@1X"BJ@!]BWB'\_ARJPBO/B(+5^C]Z@!*1I0U$!-:[`T7:"H`7>"NUZ: M?WC_`XWMLPG'V1OB+QJ@.S&PE^6HJ+-[_YNWOG=2A;U$XEA&@3*[P814N=W&W'E M!;!E>-/5V\Y1H*FK$%ZK5$BRUV!KU: M14"(04(,%"WRN$8:7K)F%X::%N]%""=(0%T=&U`**M-JJ1J!DZCW/+F&&]OB]J:@1J M]:I$2MG@-3+FT8MADO,N?XL?XC2-TX>KU34Q9#*;O0V-]5S438H$6,JM^IJE MJK/O9W$T:-@@U`2#5^N]6!N(BKQ$6TWY3$7Y9TEZY]WW-\*5]U;G:7>$UYW6 MF1K87_0;8G+)6.N=L5+B-NSLK\;S_NDA(-LU"GK.GJ!!^HKWL)"%:S=4Y9^] M#FL26)+5NWMPQ6GM1%[W MAUPQHWQGL6UDX_R].4EFA^KOBY4`=O-@L8+F;45X8(7>7Z$`1*3U]_6T?E;$ M'O`XU70K^]:AJD)OH.^J"OL(Z'OX?3NGJ@H0X?N]Y/;7Z+^J@@P-3>^^;V=7 M5<&9X`,*`Z]Q?DU8$B_M"BG(1_HL2M2?'JY"1+Y%S<>SL/Z4E!?+U@#+#%!7 M2(X)4$A(2_%G1_)!07ZW!#$&Z>@[^X-,/MB?E0BAH#C.FN\1'S`?):ODA*AH MX25[MQU5V$"'G,@!^*![GAP8$NU$(RZJYY'C=%F_F=@$.RDA^-N52CR@0"<6 M/%,_>=$GRN8M+'S0FQ%KVF@:[?*];U,M2M(HIPY+(B5+GCU/!FQ<&O`XI,64 M:KS'1#0%&L">94&I)LV*O`N'`4L:T="MVW]RF08CV5XU9L6SYH5CPM@)SO/L M?4P?/FV>#7JC/&[&WN30TP']#O$/9V+)@M1N_=O2Q?G?9U(\I$\(2BH_%PH[ M[AYB[I[C^WP;Y;LW;\@V^<;NBB@=Z_71'T!"<4>L/T?\^[E<3U1L$&\GX&H] MAPG1;;$$U!(]-@%5X M@"T8JC&H&H2J43,YZHRX(Q3XUU'`?PMA'4KRS@O&7'GN'!GV/O@^VAT=NF1/ M=X?Y/BSWYE>F3N\0_W0N1R1`\FX:;W]Y_@]&"19PTC2E,I0R_7RH['P(OL?+ M>!$EO*@S#9U[EV?;S?N+=Q;[2@?#V_N@!A%@MU6C4#L,L7&(#)S)86C(I49( M3`CA^RW1`"?9+@6Y\P49^N4L=.,$W'%_=GR?)<&+"F%1+=XCV?JSI\I'O7@AO/G!W.!_`/[W\XC],H M7<14(RPL-JI\I+?#5CJ]HH!)\S%1Y8MY2("2]F+=#6"AOH]0$!.HM(F>YL^. MZ.XG8_4P^::ZD-YEHW3CM(?JSR]DC9LZO1F]:;P2=QFR;!(9+IG6GN'[R;66 M!/3N:G)"4Y$CC=X<-)PN;3G]S\+F`?ZK.D.[>+MK^BK%N&#M"O.G>&&E@(R! M>>UN88@45'RW'H[>[E#;4(OZ07F[2@YC)B>:+3O;:JXV5/+<'\,"-6D=WH:# M]Q4'7VTJ#JZ4''R9W`O1NL@&/UD:;(>%98^%107D]0MGG6N3HFZY+]X0R4W# MFT'R&$%CA!!8?+E;TZWJCG\-:/6Z,FTR)MWPKQ.YS<@7^`OEUY!:8]3[Z_#E+KWX\SUC%."O_N7RH M1_4LQP#RF+./T=6/J/Y\!C:9FORM4Q9>J'_U"B,C=8VSKU]=_7B@H'L(I_A0 MRCM&0@XVDO2VD=<4'3NCR,H4"I0/8JJ:C2P?W_DYEM:.G8WSS!D2I!"3BRUS M:V3!/'-N.-=O.OMM&V\HS1V:]T!CO>I-``G(15A_K6HJX]\CH69"ZX!0K-6S M?E2@(G7LF=#]61)^:"GDHTD>%BV@>G]8-,=-\[!X]"P?%NT9OO_B9$G`4`^+ M=FBJ'A:/GN'#HF\V#^OJPLR)&TQO97C9=6_;W*9,`'D+-3+!!F[RP@WW>FS_ M13&\H-FP36PL8D84WU%*IH@!W5_VV'6O9=<+X]=^@).G^Y@A=M)[6S!$U8/AZY?*K"/G:+0&WH['@6=63F9XM,\H#Q`+0!FW&WF'FA%SV-!:9C2" MH5ZRWQ@-)2XR[^H MJ4R-Y`]9BM>;)-MA*YO5`(R_&[(>&4!'UC6AJI'T0BR.G8&U:LZN1FP,J>'] M?FN&ETR5[K.I9&QZI>!3@'T]&:=Z5U0_JM8,.9G.K=GUT+(K%=D55/U.QJ8C M=T_">9:?QCE>4`U_G"[/*N`.#[-FD#R&1Q@A!%<51LU@5DJQ'CZOZ#4K]HE5 M<`TIXS^\PA@WH#2QP+;(E&TOCF_N9:I^V*;XS9_L"V[TQGDM8+P_NZ+>!OT4 M\6]G\LBOH+I8#4*ZQA#%BF6(0'4W*FI#A3>>%[4'..S?Q:M5EB_?1_>QS7N] M9)C7I_K^_,#.JCY$[,LY>'I@@C=CH5L/^EH_(R('"0428Z*[!;1 MH?1S%&+GX**+=)'CJ,!7JXMTB==IO(H7C*!GGS&H&C\/X]*.B6(E-U/B>-:1YI@!M?8XWS([OKU`QCF'/IVE2X?.T/U1 M'J__OP_P@TB=1O;)EV9_ZNZ%`]I+"$AL:K=\W.AL>.UNMZ? M%[2>4'2?8'*/W]NI#N>J'IJWN!UCE'0GZP6K'44AL.R(?6T=?G-:L[*GI,UH MY#N6QPH[Y2$;MRQQ'Z*4UL#^VL$1UQ_I30](IU?YXOC'Z&O0 M&Q?$/032ON,@DB_4]\8%,0$]G%]9[ZAVC/_-U,RM MWD?DL]ELH1Z)]UC:75*(C=/!0+%GI%1]%F1UW227<70?)S$-,_XYCTM\M5I9 M;!=XM,^-`V(!;"'A>\0&(#)B#GS7,J.1`/62_6XQ)2ZRS=:C_ZM,2O]GRP#7 MS5@]^![9=V_>'^:[T_+K`AZ,YM0H&2+[_#+^_//^-1B18*`,>CJ"6S,^' MRLXO!>2(/,G28IN4_!3;880B&($J8>=+@:E>A?**@9:`BO M+!T00762K==9.KA\E`$8?SI$CPR@.?A`J\J:W@7+G&%MRU4S>GC7"V9X2;O> M2ABEJS/U**#\`=MXSWN#_#U4[\T, MO4>3SQ#_;A8;%*)R^S`I6Y?W-V0)$M*G8C5UGPEY!W1NJVIJMCFV%GL''.S/ M:H%0T!:>%[+:+"1E.`5BP+,`>U-@H'!EPIFFI-O$93 M0KA"FC&H$Q(H3_@$D3M&1[ M6"BE9L2@%\(AQW#+NY-C6FG-8@]W1WAUX7>FALKIG!RS6GESV(I2XK9E0WJK M\>RL[R$@+8\#TW/V!'7VRU\5FQSO;K-M^7AY>6*Q.:0#?;XRRQ"`BJJP3Q'[ M%I&/Y[!C5(1OZSQ`:_3[H@RA(:V,(M#Z`"#VP MH>/=AE;K.]$;1@5Z23@P(/WS)+[SN=OX5M[':;S>KNL6&#?XMVV<8_IVZN+@ MU$+S]HQGC)+>X5E!:)N<"#!FH-VM6=EWL!G1R/=;H15V&I>H'0M?+`_='R3O M3H[?)=E]E)SDQ`0HWT<%8=[Y-EU>7MLY4350?#M6U>@HG*U\(.(C$1^*Z%AT M>3T#I6#,+]&-:$`,_[Y:/5*0_Q9DT8&41V$0OY]P`&^@V7@WEA4+98"2,1K_4XT-?QBTXU][Q M3.GB\7WZ>+'(MFE95+=.@AKY3;[%2R&IYS0N%DE6;'-\AS^7;XE`_RJB*],' M`\$&=5#:O:"*6QI7')6BQB`CLMHP=\M;K=;C;)[CJ/%QCBF3&` ML%K7&,T>[RPIY--U??L8Y?@MP6U)W0TX+?AY0+O7/;#[Q-M=^PG1(8VHT7Z: M]`PA:H(=*\55^8CSN\$^#@&'$I\=O-_3'+RSNJA'A;Q^J#&3L%R_ M?'\AQK?Q`R^I1>2*&S1$8*ZS)%X0\\6<.590`O<6M\*USSX'@GFM%$&?FXX? M"J=;^%K6^S*HXNVCT[]G`6OSJ'A9:F5EVQZGRZH/N&CF-C(`6BGF M(((RQ`+/OGEB2R;?+.39L:?;G)I-K.HSV\U%O\`KM'TLP81LE&R'J9R9M@3S M]A[0.EVHI)UDS!+&Z<+-M>P&+9POP0W?'HN'$-'KK?T#+B^SHKCB.>Y_QL"$]"VDGP:,IZJAXSD,@BLS;,_DARG]WH?[/V(/M@;O([B ME/R>:GPJ6-LHJ?T9H--^)CB&];7.APYR9_Y,D&O]^L$*U()^Q_ZGX=24!)F^ MVQ%:F]_78.%E\Q2O"-/+^`G_D,5I^1/Y/3FM&L\HZ'@P!Q'6(V&.9]]584LF MWQ?@QRQ9XKS@>Y[F?SF87-:``KZYVJ(JOP7;4\WKYNR^3+PGNO@QV54JWNS] MI3MF1B\Q7<0T;S*RE8?W,/T4)5M)!R%+!Q,`)?!KIA6NIAXF)<'\WGY85!:N M?%Z=JT);SP2^$)F,#KK7S%"4W)S,Z>)Q_YU'"VHH[/ M3=Q2K]%K4B+.?&SFT3_.")OHI?&W@@)".+Q"I'MDUZ_78MZ$] M,&^)EBY6,9Q=(/LV)+EE^*@L@KT%^B/R=8XW_+*E<[OUOPP<=;*/CB3J1+XV MCQ:7<*[4N0:-*N.Q,'?96US_"11O2S#SZ"5@@JGT/=N:8-Y>.-]EV?)3G"3$ M%KA(2\*AF&9N%04N74(6W*`%S)!RPK?'XB%$])N8'GV^C''*Q0[:FIV/@FK$ M#B8]JDL6XS-Y,.-/3`N0"[H2`\*5?MY.)/Z@\1Z7CQG1ID^X:&+!Q"\TCW=X7U-F;EF=/5ED&VH%A8YQUV/6?*LP(X?%0O$AY M<;]>D3_SIR8+$&$;MYCCV??2V9+)#PNWQ:N'*!J0@FN?:"M];*2P7[&0("0B M@`0,T/T.B=]56""&Q@&J$"$_M*@_4`B(@0A5Z\UNH5).6Y#(L]Y^%\5IF_VS M^YCF>)'1ND.MPT?J9R'#D##N`+4CT;Y/*P2S-.N2</2JJJL)@_6D\$$$=*4S^<>(?(WHYT'VN98I5"[4 M*_3A66VN`'5UB.QXP>HXF^[2>B"]^E1#%3LUR-U'MS3IEA)MXC)*Y!+N,15"W6N1FZ('?B0 MQK6C4'J\MM.SO=L@@"@&U$JJ<#A`D!U&_L*:TC=&5H,,JK"I5;&`3VAQ\D1V MZ?'OD^.^5=-`UP"K+5MR<$ M-[6+E+'/D#+/Y40@`L@53#_9WZ.KGV#QBJ.!.!ZBF:QY`'A>AX8%O4<]1:SY M[.8:.28@EQ3L>1(]#'>)=,'YN3+TY@4\(,TWB'X42!Y!FM<>C_Y*O+NHH0`9 M?800XB/DKSQ!MCVT%NE>52_<[P6XEYIHG)(YIS>V'G+R$UJZ5"_)+WU?R%F> M9_E)EN=X4>?[71,+/N=VO'A+M7$H,:A(`,M:&#'`M1M`]#DH'4UA_4SV]%'[ MGESI[7L[%IB0ZY%@=TH,RB1C\;\T+2XM,#"=\6IE M'+0DU9Z!8FQ[GK$N9R>8%AQ+:`3GYQ]Q(U'N-J@0=4)2-7UZ5Y'/$=O)\;%3I,N2727C!@:RE\RC. M694?_O!'=+Y0Y>X]CFCVP_(J)2;>-J&Q?,N+$RG^@TB,US4+V:LM-4 MF`O5DR&B@9OI$)M/94Z%-:9&()_:NAJ-/U[E2Q+J3W.X8V)0K#"Q%)>5-4&6 MPTIE^Q-@X.LS3`F4`R:)((FB)BX44$F#T/HZ56C-W)KTA73 M7HW44%$%EO&\`MQ1)JK[5UB-84\8M8)P);1?X_TZSQ88+PM:E.<2/T3)+2[+ MA#E0X>";:@RBI$1L%!*&!=_>JC5)HVZT-`@6<'-.RZ/BR_@)]U+Y'XY:N/.YZ9J30,9+6P)ZW5JG M>)/3)BRJH$+QF^#6AXB,W`>XOR"O]!3OK=MUG:;!B]"=QD_Q$J=-TSZ(WJW3 M``E0#E`-!]6`ZNB&\#:AS;)E7+,GF]L&"I25QZDN'F07/1M0WM^`9P]*% MZ,SV_J(%\ENGLYP3S1["B\ZE['(1H]?8;ROCF01.I[#6`R@$;<;!7/$3XIF@^"IL0Y4('&=O=Z>GW)8 ME.Q5_M4,*CE4^,J?R/;7XY6<-.>],.='Y9+%H>Q6-),\_.9Z#! MIC)X1\NI4)$ZACQ1KMFW\Y_Z.&_PIJ[`S)QL)4V`Z==:4#N#!2#,D56!V?<. M!VP]X;)FT"]L13.OCZ^F_=%,NLG](2)J_R]U<@@%-$N/I/&:07::$VPF[S1< MO(0$-J>WFMHF%.$$]YX9K]CBT08BEV]N"L_Q1&WT10]BHAC50+4K_SHXJW3+ MD3[F&)%`M/=M0U&W>4[NZ41#TTHTZ<-M&95C^-64T/TYUU1H:,)3^1C4#$)\ M5%`WFPG/]@)6X:7[WLX?\">A=%R>I>3'!8_EX+X@0V<;?2P7Z^QU(,TVL\!V M]3)MX$9!W\GWN.0U4NOZH5]+>;A72;57-I7X!$X$B`/L-J6@,II'R1'T)TSUKT+H^6;2QX%2!\ M@Q^CS_%ZNYZP0ILVLJU%"%&,#E"%4^!$1U^D']78O4%=I:,%T%3I8(JMK=VQU],BU,._ MR4JA2`!S*GFVL*0/,U+G&/A@K'.`SN.MV.Q1.$C_KM,MOLN$&)X8%]7K!]&A MM(@I_P>XB[:,[&+44RSFXP79+V9+DFX7&VKXO!8*M75,$B*$SZ%TB#"\`=8A M/<=52^[N$OLJEJ>X6.3Q1DQJ&J&8I0C5BVT!S:ZM;"E\&V:SZKC1*W.YOSI' M":B3*>[(=\,YWX'F0Q_L3ZI+>*'?!._<(M)Z/ZFE683GMA%I&2_C9$M]ZK>T MI@WSM)]]IGTI\9*F8-'+_[:LF@R=17D:IP_%-<[9W5_=)$T$CEKHJ`;/T]2$ M"5CAQVH*&CG%73H]XS.0SAZ%5C(-/R(3?)[%)I50;&PHTV(S8:TJUU5+&3^( M@M[C(STX!.-T?IY@CM.+]P3S98;R!(N,]Y[,R=PW=]%GXT<_]KI$!ACF8P8J MAB9=E/S93T4`OR4JB1PU7;Q!';!?,C;8GE3W.A<6XKW\UX;<&7?72<2.#NI8 M856%#26\'D_DFT)H`J$WW!DX6Z$W7;>,8W8T\\O/IK90]1`,IB"T18CJ+X.> M6SV\I2YT^>*\/DK-J)6;R4;\QG.)8CZ'WEF["(QT7N!8YO"`9$_0$ M\.R0OB]TL%9ZL;H+\KS8;'O$C,T(,'O:1+^-Z-Y:![90E]+3%>LM0:L"28WWHX MBM*M_-?G64Z5\8`"M]4?5[0A%($T@Z@&DP6#P0[FU/(>6I<5Y=7J798MB]LL M6<*OZD5)+3WV(:)?ACZB]A"7/Z-+UN;W%G^2K=U#HTHXEW]T+3,F^_G6+;0F\OUL*DF^2,#4C; M);1D*/(_$)VAJ*"[YT,21J-V>'MA"*Y8#1:K=S$I:#2' M;".>/DRT/KG`$_F*GS`U?0MU7B7T6%PGB+/#LP'(K@W%7),`',AB_I!K0-V! M'0O)R9VE3-!X=2`AX;L>-+A8C&H.7V:`&3J:TC%L9*U^^&"Q6$$H4]N.G7MU M9'34\%_"M;<+JKI5V_(QR^-_X.7'=(ESAC+?'VQ/=.K1WM#PA\OL$\[Y3S$Q M3^V54<7A=F*TI3-S`:A5%9N\5PR834N.*(H"_P=B2,S@77PB\IHKM3'9&;B5 MGTF4F&4K/_M0NU`Q+`ZT`")8CK2@$3@A M(SU[09K6EI8MVX6NH/WV[7,K'J9;I93/1I3Q:K#WGF>%7GLV+]C"L.";5[4F MHR?J'@T6`KG21:58[%>!.DK6[4WLYKE_$/$O@R7F0QRH,OO_57- MXH%9*A0>`YADG7I:[9GD[M^$B4)7K[=C=``4="8 M;04!#I]*MJ(;8BCC>2"-I+%/8Y#]N926YU6@VM)S8W^PF/\ZKZEH!K5<2Y)-BVJI4C3!]>ZLC6GGYEGR"*M^#? M"2[*L^'AJ.;$-`+FM_ML^Z)NDAK7#2J0Y\6%B@J5+`,*_P17[%FU[55$+81B MJ>J8I/U2L40WB*5D9QP\J%VR_-75B$Z#?$,_9@^9B[BN;09PK@2]=Q(%NDS^?V)O6\VX9'G5G?:3T4>%M*%B#;B.`ZO??+ MA!H&?L"?V)\*9>U337-%VMR+0PEO.1DM5FK66)#)\[EWF:4/].I9/\^W*1E5 M_9ZJ1J,X>L!H95W1K'Q;`?H,?8G)9)!OS0]26@1]J8NY!]58H5S:[VKQL MOT7TXT`VCXX?7=-2LC[/IZ5)A*E%WJ=IS.YL4T`=Z0%L=W?2!JCNKTOYOL7Y M4[QP,W[[2?(UM.`%\2B)XB=;KG!M:>V2$X:;=P&4M=2#>[ MJM:%IJEQG40&O1=UDLS``][@+;(PC>1H,%*^.':3".($D>+96 M"%9/K'^R:;\\8<1L.^3!JY(:#QH:>"\^OMY$<4Y%Z6HE?R]+Z'L9^*+8#*>6 M(OR^R(`$W^2&BY6^)=K027"76KIZ?L9)\F.:?4IO<51D*5ZR:T;S_5"?#P3> M?_@Y@(G:$40'O?J5CD+U,'[QS(/[A#2,ZSJ'5(N?0_D\_M@C/Y#>Y8I72I-7 M,K@6`0,=^L+H2A+KMS0M>6=GBKKTV3B-G^(E3I>TRT;(I,0:#]95Y7G&NIN2 M>=1@-3O>>E5>#6H7Z6;+KW34*ZN2-$%,^*"#MLI=1S!":1_%FF1LU9(@<.T0 MFH>7$GO'OD2(,#+TB:!87U8U"F]LVJ_XM9X)6`?HE/\ MA).,87%;TJM[6N)\D\=4IE;Q(BZ/%XOM>LO\S=RRV!\!WZB;[Q#[$+6PB3+D MT)$`OC;C>@,#7[J'$DA^.1^'[-XMMUX3:UJEAGJTZT*8Q0U>X/BI[MQKU]V; M`B-VNP@.M?!F4`_;=.F@C6Y'.[]>,W8C($IJ!9=W8Y\@_DWHTU)`5^J3WU_- ML[GE5%[6GW!!=G_M8O61Y=,XUOG4HE==EJOSK.XT:J*.>I,QX9]7<[F*&;DA M"%KVJ64Q-S=X!KU9U$M0A,JI5^T:+U=!/"?WH"CY&X[RLW1Y*MR=W/VG(&2? MKE,("(#B#6WI*E^05TF.J85/M*E:MUJNA1=SOG("L-0'XW0MH. M#-I;8"6(`B`>37?Z2CZJGEQL2,@ROUHN[3>OER_8>]7W;('QLJ#]TH5"K\VK M+/B$5@_D[>C%NKM%\T@>-O-`NS3@6FU"#_]NJM0!3;)UNO9XUMB`K.L6NBNLM$0U3+(7W^MET)^1?Y%'3QL M;_[_4$L#!!0````(`*%DHD)OF24?P5$``)[]!0`5`!P`&UL550)``,NEH)1+I:"475X"P`!!"4.```$.0$``.U];7/<-K+N M]UMU_X-/[I=[ZY1C67;B.)5LU6@D><>1-+.2;&_.J5,IBL3,(.&0$Y"4-?GU M%^#+#,DA2+P2H,+]L+%E$=UXNM%H-!K=/_W'RY/EB&FZV=RY\,0MB_*]N#!\!_EGP"!#^._[W=1QO?WSUZNO7K]^Z^%.++YC.M;-[GK']^< M_GCZ]L6G^^F+TY/7;[*/\!<^#/YX<"+PXFGC!]'/WY2(/3T@_]L0K5Z=GIR\ M>57\XC?9;_[X1'Y0^?VO;]+??OW^_?M7Z;_N?S6"3;^(AWW]ZM_75W?N&FR< MES"(8B=P"8$(_ABE/[P*72>&8<#`UPOJ;Y"_O2Q^[27YT&W(L7/Z'0![=@^2)E_<=XMP4_?Q/!S=8G'*4_6R.P_/D;M'&W>)37IZ]/ MLS'^#_G);UAB4>A#CV!_YOAD)G=K`.)O7I"!/]W.*G-`X#'T$S*U:`,\Z#H^ M$>4K\JNOJ".]^H=F7G];.`@$\1K$A*-('>OU@;7,9!9@/L!=C/^\P<3DN*\/ M]DJ9HMRM,1;KT/<`BB[^3&"\N\=#G(;H#3_'+6.]^H=ZA*=.M+[TPZ]RT.Y' M>578+7DN;\(8\'.5?J5,%\EH)V),G*C&XD24D1-EBI,-)\S'B<(EEX\HSDO* MC$I.)%@Y4:RQLNQHT%UIEI1KL3Q'.O19`5?J-5L%4UIT7`ECNK1=#7-Z]%X1 M;RI7P,1UPR2(8;!:8+?"A2`ZVZ5_VO'SV3*62C3OG08U!5T'J`/8[P97`,G2A#PPN`6N`E">)\X!BR:4A M\7!Y#A!\=,AU02'1G2#DS",KU)2R'4PVVY0Q=3/B&EV=98I#]X]Y1@VOMR\. M0GCGBN9)3*XV/&S-)^1Z1VIYM*T`5?QI6@O*V-.W*M2QJ'5] M*&13XTI1R:7>-:.44Q6KYSQT$^+ID&-T$&-/=18L0[1)W2)^/EM'*YC=(A#A MWTE_>(5YJW`-GF(0>,`K^";#RB>T'!8(IN^';H6D3W)_0E10])T'X/_\3?G[ M:/(0Q21CBDGJS5_FLV>FGT0O5XY#7/T\,R3W=+5-S]DOW37T]VJY1.&F0T?BD"[$$'D`_?S-ZV]+&PP_ MWB0GY\R)@/H0N/IKA4UM$$WL7%+_%43A-?"NP>8!("8[5/W"V")1JZY$ M'#4HP(J5'<&H62A32)])$S4T:[#HH1 M4S1-$)E-FX!H*;>-7Q[H6X<[9:JE)2H%._":9!ICPT+^0RXC'QV?!(\G M\=1!:`>#57I#H&/-L!$V9--;%;.\C!CA$U]=?DG"0@*>!8^8I1#M;H`6VU<9 MWW9Q5<$07WS24ED@L'6@=_&T!4$$9D!%#R2PE"C@E9T!<7!(>A$8I M50D8<]:8)50#))?,&X%=+(P=7WX7JZ1!E?-J-!F]5GKV^-JM'F`[9DH6F_"6 M54TRP@Q=/+E^0J[NR4GH*_1]/5L9`UV+?4P^_,07K:PYU2G#LIR&L`J/Y/'6 MQ(K+]$3?SC:$55-@D,OA._G-C$L4I91#;(S3'*;\U>HY6$(7QESG8_;1+)8, M!R2YT+[O_1R=^T!E5@7B&$V?6RR8MDGGDGAG+*)12^J=-"7UZG3E.C`Q%F7G(EP2(VE6^"31(B%@_I=K,UT309+Q$1* MP:__`$K.SV6(9H$'-L$^;YEI9:YJ2WX_(D`\#0*EX?\0/P<+D3%CXGR?L[Q,QV]VV0K MO8$(MQTS\?.CO#1+_.@07GGX`;@R%33$#Y.R,N1A_Z-'KD0V@=83,[!4(2YCLO9&$PT5!,&516V))$QDS M&5D,.EB[]C[&1T4X1=@`AH%>41W1,+(_<8KI&!B3@1//@P0BQU\XT)L%4V<+ M8T?+S1J-E#'_CU-N5*@4A$4$7YT<^,\JDY(#R%WR$+D(9L_7;X$+L->J[?D, M#P.FCNN<8N9$52`@\SX3?@!6Y(0H?V%Q#AZ!'Z:I%WAK7X$+4N1ZBV`$BNFZ M;K))TO/H>4(*WM2_T'/FD^9J"-9!,&+O;/,0-XM%5:4AU$6N(&BC@S97GX3D"JQ%!X$R*I^#()"`T'\-JM M>S8KS3&*9II6'[G8D2MD*Y+OWY@I^=.K^IODXJ5Z_V^5ZV6=QJ?+K:9Q?+H\ M/ET>GRZ/3Y<'\BAU?+JL(O?!:%49KR MPY9ERCZ<:4ULSSOE@$5!X%PPFO,0SP+LE:3EA#HEIBI8TT74GE74>H1B0$]- MM%W%%18^[\Q1.B\OO0E8`)3:/?VW6E3*`Q$S*XXF7Z%5>4P9BB9)O`X1T4?] M,CZB.(PP6!=L*C(@E_G^TVB^G&])[W9" MDS/7MG4("X_'IC@<%WIRN-^Y('`0#+5=TS42LN/\T!W8KJ)3!5X, M]WS`3T&T!6[ZM$KC[0R5F#5N?I/Z521!QZL4Z;:D\FC_-5YOP2,($CUO<_9C M#\1W.6!ALA;#-(SB^3+G18^;628P$-G44#%QEW$51M$\6"3(73L1*+W;8O+5 MZ%];8TH;!=`R:S67#!*+)+TBOPM]32?J*@F[Q40%1EF)2;&*=0BKSP*%2ZCE M^K8\O!T>8:MP*FB(7P^J9;L$W;<( MX,F24MJEYQ4YEWI\NC:"EKC1'5Y>*V0*@OZ"Z2^8FIMUR<5_]D$*7.!-LD2. MAN(_JC)@&.@.P+:RX6>N+L('$&`;XA..O`T,(+$?I*B&QK7:17(`4NU$3W2*K(2F2&L MN$9X"JD)1%QD#O/S>`U0QD>N05RWE"V?6^R!M$VZD(-(4$7^$0_IQ1.E,;B, M/9T/T:FTAK"&Z$`5`NR_^&3!@T:WOTYB&"&6(V`*&?%$5E17&*EKD,968'4R M0UQ@E>9@_:=-$B\U(CLEP([JQ1/9/1,8K0E_\R5Y(*/+N6\G.I`;-@;T"M'* MA$\DZ[:63B+[GVE:E=U$!R)9!O0*R.R@.8[?L M@JV0IUQ\1;"\=H_"'+HM<7AI]&)(JPU&(1D'T1&R)@?@0 M%C!5HXR?B2&XM`+0%MH@E0&2B$>Z0P8(1%]`7"UQF?1R2.V M\BMPDY`J,/-E^C:B]#3BS(F@2VZDH9_$>EX("7(RA$4K"G*A&OV'@2X<%&". MHN*Q80_R[R)I<2R6&;5"H)+-14R]+THG5:E\>(\'/0W1FV]X%:W\2.2XH*+P M*Z.6H63B;.-SHV$\-^K6))XZ@J*)%U\=Y)&%H>O%496`/5X/]75(#1&I>HVE M!YS9&]Q%@J+$P=3#CR$,XL^8D00!CLI^?".:/@TV:E=60XL+&%5U_GCE]\5! M"#,5?2#_KT!Z/.,97RI4X7&A(OZX1":E]^()(!=&(#K;W:\A*CJH78:H*/O' M(37FP:Q=;NQPB#]#D5MI=`ZG3K16(JS20$;=(,BV62\;K/%5A/# M,&:/R>R;%GW]B#Q$J4E'LB8M9I;$OG/@L*5>97[GV>[P.PMG1WZ63O@PZ\!; M^$YPXVQ`'Y5J%?)IJ=KHE4WIR0R_VEP$,3EV'+G^--MZ^'736QW=CR_/2>%N MQ@?LWG[OLK2.$/&82/K7IF`_5A0"=B611L$U?FC&OP[GX[4>K?V;-*6">OREAI.2A)2^?8Q;-?/L<0&'.^"U9( M3]OT&I4L\?ERB7^&L%=PD1>U%S%QC$-:)#%>,-0YY9RY_EFGOSQ.DEYZ`P%! M,0QCQO5ME@[+K,T\])8^NW:>6BW:=IC.J0)YQ0H>7>0!Q";@%5W/5PA8)A@* M"J77U-R;>$KGMZ;C>NM)[K=*_3%K`*I-I_0J62(P4IP7LYLV<@+'9HGTB=== M::^1H"6)(-TETIKA*KE!$L],JS7!]5F#1CK6!##:%))>0;WAG*VH.J\^.1P3 ML>7%+ZL,&F!24?Z3TA1O;*CH(A*#9BSELS-?9@URHR/ M`SLRT)AER`EO=0,2K/94]%^/+C'SI6PH[49%%J/T0 MY^PAS#%3-)O&NB.X\`,9H.6,JA!4XT]2-+3&B%#N7OQ+D$E;UV"03 M_&,;R98=O$U>C)BHNRT4.Y.69J!OMVF@8CSSDDF(;3"I.?.<)1$,0!1-7+R; M967*=&TT-%+VB(*ZSU!1DLK,F>+%%EY#\D*')[?NZ"O#YJA#A=+-XWBF1MJZ M7SM/3V$P_^4R3$@*!<_.0/G4?NQIMKKL M-2XYS!Y!]$_@^/&:G%^<@$<,M&^-VW$&05#GK2SI0U0,?O(@)H/#AZ;/$7SX MER9L*G>#<$,*-7$"7_K$>LM3GZ*RI`Q.5\<'#IIMG!4H\3H-T9;'\>D8PVCT MB,4)ZL)`5;Z&TL,`^2,"&I\)=!,=PL;"`6$U"<3JG,>)LA3--$,3'[M))OHA@LNTW[*/9L>]3:.<."!1TYV-TP.-R+-J%\R7 M)5;(+>O]&A0YZZ1I;=:Q-O"*9]GYPX),^]@<5R64+-FP&D6M"$MUZ?_RFL!5 M=J9]A,%)[JAZ?-_O;9OU*5,6><'4![+8AK(!H>YDJ4A.!6LGV?^D1%4?:W"K MJ0D/=>=-#?)2*"[;G7Y60,1[L4G%*%FX4RH[E$LEQ`##,J:I*F[_IMCWX MX+/C)V`217`5Z`D'2W)DM2>I"G4EG=FTJ4Q4Y[Y2:ESC38(BSNSVGU2+0:2# MG*(F.*4LY>Q5V"*]$$F5?1H&C]C`I1UTLS_'$,_A#KCX-TD9%VUWA\(,67PZ M4H2XDJYU@LI"$EH.+.8,`F\6X*TT2=\1EM3ZM0[MX.1@`.K`BZF*UG;4$==EH+GY&,2!00QAB>9X\L>$DAIG M*GJ7/$0N@ME5O`[Q=U"TVY"SPB;154]TF58G:*AWZC!7VL>-N')2Q\P62-V5[9^PFC$&T<';'[=DZV@9UCV;Q\N&` MI)"83/Q(^99Y"[!?#=TXKYJ0]F3X@#3UBA5CQ/(3JR3*A5;(1)74;Z(VJ$47 M)S;;;5F0"ZV0"E4)5FW\/8GBM''+?4@I0CB/U[HJ.+(2MWA+$$"R$+=<^(K[ MZ0S>I?Y*<4NS*/;->Z9AO1T\_;U,VQ!VGWVZYE^\BC`2/VKNJJ3%^#93LCHT MT852(3JY,)&.PVF/.GHZ2FZ!H&(2JE,IC: M:#NX&H"RJ,"^T!V!6)>P[K2^#I-(\*QG=]HJOZ[Y%S)143Y%M,@_#%%F>FZ! M2VK5[:\G#TJG8^&R$1[$[LV(82%LR4"7F)P+.W#Q1+83<)<\8'9@0"IZI\&= M2>"=@P>0]H;6XZ3OZR.(=\GB"!#H4QNTA1KT'WBJ,%0$R&*(]`B\A9K%RY8%JT*"?<:2 M>!SNYD-:J5H)GDJ6U`WRVZZ]CQ"N`JCKO-P7ZP.YS>A-DD6IBW[+XA;3O`'Q M+'###;C2=+=1)3`0X==0*40D$$Y[!.@AU%.3?.>I+ MR"*%4XPE8Z7$!["K$^#X0[MC?LUS+2"7?$HG#GLF>V'P:Y];K/AMDRZD(!/K M4>XREH^/10W+WD-^S4P,/>1'@;90`ZF`D894"<.*T,:%W397!MZBIJ6"VE,2 M#>VPL[L$,&:TS+1O+?8=<8%N^2G=,O1"*30228:!"Z M`'AI'^+\K4&Q6O4BHGYLLS-"GW$! M?I^OQO;QDUNPS8[B\R5Y4LY\W&W\V&;\Z3,N\._SU1AIR'2/M2!RW*P0/5?P MGO:QU?A39US@KZ+CD4@;0K[Z^DK2B?C_U]MD*3R_''7]L M%5,[/(7(!"(263N9B\"3ORXW)[]XJJA4@A*(&9P+"@R^9]>E>>. M>?DC%^!/]9]70`%/,0B\PSGQ"!8$'D,_2:WP!COTKN-_ZX:;C),I_F'H0X\D M'I*[E4L__/H-YW+?PQ?-E\48?#M<^P@2L96F5F=J+4^%@CRG1QJHA=L#%6-K MCTEI&KO2W5>>DK_^]D1X?TI?'M[!5597*XAOPL#%K)3=EK/=IP#^F8!SL"\$ MHZM3N@0W]EA0:E-!&:RKHA9PO;.BRYP-7RL?&?7ZY/6T\,BK0*CJQLY_#;5O MBIINJKD/](ET*K];ARC&Q[8-M\RX!S6^:M3(E1],54W@=5G=&V>CL?4L%WVS MYP@U"B(&?*DQHBWY0R(=:^O\,QJHPB,A\=,Y=M<=TCMR@D%Z3"LA\[4Q8!W, M[BLU=DP4[BMC1G.+W'BUM#N_N7>157+L25)\X$(?8.8(6_(U*26 M78>J:!GQ!45DK0Q<90Z#<'UA3-6%*<[XSSY(`0^\NY@U($/3?'& MR$HRZO^FQ5]DY-I5^J/G=)92=LUUZ.W?M>`CX!>.C;ZPX:XLX*EN%ZDQ?@M\HI<+!QG3E!H+ID(W MVG6D#K5X#%4TL--@]C+6CKM!LJ4T<8QGSM<7%2P76N*Q5C7EMLB)9H'"1^@! M[VQ'O7_3='/-2MV6K(_&`X((FA(&/HP=7_B44#G`$I.3Z8+_O5!0[R=D3K>-6!!U_QF(_P*TZJVLXPML&*1)'U'?J[ MB0Y3YMU8"NS;*B*T+1R2&:8_ZTG0!WK/1<8E!`4V>)7BI7B0#5/LT1]OHCYD M?[P138ECF#I__!(&3N`J\L?;!AN0/]Z*B7B*BR)_O.0D3,,@1O`A21^OIO6X M=?M=#12MN`5G4&.:I]4$HG@ZN-C==\7S.V3*88]O7[S&;:SX0ZW#Q#Z>'5LJ MHP"Y@%+@(DLOT4/M[N-Z,^J79XV:^=1LB7591TX\?"59HK#,5"DNONM#H$?T M!K5:V1!4*WAT835N,Y1Z@C3,=314IX`IWW5+'C/XVWS+10:YJ!BP%$L)566W*(;MACCV&+)JH#SED MT8BFN-#E0A8%KX11[.N3_Y!0^*/C$Q.4U32N7X'KD#T7_2'48.,#5.)50$7\ M"F4_P^I]5=L/,H%C^OI&)6ST%^CAD_DRD M7BKIIZ2B'[?4[Y+MUD\GX_CD/9(?1@D"A^IHLV`9HDV&+E=Q/8%Q+2YR*@13 M$0DSTV&Q>%I$.D?JR=HLC6_(#DMH;U-?[`PJ!6%H4=N;%4>Y=Y[(T4Z7V*HD M3%TD*!-=#3$5&1I<>>++I=IQ#6FPW><$II"?]J$K,]4D?9D;I M`]WTP#W9D/3L_+TF\%YK<7HZB1IS>,14N^($=2.JQMRJ[X>UK^6?5ZPC18OQ M41VEP&NJE"O,S8!51$8&:M+Q^'2G_')_'I3>3-MSF$33,MFA&^`I"6G/P"XW56G90MW89Q+#.Q)W&Q,6/4_T,D%NN0YO5E M)5-ZM\<5VL-;L/SPJB@5);>`TT=510JGV+JM#C$\L75AHJ02U-^X?Z"X9*@P MJ+BQXQ-(\9;4):2)ABP2Y*X=TA6,\E*$)AZFD0R%?B1$Q0:0^+5+)8_-1'\5 MXG5](Q(,/I3ISE\FDQTA]*&+H;S'+)WYY`C'%0?F&U*\Z=/8=,7:IBM"6L7> MA456$'AJL=),R(Z@77=Q^RHZ"OK?%`-^"J(M<+%B8-=36]L%.C%K M7D8TJ5]%$G2\2J$S2](>^FN6L!^8R;IHT2TVR@.YKF;%477['E/^T0EOP[D/ M(09D&@8N0`$9@,L-HGX\MIE[AAY/EZIH[C`W>C:C9V.#"$;/1LJSN8)_)M"# M\>Z0'E$W+#H4BX6L-2K6ZM(P`:C,GS'JS!!OAOOQ:W.1DP-88A$?H8$5'.-' M/\@Z/TA&QWCB/Z.;-+I)HYMDQ63Z=Y-XC(P.#>.B;XF46MTF/D!5^4]FW:?4 M?^*-!X7>5^C[Z<5CM7J8K`LE./082WJ&/I23*Y(SG`,,WWU>9L-=&Q9J^G;X^-\$AB_RN(PFO@78/-`^-CD>H7YK,_ M6I2&H%>;H,+T#OXZ!"4VF]S9ME(#QY^:+@W2@3MMPE1]M7/-Z7))!:VR#G,H MRHHU%K/53Q4&^IE:=<88S+\\_,V&?5FS'ZW8UL;(W=CY,YF M-XEB3G0H$XV4/5YJJY]#1>K9)+07O@S?N6L=HO@>H`W!1_")7_L0*C)T1D?& M.D>&37$X_!@QW"MOK\3SY((F>\NP;Q M.O1*S3`G@?+T%"_EH#X(IXH'S>?E:`D\#CGD=9`-CC2[A<$*!*Z"/$;!H5UZ&,< MHLP3)2/*^E+\HXYNU#-THX25:_2@;-CQ1@]J]*!L]J"8S8N>IW[^E6(]'.__[-@G1[]K]+ML]KLDS8X.I9-ER9[#3Y++XE5?<:[0!NVL-$E M&ETBNUVBFCW1X_C4B0PBP[P!FV>62"Z837Z7/$3@SP3S=_$H?D/7/Q3CV-*UBN#+`(/2?4=R4=PX&XU%L:BTS/IN M[1+L!HJR3JQ\WWAT?'(>RLX+>M\0,Q&VQ9*VBIT1PY*!-5+W\AXY'FDG,H_7`!5=1K"> M`LPQWB?R,Z(&4;,1'H2H&3',1?W&E*A).:``__.NAX5,I36$K9D.5"["MX8V M:4K'[Q[DR4Q[&*$^=BASB7]GY@16[TEZ"0,8@ROX"#Q]EKF;Z$`\+P;T M6^`>[`L^)"0`'_/"%78K,)0]2+N;Z$!<,P;T"@E+A\'$;F3W[U[++V/G:80. M;RFSP,53Q-:(G"`B??NQ"!L#6.A"Z!8*82Q6AMD*-^#>>>HE@$*A-8P`"@VH M0H;R03"Q6N,."F"PBA8`I2K8@R"[2`Y@M7:B5DA5.BXFNC+KJ5N]N5]LA`=Q M3F;$L)"U?$1,5-@WX&LI90B%`?ZCF\ZO/[ES\S`0OXP?VT(?I$-H)E]^I#D1 M$7=7UK8<-L'7'WQ#CA4__F:9D>:*?5"O3,YV]SM]'5U9R%H3D*2F5C&!)_ET MI\@E\CY%8)GX5W#)DTU)_]HTNAR*1R!O@<%PBA5E&F02^O(J6<@.3,)IY=:6)FKZ#S`'T88\JH]XBLE,%A'*75RD1Q;VRSARS^VD#4)2A;8U%H MX/$YVG,\=,GHF/[7:>-K?";':7R-/[[&'QWQT1%7XH@;]I($Z@]]"$/O*_3] M]`*]FODJZRD)#CW66GR&KI*/ETQ`7ZL44I&MTP$\L&7J*RX9V*-=,&# M])U@UQACQN7SZ3J/K-`S7Z6X=HO@>H`VQ,#VY1Q2:`\N; MHB'W3#J-'/P<[H:SS3,_HXHX\S^C@V3,:D MCW,HS'.H@*VYSP@K;6N4C='IZ8+2;#7X?2K[+-@F<50*1?TK<8(8QCGGRQ!M M4I3U!P5E61K(HVQIY%47E+;`;>9_1G"(\,R7Y:HS>;/F:1C%T:$NS<+959CA&)>WPL$:/??38;?38[V)L-++*:N3YX1<'(>PS1'/L M2,1.X,%@17'1:,$CCO$L]Z^XH'EF]ZM"'8Z/6C^+>4<,PXPO!YZAY\.N/N,K M`1NVH-&E&5T:&UV:X\C9!4(AFH9X2W:+W;S4=NO09JNOP*0`/]8H)6.P4@3R MP?M01\6E'D$4+BM/4YWRT]1T27#K=Q.5^9+Z`);+]Q(=>[P4?I8NF:2JZ;XM M'HL.6EYTL*!U[6!6`X!V93I-Y0?5"*B-G.%,)\%B=JT`UIP]P?N[!`60-)?& M%"[A$_E3I$]"+=2,'G\$Q=,&G@I#=P6<"*Q#WYMMMBA\S"HNZY-.&[EAKI]6 M`#57;QD+>.HOX/EF+.!YC-.AQ&VOFE M!=W(P,!%W@RJ>(:,;SPH4:LQZC36&`V;:HP*%$$XRDGB*6S:'*E0G`LFQ-"8 M://\8AM*557SC=2>Q[/=_H__A`#A6:YW5Z1_J:Y8!R-EXU+L]K]8,522%57/ MR23#O]9XG&XA9_C`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`8]>OM911-ZYMD'D$.F[&LD8GK)ILD+1EP#C!E%Z;@X3_[($4Q M\":;$,7PK_3GU'GHD+PRW@815U$G"77Q%W7FX09H49%6>O9<-HO9AA2SDM66 M$*;I:%JX;&P,PUVULHA_U$<3BZ!11QG[GSSS^%F7_O30X:2E:=+9[MKY/413 M\LQ=6\(.!WE[#"D]:X<'326I.PO,DM8X3I6`<1D(Z&MEEZO"U?SPG#.N!ET0 M1#!8358(:(^J48F9/H%("J8%136W!"W\';B[<38:`Q>\+)C.X9&3*#?@CRJ\JM[( MJ-0%3=&)#HJ#E[&R`(7QZ$2M59I#;94F'+%@:<8F%L7@&GF,;#SSR(:(GHW] M7&UQ:\=:>6.M/)N/237K,DT0818;F9LP<+._:+H)["1KC8JU>E-,`)J\#29; M!68.C^;?.T\@ZE'$3*0M67I=0F:#4<%92$;.=XZ/;5WO,FXE.YAEW`V@JI,1 MMWCQ.0U@Y.*>K30+V6&(EPG`4C98O^*=QVN`CKWZOL3,0][XK16;O+D0S>7^ M5D%&AJS_U7BZ,^24L?-BQV&,QTWCP#G7CN\$BA.'L>.7FF29[/!03%RP]'`! M8WDHG55[&NF,M8:?9:2+1;?&@)8M`0AE`:U9X/H):::3-SA;."@KO'2<\$$) MF+>/8,FYDA:?ZIB^JI+X8XS1BABC7&_LY"&"'G30#A]/P7R9]J?29IVHQ*P1 M!]U(T8&J!TN%T^%)J02P\!T7Z'U^2Z%D.H.D2Q6K>?#-8"DI6UZB3S*?YLM[ MY`21DS8=T6BLNJD:WG=X!,2"H2+OJCA_I4[>5>BDC6$N8>`$;KH'N@#K"FE" M=[:[`BO'OR#]BW>D$VI"0C=XXK'6$@1*^;/3#W[XX/A33`W&UTZ$1[M,`N]JP2'([E&,AQ-T290!0/%[HOK:%&X; MLI\0F4)U4OJ\(Q:RSW6AK)(H?B>@ M[$_^6.S,:%._"DS%L^+D#IB8H:N\>36 MIV0A-M9\I\-__*'URM\P5XF4`UGEOW9VKT]$<*]^9K^E/YIH#OKWABS]Z3M^ MU!N^-!H"8S3TU:GFN+_K_;!,MGLG(/[M&W[H&[ZT&_JFJ>;0_V`$>NQII?XM M+_#U[RS?6X_GF:/^ON=MM9ECO64:J+1L%EHW4,5);'^#:74PI.7MT'="P9!I M&#P"%)-GPPO,"XRB$.U(/"U/WFJHKT!9SVPCF;[S;DTP901#P0L@!:O]4^!D M3_>!1[IVD,BD_F7?1-2X?\C:&J,3/851&3$)EQ2PG$$YU9!C$OB8!#XF@8]) MX&,2N,BB&)/`I04T)H&/2>!C$KCEV85C$OB0I3!C$OB8!#XF@8])X&,2^)@$/B:!CTG@8Q+X MF`1N:Q)X,T!%G>U;3"TEZ2T`<@D:*RT)=QS435^:"R0Q,3FT(M#C,K70,QZR8763VC`3=XRV>-S0PSR@6"QY M>A9%B1.X8+X\>'%L3R&;O[3#R#;*@C)5%=V`19?2+'`1<")P#K+_SH)&1=&Q MJEA)6V+F6E<7,XP*^F'Q^O:DTSW>0MP4M4L\N<-I(;SX,R&>6#2Y!5'BQ_,E M2>_(WOE%Y`S"ZN]+T;#<@DI#:*Q)5IO-_^W$R$YIJY!9(1._V\LVRHO`JVR3 M)N((EPY$GQT_(1W,D\TV_:666`+WWL(X/E=,@7=,B0<28U3!VJB"H&9Q11:$ M1''K!"MM;RP.@UMB0:DGOA(,:G"]A@'<)!M]S\6J!(Q[(D=Z5$:W!H:2YV#7 MSI-F@"L$+`>X"D9=A?D<;T*H*KS\T.I;&F\$TL7CQM@1L#[QZ@35]2KM"T9?%Q M"[>*G)KPEW*QGL-'Z.%#5I^+N)'VS2I/:O#O+R+;*T+]XDNN*CZIFT8TMK/3MHD(S:#"8+5.X+@*LU/DM- M'@%R5N#B"2`71F"!H*O'K>Z)=>.FM'<5;9>D^.8HG7I7F>M#]UP?N.=Z"\AV MA'\^#8/T.)$X/HGZG6K3X)ZG,8S@G!$!B\?YFBVR$8/\&41DLH&WCUF'Y$?E M(_-JA<`*2V&&`8!!!-TT*F:CB1:?S-_`IY"0M'AXTR;?XT,:#)H%V=FMH2.- M'4KU2^0BJ6 MLJ=%?_FY&,A93`!>@5H_[S-U"%*'U=/O7'9M"L5LAKO/\\U@(,K8LUC%*R?A MX1Y"B;L@53[X98B6`,8)EFAFZB%*1]@#8..9J9OIY^&9RLM.O,B4&G]4Y:6( MGB=^6BZLGK_N-4JG7!!+^CFA#8K79OVM5\?._?QOI*-=@BPT5_C:JJ*Y0[FU MTJC"_=];#4*;^Y=OH=G"]U8UFSRL:RL[C;34Q=7SM]M2TB[T7?CVRJP/6P757M,%KK+4YC=J M6?#5JVZK'`Q>WFVVV/T+LE!;@?8:@J^4-<\-<%RX]>Y5L'`X`*-K3GJ%N@I< MK(DG#.C;:)KG;*D#PP3,FB16/&"1; MAMCB"NQG9K$SP,:CU;II&IR]VDH55;+LK)5G;P!OF,>M8_:M5F$C\BS45JHV ME,U7$)9=KW%>0CQ;7>648*&FJJ[,+'$.!/-XK+Z#L-?`&L>GK,E*ZME;%$#@ MCU3S:+4E+-MLDFW"J:SHPA=N-C1NJ'8_3;S?DRA.03N4(93J M%D/2I)L)\#:$Y!U6)G=JK$!H;05"<07CJ#\XMH8<8&O(!39\,$PB?W<+MB'" M5EU?3X).FK:)$&QO`J*"I<,2U2>?-G)#$4TK9&H*IHY=5<56 M"[VKZM^Z7.(DBD"]\Z8:W"=F,`7QP@^)#%9T/?A31BXY'@:^GBT5='>1(^C MJ80S:\Q[>^A7D1B,-:?`_@+`H*SQ@>@.*Z81+$ M:C+%^@B:72I M]J02S/!KW`=NG$UCGT6=QKQ$T[!3W;.@NT50SPH0O)@B&;NZ-NC#X)9<.%'W MTQ(,:G"]A@'<)!M]5K%*P/CU_I$>E=&M@5'/6A,#V'G2#'"%@.4`5\&0V@12 M0AS]=,N_;W0K;D2H,AM*(I65%JDE$>R-U,*YQ(LQ!E=X7_%F>-+!BC@3:6;4 MIP@L$_\*+K5$"YCHVG'L:HV;L>&GK@?YF&]B4[Z)=)=S$X&9R8:$F"P,P>2, M#4$]%(E`/`/M6(W,1M)/ON&-]WX(L]=[+D`!&8RA\?"XVP.=BXYL756]>3O[.;UXJR6G:4_K,QP@$4O9D3BK4:B>&'9,3_J?Q M"Q3BV<2[A4^N9(.T3D'J_Y_#R/7#*$%`[+)?:&!QC1]]&GM]&AD=X[GZ%Y,' ME;NSW3W^7)<#Q$+6FNV8NH,Q@7^A^EXB4NFGA=5X;E9;QW`^-[% MH7\$^78TU$7?%"\F,A5]'BT+6=.+B5/.7(@J.('DZ5@1<2>BJ]!),S#V.9&W MP`7PD5B!Z&QW!5:.?Q'$,-[-EU/R%4!X_K%6>ZF4/\O/F6IE43U1\)G>S-G, M\J$)RQ]0F&RO9Q]XK&_'&&:S6#1H?6JENX`S?$U2F@QAOSHA?7::A:QI.ZU+ M);B@;R[]9*6QTG9?>P[P?%V8SE:',E;&M^5:O#6`447$M*^77OW.-EL'(L+Y M=.V@E9X7*!1*@Y`9#255UZK*/76\4^F)&790-&WWV<39!9NJ:T[>*![89B?! M+PC&>$]9,L;HCCXS?AQN%T/31,4+8LA`7O!+*@"0PJS8-P"!N_L48`M-./+T MY1YTD;3C=-.ZC#I1$R^+T>0?FX[+9X%YWJ2!T/L*?5(ZI)9N%(98D?3[%.TLBO*=$T<3%!Y,( MIA/49#]II(PK8[=!I:(D)8.I#QPTVS@KP!$>/_K(J)9VJ`_!\'B6"@-1ZI2> M_!$!C7>.W42-+P0&:7)`J*(=`?T-272VNW9^#]&4-%+09;)XR!N77K<9XT)3 M24S^"KH@B$B1G!76#&HBAJIJSC1BIF.%`FI<+?9,15%-8X,6_@[.I03E;2E@0&6D.IS#`: M+9\RV9!RY7_EC\3J?&JY-&RG:'H+8;P][(!-V2VBV#.#,'"=:#U'"P?%^5]* M#F11?CYW)+W7.L3,S8,]?EVKY/FQ57;U*&K0T_)-LRA*@'>>(%+8+7TGD3X# M+1\L-,7468G;L=^V"I\#266WGX(R)RSEW=DU"/4P^C#L=1D.95>8JF(BBP2Y M:R=ODSOQT^_QC_E;QA,4\@P%/E4J4F47SHZ<'DF3$]=%>-,J=;.2S560I2'GT(QY"[;F M+2C2/:[WA:*50S?;,$C/YVG3[^P-,G;IPWUO`4WA;D;*]IR(J$$H5@RE[I9+ MFE-D%W)N\!6@I9$?NE7?^UPR=5RS7?2.\=WT([#!#9]9Q9()JTBN#9. MV;2MJ_DX^FY:FPD9/7TS2ZX#+(DLU'U3OSQ#L#C7WX(TYDK6)\?B8!]M&+AS MH*.R]A]/91M2)*%@BT-2S5\.0RJ46:N*$G-)8/\V2D`&M&^-GU68)4&=O=JG M+>*.5LG)OP8..25[\^"65/@D-PZDVV'T*0@?(H#2]\ZS8)O$^)_#P,5?I9#7 M(="83:*=:=/Y)[S;70]B+`6HQ0-3>>=,X)%(*GE*CT\18+/UPQT`=Y@GZ(+H M'CE!Y+@9+W?)=NM#@+15GI3CR):H-3U?1Q+Q6IX@E]1_!5%X#3P..U_]PKAU M5Z.N1!PU*(PFW_#.JIB3QA*D M0VA?]'K#EB!I(]B-\U27(B=DGDJQ=!WVJ#S\``Q0!0W#:6Q78;"Z!V@?Q)J& MFPU,"[?=PPW(LN]TB(R)[@!DR8:?X<@'G^H/`1?U@W70+I"N\0J5>]:\AFI06*F4>S>`ES0*(PZ4W)A9A>W[Z) MDNF#)ZMGWXA2+KYW?5]GDHS)>7"L9Q&;XTG]VG1>38<#2I]U+H@?GDWR*,D> MY5()TL-9-C.T:PSI'DACUJ=U69^,>L.3U2F&?/(084\&CWKQ"+):[-KN*RBD M[`EVT.-\-)1TR$!?=DPS(;,N7;O^M0B!6FA`V4+0>&M`)6;<%1"61QDQ-<7= MQAY^3'PE#)6:-..AO7^A`U6LZ<8HB M'_+U?NW.`@\^0B]Q_&P5QZ361-H(@\.4\8]J^)E$ER(280A`9:PL7L[KJ1:Q M/64QHEI?,?60LZPK\DD8B;8E-0\ MS)5HD39V.J1@16>[\K]HJU+.3MV6(P*]CCD'DK5\,+$EM89@.2^>+,Z72^@" MI"].U$;.L&SX=;BRQMIP5!1(*O.AS^HU4#$>1Y6331-N8SO0L1UH5SO0[P24 MXWXZ^>"'#]B)PKX1C*^="`]_F03>U8+#X^P>Q?B2U-4#D@%`X\74Q]:@0VP- MRKG9CGUU:C"44IO&OCIC7YUA`#SVU>FMKPY)/)D%48P28E%TFD,'RF@!D*IZETS5(5DO?>*EI4,+.W$[XO"M M`N9`4EVBB%J9GX$`+*$+BSVKE*K9J_C;^+#%U(KI0BO""A--Q&[V*BVEB@H9SZ9=U$="!KF@$]\6(%ZM;T82_)%9'T M&MT?;-*B0MK\-R;:PUG3;%`J*W>@1^19-[BL2YP9P5`E%4@V?6;Z1-DTT1_R]&>/9VD#S!GQ-_ZG_/J0'RI9+E!?'(M;1;WBK MI'=W&+N(/%'D76*'#^UV7YKG6N#>_VND?6YX[=Y#8V281FH@:XF*5"'$?OMC M-)]^BH/M+9Y1.BWO4`U,_R&RE;K5'HD(FH7<%=S;*KC7(:;<"5R01;5TW^S4 MJ`W@[-"&52%)!94M%3X>O$G(%?1\>4>:0:25<*>.[P/O;%>\C\Q_L;\G]QPL M#<6JRR)?Z$Z_A3!;V;]XPE8*Y@VL]__8O[9T\3&('4$,X4(KS-7:/+0D(-T@ M01#ET"*26TMF?;8[_`KV9=*S]U<'>:3Q4;P[;()16NCY?NT$\VWZL.U#.M=9 MD)TEO@`R9>!-L'.$M\7T'\\QL/L&-UI.:=9,;A`Z;`]<^X6AHHJI9`.M"?8" M-MDT;F'TQR4"H.SPZ=!;9MIV'V;YH2S$KJ!FJC*AD\L_%VOKY]#'T)+#>9]B MIU`?A#WA0;.0O'PD48?LSTGZ)P@*HZ>W4S$+_2%DR?$!6B3,R#^&4"Y]4O*^ M;XFG-`>_RC/D"M$J"U]:4`J;U,+FT[2[=8AB`@@))HC5PNX80D4UT;$:-HV* ML4@%F^)P%,,>Z\WV7&]6ID3+6,^T6_WXZIF>5)>!W?IT=?3&0^R%]MZURXH'MXQK?8KN0%2]0)#A1A3 M1UBM%&E#VK$C\HB0"HZQJIPW(,X:^*0<_Q/XWBRX(]N&X^=5@`1E*32PUE\80YGC`M$,%XPA0[89;ZB9Z#)0Q@#!]!V1<0%C;*#J*2M,^8.._IWR6;CH-W'Q%OMLT`8L_)9Q[+$@#;*D1D/=2=;OCJ/`!N5 M@%26W;^@8I)-TWVY^&`:GJ#P(7RI\U!8>6 M/[:-!TSK#IAR:L9^J!1]^;`%*-XM?&RO,7OD-+S-,AEUMBU@(6O-<8=Z0F`" M[ZB9*9^@KD/?PW2\)&V&460#<106;!W`N#?(H7\$^78T3'?6I$Z&3$5?Q("% MK.G%Q"EG+D05F,&QMY4JFRC0V^I4)NLF[//>-LZ1GW9NP9-_:, MH_6,$U&.C]?`@1<,K"7 M%>[3H9]=).W8RQOOL9A1,[17E`)6^^HXZ5*X`W'L`VUO8EOI&7?/^2L*'6-F M[$J_,P:I+;.C@Z+I+819JJVPF6F(M=\&HPC$L\W6@2@M:;YVT$I/(4P*)5L" MN:TRI*&D+H&`-VLC32-G MF_-YO881+:_Q^#/+Q=`T4?%2^3*03X(@P1NHXSMHQY=-VOREQ2XA9:K*JM7S M&J6:WO31)55B)>`_!J?"];^+L\*$`"_-L"@Q%"?O*I* M[Q:E^.4Y?@+/4->AC]&(LJ<^Z<"2^7W\HXZI?<\PM4]8N31G]8T/Q9A">LH> MBA5U2_$Q=U[4=\H*FWH@#$@H3!+;WS.9\=S/JFZ28M"!SX% M,([.=J3KL+Z\8PHMVZ\AZ"`=Y9#PN4<`01!A=K_?4T@W-0ZSU3&$:37O4J^T M'$<'"L9-5G42:2EMG?G$-&)#D"4#9(I2Y/:K-B]MGKU&U.UI'1$S+10.A^L8 MJ&I&C6+S]=N)(@-F`;@T'>LV7P0%0[>B>\;>R^\NS4-8H_Q,\J'`8*0^USY! MM<2XOCVE@8H]AYDVV;7!).=ZC6]/+'A[\E;DY/(!+I?X^VOG`0(.4];PF?$U M()9`W02`JBV&2Q*7(=H`A*UJ1(JEQQS":/[2Z%XO)@L*!`K39L8W"7:\23@= MWR2,;Q)H;Q*^$U".^S5$F:9EA>]"%!WN$]E-*<,P9L-KNG*>6?`SLBV.>?"# MRH-_/>P\^.^E\N"K1^(\CRV)H]@)/"P)K0%."DD[]H^K]NS:#M0,Y\&G;-V" M;8+<-6F&AQ?7+8@A:BI9KB=07_3*"7`IK]`PA< M+6DL+&1-[SHBBYL"H-G\^2J+GT/R($=?5]P6:H.SU56LU);BXP_^'M+%=9VQ?3$-*66I]5);+:T=R`WXFOY3GQ5HZY0'(F%6',43^Q\!>@BU%B`V M(>X:85MN"41D7<=0X5L"]4L[^SDIK0O0(W0-+/%C#@:P&_-BJNQE@X0*'*48 MWR4/D8M@WBEZ'ZS0I@',#`S#P>8$5>E;"FX-($TM#V_YLC_%P#LTDR^K[FL= M*L#)P0",`"^FN08(]-X^VO-%#4$GR]G;0S,*4-`>QO)GA[*(HY@*HQ%.#VSE MG$)LE,Y``):0U$DZ3.02.*13ABX%X.9C$)Z@&,*%7IBK2M'JQJ3_6']_T;M[ MV,S%,$R$"+R%4@B$Y)3M$FT'&]-:T<+$8"+P?-`6&B$?WA-3!J*M9^2V8!IN MMB"(Q%EJL(,0I75.K-QO6370@84T&]`H!2]*);??L!G(+\#.$:RW3"+YQ`!-\WZ#KR+S=8/ M=P`4S/()CF$D6Z*I+2)CP4-=O]>Q^(L=Q5_>B#RA+(9/PQ):'Q95"-AS9J>_ M#JHB(M5QOG(:S,_]^GHX-5`QCG>C?AT=E&O0U-J=]1Q[/;`<>*1X-BERHM%$ MZ>#3\'.O3IEKD8V24]0M84';6__]X):X?_27_`<8CBK$".%Z#0.X23;ZC%^5 M@'&[=Z1'971K8-2[.XH![#QI!KA"P'*`JV!(68:44)/]IQ6V+_V^V7(&30A5 M9D/Q;:RT2-KZ`'5N1K2]Z"8AVC5?9CD)DR1>APC^I>E&7SF3=L3KVN]0U$O& MAE>9U*R6QNEJ:W(CS,L0-$<89W5E6Q0:H[H>?PHPDZ6#$_&$HTK20&KFK\*O M`&5_@ANHI:.95GYMV9,$C)0JB1F/UI%Y/'2;X`=*IDOI27PMQ^46$!\$_YQT MDR,798GCDU86I]K4M.=I6!-A[%;?O@6L[-%MOPY?/N7/:<.G(G7KTH$HS>JP MRNWK8'7`EE6!G!2^&!92P#TKLV"+EP])-"#/'6XQ*#J4J(W<(!2A%2]E;;[Z MWB'WLYI@/W53Y`1N@8N5EMA)+0^)-'+[S/<[!G$I>ZW<[[;6-K//H8^'\6&\ M(ZLMCUM:M=/QIG>A#^9`^R$W^O+N>5YD>?+/19=D^8KJ[H7]OMW+7,6N$#&*LC0M_H8K4JTBIVL(EA=/P,6V\1',ETOH`J0OY:B-G&'9R#69:,6QG@XF M6KHF?PR@3SPU"F9S&N4$4@=+9K%D#6':X&]MB=.`ZO!P;<9`W6TVGR<>86*[ MNS")UU=74PZ!-'XX3($T8V"Z^C$Q@_,M0`YY9M;/=D(A-_SMA(9C/4E2R)I- M+^?5+GY+WK."-VECV?*^RY:;ZV%^ M!9P(I&U+,(P^"D*F=-(#60WI2)EO,U+M5#QI\#9A)C/O\C-;Y:/J&6I=A(=B%P9 MT%/XA/LBG7`J6MV,81OY*;;S\L_#RCU5]V._ZQIIT M`ZA)5Q?\?%GNJ7)HJ<(1R^,/$Q]%SXPH<;&.01`Q=#M8<'A?%GC MBW^Q,0YESQFK2VI=F!@[11?&8*]6]^'=_.8Z.T`)F,>V<09C&5O!4';;.);I MM*),Y_?57"*[3R2J+QL7&!J478S5??")]WL2Q1M-L6XVPK8XP*TA-$8,%=XS MVA5&R^)H?/I'CG?@SP2S>?$(A-M$=(\BUS)LC*39&DECUA^>I'E1]*N\Z"S: M3"-ECR-,W\)H**EILE$=76,MYT9"9H^.[?K7(@3%F>T-C&CT3:G$C/NFPO(H M(W9DG,9`?\^!_E.QYC-W(([]=-3Y,D]VN7-\/#IO[XON@>R`MZ7Q!0,6AD+Y MQ\R1R^XBK4%*4`T##4U035@8RK8KM4^Y!*+M8TI?6B^*IMD:RHG[XI#:"S%I M6U-OCLDAA^Y1['%?:7)A0$)=U'T,#5H2&GP[[-#@&ZDC%<%DH!WUYA@JTK>:44M$^*N$1[$)1`CA@J=1/5+VV13>1H' M`]C4>3%5E^NA?+6;U``*`\/8VCE!5?BDPMQM\'GH9EY+X%T$,8QWLV`9HDU* M2>!*N&TXKEMAIH%X`[L>@+]EH]V"%22#!#%I;,$@WB\P]*+5I465) M6FD,2AXLF!U5T1&4S")Y\*%[Z8=.2[H;GR#*0P[&XC2@47)6A,S.!//@$3XN M?4>!EE>',W0X%(&VAD,M_50"UW.P?RJE$-[RJ,-Q1YI!*?52$'5'"2M=!Z;4!T#I5.Q>S,)DPW_&)T`,`=I=0A\@9>C7AQV>SA\!4RYJ+[159N.FPTVQ MX[D*D3(34QUT@'Y@#95RT7HYF_X%^/XO0?@UN`-.%`;`2P,V+=FC?,#3AA^@ M"*A(%<(X57#>SR)GRHZFS<,.R=A0@"DP?R-J;(IQ#^?=2_P3!?:=-O"`-E8J M-@7J$@?.ZMAY%TP=R)>''HX'WP)/`?YW!Z>2$OC^Z149DS0+3/_Z_P%02P,$ M%`````@`H62B0A#4UHE*%P``*!D!`!$`'`!R;6-P+3(P,3(Q,C,Q+GAS9%54 M"0`#+I:"42Z6@E%U>`L``00E#@``!#D!``#M76USVS:V_GYG[G_@^L[1@NSXZ.'A\??W;(J]CQ$,`P0@[`](%U>/C6HO_]]W^] MIA_I(4`_<69])-\9V"NKT;1:S;-VZZS5L>['/:O5:+;C0J3$$S[#SAPL;.MI MX0?X[&F"?._-0>Z;],G/$,V.6HU&^\@+<&@'#CA(W@^B!?]M-T1'X6H)CL@; M`'E.6@`MG&6A!`(/T(]"#P9X`5S/L7TJ%?E:L]5LM9L'5FBC&0@_V`N`E[8# MJA5.I,*%4H_M5*#FT:?!S8@U0"81##2$@L%A2;`(']*?UE^:VGC"2J6_,%B' MC>9A#ICO!5]XV)JGIZ='[-?TU8TWB\30GR<`]R/+MA5E^^KN.C^,>#MZQ361;M)'80P-"F#9T^39XOEUXPA6_3 M9^0I17*6PKD#4XN)<4:;X,T!]A9+G_8>]FR.P/3-`>T2AREEO_OVY&>",7W% M1@Z"/I"WT=$2P271%X\T\KHAX@HV2A?;C?Y\1+X)_)LUY(.CMWN39XG`-Y>' M?!.3+L#X*HFU/Z)<,/WF@I%O>H''$6M?0M$1Y%L+1;[I1#Z7K*)8].TQ$<2B M?]S?]76&0O8%,IU@Z'LNG1C.;9\.X*,Y`.&!Y;EQ"_PN?&7=MBF,-0EOR0A* M9J@1Z6ELS"%_)V4M5AB_/BJ7V*@MPL`=!F_9W^5^FQ1/7K&D98M=HUS2DA4-8@;5C*6NT'HM65"N:)DD?8`ARI+!_*J:I7TBS7WC8 M\2&.$"#_H(4L9GM$BX6-5M:0Z(\W"XB3X]B$I:[CP"@(O6!FW1+&'6*;<>>N MFB$10XT210VUHIQP6:(FQA6D3!#U#R0F?^9";!UJV]L@D[C!SR$$7`M6X\>^+Y7BB87FJB)$3Q MF&HH#(%FD\O3"0NCLY`Y52#V,".L)J8J,5QFU/-_L\4EA\Y#J>Y,(2(#G0L6 ML:%&R]73SA8$\1G2,0OHV@_/E*8#X,!^>H+!T94/)\"Z)B9;:/U&&IJ^UITA M`&HK85NZ!'PI[85FA\]6,UXW7'AA[(?2.8D,@-3?`8'(V:E)4I`D8DG'@#CF M$]5BYC:8`H2(N<`B/`E9BP4,D@=C9`>8KOSRHW4U[][ MH)9&';O39VD=@TY#T.;+K;`*>/8P8Q*6E=`IO%?>O9;$?R).QI MV1^"4(=^>*J>Y_9`HHQ%M7&B%_^H=6TKFBY`:'M^B9_DH7)X%(0^*GIF\==J MWK1Y>X=#;T'#M/<83"/_ADY"<)HZ5+>^36UV-_.IF%[D&-ZJN$))V_P,D"V[ M`BF5@;1BE!:#23-&,\>1(;5L=1)6W8MXO>C2]M!OMA^!+L8@Q*0=<_[!`-B4 M1Q<&=\")$"(TG=O8P^6^M$,E2C>GO9_`S[I/4;`60_N3%>-EO2?O%J60+6+$ M9:`MAKH>GZK/*^6)/WVJMMS:_,C11C:L?/JH^5'P(R!(:92U^1$C66"OGN:K M[JB)![EA-C5W)9.ZQLORT$2;'U328+0X'M?9T7O43I%Z:@0)V_Q0DSRF*QU+ M:[HD6@JGZU:-;0N!AHI>5#E;;7XL2HO/G(82`WK]>F(%U8'%+313J)JJ&'"; M'Y.J%KT7*VK-G$Q)TQ9.&IB8_TGSYEI7J+CZA97*S(]I;=4'BLJ]4=S6WV]1 M#_$Z>B]6?/6"0IL?,5.L_]3*7IFN5$?+NKSYF\+1Z?`#6WJ,)6_7>VEVIE!\ MDH?R517!6^R)$A*L=^)'S;G&*"L99G7B1YVM=E/548K*M-T!!P8.L2H8!#A= M+XRGUL:J/`AK%U%-IQU^%*K"^OQ:CXN@J"FUKB(SG+A'B?SG=0QV$N*_/@Y^ MZ_S[7Y^<9?3T.3@^=?\\>9A]7@7W%]'CU0DZ/7G?^N-^O,+^R8/S9\._#E_= M]VYNW<__]-O'P:?)L'?17UV-OX)._^'+>/[UU:N+J7MZ_^''\Y/>Q/GEQE\& MTX@TS>CK2:=_,UO.WHW>G]RY]U__;`^^/"[G4]O#[SNCV:^M?]S?_0K]\X]> M=/G;EY-_3EZ]^C`8?O)'=Y^^1.,?'R8?NPO<'3[>S_[H=_\D3/T63IZN6L/3 MV77G$GW%/_;OAI_/[SJ3RW!YU;AV5][P>GPW1N?'_9/._-UH!/X!.Q-OV<;O M>^/HU9PL4YWOVH](>[.GY1`C4AN1[#'3KF+M?8< M=Z9.SITJU-<1I)]5WM8J5<.:2CTJ%5RJHS<=029:E6S">H6E>O"6-FW2LJ09 MTW;--6N7'OO-C]U6+JO0:$'*VQ9=8*.$+2JQAEBK_P[JK])_G;#"L2#/3;YW MNK:B]D.@DD&E/7PLR"G;2":N":L>!_)MC+-0&AUN;Y$'T2WQ!Z';=?^(<&RH M[ MUT>%FT'8T_A9X1:1^#EY["V6$(56P+WB173_3'QMS0V,!SQ)$?JOP[3<(7UT MV&P=MIL_/V$WNV2A(@PJ>'S-0S48:;FM8,@OE!$`82#R)6>VO60%CX`?XJRN MPW5=&:**+;-YY8].XY1+T:8YI4W3_&5W(/EK>JJ!@<$'"1X-1-PK=72[2UJ` M?OQXLQF2*W[85]\Q$QC8V[%XA&"W3CWBD^MS4 MR(>5W-6R*44O0G3A.4[H,T<*/BRA%+D$)3(+Y$_TOR`#LN.%YDBF#U7%6;XF M8\238!/*DRRL7T)46E8OBK.``3''T(HGT-3V,5>B>`8*TY\FL7:\.7`0L5S" M[>448SXJ3+)%28WNF8J^*)(IE^W"D'%<+J^!\8D?J7X9/WV!F(\#&XCY,R)&95;/-H#I6O!]LNI M&+-,TF$X!RB^$^C=TQ($&)A#H`2;<&S-DYY7\/B&&W-DT\19,@.+LL;.W^\7 M<&%[V=P17RQYYK*'6W;,;84J`A*/'#V`$!P0QS&8Q8OKPR\#@&8`F<./&J*4 MFK2,.0)M(!*J4/\!X'Q4WAP9A,C$7:V/<42'U^$T7C1FND:L&(.$4B&4V"(T MA.<@+UX88Y>&82^(_U\2C#W[QL.!#)UL3KH`DSB_!ALCR@:D[7MCVGE2_-=>IP$W`Y][R5TOH:& M@#V(0^/&.PFX72A[$9PUI".Z1OF7(65#;#9U8]>986`U4(^%_8OVA^=T''>- M[2B02^<"G39[(=0V9)86K0"XI,0=6-HK^L-P2HR"_?*ZBW1<<+M3]U*X4Y@L M>G6\&&%E4^2[)X`<#Y,:TB0Y8R9((32%XO$:A%Z(:[X35T`I]KAYI0T7;EO? MVW0WJ.P#"99PTJSTE.@I()7OUPO:]PJ.`+)XF8I?P""#6X50W#6)R1/163*7 M]WQ%!R32!ZG6KKN#R8SJ"U'5_4!P,9Z#]7"=I%YWUYGAR=AF3%?8CQR2>2@I MFIE:(X`>/*."^O"R:KOD;(J(]6-G#G>D?66J45 M[1$(P[B,$7)70RR)=E6IQZ!!?CO<6@N$5/,O??AHT!*'')Z$W?1=.N8EJ]WY M33OF2*B-5*;&^61WF!Y)`#Z`D*Z"CR'Y@W[F'@.W'QC=&OL21-+?,^-@`-U, M99(%=8/S&13`I8/\W`YF(-]@<5Y=X=1E<_I`-;C2.&M`;$H;@PL0_[\?/&>N MV7,Q7T4*^4)5?JCI$V,!FSH,:".5=OM\)9=>0,AX">+*D,I]<.@`X+(Z3VB)C3$;8!+9SJ/L"`E>^4;'_BGB%8Q2[C"*YBX+JO#D2"I%)^G'^#J#\!0+K*G MLVFK>%2[T>VP)6[)8D+QO.LN[[QKHUMD5P'4=NEJO1_!G'1U`3*I-*DA8RR7 M*H#B0-$5#$`X1RZ:T.%!EC8<7[):7YFZ^@>9!!O ML%QO%B+U%<[&,[I-ML0MV])6WHG#3MXPN0VJ0Q:+7_#`QNGFIEHM>Y+$*'&)!6Q(ZSR.U*,[BK;@):T0.DL(",%5F*4C`79\3CQ MZ3@&RJ>&*+?,9+Z=05)JP93MDLH=;MCE'FZ8-5S)+`W3Y]_:,JV`6+Y%E'.' M[7`J]`3-(7U;X-+8B^SN/W-$UX,IW1685%!V;PV440A1X5,FQ74\5P.EK@1; M$2[.0NFDNRP\C"%B%F!2-8&#][$$\%SGBNCAEW3VXGT40]XE&>9T@"I@-?TRZSO83"Z*785 M36B2:UZ`88XZ5`4L&P9H"HTYH<4\G)TL4Q/7K;="+3M1"0&&Z(+8>^90R$$E M<1:S8$(^W-"E#3-C[YVO-N(-W4<;N;&VY\9$=NC->&X'20/G6O4C\&9S8A)W MR5!@S[*T]EOD.5DB'VTNT@[L8]_::?GN;2#3-/KEB1K<9(_@[@#M-?'J(FO^ MR/9I`+NHP6G#?P^V3&F0[Z%8;*L,[8>Q(?V%U6GBHTA#8`\ M6V=*N\U?5YWT6D#&SD:TNBLZW]\<4W`+S(IMMU!:WK<21356Y MT?XBN9/E`>0SP[)Q<=?)*AO5MIZK*F"5=8G$,;JC&1"8ME>RO'8=N;/,;C?[ M3!9=$:3K7Z3%@L*Q%P8,?#Q44B%8`X!D9"R46R]]["S7SEU7$Z=T-B9F6.!X M2Z+HS$"YB$PV-3A@I<)U@R"R_1'Y/%IMC#@&CL-\O.)[5T#>PMQ3\&GG7LE! M)3:BBB\/8!#.B6L0^[%&&`U2@+H']-!3`ARBI\;$!\7H)"?YL>/TNT]>^1B6 MYP_TN.&9ZQ$H.&FIC4/^&2KI9G0?V*B_(+-\U_D:>9A=$M>#:#D`B\EZP^9W M7>%30)1TMG3-,YG`B8=)TQN(MYDW8\R1M`I<<7]DAXH%-"F!=+_TB*DDOLG2 MF,+&SZUC`T3Z/4!+1#?B]P/''"G%X(336-H=DH3P,22>AO?@ MN60J+&_--D?.ZJ"EWG32'=CRB3>)2(WGJ^&4^%H`T7S+Q=*'*V"2_!412P8O M8L5UHUF$P]9)J]%LFR,B'YC,[16="V..3"J($NG2I2-\OAK//<0V;G@@/;+0 M'!&U<$KD9",84UQZ.Z@Y]YF>?[B16FZ.?%HX):,$*7_A(>(W M071IU,3,!R:;?Y-SS>@.#["T/7=MI2:GVYDCG#96\;CX`FQ+35-26P/I5@X6 M5/),DE(+I\)N)#Z&W_K%K'F:BTO8'S,3915OHX<(KZ--QLBD@;+2,<>F1RBJ M`1:2N[%M<&J0C&)P4J/R5V#[X;SG1Q-S1.'BTMXK3C-2UE<#DE^!]V"6L5(1 MLZ@4U>;C6- MBY!LXA+JW?7@FAHQ!DW5)42*"%WL#YT:[['Q$8HS[;)U![:,G!S>=4@Q0*>@YD7T-Q\XC0Q4.:()8(F M%N8SP'!@$C-%0)*38[,>:P[V#4RRJ&C./5N9(P(/EFP8SV+Z)^8YC1NX9$&V M!4"W]$I7UR@_D0],;MF,P#)D[S5/C>.$CTV9%[NY&]D0`I4FOA9W_QL7C M9?#DAY806PD.V/8UG?K*:!_TK<^11091,2`/B M2B3^.?E(>A:C0:+)\(E)(YYN4)43>QT%@"5.F.4=;<"2 M[@3UIE.(W($]\0R:&CBHI!YXDF=52A,V+B-,$ZEL6Y-KWL+()BCY^:N!\FI2 M8Y M/.9((08GOH`SGJ^:QJVFE%'MMK>OTS!'N$IX*V5*&NDX:Z"4"4G3]4S+*-G` M)(L1)[&0M<]BCAQ";/*S_A(_VN#E/25&^6EWO2X-!Y@C3A&0>"0+HP-3)ZH:+I1T8-)J) MH,EN:DB&";IVOH@6:2"4GI5#;%FSME7H@Y6%]7K=*Q].;+_'3M<9V#@$Z#(* MW)M;U8+)=/!UT=$1.S,P<*. M6?U_4$L!`AX#%`````@`H62B0OB9NW@G-P$`*$`5`!$`&````````0```*2! M`````')M8W`M,C`Q,C$R,S$N>&UL550%``,NEH)1=7@+``$$)0X```0Y`0`` M4$L!`AX#%`````@`H62B0FW4O5OL"@``:H$``!4`&````````0```*2!`Q0````(`*%DHD)A_M$0NDT``";[!0`5`!@```````$```"D@:U" M`0!R;6-P+3(P,3(Q,C,Q7V1E9BYX;6Q55`4``RZ6@E%U>`L``00E#@``!#D! M``!02P$"'@,4````"`"A9*)"Q:.`T/N-```(L@<`%0`8```````!````I(&V MD`$`&UL550%``,NEH)1=7@+``$$)0X```0Y M`0``4$L!`AX#%`````@`H62B0F^9)1_!40``GOT%`!4`&````````0```*2! M`!\"`')M8W`M,C`Q,C$R,S%?<')E+GAM;%54!0`#+I:"475X"P`!!"4.```$ M.0$``%!+`0(>`Q0````(`*%DHD(0U-:)2A<``"@9`0`1`!@```````$```"D M@1!Q`@!R;6-P+3(P,3(Q,C,Q+GAS9%54!0`#+I:"475X"P`!!"4.```$.0$` 7`%!+!08`````!@`&`!H"``"EB`(````` ` end XML 31 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 1 - Summary Of Significant Accounting Policies (Detail) (USD $)
 12 Months Ended 197 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Research and Development Expense (in Dollars) $ 35,544 $ 57,000 $ 2,935,949
Stock Options and Warrants [Member]
      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares) 14,980,000 18,845,350  
Convertible Debt Securities [Member]
      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares) 6,603,582 4,637,152  
Minimum [Member]
      
Finite-Lived Intangible Asset, Useful Life 17 years    
Maximum [Member]
      
Finite-Lived Intangible Asset, Useful Life 20 years    

XML 32 R31.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 1 - Summary Of Significant Accounting Policies (Detail) - Estimated Useful Lives of Property Plant and Equipment
 12 Months Ended
Dec. 31, 2012
Machinery and Equipment [Member]
  
Property and Equipment, Estimated Useful Lives 5 years
Furniture and Fixtures [Member]
  
Property and Equipment, Estimated Useful Lives 7 years
Leasehold Improvements [Member]
  
Leasehold improvements Shorter of leasehold improvement life or remaining term of lease
XML 33 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 2 - Going Concern
 12 Months Ended
Dec. 31, 2012
Going Concern Note
NOTE 2 – GOING CONCERN

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company is in the development stage and has not established sources of revenues to fund the development of its business and pay operating expenses, resulting in a cumulative net loss of $37,938,721 for the period from inception (August 16, 1996) to December 31, 2012. The ability of the Company to continue as a going concern during the next year depends on the successful completion of the Company’s capital raising efforts to fund the development of its retractable safety syringe. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

XML 34 R32.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 1 - Summary Of Significant Accounting Policies (Detail) - Fair Value, Assets and Liabilities Measured on Recurring Basis (USD $)
Dec. 31, 2012
Dec. 31, 2011
Cash and cash equivalents $ 54 $ 4,844
Derivative liability 364,802 442,311
Fair Value, Inputs, Level 1 [Member]
    
Cash and cash equivalents 54 4,844
Fair Value, Inputs, Level 3 [Member]
    
Derivative liability $ 364,802 $ 442,311
XML 35 R40.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 7 - Convertible Notes Payable (Detail) (USD $)
 12 Months Ended 197 Months Ended 0 Months Ended 4 Months Ended 12 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Jan. 03, 2013
Subsequent Event [Member]
TCA Note [Member]
Apr. 30, 2013
Subsequent Event [Member]
Dec. 31, 2012
Related to Conversion Feature [Member]
Individual Convertible Notes [Member]
Dec. 31, 2012
Warrant 1, Related to Individual Convertible Notes [Member]
Dec. 31, 2012
Warrant 2, Related to Individual Convertible Notes [Member]
Dec. 31, 2012
Warrants, Related to Individual Convertible Notes [Member]
Minimum [Member]
Dec. 31, 2012
Warrants, Related to Individual Convertible Notes [Member]
Maximum [Member]
Dec. 31, 2012
Warrants, Related to Individual Convertible Notes [Member]
Dec. 31, 2012
Chief Operating Officer [Member]
Individual Convertible Notes [Member]
Dec. 31, 2012
Chief Operating Officer [Member]
Jan. 03, 2012
TCA Global Credit Master Fund, LP [Member]
Dec. 31, 2012
TCA Global Credit Master Fund, LP [Member]
Dec. 31, 2012
Minimum [Member]
Dec. 31, 2011
Minimum [Member]
Dec. 31, 2012
Maximum [Member]
Dec. 31, 2011
Maximum [Member]
Dec. 31, 2012
Asher Notes 2012 [Member]
Dec. 31, 2012
TCA Note [Member]
Dec. 31, 2012
JMJ Note [Member]
Dec. 31, 2011
JMJ Note [Member]
Feb. 22, 2011
JMJ Note [Member]
Dec. 31, 2012
JMJ Note 2 [Member]
Dec. 31, 2011
JMJ Note 2 [Member]
Feb. 28, 2011
JMJ Note 2 [Member]
Dec. 31, 2012
Individual Convertible Notes [Member]
Proceeds from Notes Payable                                       $ 269,000                
Debt Instrument, Convertible, Conversion Price (in Dollars per share)                                       $ 0.00009                
Debt Instrument, Convertible, Beneficial Conversion Feature (in Dollars) 237,774 94,624                                   237,774 174,448             777,766
Amortization of Debt Discount (Premium) 1,428,978 489,080 1,861,218                                 170,844                
Debt Instrument, Convertible, Interest Expense 182,733 165,442 396,474     182,733                           118,268 174,448 80,000 263,309         885,418
Debt Instrument, Unamortized Discount 42,534 0 42,534                 42,534 42,534             66,930   106,691 186,691 450,000       55,952
Debt Conversion, Converted Instrument, Amount (in Dollars) 1,420,446 963,096   27,840 79,540                             357,000 162,835 15,498     500,000     856,501
Debt Conversion, Converted Instrument, Shares Issued (in Shares) 13,669,072 3,021,738   300,000 1,466,657                             4,952,916 1,601,255 180,000           6,934,901
Common Stock Purchase Agreement, Amount to be Purchased                           2,000,000                            
Facility Fee Payable                           100,000 48,076                          
Stock Issued During Period, Shares, New Issues (in Shares)                             559,268                          
Facility Fee Satisfied                             51,924                          
Convertible Notes Payable                       75,000 75,000               225,000 191,663 207,161 1,050,000 0 0 500,000  
Debt Instrument, Interest Rate, Stated Percentage                                         12.00%     8.00%     8.00% 8.00%
Proceeds from Issuance of Debt $ 1,450,501 $ 770,500 $ 2,976,001               $ 347,097                                 $ 956,501
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)             3,826,005 1,913,003                                        
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)             0.25 0.50                                        
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)                     $ 589,416                                  
Fair Value Assumptions, Risk Free Interest Rate                     3.90%         0.11% 0.17% 0.16% 0.19%                  
Fair Value Assumptions, Expected Volatility Rate                 155.60% 218.64%           130.00% 0.00% 219.00% 205.00%                  
Fair Value Assumptions, Expected Dividend Payments (in Dollars per share)                     $ 0                                  
Fair Value Assumptions, Expected Term                 109 days 1 year           3 days 0 years 2 years 36 days 3 years                  
XML 36 R53.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 15 - Restatement (Detail) - Reclassifications and Prior Period Adjustments (USD $)
 12 Months Ended 197 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Total current assets $ 790,047 $ 1,610,078 $ 790,047
Total current liabilities   2,855,821  
Total equity (3,616,504) (1,245,743) (3,616,504)
Research and development 35,544 57,000 2,935,949
General and administrative expenses 4,046,080 3,781,286 27,298,804
Net income available to common shareholders   (4,541,518)  
Income per common share – basic and diluted (in Dollars per share) $ (0.12) $ (0.09)  
Net cash used in operating activities (1,674,342) (2,563,073) (13,788,652)
Net cash used in investing activities (39,224) (129,091) (1,415,648)
Net cash provided by financing activities 1,708,776 2,627,491 15,204,354
Scenario, Previously Reported [Member]
      
Total current assets   1,978,711  
Total current liabilities   2,294,274  
Total equity   (315,563)  
Research and development   111,832  
General and administrative expenses   3,714,214  
Gain from litigation   311,000  
Net income available to common shareholders   (4,218,278)  
Income per common share – basic and diluted (in Dollars per share)   $ (0.09)  
Net cash used in operating activities   (3,010,275)  
Net cash used in investing activities   (471,347)  
Net cash provided by financing activities   3,416,949  
Restatement Adjustment [Member]
      
Total current assets   (368,633)  
Total current liabilities   561,547  
Total equity   (930,180)  
Research and development   (54,832)  
General and administrative expenses   67,072  
Gain from litigation   (311,000)  
Net income available to common shareholders   (323,240)  
Net cash used in operating activities   447,202  
Net cash used in investing activities   342,256  
Net cash provided by financing activities   $ (789,458)  
XML 37 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
Balance Sheets (USD $)
Dec. 31, 2012
Dec. 31, 2011
Current assets:    
Cash and cash equivalent $ 54 $ 4,844
Inventories 321,791  
Prepaid expenses and other current assets 4,859 279,868
Total current assets 326,704 284,712
Property and equipment, net 356,656 1,185,664
Intangibles 106,687 116,426
Goodwill   23,276
Total assets 790,047 1,610,078
Current liabilities:    
Accounts payable and accrued liabilities 1,122,371 468,468
Accounts payable and accrued liabilities, related parties 73,957 87,944
Payable for indemnification 1,347,806 1,424,019
Convertible notes, net of discounts of $187,039 and $307,126, respectively 184,289 80,535
Convertible notes, related parties, net of discount of $42,534 and $0, respectively 32,466  
Derivatives, note conversion feature 364,802 442,311
Total liabilities 4,406,551 2,855,821
Commitments and contingencies 0 0
Stockholders’ deficit:    
Series 2006 Preferred stock, $0.001 par value, 5,000,000 shares authorized; 1,000,000 shares issued and outstanding 1,000 1,000
Common stock, $0.001 par value; 250,000,000 shares authorized; 72,784,907 and 54,729,606 shares issued and outstanding, respectively. 72,785 54,730
Additional paid-in capital 34,319,432 29,497,937
Subscriptions receivable (71,000) (25,000)
Deficit accumulated during the development stage (37,938,721) (30,774,410)
Total stockholders' deficit (3,616,504) (1,245,743)
Total liabilities and stockholders’ deficit 790,047 1,610,078
Yeso Med [Member]
    
Current liabilities:    
Payable to Yeso-med $ 1,280,860 $ 352,544
XML 38 R45.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 9 - Derivatives - Note Conversion Feature (Detail) - Fair Value Assumptions, Derivative Liability
 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dividend Yield 0.00% 0.00%
Minimum [Member]
    
Risk free interest rate 0.11% 0.17%
Expected life (years) 3 days 0 years
Volatility 130.00% 0.00%
Maximum [Member]
    
Risk free interest rate 0.16% 0.19%
Expected life (years) 2 years 36 days 3 years
Volatility 219.00% 205.00%
XML 39 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
Statements of Cash Flows (USD $)
 12 Months Ended 197 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Cash flows from operating activities:      
Net loss $ (7,164,311) $ (4,541,518) $ (37,938,721)
Depreciation and amortization 102,971 17,023 205,111
Stock-based compensation expense 1,491,072 1,065,458 12,616,731
Stock option modification expense     50,000
Impairment of assets 878,276   4,570,007
Gain on disposal of assets     (794)
Amortization of debt discounts 1,428,978 489,080 1,861,218
Interest expense incurred on issuance of convertible debt 182,733 165,442 396,474
(Gain) loss on change in fair value of derivative liabilities (131,397) 119,138 45,976
Change in operating assets and liabilities:      
Inventories (321,791)   (321,791)
Prepaid expenses and other current assets 275,009 162,181 (4,859)
Accounts payable and accrued liabilities 1,533,758 (11,439) 3,074,372
Accounts payable and accrued liabilities – related parties (13,987) 63,659 73,957
Payable for indemnification 64,347 67,071 1,805,396
Net cash used in operating activities (1,674,342) (2,563,073) (13,788,652)
Cash flows from investing activities:      
Purchase of property and equipment   (31,777) (992,907)
Proceeds from sale of fixed assets     794
Purchase of license and patents (39,224) (97,314) (161,538)
Investment in Ives Health Company and The Health Club     (261,997)
Net cash used in investing activities (39,224) (129,091) (1,415,648)
Cash flows from financing activities:      
Capital contribution     802,154
Proceeds from issuance of common stock through cash- exercise of stock options and warrants 258,275 1,654,420 3,412,412
Proceeds from issuance of notes for cash 1,450,501 770,500 2,976,001
Proceeds from loans from shareholders     15,707
Repayment of loans from shareholders     (8,005)
Repayment of notes     (157,325)
Proceeds for issuance of common stock for cash   202,571 8,163,410
Net cash provided by financing activities 1,708,776 2,627,491 15,204,354
Net change in cash (4,790) (64,673) 54
Cash at beginning of period 4,844 69,517  
Cash at end of period 54 4,844 54
Supplemental disclosure of cash flow information:      
Interest paid 0 0 0
Taxes paid 0 0 0
Non-cash financing and investing activities:      
Common stock issued for conversion of debt 2,318,772 962,296 4,687,415
Shares issued for indemnification agreement 140,560 184,000 457,590
Debt discount on convertible notes 584,871 769,624 2,405,422
Common stock issued for investment     358,762
Preferred stock forfeited   500 500
Payable recorded for purchase of equipment   352,544 289,009
Ives Merger [Member]
      
Non-cash financing and investing activities:      
Common stock issued in connection with Merger     300
Clear Image Shareholders under Short Form Merger [Member]
      
Non-cash financing and investing activities:      
Common stock issued for acquisition of Clear Image     $ 3,093,948
XML 40 R35.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 3 - Property And Equipment (Detail) - Summary Of Property And Equipment (USD $)
Dec. 31, 2012
Dec. 31, 2011
Property and Equipment $ 446,382 $ 1,206,382
Less: accumulated depreciation (89,726) (20,718)
Property and equipment, net 356,656 1,185,664
Equipment [Member]
    
Property and Equipment 353,235 1,113,235
Leasehold Improvements [Member]
    
Property and Equipment 44,000 44,000
Furniture and Fixtures [Member]
    
Property and Equipment $ 49,147 $ 49,147
XML 41 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 1 - Summary Of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2012
Property, Plant and Equipment [Table Text Block]
   
December 31, 2012
   
December 31, 2011
 
Equipment
  $ 353,235     $ 1,113,235  
Leasehold improvement
    44,000       44,000  
Furniture
    49,147       49,147  
Subtotal
    446,382       1,206,382  
Less: accumulated depreciation
    (89,726 )     (20,718 )
Property and equipment, net
  $ 356,656     $ 1,185,664  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
   
Level 1
   
Level 2
   
Level 3
   
Total
 
Cash and cash equivalents
 
$
54
   
$
—
   
$
—
   
$
54
 
                                 
Derivative liability
 
$
—
   
$
—
   
$
364,802
   
$
364,802
 
   
Level 1
   
Level 2
   
Level 3
   
Total
 
Cash and cash equivalents
 
$
4,844
   
$
—
   
$
—
   
$
4,844
 
                                 
Derivative liability
 
$
—
   
$
—
   
$
442,311
    $
442,311
 
Estimated Useful Life [Member]
  
Property, Plant and Equipment [Table Text Block]
Asset Category
 
Useful Lives
Machinery and equipment (years)
 
5 
Furniture and fixtures (years)
 
7 
Leasehold improvements
 
Shorter of leasehold improvement life or remaining term of lease
XML 42 R36.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 4 - Intangibles And Goodwill (Detail) (USD $)
Share data in Millions, except Per Share data, unless otherwise specified
 12 Months Ended 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2007
Minimum [Member]
Clear Image [Member]
Dec. 31, 2007
Maximum [Member]
Clear Image [Member]
Dec. 31, 2012
Clear Image [Member]
Dec. 31, 2007
Clear Image [Member]
Dec. 31, 2012
Licensing Agreements [Member]
Impairment of Intangible Assets, Finite-lived             $ 15,000
Amortization of Intangible Assets 33,963 5,888          
Noncash or Part Noncash Acquisition, Interest Acquired           62.20%  
Stock Issued During Period, Shares, Acquisitions (in Shares)           8.2  
Share Price (in Dollars per share)     $ 0.40 $ 0.50      
Business Acquisition, Purchase Price Allocation, Goodwill Amount           23,276  
Goodwill, Impairment Loss         $ 23,276    
XML 43 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 4 - Intangibles And Goodwill (Tables)
 12 Months Ended
Dec. 31, 2012
Schedule of Finite-Lived Intangible Assets [Table Text Block]
   
December 31, 2012
   
December 31, 2011
 
Patent
  $ 146,538     $ 107,314  
Licensing agreement
    -       15,000  
Subtotal
    146,538       122,314  
Less: accumulated amortization
    (39,851 )     (5,888 )
Intangibles , net
  $ 106,687     $ 116,426  
XML 44 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 45 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 1 - Summary Of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2012
Significant Accounting Policies [Text Block]
NOTE 1 –DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization and Nature of Operations

Revolutions Medical Corporation, a Nevada corporation, (“the Company” or “RevMed”) has been endeavoring to design, develop and commercialize auto retractable vacuum safety syringes.  Our present product development effort is focused on the RevVac™ Auto Retractable Vacuum Safety Syringe, which is designed specifically to reduce accidental needle stick injuries and lower the spread of blood borne diseases.  The Company also has developed a suite of proprietary MRI software tools; RevColor™, Rev3D™, and RevDisplay™.  These tools are designed to enhance general diagnostic confidence through education and research use and in the future the Company believe will have specific commercial applications. The Company’s administrative facilities are located in Charleston, South Carolina. The Company’s primary manufacturing facility is located in Wuxi, China.

Development Stage Company

Since its inception in 1996, the Company has been considered a development stage enterprise for financial reporting purposes as significant efforts have been devoted to raising capital and to research and development of various safety syringes and its proprietary MRI software tools.

Accounting Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ significantly from those estimates.

Reclassification

Certain prior period amounts have been reclassified to conform to current period presentation.

Cash and Cash Equivalents

The Company considers highly liquid investments (those readily convertible to cash) purchased with original maturity dates of three months or less to be cash equivalents.

Accounts Receivable

The Company records trade receivables when revenue is recognized.  No product has been consigned to customers.  The Company’s allowance for doubtful accounts is primarily determined by review of specific trade receivables.  Those accounts that are doubtful of collection are included in the allowance.  These provisions are reviewed to determine the adequacy of the allowance for doubtful accounts.  Trade receivables are charged off when there is certainty as to their being uncollectible.  Trade receivables are considered delinquent when payment has not been made within contract terms.

The Company requires certain distributors to make a prepayment prior to beginning production or shipment of their order.  Distributors may apply such prepayments to their outstanding invoices or pay the invoice and continue to carry forward the deposit for future orders.  Such amounts are included in other accrued liabilities on the balance sheets.  The Company records an allowance for estimated returns as a reduction to accounts receivable and gross profit.  To date, returns have been immaterial.

Inventories

Inventories include only finished goods and are valued at the lower of cost or market, with cost being determined using weighted average cost.  The Company compares the average cost to the market price and records the lower value.  Management considers such factors as the amount of inventory on hand and in the distribution channel, estimated time to sell such inventory, the shelf life of inventory, and current market conditions when determining excess or obsolete inventories.  A reserve is established for any excess or obsolete inventories or they may be written off. For the years ended December 31, 2012 and 2011, no allowance for inventory was recorded.

Property and Equipment

Property and equipment, including significant improvements, are stated at cost. Expenditures for maintenance and repairs are charged to operating expenses as incurred. When properties are retired or otherwise disposed of, the cost of the asset and the related accumulated depreciation are removed from the accounts with the resulting gain or loss being reflected in results of operations.

Depreciation and amortization expense is recorded on a straight-line basis over the estimated useful life of the asset as listed below:

Asset Category
 
Useful Lives
Machinery and equipment (years)
 
5 
Furniture and fixtures (years)
 
7 
Leasehold improvements
 
Shorter of leasehold improvement life or remaining term of lease

Intangibles

Intangible assets include patents and trademarks, which are valued at acquisition through independent appraisals and amortized on a straight-line basis over periods varying from 17 to 20 years.

Impairment of Long-lived Assets

The Company reviews the carrying value of the long-lived assets periodically to determine if facts and circumstances exist that would suggest that assets might be impaired or that the useful lives should be modified. Among the factors the Company considers in making the evaluation are changes in market position and profitability. If facts and circumstances exist which may indicate impairment, the Company will prepare a projection of the undiscounted cash flows of the asset group and determine if the long-lived assets are recoverable based on these undiscounted cash flows. If impairment is indicated, an adjustment will be made to reduce the carrying amount of these assets to their fair value.

Research and Development

Research and development costs are expensed as incurred.  The Company incurred $35,544, $57,000 and $2,935,949 of research and development expenses for the years ended December 31, 2012 and 2011, and for the period from August 16, 1996 (inception) through December 31, 2012.

Beneficial Conversion Feature

From time to time, the Company may issue convertible notes that have conversion prices that create an embedded beneficial conversion feature on the issuance date. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of any attached equity instruments, if any related equity instruments were granted with the debt. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital.  The debt discount is amortized to interest expense over the life of the note using the effective interest method.

Derivative Instruments

Derivatives are measured at their fair value on the balance sheet.  In determining the appropriate fair value, the Company uses the Black-Scholes option pricing formula.  Changes in fair value are recorded in the statement of operations.

Fair Value of Financial Instruments

The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e. exit price), in an orderly transaction between market participants at the measurement date.  The Company categorizes its assets and liabilities measured at fair value based upon the level of judgment associated with the inputs used to measure the fair value. Level inputs are classified as follows:

 
·
Level 1 – quoted prices in active markets for identical assets or liabilities.

 
·
Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

 
·
Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.

The following table summarizes fair value measurements by level at December 31, 2012, for assets and liabilities measured at fair value on a recurring basis:

   
Level 1
   
Level 2
   
Level 3
   
Total
 
Cash and cash equivalents
 
$
54
   
$
—
   
$
—
   
$
54
 
                                 
Derivative liability
 
$
—
   
$
—
   
$
364,802
   
$
364,802
 

The following table summarizes fair value measurements by level at December 31, 2011, for assets and liabilities measured at fair value on a recurring basis:

   
Level 1
   
Level 2
   
Level 3
   
Total
 
Cash and cash equivalents
 
$
4,844
   
$
—
   
$
—
   
$
4,844
 
                                 
Derivative liability
 
$
—
   
$
—
   
$
442,311
    $
442,311
 

Revenue Recognition

Revenue is recognized for sales when title and risk of ownership passes to the customer, generally upon shipment from the manufacturing facility in Wuxi, China or from our warehouse facility in Ladson, South Carolina; when price is fixed or determinable; and when collection is reasonably assured.

Share-based Compensation

The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the trading price on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.

Income Taxes

The Company uses the liability method of accounting for income taxes.  Under the liability method, deferred taxes are determined based on the differences between the financial statement and tax basis of assets and liabilities at enacted tax rates in effect in the years in which the differences are expected to reverse.

Earnings (Loss) Per Common Share

Basic net income (loss) per common share is calculated by dividing net income (loss) available to common stockholders for the period by the weighted average shares of common stock outstanding during the period. Diluted net income per common share is computed by dividing the net income for the period by the weighted average number of common and common equivalent shares outstanding during the period. The calculation of diluted income (loss) per common share assumes the dilutive effect of stock options, warrants and any other potentially dilutive securities outstanding. During a loss period, the potentially dilutive securities have an anti-dilutive effect and are not included in the calculation of dilutive net loss per common share. For the year ended December 31, 2011, potentially issuable shares, including options and warrants to purchase 18,845,350 shares of the Company’s common stock and notes payable convertible to 4,637,152 shares of the Company’s common stock, have been excluded from the calculation. For the year ended December 31, 2012, potentially issuable shares, including options and warrants to purchase 14,980,000 shares of the Company’s common stock and notes payable convertible to 6,603,582  shares of the Company’s common stock have been excluded from the calculation.

Subsequent Events

The Company has evaluated all transactions occurring between the end of its fiscal year, December 31, 2012, through the date of issuance of the financial statements for subsequent event disclosure consideration.

New Accounting Standards

The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company.

XML 46 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
Balance Sheets (Parentheticals) (USD $)
Dec. 31, 2012
Dec. 31, 2011
Convertible promissory notes, discount (in Dollars) $ 187,039 $ 307,126
Convertible notes, related parties, discount (in Dollars) $ 42,534 $ 0
Preferred stock par value (in Dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 1,000,000 1,000,000
Preferred stock, shares outstanding 1,000,000 1,000,000
Common stock, par value (in Dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 250,000,000 250,000,000
Common stock, shares issued 72,784,907 54,729,606
Common stock, shares outstanding 72,784,907 54,729,606
XML 47 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 13 - Stock Options And Warrants Outstanding
 12 Months Ended
Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
NOTE 13 - STOCK OPTIONS AND WARRANTS OUTSTANDING

The Company’s 2007 Stock Option Plan, revised July 2011, permits the granting of stock options to its employees, directors, consultants and independent contractors for up to 20 million shares of its common stock.  The Company believes that such awards encourage employees to remain employed by the Company and also to attract persons of exceptional ability to become employees of the Company.  The plan allows the Company to issue either stock options or common shares.

During the year ended December 31, 2012, under the terms of the Company’s 2007 Stock Option Plan, 75,000 options were issued for consulting services exercisable at $0.25 per share, 300,000 options were issued for consulting services exercisable at $0.40 per share, and 2.5 million shares were issued to directors and an employee for service provided. The options have a term of 1~2 years and vest upon issuance. Fair value of $429,824 was calculated using the Black-Scholes Model with the following assumptions: (1) discount rate of 0.12% to 0.21% (2) expected life of 0.7 to 2.0 years (3) expected volatility of 159% to 161% and (4) zero expected dividends.

During the course of 2012 and 2011, the Company entered into several consulting agreements to perform marketing services for the Company as it begins to enter into the production stage for the RevVac™ safety syringe. Consultants are obligated under the contract to promote the product within various spheres of influence. These spheres of influence include, but are not limited to, medical product distributors, hospitals, doctors and government agencies.

Consultants are issued options at a discount to the market price at the date of issuance. These options must be exercised within a 10 day window from the time of issuance. The consultants therefore are committed to purchasing these options in order to enter into the consultant agreement and are obligated to adhere to the terms of the agreement. The agreements are recorded as a prepaid consulting expense upon the commencement of the agreement and expensed each quarter for the duration of the agreement. The amount to be determined for the consulting expense is determined based upon the options issued using the Black-Scholes model. Since the exercise window for these options is so short, the amount of the consulting expense is recorded as the difference between the exercise price and the market price as of the date of issuance. The Company also issued options with a term of 6 months to 1 year. Value for options with such term was calculated using Black-Scholes model.

The following tables summarize information about the stock options for the years ended December 31, 2012 and 2011:

   
Number of Units
   
Weighted
Average
Exercise Price
   
Weighted
Average
Remaining
Contractual
Term (in years)
   
Aggregate
Intrinsic Value
 
Outstanding, December 31, 2010
    12,834,750     $ 0.20       1.62     $ 2,708,463  
Granted
    9,307,000       0.34       1.02          
Exercised
    (6,668,000 )     0.25                  
Expired/ Forfeited
    -                          
Outstanding, December 31, 2011
    15,473,750       0.39       2.45       869,825  
Granted
    2,875,000       0.18       0.98          
Exercised
    (575,000 )      0.25                  
Expired/ Forfeited
    (5,673,750 )                        
Outstanding, December 31, 2012
    12,100,000       0.20       1.18       150,000  

The following tables summarize information about the warrants for the years ended  December 31, 2012 and 2011:

   
Number of Units
   
Weighted
Average
Exercise Price
   
Weighted
Average
Remaining
Contractual
Term (in years)
   
Aggregate
Intrinsic Value
 
Outstanding, December 31, 2010
    1,871,600     $ 0.50       3.45     $ -  
Granted
    1,500,000       0.50       1.00          
Exercised
    -                          
Expired/ Forfeited
    -                          
Outstanding, December 31, 2011
    3,371,600       0.39       2.45       -  
Granted
    5,739,008       0.33       0.15          
Exercised
    (660,000 )      0.50                  
Expired/ Forfeited
    (5,570,608 )                        
Outstanding, December 31, 2012
    2,880,000       0.33       0.30       -  

XML 48 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6
Document And Entity Information (USD $)
 12 Months Ended
Dec. 31, 2012
Apr. 22, 2013
Jun. 29, 2012
Document and Entity Information [Abstract]      
Entity Registrant Name Revolutions Medical CORP    
Document Type 10-K    
Current Fiscal Year End Date --12-31    
Entity Common Stock, Shares Outstanding   77,610,014  
Entity Public Float     $ 10,253,579
Amendment Flag false    
Entity Central Index Key 0001041009    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Filer Category Smaller Reporting Company    
Entity Well-known Seasoned Issuer No    
Document Period End Date Dec. 31, 2012    
Document Fiscal Year Focus 2012    
Document Fiscal Period Focus FY    
XML 49 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 14 - Related Party Transactions
 12 Months Ended
Dec. 31, 2012
Related Party Transactions Disclosure [Text Block]
NOTE 14 - RELATED PARTY TRANSACTIONS

In connection with the acquisition of Clear Image Acquisition Corp. by the Company, Rondald L. Wheet, Chairman and Chief Executive Officer, received 2,286,000 shares of restricted Company common stock.  Dr. Beahm, a Director, received 1,599,125 shares of restricted RevMed common stock, and Mr. O’Brien, a former Director, received 1,645,625 shares of restricted Company common stock.  Mr. Wheet and Mr. O’Brien were directors and shareholders and Dr. Beahm was a shareholder of Clear Image Acquisition Corp. prior to its acquisition by the Company.

The Company rents its office space from Osprey South, LLC. Rondald L. Wheet, Chief Executive Officer, is the sole member of Osprey.  Rent expense to Osprey was $120,000 and $99,608 for the years ended December 31, 2012 and 2011, respectively.  Rent payable to Osprey was $19,761 and $8,608 as of December 31, 2012 and 2011, respectively.

As of December 31, 2012, the Company had advances from Vincent Olmo, Chief Operating Officer, and Mr. Wheet of $9,194 and $32,502, respectively, for expenses paid on behalf of the Company. The Company also had a convertible note payable to Mr. Olmo with principal amount of $75,000 and debt discount of $42,534 at December 31, 2012.

At December 31, 2011, the Company had advances from Rhonda Vincent, former CFO, of $79,336 for expenses paid on behalf of the Company. Such payable has passed the statute of limitations and has been written off as of December 31, 2012.

XML 50 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
Statements of Operations (USD $)
 12 Months Ended 197 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Revenue $ 1,189   $ 1,189
Cost of revenue 9,200   9,200
Loss on firm purchase commitment 783,593   783,593
Cost of goods sold 792,793   792,793
Gross loss (791,604)   (791,604)
Research and development 35,544 57,000 2,935,949
Depreciation and amortization 102,971 17,023 205,111
General and administrative expenses 4,046,080 3,781,286 27,298,804
Impairment of assets 878,276   4,570,007
Gain on disposal of assets     (794)
Total operating expenses 5,062,871 3,855,309 35,009,077
Operating loss (5,854,475) (3,855,309) (35,800,681)
Interest income   10 17,286
Interest expense (1,727,512) (567,081) (2,629,705)
Investment income   0 170,753
Gain (loss) on extinguishment of debt 13,202   (139,712)
Gain (loss) on change in fair value of derivative liabilities 131,397 (119,138) (45,976)
Other income, net 273,077   305,892
Total other income (expense) (1,309,836) (686,209) (2,321,462)
Net loss (7,164,311) (4,541,518) (38,122,143)
Net loss attributable to the non-controlling interest     (183,422)
Net loss attributable to Revolutions Medical Corporation $ (7,164,311) $ (4,541,518) $ (37,938,721)
Weighted average common shares outstanding – basic and diluted (in Shares) 61,779,765 49,149,099  
Net loss per common share – basic and diluted (in Dollars per share) $ (0.12) $ (0.09)  
XML 51 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 7 - Convertible Notes Payable
 12 Months Ended
Dec. 31, 2012
Debt Disclosure [Text Block]
NOTE 7 – CONVERTIBLE NOTES PAYABLE

At December 31, 2012 and 2011, notes payable consisted of the following:

   
December 31,
2012
   
December 31,
2011
 
Convertible Promissory Note Payable to JMJ Financial, unsecured, one time interest charge of 8%, due on February 22, 2014
  $ 191,663     $ 207,161  
Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0% per annum, with payment due on April 26, 2012
    -       40,000  
Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0% per annum, with payment due on June 1, 2012
    -       45,000  
Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0% per annum, with payment due on August 7, 2012
    -       42,500  
Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0%  per annum, with payment due on September 19, 2012
    -       53,000  
Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0% per annum, with payment due on March 21, 2013, fully converted in January 2013
    7,500       -  
Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0%  per annum, with payment due on May 10, 2013
    42,500       -  
Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0%  per annum, with payment due on August 27, 2013
    42,500       -  
Convertible Promissory Note Payable to TCA Global Credit Master Fund, LP, secured by all of the Company’s assets, interest rate of 12.0%  per annum, with payment due on January 3, 2013
    62,165       -  
Convertible Promissory Note Payable issued in the course of a private placement to individuals, unsecured,  interest rate of 8.0%  per annum, with payment due on June 26, 2013
    100,000       -  
Total 
    446,328       387,661  
Less: debt discount
    (229,573 )     (307,126 )
    $ 216,755     $ 80,535  

Asher Enterprises

During the year ended December 31, 2012, the Company issued 6 convertible promissory notes to Asher Enterprises for total proceeds of $269,000 in cash (“2012 Asher Notes”). All of the notes were convertible to the Company’s common stock at a conversion price equal to the greater of (1) 55% multiplied by the average of the lowest 3 trading prices for the Company’s common stock during the 10 trading day period ending on the latest complete trading day prior to the conversion date market price and (2) a fixed conversion price of $0.00009 per share. The Company analyzed the conversion feature of the 2012 Asher Notes for derivative accounting consideration and determined that the conversion feature for the 2012 Asher Notes does not qualify for accounting treatment as a financial derivative. The 2012 Asher Notes have a beneficial conversion feature discount of $237,774, within which $170,844 has been amortized. During the year ended December 31, 2012, the Company also recorded interest expense of $118,268 related to the amortization of debt discount on notes issued in 2011 to Asher Enterprises. At December 31, 2012, there was $66,930 of unamortized discount related to the 2012 Asher Notes.

During the year ended December 31, 2012, Asher Enterprises converted principal of $357,000 with accrued interest into 4,952,916 shares of the Company’s common stock.

The 2012 Asher Notes are currently in default as a result of the Company’s failure to timely file its periodically report with the SEC.

TCA Global Credit Master Fund, LP

On January 3, 2012, the Company entered into a securities purchase agreement with TCA Global Credit Master Fund, LP (“TCA”), pursuant to which, TCA would purchase up to $2,000,000 of the Company’s common stock. The Company agreed to pay a $100,000 facility fee by issuing to TCA a number of the Company’s common shares (“facility shares”). To determine the number of shares issuable to TCA for the facility fee, the Company’s common stock was valued at a volume weighted average price at January 2, 2012. The facility shares should be adjusted 9 months after January 2, 2012 by the volume weighted average prices of the Company’s common stock 5 trading days prior to the revaluation date. On August 13, 2012, the Company and TCA agreed to terminate the committed equity financing agreement based on the Company’s failure to achieve bulletin board listing as required under the agreement. The Company has issued 559,268 common shares in 2012 to TCA which only satisfied $51,924 of the facility fee upon revaluation. As of December 31, 2012, accounts payable included $48,076 for the remaining payable to TCA related to the facility fee.

In connection with the securities purchase agreement with TCA, the Company issued a convertible promissory note to TCA for a principal amount of $225,000 (“TCA Note”).  The note bears interest at a rate of 12% per annum and provides for the payment of all principal and interest 12 months from the date of the note’s respective issuance.  The conversion price was determined by multiplying 95% by the average of the two lowest daily volume weighted average prices of the Company’s common stock on the OTC Markets during the 5 business days immediately preceding the date of conversion.    The Company analyzed the TCA Note for derivative accounting consideration and determined that the TCA Note qualifies for accounting treatment as a financial derivative. The conversion feature of the TCA note was valued at $174,448 on the issuance date and recorded as debt discount. During the year ended December 31, 2011, the Company recognized $174,448 of interest expense related to the amortization of the debt discount.

TCA converted principal of $162,835 into 1,601,255 shares of the Company’s common stock during 2012 and principal of $27,840 into 300,000 shares of the Company’s common stock on January 3, 2013.

JMJ Financial

On February 22, 2011, the Company issued a $1,050,000 convertible promissory note to JMJ Financial, Inc. (“JMJ”). The note bears interest in the form of a onetime interest charge of 8%, payable with the note’s principal amount on the maturity date, February 22, 2014. The note is convertible to the Company’s common stock at a price equal to 70% of the average of the 3 lowest closing prices of the Company’s common stock in the 20 trading days prior to the conversion date. In connection with the note, the Company entered into a registration rights agreement with JMJ to provide JMJ registration rights for common shares underlying this note. The note will only be funded when the conversion price calculated on each payment date is equal to or greater than $0.015 per share and there are sufficient shares remaining in the registration statement. During 2012, JMJ converted $15,498 under this agreement into 180,000 shares of the Company’s common stock. The principal amount owed to JMJ at December 31, 2012 and 2011, is $191,663 and $207,161, respectively, from the $1,050,000 convertible promissory note. The Company analyzed the JMJ note for derivative accounting consideration and determined that the note qualifies for accounting treatment as a financial derivative and recorded an initial discount of $450,000 on the issuance date. During the year ended December 31, 2012 and 2011, the Company recorded $80,000 and $263,309 of interest expense related to the amortization of the debt discount. At December 31, 2012 and 2011, there was $106,691 and $186,691, respectively, of unamortized debt discount related to the JMJ notes.

On February 28, 2011, the Company issued a $500,000 convertible promissory note to JMJ.  The note bears interest in the form of a onetime interest charge of 8%, payable with the note’s principle amount on the maturity date, February 28, 2014.  All or a portion of this note’s principle and interest is convertible at the option of JMJ from time to time, into shares of the Company’s common stock, originally fixed at a per share conversion price equal to 70% of the average of the 3 lowest closing prices for the Company’s common stock in the 20 trading days previous to the effective date of each such conversion. No amount is owed to JMJ from the $500,000 convertible promissory note at December 31, 2012 and 2011.

The Company is currently in litigation with JMJ. See Note 11.

Individual Convertible Notes Payable

During 2012, the Company issued 22 convertible notes payable to individuals for proceeds of $956,501 in cash (“Individual Convertible Notes”). The Individual Convertible Notes mature one year from the date of issuance. Interest accrues at the rate of 8% per year on the outstanding principal amount to be paid at maturity.

The principal amount of the Individual Convertible Notes and accrued interest are convertible into the Company’s common stock at a conversion price equal to 75% of the average of the daily volume weighted average prices of the Company's Common Stock during the 5 trading days immediately prior to the conversion date, provided that in no event, shall the note holders convert any portion of the Individual Convertible Notes when the sum of 1) the number of shares of common stock beneficially owned by the holder and its affiliates and 2) the number of shares of common stock issuable upon conversion would result in beneficial ownership by the holder and its affiliates of more than 4.99% of the Company’s outstanding common shares. During 2012, $856,501 of the Individual Convertible Notes with accrued interest were converted into 6,934,901 shares of the Company’s common stock. As of December 31, 2012, Individual Convertible Notes includes principal of $75,000 payable to Vincent Olmo, the Company’s COO, with a debt discount of $42,534.

In connection with the issuance of the Individual Convertible Notes, warrants to purchase 3,826,005 shares of the Company’s common stock at $0.25 per share and warrants to purchase 1,913,003 shares of the Company’s common stock at $0.50 per share were issued to investors. The warrants have a term of less than one year and expire on December 31, 2012, March 31, 2013, or June 30, 2013. $347,097 of the proceeds received from the Individual Convertible Notes was allocated to the warrants based on a grant date fair value of $589,416 calculated using a Black Scholes Model with the following assumptions: (1) 3.9% risk-free discount rate, (2) expected volatility of 155.60 ~218.64%, (3) $0 expected dividends, and (4) an expected term of 0.3~1 years based on the term of warrant.

The Company analyzed the Individual Convertible Notes for derivative accounting consideration and determined that the conversion feature of the Individual Convertible Notes qualify for accounting treatment as a financial derivative. The conversion feature of Individual Convertible Notes was valued at $777,766 on the issuance date. As a result, some of the Individual Convertible Notes were fully discounted and the fair value of the conversion feature in excess of the principal amount allocated to the Individual Convertible Notes of $182,733 was expensed immediately as additional interest expense. During the year ended December 31, 2012, the Company recognized $885,418 of interest expense related to the amortization of the debt discount. At December 31, 2012, there was $55,952 of unamortized discount related to the Individual Convertible Notes.

XML 52 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 5 - Accounts Payable And Accrued Liabilities
 12 Months Ended
Dec. 31, 2012
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
NOTE 5 – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

The following is a summary of the Company’s accounts payable and accrued liabilities at December 31, 2012 and 2011:

   
December 31, 2012
   
December 31, 2011
 
Accounts payable
  $ 432,436     $ 99,342  
Accrued payroll liabilities and related penalties
    411,670       125,239  
Accrued salary
    143,167       120,000  
Accrued interest
    134,559       64,670  
Other accruals
    539       59,217  
Total accounts payable and accrued liabilities
  $ 1,122,371     $ 468,468  

As of December 31, 2012 and 2011, the Company had accrued $411,670 and $125,239, respectively, pursuant to employment state and federal payroll tax liabilities and related penalties.  Although the Company plans to settle these amounts, there is no assurance that its efforts to settle will be successful.  A tax lien in the amount of $1,227 was filed against the Company on June 18, 2012 by the South Carolina Department of Revenue due to these delinquent payments.  Action by federal taxing authorities has not been initiated or threatened at this point.  There is no assurance, however, that such action will not be initiated in the future.

During the year ended December 31, 2012, the Company wrote off $199,336 of accrued salary to and advances from Rhonda Vincent, former CFO, and $79,890 of payables to various vendors as such claims have passed the statute of limitations in Oklahoma, where the Company formerly conducted operations.  Other income of $279,226 was recorded in the statement of operations.

Yeso Med [Member]
  
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
NOTE 6 – PAYABLE TO YESO-MED

On December 1, 2011, the Company entered into a 5-year agreement with Wuxi Yushou Medical Appliance Co., Ltd (“Yeso-med”). Pursuant to the agreement, commencing from the date that Yeso-med demonstrates to the Company’s satisfaction that it has the capacity to commence regular production of the syringes in the 3ml size in the minimum amount of at least 2,500,000 units per month, the Company will place orders of at least 2,500,000 units per month for the term of this agreement. If the Company does not place with Yeso-med the minimum order for a single month, Yeso-med shall have the right to receive payments from the Company equal to 50% of the supply price of each unit below the minimum order amount required for that month.  The Company has the right to have the amount paid under this requirement to serve as payment against future orders provided the quantity ordered exceeds the minimum quantity for that month. In July 2012, Yeso-med met the capacity requirement. However, the Company has not yet placed any order after July 2012.  As of December 31, 2012, a payable was recorded to Yeso-med related to this minimum purchase requirement of $783,593. During the year ended December 31, 2012, $783,593 was recorded as a loss on firm purchase commitments.

The payable to Yeso-med also included amounts due for product purchased of $208,258 as of December 31, 2012 and amounts due for equipment purchased of $289,009 and $352,544 as of December 31, 2012 and 2011, respectively.

XML 53 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 3 - Property And Equipment (Tables)
 12 Months Ended
Dec. 31, 2012
Property, Plant and Equipment [Table Text Block]
   
December 31, 2012
   
December 31, 2011
 
Equipment
  $ 353,235     $ 1,113,235  
Leasehold improvement
    44,000       44,000  
Furniture
    49,147       49,147  
Subtotal
    446,382       1,206,382  
Less: accumulated depreciation
    (89,726 )     (20,718 )
Property and equipment, net
  $ 356,656     $ 1,185,664  
XML 54 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 15 - Restatement
 12 Months Ended
Dec. 31, 2012
Reclassifications [Text Block]
NOTE 15 – RESTATEMENT

The Company restated its December 31, 2011 balance sheet and the statements of operations, changes in equity, and cash flows for the year ended December 31, 2011 to reflect the following adjustments:

 
·
The reclassification of subscription receivable from shareholder of $25,000 to contra equity (originally reported as other current assets).

 
·
The elimination of $311,000 gain from litigation and the corresponding amount reflected as due from litigation as the collectability of the gain is not certain.

 
·
The decrease of $32,633 prepaid consulting expense which represents the difference between the valuation of warrants  based on the Black-Scholes Model and the original valuation improperly determined using intrinsic value.

 
·
The increase in payable for indemnification of $616,379 which represents Gifford Mabie’s federal and state tax liability retained by the brokerage firm and remitted to the Internal Revenue Service and the increase of indemnification expenses of $67,072 for the change in the value of stock issued to the special brokerage for the benefit of Gifford Mabie.

 
·
To decrease a payable to SON Medical for $54,832 for services never performed.

The impact of the reclassifications and prior period adjustments on the accompanying balance sheet at December 31, 2011 is as follows:

   
As Originally
Reported
   
Change
   
As Restated
 
Total current assets
  $ 1,978,711     $ (368,633 )   $ 1,610,078  
Total current liabilities
    2,294,274       561,547       2,855,821  
Total equity
    (315,563 )     (930,180 )     (1,245,743 )

The impact of the reclassifications and prior period adjustments on the accompanying statement of operations for the year ended December 31, 2011 are as follows:

   
As Originally
Reported
   
Change
   
As Restated
 
Research and development
  $ 111,832     $ (54,832 )   $ 57,000  
General and administrative expenses
    3,714,214       67,072       3,781,286  
Gain from litigation
    311,000       (311,000 )     -  
Net income available to common shareholders
    (4,218,278 )     (323,240 )     (4,541,518 )
Income per common share – basic and diluted
    (0.09 )             (0.09 )

The impact of the reclassifications and prior period adjustments on the accompanying statement of cash flows for the year ended December 31, 2011 is as follows:

   
As Originally
Reported
   
Change
   
As Restated
 
Net cash used in operating activities
  $ (3,010,275 )   $ 447,202     $ (2,563,073 )
Net cash used in investing activities
    (471,347 )     342,256       (129,091 )
Net cash provided by financing activities
    3,416,949       (789,458 )     2,627,491  

XML 55 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 11 - Commitments And Contingencies
 12 Months Ended
Dec. 31, 2012
Commitments and Contingencies Disclosure [Text Block]
NOTE 11 – COMMITMENTS AND CONTINGENCIES

MIG and SPD

On January 2, 2013, the Company won its arbitration proceeding concerning its counter claims against Richard Theriault, former manufacturer MIG and former consultant, Strategic Product Development ("SPD").  The monetary award included $770,000 in recoupment of production costs plus interest, legal fees and other arbitration costs, which will total close to $1 million. In other claims, Theriault was found guilty of fraud in the inducement and breach of contract and was found to have no rights to any of the Company's proprietary technology, files, drawings, designs, patents or products. The ruling determined that all production mold payments made by the Company to MIG for the manufacturing of production molds had instead been used by Mr. Theriault for other non-production related purposes. The panel of American Arbitration Association ruled that the only assets in which production was funded by MIG from the Company’s production payments were $50,000 in trial molds. The equipment asset on the balance sheet has been reduced by $710,000 and charged to impairment for the payments no longer associated with a production or trial mold. The $770,000 award is for the recovery of damages related to these production payments.  The gain related to this award will be recorded when collected. The Company has hired legal counsel in Massachusetts and South Carolina to assist in efforts to collect these damages.

On September 26, 2012, the Company filed suit in South Carolina Federal District Court against SPD, Richard H. Theriault, Vita S. Theriault, Darius R. Theriault, Raminta Theriault, Goddard Technologies, Inc. ("GTI") and others, claiming that the defendants purposely and materially misled and misrepresented capabilities and progress on a variety of initiatives related to the development and manufacture of the Company's RevVac™ Auto-Retractable Vacuum safety syringe to officers and directors of Revolutions Medical, which caused a delay in its production of approximately one year. The suit further alleges that Richard H. Theriault and other defendants defrauded the Company and misappropriated funds in violation of the United States' Racketeer Influenced and Corrupt Organizations ("RICO") Act and that GTI improperly assigned certain rights to the Company's new provisional patents to SPD without authorization. On February 2, 2013, Richard H. Theriault filed for bankruptcy in Massachusetts under Chapter 11.  The South Carolina lawsuit has been temporarily stayed until such time when the arbitration award against Richard H. Theriault and MIG can be ruled on in United States Federal District Court in Massachusetts, seeking judgment outside the bankruptcy court. On March 13, 2013, United States Federal District Court in Massachusetts granted an injunction against Richard H. Theriault and MIG, enjoining and restraining them from transferring or alienating any assets in their possession without approval from the Court and a hearing has been scheduled for May 7, 2013.

JMJ Financial, Inc.

On March 12, 2012, the Company filed a lawsuit against Justin Keener and JMJ in Charleston County, South Carolina.  The Company sought a rescission and financial relief for the convertible debt agreement signed February 22, 2011. The Company claimed that it was unable to deliver the shares requested in the common stock conversion requests dated January 9, 2012 for 1,000,000 shares and January 30, 2012 for 1,226,049 shares due to the risk of defaulting on the convertible debt agreement by losing Depository Trust Company “DTC” eligibility. The contract stated that the Company would be considered in default of the agreement if the Company lost DTC eligibility due to a “chill” placed upon the electronic transfer of the stock. The Company had previously been made aware of other companies that had entered into similar agreements losing DTC eligibility and felt that JMJ had put the Company in an untenable position of either defaulting by losing DTC eligibility or defaulting by failing to issue the requested shares.  The Company claimed that JMJ’s unreasonably high demands for conversion caused a “frustration” of the principal purpose of the contract and supports the rescission of the contract and a return of the parties to their respective positions before the contract was signed.  On April 12, 2012 the Company withdrew the lawsuit filed in South Carolina to pursue its rights and counterclaims in Miami-Dade County, Florida, described below.

The Company also claims the default notice issued by JMJ obligated the Company to pay JMJ the outstanding principal balance under the note along with the accrued and unpaid interest. The principal balance due at the time JMJ issued the default notice amounted to $191,663.  The Company disputes JMJ’s claims that the Company was liable for a sum far in excess of this amount based upon the default provision of the contract.

A lawsuit was filed against the Company by JMJ in Miami-Dade County, Florida on March 15, 2012. The lawsuit claims that the Company breached the terms of the convertible debt agreement by failing to issue shares requested in a stock conversion by JMJ on January 9, 2012 for 1,000,000 shares and on January 30, 2012 for 1,226,049 shares.  JMJ is seeking the delivery of 2,226,049 shares of common stock of the Company, plus costs and prejudgment interest. On August 30, 2012, the Company filed its counterclaims against JMJ which included Fraud by Concealment, among other claims. The Company alleges that Keener and JMJ had a responsibility and obligation under Florida law to disclose not to conceal during the negotiations of the agreement the fact that Keener and JMJ had outstanding and current issues with these type of convertible notes with DTC which could do detrimental harm to liquidity and electronic transfer of the Company's stock if DTC eligibility was "chilled". This would severely hamper future capital raises and harm its current shareholders but would solely benefit Keener and JMJ under the default clauses in this agreement.

SEC

The SEC filed a civil complaint in Federal District Court in Georgia against the Company, alleging that the Company issued four misleading press releases during the period from August 2010 through October 2010 and one misleading press release in July 2011, related to the Company’s production schedule of its auto retractable safety syringe. The SEC names the Company’s current Chief Executive Officer, Rondald L. Wheet, as a co-defendant. Among other relief, the SEC seeks an order requiring the defendants to disgorge money received from its equity line financing from August 2010 through May 2011, in addition to other civil penalty amounts.  The Company believes that these claims are unfounded and is vigorously defending against them; however, should the Company not prevail in such defense the amount of damages owed to the SEC could be substantial and could adversely affect the Company’s financial condition or cause the Company to cease operations.

Employment Agreements

Effective May 15, 2012, the Company and Mr. Wheet, Chief Executive Officer, entered into a 2-year employment agreement.  The agreement provides for an annual salary of $247,500 and other reasonable and customary fringe benefits.

Effective April 11, 2011, the Company and Mr. Olmo, Chief Operating Officer, entered into a 3-year employment agreement. The agreement provides for an annual salary of $165,000 modified with a cost of living adjustment annually and other reasonable and customary fringe benefits.  

Effective June 1, 2011, the Company and Mr. Hodges, Chief Financial Officer, entered into a 3-year employment agreement. The agreement provides for an annual salary of $165,000 modified with a cost of living adjustment annually and other reasonable and customary fringe benefits.  

Lease Agreement

On September 1, 2009, the Company entered into a 5-year lease agreement with Osprey South, LLC (“Osprey”), to lease the property at 670 Marina Drive, Suite 301, Building F, Charleston, South Carolina, 29492.  Pursuant to the lease agreement, the Company was to pay Osprey $4,500 per month.  On July 1, 2011, the Company amended the lease agreement to include the office space adjacent to the existing office space. According to the amended lease agreement, the lease ends on July 1, 2016, and the Company is to pay Osprey $10,000 per month.  Rondald L. Wheet, our Chairman and Chief Executive Officer, is the sole member of Osprey.

XML 56 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 8 - Payable for Indemnification
 12 Months Ended
Dec. 31, 2012
Payable for Indemnification [Member]
  
Short-term Debt [Text Block]
NOTE 8 – PAYABLE FOR INDEMNIFICATION

On February 5, 2009, the Company entered into an Indemnification Settlement Agreement with Gifford M. Mabie, founder and former Chief Executive Officer of the Company. Pursuant to the agreement, the Company agreed to indemnify Mr. Mabie for the payment of penalties, prejudgment interest and post-judgment interest to the United States Securities and Exchange Commission (“SEC”) that is part of the Final Judgment, dated March 11, 2005, in SEC v. Maxxon, Inc., Gifford M. Mabie, Jr., Thomas R. Coughlin, Jr. 02-CV-975-H(J) which resulted from actions taken in good faith by Mabie and Coughlin in the performance of duties as an officer and directors of the Company.  The payment amount stated in the Final Judgment is $1,088,067.

The agreement specifies that the Company is to periodically issue shares to a special account for Gifford Mabie in order that shares can be sold each day the market is open until the liability is satisfied.  The special account was initially funded by the Company’s common stock owned by Mr. Mabie. Total amount of stock traded by the special account is limited to 5% of the total trading volume each day. A percentage equal to Mr. Mabie’s federal and state tax liabilities to a maximum of 40% will be retained by the brokerage firm and remitted to the Internal Revenue Service and to the Oklahoma Tax Commission or the Tax Commission where Mr. Mabie resides. If Mr. Mabie receives a tax refund, that refund will be forwarded to the SEC.

On December 14, 2010, the Company issued 400,000 shares of the Company’s common stock, initially valued at $184,000, to the special account. An additional 400,000 shares were issued to the special account on March 15, 2012 with an initial value of $140,560 determined based upon the 10-day average share price prior to the date of issuance.  At each reporting date, the Company revalues the shares held in the special account and adjusts the outstanding balance. Net increases and decreases in the value of the Company’s common shares held in the special account are recorded in the current period statement of operations. As of December 31, 2012, the remaining principal balance, including the estimated taxes, to be paid was $1,347,806 based upon the Company’s valuation of the stock. For the years ended December 31, 2012 and 2011, net loss related to the stock held in the special account was $63,347 and $67,071, respectively.

Note Conversion Feature [Member]
  
Short-term Debt [Text Block]
NOTE 9 – DERIVATIVES – NOTE CONVERSION FEATURE

Due to the conversion feature contained in some of the notes the Company issued, the actual number of shares of common stock that would be required if a conversion of the notes was made through the issuance of the Company’s common stock cannot be predicted, and the Company could be required to issue an amount of shares that may cause it to exceed its authorized share amount. As a result, the conversion feature requires derivative accounting treatment and will be bifurcated from the note and “marked to market” each reporting period through the income statement. The fair value of the conversion future of these notes was recognized as a derivative liability instrument and will be measured at fair value at each reporting period. In determining the fair value, the Company uses the Black-Scholes option-pricing model. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option-pricing model.

The following is a reconciliation of the derivative liability:

Fair value at December 31, 2010
 
$
160,659
 
Issuance of instruments
   
840,442
 
Decrease in value
   
(40,030
)
Reclassification from liability to equity as a result of note conversions
   
(518,760
)
Fair value at December 31, 2011
   
442,311
 
Issuance of instruments
   
952,214
 
Decrease in value
   
(131,397
)
Reclassification from liability to equity as a result of note conversions
   
(898,326
)
Fair value at December 31, 2012
 
$
364,802
 

The derivative liability was valued under the Black-Scholes model with the following assumptions:

  2012   2011  
Risk free interest rate
0.11%
to
0.16%   0.17%
to
0.19%  
Expected life (years)
0.01
to
2.1   0
to
3  
Dividend Yield
 
0%
      0%    
Volatility
130%
to
219%   0%
to
205%  

XML 57 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 10 - Maxxon/Globe Joint Venture Agreement
 12 Months Ended
Dec. 31, 2012
Equity Method Investments and Joint Ventures Disclosure [Text Block]
NOTE 10 - MAXXON/GLOBE JOINT VENTURE AGREEMENT

In September 2005, the Company filed a patent on its RevVac™ safety syringe with Globe Med Tech which gives a 50% ownership of this patent to the Company and 50% to Globe Med Tech. On November 3, 2005, the Company (f.k.a. Maxxon, Inc.,) and Globe Med Tech, Inc. (“Globe”) entered into a definitive joint venture agreement to patent, develop, manufacture, market and distribute safety needle products throughout the world.  The Company and Globe each own 50% of the joint venture.  The Company contributed its safety syringe technology and patent rights related thereto and Globe contributed its safety syringe IV catheter and patent rights related thereto.  In connection with the agreement, the Company issued restricted shares of its common stock, valued at $625,066, to Globe.  Subsequent to December 31, 2006, the Company ended the joint venture and cancelled the shares of common stock and options that were issued to Globe pursuant to the agreement.  This patent was issued January 13, 2009.

On March 1, 2007, the Company filed a lawsuit in the District Court of Tulsa County, Oklahoma against Globe to rescind, terminate and seek monetary damages for the non-fulfillment and breach of a joint venture agreement entered into November 3, 2005, and other related agreements, in addition to an accounting of expenditures of funds under the terms and provisions of the agreements.  On October 29, 2008, the Company filed in the District Court of Harris County, Texas, a lawsuit for fraud and contempt of court for Globe and Andy Hu, individually.  On October 21, 2011, the Company was granted its request for summary judgment against Globe and awarded $311,440 and the return of 266,667 shares of the Company’s common stock by a Federal District Court in Tulsa County, Oklahoma.  In addition to the monetary award and the return of the Company’s common stock, Globe is also required to return all syringes, design files, and sample molds to the Company.  Furthermore, the Court ordered that Globe assign to the Company all rights to the January 2009 United States patent issued for the RevVac™ auto-retractable vacuum safety syringe.  Globe is prohibited from claiming any interest or ownership in the Company’s safety vacuum syringes going forward in the future.

On December 13, 2011, the Supreme Court of Oklahoma denied Globe’s appeal. On January 30, 2013, the court ordered a Nunc Pro Tunc decision denying all counterclaims and third party claims by Globe. Globe filed another appeal on March 1, 2013. The Company has hired legal counsel in Texas to assist in efforts to collect these damages and execute on the court order.

XML 58 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 12 - Preferred Stock And Common Stock Transactions
 12 Months Ended
Dec. 31, 2012
Stockholders' Equity Note Disclosure [Text Block]
NOTE 12 - PREFERRED STOCK AND COMMON STOCK TRANSACTIONS

PREFERRED STOCK

Shares Outstanding: Currently, 1,000,000 shares of preferred stock (“Preferred Stock”) are outstanding. Rondald L. Wheet, our Chief Executive Officer, owns 1,000,000 shares of Series 2006 Preferred Stock. Tom O’Brien, our former President, returned 500,000 shares of Series 2009 Preferred Stock upon his resignation in 2011.

Dividends: The holder of the Preferred Stock is entitled to receive, ratably, dividends when, as and if declared by the board of directors out of funds legally available therefore. If any dividend or other distributions are declared on our common stock, then a dividend or other distribution must also be declared on the outstanding Preferred Stock at the same time and on the same terms and conditions, so that each holder of Preferred Stock will receive the same dividend or distribution such holder would have received if the holder had converted his Preferred Stock as of the record date for determining stockholders entitled to receive such dividend or distribution.

Liquidation Preference: In the event of the liquidation, dissolution or winding up, the holders of Preferred Stock are entitled to receive a liquidation preference of $0.001 for each share of Preferred Stock prior to payment being made to any junior stock.

Conversion: The holders of Preferred Stock may convert each share into 1 share of common stock.

Preemption: The holders of Preferred Stock have no preemptive rights and they are not subject to further calls or assessments.

Voting Rights: The holders of Preferred Stock are entitled to 125 votes for each share of common stock into which their Preferred Stock is then convertible (currently 1 share), voting together with our common stock as a single class. Cumulative voting is not permitted. Upon conversion of a share of Preferred Stock, each share of common stock issued upon the conversion will be entitled to only one vote per share.

Redemption: There are no redemption or sinking fund provisions applicable to the Preferred Stock.

2012 COMMON STOCK TRANSACTIONS

During the year ended December 31, 2012, 400,000 shares were issued under the terms of the SEC settlement agreement with Gifford Mabie.  The initial value of these shares totaled $140,560.

In the year ended December 31, 2012, the Company issued 2,751,229 shares of common stock with a total value of $516,111 for outside services.

Also, in the year ended December 31, 2012, the Company issued 1,235,000 shares of common stock for the exercise of warrants and options. The Company received cash of $258,275 and recorded a subscription receivable of $46,000.

Also, in the year ended December 31, 2012, the Company issued 13,669,072 shares of common stock for the conversions of convertible notes and accrued interest totaling $1,420,446. The derivative fair value of $898,326 for the conversion feature of these notes was reclassified on the date of conversion to additional paid-in capital.

2011 COMMON STOCK TRANSACTIONS

During the year ended December 31, 2011, 6,668,000 shares of common stock were issued as option holders exercised their options to purchase common stock receiving proceeds of $1,654,420.  Of these options exercised, 2,000,000 options were exercised by our former President, Tom O’Brien at $0.08 per share. The remainder of the options exercised was due from consultants according to the terms of their consulting agreements. 656,015 shares were issued to third party investors and investors under the terms of a Drawdown Equity Financing Agreement. The Company received net proceeds of $202,571 in connection with these share issuances.

Also during the year ended December 31, 2011, the Company issued 1,513,874 shares of common stock with a total value of $481,100 in lieu of cash as payment for outside services.

During the year ended December 31, 2011, the Company issued 3,021,738 shares of common stock for conversions of notes and accrued interest. In connection with the conversions, the reclassification of the derivative fair value related to note conversion feature totaled $963,096.

XML 59 R34.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 3 - Property And Equipment (Detail) (USD $)
 12 Months Ended 197 Months Ended 1 Months Ended 11 Months Ended 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Jan. 02, 2013
Dec. 31, 2012
Mold Production Payments [Member]
Nov. 30, 2012
Mold Production Payments [Member]
Dec. 31, 2012
Mold Production Payments [Member]
Jan. 02, 2013
Mold Production Payments [Member]
Dec. 31, 2011
Mold Production Payments [Member]
Dec. 31, 2012
Medical Investment Group (MIG) [Member]
Depreciation $ 69,008 $ 11,135                
Asset Impairment Charges 878,276   4,570,007   50,000 710,000 710,000      
Property, Plant and Equipment, Gross 446,382 1,206,382 446,382   50,000   50,000 50,000 760,000  
Prepayment Write Off             80,000      
Gain Contingency, Unrecorded Amount       $ 770,000           $ 770,000
XML 60 R51.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 14 - Related Party Transactions (Detail) (USD $)
 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Debt Instrument, Unamortized Discount $ 42,534 $ 0
Chief Executive Officer [Member]
    
Stock Issued During Period, Shares, New Issues (in Shares) 2,286,000  
Due to Related Parties 32,502  
Director [Member]
    
Stock Issued During Period, Shares, New Issues (in Shares) 1,599,125  
Former Director [Member]
    
Stock Issued During Period, Shares, New Issues (in Shares) 1,645,625  
Osprey South, LLC [Member]
    
Operating Leases, Rent Expense 120,000 99,608
Accrued Rent 19,761 8,608
Chief Operating Officer [Member]
    
Due to Related Parties 9,194  
Convertible Notes Payable 75,000  
Debt Instrument, Unamortized Discount 42,534  
Former CFO [Member]
    
Due to Related Parties   $ 79,336
XML 61 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6
Accounting Policies, by Policy (Policies)
 12 Months Ended
Dec. 31, 2012
Use of Estimates, Policy [Policy Text Block]
Accounting Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ significantly from those estimates.
Reclassification, Policy [Policy Text Block]
Reclassification

Certain prior period amounts have been reclassified to conform to current period presentation.
Cash and Cash Equivalents, Policy [Policy Text Block]
Cash and Cash Equivalents

The Company considers highly liquid investments (those readily convertible to cash) purchased with original maturity dates of three months or less to be cash equivalents.
Trade and Other Accounts Receivable, Policy [Policy Text Block]
Accounts Receivable

The Company records trade receivables when revenue is recognized.  No product has been consigned to customers.  The Company’s allowance for doubtful accounts is primarily determined by review of specific trade receivables.  Those accounts that are doubtful of collection are included in the allowance.  These provisions are reviewed to determine the adequacy of the allowance for doubtful accounts.  Trade receivables are charged off when there is certainty as to their being uncollectible.  Trade receivables are considered delinquent when payment has not been made within contract terms.

The Company requires certain distributors to make a prepayment prior to beginning production or shipment of their order.  Distributors may apply such prepayments to their outstanding invoices or pay the invoice and continue to carry forward the deposit for future orders.  Such amounts are included in other accrued liabilities on the balance sheets.  The Company records an allowance for estimated returns as a reduction to accounts receivable and gross profit.  To date, returns have been immaterial.
Inventory, Policy [Policy Text Block]
Inventories

Inventories include only finished goods and are valued at the lower of cost or market, with cost being determined using weighted average cost.  The Company compares the average cost to the market price and records the lower value.  Management considers such factors as the amount of inventory on hand and in the distribution channel, estimated time to sell such inventory, the shelf life of inventory, and current market conditions when determining excess or obsolete inventories.  A reserve is established for any excess or obsolete inventories or they may be written off. For the years ended December 31, 2012 and 2011, no allowance for inventory was recorded.
Property, Plant and Equipment, Policy [Policy Text Block]
Property and Equipment

Property and equipment, including significant improvements, are stated at cost. Expenditures for maintenance and repairs are charged to operating expenses as incurred. When properties are retired or otherwise disposed of, the cost of the asset and the related accumulated depreciation are removed from the accounts with the resulting gain or loss being reflected in results of operations.

Depreciation and amortization expense is recorded on a straight-line basis over the estimated useful life of the asset as listed below:

Asset Category
 
Useful Lives
Machinery and equipment (years)
 
5 
Furniture and fixtures (years)
 
7 
Leasehold improvements
 
Shorter of leasehold improvement life or remaining term of lease
Intangible Assets, Finite-Lived, Policy [Policy Text Block]
Intangibles

Intangible assets include patents and trademarks, which are valued at acquisition through independent appraisals and amortized on a straight-line basis over periods varying from 17 to 20 years.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]
Impairment of Long-lived Assets

The Company reviews the carrying value of the long-lived assets periodically to determine if facts and circumstances exist that would suggest that assets might be impaired or that the useful lives should be modified. Among the factors the Company considers in making the evaluation are changes in market position and profitability. If facts and circumstances exist which may indicate impairment, the Company will prepare a projection of the undiscounted cash flows of the asset group and determine if the long-lived assets are recoverable based on these undiscounted cash flows. If impairment is indicated, an adjustment will be made to reduce the carrying amount of these assets to their fair value.
Research and Development Expense, Policy [Policy Text Block]
Research and Development

Research and development costs are expensed as incurred.  The Company incurred $35,544, $57,000 and $2,935,949 of research and development expenses for the years ended December 31, 2012 and 2011, and for the period from August 16, 1996 (inception) through December 31, 2012.
Derivatives, Policy [Policy Text Block]
Derivative Instruments

Derivatives are measured at their fair value on the balance sheet.  In determining the appropriate fair value, the Company uses the Black-Scholes option pricing formula.  Changes in fair value are recorded in the statement of operations.
Fair Value Measurement, Policy [Policy Text Block]
Fair Value of Financial Instruments

The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e. exit price), in an orderly transaction between market participants at the measurement date.  The Company categorizes its assets and liabilities measured at fair value based upon the level of judgment associated with the inputs used to measure the fair value. Level inputs are classified as follows:

 
·
Level 1 – quoted prices in active markets for identical assets or liabilities.

 
·
Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

 
·
Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.

The following table summarizes fair value measurements by level at December 31, 2012, for assets and liabilities measured at fair value on a recurring basis:

   
Level 1
   
Level 2
   
Level 3
   
Total
 
Cash and cash equivalents
 
$
54
   
$
—
   
$
—
   
$
54
 
                                 
Derivative liability
 
$
—
   
$
—
   
$
364,802
   
$
364,802
 

The following table summarizes fair value measurements by level at December 31, 2011, for assets and liabilities measured at fair value on a recurring basis:

   
Level 1
   
Level 2
   
Level 3
   
Total
 
Cash and cash equivalents
 
$
4,844
   
$
—
   
$
—
   
$
4,844
 
                                 
Derivative liability
 
$
—
   
$
—
   
$
442,311
    $
442,311
Revenue Recognition, Policy [Policy Text Block]
Revenue Recognition

Revenue is recognized for sales when title and risk of ownership passes to the customer, generally upon shipment from the manufacturing facility in Wuxi, China or from our warehouse facility in Ladson, South Carolina; when price is fixed or determinable; and when collection is reasonably assured.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]
Share-based Compensation

The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the trading price on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.
Income Tax, Policy [Policy Text Block]
Income Taxes

The Company uses the liability method of accounting for income taxes.  Under the liability method, deferred taxes are determined based on the differences between the financial statement and tax basis of assets and liabilities at enacted tax rates in effect in the years in which the differences are expected to reverse.
Earnings Per Share, Policy [Policy Text Block]
Earnings (Loss) Per Common Share

Basic net income (loss) per common share is calculated by dividing net income (loss) available to common stockholders for the period by the weighted average shares of common stock outstanding during the period. Diluted net income per common share is computed by dividing the net income for the period by the weighted average number of common and common equivalent shares outstanding during the period. The calculation of diluted income (loss) per common share assumes the dilutive effect of stock options, warrants and any other potentially dilutive securities outstanding. During a loss period, the potentially dilutive securities have an anti-dilutive effect and are not included in the calculation of dilutive net loss per common share. For the year ended December 31, 2011, potentially issuable shares, including options and warrants to purchase 18,845,350 shares of the Company’s common stock and notes payable convertible to 4,637,152 shares of the Company’s common stock, have been excluded from the calculation. For the year ended December 31, 2012, potentially issuable shares, including options and warrants to purchase 14,980,000 shares of the Company’s common stock and notes payable convertible to 6,603,582  shares of the Company’s common stock have been excluded from the calculation.
Subsequent Events, Policy [Policy Text Block]
Subsequent Events

The Company has evaluated all transactions occurring between the end of its fiscal year, December 31, 2012, through the date of issuance of the financial statements for subsequent event disclosure consideration.
New Accounting Pronouncements, Policy [Policy Text Block]
New Accounting Standards

The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company.
Beneficial Conversion Feature [Member]
  
Derivatives, Policy [Policy Text Block]
Beneficial Conversion Feature

From time to time, the Company may issue convertible notes that have conversion prices that create an embedded beneficial conversion feature on the issuance date. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of any attached equity instruments, if any related equity instruments were granted with the debt. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital.  The debt discount is amortized to interest expense over the life of the note using the effective interest method.
XML 62 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 7 - Convertible Notes Payable (Tables)
 12 Months Ended
Dec. 31, 2012
Schedule of Short-term Debt [Table Text Block]
   
December 31,
2012
   
December 31,
2011
 
Convertible Promissory Note Payable to JMJ Financial, unsecured, one time interest charge of 8%, due on February 22, 2014
  $ 191,663     $ 207,161  
Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0% per annum, with payment due on April 26, 2012
    -       40,000  
Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0% per annum, with payment due on June 1, 2012
    -       45,000  
Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0% per annum, with payment due on August 7, 2012
    -       42,500  
Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0%  per annum, with payment due on September 19, 2012
    -       53,000  
Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0% per annum, with payment due on March 21, 2013, fully converted in January 2013
    7,500       -  
Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0%  per annum, with payment due on May 10, 2013
    42,500       -  
Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8.0%  per annum, with payment due on August 27, 2013
    42,500       -  
Convertible Promissory Note Payable to TCA Global Credit Master Fund, LP, secured by all of the Company’s assets, interest rate of 12.0%  per annum, with payment due on January 3, 2013
    62,165       -  
Convertible Promissory Note Payable issued in the course of a private placement to individuals, unsecured,  interest rate of 8.0%  per annum, with payment due on June 26, 2013
    100,000       -  
Total 
    446,328       387,661  
Less: debt discount
    (229,573 )     (307,126 )
    $ 216,755     $ 80,535  
XML 63 R49.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 13 - Stock Options And Warrants Outstanding (Detail) (USD $)
 12 Months Ended
Dec. 31, 2012
Jul. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)   20,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars) $ 429,824  
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum 159.00%  
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 161.00%  
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 0.00%  
For Consulting Services, Exercisable at $0.25 [Member]
    
Stock Issued During Period, Shares, Share-based Compensation, Gross (in Shares) 75,000  
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit (in Dollars per share) $ 0.25  
For Consulting Services, Exercisable at $0.40 [Member]
    
Stock Issued During Period, Shares, Share-based Compensation, Gross (in Shares) 300,000  
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit (in Dollars per share) $ 0.40  
For Directors and Employee Services [Member]
    
Stock Issued During Period, Shares, Share-based Compensation, Gross (in Shares) 2,500,000  
Stock Options [Member] | Minimum [Member]
    
Fair Value Inputs, Discount Rate 0.12%  
Stock Options [Member] | Maximum [Member]
    
Fair Value Inputs, Discount Rate 0.21%  
Minimum [Member]
    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term 1 year  
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term 255 days  
Options Issued, Expected Term 6 years  
Options Issued, Expected Term 6 years  
Maximum [Member]
    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term 2 years  
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term 2 years  
Options Issued, Expected Term 1 year  
Options Issued, Expected Term 1 year  
XML 64 R41.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 7 - Convertible Notes Payable (Detail) - Notes Payable (USD $)
Dec. 31, 2012
Dec. 31, 2011
Less: debt discount $ 42,534 $ 0
184,289 80,535
Including Related Parties [Member]
    
Convertible Promissory Note Payable 446,328 387,661
Less: debt discount (229,573) (307,126)
216,755 80,535
Private Placement [Member] | Due June 26, 2013 [Member]
    
Convertible Promissory Note Payable 100,000  
JMJ Financial Inc [Member] | Due February 22, 2014 [Member]
    
Convertible Promissory Note Payable 191,663 207,161
Asher Enterprises Inc [Member] | Due April 26, 2012 [Member]
    
Convertible Promissory Note Payable   40,000
Asher Enterprises Inc [Member] | Due June 1, 2012 [Member]
    
Convertible Promissory Note Payable   45,000
Asher Enterprises Inc [Member] | Due August 7, 2012 [Member]
    
Convertible Promissory Note Payable   42,500
Asher Enterprises Inc [Member] | Due September 19, 2012 [Member]
    
Convertible Promissory Note Payable   53,000
Asher Enterprises Inc [Member] | Due March 21, 2013 [Member]
    
Convertible Promissory Note Payable 7,500  
Asher Enterprises Inc [Member] | Due May 10, 2013 [Member]
    
Convertible Promissory Note Payable 42,500  
Asher Enterprises Inc [Member] | Due August 27, 2013 [Member]
    
Convertible Promissory Note Payable 42,500  
TCA Global Credit Master Fund, LP [Member] | Due January 3, 2013 [Member]
    
Convertible Promissory Note Payable $ 62,165  
XML 65 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
Statements of Stockholders’ Equity (USD $)
Common Stock Issued Pursuant to Joint Venture [Member]
Common Stock [Member]
Common Stock Issued Pursuant to Joint Venture [Member]
Additional Paid-in Capital [Member]
Common Stock Issued Pursuant to Joint Venture [Member]
Warrants Granted Pursuant to Joint Venture [Member]
Additional Paid-in Capital [Member]
Warrants Granted Pursuant to Joint Venture [Member]
Exercises by Third-parties for Services [Member]
Common Stock [Member]
Exercises by Third-parties for Services [Member]
Additional Paid-in Capital [Member]
Exercises by Third-parties for Services [Member]
Exercises by Third Parties for Cash [Member]
Common Stock [Member]
Exercises by Third Parties for Cash [Member]
Additional Paid-in Capital [Member]
Exercises by Third Parties for Cash [Member]
Receivables from Stockholder [Member]
Exercises by Third Parties for Cash [Member]
Common Stock Issued for Services [Member]
Common Stock [Member]
Common Stock Issued for Services [Member]
Additional Paid-in Capital [Member]
Common Stock Issued for Services [Member]
Third-Party Investors [Member]
Common Stock [Member]
Third-Party Investors [Member]
Additional Paid-in Capital [Member]
Third-Party Investors [Member]
Services Rendered by Third Parties [Member]
Common Stock [Member]
Services Rendered by Third Parties [Member]
Additional Paid-in Capital [Member]
Services Rendered by Third Parties [Member]
Exercises by Third Parties for Cash [Member]
Common Stock [Member]
Exercises by Third Parties for Cash [Member]
Additional Paid-in Capital [Member]
Exercises by Third Parties for Cash [Member]
Exercises by Third-parties for Services [Member]
Common Stock [Member]
Exercises by Third-parties for Services [Member]
Additional Paid-in Capital [Member]
Exercises by Third-parties for Services [Member]
Services Contributed by Officer and Employees [Member]
Additional Paid-in Capital [Member]
Services Contributed by Officer and Employees [Member]
Options Granted to Non-employees [Member]
Additional Paid-in Capital [Member]
Options Granted to Non-employees [Member]
Stock Issued for Services [Member]
Common Stock [Member]
Stock Issued for Services [Member]
Additional Paid-in Capital [Member]
Stock Issued for Services [Member]
Warrant [Member]
Common Stock [Member]
Warrant [Member]
Additional Paid-in Capital [Member]
Warrant [Member]
Preferred Stock [Member]
Preferred Stock Issued for Services [Member]
Preferred Stock [Member]
Common Stock [Member]
Common Stock Issued for Services [Member]
Common Stock [Member]
Cerro Mining [Member]
Common Stock [Member]
Maxxon-OK, Founders [Member]
Common Stock [Member]
Maxxon-OK, Third-Party [Member]
Common Stock [Member]
Ives, Health Company [Member]
Common Stock [Member]
Ives, Health Club [Member]
Common Stock [Member]
Ives, Debt [Member]
Common Stock [Member]
Clear Image Acquisition Corp [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Common Stock Issued for Services [Member]
Additional Paid-in Capital [Member]
Preferred Stock Issued for Services [Member]
Additional Paid-in Capital [Member]
Cerro Mining [Member]
Additional Paid-in Capital [Member]
Maxxon-OK, Founders [Member]
Additional Paid-in Capital [Member]
Maxxon-OK, Third-Party [Member]
Additional Paid-in Capital [Member]
Ives, Health Company [Member]
Additional Paid-in Capital [Member]
Ives, Health Club [Member]
Additional Paid-in Capital [Member]
Ives, Debt [Member]
Additional Paid-in Capital [Member]
Clear Image Acquisition Corp [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit during Development Stage [Member]
Receivables from Stockholder [Member]
Treasury Stock [Member]
Common Stock Issued for Services [Member]
Preferred Stock Issued for Services [Member]
Cerro Mining [Member]
Maxxon-OK, Founders [Member]
Maxxon-OK, Third-Party [Member]
Ives, Health Company [Member]
Ives, Health Club [Member]
Ives, Debt [Member]
Clear Image Acquisition Corp [Member]
Total
Balance, amount at Aug. 15, 1996                                                                                                                                              
Business Acquisition, amount                                                                                 $ 27 $ 350 $ 29 $ 16 $ 2           $ 273 $ 6,650 $ 574,448 $ 311,246 $ 34,998                 $ 300 $ 7,000 $ 574,477 $ 311,262 $ 35,000      
Business Acquisition, Shares (in Shares)                                                                                 26,550 350,000 28,900 15,562 1,750                                                    
Convertible Debt                                                                                           1   3               26,999   128,997                     27,000   129,000
Convertible Debt, Shares (in Shares)                                                                                           926   3,225                                              
Subscriptions                                                                                               2                   69,798   (69,800)                      
Subscriptions, Shares (in Shares)                                                                                               2,638                                              
Issued for Services                                     4 173,423 173,427                                                                                                    
Issued for Services, Shares (in Shares)                                     4,525                                                                                                        
Debentures                                                                                               5                   74,995                         75,000
Debentures, Shares (in Shares)                                                                                               5,134                                              
Net Income                                                                                                                     (795,376)                       (795,376)
Issued for Cash                               11 353,709 353,720                                                                                                          
Issued for Cash, shares (in Shares)                               10,928                                                                                                              
Balance, amount at Dec. 31, 1997                                                                                               450                   1,755,536 (795,376) (69,800)                     890,810
Balance, shares (in Shares) at Dec. 31, 1997                                                                                               450,138                                              
Convertible Debt                                                                                               2                   54,998                         55,000
Convertible Debt, Shares (in Shares)                                                                                               2,241                                              
Subscriptions                                                                                                                       69,800                     69,800
Issued for Services                                     49 574,499 574,548             114,154 114,154                                                                                    
Issued for Services, Shares (in Shares)                                     49,400                                                                                                        
Compensation Cost                                                           918,187 918,187                                                                                
Debentures                                                                                               27                   274,973                         275,000
Debentures, Shares (in Shares)                                                                                               27,429                                              
Net Income                                                                                                                     (2,584,383)                       (2,584,383)
Issued for Cash                               3 90,997 91,000                                                           18                   332                         350
Issued for Cash, shares (in Shares)                               2,500                                                               17,500                                              
Certificates canceled                                                                                               (4)                   (40,261)                         (40,265)
Certificates canceled (in Shares)                                                                                               (4,579)                                              
Exercises of Options                                           27 359,873 359,900 1 18,099 18,100                                                                                        
Exercises of Options, Shares (in Shares)                                           27,293     1,207                                                                                            
Balance, amount at Dec. 31, 1998                                                                                               573                   4,121,387 (3,379,759)                       742,201
Balance, shares (in Shares) at Dec. 31, 1998                                                                                               573,129                                              
Issued for Services                                     8 166,735 166,743             280,000 280,000                                                                                    
Issued for Services, Shares (in Shares)                                     8,203                                                                                                        
Compensation Cost                                                           89,728 89,728                                                                                
Net Income                                                                                                                     (1,014,555)                       (1,014,555)
Issued for Cash                               20 342,404 342,424                                                                                                          
Issued for Cash, shares (in Shares)                               19,535                                                                                                              
Issuance Cost                                                                                                                   (16,743)                         (16,743)
Exercises of Options                                           15 149,985 150,000                                                                                              
Exercises of Options, Shares (in Shares)                                           15,000                                                                                                  
Balance, amount at Dec. 31, 1999                                                                                               616                   5,133,496 (4,394,314)                       739,798
Balance, shares (in Shares) at Dec. 31, 1999                                                                                               615,867                                              
Issued for Services                                                                                                                   405,000                         405,000
Net Income                                                                                                                     (1,347,859)                       (1,347,859)
Issued for Cash                               43 250,345 250,388                                                                                                          
Issued for Cash, shares (in Shares)                               43,139                                                                                                              
Balance, amount at Dec. 31, 2000                                                                                               659                   5,788,841 (5,742,173)                       47,327
Balance, shares (in Shares) at Dec. 31, 2000                                                                                               659,006                                              
Convertible Debt                                                                                               3                   7,497                         7,500
Convertible Debt, Shares (in Shares)                                                                                               2,500                                              
Issued for Services                                     23 422,427 422,450                     10 1,487,690 1,487,700                                                                          
Issued for Services, Shares (in Shares)                                     22,500                         10,000                                                                              
Amortization of Compensation Cost                                                                                                                   (1,048,754)                         (1,048,754)
Net Income                                                                                                                     (2,199,085)                       (2,199,085)
Issued for Cash                               328 1,604,372 1,604,700                                                           183                   547,317   (547,500)                      
Issued for Cash, shares (in Shares)                               327,917                                                               182,500                                              
Issuance Cost                                                                                                                   (85,575)                         (85,575)
Balance, amount at Dec. 31, 2001                                                                                               1,206                   8,723,815 (7,941,258) (547,500)                     236,263
Balance, shares (in Shares) at Dec. 31, 2001                                                                                               1,204,423                                              
Compensation Cost                                                               60 324,440 324,500                                                                          
Compensation Cost, Shares (in Shares)                                                               60,000                                                                              
Net Income                                                                                                                     (1,933,676)                       (1,933,676)
Issued for Cash                               181 362,319 362,500                                                                                                          
Issued for Cash, shares (in Shares)                               181,250                                                                                                              
Issuance Cost                                                                                                                   759,795                         759,795
Exercises of Options                                                                                               100                   (100)                          
Exercises of Options, Shares (in Shares)                                                                                               100,341                                              
Issued for repayment of debt                                                                                                                       102,803                     102,803
Balance, amount at Dec. 31, 2002                                                                                               1,547                   10,170,269 (9,874,934) (444,697)                     (147,815)
Balance, shares (in Shares) at Dec. 31, 2002                                                                                               1,546,014                                              
Convertible Debt                                                                                                                       69,201                     69,201
Amortization of Compensation Cost                                                                                                                   288,959                         288,959
Compensation Cost                                                                                               350                   139,650                         140,000
Compensation Cost, Shares (in Shares)                                                                                               350,000                                              
Net Income                                                                                                                     (1,391,518)                       (1,391,518)
Issuance Cost                                                                                               200                   79,800                         80,000
Issuance Cost, Shares (in Shares)                                                                                               200,000                                              
Exercises of Options                                                                                               57                   140,643                         140,700
Exercises of Options, Shares (in Shares)                                                                                               57,000                                              
Balance, amount at Dec. 31, 2003                                                                                               2,154                   10,819,321 (11,266,452) (375,496)                     (820,473)
Balance, shares (in Shares) at Dec. 31, 2003                                                                                               2,153,014                                              
Convertible Debt                                                                                                                       18,750                     18,750
Issued for Services                                                               1,643 912,357 914,000                                                                          
Issued for Services, Shares (in Shares)                                                               1,642,500                                                                              
Net Income                                                                                                                     (1,552,008)                       (1,552,008)
Issued for Cash                               5 4,995 5,000                                                                                                          
Issued for Cash, shares (in Shares)                               5,000                                                                                                              
Exercises of Options                                                                                               293                   253,807                         254,100
Exercises of Options, Shares (in Shares)                                                                                               293,300                                              
Exercise of Warrants                                                                                               73                   73,027   (1,000)                     72,100
Exercise of Warrants, Shares (in Shares)                                                                                               73,100                                              
Balance, amount at Dec. 31, 2004                                                                                               4,168                   12,063,507 (12,818,460) (357,746)                     (1,108,531)
Balance, shares (in Shares) at Dec. 31, 2004                                                                                               4,166,914                                              
Business Acquisition, amount 292 137,541 137,833 499,733 499,733                                                                                                                                    
Business Acquisition, Shares (in Shares) 291,667                                                                                                                                            
Subscriptions                                                                                               260                   33,740   (34,000)                      
Subscriptions, Shares (in Shares)                                                                                               260,000                                              
Issued for Services                                                               1,063 475,437 476,500                                                                          
Issued for Services, Shares (in Shares)                                                               1,062,500                                                                              
Compensation Cost                                                                                                                   130,900                         130,900
Reclassification of receivables against amounts owed                                                                                                                       357,746                     357,746
Net Income                                                                                                                     (1,310,783)                       (1,310,783)
Issued for Cash                               652 290,048 290,700                                                                                                          
Issued for Cash, shares (in Shares)                               651,959                                                                                                              
Exercises of Options                                                                                               90                   44,910                         45,000
Exercises of Options, Shares (in Shares)                                                                                               90,000                                              
Balance, amount at Dec. 31, 2005                                                                                               6,525                   13,675,816 (14,129,243) (34,000)                     (480,902)
Balance, shares (in Shares) at Dec. 31, 2005                                                                                               6,523,040                                              
Subscriptions                                                                                                                       34,000                     34,000
Issued for Services                                                                           1,000   275                 107,225 19,000                       107,500 20,000                
Issued for Services, Shares (in Shares)                                                                           1,000,000   275,000                                                              
Capital contributed by shareholder                                                                                                                   3,000                         3,000
Compensation Cost                                                                                                                   50,000                         50,000
Debentures                                                                                                                   (625,066)                         (625,066)
Treasury Stock                                                                                               (25)                   (12,475)                         (12,500)
Treasury Stock, shares (in Shares)                                                                                               (25,000)                                              
Net Income                                                                                                                     (598,302)                       (598,302)
Exercises of Options           50 950 1,000 150 74,850   75,000                                                                                                                      
Exercises of Options, Shares (in Shares)           50,000     150,000                                                                                                                            
Exercise of Warrants                                                                                               300                   5,700                         6,000
Exercise of Warrants, Shares (in Shares)                                                                                               300,000                                              
Balance, amount at Dec. 31, 2006                                                                             1,000                 7,275                   13,299,000 (14,727,545)                       (1,420,270)
Balance, shares (in Shares) at Dec. 31, 2006                                                                             1,000,000                 7,273,040                                              
Business Acquisition, amount                                                                                             8,274                   3,301,241                         3,309,515  
Business Acquisition, Shares (in Shares)                                                                                             8,273,788                                                
Issued for Services                                                               1,225 388,775 390,000                                                                          
Issued for Services, Shares (in Shares)                                                               1,225,000                                                                              
Issuance of restricted stock                                                                                               40                   9,960                         10,000
Issuance of restricted stock (in Shares)                                                                                               40,000                                              
Compensation Cost                                                                                                                   223,246                         223,246
Net Income                                                                                                                     (4,475,017)                       (4,475,017)
Issued for Cash                                                                                               845                   299,155                         300,000
Issued for Cash, shares (in Shares)                                                                                               845,000                                              
Exercises of Options                 125 9,875   10,000                                                                                                                      
Exercises of Options, Shares (in Shares)                 125,000                                                                                                                            
Exercise of Warrants                                                                     346 6,568 6,914                                                                    
Exercise of Warrants, Shares (in Shares)                                                                     345,662                                                                        
Balance, amount at Dec. 31, 2007                                                                             1,000                 18,130                   17,537,820 (19,202,562)                       (1,645,612)
Balance, shares (in Shares) at Dec. 31, 2007                                                                             1,000,000                 18,127,490                                              
Business Acquisition, amount                                                                                             43                   12,164                         12,207  
Business Acquisition, Shares (in Shares)                                                                                             43,600                                                
Convertible Debt                                                                                               271                   132,759                         133,030
Convertible Debt, Shares (in Shares)                                                                                               271,491                                              
Issued for Services           1,419 258,501 259,920                                                                                                                              
Issued for Services, Shares (in Shares)           1,419,704                                                                                                                                  
Compensation Cost                                                                                                                   342,801                         342,801
Acquired deficit of former Minority interest now Owned 100%                                                                                                                   (209,776)                         (209,776)
Net Income                                                                                                                     (1,335,154)                       (1,335,154)
Issued for Cash                                                                                               4,722                   300,101                         304,823
Issued for Cash, shares (in Shares)                                                                                               4,720,978                                              
Exercises of Options                 2,300 395,317   397,617                                                                                                                      
Exercises of Options, Shares (in Shares)                 2,300,000                                                                                                                            
Balance, amount at Dec. 31, 2008                                                                             1,000                 26,885                   18,769,687 (20,537,716)                       (1,740,144)
Balance, shares (in Shares) at Dec. 31, 2008                                                                             1,000,000                 26,883,193                                              
Convertible Debt                                                                                               667                   306,074                         306,741
Convertible Debt, Shares (in Shares)                                                                                               667,000                                              
Issued for Services                                                                           500                       249,500                         250,000                
Issued for Services, Shares (in Shares)                                                                           500,000                                                                  
Compensation Cost                                                                                                                   1,452,231                         1,452,231
Acquired deficit of former Minority interest now Owned 100%                                                                                                                   (17,998)                         (17,998)
Net Income                                                                                                                     (2,463,751)                       (2,463,751)
Issued for Cash                                                                                               5,946                   1,396,188                         1,402,134
Issued for Cash, shares (in Shares)                                                                                               5,946,446                                              
Exercises of Options                 171 13,529   13,700 1,530 346,770 348,300                                                                                                                
Exercises of Options, Shares (in Shares)                 171,250       1,530,000                                                                                                                    
Balance, amount at Dec. 31, 2009                                                                             1,500                 35,199                   22,515,981 (23,001,467)                       (448,787)
Balance, shares (in Shares) at Dec. 31, 2009                                                                             1,500,000                 35,197,959                                              
Convertible Debt                                                                                               400                   530,356                         530,756
Convertible Debt, Shares (in Shares)                                                                                               399,441                                              
Issued for Services                                                                               2,194                 558,578                         560,772                  
Issued for Services, Shares (in Shares)                                                                               2,194,891                                                              
Treasury Stock                                                                                                                         (969)                   (969)
Net Income                                                                                                                     (3,231,425)                       (3,231,425)
Issued for Cash                                                                                               4,810                   1,525,181                         1,529,991
Issued for Cash, shares (in Shares)                                                                                               4,810,287                                              
Exercises of Options                 150 37,350   37,500                                                                                                                      
Exercises of Options, Shares (in Shares)                 150,000                                                                                                                            
Exercise of Warrants                                                                                               117                   58,583                         58,700
Exercise of Warrants, Shares (in Shares)                                                                                               117,400                                              
Balance, amount at Dec. 31, 2010                                                                             1,500                 42,870                   25,226,029 (26,232,892)   (969)                   (963,462)
Balance, shares (in Shares) at Dec. 31, 2010                                                                             1,500,000                 42,869,978                                              
Business Acquisition, amount                                                                                               656                   201,915                         202,571
Business Acquisition, Shares (in Shares)                                                                                               656,015                                              
Convertible Debt                                                                                               3,191                   959,105                         962,296
Convertible Debt, Shares (in Shares)                                                                                               3,191,367                                             3,021,738
From convertible debt beneficial conversion feature                                                                                                                   94,624                         94,624
Issued for Services                                                                               1,514                 479,586                         481,100                 481,100
Issued for Services, Shares (in Shares)                                                                               1,513,874                                                             1,513,874
Compensation Cost                                                                                                                                             1,065,458
Treasury Stock                                                                                               (169)                         969                   800
Treasury Stock, shares (in Shares)                                                                                               (169,628)                                              
Issuance of unexercised options                                                                                                                   863,426                         863,426
Net Income                                                                                                                     (4,541,518)                       (4,541,518)
Exercises of Options                 6,668 1,672,752 (25,000) 1,654,420                                                                                                                     1,654,420
Exercises of Options, Shares (in Shares)                 6,668,000                                                                                                                           6,668,000
Preferred stock forfeited                                                                             (500)                                     500                         500
Preferred stock forfeited (in Shares)                                                                             (500,000)                                                                
Balance, amount at Dec. 31, 2011                                                                             1,000                 54,730                   29,497,937 (30,774,410) (25,000)                     (1,245,743)
Balance, shares (in Shares) at Dec. 31, 2011                                                                             1,000,000                 54,729,606                                              
Issuance of common stock from the exercise of options and warrants for cash                                                                                               1,235                   303,040   (46,000)                     258,275
Issuance of common stock from the exercise of options and warrants for cash (in Shares)                                                                                               1,235,000                                              
Convertible Debt                                                                                               13,669                   2,305,103                         2,318,772
Convertible Debt, Shares (in Shares)                                                                                               13,669,072                                             13,669,072
Common stock issued for indemnification settlement                                                                                               400                   140,160                         140,560
Common stock issued for indemnification settlement (in Shares)                                                                                               400,000                                              
From convertible debt beneficial conversion feature                                                                                                                   237,774                         237,774
Issued for Services                                                                               2,751                 513,360                         516,111                  
Issued for Services, Shares (in Shares)                                                                               2,751,229                                                             2,751,229
Options issued for services                                                                                                                   974,961                         974,961
Warrants issued with convertible notes payable                                                                                                                   347,097                         347,097
Compensation Cost                                                                                                                                             1,491,072
Net Income                                                                                                                     (7,164,311)                       (7,164,311)
Exercises of Options, Shares (in Shares)                                                                                                                                             575,000
Balance, amount at Dec. 31, 2012                                                                             $ 1,000                 $ 72,785                   $ 34,319,432 $ (37,938,721) $ (71,000)                     $ (3,616,504)
Balance, shares (in Shares) at Dec. 31, 2012                                                                             1,000,000                 72,784,907                                              
XML 66 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 4 - Intangibles And Goodwill
 12 Months Ended
Dec. 31, 2012
Goodwill and Intangible Assets Disclosure [Text Block]
NOTE 4 – INTANGIBLES AND GOODWILL

Intangibles

The following is a summary of the Company’s intangibles at December 31, 2012 and 2011:

   
December 31, 2012
   
December 31, 2011
 
Patent
  $ 146,538     $ 107,314  
Licensing agreement
    -       15,000  
Subtotal
    146,538       122,314  
Less: accumulated amortization
    (39,851 )     (5,888 )
Intangibles , net
  $ 106,687     $ 116,426  

The Company owns one published patent on its Auto Retractable Vacuum RevVac™ safety syringe issued in January 2005 and one published patent on its safety blood drawing device issued in June 2003.  In January 2009, a second patent for the RevVac™ auto retractable vacuum safety syringe was issued by the U.S. patent office and published in April 2009 related to the Globe/Revolutions Medical Joint Venture.  Upon the ruling in the Globe Med Tech lawsuit, the Company now has full ownership of the entire patent.  The Company also filed international patent protection rights regarding the RevVac™ Auto Retractable Vacuum Safety Syringe in the following countries: Australia, China, Japan, Taiwan, Mexico, Canada and in Europe. Patents in Mexico and in China were issued in June 2011 and January 2012, respectively. The Japan patent was issued in the third quarter of 2012.

The Company filed a U.S. provisional patent on May 2, 2011, on its new vacuum design for the pre-filled market.  On May 2, 2012, the Company also filed an international Patent Cooperation Treaty (PCT) for this new design.

The Company is also engaged in the development of technology which can segment and reference MRI images.  By “segmenting” an image, the Company’s technology will let the user select a part of the image (bone, fluid, tissue) and render that selection in three dimensions.  Essentially, different components of an image are given different colors and the user can choose the color or colors to be studied, thus eliminating those portions colored with the colors being discarded.  By “referencing” the image to a database, the user can obtain similar, identified images to aid the user in interpretation of the image being studied.  The Company currently owns 4 separate patent applications, filed in June of 2007, each of which received USPTO office actions during 2010, 2011 and 2012.

The licensing agreement provided licensing rights to a Traxis biopsy software product. The Company decided not to pursue this technology and impaired the cost of $15,000 during 2012.

For the years ended December 31, 2012 and 2011, the Company recognized amortization expense of $33,963 and $5,888, respectively.

Goodwill

In 2007, the Company acquired a 62.2% interest in Clear Image, Inc. (“Clear Image”).  Clear Image was a privately held company and was conducting research and development on Color MRI Technology.   The Company exchanged approximately 8.2 million of its common shares which were trading between $0.40 and $0.50 per share at the time of the acquisition.  To arrive at a value for the Color MRI Technology, the Company and Clear Image determined the amount of funding provided for the research and development of this technology by evaluating the amount expended from 1999 until the acquisition date.  The value of the Company’s stock exchanged for the controlling interest exceeded net assets acquired by $23,276 which was recorded as goodwill.  During 2012, all goodwill was impaired.

XML 67 R27.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 9 - Derivatives - Note Conversion Feature (Tables)
 12 Months Ended
Dec. 31, 2012
Schedule of Derivative Instruments [Table Text Block]
Fair value at December 31, 2010
 
$
160,659
 
Issuance of instruments
   
840,442
 
Decrease in value
   
(40,030
)
Reclassification from liability to equity as a result of note conversions
   
(518,760
)
Fair value at December 31, 2011
   
442,311
 
Issuance of instruments
   
952,214
 
Decrease in value
   
(131,397
)
Reclassification from liability to equity as a result of note conversions
   
(898,326
)
Fair value at December 31, 2012
 
$
364,802
 
Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]
  2012   2011  
Risk free interest rate
0.11%
to
0.16%   0.17%
to
0.19%  
Expected life (years)
0.01
to
2.1   0
to
3  
Dividend Yield
 
0%
      0%    
Volatility
130%
to
219%   0%
to
205%  
XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 477 294 1 false 114 0 false 5 false false R1.htm 000 - Disclosure - Document And Entity Information Sheet http://www.revolutionsmedical.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 001 - Statement - Balance Sheets Sheet http://www.revolutionsmedical.com/role/ConsolidatedBalanceSheet Balance Sheets false false R3.htm 002 - Statement - Balance Sheets (Parentheticals) Sheet http://www.revolutionsmedical.com/role/ConsolidatedBalanceSheet_Parentheticals Balance Sheets (Parentheticals) false false R4.htm 003 - Statement - Statements of Operations Sheet http://www.revolutionsmedical.com/role/ConsolidatedIncomeStatement Statements of Operations false false R5.htm 004 - Statement - Statements of Stockholders’ Equity Sheet http://www.revolutionsmedical.com/role/ShareholdersEquityType2or3 Statements of Stockholders’ Equity false false R6.htm 005 - Statement - Statements of Cash Flows Sheet http://www.revolutionsmedical.com/role/ConsolidatedCashFlow Statements of Cash Flows false false R7.htm 006 - Disclosure - Note 1 - Summary Of Significant Accounting Policies Sheet http://www.revolutionsmedical.com/role/Note Note 1 - Summary Of Significant Accounting Policies false false R8.htm 007 - Disclosure - Note 2 - Going Concern Sheet http://www.revolutionsmedical.com/role/Note0 Note 2 - Going Concern false false R9.htm 008 - Disclosure - Note 3 - Property And Equipment Sheet http://www.revolutionsmedical.com/role/Note00 Note 3 - Property And Equipment false false R10.htm 009 - Disclosure - Note 4 - Intangibles And Goodwill Sheet http://www.revolutionsmedical.com/role/Note000 Note 4 - Intangibles And Goodwill false false R11.htm 010 - Disclosure - Note 5 - Accounts Payable And Accrued Liabilities Sheet http://www.revolutionsmedical.com/role/Note0000 Note 5 - Accounts Payable And Accrued Liabilities false false R12.htm 011 - Disclosure - Note 7 - Convertible Notes Payable Notes http://www.revolutionsmedical.com/role/Note00000 Note 7 - Convertible Notes Payable false false R13.htm 012 - Disclosure - Note 8 - Payable for Indemnification Sheet http://www.revolutionsmedical.com/role/Note000000 Note 8 - Payable for Indemnification false false R14.htm 013 - Disclosure - Note 10 - Maxxon/Globe Joint Venture Agreement Sheet http://www.revolutionsmedical.com/role/Note0000000 Note 10 - Maxxon/Globe Joint Venture Agreement false false R15.htm 014 - Disclosure - Note 11 - Commitments And Contingencies Sheet http://www.revolutionsmedical.com/role/Note00000000 Note 11 - Commitments And Contingencies false false R16.htm 015 - Disclosure - Note 12 - Preferred Stock And Common Stock Transactions Sheet http://www.revolutionsmedical.com/role/Note000000000 Note 12 - Preferred Stock And Common Stock Transactions false false R17.htm 016 - Disclosure - Note 13 - Stock Options And Warrants Outstanding Sheet http://www.revolutionsmedical.com/role/Note0000000000 Note 13 - Stock Options And Warrants Outstanding false false R18.htm 017 - Disclosure - Note 14 - Related Party Transactions Sheet http://www.revolutionsmedical.com/role/Note00000000000 Note 14 - Related Party Transactions false false R19.htm 018 - Disclosure - Note 15 - Restatement Sheet http://www.revolutionsmedical.com/role/Note000000000000 Note 15 - Restatement false false R20.htm 019 - Disclosure - Note 16 - Subsequent Events Sheet http://www.revolutionsmedical.com/role/Note0000000000000 Note 16 - Subsequent Events false false R21.htm 020 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.revolutionsmedical.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) false false R22.htm 021 - Disclosure - Note 1 - Summary Of Significant Accounting Policies (Tables) Sheet http://www.revolutionsmedical.com/role/NoteTables Note 1 - Summary Of Significant Accounting Policies (Tables) false false R23.htm 022 - Disclosure - Note 3 - Property And Equipment (Tables) Sheet http://www.revolutionsmedical.com/role/NoteTables0 Note 3 - Property And Equipment (Tables) false false R24.htm 023 - Disclosure - Note 4 - Intangibles And Goodwill (Tables) Sheet http://www.revolutionsmedical.com/role/NoteTables00 Note 4 - Intangibles And Goodwill (Tables) false false R25.htm 024 - Disclosure - Note 5 - Accounts Payable And Accrued Liabilities (Tables) Sheet http://www.revolutionsmedical.com/role/NoteTables000 Note 5 - Accounts Payable And Accrued Liabilities (Tables) false false R26.htm 025 - Disclosure - Note 7 - Convertible Notes Payable (Tables) Notes http://www.revolutionsmedical.com/role/NoteTables0000 Note 7 - Convertible Notes Payable (Tables) false false R27.htm 026 - Disclosure - Note 9 - Derivatives - Note Conversion Feature (Tables) Sheet http://www.revolutionsmedical.com/role/NoteTables00000 Note 9 - Derivatives - Note Conversion Feature (Tables) false false R28.htm 027 - Disclosure - Note 13 - Stock Options And Warrants Outstanding (Tables) Sheet http://www.revolutionsmedical.com/role/NoteTables000000 Note 13 - Stock Options And Warrants Outstanding (Tables) false false R29.htm 028 - Disclosure - Note 15 - Restatement (Tables) Sheet http://www.revolutionsmedical.com/role/NoteTables0000000 Note 15 - Restatement (Tables) false false R30.htm 029 - Disclosure - Note 1 - Summary Of Significant Accounting Policies (Detail) Sheet http://www.revolutionsmedical.com/role/NoteDetail Note 1 - Summary Of Significant Accounting Policies (Detail) false false R31.htm 030 - Disclosure - Note 1 - Summary Of Significant Accounting Policies (Detail) - Estimated Useful Lives of Property Plant and Equipment Sheet http://www.revolutionsmedical.com/role/EstimatedUsefulLivesofPropertyPlantandEquipmentTable Note 1 - Summary Of Significant Accounting Policies (Detail) - Estimated Useful Lives of Property Plant and Equipment false false R32.htm 031 - Disclosure - Note 1 - Summary Of Significant Accounting Policies (Detail) - Fair Value, Assets and Liabilities Measured on Recurring Basis Sheet http://www.revolutionsmedical.com/role/FairValueAssetsandLiabilitiesMeasuredonRecurringBasisTable Note 1 - Summary Of Significant Accounting Policies (Detail) - Fair Value, Assets and Liabilities Measured on Recurring Basis false false R33.htm 032 - Disclosure - Note 2 - Going Concern (Detail) Sheet http://www.revolutionsmedical.com/role/NoteDetail0 Note 2 - Going Concern (Detail) false false R34.htm 033 - Disclosure - Note 3 - Property And Equipment (Detail) Sheet http://www.revolutionsmedical.com/role/NoteDetail00 Note 3 - Property And Equipment (Detail) false false R35.htm 034 - Disclosure - Note 3 - Property And Equipment (Detail) - Summary Of Property And Equipment Sheet http://www.revolutionsmedical.com/role/SummaryOfPropertyAndEquipmentTable Note 3 - Property And Equipment (Detail) - Summary Of Property And Equipment false false R36.htm 035 - Disclosure - Note 4 - Intangibles And Goodwill (Detail) Sheet http://www.revolutionsmedical.com/role/NoteDetail000 Note 4 - Intangibles And Goodwill (Detail) false false R37.htm 036 - Disclosure - Note 4 - Intangibles And Goodwill (Detail) - Summary of Intangible Assets Sheet http://www.revolutionsmedical.com/role/SummaryofIntangibleAssetsTable Note 4 - Intangibles And Goodwill (Detail) - Summary of Intangible Assets false false R38.htm 037 - Disclosure - Note 5 - Accounts Payable And Accrued Liabilities (Detail) Sheet http://www.revolutionsmedical.com/role/NoteDetail0000 Note 5 - Accounts Payable And Accrued Liabilities (Detail) false false R39.htm 038 - Disclosure - Note 5 - Accounts Payable And Accrued Liabilities (Detail) - Summary of Accounts Payable and Accrued Liabilities Sheet http://www.revolutionsmedical.com/role/SummaryofAccountsPayableandAccruedLiabilitiesTable Note 5 - Accounts Payable And Accrued Liabilities (Detail) - Summary of Accounts Payable and Accrued Liabilities false false R40.htm 039 - Disclosure - Note 7 - Convertible Notes Payable (Detail) Notes http://www.revolutionsmedical.com/role/NoteDetail00000 Note 7 - Convertible Notes Payable (Detail) false false R41.htm 040 - Disclosure - Note 7 - Convertible Notes Payable (Detail) - Notes Payable Notes http://www.revolutionsmedical.com/role/NotesPayableTable Note 7 - Convertible Notes Payable (Detail) - Notes Payable false false R42.htm 041 - Disclosure - Note 7 - Convertible Notes Payable (Detail) - Notes Payable (Parentheticals) Notes http://www.revolutionsmedical.com/role/NotesPayableTable_Parentheticals Note 7 - Convertible Notes Payable (Detail) - Notes Payable (Parentheticals) false false R43.htm 042 - Disclosure - Note 8 - Payable for Indemnification (Detail) Sheet http://www.revolutionsmedical.com/role/NoteDetail000000 Note 8 - Payable for Indemnification (Detail) false false R44.htm 043 - Disclosure - Note 9 - Derivatives - Note Conversion Feature (Detail) - Reconciliation of Derivative Liability Sheet http://www.revolutionsmedical.com/role/ReconciliationofDerivativeLiabilityTable Note 9 - Derivatives - Note Conversion Feature (Detail) - Reconciliation of Derivative Liability false false R45.htm 044 - Disclosure - Note 9 - Derivatives - Note Conversion Feature (Detail) - Fair Value Assumptions, Derivative Liability Sheet http://www.revolutionsmedical.com/role/FairValueAssumptionsDerivativeLiabilityTable Note 9 - Derivatives - Note Conversion Feature (Detail) - Fair Value Assumptions, Derivative Liability false false R46.htm 045 - Disclosure - Note 10 - Maxxon/Globe Joint Venture Agreement (Detail) Sheet http://www.revolutionsmedical.com/role/NoteDetail0000000 Note 10 - Maxxon/Globe Joint Venture Agreement (Detail) false false R47.htm 046 - Disclosure - Note 11 - Commitments And Contingencies (Detail) Sheet http://www.revolutionsmedical.com/role/NoteDetail00000000 Note 11 - Commitments And Contingencies (Detail) false false R48.htm 047 - Disclosure - Note 12 - Preferred Stock And Common Stock Transactions (Detail) Sheet http://www.revolutionsmedical.com/role/NoteDetail000000000 Note 12 - Preferred Stock And Common Stock Transactions (Detail) false false R49.htm 048 - Disclosure - Note 13 - Stock Options And Warrants Outstanding (Detail) Sheet http://www.revolutionsmedical.com/role/NoteDetail0000000000 Note 13 - Stock Options And Warrants Outstanding (Detail) false false R50.htm 049 - Disclosure - Note 13 - Stock Options And Warrants Outstanding (Detail) - Stock Options and Warrants Outstanding Activities Sheet http://www.revolutionsmedical.com/role/StockOptionsandWarrantsOutstandingActivitiesTable Note 13 - Stock Options And Warrants Outstanding (Detail) - Stock Options and Warrants Outstanding Activities false false R51.htm 050 - Disclosure - Note 14 - Related Party Transactions (Detail) Sheet http://www.revolutionsmedical.com/role/NoteDetail00000000000 Note 14 - Related Party Transactions (Detail) false false R52.htm 051 - Disclosure - Note 15 - Restatement (Detail) Sheet http://www.revolutionsmedical.com/role/NoteDetail000000000000 Note 15 - Restatement (Detail) false false R53.htm 052 - Disclosure - Note 15 - Restatement (Detail) - Reclassifications and Prior Period Adjustments Sheet http://www.revolutionsmedical.com/role/ReclassificationsandPriorPeriodAdjustmentsTable Note 15 - Restatement (Detail) - Reclassifications and Prior Period Adjustments false false R54.htm 053 - Disclosure - Note 16 - Subsequent Events (Detail) Sheet http://www.revolutionsmedical.com/role/NoteDetail0000000000000 Note 16 - Subsequent Events (Detail) false false All Reports Book All Reports Element us-gaap_FairValueAssumptionsExpectedVolatilityRate had a mix of decimals attribute values: 2 4. 'Shares' elements on report '048 - Disclosure - Note 13 - Stock Options And Warrants Outstanding (Detail)' had a mix of different decimal attribute values. Process Flow-Through: 001 - Statement - Balance Sheets Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: Removing column 'Mar. 11, 2009' Process Flow-Through: 002 - Statement - Balance Sheets (Parentheticals) Process Flow-Through: 003 - Statement - Statements of Operations Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2010' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2009' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2008' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2007' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2006' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2005' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2004' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2003' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2002' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2001' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 2000' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 1999' Process Flow-Through: Removing column '12 Months Ended Dec. 31, 1998' Process Flow-Through: Removing column '16 Months Ended Dec. 31, 1997' Process Flow-Through: 005 - Statement - Statements of Cash Flows rmcp-20121231.xml rmcp-20121231.xsd rmcp-20121231_cal.xml rmcp-20121231_def.xml rmcp-20121231_lab.xml rmcp-20121231_pre.xml true true XML 69 R38.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 5 - Accounts Payable And Accrued Liabilities (Detail) (USD $)
 12 Months Ended 197 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended
Dec. 31, 2012
Dec. 31, 2012
Jun. 18, 2012
Dec. 31, 2011
Dec. 31, 2012
Liabilities Write-off [Member]
Dec. 31, 2012
Accrued Salary [Member]
Dec. 31, 2012
Accounts Payable [Member]
Dec. 31, 2012
Related to Minimum Purchase Requirement [Member]
Yeso Med [Member]
Dec. 31, 2012
Product Purchase [Member]
Yeso Med [Member]
Dec. 31, 2012
Equipment Purchase [Member]
Yeso Med [Member]
Dec. 31, 2011
Equipment Purchase [Member]
Yeso Med [Member]
Dec. 31, 2011
Yeso Med [Member]
Dec. 31, 2012
Yeso Med [Member]
Accrued Payroll Taxes, Current $ 411,670 $ 411,670   $ 125,239                  
Tax Lien, Amount     1,227                    
Liabilities, Write-off           199,336 79,890            
Other Income         279,226                
Long-term Purchase Commitment, Time Period                       5-year  
Long-term Purchase Commitment, Minimum Quantity Required                       2,500,000  
Purchase Commitment, Percentage of Supply Price                       50.00%  
Accounts Payable, Current               783,593 208,258 289,009 352,544 352,544 1,280,860
Loss on Purchase Commitments $ 783,593 $ 783,593                     $ 783,593
XML 70 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6
Note 16 - Subsequent Events
 12 Months Ended
Dec. 31, 2012
Subsequent Events [Text Block]
NOTE 16 – SUBSEQUENT EVENTS

Subsequent to December 31, 2012, the Company issued 1,466,657 common shares for the conversion of notes payable of $79,540; 789,700 common shares to officers for settlement of  $71,073 of accrued salaries based on the grant date fair value of the shares; 102,500 common shares valued at  $5,466 to service providers for settlement of accounts payable; 262,500 common shares valued at $26,250, for investor relation services; 1,453,750 shares valued at $130,838 for director fees;  and 750,000 common shares for net cash proceeds of $75,000 related to warrants and options exercised.